pmid,title,abstract,journal,pubdate,year,month,day,authors,rochester_authors,affiliations,authors_display,url,llm_summary
41319695,A modified Delphi consensus on periprosthetic infection in orthopaedic oncology : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).,"The aim of this study was to achieve consensus for important topics related to periprosthetic infection (PJI) in orthopaedic oncology, and to identify areas for future research.In January 2024, the Birmingham Orthopaedic Oncology Meeting (BOOM) held in Birmingham, UK, gathered 309 delegates from 53 countries to debate 20 consensus statements on PJI in orthopaedic oncology using a modified Delphi process.Of 20 questions and statements on PJI in orthopaedic oncology, none achieved unanimous consensus, 18 achieved strong consensus, one achieved moderate consensus, and one achieved weak consensus. The statements that reached consensus with notable agreement were on the prophylaxis of infection, management of leaking wounds, and surgical strategies for the treatment of PJI. Short-duration antibiotic prophylaxis was deemed as effective as longer courses for lower-risk reconstructions, and aggressive management was recommended for wounds draining beyond five to seven days to prevent deep infection. Furthermore, single-stage, two-stage, and 1.5-stage revision were recognized as valid strategies, with two-stage revision remaining the most reliable. The statements that did not achieve consensus were on the role of debridement, antibiotics, and implant retention and prolonged antibiotic use post-revision.The BOOM meeting achieved consensus for important topics on periprosthetic infection in orthopaedic oncology, but highlighted the low quality of the underlying evidence. This study has provided recommendations for the treatment of leaky wounds, duration of postoperative antibiotic prophylaxis, and choice of revision strategy.© 2025 Jeys et al.",The bone & joint journal,"Dec 01, 2025",2025,Dec,01,Jeys L|Botello E|Boyle R A|Ebeid W|Houdek M T|Kurisunkal V J|Morgan-Jones R|Morris G V|Puri A|Ruggieri P|Laitinen M K|Abad Repiso S|Abdelbary H|Abiad Mejia A|Abood A A|Abou-Nouar G|Abril Martin J C|Abu Elhamd A|Abudu A|Acosta M|Ae K|Agarwal M|Ajit Singh V|Akiyama T|Albergo J I|Alexander J|Alfaro P A|Alpan B|Alshaygy I|Amaya-Valero J|Anderson M|Andreou D|Annabell L|Anthony C|Aoude A|Arteagoitia-Colino I|Asavamongkolkul A|Aston W|Asua Mentxaka L|Azzopardi C|Baad-Hansen T|Badr I T|Baixauli-Garcia F|Baker G|Balach T|Baldi G G|Barry J|Basile G|Bastoni S|Basuki M H|Bauer H|Bayliss L|Becker R G|Bedi A|Benevenia J|Bengoa F|Bergh P|Bergovec M|Bernthal N|Binitie O|Boddie D|Boffano M|Bonilla Huertas P|Borgognoni A B|Botchu R|Bramer J|Branford-White H|Brar R|Broekhuis D|Broida S E|Budny T|Burke Z D|Cabrolier J|Calvo Tapies J R|Calvo-Haro J A|Campanacci D|Cardoso R|Carey Smith R|Carvallo P I|Casales Fresenga N|Casanova J M|Ceballos O|Cebrian Parra J L|Certain L K|Chacon Cartaya S|Chan C M|Cho Y J|Choong P|Chung Y|Ciechanowicz D|Clara-Altamirano M A|Clever D|Colina S M|Consuegra L|Couch C|Cribb G|Cuervo C|Cusick L A|Dadia S|Dagher T|Dammerer D|Davies M|Davies N|de la Rosa Martino L P|de Santos de la Fuente F J|de Vaal M|Deckers C|Delgado Obando J|Deo S|Deventer N|Di Bella C|Domson G|Donati D M|Dorleijn D M|Du Toit J|Dunne D|Duran Ciarrochi R|Ekman E|El Ghoneimy A M|Endo M|Eralp L|Etaiwi M|Evans S|Evrard R|Eward W|Farese A|Ferguson P C|Ferreira Cardoso P F|Fiorenza F|Flint M|Flores H|Freitas J|Fuchs B|Fujiwara T|Funovics P T|Galli Serra M|Gamie Z|Garces-Zarzalejo C|Gazendam A|Gebert C|Gerbers J G|Gerrand C|Ghert M|Ghosh K M|Gibbons M|Gomez-Mascard A|Gomez-Mier L C|Gomez-Vallejo J|Gonzalez M R|Gonzalez-Lizan F|Gosheger G|Goudie S|Goulding K|Goumenos S D|Griffin A|Gulia A|Gupta S|Gupta A|Guzman M|Haitham M|Hardes J|Hardoy F|Hasan Y|Hauer G|Havard H|Haydon R|Healey J|Hernandez Gonzalez N|Hernandez-Lopez A|Hesla A|Hess M|Hilton T|Hongsaprabhas C|Hornicek F|Hosking K|Houghton E|Idowu O K|Ippolito J|Isler M|Iwata S|Jagiello J|Jenkins N|Jeys T|Jeys C|Johnson L|Johnston A|Joo M W|Jutte P C|Kaldas K|Kamat A|Kannan S|Kapanci B|Khan Z|Kobayashi H|Kollender Y|Koob S|Kotrych D|Kyte R|Lamo de Espinosa Vazquez de Sola J M|Lazarides A L|Le Nail L|Legosz P|Lehner B|Leithner A|Lejoly M|Lewis V O|Lin P|Linares F|Lozano-Calderon S|Mahendra A|Mahyudin F|Mandia Mancebo F J|Martos Torrejon S|Marx C|Mascard E|Mattei J|McCullough L|McMahon S|Medellin Rincon M R|Miller B|Miwa S|Molina Uribe G|Moon B|Moriel Garcesco D J|Morris C|Morrison S|Mottard S|Moura M|Muster L|Nakayama R|Narhari P|Navas A|Nayak P|Neugebauer J|Newman E T|Nieminen J|Nyqvist E|Nystrom L|O'Reilly-Harbidge S|O'Toole G|Oliveira V|Olivier A|Omar M|Ortiz-Cruz E J|Ozger H|Ozkan K|Pala E|Palmerini E|Pang G|Papagelopoulos P|Paraliticci G|Parry M C|Patton S|Peake D|Peiro Ibanez A|Perez Munoz I|Perianayagam G R|Petersen M M|Ploegmakers J|Pollock R|Powell G|Pretell J|Puetzler J|Qamar F|Raja A|Rajasekaran R B|Ramkumar D B|Randall R L|Rankin K S|Raskin K A|Rassppan K|Repsa L|Ropars M|Rose P|Sadek W|Salcedo G|Saleemi A|Sambri A|Sar H|Scanferla R|Schubert T|Schwarze J|Scoccianti G|Scrimshire A|Sekita T|Shehadeh A|Shoaib A|Shreemal B|Shumelinsky F|Siegel G|Silveri C|Silverwood R|Sinnaeve F|Sison J|Slade A|Smolle M A|Snyman F|Sommerville S|Sood S|Spiguel A|St-Yves H|Staals E L|Stacchiotti S|Stavropoulos N|Steadman P|Stevenson J D|Sullivan M|Sys G|Szostakowski B|Tamburini A|Taniguchi Y|Temple T|Theil C|Thorkildsen J|Tibbo M|Tillman R|Toda Y|Tootsi K|Torner Rubies F|Traub F|Trikoupis I|Tsagkozis P|Tsoi K|Tsuchiya H|Vainio V|Valcarcel A|Valencia J|Van Beeck A|Van de Sande M|Van Den Berghe T|Van der Geest I|Van der Heijden L|Van der Wal R|Van Langevelde K|Vaz G|Velez Villa R|Verspoor F|Verstraete K|Visgauss J|Vyrva O|Wafa H|Walter S|Wan Ismail W F|Wang E|Wang P Q|Warnock D|Werier J|Weschenfelder W|Wong K|Woulthuyzen-Bakker M|Wunder J|Wysinghe I|Yamamoto N|Ye Z|Yoon S|Zainul Abidin S|Zamora T|Zecchetto P|Zhang L|Zumarraga J P,Houdek M T|Broida S E|Couch C|Goulding K|Rose P|Sullivan M|Tibbo M,"Royal Orthopaedic Hospital, Birmingham, UK.|Pontificia Universidad Catolica de Chile, Santiago, Chile.|Royal Prince Alfred Hospital, Sydney, Australia.|Orthopedic Surgery Department, Cairo University, Cairo, Egypt.|Mayo Clinic Department of Orthopaedic Surgery, Rochester, Minnesota, USA.|East Suffolk and Essex Orthopaedic Centre, Colchester Hospital University, Colchester, UK.|Homi Bhabha National Institute, Tata Memorial Hospital, Mumbai, India.|Department of Orthopedics and Orthopedic Oncology, University of Padova, Padova, Italy.|Department of Orthopedics and Traumatology, Helsinki University Central Hospital, Helsinki, Finland.|Hospital Marques de Valdecilla, Cantabria, Spain.|The Ottawa Hospital, Ottawa, Canada.|Clinica Somer, Clinica Vida, Clinica del Campestre, Medellin, Colombia.|Department of Orthopaedic Surgery, Aarhus University Hospital, Aarhus, Denmark.|Jordanian Medical Services, Amman, Jordan.|Hospital Del Nino Jesus Madrid, Madrid, Spain.|Orthopaedic Department, Cairo University, Cairo, Egypt.|Instituto Anatomopatologico 'Dr Jose A O'Daly Universidad Central de Venezuela/Laboratorio de Patología Marín, Stato Miranda, Venezuela.|Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.|Nanavati Max Superspeciality Hospital, Mumbai, India.|National Orthopaedic Centre of Excellence in Research & Learning (NOCERAL), Department of Orthopaedic Surgery, Faculty of Medicine, University Malaya, Kuala Lumpur, Malaysia.|Saitama Medical Center, Jichi Medical University, Saitama, Japan.|Hospital Italiano de Buenos Aires, Buenos Aires, Argentina.|The James Cancer Hospital, Columbus, Ohio, USA.|Universidad de Concepción, Concepcion, Chile.|Acibadem Maslak Hospital, Istanbul, Turkey.|Department of Orthopaedics, College of Medicine, King Saud University, Riyadh, Saudi Arabia.|Hospital La Fe Valencia, Valencia, Spain.|Boston Children's Hospital / Harvard Medical School, Boston, Massachusetts, USA.|University Hospital of Essen, Essen, Germany.|The Royal Children's Hospital, Melbourne, Victoria, Australia.|Royal National Orthopaedic Hospital, London, UK.|McGill University, Montreal, Canada.|Cruces University Hospital, Barakaldo, Spain.|Faculty of Medicine Siriraj Hospital, Bangkok, Thailand.|Royal National Orthopaedic Hospital, Stanmore, UK.|Hospital Universitario Cruces - Bizkaia, Bizkaia, Spain.|Aarhus University Hospital, Aarhus, Denmark.|Menoufia University, Menoufia, Egypt.|Musgrave Park Hospital, Belfast, UK.|The University of Chicago, Chicago, Illinois, USA.|Department of Medical Oncology, Hospital of Prato, Azienda USL Toscana Centro, Prato, Italy.|Maisonneuve-Rosemont Hospital, Université de Montréal, Montreal, Canada.|Istituto ortopedico Gaetano Pini, Milano, Italy.|Universitas Airlangga Surabaya Indonesia, Surabaya, Indonesia.|Karolinska University Hospital, Stockholm, Sweden.|Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.|University Medical Center Groningen, Groningen, Netherlands.|Rutgers New Jersey Medical School, Newark, New Jersey, USA.|RedSalud - Fundacion Arturo Lopez Perez, Santiago, Chile.|Sahlgren University Hospital, Gothenburg, Sweden.|University Hospital of Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|UCLA Department of Orthopaedic Surgery, Los Angeles, California, USA.|Moffitt Cancer Center, Tampa, Florida, USA.|Woodend Hospital Aberdeen, Aberdeen, UK.|Orthopaedic Oncology Unit, AOU Citta' della Salute e della Scienza, Torino, Italy.|Hospital del Nino Dr. Jose Esquivel, Panama, Panama.|Amsterdam University Medical Centre, Amsterdam, Netherlands.|Oxford Sarcoma Service, Oxford, UK.|Homo Bhabha Cancer Hospital & Reseacrh Centre, New Chandigarh, Tata Memorial Centre, New Chandigarh, India.|Leiden University Medical Center, Leiden, Netherlands.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Universitätsklinikum Münster Klinik für Allgemeine Orthopädie und Tumororthopädie, Münster, Germany.|Cleveland Clinic/Sarcoma Program, Cleveland, Ohio, USA.|Instituto Traumatologico Teodoro Gebauer/Clinica Alenama Universidad Del Desarrollo, Santiago, Chile.|Hospital Clinico Lozano Blesa, Zaragoza, Spain.|Hospital General Uniiversitario Gregorio Maranon, Madrid, Spain.|Ortopedia Oncologica e Ricostruttiva presso Azienda Ospedaliero-Universitaria Careggi, Florence, Italy.|Instituto Nacional de Traumatologia e Ortopedia, Rio De Janeiro, Brazil.|Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.|Hospital Oncológico Padre Machado, Caracas, Venezuela.|National Orthopaedic and Trauma Institute, Montevideo, Uruguay.|Centro Hospitalar Universitário de Coimbra, EP, Coimbra, Portugal.|Instituto Traumatologico Chile, Santiago, Chile.|Hospital Univ Clínico San Carlos, Madrid, Spain.|Musculoskeletal Infection Society, Salt Lake City, Utah, USA.|Virgen del Rocío University Hospital, Sevilla, Spain.|National University Hospital, Singapore, Singapore.|St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.|Department of Surgery, St Vincent's Hospital Melbourne, The University of Melbourne, Melbourne, Victoria, Australia.|Seoul St. Mary's Hospital/The Catholic University of Korea, Seoul, South Korea.|Pomeranian Medical University of Szczecin, Szczecin, Poland.|National Cancer Institute of Mexico, Mexico City, Mexico.|Mount Sinai Hospital MSK Oncology Unit, Toronto, Canada.|Hospital Metropolitano / Departamento de Ortopedia y Traumatología, Quito, Ecuador.|Pediatric Specialitis hospital / HEP, Caracas, Venezuela.|Robert Jones & Agnes Hunt, Oswestry, UK.|Hospital Universitario, Monterrey, Mexico.|Tel Aviv Medical Center, Tel Aviv, Israel.|University Hospital Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|Clinica Delgado, Lima, Peru.|Virgen de la Victoria - Málaga, Malaga, Spain.|Radboud University Medical Centre, Nijmegen, Netherlands.|Clínica Alemana, Santiago, Chile.|North Island Sarcoma Services, Auckland City Hospital, Auckland, New Zealand.|St. Vincents Hospital, Melbourne, Victoria, Australia.|Virginia Commonwealth University, Richmond, Virginia, USA.|IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.|Department of Orthopaedic Surgery and Traumatology, Ghent University Hospital, Ghent, Belgium.|Mediclinic Sandton, Johannesburg, South Africa.|University Hospital Coventry and Warwickshire, Coventry, UK.|Las Higueras Hosp, Concepcion, Chile.|Turku University Hospital, Turku, Finland.|Childrens Cancer Hospital, Cairo, Egypt.|Kyushu University, Fukuoka, Japan.|Acibadem Hospital Group, Complex Extremity Recon. Unit, Istanbul, Turkey.|Cliniques Universitaires Saint-Luc, CUSL, Brussels, Belgium.|Duke University, Durham, North Carolina, USA.|Infective Diseases Unit, Careggi University Hospital, Florence, Italy.|University of Porto, Porto, Portugal.|Dupuytren Teaching Hospital, Limoges, France.|Ortopedia y Traumatología HCVB, Pisa, Italy.|Centro Hospitalar Universitário de Coimbra, EPE, Coimbra, Portugal.|Sarcoma Service, LUKS University Hospital, Luzern, Switzerland.|Okayama University Hospital, Okayama, Japan.|Medical University of Vienna, Vienna, Austria.|Hospital Universitario Austral / Orthopedic Oncology Unit, Buenos Aires, Argentina.|Newcastle University, Newcastle, UK.|Hospital Marqués de Valdecilla, Cantabria, Spain.|Klinik Volmarstein, Volmarstein, Germany.|University of Maryland and McMaster University, Baltimore/Hamilton, USA/Canada.|Newcastle Hospitals NHS Foundation Trust, Newcastle, UK.|Oxford University Hospital, Oxford, UK.|Insitut Universitaire du Cancer de Toulouse, Toulouse, France.|Instituto Nacional de Cancerología, Bogotá, Colombia.|Massachusetts General Hospital, Boston, Massachusetts, USA.|Hospital Del Ramon Y Madrid, Madrid, Spain.|Royal Infirmary Edinburgh, Edinburgh, UK.|Department of Orthopedic Surgery, Mayo Clinic, Phoenix, Arizona, USA.|First Department of Orthopaedic Surgery, Attikon University General Hospital, National and Kapodistrian University of Athens, Athens, Greece.|Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh, Tata Memorial centre, New Chandigarh, Punjab, India.|Glasgow Royal Infirmary, Glasgow, UK.|Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.|Al Warith Cancer Institute, Baghdad, Iraq.|Department of tumor orthopedics, University of Essen, Essen, Germany.|Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria.|Memorial Sloan Kettering Cancer Center, New York, New York, USA.|Tec Salud, Monterrey, Mexico.|University of Alabama, Birmingham, USA.|Groote Schuur Hospital, Cape Town, South Africa.|Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.|University of Miami, Miami, Florida, USA.|Fremantle Hospital, Fremantle, Western Australia, Australia.|National Orthopaedic Hospital, Lagos, Nigeria.|National Cancer Center Hospital Japan, Tokyo, Japan.|South Australian Bone & Soft Tissue Tumour Unit, Flinders Medical Centre, Adelaide, South Australia, Australia.|University of Liverpool, Liverpool, UK.|University of Bristol, Bristol, UK.|Orthopaedic Surgery, University Medical Center Groningen, Groningen, Netherlands.|North-Estonian Regional Hospital, Tallinn, Estonia.|Institut Jules Bordet, Brussels, Belgium.|Rehman Medical Institute and Medical College, Peshawar, Pakistan.|The University of Tokyo Hospital, Tokyo, Japan.|Barzelai Medical Center, Ashkelon, Israel.|University of Bonn, Bonn, Germany.|Johannesburg Hospital, Johannesburg, South Africa.|Clínica Universitaria de Navarra - Navarra, Navarra, Spain.|University Hospital of Tours, Tours, France.|Infant Jesus Teaching Hospital, Medical University of Warsaw, Warsaw, Poland.|Orthopedic University Hospital Heidelberg, Heidelberg, Germany.|Department of Radiology and Medical Imaging, Ghent University Hospital, Ghent, Belgium.|MD Anderson Cancer Center, Houston, Texas, USA.|The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, China.|Pontificia Universidad Javeriana, Bogota, Colombia.|Airlangga University, Surbaya, Indonesia.|Complexo Hospitalario Universitario de Santiago de Compostela, Santiago de Compostela, Spain.|Fundacion Hospital de Alcorcon, Madrid, Spain.|Hospital Necker, Gustave Roussy Institute, Paris, France.|Aphm Aix Marseille Université & Hôpital Européen Marseille, Marseille, France.|NHS Grampian, Aberdeen, UK.|Fundación CTIC Luis Carlos Sarmiento Angulo / Sarcoma Unit, Bogota, Colombia.|University of Iowa, Iowa City, Iowa, USA.|Kanazawa University, Kanazawa, Japan.|AUNA - The Americas / HPTU., Mendellin, Colombia.|Hospital Regional Universitario de Malaga, Malaga, Spain.|Federal University of Parana, Curitiba, Parana, Brazil.|South Australian Bone & Soft Tissue Tumour Unit, Flinders Medical Centre, Adelaine, South Australia, Australia.|Keio University School of Medicine, Tokyo, Japan.|Orthopaedic Oncology Unit Penang General Hospital, George Town, Malaysia.|Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India.|University of Krems, Dept. of Orthopaedics and Traumatology, Krems, Austria.|Coxa Hospital for Joint Replacement, Tampere, Finland.|Cleveland Clinic, Cleveland, Ohio, USA.|St Vincent's Hospital, Melbourne, Victoria, Australia.|St. Vincent's University Hospital Dublin, Dublin, Ireland.|Centro Hospitalar Universitário de Santo António, Porto, Portugal.|Vergelegen Mediclinic, Cape Twon, South Africa.|Hannover Medical School, Hannover, Germany.|Hospital Universitario La Paz, Madrid, Spain.|Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.|Istanbul Medeniyet University, Istanbul, Turkey.|University of Padova, Padova, Italy.|Miami Cancer Institute, Miami, Florida, USA.|Hospital Sant Pau, Barcelona, Spain.|Hospital Ramón Y Cajal, Madrid, Spain.|Doncaster and Bassetlaw NHS Trust, Doncaster, UK.|Rigshospitalet/University of Copenhagen/ Department of Orthopedics, Copenhagen, Denmark.|Newcastle University, Newcastle Upon Tyne, UK.|Evercare Hospital, Lahore, Pakistan.|Cancer Institute (WIA), Chennai, India.|Ganga Medical Centre & Hospitals, Coimbatore, India.|Lahey Clinic, Burlington, Massachusetts, USA.|University of California, Davis, Sacramento, California, CA.|Northumbria Healthcare NHS Foundation Trust, Newcastle Upon Tyne, UK.|Hospital of Traumatology and Orthopaedic Latvia, Riga, Latvia.|Rennes University Hospital, Rennes, France.|Clinica Sebastian De Belalcazar Cali Colombia, Cali, Colombia.|Walsall Healthcare NHS Trust, Walsall, UK.|IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, Italy.|Department of Orthopedics Oncology and Reconstructive Surgery, University Hospital Careggi, Florence, Italy.|Cliniques Universitaires Saint-Luc, Brussels, Belgium.|Orthopaedic Oncology, Careggi University Hospital, Florence, Italy.|King Hussein Cancer Center/Orthopedic Unit, Amman, Jordan.|Saleem Memorial Hospital, Lahore, Pakistan.|Michigan Medicine / University of Michigan, Ann Arbor, Michigan, USA.|Inot oncólogy orthopaedic, Montevideo, Uruguay.|University Hospitals Leuven, Leuven, Belgium.|Johannesburg Surgical Hospital, Johannesburg, South Africa.|The Wesley Hospital, Brisbane, Queensland, Australia.|Homi Bhabha Cancer Hospital & Research Centre, New Chandigarh, Tata Memorial centre, New Chandigarh Punjab, India.|University of Florida, Gainesville, Florida, USA.|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.|First Department of Orthopaedic Surgery 'ATTIKON' University General Hospital, Athens, Greece.|Princess Alexandra Hospital, Brisbane, Australia.|The Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.|Department of Paediatric Haematology-Oncology AOU ""Anna Meyer"" IRCCS, Florence, Italy.|Medical and Health Services, Vestreviken Hospital Trust, Division of Orthopaedic Oncology, Oslo University Hospital, Oslo, Norway.|Mayo Clinic Orthopedics, Phoenix, Arizona, USA.|Department of Orthopaedics, Tartu University Hospital, University of Tartu, Tartu, Estonia.|Hospital Sant Joan de Deu, Barcelona, Spain.|University Medical Center of the Johannes Gutenberg University Mainz, Mainz, Germany.|Tamepere University Hospital, Tampere, Finland.|Hospital Univ. Virgen de la Arrixaca, Murcia, Spain.|Centro Oncológico Antioquia, Antioquia, Colombia.|UZA Orthopaedic Oncology and Traumatology, Antwerp, Belgium.|Leiden University Medical Centre, Leiden, Netherlands.|Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.|Centre Léon Berard, Lyon, France.|Hospital Universitari Vall D'Hebrón - Barcelona, Barcelona, Spain.|Amsterdam University Medical Centers, Amsterdam, Netherlands.|Department of Radiology and Medical Imaging, Ghent University Hospital, Department of Diagnostic Sciences, Ghent University, Ghent, Belgium.|Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine.|Leuven University Hospitals, Leuven, Belgium.|University Hospital Cologne, Cologne, Germany.|Universiti Sains Malaysia, Penang, Malaysia.|University of the Philippines, Philippine General Hospital, Manila, Philippines.|University Hospital Jena, Jena, Germany.|Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China.|Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.|Department of Orthopaedics, University Medical Center Groningen, Groningen, Netherlands.|Singapore General Hospital, Singapore, Singapore.|Pontificia Universidad Católica de Chile, Santiago, Chile.|McMaster University - Juravinski Cancer Centre, Hamilton, Canada.","Jeys L, Botello E, Boyle R A, Ebeid W, Houdek M T, Kurisunkal V J, Morgan-Jones R, Morris G V, Puri A, Ruggieri P, Laitinen M K, Abad Repiso S, Abdelbary H, Abiad Mejia A, Abood A A, Zumarraga J P, et al.",https://pubmed.ncbi.nlm.nih.gov/41319695/,"The key finding of this medical research is that a group of experts reached consensus on several important topics related to periprosthetic infection in orthopaedic oncology, such as the effectiveness of short-duration antibiotic prophylaxis, the management of leaking wounds, and the validity of different revision strategies. This consensus provides valuable guidance for healthcare professionals in the treatment of these complex infections, although the researchers also highlighted the need for more high-quality evidence in this area."
40633895,"Leveraging a randomized trial to assess relationships between transeptal puncture, brain emboli, and migraine symptoms.","Catheter ablation procedures with transseptal punctures (usually for atrial fibrillation) are often associated with migraine-related visual auras, but the mechanism remains unknown. Whether this phenomenon is mediated by the creation of an atrial septal defect from transseptal puncture or by silent acute brain emboli detected on magnetic resonance imaging related to the procedure remains to be investigated.This study aimed to evaluate whether randomization to a transseptal puncture during catheter ablation for ventricular arrhythmias is associated with postprocedural visual auras and assess the relationship between occipital and parietal lobes acute brain emboli and migraine-related visual auras.In the Transseptal Versus Retrograde Aortic Ventricular Entry to Reduce Systemic Emboli trial, patients undergoing catheter ablation for ventricular arrhythmias were randomized to ventricular access via transseptal puncture vs a retrograde aortic approach. All had brain magnetic resonance imaging the day after their procedure and underwent a validated migraine assessment at 1 month.No differences in postablation visual auras were observed between transseptal (16% of 63) and retrograde aortic approaches (14% of 57; P = .78). However, more participants with acute brain emboli in the occipital or parietal lobes experienced migraine-related visual auras (38% vs 11%; P < .01). After multivariable adjustment, the presence of acute brain emboli was associated with 12-fold greater odds of visual auras.Transseptal puncture was not associated with visual auras; however, acute brain emboli involving the visual cortex were associated with such symptoms. These data suggest that transseptal puncture is not causal in migraine-related visual auras and that postprocedure acute brain emboli are apparently not always clinically silent.Copyright © 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.",Heart rhythm,"Dec, 2025",2025,Dec,,Elias A|Tung R|Gerstenfeld E P|Hue T F|Lin F|Cheng J|Weiss J P|Tzou W S|Hsia H|Ehdaie A|Cooper D H|Bunch T J|Arkles J|Nazer B|Lee A|Hadjis A|Nguyen D T|Chelu M G|Moss J D|Hsu J C|Valderrábano M|Bhave P D|Montenegro G|Kim A S|Dillon W P|Marcus G M,Nguyen D T,"Division of Cardiology, University of California, San Francisco, San Francisco, California.|Division of Cardiology, University of Arizona College of Medicine - Phoenix, Phoenix, Arizona, and Banner - University Medical Center Phoenix, Phoenix, Arizona.|Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, California.|Oral Epidemiology & Dental Public Health, University of California, San Francisco, San Francisco, California.|Division of Cardiology, University of Colorado Anschutz Medical Center, Aurora, Colorado.|Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California.|Division of Cardiovascular, Washington University School of Medicine, St. Louis, Missouri.|Division of Cardiovascular Medicine, University of Utah, Salt Lake City, Utah.|Division of Cardiovascular, University of Pennsylvania, Philadelphia, Pennsylvania.|Division of Cardiology, University of Washington, Seattle, Washington.|Division of Cardiology, Hôpital du Sacré-Coeur de Montréal, University of Montreal, Montreal, Quebec, Canada.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Medicine - Cardiology, Cardiovascular Research Institute, Baylor College of Medicine and Texas Heart Institute at Baylor St. Luke's Medical Center, Houston, Texas.|Division of Cardiology, University of California, San Diego, San Diego, California.|Department of Cardiology, Houston Methodist Hospital, Houston, Texas.|Department of Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina.|Department of Neurology, University of California, San Francisco, San Francisco, California.|Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.|Division of Cardiology, University of California, San Francisco, San Francisco, California. Electronic address: greg.marcus@ucsf.edu.","Elias A, Tung R, Gerstenfeld E P, Hue T F, Lin F, Cheng J, Weiss J P, Tzou W S, Hsia H, Ehdaie A, Cooper D H, Bunch T J, Arkles J, Nazer B, Lee A, Marcus G M, et al.",https://pubmed.ncbi.nlm.nih.gov/40633895/,"The key finding of this study is that acute brain emboli, rather than the transseptal puncture procedure itself, are associated with migraine-related visual auras in patients undergoing catheter ablation. This suggests that brain emboli during these procedures may not always be clinically silent, and highlights the importance of monitoring for and preventing such embolic events."
40768371,Characterizing primary mediastinal large B-cell lymphoma based on molecular classification: a multi-center retrospective pilot study.,No abstract available.,Leukemia & lymphoma,"Dec, 2025",2025,Dec,,Superdock M A|Rimsza L M|Wallace D S|Strawderman M|Ramsower C A|Steiner R E|Faugh T|Maurer M J|Link B K|Rosenthal A C|Burack W R|Syrbu S I|Feldman A L|Rock P J|Robetorye R S|Cerhan J R|Flowers C R|Friedberg J W|Casulo C,Wallace D S|Strawderman M|Faugh T|Maurer M J|Rosenthal A C|Burack W R|Feldman A L|Rock P J|Robetorye R S|Cerhan J R|Friedberg J W|Casulo C,"Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.|Department of Pathology and Laboratory Medicine, The University of Arizona, Tucson, AZ, USA.|Department of Medicine, Division of Hematology and Oncology, University of Rochester Medical Center James P. Wilmot Cancer Institute, Rochester, NY, USA.|Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, NY, USA.|Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Internal Medicine, Division of Hematology, Oncology, and Bone & Marrow Transplantation, University of Iowa, Iowa City, IA, USA.|Department of Internal Medicine, Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ, USA.|Department of Pathology and Laboratory Medicine, University of Rochester Medical Center, Rochester, NY, USA.|Department of Pathology, University of Iowa, Iowa City, IA, USA.|Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine & Pathology, Mayo Clinic, Phoenix, AZ, USA.","Superdock M A, Rimsza L M, Wallace D S, Strawderman M, Ramsower C A, Steiner R E, Faugh T, Maurer M J, Link B K, Rosenthal A C, Burack W R, Syrbu S I, Feldman A L, Rock P J, Robetorye R S, Casulo C, et al.",https://pubmed.ncbi.nlm.nih.gov/40768371/,"This research likely explores the different types or subtypes of a specific type of lymphoma called primary mediastinal large B-cell lymphoma. The researchers may have used various molecular techniques to classify and understand the different characteristics of this type of lymphoma, which could help improve diagnosis and treatment."
40779661,"Perioperative Antimicrobial Strategies in Inflatable Penile Prosthesis Surgery: Associations Between Antifungals, Oral Antibiotics, and Intravenous Antibiotic Duration, and Infection Outcomes.","This study aims to evaluate the association between antimicrobial practices, including oral antibiotics, IV antibiotics, and antifungal prophylaxis, and infection outcomes in patients undergoing primary or revision inflatable penile prosthesis surgery.We conducted a multicenter, retrospective cohort study of 5261 patients who underwent primary or revision inflatable penile prosthesis surgery at 16 specialized centers across the United States, Europe, and Korea from July 2016 to July 2021. Patient data included demographic and clinical characteristics, antibiotic and antifungal administration, and infection outcomes. The primary outcome was infection after inflatable penile prosthesis placement. Univariable and multivariable regression analyses were performed to identify predictors of infection.The overall infection rate was 1.9% (n = 102), with higher rates among diabetic patients (P = .023), those with prior inflatable penile prosthesis infection (P < .001), or undergoing revision surgery (P < .001). Multivariable analysis identified diabetes (odds ratio [OR] = 1.68, P = .022) and previous inflatable penile prosthesis infection (OR = 4.67, P < .001) as independent risk factors for infection. Perioperative IV antifungal use was significantly associated with a lower infection risk (OR = 0.22, P < .001), whereas postoperative oral antibiotics (P = .5) and prolonged IV antibiotic prophylaxis (>24 hours; P = .2) did not demonstrate protective effects. Preoperative and postoperative oral antibiotics were not associated with a statistically significant reduction in infection after adjustment for confounding variables.This large multicenter study highlights a significant association between perioperative antifungal prophylaxis and lower infection risk in inflatable penile prosthesis surgery while demonstrating the limited utility of preoperative and postoperative oral antibiotics and prolonged IV prophylaxis. These findings support evidence-based antimicrobial stewardship to optimize outcomes and minimize complications, including antibiotic resistance.",The Journal of urology,"Dec, 2025",2025,Dec,,Abou Chawareb E|Hammad M A M|Azad B|Gross M S|Payne B|Swerdloff D|Miller J A|Andrianne R|Burnett A L|Gross K|Hatzichristodoulou G|Hotaling J M|Hsieh T|Jones J M|Lentz A|Modgil V|Osmonov D|Park S H|Pearce I|Perito P|Sadeghi-Nejad H|Sempels M|Suarez-Sarmiento A|Simhan J|van Renterghem K|Warner J N|Ziegelmann M|Yafi F A|Barham D W,Warner J N|Ziegelmann M,"Department of Urology, University of California, Irvine, Irvine, California.|Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana.|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.|Brooke Army Medical Center, Fort Sam Houston, Texas.|Fox Chase Cancer Center, Philadelphia, Pennsylvania.|University Hospital of Liège, Liège, Belgium.|Department of Urology, Johns Hopkins University, Baltimore, Maryland.|Department of Surgery, University of Utah, Salt Lake City, Utah.|Martha-Maria Hospital Nuremberg, Nuremberg, Germany.|University of Utah Medical School, Salt Lake City, Utah.|Department of Urology, University of California, San Diego, San Diego, California.|Department of Urology, Duke University, Durham, North Carolina.|Manchester University NHS Foundation Trust, Manchester, United Kingdom.|University Hospital Schleswig-Holstein, Lübeck, Germany.|Sewum Prosthetic Urology, Seoul, Republic of Korea.|Perito Urology, Coral Gables, Florida.|Department of Urology, New York University, New York, New York.|Jessa Hospital, Hasselt, Belgium.|Mayo Clinic, Rochester, Minnesota.","Abou Chawareb E, Hammad M A M, Azad B, Gross M S, Payne B, Swerdloff D, Miller J A, Andrianne R, Burnett A L, Gross K, Hatzichristodoulou G, Hotaling J M, Hsieh T, Jones J M, Lentz A, Barham D W, et al.",https://pubmed.ncbi.nlm.nih.gov/40779661/,"This study found that using antifungal medications during inflatable penile prosthesis surgery was associated with a lower risk of infection, while oral antibiotics and prolonged intravenous antibiotics did not provide additional benefits. These findings suggest that targeted antimicrobial strategies, including the use of antifungals, can help improve outcomes and reduce complications in this type of surgery."
40780562,Donor-derived cell-free DNA significantly improves rejection yield in kidney transplant biopsies.,"Donor-derived cell-free DNA (dd-cfDNA) is a biomarker that enables the early detection of immune-mediated graft injury. This study evaluated the clinical utility of dd-cfDNA in predicting the presence of biopsy-proven rejection (BPAR). We analyzed 1070 biopsies from 1743 kidney transplant recipients enrolled in the prospective, multicenter Kidney Allograft Outcomes AlloSure Registry. Biopsies were grouped into surveillance or for-cause groups and stratified by dd-cfDNA status: elevated, nonelevated, or not tested. Rejection yield was significantly higher when dd-cfDNA was elevated: 39% vs 7% in the surveillance group and 47% vs 12% in the for-cause group (P < .0001). Biopsies with elevated dd-cfDNA and rejection diagnoses more frequently demonstrated antibody-mediated rejection and mixed rejection, whereas biopsies performed with nonelevated dd-cfDNA most often showed no rejection, borderline, or T cell-mediated rejection 1A. The area under the receiving operating characteristic curve for BPAR detection was 0.789. These findings demonstrate that dd-cfDNA levels can improve the pretest probability of BPAR in both surveillance and for-cause settings. Therefore, dd-cfDNA can optimize biopsy utilization by identifying kidney transplant patients who are most likely to have histologic rejection.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.",Am J Transplant,"Dec, 2025",2025,Dec,,Bromberg J S|Brennan D C|Taber D J|Cooper M|Anand S|Akalin E|Huang E|Klein J A|Glehn-Ponsirenas R|Rogers J|Chuang P|Kothari A S|Shen L|Woodward R N|Kumar D|Wojciechowski D|Mandelbrot D|Costa N|Bu L|Weir M R,Bu L,"Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA. Electronic address: jbromberg@som.umaryland.edu.|Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, USA.|Division of Transplant Surgery, Department of Surgery, Medical University of South Carolina, Charleston, South Carolina, USA.|Department of Surgery, Division of Transplant Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Abdominal Transplant Service, InterMountain Medical Center, Murray, Utah, USA.|Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.|Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, California, USA.|Department of Internal Medicine, Division of Nephrology and Hypertension, University Of Kansas Medical Center, Kansas City, Kansas, USA.|Research and Development, CareDx Inc, Brisbane, California, USA.|Department of Internal Medicine, Division of Nephrology, Virginia Commonwealth University, Richmond, Virginia, USA.|Division of Nephrology, University of Texas Southwestern, Dallas, Texas, USA.|Division of Nephrology, Department of Medicine, School of Medicine and Public Health, University of Wisconsin Medical Center, Madison, Wisconsin, USA.|Department of Medicine, Division of Nephrology, Georgetown University Medical Center, Washington, DC, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Nephrology, Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.","Bromberg J S, Brennan D C, Taber D J, Cooper M, Anand S, Akalin E, Huang E, Klein J A, Glehn-Ponsirenas R, Rogers J, Chuang P, Kothari A S, Shen L, Woodward R N, Kumar D, Weir M R, et al.",https://pubmed.ncbi.nlm.nih.gov/40780562/,"The key finding of this medical research is that measuring donor-derived cell-free DNA (dd-cfDNA) can significantly improve the detection of rejection in kidney transplant biopsies. Elevated dd-cfDNA levels were associated with a higher likelihood of finding biopsy-proven rejection, which can help doctors identify patients who are most likely to have rejection and optimize the use of biopsies."
40781877,Severe hypertriglyceridemia associated with calaspargase pegol.,"Calaspargase pegol is currently the only pegylated asparaginase product accessible to children, adolescents, and young adults aged 1 month to 21.5 years in the United States. Despite a growing recognition of its real-world toxicity profile, hypertriglyceridemia has not yet been described in depth with calaspargase pegol. Herein we describe our clinical observations of six patients who experienced significant hypertriglyceridemia following exposure to calaspargase pegol, warranting intensive care in several cases. Potential confounding risk factors and management strategies of this presumed toxicity are explored.",Leukemia & lymphoma,"Dec, 2025",2025,Dec,,Kuhn A K|O'Keefe M|Kohorst M|Kalmes J|Galardy P|Walter A|Guggenberger J|Salama M|Pittock S|Martin C,Kuhn A K|O'Keefe M|Kohorst M|Kalmes J|Galardy P|Walter A|Guggenberger J|Salama M|Pittock S|Martin C,"Department of Pharmacy, Rochester, MN, USA.|Division of Pediatric Hematology/Oncology, Rochester, MN, USA.|Division of Pediatric Endocrinology, Mayo Clinic, Rochester, MN, USA.","Kuhn A K, O'Keefe M, Kohorst M, Kalmes J, Galardy P, Walter A, Guggenberger J, Salama M, Pittock S, Martin C",https://pubmed.ncbi.nlm.nih.gov/40781877/,"The study found that the cancer drug calaspargase pegol can cause severe hypertriglyceridemia (high triglyceride levels) in some patients, which can require intensive medical care. This side effect has not been widely reported before, and the study explores potential risk factors and ways to manage this issue."
40789362,Delphi-Based Global Consensus on Fuchs Endothelial Corneal Dystrophy. An Endothelial Keratoplasty Learners Group Initiative.,"To identify areas of consensus among global experts for the management of Fuchs endothelial corneal dystrophy (FECD) in clinical practice, including its diagnosis, evaluation, decision-making principles with respect to intervention, and recommendations for performing cataract surgery in patients with FECD, including when to combine with keratoplasty.Modified Delphi-based global consensus.Thirty-seven ophthalmologists from around the world with significant expertise in the management and mechanisms of FECD.A series of consensus statements about FECD were developed from three iterative rounds of structured questions and statements posed to the panel of experts. Two rounds were asynchronous electronic questionnaires, and the third round was a live virtual meeting. Experts responded anonymously to statements assessing consensus and to open-ended questions that invited diverse input.Consensus was defined as 70% agreement among experts.Consensus was reached for 90 of 91 statements after three rounds. Experts agreed that FECD is defined by the presence of central or paracentral scattered or confluent guttae with or without edema. There was strong consensus that a chronic state of subclinical edema precedes the onset of clinically detectable edema that may or may not cause symptoms. With near-unanimous consensus, disease evaluation recommendations included assessing for findings that implicate the cornea as a source of decreased vision to separate it from the effect of comorbid conditions, as this would inform whether corneal intervention is appropriate. These findings include diurnal variation in vision, clinical or subclinical (tomographic) edema, and changes or differences in central corneal thickness. Based on current evidence, experts agreed that there are no effective medical therapies for FECD, and that Descemet membrane endothelial keratoplasty is the surgical treatment of choice when indicated.The consensus statements provide current globally endorsed recommendations for the diagnosis and management of FECD. The guidelines are important and relevant for general ophthalmologists, who typically first diagnose and evaluate FECD, and for cornea specialists, by allowing them to benchmark their current practice patterns against expert recommendations. This could help improve patient outcomes and establish a framework adaptable to future advances and evolving technologies in the management of FECD.Copyright © 2025 Elsevier Inc. All rights reserved.",American journal of ophthalmology,"Dec, 2025",2025,Dec,,Patel S V|Gupta N|Bhogal M|Jurkunas U V|Okumura N|Romano V|Allan B D|Baratz K H|Basak S K|Baydoun L|Chamberlain W|Chaurasia S|Colby K|Cursiefen C|Giobellina T|Greiner M A|Hjortdal J|Kobayashi A|Kocaba V|Koo E H|Lee W B|Livny E|Males J J|Matthaei M|Mehta J S|Mejia L|Moloney G|Mootha V V|Muraine M|Oie Y|Pereira N C|Price F W|Srikumaran D|Terry M A|Veldman P B|Verdier D D|Vaddavalli P K|Pineda R,Patel S V|Baratz K H,"From the Department of Ophthalmology (S.V.P., K.H.B.), Mayo Clinic, Rochester, MN, USA. Electronic address: patel.sanjay@mayo.edu.|Cornea Department, Dr. Shroffs Charity Eye Hospital (N.G.), New Delhi, India; Singapore Eye Research Institute (N.G., V.K., J.S.M.), Singapore.|Department of Ophthalmology, St. Thomas' Hospital (M.B.), London, UK.|Department of Ophthalmology, Massachusetts Eye and Ear (U.V.J., R.P.), Harvard Medical School, Boston, MA, USA.|Department of Biomedical Engineering, Faculty of Life and Medical Sciences (N.O.), Doshisha University, Kyoto, Japan.|Department of Medical and Surgical Specialties, Eye Unit, Radiological Sciences, and Public Health (V.R.), University of Brescia, Brescia, Italy.|Cornea Service, Moorfields Eye Hospital (B.D.A.), London, UK.|From the Department of Ophthalmology (S.V.P., K.H.B.), Mayo Clinic, Rochester, MN, USA.|Cornea & External Diseases, Disha Eye Hospitals (S.K.B.), Kolkata, India.|ELZA Institute Dietikon/Zurich (L.B.), Switzerland.|The Casey Eye Institute (W.C.), Oregon Health & Science University, Portland, OR, USA.|LV Prasad Eye Institute (S.C., P.K.V.), Hyderabad, India.|Department of Ophthalmology, NYU Grossman School of Medicine (K.C.), New York, NY, USA.|Department of Ophthalmology (C.C., M.M.), University of Cologne, Cologne, Germany.|Reyes-Giobellina Eye Clinic (T.G.), Córdoba, Argentina.|Department of Ophthalmology and Visual Sciences (M.A.G.), University of Iowa Carver College of Medicine, Iowa City, IA, USA.|Department of Ophthalmology, Aarhus University Hospital (J.H.), Aarhus, Denmark.|Department of Ophthalmology (A.K.), Kanazawa University Hospital, Kanazawa, Japan.|Singapore Eye Research Institute (N.G., V.K., J.S.M.), Singapore; Clinique de la Part-Dieu & Bellecour Vision Clinic (V.K.), Lyon, France.|Department of Ophthalmology (E.H.K.), Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL, USA.|Eye Consultants of Atlanta (W.B.L.), Atlanta, GA, USA.|Rabin Medical Center (E.L.), Petach Tikva, Israel; Department of Ophthalmology, Tel Aviv University (E.L.), Tel Aviv, Israel.|Save Sight Institute, University of Sydney (J.J.M., G.M.), Sydney, Australia.|Singapore Eye Research Institute (N.G., V.K., J.S.M.), Singapore; Singapore National Eye Centre (J.S.M.), Singapore.|Clínica COM (L.M.), Medellín, Colombia.|Save Sight Institute, University of Sydney (J.J.M., G.M.), Sydney, Australia; Department of Ophthalmology, University of British Columbia (G.M.), Vancouver, Canada.|Department of Ophthalmology, University of Texas Southwestern Medical Center (V.V.M.), Dallas, TX, USA.|Charles Nicolle Hospital (M.M.), Rouen University Hospital, Rouen, France.|Department of Ophthalmology (Y.O.), University of Osaka Graduate School of Medicine.|Sorocaba Eye Hospital (N.C.P.), Soracaba, Brazil.|Price Vision Group (F.W.P.), Indianapolis, IN, USA.|Wilmer Eye Institute, Johns Hopkins University (D.S.), Baltimore, MD, USA.|Legacy Devers Eye Institute (M.A.T.), Portland, OR, USA.|Department of Ophthalmology and Visual Science (P.B.V.), University of Chicago, Chicago, IL, USA.|Grand Rapids (D.D.V.), Verdier Eye Center, MI, USA.","Patel S V, Gupta N, Bhogal M, Jurkunas U V, Okumura N, Romano V, Allan B D, Baratz K H, Basak S K, Baydoun L, Chamberlain W, Chaurasia S, Colby K, Cursiefen C, Giobellina T, Pineda R, et al.",https://pubmed.ncbi.nlm.nih.gov/40789362/,"The key finding of this medical research is that a global consensus was reached among experts on the diagnosis, evaluation, and management of Fuchs endothelial corneal dystrophy (FECD), a common eye condition. The experts agreed that Descemet membrane endothelial keratoplasty is the preferred surgical treatment when indicated, and that there are no effective medical therapies for FECD. This consensus provides a framework for improving patient outcomes and guiding future"
40810832,The Association of Clinical Stage at Presentation with Overall Survival of Patients who have HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.,"Pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) in human epidermal growth factor receptor 2-positive (HER2+) breast cancer is associated with improved survival. This study evaluated the association of disease extent at presentation and response to NAC with overall survival (OS) in HER2+ breast cancer.Patients with clinical stage I to III HER2+ breast cancer (2013-2020) who underwent NAC and received HER2-targeted therapy were identified from the National Cancer Database. Overall survival was assessed by clinical stage at presentation and chemotherapy response, stratified by hormone receptor (HR) status using multivariable Cox proportional hazards regression.The study included 57,671 patients. Among the patients with pCR, OS at 5 years was 98% for stage I, 97% for stage II, and 91% for stage III disease (p < 0.001). Among patients with residual disease, OS at 5 years was 95% for stage I, 91% for stage II, and 80% for stage III disease (p < 0.001). Multivariable analysis showed that stage III HR-/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 1.17; p = 0.34). Stage II HR+/HER2+ disease with pCR did not have OS different from stage I breast cancer with residual disease (hazard ratio, 0.94; p = 0.61), and stage III disease with pCR had worse OS (hazard ratio, 1.90; p < 0.001).Among the patients who had HER2+ breast cancer treated with NAC, the clinical stage at presentation was associated with OS for those with pCR and residual disease. Patients with stage III HER2+ breast cancer and those with stage II HR+/HER2+ breast cancer who achieve pCR could benefit from further studies that evaluate potential escalation of adjuvant therapies.© 2025. Society of Surgical Oncology.",Annals of surgical oncology,"Dec, 2025",2025,Dec,,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.|Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.Judy@mayo.edu.","Tashjian N L, Hoskin T L, Leon-Ferre R A, Boughey J C",https://pubmed.ncbi.nlm.nih.gov/40810832/,"This study found that in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy, the clinical stage at diagnosis was associated with overall survival, even for those who achieved a complete response to treatment. Patients with stage III HER2-positive disease or stage II hormone receptor-positive/HER2-positive disease who achieved a complete response had similar survival to patients with stage I disease who had residual disease, suggesting they may benefit from more intensive adjuv"
40816344,"Pitfalls of biopsy margin assessment: Response to ""Roland-McGowan JN et al. Development of a treatment decision aid for patients with dysplastic nevi who are candidates for re-excision."".",No abstract available.,Journal of the American Academy of Dermatology,"Dec, 2025",2025,Dec,,Peters M S|Agrawal S|Grant-Kels J M,Peters M S|Agrawal S,"Departments of Dermatology and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: peters.margot@mayo.edu.|Departments of Dermatology and Laboratory Medicine & Pathology, Mayo Clinic, Rochester, Minnesota.|Department of Dermatology, University of Connecticut Health Center, Farmington, Connecticut; Department of Dermatology, University of Florida, Gainesville, Florida.","Peters M S, Agrawal S, Grant-Kels J M",https://pubmed.ncbi.nlm.nih.gov/40816344/,This research likely explores the challenges and potential issues associated with accurately assessing the margins of a biopsy sample. It may discuss the limitations or difficulties in determining the appropriate treatment decisions for patients with dysplastic nevi (atypical moles) based on the biopsy margin assessment.
40818595,The effect of isotretinoin treatment for acne vulgaris on height in adolescents: A retrospective cohort study using the Rochester Epidemiology Project.,"Isotretinoin is the first-line treatment for severe acne, but its effects on adolescent growth remain unclear.To assess the effects of isotretinoin on final adult height and height velocity in adolescents treated for acne.This retrospective cohort study used the Rochester Epidemiology Project to identify patients diagnosed with acne between 2005 and 2021 who initiated isotretinoin or oral antibiotics before age 15. Height velocity was calculated using measurements taken within 1 year pre- and postmedication initiation, and final height was recorded at 18 years. Multivariable regression models adjusted for age and sex.Among 226 patients treated with isotretinoin and 1179 controls, final height did not differ significantly between groups (-0.67 cm; CI: -2.21 to 0.87). However, patients treated with isotretinoin had a lower postmedication initiation height velocity (-0.12 cm/month; CI: -0.21 to -0.04, P = .005) and a greater reduction in post- versus premedication initiation height velocity (-0.31 cm/month; CI: -0.54 to -0.07, P = .011). No significant dosage effects were observed.The study was limited by sample size, potential unmeasured confounders, and a predominantly non-Hispanic white population.While isotretinoin may reduce height velocity, it is not associated with negative effects on final adult height among adolescents treated for acne.Copyright © 2025 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.",Journal of the American Academy of Dermatology,"Dec, 2025",2025,Dec,,Xu K K|Aghazadeh N|Tebben P|Todd A|Tollefson M|Barbieri J S,Xu K K|Aghazadeh N|Tebben P|Todd A|Tollefson M,"Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Dermatology, Mayo Clinic, Rochester, Minnesota; Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota.|Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota; Division of Pediatric Endocrinology, Mayo Clinic, Rochester, Minnesota.|Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.|Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts. Electronic address: jbarbieri@bwh.harvard.edu.","Xu K K, Aghazadeh N, Tebben P, Todd A, Tollefson M, Barbieri J S",https://pubmed.ncbi.nlm.nih.gov/40818595/,"This study found that while isotretinoin, a common acne medication, may temporarily slow down growth rate in adolescents, it does not affect their final adult height. This is an important finding, as it suggests that the benefits of isotretinoin treatment for severe acne outweigh any potential impact on height."
40819148,Evaluating Variation in Lymph Node Sampling During Sentinel Lymph Node Biopsy for Melanoma.,"The operative standard for melanoma, implemented by the Commission on Cancer (CoC), addresses margin width and excision depth, but does not collect information on sentinel lymph node biopsy (SLNB). However, SLNB, an implemented technical standard in breast cancer, is also critical in the management of melanoma through its impact on nodal staging. This study aimed to characterize the current facility-level variation in nodal yield and nodal positivity to determine if there is an opportunity for improvement through standardization.Using the National Cancer Database, we identified patients with T1b-T4 melanoma of the trunk and upper extremities who underwent SLNB from 2018 to 2022. Reliability-adjusted estimates for nodal yield and nodal positivity were calculated using Poisson regression and logistic regression with random intercepts for hospitals.We identified 48,653 melanoma patients from 1167 facilities. SLNB median nodal yield was 2.4 (IQR 2.2-2.7), ranging from 1.4 to 7.0. SLNB median nodal positivity was 18.0% (IQR 17.1-19.5%), ranging from 11.6 to 40.5%. A weak correlation between nodal yield and nodal positivity was observed (Spearman correlation coefficient = 0.08, p = 0.009).Facility-level variation in nodal yield was minimal and weakly correlated with nodal positivity. This suggests that SLNB performed for melanoma of the trunk and upper extremities is well standardized across CoC hospitals in the absence of a defined operative standard. Future efforts to improve the quality of melanoma nodal surgery may be best focused on technical elements of other procedures, such as lymphadenectomy or more novel lymph node dissection approaches following neoadjuvant therapy.© 2025. The Author(s).",Annals of surgical oncology,"Dec, 2025",2025,Dec,,Taylor C D|Niba V S|Baskin A S|Mott N M|Kim E|Kappelman A|Wang T|Sinco B R|Francescatti A B|Boffa D J|Hendren S|Boughey J C|Hieken T J|Weigel R J|Hughes T M|Dossett L A,Boughey J C|Hieken T J,"Department of Surgery, Michigan Medicine, Ann Arbor, MI, USA.|Center for Health Outcomes and Policy, Michigan Medicine, Ann Arbor, MI, USA.|Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA.|National Clinician Scholars Program, University of Michigan, Ann Arbor, MI, USA.|Department of Surgery, University of California San Francisco, San Francisco, CA, USA.|Department of Surgery, University of Colorado, Aurora, CO, USA.|Veterans Affairs Center for Clinical Management Research, Ann Arbor, MI, USA.|University of Michigan Medical School, Ann Arbor, MI, USA.|Department of Surgery, Duke University, Durham, NC, USA.|American College of Surgeons Cancer Research Program, Chicago, IL, USA.|Department of Surgery, Section of Thoracic Surgery, Yale University School of Medicine, New Haven, CT, USA.|Department of Surgery, Indiana University, Indianapolis, IN, USA.|Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Surgery, University of Iowa, Iowa City, IA, USA.|Department of Surgery, Michigan Medicine, Ann Arbor, MI, USA. ldossett@umich.edu.|Center for Health Outcomes and Policy, Michigan Medicine, Ann Arbor, MI, USA. ldossett@umich.edu.|Institute for Healthcare Policy and Innovation, University of Michigan, Ann Arbor, MI, USA. ldossett@umich.edu.|American College of Surgeons Cancer Research Program, Chicago, IL, USA. ldossett@umich.edu.|Division of Surgical Oncology, University of Michigan, Ann Arbor, MI, USA. ldossett@umich.edu.","Taylor C D, Niba V S, Baskin A S, Mott N M, Kim E, Kappelman A, Wang T, Sinco B R, Francescatti A B, Boffa D J, Hendren S, Boughey J C, Hieken T J, Weigel R J, Hughes T M, Dossett L A",https://pubmed.ncbi.nlm.nih.gov/40819148/,"This study found that there is minimal variation in the number of lymph nodes removed during sentinel lymph node biopsy for melanoma across different hospitals, and this is weakly correlated with the rate of positive lymph nodes. This suggests that the procedure is well-standardized, and future efforts to improve the quality of melanoma treatment may be better focused on other surgical techniques rather than the sentinel lymph node biopsy itself."
40820933,Treg-specific IL-6R signaling: a novel role in the regulation of the intestinal epithelium.,"Mucosal homeostasis requires coordinated immune regulation and epithelial repair. Inflammatory bowel disease (IBD) arises from disrupted coordination between the immune system and intestinal epithelium, where resolution and repair must occur in parallel. Interleukin-6 (IL-6) plays a dual role: it promotes epithelial regeneration but destabilizes regulatory T cells (Tregs). We aimed to determine the contribution of Treg IL-6 receptor (IL-6R) signaling to intestinal inflammation and epithelial integrity. We developed a conditional knockout mouse model in which IL-6R was deleted from Tregs (Treg IL-6R knockout). These mice were subjected to dextran sodium sulfate (DSS)-induced colitis and a T cell transfer model of colitis. Soluble IL-6R production by Tregs was assessed in vitro, and transcriptional changes in epithelial cells were analyzed by RNA-seq. Human colonic organoids from patients with IBD were treated with IL-6 or hyper-IL-6 (IL-6/sIL-6R fusion protein) to test downstream signaling effects. Tregs lacking IL-6R improved colitis to a similar extent as control Tregs in the adoptive transfer model, indicating intact suppressive function. However, Treg IL-6R knockout mice were more susceptible to DSS colitis than controls, suggesting a physiologic role for Treg IL-6R signaling in epithelial protection. In vitro, Tregs shed soluble IL-6R, enabling IL-6 trans-signaling to epithelial cells. Intestinal epithelial cells from Treg IL-6R knockout mice compared with WTcre controls revealed widespread transcriptional downregulation of genes related to survival and repair pathways at baseline, and impaired transcriptional responses following DSS treatment. In human organoids, IL-6 trans-signaling elicited stronger STAT3 activation than IL-6 alone. These findings reveal a previously unrecognized role for Treg-derived IL-6R in promoting epithelial resilience and maintaining mucosal homeostasis.NEW & NOTEWORTHY This study reveals a novel role for Treg-derived IL-6R in supporting epithelial repair. Despite preserved immune-suppressive capacity, deletion of IL-6R from Tregs impairs epithelial transcription and worsens injury in colitis. We demonstrate that human intestinal organoids preferentially respond to trans- over classic IL-6 signaling. These findings introduce a Treg-specific role in immune-epithelial cross talk relevant to mucosal healing and inflammatory bowel disease.",American journal of physiology. Gastrointestinal and liver physiology,"Dec 01, 2025",2025,Dec,01,Klatt E E|Hamdan F H|Pérez I|Smith H M|Kossick K|Fedyshyn Y|Sagstetter M R|Chiang D|Chini L C S|Davidson H M|Westphal M S|Gades N M|Mopuri R|Sun Z|Bamidele W O|Druliner B R|Faubion W A,Klatt E E|Hamdan F H|Pérez I|Smith H M|Kossick K|Fedyshyn Y|Sagstetter M R|Chiang D|Chini L C S|Davidson H M|Westphal M S|Gades N M|Mopuri R|Sun Z|Bamidele W O|Druliner B R|Faubion W A,"Department of Immunology, Mayo Clinic, Rochester, Minnesota, United States.|Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota, United States.|Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, United States.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.|Department of Comparative Medicine, Mayo Clinic, Scottsdale, Arizona, United States.|Division of Computational Biology, Mayo Clinic, Rochester, Minnesota, United States.","Klatt E E, Hamdan F H, Pérez I, Smith H M, Kossick K, Fedyshyn Y, Sagstetter M R, Chiang D, Chini L C S, Davidson H M, Westphal M S, Gades N M, Mopuri R, Sun Z, Bamidele W O, Faubion W A, et al.",https://pubmed.ncbi.nlm.nih.gov/40820933/,"The key finding of this research is that regulatory T cells (Tregs) play a crucial role in maintaining intestinal epithelial integrity through their production of soluble IL-6 receptor, which enables IL-6 signaling to epithelial cells and promotes their survival and repair. This discovery has important implications for understanding and potentially treating inflammatory bowel diseases, where disruption of the coordination between the immune system and the intestinal epithelium is a central problem."
40823944,Injury epidemiology in young female American football athletes: a 10-year analysis using NEISS data.,"American football has traditionally been male-dominated, but female participation in youth football is increasing, especially with the rise of flag football. This study aimed to (1) describe the epidemiology of injured body parts and diagnoses in female youth football athletes, and (2) compare injury patterns between pre-high school (≤14 years) and high school (≥15 years) players.American football-related injury data were obtained from the National Electronic Injury Surveillance System (NEISS) from 2012-2021, representing U.S. emergency department visits. All participants were female and ≤18 years. Injuries were classified by body part and diagnosis, then compared between pre-high school and high school groups. Descriptive statistics summarized injury characteristics. Chi-square tests assessed group differences, with odds ratios (OR), 95% confidence intervals (CI), and p-values for significance. NEISS data lack detail on injury context, which may limit interpretation.A total of 3,348 injuries were identified: 2,342 in pre-high school and 1,006 in high school athletes. The most common injury sites for both groups were the upper extremity (pre-high school: 57.9%; high school: 43.1%), followed by the lower extremity (22.1% vs. 30.6%) and head/trunk (18.7% vs. 25.1%). Pre-high school athletes sustained proportionally more finger injuries (38.8% vs. 27.1%, p=0.001) and fractures (31.8% vs. 20.4%, p=0.001). High school athletes had higher proportions of head (20.5% vs. 14.1%), ankle (12.7% vs. 10.2%), and knee injuries (10.3% vs. 5.3%) (all p<0.05), as well as more sprains/strains (39.3% vs. 33.9%, p=0.003) and concussions (11.1% vs. 7.4%, p=0.001).Injury patterns differ by age among female youth football players. Pre-high school athletes more often sustain finger injuries and fractures, while high school athletes experience more head, ankle, and knee injuries, along with higher rates of sprains/strains and concussions. These differences may reflect variations in physiology and style of play, and findings may inform age-specific injury prevention strategies and guide future research on female football athletes.",The Physician and sportsmedicine,"Dec, 2025",2025,Dec,,Mikhail D|Sugimoto D|Schultz C|Radel L|Soma D|Ulman S|Jones J,Radel L|Soma D,"Department of Orthopedics, University Texas Southwestern Medical Center, Dallas, TX, USA.|Division of Sports Medicine, Boston Children's Hospital, Boston, MA, USA.|Division of Sports Medicine, The Micheli Center for Sports Injury Prevention, Waltham, MA, USA.|Department of Pediatric Orthopedics, Scottish Rite for Children, Dallas, TX, USA.|Department of Pediatrics, Mayo Clinic, Rochester, MN, USA.","Mikhail D, Sugimoto D, Schultz C, Radel L, Soma D, Ulman S, Jones J",https://pubmed.ncbi.nlm.nih.gov/40823944/,"This study analyzed 10 years of injury data for young female American football players. It found that pre-high school athletes more often sustained finger injuries and fractures, while high school athletes experienced more head, ankle, and knee injuries, as well as higher rates of sprains/strains and concussions. These differences may reflect variations in physiology and playing style, and could inform age-specific injury prevention strategies for female football players."
40828145,Post-Operative Bleed Risks Associated with Perioperative Nonsteroidal Anti-Inflammatory Drugs: A Narrative Review.,"Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used medications that function by inhibiting cyclooxygenase enzymes. Although they are highly effective in managing pain and inflammation, their potential for increasing bleeding risks continues to be a concern. Due to the increased risk for bleeding complications following surgical procedures, the safety of perioperative NSAIDs is debated. The primary objective of this article is to examine literature published in the past 10 years focused on post-operative bleeding risks associated with perioperative NSAID use. A systematic search was designed to include randomized controlled trials, systematic review meta-analyses, and retrospective or prospective reviews examining post-operative bleeding events associated with perioperative NSAID use in adults. Following the screening process and review, 11 articles were included. The reviewed literature primarily examines post-operative bleeding incidence, blood loss, hemoglobin decline, and the frequency of hematomas or hemorrhages. Overall, the evidence suggests that perioperative NSAIDs have minimal impact on post-operative bleeding risk. COX-2 selective NSAIDs may be a safer alternative to nonselective NSAIDs, with some studies indicating a lower risk of post-operative bleeding following their use. Ultimately, the decision to use NSAIDs in the perioperative period should be tailored to the specific surgical procedure and individual patient factors.",Journal of pain & palliative care pharmacotherapy,"Dec, 2025",2025,Dec,,Seitz L L|Juresic S|Siegel L R|Smith N T,Seitz L L|Juresic S|Siegel L R|Smith N T,"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pharmacy, Division of Pain Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pharmacy, Center for Palliative Care, Mayo Clinic, Rochester, Minnesota, USA.","Seitz L L, Juresic S, Siegel L R, Smith N T",https://pubmed.ncbi.nlm.nih.gov/40828145/,"This medical research examined the risk of post-operative bleeding associated with the use of nonsteroidal anti-inflammatory drugs (NSAIDs) during and around the time of surgery. The key finding is that perioperative NSAIDs have a minimal impact on the risk of post-operative bleeding, and COX-2 selective NSAIDs may be a safer alternative. The decision to use NSAIDs around the time of surgery should be based on the specific surgical"
40833824,Assessing Alignment of Referrals with Guidelines for the Treatment of Children with Obesity.,"It is unknown how many children with obesity are offered treatments aligned with clinical practice guidelines. This study examined electronic medical record data from a Midwest, USA, health system to quantify referrals to obesity treatment among patients 2-17 years old with obesity presenting for well-child visits in 2022 and/or 2023. Mixed-effects logistic regression models tested associations of referral placement with child characteristics, the Area Deprivation Index, and distance to specialty care. Of 14,893 patients, 591 (4.0%) received a referral. Referrals were associated with severe obesity (p < 0.001), older age (p < 0.001), proximity to specialty care (p < 0.001), number of well-visits (p ≤ 0.001), and identification with a minoritized race or ethnicity (p < 0.05-0.001). Findings indicate a large gap from the current state of referrals to alignment with practice guidelines for pediatric obesity. Furthermore, research needs to explore and address barriers to referrals and treatment access.",Childhood obesity (Print),"Dec, 2025",2025,Dec,,Biggs B K|Borkar S R|Standen E C|Kumar S|Menser T,Biggs B K|Borkar S R|Standen E C|Kumar S|Menser T,"Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, USA.|Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.|Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA.|Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Jacksonville, FL, USA.","Biggs B K, Borkar S R, Standen E C, Kumar S, Menser T",https://pubmed.ncbi.nlm.nih.gov/40833824/,"This study found that only 4% of children with obesity received referrals for treatment, despite clinical guidelines recommending comprehensive care. Referrals were more likely for children with severe obesity, older age, and living closer to specialty care, suggesting significant gaps in access to recommended obesity treatment for many children."
40834671,Comparison of anterior knee laxity measurements recorded by manual versus mechanical arthrometers in ACL reconstruction patients at return to sport.,"Arthrometers are devices used to evaluate knee laxity by quantifying anterior tibiofemoral displacement. The purpose of this study was to assess the congruence of tibiofemoral displacement measurements between manual and mechanical knee arthrometers in anterior cruciate ligament reconstructed (ACLR) patients.This investigation evaluated 44 limbs in 22 subjects who underwent ACLR. All subjects were cleared for return to sport prior to enrollment. Participants underwent manual and mechanical arthrometer assessments of anterior knee laxity in the same visit. Both involved and uninvolved limbs were assessed. The magnitude of raw knee laxity measurements between arthrometers, inter-device associations, and rank-order significance of limb measurements were assessed. The impact of different post-operative training protocols on device measurements was also evaluated.Mean tibiofemoral displacement measurements for involved and uninvolved limbs were comparable for the mechanical arthrometer at 134 N and manual arthrometer at 89 N (P = 0.33), however, mean displacement values varied significantly between the two arthrometers at 134 N (P < 0.01). Overall, significant associations between mechanical and manual arthrometer measurements were not observed. Rank order trended toward lower difference when comparing Side and Device (P > 0.06). Consilience between mechanical and manual arthrometers was not observed in this investigation.Multi-center studies or literature syntheses that incorporate more than one type of arthrometer should focus on reporting delta values as the present data demonstrated no significant repeated measures deltas between-devices.Copyright © 2025 The Authors. Published by Elsevier B.V. All rights reserved.",The Knee,"Dec, 2025",2025,Dec,,Fischbach A H|Myer G D|Barber-Foss K D|Schilaty N D|Sheldon A N|Nagelli C V|McPherson A L|Krych A J|Bates N A,Nagelli C V|Krych A J,"Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Ohio University, Athens, OH, USA.|Emory Sports Performance and Research Center, Emory University, Flowery Branch, GA, USA; Emory Sports Medicine Center, Atlanta, GA, USA; Department of Orthopaedics, Emory University School of Medicine, Atlanta, GA, USA.|Department of Neurosurgery & Brain Repair, University of South Florida, Tampa, FL, USA; Department of Medical Engineering, University of South Florida, Tampa, FL, USA.|Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; College of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA.|Department of Orthopaedic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Emory Sports Performance and Research Center, Emory University, Flowery Branch, GA, USA; Emory Sports Medicine Center, Atlanta, GA, USA; Department of Orthopaedics, Emory University School of Medicine, Atlanta, GA, USA.|Department of Orthopaedics, The Ohio State University Wexner Medical Center, Columbus, OH, USA. Electronic address: nathaniel.bates@osumc.edu.","Fischbach A H, Myer G D, Barber-Foss K D, Schilaty N D, Sheldon A N, Nagelli C V, McPherson A L, Krych A J, Bates N A",https://pubmed.ncbi.nlm.nih.gov/40834671/,"The study found that measurements of knee laxity using manual and mechanical arthrometers in patients who had undergone ACL reconstruction did not consistently match. This suggests that different types of arthrometers may not provide interchangeable results, which is important for healthcare providers to consider when evaluating and monitoring these patients."
40835175,Are we Growing Leaders? Exploring Leadership Training in Hospice and Palliative Medicine Fellowship.,"Although leadership competencies are recognized as critical to the practice of hospice and palliative medicine (HPM), the specific leadership content that matters most, and whether that content is taught in fellowships, remain unclear.The purpose of this study was to characterize the current state of leadership curricula in HPM fellowships and understand which leadership topics fellowship program directors (PDs) consider to be most important to include in a leadership curriculum for fellows.A needs assessment survey was sent to 194 individuals identified as PDs by the American Academy of Hospice and Palliative Medicine (AAHPM). Descriptive statistics were used for analysis.Most respondents reported that leadership topics are important for fellows to learn. Six topic areas related to communication and self-management were rated as having great need or were included in existing curricula by more than 60% of respondents. PDs identified ten topics to be of great need for fellows, all but one of which were included in at least 40% of programs' curricula. Negotiation was the exception being included in only 20% of programs' curricula. The response rate was 20%.Respondents rated leadership topics as important for training, yet many topics are not included in fellowship curricula.Published by Elsevier Inc.",Journal of pain and symptom management,"Dec, 2025",2025,Dec,,Flint L A|Wallingford G|Tatum P|Bruno J|Fernandez H|Carey E C,Carey E C,"San Francisco VA Health Care System (L.F.), University of California San Francisco, San Francisco, California. Electronic address: lynn.flint@ucsf.edu.|Dell Medical School at The University of Texas at Austin (G.W.), Austin, Texas.|Washington University in St. Louis (P.T.), St. Louis, Missouri.|American Academy of Hospice and Palliative Medicine (J.B.), Schaumburg, Illinois.|Icahn School of Medicine at Mount Sinai (H.F.), New York, New York.|Division of Community Internal Medicine, Geriatrics & Palliative Care (E.C.), Department of Medicine, Mayo Clinic, Rochester, Minnesota.","Flint L A, Wallingford G, Tatum P, Bruno J, Fernandez H, Carey E C",https://pubmed.ncbi.nlm.nih.gov/40835175/,"The study found that while hospice and palliative medicine fellowship directors consider leadership skills important for trainees, many key leadership topics are not included in current fellowship curricula. The findings suggest a need to better integrate leadership training into these medical education programs."
40767895,Summary of the collection on 'immunotherapy in pediatric brain tumors-an update'.,No abstract available.,Journal of neuro-oncology,"Dec, 2025",2025,Dec,,Khatua S|Bouffet E,Khatua S,"Department of Pediatric Hematology/Oncology, Mayo Clinic College of Medicine and Science, Rochester, MN, 55905, USA. skhatua.bappa@gmail.com.|Division of Hematology/Oncology, The Hospital for Sick Children's, Toronto, M5G 1E8, Canada.","Khatua S, Bouffet E",https://pubmed.ncbi.nlm.nih.gov/40767895/,"This research likely explores the use of immunotherapy, a type of treatment that uses the body's immune system to fight cancer, in the context of pediatric brain tumors. The summary suggests that this research provides an update on the current state of knowledge and developments in this field of study."
40749779,Synchrotron Microbeam Radiation Therapy in Combination With Gold Nanoparticles Improves Control of Mouse Melanoma.,"Microbeam radiation therapy (MRT) is a preclinical, spatially fractionated radiation therapy technique that delivers ultranarrow synchrotron x-ray beams at ultrahigh dose rates. MRT has demonstrated superior tumor control compared with synchrotron broad beam by triggering infiltration of CD8+ T cells and inducing a transient vascular permeability window. This study aimed to investigate the effects of combining MRT with gold nanoparticles (AuNPs) on tumor growth, while also assessing whether MRT could enhance intratumoral accumulation of AuNPs.Mice bearing B16-F10 melanoma in their ears were assigned to 7 experimental groups, each receiving distinct combinations of priming MRT (150 Gy peak dose), AuNPs, broad beam (6.1 Gy), and therapeutic MRT (400 Gy peak dose). MRT was delivered as an array of 50-µm-wide beams spaced 200 µm apart. Tumor growth was monitored daily, whereas 15-nm AuNP uptake was assessed with microCT imaging, electron microscopy, and Image Mass Cytometry.Priming MRT increased intratumoral AuNP accumulation by 2.5-fold on day 3 and 2.3-fold on day 5 compared with nonprimed controls. Image Mass Cytometry showed that AuNPs distributed across the tumor stroma and concentrated at the tumor periphery, near areas with high vascular density and in M2-like macrophages. Combining priming MRT with AuNPs and therapeutic MRT achieved the best tumor growth delay and regression with a median survival to 39.5 days; significantly longer than the 17 days achieved with priming MRT, AuNPs, and broad beam. The sensitizer enhancement ratio of 1.38 highlighted the efficacy of AuNP-enhanced MRT.Our study introduces a novel approach in cancer therapy, demonstrating that MRT serves as both a potent standalone treatment and an effective enhancer of drug delivery. MRT increased the tumoral concentration of AuNPs and could potentially do the same with other therapeutic agents. Our findings strongly advocate for the continued development of MRT-based combination regimens and highlight the clinical potential of this dual-mechanism approach.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.","International journal of radiation oncology, biology, physics","Dec 01, 2025",2025,Dec,01,Fernandez-Palomo C|Potez M|Haberthür D|Trappetti V|Pellicioli P|Fazzari J|Grams M|Hlushchuk R|Djonov V,Fazzari J|Grams M,"Institute of Anatomy, University of Bern, Bern, Switzerland.|Institute of Anatomy, University of Bern, Bern, Switzerland; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.|Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.|Institute of Anatomy, University of Bern, Bern, Switzerland. Electronic address: valentin.djonov@unibe.ch.","Fernandez-Palomo C, Potez M, Haberthür D, Trappetti V, Pellicioli P, Fazzari J, Grams M, Hlushchuk R, Djonov V",https://pubmed.ncbi.nlm.nih.gov/40749779/,"This study found that combining microbeam radiation therapy (MRT) with gold nanoparticles (AuNPs) significantly improved the control of mouse melanoma tumors. MRT increased the accumulation of AuNPs within the tumors, and the combination of MRT, AuNPs, and therapeutic MRT achieved the best tumor growth delay and regression. This dual-mechanism approach, where MRT enhances drug delivery, shows great potential for future cancer therap"
40734292,Interobserver Reproducibility of Pelvicalyceal Invasion in Renal Cell Carcinoma Nephrectomies Among Genitourinary Pathologists.,"Pelvicalyceal invasion (PCI) is a relatively novel pT3a staging parameter for renal cell carcinoma (RCC) nephrectomies. While interobserver reproducibility staging studies of sinus/vascular invasion in RCC exist, a similar evaluation for PCI has not been performed. Moreover, in our experience, there is also diagnostic variability in how pathologists interpret PCI. Herein, we explore interobserver reproducibility among genitourinary (GU) pathologists. Twenty hematoxylin and eosin-stained digitized slides from RCCs (all grossly approaching the renal pelvis) were distributed to 31 GU pathologists to classify each as PCI or not PCI based on their respective clinical practices; slides with concomitant sinus/fat/vascular invasion were excluded. Slides were then evaluated for the following 4 morphologic features: tumor abutting renal pelvis, tumor pushing/indenting into the renal pelvis, polypoid configuration of tumor into the renal pelvis, and tumor eroding through renal pelvic urothelium. Interobserver reproducibility was assessed, and the morphologic features were correlated with PCI. Relationships between pathologists' interpretations, morphologic features, and PCI were evaluated using hierarchical clustering. Although the diagnosis of PCI was relatively uniform with a majority agreement (>67%) reached in 16/20 slides, overall interobserver reproducibility was only moderate (kappa=0.601). While all 4 morphologic features were sensitive for PCI, polypoid configuration of the tumor into the renal pelvis and the tumor eroding through the renal pelvic urothelium were most specific (90%, 100%, respectively). Although we show general consensus among genitourinary pathologists on PCI assessment, clarifying the diagnostic guidelines with specific criteria should be included in pathologic staging systems.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",The American journal of surgical pathology,"Dec 01, 2025",2025,Dec,01,Sangoi A R|Akgul M|Mubeen A|Humble R|Wu D J|Pacheco R|Acosta A|Amin M|Aron M|Brimo F|Chan E|Cheng L|Cheville J|Collins K|Cornejo K|Dhillon J|Downes M R|Epstein J I|Hirsch M|Kapur P|Lobo A|Mehra R|Mohanty S|Netto G|Osunkoya A O|Paner G|Rao P|Saleeb R|Shah R B|Shen S|Smith S|Tickoo S|Tretiakova M|Trpkov K|Wobker S|Tamboli P|Zynger D|Williamson S R,Cheville J,"Stanford Medical Center, Stanford.|Brigham and Women's Hospital, Boston, MA.|University of New Mexico, Albuquerque, NM.|University of Michigan, Ann Arbor, MI.|Albany Medical Center, Albany.|Indiana University, Indianapolis, IN.|University of Tennessee, Knoxville, TN.|University of Southern California, Los Angeles, CA.|McGill University, Montreal, Quebec.|Brown University Providence, RI.|Mayo Clinic, Rochester, MN.|Massachusetts General Hospital, Boston, MA.|H. Lee Moffitt Cancer Center, Tampa, FL.|Sunnybrook Health Sciences Centre.|IMP Pathology, Garden City.|UT Southwestern Medical Center, Dallas, TX.|Kapoor Centre of Urology and Pathology, Raipur, India.|CORE Diagnostics, Gurgaon.|University of Pennsylvania, Philadelphia, PA.|Emory University School of Medicine, Atlanta, GA.|University of Chicago, Chicago, IL.|MD Anderson Cancer Center.|University of Toronto, Toronto, Ontario.|Houston Methodist Hospital, Houston.|Virginia Commonwealth University, Richmond, VA.|Memorial Sloan Kettering Cancer Center, New York, NY.|University of Washington, Seattle, WA.|University of Calgary, Calgary, Alberta, Canada.|University of North Carolina, Chapel Hill, NC.|The Ohio State University, Columbus.|Cleveland Clinic, Cleveland, OH.","Sangoi A R, Akgul M, Mubeen A, Humble R, Wu D J, Pacheco R, Acosta A, Amin M, Aron M, Brimo F, Chan E, Cheng L, Cheville J, Collins K, Cornejo K, Williamson S R, et al.",https://pubmed.ncbi.nlm.nih.gov/40734292/,"The key finding of this study is that while there is general consensus among genitourinary pathologists on the assessment of pelvicalyceal invasion in renal cell carcinoma, the overall interobserver reproducibility is only moderate. The study suggests that clarifying the diagnostic guidelines with specific criteria should be included in pathologic staging systems to improve consistency in the interpretation of this important prognostic factor."
40685298,The impact of work-related pain on surgical team members' burnout and personal and professional performance.,"Musculoskeletal disorders and pain are common among surgeons, but literature is limited on the broader surgical team, particularly in relation to how work-related pain impacts burnout and subjective performance impairment.We surveyed surgical teams and collected self-reported data on musculoskeletal pain (intraoperative and related to computer use), burnout, and subjective measures of personal and professional performance. We assessed the relationships between pain and burnout and pain and subjective performance impairment.Overall, 62 ​% of the 488 participants reported musculoskeletal pain from surgery and 31 ​% from computer work. 42 ​% reported burnout. Work-related pain and burnout were correlated across most roles (r ​= ​0.14-0.42). The intensity of pain was associated with increasing numbers of subjective performance impairments (p ​< ​0.001).Work-related pain is prevalent among surgical team members and strongly associated with burnout and performance impairments. Targeted interventions are needed to mitigate work-related pain and improve the well-being of surgical teams.Published by Elsevier Inc.",American journal of surgery,"Dec, 2025",2025,Dec,,Steadman S|Seibel C|Hallbeck M S|Norasi H|Zhang A|Chrouser K,Hallbeck M S|Norasi H,"Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: steadmas@med.umich.edu.|Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: cseibel@med.umich.edu.|Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. Electronic address: hallbeck.susan@mayo.edu.|Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. Electronic address: norasi.hamid@mayo.edu.|Department of Ophthalmology & Visual Sciences, University of Michigan Kellogg Eye Center, Ann Arbor, MI, USA. Electronic address: amydz@med.umich.edu.|Department of Urology, University of Michigan, Ann Arbor, MI, USA; VA Ann Arbor Healthcare System, Ann Arbor, MI, USA. Electronic address: chrouser@med.umich.edu.","Steadman S, Seibel C, Hallbeck M S, Norasi H, Zhang A, Chrouser K",https://pubmed.ncbi.nlm.nih.gov/40685298/,"This study found that work-related pain, such as from surgery and computer use, is common among surgical team members and is strongly linked to burnout and reduced personal and professional performance. The findings suggest that interventions are needed to address work-related pain and improve the well-being of surgical teams."
40643816,Boosting Hepatitis B Vaccination Rates Among Healthcare Workers in the State of Minnesota.,"Hepatitis B is a severe liver infection caused by the Hepatitis B virus (HBV), potentially leading to liver cirrhosis, failure, and carcinoma. Transmission occurs through contact with infected bodily fluids, such as blood. Immunization against HBV is the most effective measure to prevent infection. Healthcare employees, particularly those who are under-vaccinated, are at elevated risk due to potential exposure. Although healthcare workers should have access, 24% of the healthcare workforce worldwide remains unvaccinated. Ensuring adequate immunization for this group is essential to maintaining a safe workplace and minimizing the risk of downstream transmission. We aimed to decrease the number of overdue Hepatitis B vaccinations among employees and dependent patients in an Internal Medicine (IM) practice at a large academic medical center At baseline, 3,052 IM patients were under-vaccinated. Our intervention identified 1,000 random patients. An EMR message was sent to the intervention group. The message provided instructions on scheduling an appointment or retrieving documentation from their occupational health records. Four weeks after the initial message, a follow-up message was sent as a reminder. The intervention resulted in a 14% increase in HepB medical record compliance updates. 780 patients interacted at least once with message broadcasts. Our intervention significantly increased Hepatitis B vaccination and documentation for patients within the intervention group. This study identified several barriers, such as a lack of willingness to receive recommended vaccines or update records to reflect accurate vaccination status. Additionally, limitations in record retrieval and difficulties pulling vaccination records from external databases hindered documentation.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Journal of community health,"Dec, 2025",2025,Dec,,Strelow B|Roxas E G|Perkins K M|Frick S J|Wagner E L|Petersen E E|Alimire M|Olson R|Wingo M|O'Laughlin D,Strelow B|Roxas E G|Perkins K M|Frick S J|Wagner E L|Petersen E E|Alimire M|Olson R|Wingo M|O'Laughlin D,"Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, USA. strelow.brittany@mayo.edu.|Mayo Clinic Physician Assistant Program, Rochester, MN, USA.|Mayo Clinic Knowledge and Evaluation Research Unit, Rochester, MN, USA.|Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, MN, USA.","Strelow B, Roxas E G, Perkins K M, Frick S J, Wagner E L, Petersen E E, Alimire M, Olson R, Wingo M, O'Laughlin D",https://pubmed.ncbi.nlm.nih.gov/40643816/,"This study aimed to increase Hepatitis B vaccination rates among healthcare workers in Minnesota. The intervention involved sending electronic messages to a group of patients, which resulted in a 14% increase in Hepatitis B vaccination documentation. The findings highlight the importance of addressing barriers, such as reluctance to get vaccinated and difficulties in retrieving vaccination records, to improve vaccination coverage among healthcare workers."
40659906,Universal same-day discharge after colonic resection: a matched cohort study.,"Enhanced Recovery Protocols (ERPs) have improved outcomes in colorectal surgery. Same-day discharge (SDD) after colonic resection is promising but often limited to highly selected patients. This study evaluates the safety and efficacy of a universal same-day discharge (USDD) program compared to traditional ERPs. The objective was to assess if USDD in a broader patient population is non-inferior to traditional ERP in terms of 30-day complications, readmissions, and reoperations. This was a retrospective matched cohort study at a single U.S. institution that launched a USDD program in May 2022. Thirty-six patients in the USDD program were compared to a matched control group receiving traditional ERP. USDD eligibility criteria included outpatient agreement, minimally invasive approach, no new stoma, and caregiver availability. Main outcome measures were 30-day post-operative complications, ED visits, readmissions, and reoperations. The USDD group had shorter operative times, increased TAP block use, and lower intraoperative fluid administration. No significant differences were found in 30-day complications or reoperations between groups. However, ED visits and readmission rates were higher in the USDD group. USDD appears to be safe and non-inferior to traditional ERP for selected patients. SDD can potentially be safely expanded to a wider patient population, but further prospective studies are needed.© 2025. Italian Society of Surgery (SIC).",Updates in surgery,"Dec, 2025",2025,Dec,,Violante T|Ferrari D|Gomaa I A|Novelli M|Larson D W|Shawki S F,Violante T|Ferrari D|Gomaa I A|Larson D W|Shawki S F,"Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA. tommyviolante@gmail.com.|Orsi Academy, Melle, Belgium. tommyviolante@gmail.com.|Division of Colon and Rectal Surgery, Mayo Clinic, 200 First St. Southwest, Rochester, MN, 55905, USA.|Department of Statistical Sciences, University of Bologna, Bologna, Italy.","Violante T, Ferrari D, Gomaa I A, Novelli M, Larson D W, Shawki S F",https://pubmed.ncbi.nlm.nih.gov/40659906/,"This study found that a universal same-day discharge (USDD) program for colonic resection surgery is safe and non-inferior to traditional enhanced recovery protocols (ERPs) in terms of 30-day complications and reoperations, but had higher rates of emergency department visits and readmissions. The study suggests that same-day discharge can be safely expanded to a wider patient population, but further research is needed."
40660739,Functional Lumen Imaging Probe as Part of Multimodality Assessment of Esophagogastric Junction Opening Is Important in Longitudinal Follow-Up of Patients With Treated Achalasia.,"Functional lumen imaging probe (FLIP) utility is established in treatment-naïve achalasia but less clear following lower esophageal sphincter (LES) directed therapy.Achalasia patients with LES directed therapy across three tertiary care centers between 2017 and 2024 with post-treatment FLIP and timed barium esophagram (TBE) were retrospectively identified. Reduced esophagogastric junction (EGJ) opening was defined by distensibility index (DI) < 2 mm2/mmHg and diameter < 12 mm. Abnormal emptying on TBE was defined as column height ≥ 5 cm at 5 min and/or retained tablet. Eckardt scores ≤ 3 defined clinical response.The study included 222 patients (46% peroral endoscopic myotomy, 46% laparoscopic Heller myotomy, 8% pneumatic dilation) with a median of 1.4 years to post-treatment TBE/FLIP. Abnormal emptying on TBE was associated with a narrower median EGJ diameter (13.2 vs. 14.8 mm, p = 0.008), a greater frequency of EGJ diameter < 12 mm (36% vs. 21%, p = 0.012), and a smaller change in EGJ diameter (+4.6 vs. +8.6 mm, p = 0.002). Abnormal emptying on TBE occurred more frequently in patients with EGJ DI < 2 mm2/mmHg (8.5% vs. 2.6%, p = 0.052), but was not associated with median EGJ DI (4.5 vs. 5.1 mm2/mmHg, p = 0.29) nor median change in EGJ DI (+2.9 vs. +3.9 mm2/mmHg, p = 0.25). Patients with reduced EGJ DI or EGJ diameter more often had abnormal TBE (37% vs. 22%, p = 0.012). Only the change in DI (+3.8 vs. +1.5 mm2/mmHg, p = 0.012) and diameter (+8.2 vs. +1.6 mm, p = 0.002) on FLIP was associated with a clinical response based on Eckardt ≤ 3.FLIP following achalasia therapy generally correlates with TBE, although discrepant findings are not uncommon. In particular, FLIP EGJ-diameter has a strong association with esophageal emptying on TBE. Both TBE and FLIP have limited association with clinical response based on Eckardt, with change in DI and diameter on FLIP most strongly associated. Consequently, FLIP as part of multimodal assessment appears useful in the longitudinal follow-up of treated achalasia.© 2025 John Wiley & Sons Ltd.",Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Kamboj A K|Sood S|Truong B|Wong Kee Song L M|Wells M|Wigle D|Codipilly D C|Snyder D L|Alexander J A|Leggett C|Lennon R J|Koop A|Vela M|Ravi K,Sood S|Wells M|Wigle D|Lennon R J|Koop A|Vela M|Ravi K,"Division of Gastroenterology and Hepatology, Cedars-Sinai Medical Center, Los Angeles, California, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Internal Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.|Division of Radiology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Thoracic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, Arizona, USA.","Kamboj A K, Sood S, Truong B, Wong Kee Song L M, Wells M, Wigle D, Codipilly D C, Snyder D L, Alexander J A, Leggett C, Lennon R J, Koop A, Vela M, Ravi K",https://pubmed.ncbi.nlm.nih.gov/40660739/,"The study found that the functional lumen imaging probe (FLIP) test, which measures the opening of the esophagogastric junction, is an important tool for monitoring patients with treated achalasia, a condition that affects the swallowing of food. The FLIP results correlated with the timed barium esophagram test, which measures how well the esophagus is emptying. Both tests had limited association with clinical symptoms, but changes in the FLIP measurements"
40668525,Determinants of exercise tolerance in HFpEF: role of the heart versus the periphery.,No abstract available.,Heart failure reviews,"Dec, 2025",2025,Dec,,Bergeron N P|Reddy Y N V,Bergeron N P|Reddy Y N V,"Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA. reddy.yogesh@mayo.edu.","Bergeron N P, Reddy Y N V",https://pubmed.ncbi.nlm.nih.gov/40668525/,This research likely explores the factors that influence a person's ability to exercise when they have a specific type of heart failure called HFpEF. It aims to understand the role of the heart itself versus other parts of the body in determining a person's exercise tolerance or capacity.
40668961,Nylon Suture Snare for Intraocular Foreign Body Removal: A Case Series.,"To describe an improved snare technique for the removal of an intraocular foreign body (IOFB) from the posterior segment.The snare is fashioned from a 23 or 25-gauge blunt-tipped cannula, a 5-0 or 6-0 nylon suture, and a cotton-tipped applicator. The snare is introduced through a 23 or 25-gauge vitrectomy port and tightened around the IOFB, maintaining a closed system. The IOFB can be extracted from the eye by pulling the cannula and extending the circumferential sclerotomy.Four cases of IOFBs were treated using the improved nylon suture snare technique. Three of the four were traumatic open-globe injuries with retained IOFB, for which the snare technique was suitable for removal of the object. In the fourth case, the snare technique was used to remove a posteriorly dislocated silicone intraocular lens optic. No cases of postoperative retinal detachments or endophthalmitis were observed.This snare is fashioned from readily available, inexpensive materials and provides a safe and reliable method for IOFB removal through the vitrectomy port. By maintaining a closed system during IOFB mobilization and removal, the view through the cornea remains stable and intraocular pressure remains constant. Moreover, the snare can grasp irregularly shaped or large IOFBs.","Retina (Philadelphia, Pa.)","Dec 01, 2025",2025,Dec,01,Krivit J|Giacalone J C|Andrade Romo J|Reiter G S|Ye R Z|Iezzi R,Krivit J|Giacalone J C|Andrade Romo J|Reiter G S|Ye R Z|Iezzi R,"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota; and.|Department of Ophthalmology, Medical University of Vienna, Vienna, Austria .","Krivit J, Giacalone J C, Andrade Romo J, Reiter G S, Ye R Z, Iezzi R",https://pubmed.ncbi.nlm.nih.gov/40668961/,"This medical research describes an improved technique using a nylon suture snare to safely remove intraocular foreign bodies from the eye. The snare, made from common materials, allows for the removal of the foreign object while maintaining a closed eye system, which helps prevent complications like retinal detachment or infection. The technique was successfully used in several cases, demonstrating its effectiveness and potential to improve the management of these types of eye injuries."
40683396,Treatment and outcomes of type IIIb endoleaks affecting the main fenestrated-branched aortic stent graft component among patients treated for complex abdominal and thoracoabdominal aortic aneurysms.,"Type IIIb endoleak (T3bE) owing to fabric tears or integrity issues is infrequent, but has been poorly described among patients undergoing fenestrated-branched endovascular aortic repair (FB-EVAR). This study aimed to describe the incidence, management, and outcomes of T3bE after FB-EVAR for the treatment of complex abdominal aortic aneurysms (CAAAs) and thoracoabdominal aortic aneurysms (TAAAs).Clinical data, imaging, and outcomes of consecutive patients enrolled in prospective, nonrandomized physician-sponsored investigational device exemption studies evaluating company-manufactured devices for FB-EVAR at three centers were reviewed from 2013 to 2024. Patients with unequivocal diagnosis of T3bE affecting the main fenestrated-branched aortic device component, confirmed by contrast-enhanced ultrasound examination, standard or dynamic computed tomography angiography (CTA), and/or diagnostic angiography, were included. The primary end point was the cumulative incidence of T3bE. Secondary end points included treatment approaches, mortality, major adverse events, secondary interventions, and aneurysm rupture.A total of 717 patients (69% male; mean age, 74 ± 8 years old) were treated by FB-EVAR in the two centers. After a median follow-up of 37 months (interquartile range [IQR], 25-40 months), eight patients (1.1%) had unequivocal diagnosis of T3bE affecting the main component of a fenestrated-branched device. Cumulative incidence of T3bE at 3 and 5 years was 1.1% (95% confidence interval, 0.0%-2.2%) and 2.4% (95% confidence interval, 0.6%-4.3%), respectively. All patients had prior imaging showing no T3bE. Surveillance imaging with a final diagnosis of T3bE was established by angiography in three patients, contrast-enhanced ultrasound examination in two, dynamic CTA in two, and CTA in one. Of the eight patients, seven underwent endovascular repair with redo fenestrated-branch device in three, and parallel stent graft, cuff extension, or endovascular plug/coils in one each. Seven secondary interventions successfully resolved the T3bE with one patient presenting with an aneurysm rupture leading to mortality. One patient was managed conservatively with clinical surveillance and had spontaneous resolution of the endoleak. The overall median follow-up was 55 months (IQR, 42-62 months), and the median follow-up after T3bE reintervention was 20 months (IQR, 5-28 months).T3bEs from fabric tears or integrity issues are uncommon after FB-EVAR, but pose diagnostic and treatment challenges, particularly when the affected segment involves fenestrations and directional branches. Redo endovascular repair is effective in selected patients. Persistent leaks may lead to aneurysm sac expansion and rupture, emphasizing the need for vigilant surveillance and timely intervention.Copyright © 2025. Published by Elsevier Inc.",Journal of vascular surgery,"Dec, 2025",2025,Dec,,Ruiter Kanamori L|Dias-Neto M|Porras-Colon J|Lima G B|Huang Y|Figueroa A|Han S M|Mendes B C|Macedo T A|Saqib N|Maximus S|Timaran C H|Oderich G S,Lima G B|Mendes B C,"Advanced Endovascular Aortic Research Program, Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Baylor College of Medicine, Houston, TX.|Angiology and Vascular Surgery, Centro Hospitalar Universitário de São João, Porto, Portugal; Department of Surgery and Physiology, Faculdade de Medicina da Universidade do Porto, Porto, Portugal.|Division of Vascular and Endovascular Surgery, The University of Texas Southwestern Medical Center, Dallas, TX.|Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.|Comprehensive Aortic Center, Keck Hospital of the University of Southern California, Los Angeles, CA.|Division of Vascular and Endovascular Surgery, The University of Texas Southwestern Medical Center, Dallas, TX; Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.|Department of Cardiothoracic & Vascular Surgery, The University of Texas Health Science Center at Houston, Houston, TX.|Advanced Endovascular Aortic Research Program, Division of Vascular Surgery and Endovascular Therapy, Department of Surgery, Baylor College of Medicine, Houston, TX. Electronic address: gustavo.oderich@bcm.edu.","Ruiter Kanamori L, Dias-Neto M, Porras-Colon J, Lima G B, Huang Y, Figueroa A, Han S M, Mendes B C, Macedo T A, Saqib N, Maximus S, Timaran C H, Oderich G S",https://pubmed.ncbi.nlm.nih.gov/40683396/,"The study found that type IIIb endoleaks, which are rare complications of fenestrated-branched endovascular aortic repair, can be effectively treated with redo endovascular procedures in most cases. However, persistent leaks can lead to aneurysm rupture, highlighting the importance of close monitoring and prompt intervention for patients undergoing this complex procedure."
40691251,Re: Prostate MRI and clinicopathologic risk calculator to predict laterality of extraprostatic extension at radical prostatectomy.,No abstract available.,Prostate cancer and prostatic diseases,"Dec, 2025",2025,Dec,,Li E V|Ross A E|Patel H D,Li E V,"Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. Li.Eric@mayo.edu.|Department of Urology, Mayo Clinic, MN, 55905, Rochester, USA. Li.Eric@mayo.edu.|Department of Urology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA.","Li E V, Ross A E, Patel H D",https://pubmed.ncbi.nlm.nih.gov/40691251/,"This research likely explores the use of prostate MRI and a risk calculator to predict the spread of prostate cancer beyond the prostate gland. The findings could help doctors better understand the extent of prostate cancer and plan appropriate treatment for patients undergoing radical prostatectomy, which is the surgical removal of the prostate."
40730330,Endoscopic ultrasound-guided pancreatic ring drainage via a pancreaticoenteric fistula.,No abstract available.,Endoscopy,"Dec, 2025",2025,Dec,,Khan R|Law R,Khan R|Law R,"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, United States.","Khan R, Law R",https://pubmed.ncbi.nlm.nih.gov/40730330/,This research likely explores a procedure where a doctor uses an endoscope and ultrasound to create a connection between the pancreas and the intestines to drain fluid from the pancreas. The goal of this procedure is to help manage a condition related to the pancreas.
40693984,Association of frailty with outcomes of patients undergoing transvenous lead removal for cardiac implantable electronic device infections in the United States.,"Frailty, marked by reduced physiological resilience, is associated with adverse outcomes in patients undergoing various cardiovascular procedures. The rising incidence of cardiac implantable electronic device (CIED) infections necessitate transvenous lead removal (TLR), yet the impact of frailty on TLR outcomes remains unclear.The purpose of this study was to evaluate the association between frailty and outcomes in patients undergoing TLR for CIED infections.This retrospective study analyzed the National Readmissions Database (2016-2021) for patients hospitalized with CIED infections who underwent TLR, identified using International Classification of Diseases, Tenth Revision codes. Frailty was defined using Johns Hopkins frailty-defining diagnoses. Outcomes, including in-hospital mortality, procedural complications, discharge disposition, length of stay, and 30-, 90-, and 180-day readmissions, were compared between frail and nonfrail patients by using multivariable logistic regression.Of the 44,370 patients undergoing TLR, 10,116 (22.8%) were frail. Frail patients were older (69.8 years vs 66.4 years) with higher comorbidity burden and systemic infections (6707 (66.3%) vs 16,202 (47.3%)) (P < .01). Frailty was independently associated with higher in-hospital mortality (1224 (12.1%) vs 1713 (5.0%); adjusted odds ratio 1.95; 95% confidence interval 1.74-2.21) and periprocedural complications, including cardiac arrest, pulmonary complications, and longer hospital stays. Frail patients had higher rates of non-home discharge and higher readmissions at 30, 90, and 180 days (P < .01 for all). Malnutrition and decubitus ulcers were strongly associated with mortality.Frailty is a key predictor of adverse outcomes in TLR for CIED infections. Preoperative frailty assessment and tailored management strategies are essential to mitigate risks in this high-risk population.Copyright © 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.",Heart rhythm,"Dec, 2025",2025,Dec,,Agarwal S|Qamar U|Patel H P|Abideen Asad Z U|Munir M B|Kowlgi G N|Lee J Z|Tan N Y|Sugrue A|Mulpuru S K|Cha Y|DeSimone D C|Deshmukh A|DeSimone C V,Agarwal S|Qamar U|Kowlgi G N|Tan N Y|Sugrue A|Mulpuru S K|Cha Y|DeSimone D C|Deshmukh A|DeSimone C V,"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Cardiology, Southern Illinois University School of Medicine, Springfield, Illinois.|Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.|Division of Cardiovascular Medicine, University of California Davis, Sacramento, California.|Division of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Division of Infectious Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: desimone.christopher@mayo.edu.","Agarwal S, Qamar U, Patel H P, Abideen Asad Z U, Munir M B, Kowlgi G N, Lee J Z, Tan N Y, Sugrue A, Mulpuru S K, Cha Y, DeSimone D C, Deshmukh A, DeSimone C V",https://pubmed.ncbi.nlm.nih.gov/40693984/,"This study found that frailty, a condition marked by reduced physical resilience, is associated with higher risk of complications, longer hospital stays, and higher mortality rates in patients undergoing transvenous lead removal for cardiac device infections. The findings highlight the importance of assessing frailty before these procedures and developing targeted strategies to manage the risks in this vulnerable patient population."
40702591,Artificial Neural Networks and Deep Learning in Solid Organ Transplantation.,"Artificial neural networks are now used across many fields, from medicine to chatbots. However, they are often complicated and give ""black-box"" predictions. To better understand these models, we outline some of the terminology, provide example applications in solid organ transplantation, and offer recommendations for those interested in starting to use such models. Examples and definitions are sourced from PubMed searches as well as a review of several applied texts in machine and deep learning. Neural networks have been applied in transplantation since the 1990s, but more recent applications involve their use to process nontabular data, such as images and text. Although interpretations of model results should take context into account, the power of these models holds great potential for the future in transplantation.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Transplantation,"Dec 01, 2025",2025,Dec,01,Smith B H|Denic A,Smith B H|Denic A,"Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.|Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN.","Smith B H, Denic A",https://pubmed.ncbi.nlm.nih.gov/40702591/,"Artificial neural networks, a type of machine learning, are increasingly being used in solid organ transplantation. These models can analyze complex data, such as medical images and text, to help with decision-making in transplant care. While the inner workings of these models can be difficult to interpret, they have great potential to improve outcomes for transplant patients."
40704424,Primary Sclerosing Cholangitis in the Absence of Inflammatory Bowel Disease Increases the Risk of Colorectal Cancer: A Multi-Centre Propensity Score Matched Analysis.,"Patients with primary sclerosing cholangitis (PSC) and concomitant inflammatory bowel disease (IBD) are at increased risk of colorectal cancer (CRC). However, the risk of CRC in patients with PSC without IBD remains uncertain. We aimed to evaluate the risk of CRC in patients with PSC without a history of IBD using a large national database.We conducted a retrospective cohort study using the TriNetX database to identify patients ≥ 18 years with PSC. Patients were then divided into two groups, PSC with IBD (PSC-IBD cohort) and PSC without IBD (PSC non-IBD cohort), and were matched with patients without a history of PSC or IBD (non-PSC/non-IBD group) by using 1:1 propensity score matching. The primary outcome was the risk of first diagnosis of CRC. With censoring applied, Kaplan-Meier analysis with hazard ratios (HRs) and 95% CIs was used to compare time-to-event rates at daily time intervals.PSC patients without IBD were at increased risk of CRC compared to the non-PSC/IBD cohort (aHR = 2.91; 95% CI: 1.6-6.0). Patients with PSC and IBD exhibited a higher risk of CRC (aHR = 6.5; 95% CI: 3.78-11.2), especially among the UC cohort (aHR = 6.3; 95% CI: 3.2-12.4). Patients with PSC were at increased risk of various gastrointestinal malignancies (aHR = 10.5; 95% CI: 7.3-15; p < 0.0001), including hepatobiliary cancers, pancreatic cancer, and hepatocellular carcinoma.Our findings provide real-world evidence that PSC is an independent risk factor for colorectal cancer, even in the absence of concomitant IBD. These results support the need for further research to determine whether patients with isolated PSC may benefit from tailored CRC surveillance strategies.© 2025 John Wiley & Sons Ltd.",Alimentary pharmacology & therapeutics,"Dec, 2025",2025,Dec,,Alsakarneh S|Aburumman R|Bilal M|Faye A S|Hashash J G|Shaukat A,Alsakarneh S|Aburumman R|Hashash J G,"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Gastroenterology and Hepatology, University of Colorado, Denver, Colorado, USA.|Department of Gastroenterology and Hepatology, New York University, New York City, New York, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida, USA.","Alsakarneh S, Aburumman R, Bilal M, Faye A S, Hashash J G, Shaukat A",https://pubmed.ncbi.nlm.nih.gov/40704424/,"This study found that patients with primary sclerosing cholangitis (PSC) without inflammatory bowel disease (IBD) have a significantly higher risk of developing colorectal cancer compared to those without PSC or IBD. Additionally, patients with both PSC and IBD have an even higher risk of colorectal cancer. These findings suggest that patients with isolated PSC may benefit from tailored colorectal cancer screening strategies, even in the absence of IBD."
40717228,Unravelling the myriad physiologic roles of transthyretin: critical considerations for treating transthyretin amyloidosis.,"Transthyretin (TTR) is a highly conserved protein with crucial and broadly protective physiologic roles across organ systems and diseases. Evidence shows that TTR contributes to neuroprotection, cognition, glucose regulation, pregnancy, muscle development, and bone mineralization. In several disease states, including diabetes, Alzheimer's disease, Lewy body dementia, cerebrovascular disease, and osteoporosis, higher TTR levels may be protective. Numerous studies have shown that low levels of TTR are associated with increased mortality overall and in relation to cardiovascular disease and several malignancies.There is a growing portfolio of approved and investigational transthyretin amyloidosis (ATTR) treatments that differ in their mechanisms and effects on circulating TTR. When selecting an ATTR therapy, clinicians must decide whether to stabilize and preserve TTR and its functions or knockdown and drastically reduce TTR. This review summarizes the vital physiologic roles of TTR in health and disease. We consider the potential effects on normal biologic pathways that may occur while therapeutically suppressing TTR and discuss clinical decisions concerning ATTR therapies in the context of the summarized literature.TTR is essential for a broad range of physiologic processes and may confer clinically protective effects in neurologic and other organ systems. While a link between low TTR and severe disease and mortality is well established, it remains unclear whether long-term TTR suppression via ATTR therapies increases risk of disease. Clinical decisions in ATTR, however, should reflect the current understanding of the roles of TTR and the patient's clinical history.TTR serves vital physiologic roles across organ systems. Given its clinically protective properties, continued investigation into the potential long-term impact of TTR suppression via knockdown or gene editing therapies is prudent. ATTR treatment selection should reflect an awareness of the physiologic importance of TTR, as well as consideration of the potential long-term impact of chronic TTR suppression.",Annals of medicine,"Dec, 2025",2025,Dec,,Gertz M A|Aras M A|Bart N|Brannagan T H|Griffin J M|Kontorovich A R|Rosen A M,Gertz M A,"Division of Hematology, Mayo Clinic, Rochester, MN, USA.|Department of Medicine, Division of Cardiology, UCSF Medical Center, University of California San Francisco, San Francisco, CA, USA.|Department of Cardiology, St Vincent's Hospital, Sydney, NSW, Australia.|School of Clinical Medicine, Faculty of Health and Medicine, The University of New South Wales, Sydney, NSW, Australia.|The Victor Chang Cardiac Research Institute, Sydney, NSW, Australia.|Department of Cardiology, Brigham and Women's Hospital, Boston, MA, USA.|Harvard Medical School, Boston, MA, USA.|Department of Neurology, Columbia University, Vagelos College of Physicians and Surgeons, New York, NY, USA.|Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, SC, USA.|Fuster Heart Hospital and Cardiovascular Research Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.|BridgeBio Pharma, Inc, San Francisco, CA, USA.","Gertz M A, Aras M A, Bart N, Brannagan T H, Griffin J M, Kontorovich A R, Rosen A M",https://pubmed.ncbi.nlm.nih.gov/40717228/,"Transthyretin (TTR) is a crucial protein that plays important roles in various bodily functions, including neuroprotection, glucose regulation, and bone health. While low levels of TTR are associated with increased mortality, the long-term impact of therapies that suppress TTR for treating transthyretin amyloidosis (ATTR) remains unclear. Clinicians should consider the potential effects of TTR suppression on normal biological pathways when selecting"
40721556,Harlequin syndrome: using clinical features and autonomic testing to unmask the disorder.,"Harlequin syndrome is a rare autonomic disorder characterized by unilateral facial flushing and contralateral anhidrosis. We sought to delineate underlying causes, clinical presentations, and autonomic testing profiles of patients with Harlequin syndrome.Retrospective chart review was performed of the Mayo Clinic electronic health record for patients with a Harlequin syndrome diagnosis from 1998 to 2024. Clinical, laboratory, imaging, and autonomic function testing results, including autonomic reflex screen (ARS) and thermoregulatory sweat test (TST), were reviewed.Of 51 patients with Harlequin syndrome, 39 (76%) were women. Median age of onset was 52 years (range 8-73 years). Harlequin syndrome was often idiopathic (N = 19; 37%), followed by postsurgical (N = 9; 17%), neoplasm (N = 5; 9.8%), trauma (N = 4; 7.8%), small fiber neuropathy (N = 4; 7.8%), systemic causes (N = 3; 5.9%), autoimmune (N = 3; 5.9%), pure autonomic failure (N = 2; 3.9%), and multiple sclerosis (N = 1; 2%). Pupil abnormalities were found in 13 patients (25.5%) with abnormal muscle stretch reflexes in 17 (33.3%). Headache was a comorbidity in 20 patients (39%). Of those with postsurgical onset, various surgeries preceded Harlequin syndrome onset, including heart, lung, and neck operations. Onset was acute or subacute in the majority of postsurgical patients (57%), while insidious onset was most common in nonsurgical patients (89%; p = 0.001). Median anhidrosis on TST was 9% (range 0.6-63%; N = 27). Median composite autonomic severity score was 1 (interquartile range (IQR) 0-3; N = 31).Harlequin syndrome commonly has an insidious onset and occurs without an identifiable cause, which could be considered primary Harlequin syndrome. Secondary Harlequin syndrome can occur following surgeries in the vicinity of sympathetic pathways, which most commonly leads to an acute or subacute presentation.© 2025. Springer-Verlag GmbH Germany.",Clin Auton Res,"Dec, 2025",2025,Dec,,Padilla H|Cheshire W P|Benarroch E E|Berini S E|Cutsforth-Gregory J K|Mauermann M L|Sandroni P|Shouman K|Low P A|Singer W|Coon E A,Padilla H|Cheshire W P|Benarroch E E|Berini S E|Cutsforth-Gregory J K|Mauermann M L|Sandroni P|Shouman K|Low P A|Singer W|Coon E A,"Alix School of Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.|Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.|Department of Neurology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. Coon.elizabeth@mayo.edu.","Padilla H, Cheshire W P, Benarroch E E, Berini S E, Cutsforth-Gregory J K, Mauermann M L, Sandroni P, Shouman K, Low P A, Singer W, Coon E A",https://pubmed.ncbi.nlm.nih.gov/40721556/,"Harlequin syndrome is a rare disorder that causes unilateral facial flushing and reduced sweating on the opposite side. The study found that Harlequin syndrome can have various underlying causes, including surgery, cancer, and autoimmune conditions. Understanding the different causes and clinical features of Harlequin syndrome can help healthcare providers diagnose and manage this disorder more effectively."
40730019,Using artificial intelligence to improve cell therapy assays: automated quantitative image analysis of cells on matrices.,"As the field of cell therapy continues to advance, the combination of cells and directed delivery methods (such as three-dimensional scaffolds, cell printing etc.) continues to grow. These technologies require methods to accurately determine cell numbers and viability to enhance process optimization and develop appropriate release tests. Current methods have limited dynamic range and require substantial manual effort to produce results. Here we describe a simple fluorescent imaging-based method for counting live and dead cells in scaffold cultures that is consistent, automated, and quantitative. First, we optimized labware to control the samples providing uniform imaging fields with standard methods for cell number and viability. We then used a traditional, nondynamic image quantitation software (Gen5, Winooski, VT) across a range of cell concentrations and compared it to the ability of a trained artificial intelligence software (Aiforia, Helsinki, Finland) to determine both cell counts and cell viability in image analysis. Using Aiforia, the live cell counts were highly correlative to seeding concentration (p = 0.0007; r2=0.96) across all tested ranges whereas Gen5 showed no correlation (p = 0.6; r2=0.09). Dead cell counts measured by the two methods were correlated to each other (p = 0.004; r2=0.90) indicating that both systems were equally capable using Propidium Iodide based detection. After completing proper training of the AI system, it provided a clear improvement in data accuracy from its ability to recognize cells amidst highly dynamic backgrounds typical of scaffold culture images. We believe that cell therapy will significantly benefit from AI based approaches.Copyright © 2025 Elsevier Ltd. All rights reserved.",Tissue & cell,"Dec, 2025",2025,Dec,,Bornschlegl A M|Dietz A B,Bornschlegl A M|Dietz A B,"Department of Lab Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. Electronic address: Bornschlegl.Alexander@mayo.edu.|Department of Lab Medicine and Pathology, Division of Experimental Pathology, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. Electronic address: Dietz.Allan@mayo.edu.","Bornschlegl A M, Dietz A B",https://pubmed.ncbi.nlm.nih.gov/40730019/,"The key finding of this research is that an artificial intelligence (AI) software can accurately count live and dead cells in scaffold cultures, which is a significant improvement over traditional image quantitation methods. This AI-based approach can enhance the optimization and development of cell therapy processes by providing more accurate and automated cell counting and viability assessment."
40836154,ASO Author Reflections: Survival of Patients with HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy Based on Presenting Clinical Stage and Response to Neoadjuvant Chemotherapy.,No abstract available.,Annals of surgical oncology,"Dec, 2025",2025,Dec,,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.|Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.Judy@mayo.edu.","Tashjian N L, Hoskin T L, Leon-Ferre R A, Boughey J C",https://pubmed.ncbi.nlm.nih.gov/40836154/,This research likely explores the survival rates of patients with a specific type of breast cancer (HER2-positive) after they receive chemotherapy before surgery. The study examines how the patient's initial cancer stage and their response to the pre-surgery chemotherapy treatment may affect their overall survival.
40836583,State-of-the-art management of Dravet syndrome.,"Dravet syndrome is a severe developmental and epileptic encephalopathy caused by heterozygous, loss-of-function, pathogenic variants in the SCN1A gene. It is characterized by frequent, often prolonged convulsive seizures. Dravet syndrome is associated with diverse comorbid conditions, including developmental impairment, intellectual disability, and behavioral disturbances, in addition to high mortality rates. Prompt diagnosis and treatment initiation are essential to reduce seizure frequency, status epilepticus, and potentially improve neurodevelopmental outcomes. Currently available therapies such as fenfluramine, stiripentol, and cannabidiol have demonstrated significant reduction in convulsive seizure frequency, based on randomized controlled trials and real-world studies; however, they have not markedly affected non-seizure symptoms. Emerging therapies such as genetic modulation are promising given their potential for disease modification, seizure frequency reduction, and improvement of non-seizure outcomes. This review of observational studies and randomized clinical trials provides an overview of the natural history of Dravet syndrome, current treatment guidelines with recently approved medications, addressing both safety and efficacy, and new therapeutic approaches, including disease-modifying therapies. The therapeutic landscape in Dravet syndrome is evolving, with the use of new antiseizure agents and precision therapies that target the SCN1A variant. Goals of treatment include improvement of seizure burden, neurodevelopment, comorbidities, and quality of life in individuals with Dravet syndrome.© 2025 Mac Keith Press.",Developmental medicine and child neurology,"Dec, 2025",2025,Dec,,Vasquez A|Wirrell E C,Vasquez A|Wirrell E C,"Department of Neurology, Mayo Clinic, Rochester, MN, USA.","Vasquez A, Wirrell E C",https://pubmed.ncbi.nlm.nih.gov/40836583/,"Dravet syndrome is a severe genetic disorder characterized by frequent, prolonged seizures and developmental impairment. Recent advancements in treatment, including new medications and emerging therapies targeting the underlying genetic cause, have shown promise in reducing seizure frequency and potentially improving overall outcomes for individuals with Dravet syndrome."
40840401,Assessing the impact of emergency medicine pharmacists on fibrinolytic door-to-needle times in acute ischemic stroke: A systematic review and meta-analysis (Pharmacist-assisted Stroke Treatments I (PhAST-1)).,"Acute ischemic stroke (AIS) requires time-sensitive fibrinolytic therapy measured by door-to-needle (DTN) time. Emergency medicine pharmacists (EMPs) are integral in emergency departments (EDs) for optimizing AIS care as they possess expertise in drug therapy and emergency response.The purpose of this systematic review and meta-analysis (SR/MA) is to evaluate EMP impact on DTN time.This SR/MA searched multiple databases. Eligibility criteria included adult ED patients with AIS receiving fibrinolytics with defined EMP involvement. The primary endpoint was fibrinolytic DTN time. Secondary endpoints included achievement of timely fibrinolytic and length of stay (LOS). Meta-analysis was conducted using random-effects models.Of 494 total citations identified, 214 citations met screening criteria with 22 studies undergoing full text review and 9 observational, retrospective, cohort studies included. A total of 1064 patients were included for MA with 441 (41.4 %) in the EMP present group and 623 (58.6 %) in the EMP absent group. EMP presence was associated with reduced mean DTN time by 14.6 min (95 % CI -18.1, -11.1 min). Odds of achieving a DTN within 60- and 45-min was higher with EMP presence, OR 2.85 (95 % CI 1.40, 5.79) and 2.75 (95 % CI 1.99, 3.79), respectively. ICU LOS was longer by 2.07 days in the EMP present group, but hospital LOS was not different between groups.EMP presence during AIS management is associated with a reduction in fibrinolytic DTN time compared to no EMP presence. These findings highlight the importance of EMPs in optimizing patient outcomes related to stroke care.Copyright © 2025 Elsevier Inc. All rights reserved.",The American journal of emergency medicine,"Dec, 2025",2025,Dec,,Mercer K J|Howington G T|Brown C S|Gilbert B W|Cole K|Acquisto N M|Zimmerman D E|Ray L|Gerberi D|Mattson A E|Faine B|Rech M A,Brown C S|Cole K|Acquisto N M|Gerberi D|Mattson A E,"The University of Texas at Austin College of Pharmacy, 2409 University Ave, A1910, Austin, TX 78712, United States. Electronic address: kevinmercer.pharmacy@gmail.com.|University of Kentucky College of Pharmacy, 789 S Limestone St, Lexington, KY 40536, United States; University of Kentucky HealthCare, 1000 S Limestone St, Lexington, KY 40506, United States. Electronic address: gavin.howington@uky.edu.|Department of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55902, United States. Electronic address: brown.caitlin1@mayo.edu.|Department of Pharmacy, Wesley Medical Center, 550 N Hillside St, Wichita, KS 67214, United States. Electronic address: brian.gilbert@wesleymc.com.|Department of Quantitative Health Sciences, Mayo Clinic, 200 1st St SW, Rochester, MN 55902, United States. Electronic address: cole.kristin@mayo.edu.|University of Rochester Medical Center, 601 Elmwood Ave Box 638, Rochester, NY 14642, United States. Electronic address: nicole_acquisto@urmc.rochester.edu.|Duquesne University School of Pharmacy, 600 Forbes Ave, Pittsburgh, PA 15282, United States. Electronic address: zimmerm6@duq.edu.|Department of Pharmacy, Denver Health, 777 Bannock St, Denver, CO 80204, United States. Electronic address: lance.ray@dhha.org.|Mayo Clinic, 200 1st St SW, Rochester, MN 55905, United States. Electronic address: gerberi.danielle@mayo.edu.|Department of Pharmacy, Mayo Clinic, 200 1st St SW, Rochester, MN 55902, United States. Electronic address: mattson.alicia@mayo.edu.|University of Iowa College of Pharmacy, 180 S Grand Ave, Iowa City, IA 52242, United States. Electronic address: brett-faine@uiowa.edu.|Department of Veterans Affairs, Center of Innovation for Complex Chronic Healthcare, Edward Hines, Jr. VA Hospital, 5000 5th Ave, Hines, IL 60141, United States. Electronic address: megan.a.rech@gmail.com.","Mercer K J, Howington G T, Brown C S, Gilbert B W, Cole K, Acquisto N M, Zimmerman D E, Ray L, Gerberi D, Mattson A E, Faine B, Rech M A",https://pubmed.ncbi.nlm.nih.gov/40840401/,This study found that the presence of emergency medicine pharmacists in the emergency department can significantly reduce the time it takes to administer life-saving fibrinolytic therapy for patients experiencing an acute ischemic stroke. This highlights the important role pharmacists can play in optimizing stroke care and improving patient outcomes.
40932302,A cautionary case series: tafamidis mistreatment following erroneous diagnosis of transthyretin cardiac amyloidosis.,No abstract available.,Amyloid,"Dec, 2025",2025,Dec,,Muchtar E|Gonzalez Bonilla H|Sanchorawala V|Gurijala N|Masri A|Davis B|Abou Ezzeddine O|Milani P|Palladini G|Cuomo M|Maurer M|Grogan M,Muchtar E|Gonzalez Bonilla H|Abou Ezzeddine O|Grogan M,"Division of Hematology, Mayo Clinic, Rochester, MN, USA.|Division of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, USA.|Division of Cardiovascular Diseases, University of Alabama, Birmingham, AL, USA.|Amyloidosis Center, Boston University Chobanian & Avedisian School of Medicine and Boston Medical Center, Boston, MA, USA.|Division of Cardiology, Oregon Health and Science University Hospital, Portland, OR, USA.|Department of Molecular Medicine, University of Pavia, Pavia, Italy.|Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy.|Division of Cardiology, Columbia University, New York, NY, USA.","Muchtar E, Gonzalez Bonilla H, Sanchorawala V, Gurijala N, Masri A, Davis B, Abou Ezzeddine O, Milani P, Palladini G, Cuomo M, Maurer M, Grogan M",https://pubmed.ncbi.nlm.nih.gov/40932302/,"This research likely explores cases where patients were incorrectly diagnosed with a specific type of heart disease, called transthyretin cardiac amyloidosis. The research may examine the consequences of these erroneous diagnoses, including the potential misuse of a medication called tafamidis that is used to treat this condition."
40921901,ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Adaptive Narrow Excision Versus Wide Excision for Adults with AJCC Stage I Cutaneous Melanoma.,No abstract available.,Annals of surgical oncology,"Dec, 2025",2025,Dec,,Bichakjian C K|Swetter S M|Carroll B T|Vidal N Y|Simons E A|Vetto J T|Yu W Y,Vidal N Y,"Department of Dermatology, University of Michigan, Ann Arbor, MI, USA.|Department of Dermatology/Pigmented Lesion and Melanoma Program, Stanford Medicine and Cancer Institute, Palo Alto, CA, USA.|University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.|Division of Dermatologic Surgery, Department of Dermatology, Mayo Clinic, Rochester, MN, USA.|Department of Dermatology, Oregon Health and Science University, Portland, OR, USA.|Department of Dermatology, Oregon Health and Science University, Portland, OR, USA. yuwe@ohsu.edu.|Operative Care Division, Veterans Affairs Portland Medical Center, Portland, USA. yuwe@ohsu.edu.","Bichakjian C K, Swetter S M, Carroll B T, Vidal N Y, Simons E A, Vetto J T, Yu W Y",https://pubmed.ncbi.nlm.nih.gov/40921901/,"This research likely explores different surgical approaches for treating early-stage skin cancer (melanoma). It compares the outcomes of two surgical techniques: adaptive narrow excision and wide excision, in order to determine the most effective method for adults with stage I melanoma."
40925049,Reply by Authors.,No abstract available.,The Journal of urology,"Dec, 2025",2025,Dec,,Abou Chawareb E|Hammad M A M|Azad B|Gross M S|Payne B|Swerdloff D|Miller J A|Andrianne R|Burnett A L|Gross K|Hatzichristodoulou G|Hotaling J M|Hsieh T|Jones J M|Lentz A|Modgil V|Osmonov D|Park S H|Pearce I|Perito P|Sadeghi-Nejad H|Sempels M|Suarez-Sarmiento A|Simhan J|van Renterghem K|Warner J N|Ziegelmann M|Yafi F A|Barham D W,Warner J N|Ziegelmann M,"Department of Urology, University of California, Irvine, Irvine, California.|Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana.|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.|Brooke Army Medical Center, Fort Sam Houston, Texas.|Fox Chase Cancer Center, Philadelphia, Pennsylvania.|University Hospital of Liège, Liège, Belgium.|Department of Urology, Johns Hopkins University, Baltimore, Maryland.|Department of Surgery, University of Utah, Salt Lake City, Utah.|Martha-Maria Hospital Nuremberg, Nuremberg, Germany.|University of Utah Medical School, Salt Lake City, Utah.|Department of Urology, University of California, San Diego, San Diego, California.|Department of Urology, Duke University, Durham, North Carolina.|Manchester University NHS Foundation Trust, Manchester, United Kingdom.|University Hospital Schleswig-Holstein, Lübeck, Germany.|Sewum Prosthetic Urology, Seoul, Republic of Korea.|Perito Urology, Coral Gables, Florida.|Department of Urology, New York University, New York, New York.|Jessa Hospital, Hasselt, Belgium.|Mayo Clinic, Rochester, Minnesota.","Abou Chawareb E, Hammad M A M, Azad B, Gross M S, Payne B, Swerdloff D, Miller J A, Andrianne R, Burnett A L, Gross K, Hatzichristodoulou G, Hotaling J M, Hsieh T, Jones J M, Lentz A, Barham D W, et al.",https://pubmed.ncbi.nlm.nih.gov/40925049/,This research likely explores the authors' response to previous work or comments made about their research. It suggests the authors are addressing or clarifying something related to their previous published findings or conclusions.
40925054,Predicting left-without-being-seen in an emergency department as a dynamic risk.,"Accurately predicting which Emergency Department (ED) patients are at high risk of leaving without being seen (LWBS) could enable targeted interventions aimed at reducing LWBS rates. Machine Learning (ML) models that dynamically update these risk predictions as patients experience more time waiting were developed and validated, in order to improve the prediction accuracy and correctly identify more patients who LWBS.The study was deemed quality improvement by the institutional review board, and collected all patient visits to the ED of a large academic medical campus over 24 months. The first 18 months of data were used to develop two types of classification models using XGboost: (1) a static model that uses patient and ED census information at the time of arrival to predict the risk to LWBS; and (2) a dynamic model that updates the predictions based on new information after 30 min for patients who are still waiting in the ED. The final six months of data were then used as an experimental period to test the accuracy of the two models.For a cohort of 150,959 ED patient arrivals, the mean patient age was 46, 51 % of arrivals were female, and 2.17 % of patients LWBS during their wait. The models achieved an area under the receiver operating characteristic curve (AUROC) of 0.86 when dynamically updating LWBS risk levels over time. This was in contrast to an AUROC of 0.80 for the static model from past literature that does not update the score after the moment of arrival. Over the experimental period, the dynamic model also showed the ability to reduce the number of missed LWBS cases by approximately 50 % as compared to the static model, without incurring any additional false-positives.Dynamically updating patients' risk to LWBS as their wait goes on significantly reduces the number of patients who LWBS that are missed by prediction models as compared to traditional static prediction approaches.Copyright © 2025 Elsevier Inc. All rights reserved.",The American journal of emergency medicine,"Dec, 2025",2025,Dec,,Ravid Y|Ibrahim R|Hu J|Pasupathy K|Nestler D M|Sarhangian V|Afèche P,Nestler D M,"University of Toronto, Rotman School of Management, Canada. Electronic address: y.ravid@rotman.utoronto.ca.|University College London, School of Management, UK.|Old Dominion University, Strome College of Business, United States.|University of Illinois Chicago, Biomedical & Health Information Sciences, United States.|Mayo Clinic, Rochester, MN, United States.|University of Toronto, Department of Mechanical & Industrial Engineering, Canada.|University of Toronto, Rotman School of Management, Canada.","Ravid Y, Ibrahim R, Hu J, Pasupathy K, Nestler D M, Sarhangian V, Afèche P",https://pubmed.ncbi.nlm.nih.gov/40925054/,"This study developed a machine learning model that can dynamically update a patient's risk of leaving the emergency department without being seen, as they wait longer. This model was more accurate at identifying high-risk patients compared to traditional static models, allowing for targeted interventions to reduce the number of patients who leave without being treated."
40925989,Evaluation of pulmonary hypertension in heart failure with preserved ejection fraction.,"In contemporary clinical practice, pulmonary hypertension (PH) is most commonly caused by heart failure with preserved ejection fraction (HFpEF). This high prevalence of HFpEF-related PH has contributed to complexity in diagnosis and evaluation of PH in the context of other diseases such as the presence of risk factors for group 1 PH. In this review, we discuss emerging concepts guiding the evaluation, pathobiology, and treatment of PH in patients with HFpEF or HFpEF-associated risk factors.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Heart failure reviews,"Dec, 2025",2025,Dec,,Cao J J L|Reddy Y N V,Cao J J L|Reddy Y N V,"Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA.|Department of Cardiovascular Medicine, Mayo Clinic College of Medicine, 200 First Street SW, Rochester, MN, 55905, USA. reddy.yogesh@mayo.edu.","Cao J J L, Reddy Y N V",https://pubmed.ncbi.nlm.nih.gov/40925989/,"Pulmonary hypertension (high blood pressure in the lungs) is commonly caused by heart failure with preserved ejection fraction (a type of heart disease). This makes it challenging to diagnose and treat pulmonary hypertension in patients with other risk factors. The review discusses new ways to evaluate, understand, and treat pulmonary hypertension in people with this type of heart disease."
40928026,Reply by Authors.,No abstract available.,The Journal of urology,"Dec, 2025",2025,Dec,,Abou Chawareb E|Hammad M A M|Azad B|Gross M S|Payne B|Swerdloff D|Miller J A|Andrianne R|Burnett A L|Gross K|Hatzichristodoulou G|Hotaling J M|Hsieh T|Jones J M|Lentz A|Modgil V|Osmonov D|Park S H|Pearce I|Perito P|Sadeghi-Nejad H|Sempels M|Suarez-Sarmiento A|Simhan J|van Renterghem K|Warner J N|Ziegelmann M|Yafi F A|Barham D W,Warner J N|Ziegelmann M,"Department of Urology, University of California, Irvine, Irvine, California.|Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana.|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.|Brooke Army Medical Center, Fort Sam Houston, Texas.|Fox Chase Cancer Center, Philadelphia, Pennsylvania.|University Hospital of Liège, Liège, Belgium.|Department of Urology, Johns Hopkins University, Baltimore, Maryland.|Department of Surgery, University of Utah, Salt Lake City, Utah.|Martha-Maria Hospital Nuremberg, Nuremberg, Germany.|University of Utah Medical School, Salt Lake City, Utah.|Department of Urology, University of California, San Diego, San Diego, California.|Department of Urology, Duke University, Durham, North Carolina.|Manchester University NHS Foundation Trust, Manchester, United Kingdom.|University Hospital Schleswig-Holstein, Lübeck, Germany.|Sewum Prosthetic Urology, Seoul, Republic of Korea.|Perito Urology, Coral Gables, Florida.|Department of Urology, New York University, New York, New York.|Jessa Hospital, Hasselt, Belgium.|Mayo Clinic, Rochester, Minnesota.","Abou Chawareb E, Hammad M A M, Azad B, Gross M S, Payne B, Swerdloff D, Miller J A, Andrianne R, Burnett A L, Gross K, Hatzichristodoulou G, Hotaling J M, Hsieh T, Jones J M, Lentz A, Barham D W, et al.",https://pubmed.ncbi.nlm.nih.gov/40928026/,"This research likely explores the authors' response or reply to something, such as a previous publication, a critique, or a question. The study may involve the authors addressing or clarifying points made in their earlier work or providing additional insights or perspectives on the topic."
40928066,Association between physician specialty and first-attempt intubation success in the emergency department.,"Emergency airway management in the emergency department (ED) is a high-risk procedure associated with patient outcomes. First-attempt success is a widely recognized quality metric, as multiple attempts are associated with an increased risk of peri-intubation complications. In Brazil, where emergency medicine is a recently established specialty, many ED are staffed by physicians without formal emergency medicine training. The association between emergency medicine training and intubation outcomes in this setting has not been well characterized.To assess the association of physician specialty with first-attempt success and immediate peri-intubation complications in Brazilian EDs.Secondary analysis of a multicenter, prospective cohort study from the Brazilian Airway Registry Cooperation.This study included adult patients who underwent tracheal intubation in EDs between March 2022 and April 2024. Patients were excluded if the intubation occurred outside the ED, during cardiopulmonary resuscitation, or for elective procedures. Intubations performed by medical students were also excluded. Physicians were categorized by specialty as emergency medicine or nonemergency medicine.The primary outcome was first-attempt success; secondary outcomes included peri-intubation complications (severe hypoxemia, hemodynamic instability, and cardiac arrest). Multivariable logistic regression was used to assess the association between physician specialty and outcomes.Among 2582 patients, 1087 (42.1%) were intubated by emergency physicians and 1495 (57.9%) by other physicians (mainly internal medicine and surgery). Intubations by emergency physicians were associated with a higher rate of first-attempt success [80.4 vs. 70.9%, adjusted odds ratio [aOR]: 1.63, 95% confidence interval (CI): 1.34-1.97]. There was also a higher odds of intubations without major complications (aOR: 1.20, 95% CI: 1.01-1.42).In this study, there was a higher rate of first-attempt success in intubations performed by board-certified emergency physicians compared with other physicians working in Brazilian EDs.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Eur J Emerg Med,"Dec 01, 2025",2025,Dec,01,Oliveira J E Silva L|Von Hellmann R|Pinheiro Besen B A M|de Carvalho J M D|Hajjar L A|Pedrollo D|Goncalves Nogueira C|Figueiredo N M P|Miranda C H|Martins D|Baumgratz T D|Bergesch B|Costa D|Colleoni O|Zanettini J|Freitas A P|Moreira N P|Gaspar P L|Tambelli R|Costa M C|Silveira S|Correia W|de Maria R G|Vinholes Filho U A|Weber A P|da Silva Castro V|Dornelles C F D|Tabach B S|Guimarães H P|Stanzani G|Gava T F|Mullan A|Alonso Silva G P|de Oliveira G C|Sandefur B J|Bellolio F|Alencar J C G|Ward A Maia I,Oliveira J E Silva L|Mullan A|Sandefur B J|Bellolio F|Ward A Maia I,"Division of Emergency Medicine, Universidade Federal do Rio Grande do Sul, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil.|Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Intensive Care Medicine, Monash Health, Melbourne, Victoria, Australia.|IDOR Education and Research Institute, Rio de Janeiro.|Department of Emergency Medicine, Hospital das Clínicas da Faculdade de Ciências Médicas da Universidade de São Paulo, São Paulo, São Paulo.|Department of Emergency Medicine, Hospital Metropolitano Odilon Behrens, Belo Horizonte, Minas Gerais.|Department of Emergency Medicine, Ribeirao Preto School of Medicine, University of Sao Paulo, Ribeirao Preto.|Department of Emergency Medicine, Hospital das Clínicas da Faculdade de Medicina de Botucatu, Botucatu, Sao Paulo.|Department of Emergency Medicine, Hospital Regional de Sao José - Dr. Homero de Miranda Gomes, São José, Santa Catarina.|Department of Emergency Medicine, Hospital Sao Lucas da Pontificia Universidade Católica Do Rio Grande Do Sul.|Department of Emergency Medicine, Hospital de Pronto Socorro, Porto Alegre, Rio Grande Do Sul.|Department of Emergency Medicine, Hospital Geral de Fortaleza.|Department of Emergency Medicine, Hospital Dr. Carlos Alberto Studart Gomes, Fortaleza, Ceara.|Department of Emergency Medicine, Hospital das Clínicas da Faculdade de Medicina de Marilia, Marilia.|Department of Emergency Medicine, Hospital Augusto de Oliveira Camargo, Indaiatuba, Sao Paulo.|Department of Emergency Medicine, Hospital Regional Alto Vale, Rio Do Sul, Santa Catarina.|Department of Emergency Medicine, Hospital Santo Antonio, Sinop, Mato Grosso.|Department of Emergency Medicine, Hospital Nossa Senhora da Conceição, Porto Alegre.|Department of Emergency Medicine, Hospital Bruno Born, Lajeado.|Unidade de Pronto Atendimento de Lajeado, Lajeado.|Department of Emergency Medicine, Hospital Santa Cruz, Santa Cruz, Rio Grande Do Sul.|Faculdade de Medicina de Bauru, Universidade de Sao Paulo, Bauru, Sao Paulo, Brazil.","Oliveira J E Silva L, Von Hellmann R, Pinheiro Besen B A M, de Carvalho J M D, Hajjar L A, Pedrollo D, Goncalves Nogueira C, Figueiredo N M P, Miranda C H, Martins D, Baumgratz T D, Bergesch B, Costa D, Colleoni O, Zanettini J, Ward A Maia I, et al.",https://pubmed.ncbi.nlm.nih.gov/40928066/,This study found that emergency physicians in Brazil had a higher rate of successful first-attempt intubations and fewer immediate complications compared to other physicians working in emergency departments. This suggests that specialized emergency medicine training may improve critical airway management skills and patient outcomes.
40937730,Reply by Authors.,No abstract available.,The Journal of urology,"Dec, 2025",2025,Dec,,Abou Chawareb E|Hammad M A M|Azad B|Gross M S|Payne B|Swerdloff D|Miller J A|Andrianne R|Burnett A L|Gross K|Hatzichristodoulou G|Hotaling J M|Hsieh T|Jones J M|Lentz A|Modgil V|Osmonov D|Park S H|Pearce I|Perito P|Sadeghi-Nejad H|Sempels M|Suarez-Sarmiento A|Simhan J|van Renterghem K|Warner J N|Ziegelmann M|Yafi F A|Barham D W,Warner J N|Ziegelmann M,"Department of Urology, University of California, Irvine, Irvine, California.|Department of Urology, Tulane University School of Medicine, New Orleans, Louisiana.|Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.|Brooke Army Medical Center, Fort Sam Houston, Texas.|Fox Chase Cancer Center, Philadelphia, Pennsylvania.|University Hospital of Liège, Liège, Belgium.|Department of Urology, Johns Hopkins University, Baltimore, Maryland.|Department of Surgery, University of Utah, Salt Lake City, Utah.|Martha-Maria Hospital Nuremberg, Nuremberg, Germany.|University of Utah Medical School, Salt Lake City, Utah.|Department of Urology, University of California, San Diego, San Diego, California.|Department of Urology, Duke University, Durham, North Carolina.|Manchester University NHS Foundation Trust, Manchester, United Kingdom.|University Hospital Schleswig-Holstein, Lübeck, Germany.|Sewum Prosthetic Urology, Seoul, Republic of Korea.|Perito Urology, Coral Gables, Florida.|Department of Urology, New York University, New York, New York.|Jessa Hospital, Hasselt, Belgium.|Mayo Clinic, Rochester, Minnesota.","Abou Chawareb E, Hammad M A M, Azad B, Gross M S, Payne B, Swerdloff D, Miller J A, Andrianne R, Burnett A L, Gross K, Hatzichristodoulou G, Hotaling J M, Hsieh T, Jones J M, Lentz A, Barham D W, et al.",https://pubmed.ncbi.nlm.nih.gov/40937730/,"This research likely explores the authors' response or reply to something, such as a previous publication, a critique, or a comment. The study may involve the authors addressing or clarifying points made in their earlier work or by others."
40915889,Diagnostic Approaches for Clostridioides difficile Infection.,"This article offers a clinically focused overview of Clostridioides difficile infection (CDI) diagnosis, emphasizing the need to test only symptomatic patients and to distinguish true infection from colonization. It reviews multistep diagnostic algorithms that pair glutamate dehydrogenase (GDH) testing or nucleic acid amplification tests (NAAT) with toxin assays to improve accuracy. The limitations of PCR-only approaches are discussed, with a strong emphasis on clinical correlation. Guideline-based recommendations are integrated throughout, providing evidence-based direction for clinicians managing CDI in both inpatient and outpatient settings.Copyright © 2025 Elsevier Inc. All rights reserved.",Infectious disease clinics of North America,"Dec, 2025",2025,Dec,,Berry P|Khanna S,Berry P|Khanna S,"Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.|Division of Gastroenterology & Hepatology, Department of Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: Khanna.Sahil@mayo.edu.","Berry P, Khanna S",https://pubmed.ncbi.nlm.nih.gov/40915889/,"Clostridioides difficile infection (CDI) is a serious condition that requires accurate diagnosis. This research recommends using a combination of tests, such as glutamate dehydrogenase (GDH) or nucleic acid amplification tests (NAAT) along with toxin assays, to improve the accuracy of CDI diagnosis. The study emphasizes the importance of testing only symptomatic patients and correlating the test results with the clinical presentation to distinguish true"
40939241,Effect of hyperangulated videolaryngoscopy on first-attempt success in tracheal intubations: A systematic review and meta-analysis.,"To determine whether hyperangulated videolaryngoscopy (HAVL) improves first-attempt success (FAS) in adult orotracheal intubations compared to standard-geometry videolaryngoscopy (SGVL), with a focus on emergency settings.We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) and comparative observational studies evaluating HAVL versus SGVL in adult tracheal intubations. Comprehensive searches were performed in Ovid MEDLINE, Embase, Cochrane, Scopus, and web of science from inception through November 2024. Risk of bias was assessed using RoB2 and Newcastle-Ottawa tools, and certainty of evidence was rated using GRADE. Both emergency and operating room intubations were included; most emergency data derived from large cohort studies.Of 4445 screened records, 25 studies (17 RCTs, 8 observational; 38,597 patients) were included. HAVL was associated with lower FAS overall (87.2 % vs 91.0 %; pooled RR 0.96, 95 % CI 0.94-0.99; p = 0.002). In emergency intubations (8 studies; n = 34,927), HAVL yielded reduced FAS (RR 0.97, 95 % CI 0.95-0.99; p = 0.003). There was no significant difference in difficult airways (RR 0.98, 95 % CI 0.92-1.05; p = 0.57). HAVL was linked to higher rates of airway trauma (7.5 % vs 2.9 %; RR 1.88, 95 % CI 1.01-3.49; p = 0.046) and numerically more adverse events. Certainty of evidence was low due to risk of bias and heterogeneity.In emergency intubations, HAVL was associated with lower first-attempt success and increased airway trauma compared to SGVL. These findings support prioritizing SGVL for emergency airway management, with careful operator training if HAVL is used.Copyright © 2025 Elsevier Inc. All rights reserved.",The American journal of emergency medicine,"Dec, 2025",2025,Dec,,von Hellmann R|Dorn de Carvalho J M|Subramaniam A|Bellolio F|Gerberi D|Maia I W A|Oliveira J E Silva L,Bellolio F|Gerberi D|Oliveira J E Silva L,"Department of Intensive Care Medicine, Monash Health, Victoria, Australia.|Department of Emergency Medicine, Hospital das Clínicas da Faculdade de Ciências Médicas da Universidade de São Paulo, São Paulo, Brazil.|Department of Intensive Care Medicine, Monash Health, Victoria, Australia; Australia and New Zealand Intensive Care Research Centre, School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Peninsula Clinical School, Monash University, Frankston, Victoria, Australia.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA.|Mayo Clinic Libraries, Rochester, MN, USA.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA; Universidade Federal do Rio Grande do Sul, Division of Emergency Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil. Electronic address: lojsilva@hcpa.edu.br.","von Hellmann R, Dorn de Carvalho J M, Subramaniam A, Bellolio F, Gerberi D, Maia I W A, Oliveira J E Silva L",https://pubmed.ncbi.nlm.nih.gov/40939241/,"The study found that hyperangulated videolaryngoscopy (HAVL) was associated with lower first-attempt success and higher rates of airway trauma compared to standard-geometry videolaryngoscopy (SGVL) in emergency intubations. These results suggest that SGVL should be prioritized for emergency airway management, with HAVL used only with proper operator training."
40940245,"ECMO in Pregnancy: Analysis of Indications, Management and Outcomes.","Extracorporeal membrane oxygenation (ECMO) has become a critical rescue therapy for pregnant and peripartum patients experiencing life-threatening cardiac or respiratory failure that is refractory to standard treatments. Pregnancy induces unique physiologic changes that influence ECMO initiation, cannulation, and management, necessitating specialized approaches to optimize outcomes for both mother and fetus. Pharmacologic challenges include altered drug kinetics and the risks associated with placental drug transfer, while anticoagulation strategies require a careful balance between thrombosis and bleeding, particularly around delivery. Obstetric management involves continuous fetal monitoring, individualized timing of delivery, and multidisciplinary coordination among critical care, obstetrics, neonatology, and anesthesiology teams. Evidence from case series, registries, and meta-analyses indicates favorable maternal survival, especially with venovenous ECMO, although fetal outcomes vary depending on gestational age and clinical circumstances. Ethical considerations are complex, emphasizing maternal autonomy alongside fetal well-being, often requiring decisions amid considerable uncertainty. Emerging technologies, such as artificial placenta systems, may offer future support options. Despite encouraging results, significant gaps remain in prospective data, standardized fetal monitoring, and ethical guidance. This review synthesizes current knowledge and underscores the need for ongoing research and multidisciplinary collaboration to improve care for pregnant patients requiring ECMO.Copyright © 2025 Elsevier Inc. All rights reserved.",Journal of cardiothoracic and vascular anesthesia,"Dec, 2025",2025,Dec,,Ripoll J G|Kahn-Pascual Y O|Seelhammer T G|Bittner E A|Chang M G|Ortoleva J|Diaz Soto J C|Elmadhoun O|Naoum E E|Wieruszewski P M|Nabzdyk C G|Ramakrishna H,Ripoll J G|Kahn-Pascual Y O|Seelhammer T G|Diaz Soto J C|Elmadhoun O|Wieruszewski P M|Nabzdyk C G|Ramakrishna H,"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.|Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, MA.|Department of Anesthesiology, Boston Medical Center, Boston, MA.|Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN. Electronic address: ramakrishna.harish@mayo.edu.","Ripoll J G, Kahn-Pascual Y O, Seelhammer T G, Bittner E A, Chang M G, Ortoleva J, Diaz Soto J C, Elmadhoun O, Naoum E E, Wieruszewski P M, Nabzdyk C G, Ramakrishna H",https://pubmed.ncbi.nlm.nih.gov/40940245/,"Extracorporeal membrane oxygenation (ECMO) is a critical treatment for pregnant women experiencing severe heart or lung failure. While ECMO can be effective, it requires specialized management due to the unique physiological changes during pregnancy. The review highlights the need for further research and multidisciplinary collaboration to improve care for pregnant patients requiring ECMO."
40940273,Revisional bariatric surgery in the elderly: a comprehensive review of the safety and efficacy profile.,"Despite the well-known safety and efficacy of metabolic and bariatric surgery, certain patients require revisional bariatric surgery (RBS) due to weight-related and/or procedure-related complications. Date on long-term RBS outcomes remains limited in the elderly.To evaluate the safety and efficacy of RBS in the elderly.Tertiary referral centers with prospectively maintained metabolic and bariatric surgery databases.A retrospective review was conducted for patients aged ≥ 60 years who underwent RBS between 2008 and 2023. Patient demographics, type of revisional procedure, postoperative outcomes, weight loss data, and nutritional parameters were collected. All patients had at least a 6-month follow-up and were followed at least 5 years after RBS when possible.201 patients were included. The most common indication for RBS was gastroesophageal reflux (37.8%). Conversion to Roux-en-Y gastric bypass was the most common RBS procedure (65.2%). This subgroup achieved significantly sustained mean percentage of total weight loss throughout follow-up. Conversion to sleeve gastrectomy subgroup only maintained a significant mean percentage of total weight loss at 6 months, 1 year, and 2 years postoperatively. The overall 30-day and late complication rates within the cohort were 17.4% and 26.9%, respectively. A .5% 30-day mortality rate and 0% long-term RBS-related morality rate were reported. For patients indicated for revision, RBS was successful in resolving malnutrition and did not result in recurrence of any nutritional deficiencies.Our study demonstrated that RBS is safe and effective in elderly patients in the long term. Proper RBS procedure selection is integral to address revision indication and decrease the risk of long-term complications.Copyright © 2025 American Society for Metabolic and Bariatric Surgery. Published by Elsevier Inc. All rights reserved.",Surg Obes Relat Dis,"Dec, 2025",2025,Dec,,Jawhar N|Sample J W|Pontecorvo A|Cornejo J|Evans L A|El Ghazal N|Laplante S J|Elli E F|Ghanem O M,Jawhar N|Sample J W|Pontecorvo A|Cornejo J|Evans L A|El Ghazal N|Laplante S J|Elli E F|Ghanem O M,"Department of Surgery, Mayo Clinic, Rochester, Minnesota.|Department of Surgery, Mayo Clinic Florida, Jacksonville, Florida.|Department of Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address: Ghanem.Omar@Mayo.Edu.","Jawhar N, Sample J W, Pontecorvo A, Cornejo J, Evans L A, El Ghazal N, Laplante S J, Elli E F, Ghanem O M",https://pubmed.ncbi.nlm.nih.gov/40940273/,"This study found that revisional bariatric surgery is safe and effective for elderly patients, with successful weight loss and resolution of nutritional deficiencies. The most common revision procedure was conversion to Roux-en-Y gastric bypass, which led to sustained weight loss over the long term. These findings suggest that revisional surgery can be a viable option for elderly patients who require additional treatment after initial bariatric surgery."
40944630,Third-Generation Bruton tyrosine kinase Inhibitors for the Treatment of Monoclonal Gammopathy of Thrombotic Significance (MGTS).,No abstract available.,American journal of hematology,"Dec, 2025",2025,Dec,,Man L|Kanack A J|Mauch E E|Splinter N P|Padmanabhan A,Kanack A J|Mauch E E|Splinter N P|Padmanabhan A,"Department of Medicine, University of Virginia, Charlottesville, Virginia, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.","Man L, Kanack A J, Mauch E E, Splinter N P, Padmanabhan A",https://pubmed.ncbi.nlm.nih.gov/40944630/,"This research likely explores the use of a new generation of a specific type of drug (Bruton tyrosine kinase inhibitors) to treat a condition called monoclonal gammopathy of thrombotic significance (MGTS). MGTS is a disorder that can lead to blood clots, and this study is investigating whether these third-generation drugs can be an effective treatment for this condition."
40947335,Heart Failure in 2025: Update With Perioperative Considerations.,No abstract available.,Journal of cardiothoracic and vascular anesthesia,"Dec, 2025",2025,Dec,,Mendapara P|Ramakrishna H|Stawiarski K,Ramakrishna H,"Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY.|Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN.|Department of Cardiology, Zucker School of Medicine at Hofstra/Northwell Health, Manhasset, NY. Electronic address: Kmstawiarski@gmail.com.","Mendapara P, Ramakrishna H, Stawiarski K",https://pubmed.ncbi.nlm.nih.gov/40947335/,"This research likely explores the current state and future projections of heart failure, a serious medical condition, in the year 2025. It may also consider the specific challenges and considerations that healthcare providers need to take into account when treating heart failure patients during surgical procedures or the perioperative period."
40947912,X-CircuiT and conventional exercise in home-based cardiac rehabilitation for patients with coronary artery disease and risk factors: a randomized controlled non-inferiority trial.,"This study evaluated the effectiveness of Xiangya Hospital Circuit Training (X-CircuiT), a multi-component exercise program, as an alternative to conventional exercise (ConEx) in improving cardiorespiratory and muscular fitness within home-based cardiac rehabilitation (HBCR) for patients with coronary artery disease and risk factors (CADRF).This randomized controlled non-inferiority trial consecutively enrolled patients with CADRF at Xiangya Hospital, China, between April and December 2020. Patients were assigned to a smartphone-guided X-CircuiT-HBCR or telephone call-guided ConEx-HBCR group for 12 weeks. Primary outcomes were cardiorespiratory fitness (peak oxygen uptake, V̇O2peak), and muscular fitness (30-sec arm curl and chair stand tests). The non-inferiority margins were 2.17 mL/kg/min, 2.70 reps, and 1.23 reps, respectively. Secondary outcomes included V̇O2 pulse, V̇O2 at ventilatory threshold, balance, flexibility, body mass index, health-related quality of life (HRQoL), self-efficacy, physical activity, safety, and exercise adherence.This trial included 54 participants (median age 53 yr, 37% females), with 27 per group. Both groups showed significant improvements in fitness. There were no significant differences between groups in the improvements in V̇O2peak (mean difference, -0.13 [95%CI, -1.76 to 1.50] mL/kg/min), arm curl test (0.21 [-1.35 to 1.77] reps), and chair stand test (1.30 [-0.18 to 2.77] reps), with 95% CIs within the non-inferiority range. No significant differences were found in HRQoL, self-efficacy, and exercise adherence (all p > .05). No adverse events occurred.X-CircuiT is non-inferior to ConEx in HBCR for CADRF patients, suggesting it as an effective alternative or supplement in HBCR programs.ChiCTR2000032451.",Annals of medicine,"Dec, 2025",2025,Dec,,Gong X|Ye Q|Zhang W|Shen Y|Cao Z|Dun Y|Liu S,Dun Y,"Division of Cardiac Rehabilitation, Department of Physical Medicine & Rehabilitation, Xiangya Hospital, Central South University, Changsha, Hunan, China.|National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.|Division of Preventive Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Physical Medicine & Rehabilitation, Xiangya Hospital, Central South University, Jiangxi (National Regional Center for Neurological Diseases), Nanchang, Jiangxi, China.","Gong X, Ye Q, Zhang W, Shen Y, Cao Z, Dun Y, Liu S",https://pubmed.ncbi.nlm.nih.gov/40947912/,"The study found that the Xiangya Hospital Circuit Training (X-CircuiT), a multi-component exercise program, is as effective as conventional exercise in improving cardiorespiratory and muscular fitness in home-based cardiac rehabilitation for patients with coronary artery disease and risk factors. This suggests that X-CircuiT can be an effective alternative or supplement to traditional cardiac rehabilitation programs."
40916763,Language Proficiency and Maternal and Neonatal Adverse Outcomes: A Retrospective Cohort Study.,"To compare maternal and neonatal adverse outcomes between women who are English proficient (EP) and those who have limited English proficiency (LEP).Retrospective cohort study.Single US academic medical centre with interpreter services.All pregnant women with deliveries during the study period.We retrospectively identified EP and LEP individuals (categorised by self-report) who delivered at Mayo Clinic, Rochester, Minnesota, USA, from 2015 to 2019. Overall composite adverse outcomes, as well as maternal and neonatal composite outcomes, were measured with generalised linear models and logistic regression, reporting estimates and 95% CIs. Multivariable logistic regression analysis was used to assess associations between language proficiency and outcome measures while controlling for other clinical factors.Composite overall, maternal and neonatal adverse outcomes.Among 10 427 EP and 900 LEP participants, the LEP group had a higher incidence of gestational diabetes, unplanned intensive care unit admission, uterine rupture, postpartum haemorrhage with transfusion, neonatal death and 5-min Apgar score less than 7. The composite overall, maternal and neonatal adverse outcomes were more prevalent in the LEP group than the EP group in unadjusted analysis. Of these, the composite adverse outcome remained significant when the model was adjusted (odds ratio, 1.40; 95% CI, 1.03-1.90).Pregnant women with LEP had increased incidence of adverse delivery outcomes, even in a setting with universal availability of medical interpreters.© 2025 John Wiley & Sons Ltd.",BJOG : an international journal of obstetrics and gynaecology,"Dec, 2025",2025,Dec,,Melson V|Gorman B G|Rajput S|Lu L|VanLith C J|Branda M E|Carranza L|Theiler R N,Melson V|Gorman B G|Rajput S|Lu L|VanLith C J|Branda M E|Carranza L|Theiler R N,"Mayo Clinic Alix School of Medicine, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.|Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.|Division of Clinical Trials and Biostatistics and, Mayo Clinic, Rochester, Minnesota, USA.|Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.","Melson V, Gorman B G, Rajput S, Lu L, VanLith C J, Branda M E, Carranza L, Theiler R N",https://pubmed.ncbi.nlm.nih.gov/40916763/,"This study found that pregnant women with limited English proficiency had a higher risk of adverse maternal and neonatal outcomes, even in a setting with access to medical interpreters. The key finding is that language barriers can contribute to poorer health outcomes for mothers and babies, highlighting the importance of addressing language access in healthcare."
40907619,A Decade of Interactive Educational Exchange: Impacting Interprofessional Palliative Care Education.,"The interprofessional clinical practice model is arguably the most impactful and generative aspect of hospice and palliative care (HPC) clinical practice. This article describes the innovative, shared interprofessional leadership model, andragogical infrastructure, program development, educational impact, and critical lessons from the Interactive Educational Exchange (IEE). In response to a deficit in interprofessional HPC educational opportunities for rapid scholarship dissemination and mentorship, interprofessional leaders from medicine, social work and nursing proposed and implemented the IEE at the Annual Assembly of Hospice and Palliative Care presented by the American Academy of Hospice and Palliative Medicine and Hospice and Palliative Nurses Association from 2010 to 2020. The reported outcome measures for interprofessional scholarship and engagement, session evaluations, and attendance demonstrate why this successful innovation was repeated annually for over a decade pre-COVID. Scholarship dissemination was rapid, with robust community engagement, inclusive of multiple professional disciplines over time. Indeed, the IEE became a step in the career trajectory of many interprofessional HPC clinician-educators during that decade. The highlighted lessons around vision, structure, and community leave us with an IEE model that can be flexibly adapted to other settings. In championing the interprofessional HPC clinical model forward to achieve the highest quality of care for our patients, we recommend prioritizing intentional models to promote and support interprofessional HPC educators in dissemination of scholarship, collaborative mentorship, and community building so all can thrive.Copyright © 2025 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.",Journal of pain and symptom management,"Dec, 2025",2025,Dec,,Morrison L J|Otis-Green S|Bruno J|Fordham P N|Carey E C,Carey E C,"Yale Palliative Care Program, Department of Medicine (L.M.), Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: laura.morrison@yale.edu.|Collaborative Caring (S.O.), Toluca Lake, California, USA.|American Academy of Hospice and Palliative Medicine (J.B.), Chicago, Illinois, USA.|University of Alabama Birmingham (P.F.), Birmingham, Alabama, USA.|Division of General Internal Medicine (E.C.), Geriatrics & Palliative Care, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Morrison L J, Otis-Green S, Bruno J, Fordham P N, Carey E C",https://pubmed.ncbi.nlm.nih.gov/40907619/,"The key finding of this research is that the Interactive Educational Exchange (IEE) program, which ran for over a decade, successfully promoted interprofessional education and collaboration in hospice and palliative care. The IEE provided a platform for rapid dissemination of research, mentorship, and community building among clinicians from different disciplines, which helped advance the interprofessional model of palliative care. The success of the IEE highlights the importance of intentional"
40840773,Extracorporeal membrane oxygenation in cardiogenic shock: A bridge in need of a destination.,No abstract available.,J Heart Lung Transplant,"Dec, 2025",2025,Dec,,Jentzer J C,Jentzer J C,"Division of Critical Care Cardiology, Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: jentzer.jacob@mayo.edu.",Jentzer J C,https://pubmed.ncbi.nlm.nih.gov/40840773/,"This research likely explores the use of extracorporeal membrane oxygenation (ECMO) in patients with cardiogenic shock, a condition where the heart is unable to pump blood effectively. The title suggests that ECMO may be used as a temporary measure, or ""bridge,"" to support these patients, but the researchers may be investigating the challenges or limitations in finding a long-term solution or ""destination"" for these patients."
40874657,Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease.,"Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data.The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health.The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements.Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.© 2025 The American Gastroenterological Association, British Society of Gastroenterology, The American College of Gastroenterology, European Crohn’s and Colitis Organisation, John Wiley & Sons Limited and Crohn’s and Colitis Foundation. Published by Elsevier Inc on behalf of The American Gastroenterological Association, by BMJ Publishing Group Ltd on behalf of British Society of Gastroenterology, by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology, by Oxford University Press on behalf of European Crohn’s and Colitis Organisation, by John Wiley & Sons Limited and by Oxford University Press on behalf of Crohn’s and Colitis Foundation. All rights are reserved, including those for text and data mining, AI training, and similar technologies.",Alimentary pharmacology & therapeutics,"Dec, 2025",2025,Dec,,Mahadevan U|Seow C H|Barnes E L|Chaparro M|Flanagan E|Friedman S|Julsgaard M|Kane S|Ng S|Torres J|Watermeyer G|Yamamoto-Furusho J|Robinson C|Fisher S|Anderson P|Gearry R|Duricova D|Dubinsky M|Long M,Kane S,"Division of Gastroenterology, Department of Medicine, University of California, San Francisco, California, USA.|Inflammatory Bowel Disease Unit, Division of Gastroenterology and Hepatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.|Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.|Gastroenterology Department, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria Princesa (IIS-Princesa), Universidad Autónoma de Madrid (UAM), and Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Madrid, Spain.|Department of Gastroenterology, St Vincent's Hospital Melbourne, Australia, Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.|Division of Gastroenterology and Hepatology, Tufts Medical Center, Boston, Massachusetts, USA.|Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.|Institute of Clinical Medicine, Health, Aarhus University, Aarhus, Denmark.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Microbiota I-Center (MagIC), Hong Kong, SAR, China.|Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, SAR, China.|Li Ka Shing Institute of Health Sciences, State Key Laboratory of Digestive Disease Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, SAR, China.|Division of Gastroenterology, Hospital da luz Lisbon, Division of Gastroenterology, Hospital Beatriz Ângelo, Portugal Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.|Department of Medicine University of Cape Town and Groote Schuur Hospital, Cape Town, South Africa.|Inflammatory Bowel Disease Clinic, Department of Gastroenterology, National Institute of Medical Sciences and Nutrition Salvador Zubiran, Mexico City, Mexico.|Charleston Maternal Fetal Medicine, East Cooper Medical Center, Mount Pleasant, South Carolina, USA.|Department of Obstetrics and Gynecology, University of California, San Francisco, California, USA.|Skaggs School of Pharmacy and Pharmaceutical Sciences, San Diego, California, USA.|Department of Medicine, University of Otago, Christchurch, New Zealand.|Clinical and Research Center for IBD, ISCARE a.s., Prague, Czech Republic.|Division of Pediatric Gastroenterology, Susan and Leonard Feinstein IBD Clinical Center, Icahn School of Medicine, New York, New York, USA.","Mahadevan U, Seow C H, Barnes E L, Chaparro M, Flanagan E, Friedman S, Julsgaard M, Kane S, Ng S, Torres J, Watermeyer G, Yamamoto-Furusho J, Robinson C, Fisher S, Anderson P, Long M, et al.",https://pubmed.ncbi.nlm.nih.gov/40874657/,"This medical research provides a global consensus statement on the management of pregnancy in inflammatory bowel disease (IBD). The key finding is that the group of experts and patient advocates aimed to provide data-driven and practical guidance to improve the care of women with IBD during pregnancy, as pregnancy can be a complex and risk-filled event for this population."
40844321,Increased reflux secondary bile acids are associated with changes to the microbiome and transcriptome in Barrett's esophagus.,"Bile acids are a major component of gastro-esophageal refluxate, thought to contribute to the development of Barrett's esophagus (BE) and esophageal adenocarcinoma (EAC). As the microbiome shifts with EAC progression and bile acids influence bacterial composition, we examined these connections in a multi-center, cross-sectional study. We analyzed biospecimens from patients undergoing endoscopy using LC-MS to quantify bile acids in gastric aspirates, 16S rRNA sequencing for tissue microbiome profiling, and RNA sequencing on BE or cardia tissue. Among 153 patients (52 controls, 101 BE: 50 no dysplasia, 10 indefinite, 17 low-grade dysplasia, 17 high-grade dysplasia, and 7 EAC), we observed increased Streptococcus in BE tissue; dysplasia and EAC were associated with more Lactobacillus and decreased Actinomyces and other genera. Refluxate bile acids were mainly conjugated, indicating minimal bacterial metabolism, while BE patients had elevated secondary bile acid levels. Streptococcus correlated with upregulation of IL6, FGF2, and HGF, and decreased Actinomyces showed the most associations with gene expression, including the oxidative phosphorylation pathway. We identified two distinct BE gene expression clusters independent of histology, bile acid, or microbiome composition. These findings suggest bile acids shape the BE microbiome and associate with gene expression changes potentially relevant to EAC development.",Gut microbes,"Dec, 2025",2025,Dec,,Tanes C|Li Y|Falk G W|Ginsberg G G|Wang K K|Iyer P G|Lightdale C J|Del Portillo A|Lagana S M|Wang T C|Rustgi A K|Quante M|Jin Z|Wu G D|Friedman E S|Bittinger K|Li H|Abrams J A,Wang K K|Iyer P G,"Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, USA.|Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.|Division of Gastroenterology and Hepatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Scottsdale, AZ, USA.|Division of Digestive & Liver Diseases, Columbia University Irving Medical Center, New York, NY, USA.|Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY, USA.|Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, USA.|Digestive and Liver Disease Research Center, Columbia University Irving Medical Center, New York, NY, USA.|Department of Medicine II, University of Freiburg, Freiburg, Germany.|Department of Biostatistics, Mailman School of Public Health, Columbia University, New York, NY, USA.","Tanes C, Li Y, Falk G W, Ginsberg G G, Wang K K, Iyer P G, Lightdale C J, Del Portillo A, Lagana S M, Wang T C, Rustgi A K, Quante M, Jin Z, Wu G D, Friedman E S, Abrams J A, et al.",https://pubmed.ncbi.nlm.nih.gov/40844321/,"The key finding of this study is that increased levels of secondary bile acids in the refluxate of patients with Barrett's esophagus are associated with changes in the gut microbiome and gene expression patterns, which may contribute to the development of esophageal adenocarcinoma. This suggests that monitoring and managing bile acid reflux could be an important strategy for preventing the progression of Barrett's esophagus to cancer."
40848026,"Emergency Medicine Residency Match Trends and Evolving Applicant Composition, 2015-2025.",No abstract available.,Annals of emergency medicine,"Dec, 2025",2025,Dec,,Voskanov M|Johnson C|Campbell R|Homme J|Gettel C|Hunter D,Voskanov M|Johnson C|Campbell R|Homme J|Hunter D,"Department of Emergency Medicine, Mayo Clinic, Rochester, MN.|Department of Emergency Medicine, Yale University School of Medicine, New Heaven, CT.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN; Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN. Electronic address: hunter.daria@mayo.edu.","Voskanov M, Johnson C, Campbell R, Homme J, Gettel C, Hunter D",https://pubmed.ncbi.nlm.nih.gov/40848026/,"This research likely explores the trends and changes in the composition of applicants to emergency medicine residency programs over the 10-year period from 2015 to 2025. It may examine factors such as the number of applicants, their demographic characteristics, and how these have evolved during this time period."
40848117,Does direct oral anticoagulant lead-in dosing following initial parenteral therapy affect clinical outcomes in acute venous thromboembolism?: A retrospective cohort study.,"Initiation of direct oral anticoagulants (DOAC) for the management of venous thromboembolism (VTE) typically includes a lead-in dosing phase. However, some patients may receive a shortened course due to comorbid conditions and/or numerous days of parenteral therapy. Limited data exist on the outcomes of an abbreviated lead-in therapy regimen.To investigate the clinical outcomes of patients receiving abbreviated versus standard/non-abbreviated DOAC lead-in regimens following parenteral anticoagulation therapy for VTE.We conducted a retrospective cohort study including adults (≥ 18 years of age) who were admitted for acute VTE between 04/01/2019 and 12/31/2023 and received ≥ 24 h of parenteral anticoagulation before being transitioned to a DOAC with abbreviated versus non-abbreviated DOAC lead-in dose. The primary outcome was death or readmission from a thrombotic event within 30 days of discharge. Data were presented using descriptive statistics, logistic regression, and time-to-event analysis.Across 590 patients, the median (IQR) age was 67 (58-76) years and 280 (47.5%) were female. Over half had a pulmonary embolism (54.9%; N = 324), 21.0% (N = 124) had a deep vein thrombosis, and the remainder experienced a combination. Most patients received the non-abbreviated lead-in dose (83.2%; N = 491). When compared to the non-abbreviated cohort, a higher proportion of those who received an abbreviated lead-in therapy had prior VTE and heart failure. There were no significant associations between an abbreviated lead-in dose and the primary outcome (aOR 0.44; 95% CI 0.13-1.52; P = 0.20). Bleeding events were also similar between the abbreviated and non-abbreviated dose cohorts at the longest follow-up (3.0%, N = 3 vs. 2.9%, N = 14; P = 0.92; aOR 0.82; 95% CI 0.22-3.1; P = 0.77) and within 30 days of DOAC initiation (HR 1.24; 95% CI 0.26-5.82; P = 0.79).An abbreviated DOAC lead-in therapy was not associated with short-term mortality, readmission due to recurrent thrombosis, or bleeding. Further prospective studies are needed to confirm these findings and provide insights into more personalized regimens.© 2025. The Author(s), under exclusive licence to Springer Nature Switzerland AG.",International journal of clinical pharmacy,"Dec, 2025",2025,Dec,,Kim J|Heybati K|Thompson E|Sharma S|Barron D|Reynolds H|Mirzakandov M|Norville K|Reynolds J|Shiue H J,Kim J|Heybati K|Thompson E|Sharma S|Barron D|Reynolds H|Mirzakandov M|Reynolds J|Shiue H J,"Department of Internal Medicine, Mayo Clinic, Phoenix, AZ, USA.|Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.|Division of Clinical Trials & Biostatistics, Mayo Clinic, Phoenix, AZ, USA.|Alix School of Medicine, Mayo Clinic, Phoenix, AZ, USA.|Department of Pharmacy, Mayo Clinic, Phoenix, AZ, USA.|School of Health Sciences, Mayo Clinic, Phoenix, AZ, USA.|Department of Pharmacy, St. Joseph's Hospital and Medical Center, Phoenix, AZ, USA.|Department of Pharmacy, Mayo Clinic, Phoenix, AZ, USA. shiue.harn@mayo.edu.","Kim J, Heybati K, Thompson E, Sharma S, Barron D, Reynolds H, Mirzakandov M, Norville K, Reynolds J, Shiue H J",https://pubmed.ncbi.nlm.nih.gov/40848117/,"The key finding of this medical research is that an abbreviated lead-in dosing of direct oral anticoagulants (DOACs) following initial parenteral therapy for acute venous thromboembolism (VTE) was not associated with increased risk of short-term mortality, recurrent thrombosis, or bleeding, compared to the standard non-abbreviated DOAC lead-in regimen. This suggests that a shortened DOAC lead-in course may be a viable"
40856991,Disparities in access to early liver transplantation for alcohol-associated liver disease: More to do for patients in need.,No abstract available.,Liver Transpl,"Dec 01, 2025",2025,Dec,01,Mohamed K A|Lim N,Lim N,"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.|Division of Gastroenterology and Hepatology, University of Rochester, Rochester, New York, USA.|Transplant Institute, University of Rochester Medical Center, Rochester, New York, USA.","Mohamed K A, Lim N",https://pubmed.ncbi.nlm.nih.gov/40856991/,This research likely explores the differences in access to early liver transplantation for people with alcohol-associated liver disease. The study suggests that there is more work to be done to ensure that patients in need of this treatment receive it in a timely manner.
40857748,Growth Kinetics of Venous Tumor Thrombus From Renal Cell Carcinoma.,"Renal cell carcinoma (RCC) is known to form venous tumor thrombus (VTT); however, limited data exist on VTT growth rates. We sought to characterize the growth rate of VTT from RCC and identify clinicopathologic features associated with faster thrombus growth.Systemic therapy-naïve patients with RCC and VTT with 2 preoperative imaging studies performed with contrast at least 7 days apart were identified from a single institutional registry. VTT levels were assigned using the Mayo classification and measured in mm. Changes between scans were linearized to growth rate per day. Multivariable regression models identified factors associated with VTT growth.We evaluated 141 patients with a median time between scans of 20 days (IQR: 12-30) and noted a median VTT growth rate of 0.3 mm/d. Sixteen (11%) patients were reclassified on the second scan to a higher Mayo VTT level. There was a significant relationship between VTT growth and increasing tumor thrombus level (P < .001) as well as the presence of sarcomatoid/rhabdoid features (0.4 vs 0.3 mm/d, P = .003). On multivariable regression, there is a quadratic increase in VTT growth rates as thrombus level increases (P = .001). Sarcomatoid/rhabdoid features (coefficient +0.43 mm/d, P < .001) and metastatic disease (coefficient +0.30 mm/d, P = .03) were also associated with increased tumor thrombus growth rates.VTT growth is generally less than 1 mm/d, although higher level thrombi and disease with aggressive histopathology grew more rapidly. These data improve the understanding of tumor thrombus growth and can aid in preoperative triage and surgical planning.",The Journal of urology,"Dec, 2025",2025,Dec,,McLeay M T|Roberson D S|Dorr M|Morales-Martinez G A|Basourakos S P|Kline T L|Cheville J|Khanna A|Potretzke T A|Boorjian S A|Leibovich B C|Sharma V,McLeay M T|Roberson D S|Dorr M|Morales-Martinez G A|Basourakos S P|Kline T L|Cheville J|Khanna A|Potretzke T A|Boorjian S A|Leibovich B C|Sharma V,"Department of Urology, Mayo Clinic, Rochester, Minnesota.|Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota.|Department of Radiology, Mayo Clinic, Rochester, Minnesota.|Department of Pathology, Mayo Clinic, Rochester, Minnesota.","McLeay M T, Roberson D S, Dorr M, Morales-Martinez G A, Basourakos S P, Kline T L, Cheville J, Khanna A, Potretzke T A, Boorjian S A, Leibovich B C, Sharma V",https://pubmed.ncbi.nlm.nih.gov/40857748/,"The key finding of this medical research is that the growth rate of venous tumor thrombus (VTT) from renal cell carcinoma is generally less than 1 mm per day, but higher-level thrombi and those with aggressive histopathology, such as sarcomatoid/rhabdoid features, grow more rapidly. This information can help with preoperative planning and triage of patients with this condition."
40858459,Outcomes of endoscopic management for upper tract urothelial carcinoma: A multi-center international cohort analysis.,"Upper tract urothelial carcinoma (UTUC) is a rare and aggressive malignancy with significant morbidity, often requiring radical nephroureterectomy (RNU) as the standard of care. Endoscopic ablation has emerged as a kidney-sparing alternative, particularly for low-risk UTUC. Given the rarity of UTUC, generating high-quality evidence for treatment strategies remains challenging. This study presents a large, multi-institutional analysis of outcomes following primary endoscopic ablation for UTUC.A retrospective analysis of 432 patients across 11 institutions who underwent first-time endoscopic treatment for UTUC with curative intent between December 2003 and January 2023 was performed. Baseline demographics, tumor characteristics, and procedural details were collected. Recurrence was categorized as ipsilateral, distant, or bladder recurrence, with overall survival (OS) as the primary outcome. Univariate and multivariate Cox regression models were used to identify predictors of recurrence and survival.At a median follow-up of 21 months, ipsilateral recurrence occurred in 232 patients (54%), while 55 (13%) developed distant metastases. The OS rate was 86%, with 29 patients (6.7%) dying within the first 12 months. On univariate analysis, the presence of a tumor not involving the renal pelvis (HR 0.71, P = 0.04) and use of a ureteral access sheath (UAS) (HR 0.65, P = 0.03) were associated with lower ipsilateral recurrence rates. On multivariate analysis, only UAS use remained significant (HR 0.39, P < 0.01). High-grade tumors were significantly associated with poorer OS (HR 3.59, P < 0.01).Endoscopic ablation is a feasible kidney-sparing alternative for UTUC. Ipsilateral recurrence rate is approximately 50% with over 10% of patients developing metastatic disease. UAS use may reduce UTUC recurrence risk.Copyright © 2025 Elsevier Inc. All rights reserved.",Urologic oncology,"Dec, 2025",2025,Dec,,Herrera-Caceres J O|Wettstein M|Matin S F|Labbate C|Potretzke A|Rodriguez R|Singla N|Pallauf M|Huang W|Nagpal S|Kleinmann N|Shvero A|Small A|Green B|Linehan J|Choe J|Shah O|Rai A|Kaimakliotis H|Tachibana I|Canes D|Perecman A|Raman J D,Potretzke A|Rodriguez R,"Department of Urology, Penn State Health, Hershey, PA. Electronic address: jherreracaceres@pennstatehealth.psu.edu.|Department of Urology, University of Toronto, Toronto, Canada.|Department of Urology, M.D. Anderson Cancer Center, Houston, TX.|Department of Urology, Mayo Clinic, Rochester, MN.|Department ofUrology, Johns Hopkins University, Baltimore, MD.|Department of Urology, New York University, New York, NY.|Sheba Medical Center, Department of Urology, Ramat Gan, Israel.|Albert Einstein Montefiore Medical Center, Department of Urology, Bronx, NY.|Department of Urology, Providence St. John's Cancer Institute, Santa Monica, CA.|Columbia University Irving Medical Center, Department of Urology, NY, NY.|Department of Urology, Indiana University, Indianapolis, IN.|Lahey Hospital and Medical Center, Department of Urology, Burlington, MA.|Department of Urology, Penn State Health, Hershey, PA.","Herrera-Caceres J O, Wettstein M, Matin S F, Labbate C, Potretzke A, Rodriguez R, Singla N, Pallauf M, Huang W, Nagpal S, Kleinmann N, Shvero A, Small A, Green B, Linehan J, Raman J D, et al.",https://pubmed.ncbi.nlm.nih.gov/40858459/,"This study found that endoscopic ablation, a kidney-sparing treatment, is a feasible option for upper tract urothelial carcinoma (UTUC), a rare and aggressive type of cancer. However, the risk of cancer recurrence and metastatic disease remains significant, with around 50% of patients experiencing recurrence. The use of a ureteral access sheath during the procedure may help reduce the risk of recurrence."
40876216,Duration of resuscitation interruption using point-of-care ultrasound versus traditional manual pulse check: A systematic review and meta-analysis.,"Manual pulse palpation during cardiopulmonary resuscitation is unreliable and time-consuming. Point-of-care ultrasound (POCUS) has been proposed as a faster and more accurate alternative. We conducted a systematic review and meta-analysis to evaluate whether ultrasound pulse checks reduce assessment time and improve diagnostic performance compared to manual palpation.A systematic search of PubMed, Embase, and Cochrane databases was performed. We included randomized and observational studies comparing the duration of ultrasound and manual pulse checks. Outcomes included mean pulse check duration and diagnostic sensitivity and specificity. Risk of bias was assessed using the Cochrane, Newcastle-Ottawa and Quadas tools, and evidence certainty was evaluated with GRADE. Random effects models were used for the meta-analyses.Seven studies were included, comprising over 2900 ultrasound and over 1600 manual pulse checks. Ultrasound was associated with shorter pulse check durations (mean difference - 1.39 s; 95 % CI -2.20 to - 0.57). Subgroup analyses by anatomical site and clinical context consistently favored ultrasound. Pooled sensitivity and specificity for ultrasound were 99 % and 96 %, compared to 62 % and 91 % for manual palpation.Ultrasound-guided pulse checks were associated with slightly shorter pulse check durations and higher diagnostic sensitivity compared to manual palpation. These findings support integration of ultrasound into resuscitation protocols should be considered with an understanding of the current limitations in evidence quality and generalizability, with further research needed to standardize training and implementation.Copyright © 2025 Elsevier Inc. All rights reserved.",The American journal of emergency medicine,"Dec, 2025",2025,Dec,,Neto E S|Scapin M|Lazaro-Paulina F|Campbell R L|Molinari D F|Kummer T,Neto E S|Lazaro-Paulina F|Campbell R L|Molinari D F|Kummer T,"Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: saadine.eduardo@mayo.edu.|Department of Neurosurgery, Universidade Estadual De Londrina, PR, Brazil.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: Lazaro-Paulina.Francisco@mayo.edu.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: Campbell.Ronna@mayo.edu.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: FitermanMolinari.Daniel@mayo.edu.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: Kummer.Tobias@mayo.edu.","Neto E S, Scapin M, Lazaro-Paulina F, Campbell R L, Molinari D F, Kummer T",https://pubmed.ncbi.nlm.nih.gov/40876216/,This study found that using point-of-care ultrasound for checking a patient's pulse during cardiopulmonary resuscitation takes less time and is more accurate than the traditional manual pulse check. This suggests that incorporating ultrasound into resuscitation protocols could improve the efficiency and effectiveness of emergency care.
40900221,How Do Patient Outcomes in Mechanical Thrombectomy for Large-Core Stroke Vary Based on Neuroimaging Modalities Used for Patient Selection? A Multicenter Multinational Study.,"The role of different imaging modalities-non-contrast CT (NCCT), CT perfusion (CTP), and diffusion-weighted imaging (DWI)-in selecting patients with large-core stroke for endovascular thrombectomy (EVT) is a subject of ongoing debate. This study aims to determine whether patients with large-core acute ischemic stroke (AIS) undergoing EVT triaged with CTP or DWI in addition to NCCT had different clinical outcomes compared to those only triaged with NCCT. We queried the Stroke Thrombectomy and Aneurysm Registry (STAR) for patients enrolled between 2014 and 2023 who presented with anterior-circulation AIS and large ischemic core (ASPECTS < 6) who underwent EVT in 41 stroke centers in the USA, Europe, Asia, and South America. Patients were stratified by the imaging used before EVT. Propensity score matching (PSM) was used to compare balanced cohorts of patients with NCCT vs CTP and NCCT vs DWI. The primary outcome was a favorable 90-day functional status (mRS 0-3). Secondary outcomes included intracerebral hemorrhage (ICH) rates, symptomatic ICH (sICH), and successful/complete recanalization, as determined by mTICI score. A total of 403 patients were included, 121 were selected with NCCT alone, 227 with CTP, and 55 with DWI. Before PSM, 90-day mRS 0-3, successful reperfusion mTICI ≥ 2B, and sICH rates were similar across the three imaging modalities. mTICI-2C or greater rates were highest in DWI (50.9%; p < 0.01), followed by NCCT (41.3%) and CTP (27.8%). Patients selected with CTP had the highest ICH incidence (44.1%; p < 0.01). After 1:1 PSM, 104 pairs of NCCT vs CTP and 36 pairs of NCCT vs DWI were compared. There were no significant differences in any procedural or functional outcome measure between the matched groups, including mTICI ≥ 2C recanalization, 90-day mRS 0-3, ICH rates, and sICH rates. In patients with anterior large-vessel occlusion AIS with low ASPECTS, we found that selecting patients for EVT based on NCCT or employing advanced imaging to elucidate collaterals, infarct volume, and ischemic penumbra does not alter procedural or patient outcomes. NCCT alone may be sufficient to select patients for EVT in this patient population, especially in settings with limited resources.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Translational stroke research,"Dec, 2025",2025,Dec,,Alwakaa O|Abo Kasem R|Ramirez-Velandia F|Wadhwa A|Han K|Levitt M R|Alaraj A|Jabbour P|Kim J|Howard B|Alawieh A|Wolfe S Q|Starke R M|Psychogios M|Shaban A|Goyal N|Dye J|Ezzeldin M|Yoshimura S|Sconzo D|Filo J|Pettersson S|Fiorella D|Tanweer O|Romano D G|Navia P|Cuellar H|Fragata I|Polifka A|Mascitelli J|Osbun J|Siddiqui F|Moss M|Limaye K|Mokin M|Matouk C|Park M S|Brinjikji W|Daglioglu E|Williamson R|Altschul D J|Maier I|Crosa R|Gory B|Grandhi R|Paul A|Kan P|Casagrande W|Chowdhry S|Stiefel M F|Rai A|Spiotta A M|Taussky P|Ogilvy C S|Granstein J H,Brinjikji W,"Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA, 02115, USA.|Department of Neurosurgery, Medical University of South Carolina, Charleston, SC, USA.|Neurological Surgery, University of Washington School of Medicine, Seattle, WA, USA.|Neurosurgery, University of Illinois Chicago, Chicago, IL, USA.|Department of Neurosurgery, Thomas Jefferson University Hospital, Philadelphia, PA, USA.|Chonnam National University Medical School, Gwangju, Korea.|Department of Neurosurgery, Emory University School of Medicine, Atlanta, GA, USA.|Neurosurgery, Wake Forest School of Medicine, Winston Salem, NC, USA.|Department of Neurosurgery, University of Miami Miller School of Medicine, Miami, FL, USA.|Department of Neuroradiology, Clinic of Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland.|The University of Iowa Hospitals and Clinics, Iowa City, IA, USA.|Semmes-Murphey Neurologic and Spine Institute, Memphis, TN, USA.|Department of Neurosurgery, Loma Linda University, Loma Linda, CA, USA.|Department of Clinical Neuroscience, University of Houston, HCA Houston Healthcare Kingwood, Kingwood, TX, USA.|Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan.|Neurological Surgery, Stony Brook Hospital, Stony Brook, NY, USA.|Department of Neurosurgery, Baylor College of Medicine, Houston, TX, USA.|Neuroradiology, University Hospital 'San Giovanni Di Dio E Ruggi d'Aragona', Salerno, Italy.|Interventional and Diagnostic Neuroradiology, Hospital Universitario La Paz, Madrid, Spain.|LSUHSC, Shreveport, LA, USA.|Centro Hospitalar de Lisboa Central, Lisbon, Portugal.|Department of Neurosurgery, University of Florida, Gainesville, FL, USA.|Department of Neurosurgery, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA.|Washington University in Saint Louis School of Medicine, Saint Louis, MO, USA.|Department of Neuroscience, University of Michigan Health-West, Wyoming, MI, USA.|Washington Regional Medical Center, Fayetteville, AR, USA.|Department of Neurology, Indiana University, Bloomington, IN, USA.|Department of Neurosurgery, University of South Florida, Tampa, FL, USA.|Yale University, New Haven, CT, USA.|Neurosurgery, University of Virginia, Charlottesville, VA, USA.|Department of Radiology, Mayo Clinic Minnesota, Rochester, MN, USA.|Department of Neurosurgery, Health Science University, Ankara Bilkent City Hospital, Ankara, Turkey.|Department of Neurosurgery, Allegheny Health Network, Pittsburgh, PA, USA.|Department of Neurosurgery, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.|University Medicine Goettingen, Goettingen, Germany.|Neurosurgery, Médica Uruguaya, Montevideo, Montevideo, Uruguay.|Department of Diagnostic and Interventional Neuroradiology, INSERM U947, University Hospital of Nancy, Nancy, France.|Department of Neurosurgery, University of Utah, Salt Lake City, UT, USA.|Department of Neurosurgery, Albany Medical Center, Albany, NY, USA.|Department of Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, TX, USA.|Department of Cerebrovascular and Endovascular Neurosurgery, Hospital Juan Fernandez, Buenos Aires, Argentina.|NorthShore University HealthSystem, Evanston, IL, USA.|Department of Neurosurgery, Piedmont Atlanta Hospital, Atlanta, GA, USA.|Department of Neuroradiology, West Virginia University Hospitals, Morgantown, WV, USA.|Neurosurgical Service, Beth Israel Deaconess Medical Center, Harvard Medical School, 110 Francis Street, Boston, MA, 02115, USA. jgranste@bidmc.harvard.edu.","Alwakaa O, Abo Kasem R, Ramirez-Velandia F, Wadhwa A, Han K, Levitt M R, Alaraj A, Jabbour P, Kim J, Howard B, Alawieh A, Wolfe S Q, Starke R M, Psychogios M, Shaban A, Granstein J H, et al.",https://pubmed.ncbi.nlm.nih.gov/40900221/,"This study found that for patients with large-core acute ischemic stroke, selecting them for endovascular thrombectomy based on non-contrast CT (NCCT) alone or using advanced imaging like CT perfusion (CTP) or diffusion-weighted imaging (DWI) did not significantly affect their clinical outcomes or procedural success. The results suggest that NCCT alone may be sufficient for patient selection, especially in resource-limited settings."
40882514,Integrating microfluidic automation into thermoplastic devices for analysis of small volumes of blood.,"Microfluidic devices with built-in microvalves hold particular promise for minimizing sample volume requirements while automating sample preparation workflows. Such devices have typically been implemented in polydimethyl siloxane (PDMS) using multi-layer soft lithography. Both the material and assembly process of devices present challenges for scalable manufacturing and limit utilization of microfluidic automation at the point of care. Our work aims to address this challenge. It describes a microfluidic device composed of thermoplastic material, poly (methyl methacrylate) (PMMA) performing a sophisticated automated workflow of plasma extraction, sample aliquoting and sample-reagent mixing steps. Automation was accomplished using multiple on-board microvalves consisting of a pressure sensitive adhesive (PSA) membrane sandwiched between PMMA flow and control layers. In addition to novel microvalves, the device included features designed to circumvent issues arising from gas-impermeable nature of PMMA - a bubble trap and air micro-tanks to supply O2 for enzymatic reactions. The performance of the microfluidic device was rigorously characterized. The quality of plasma extracted in the device was comparable to a standard plasma isolation method involving centrifugation. Close agreement was observed between glucose levels measured in the device and by a standard assay. As a final demonstration of utility, 5 μL of blood was loaded into the device, plasma was isolated, and three analytes-glucose, lactate and H2O2 were detected. In addition to minimizing the volume of blood and eliminating standard laboratory equipment (e.g., centrifuge), the device enabled a rapid response (<10 min). The use of thermoplastic materials may pave the way for inexpensive automated microfluidic devices for rapid detection of blood biomarkers at the point of care.Copyright © 2025. Published by Elsevier B.V.",Biosensors & bioelectronics,"Dec 01, 2025",2025,Dec,01,Amador-Hernandez J U|Gonzalez-Suarez A M|Stybayeva G|Caballero-Robledo G A|Garcia-Cordero J L|Revzin A,Amador-Hernandez J U|Gonzalez-Suarez A M|Stybayeva G|Revzin A,"Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA; Laboratory of Microtechnologies Applied to Biomedicine (LMAB), Centro de Investigación y de Estudios Avanzados (Cinvestav), Monterrey, NL, Mexico.|Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA; Sersense Inc., Rochester, MN, USA.|Laboratory of Microtechnologies Applied to Biomedicine (LMAB), Centro de Investigación y de Estudios Avanzados (Cinvestav), Monterrey, NL, Mexico.|Laboratory of Microtechnologies Applied to Biomedicine (LMAB), Centro de Investigación y de Estudios Avanzados (Cinvestav), Monterrey, NL, Mexico; Institute of Human Biology, Roche Pharma Research and Early Development, Roche Innovation Center, Basel, Switzerland.|Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA. Electronic address: revzin.alexander@mayo.edu.","Amador-Hernandez J U, Gonzalez-Suarez A M, Stybayeva G, Caballero-Robledo G A, Garcia-Cordero J L, Revzin A",https://pubmed.ncbi.nlm.nih.gov/40882514/,"This research developed a microfluidic device made of thermoplastic material that can automatically process small volumes of blood to extract plasma and measure various biomarkers, such as glucose, lactate, and hydrogen peroxide. The device uses built-in microvalves and features to overcome challenges with the material, enabling rapid and automated analysis of blood samples with minimal volume requirements. This technology could lead to the development of inexpensive, automated devices for point-of-care detection of blood bio"
40882657,Forecasting the burden of obstructive sleep apnoea.,No abstract available.,The Lancet. Respiratory medicine,"Dec, 2025",2025,Dec,,Zhang Y|Somers V K|Tang X,Somers V K,"Sleep Medicine Centre, Department of Respiratory and Critical Care Medicine, Mental Health Centre and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.|Sleep Medicine Centre, Department of Respiratory and Critical Care Medicine, Mental Health Centre and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu 610041, China. Electronic address: 2372564613@qq.com.","Zhang Y, Somers V K, Tang X",https://pubmed.ncbi.nlm.nih.gov/40882657/,"This research likely explores the future impact or burden of obstructive sleep apnea, a sleep disorder that causes breathing problems. It may use data and models to predict or forecast how this sleep disorder will affect people and healthcare systems in the coming years."
40891591,"Contemporary genitourinary fistula management: treatment, trends, and innovations.","To synthesize the current literature regarding the evaluation and management of genitourinary fistula in women.Genitourinary fistula are aberrant communications between the urinary tract and genital tract that present with urinary leakage per the vagina. Initial management often involves conservative measures, such as urethral catheter or ureteral stent placement, progressing to surgical repair when needed. Key surgical principles include a tension-free, watertight closure with well-vascularized tissue including tissue interposition as appropriate, and postoperative urinary drainage. When surgical management of vesicovaginal fistula is necessary, a transvaginal repair is the most common. Other minimally invasive approaches are increasing and result in similarly high success rates with lower patient morbidity compared to open abdominal surgeries. The initial management of ureterovaginal fistula commonly includes ureteral stent placement. When not feasible or in persistent fistula, laparoscopic and robotic surgical repair with ureteral reconstruction offers high success rates with lower morbidity than an open approach.Successful management of genitourinary fistula ranges from conservative urinary tract drainage to surgical interventions based on etiology, location, and complexity. Approaches to repair are shifting toward less invasive procedures. With optimal technique and surgical planning, high success rates can be achieved, particularly in primary repairs.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Current opinion in obstetrics & gynecology,"Dec 01, 2025",2025,Dec,01,Wei N|Pfeuti C|Linder B J,Pfeuti C|Linder B J,"Departments of Urology.|Obstetrics and Gynecology, Mayo Clinic, Rochester, Minnesota, USA.","Wei N, Pfeuti C, Linder B J",https://pubmed.ncbi.nlm.nih.gov/40891591/,"This medical research summarizes the current approaches to managing genitourinary fistulas, which are abnormal connections between the urinary and genital tracts. The key finding is that while conservative measures like catheter placement are often the initial approach, surgical repair is sometimes necessary. Minimally invasive surgical techniques, such as laparoscopic and robotic procedures, are becoming more common and can achieve high success rates with lower patient morbidity compared to open surgeries."
40898402,Carcinosarcoma Arising in an Eccrine Spiradenoma and Presenting With Metastasis: Case Report and Literature Review.,"Eccrine spiradenomas are benign sweat gland neoplasms that rarely undergo malignant transformation. Carcinosarcoma arising from an eccrine spiradenoma is exceptionally rare. A 41-year-old male presented with a rapidly growing neck/shoulder mass, progressive numbness, spasticity, and weakness. Further workup additionally revealed an epidural mass with spinal cord compression. Both masses were excised and predominantly showed morphologic features of high-grade osteosarcoma, with overtly malignant spindled cells producing lace-like osteoid. However, a single section from the upper back mass contained a roughly 2 mm focus of conventional eccrine spiradenoma, with an adjacent small focus having features of a poorly differentiated non-small cell carcinoma. The final diagnosis was that of a high-grade carcinosarcoma with heterologous osteosarcomatous differentiation, arising from a pre-existing eccrine spiradenoma, with metastasis to the T4-5 epidural region. The patient experienced rapid regrowth of the spinal mass and underwent radiotherapy but had unresectable metastatic disease at 2 months follow-up. We describe what is to our knowledge only the 21st example of carcinosarcoma arising from eccrine spiradenoma, mimicking metastatic osteosarcoma. Awareness of this very rare entity, careful sampling, close microscopic examination, and, in selected cases, ancillary immunohistochemistry are the keys to making this challenging diagnosis.© 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",Journal of cutaneous pathology,"Dec, 2025",2025,Dec,,Marinelli L M|Orrock J M|Folpe A L,Marinelli L M|Folpe A L,"Department of Dermatology, Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pathology, Intermountain Medical Center, Murray, Utah, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.","Marinelli L M, Orrock J M, Folpe A L",https://pubmed.ncbi.nlm.nih.gov/40898402/,"This case report describes an extremely rare case of a carcinosarcoma (a type of cancer) that developed from a benign sweat gland tumor called an eccrine spiradenoma. The cancer had metastasized to the spine, causing spinal cord compression. Careful examination and testing were required to make this challenging diagnosis, which is only the 21st reported case of this rare condition."
40899404,Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection.,"Children with hepatoblastoma (HB) and other solid tumors frequently undergo intraoperative blood transfusion (IBT) with unknown impact on oncologic outcomes and scant data to guide transfusion in this population. This study tested the hypothesis that IBT is associated with poorer survival in children with HB.A multicenter retrospective observational study of patients aged <18 years with HB who underwent primary tumor resection, including liver transplantation, from 2010 to 2019 was performed at 19 institutions. The association of IBT with risk of recurrence and death were determined using propensity score reweighted (PSR) Cox proportional hazards regression analyses.There were 338 patients identified who met inclusion criteria and had sufficient data for inclusion. Of those, 257 (76%) received IBT, including 253 (98%) who received packed red blood cells (pRBC), 84 (33%) who received plasma, and 28 (11%) who received platelets. IBT was associated with higher pretreatment extent of disease (p < 0.001), presence of annotation factors (+VPEFR: 50%, n = 129 vs. 37%, n = 30, p = 0.035), and complex resections (extended, meso-, or total hepatectomy: 54%, n = 139 vs. 27%, n = 22, p < 0.001); these differences were mitigated after applying propensity score weighting. Patients who received IBT had greater postoperative hemoglobin (g/dL) (median 10 (I8-11) vs. 9 (8-10), p = 0.013) and required more postoperative plasma and platelet transfusions (p < 0.05). Median follow-up was 4.4 (2.0-8.3) years. Compared with non-IBT patients, those with IBT had higher incidence of death (PSR HR 2.35, 95% CI 1.10-5.02). Recurrence did not significantly differ across groups (PSR HR = 0.82, 95% CI 0.45-1.48).IBT was associated with greater hazard of death. Postoperative hemoglobin levels suggested that unnecessary transfusions occurred and a pRBC-focused approach to IBT led to coagulopathy. Development of optimal transfusion strategies for HB are needed to minimize unnecessary transfusions.© 2025 Wiley Periodicals LLC.",Pediatric blood & cancer,"Dec, 2025",2025,Dec,,Polites S F|Aldrink J H|Lautz T B|Vierkant R A|Ragan M V|Reiter A|Chen S Y|Kim E S|Rinehardt H N|Malek M M|Fleming A M|Murphy A J|Roach J P|Radhakrishnan S|Kastenberg Z J|Piche N|Osman Y|Iii H N L|Tracy E T|Favela J|Le H D|Marquart J|Craig B|Lal D R|Seemann N|Petroze R|Rich B S|Glick R D|Selesner L|Yoo A|Fialkowski E|Brown E G|Boehmer C|Dasgupta R|Langham M R,Polites S F|Vierkant R A,"Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Division of Pediatric Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USA.|Division of Pediatric Surgery, Ann & Robert H Lurie Children's Hospital of Chicago, Northwestern University, Chicago, Illinois, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.|Division of Pediatric Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.|Division of Pediatric General and Thoracic Surgery, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.|St. Jude Children's Research Hospital and Division of Pediatric Surgery, Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA.|Division of Pediatric Surgery, Department of Surgery, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora, Colorado, USA.|Primary Children's Hospital, Unviersity of Utah School of Medicine, Salt Lake City, Utah, USA.|Department of Pediatric Surgery, Centre Hospitalier Universitaire Sainte-Justine, Université De Montréal, Montréal, Québec, Canada.|Department of Pediatric Surgery, Monroe Carell, Jr. Children's Hospital At Vanderbilt, Nashville, Tennessee, USA.|Department of Surgery, Duke University Hospital, Durham, North Carolina, USA.|Division of Pediatric Surgery, American Family Children's Hospital, Unviersity of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.|Division of Pediatric Surgery, Department of Surgery, Children's Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Department of Surgery, Western University, London, Ontario, Canada.|Division of Pediatric Surgery, Department of Surgery, Pediatric Surgery, University of Florida, Gainesville, Florida, USA.|Division of Pediatric Surgery, Northwell Health, Cohen Children's Medical Center, New Hyde Park, New York, USA.|Division of Pediatric Surgery, Oregon Health & Science University, Portland, Oregon, USA.|Division of Pediatric Surgery, Department of Surgery, University of California Davis Medical Center, California, USA.|Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.|Department of Surgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA.","Polites S F, Aldrink J H, Lautz T B, Vierkant R A, Ragan M V, Reiter A, Chen S Y, Kim E S, Rinehardt H N, Malek M M, Fleming A M, Murphy A J, Roach J P, Radhakrishnan S, Kastenberg Z J, Langham M R, et al.",https://pubmed.ncbi.nlm.nih.gov/40899404/,"The key finding of this medical research is that intraoperative blood transfusion (IBT) during hepatoblastoma resection is associated with a higher risk of death, but not with a higher risk of cancer recurrence. The study suggests that unnecessary blood transfusions may occur, and that developing optimal transfusion strategies for hepatoblastoma patients is important to minimize unnecessary transfusions and improve patient outcomes."
40899786,Multi-Institutional Study of ALK-Positive Large B-Cell Lymphoma: Outcomes in the Era of ALK Inhibitors and Biologically Informed Therapies.,"Anaplastic lymphoma kinase-positive large B-cell lymphoma (ALK+ LBCL) is a rare, aggressive subtype of diffuse large B-cell lymphoma with poor outcomes using standard chemotherapy. In this multi-institutional retrospective study, we analyzed 39 cases of ALK+ LBCL identified at six US academic centers from 2002 to 2024, with treatment including conventional cytotoxic regimens in frontline and biologically informed and nonchemotherapy-based strategies in the relapsed setting. Ninety-two percent of patients received frontline anthracycline-based chemotherapy; 43% received intensified regimens, and 15% underwent upfront autologous stem cell transplantation (ASCT). Despite these approaches, outcomes remained poor. At a median follow-up of 5.4 years, median event-free survival (EFS) was 0.6 years (95% CI, 0.4-0.9), and median overall survival (OS) was 1.5 years (95% CI, 1.3-NR). One- and five-year EFS rates were 28% and 17%, while corresponding OS rates were 72% and 42%, respectively. Advanced stage and high IPI scores were associated with inferior outcomes. Twelve patients received ALK inhibitors, with alectinib showing more durable responses than crizotinib. Lenalidomide and immune checkpoint inhibitors also demonstrated activity, including durable complete responses. Five patients underwent allogeneic stem cell transplantation, with three achieving sustained remission. In conclusion, our findings highlight the limited benefit of chemotherapy, even when intensified or followed by ASCT, and support the integration of biologically targeted therapies, which may have contributed to improved OS in our cohort compared to historical outcomes. Prospective, collaborative studies are needed to better understand disease biology and define optimal use of modern therapies in this rare lymphoma.© 2025 Wiley Periodicals LLC.",American journal of hematology,"Dec, 2025",2025,Dec,,Atallah-Yunes S A|Nze C C|King R L|Rees M J|Alderuccio J P|Watkins M|Kahl B S|Easwar N|Yamshon S|Ravindra A|Farooq U|Rosenthal A C|Munoz J L|Rojas-Neira E M|Ayers A A|Moustafa M A|Habermann T M|Witzig T E|Ansell S M|Nowakowski G S|Koff J L|Flowers C R|Wang Y,Atallah-Yunes S A|King R L|Rees M J|Rosenthal A C|Munoz J L|Moustafa M A|Habermann T M|Witzig T E|Ansell S M|Nowakowski G S|Wang Y,"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Hematology, University of Miami, Miami, Florida, USA.|Division of Oncology, Washington University School of Medicine, St Louis, Missouri, USA.|Division of Hematology and Medical Oncology, Weill Cornell Medicine, New York, New York, USA.|Division of Hematology and Oncology and Bone Marrow Transplantation, University of Iowa, Iowa City, Iowa, USA.|Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, Arizona, USA.|Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, Florida, USA.|Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia, USA.","Atallah-Yunes S A, Nze C C, King R L, Rees M J, Alderuccio J P, Watkins M, Kahl B S, Easwar N, Yamshon S, Ravindra A, Farooq U, Rosenthal A C, Munoz J L, Rojas-Neira E M, Ayers A A, Wang Y, et al.",https://pubmed.ncbi.nlm.nih.gov/40899786/,"This study found that the standard chemotherapy treatments for the rare and aggressive subtype of diffuse large B-cell lymphoma called ALK-positive large B-cell lymphoma have poor outcomes. However, the use of newer targeted therapies, such as ALK inhibitors, lenalidomide, and immune checkpoint inhibitors, showed more promising results, including durable complete responses. The findings suggest that integrating these biologically informed therapies may improve overall survival compared to historical outcomes,"
40639713,Outcomes of Surgical Decompression for Functional Popliteal Artery Entrapment Syndrome.,"Functional popliteal artery entrapment syndrome (FPAES) is a rare cause of claudication, predominantly affecting young females. The optimal workup, approach and outcomes remains poorly defined. We aim to evaluate our institutional experience in surgical decompression of FPAES.This is a retrospective review of all patients undergoing surgical decompression for FPAES between January 2010 and January 2024 at our institution. Preoperative imaging, operative approach, reintervention, and symptomatic improvement at the last follow-up were analyzed.Sixty-six patients (109 limbs) with a mean age of 25 ± 12 years were identified. 53 patients (80.3%) were female. Median time from onset of symptoms to surgical management was 34 months. All patients underwent preoperative magnetic resonance imaging and ultrasound with provocative maneuvers and 39 patients (59.1%) underwent preoperative angiogram. Nine patients (13.6%) had undergone previous popliteal artery decompression at outside institutions and were referred for refractory or recurrent symptoms. A medial approach to popliteal decompression was utilized in 84 limbs (77.1%). Posterior approach was utilized in 25 limbs. Perioperative complications occurred in 6 patients (9.1%). Median follow-up was 10.5 months (interquartile range, 4-27 months). Initial symptomatic improvement was reported in 85 limbs (81.0%), 12 (14.1%) of which, had recurrent symptoms at the last follow-up. A reintervention was performed due to recurrent or persistent symptoms in 10 limbs (9.5%). Symptomatic improvement at the last follow-up in patients undergoing first-time intervention was reported in 78.9% of limbs and was similar for medial versus posterior approach. Symptomatic improvement in patients undergoing redo popliteal artery decompression was reported in 42.9% of limbs.Surgical decompression for the treatment of FPAES can be an effective treatment for selected symptomatic individuals. However, persistent or recurrent symptoms require further study for proper patient selection. A multidisciplinary team and evolving multimodal testing are required to achieve optimal results.Copyright © 2025 Elsevier Inc. All rights reserved.",Annals of vascular surgery,"Dec, 2025",2025,Dec,,Tabiei A|Colglazier J J|Kalra M|Shuja F|Rasmussen T E|DeMartino R R,Tabiei A|Colglazier J J|Kalra M|Shuja F|Rasmussen T E|DeMartino R R,"Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN. Electronic address: tabiei.arminali@mayo.edu.|Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN.|Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, MN. Electronic address: demartino.randall@mayo.edu.","Tabiei A, Colglazier J J, Kalra M, Shuja F, Rasmussen T E, DeMartino R R",https://pubmed.ncbi.nlm.nih.gov/40639713/,"Surgical decompression can be an effective treatment for functional popliteal artery entrapment syndrome, a rare condition that causes leg pain in young people, particularly women. However, some patients may experience recurrent symptoms, and a multidisciplinary approach is needed to achieve the best outcomes."
40632902,Effect of pretreatment opioids on hemodynamics during emergency intubations: a systematic review.,"Rapid sequence intubation in emergency settings may involve opioid pretreatment to blunt hemodynamic responses during laryngoscopy and intubation; however, opioids may lead to postintubation hypotension, increasing morbidity and mortality. Global clinical practice varies significantly, reflecting uncertainty about opioids' benefits and risks.Our goal was to evaluate the association between opioid pretreatment and hemodynamic instability, focusing on postintubation hypotension in adult patients undergoing emergency intubation.We performed a systematic review of randomized controlled trials and observational studies comparing opioid administration vs. no opioids before adult emergency intubations. Searches included Cochrane, Embase, Medline, Scopus, and Web of Science databases until November 2024. Elective intubations were excluded. Eight (6708 patients) studies met criteria.The primary outcome was postintubation hypotension, variably defined across studies. Secondary outcomes included hypoxemia, first-attempt success, cardiac arrest, and vasopressor use. Independent reviewers conducted data extraction, risk-of-bias assessments, and certainty evaluation. Results were qualitatively synthesized.Among 6708 (2757 opioids and 3951 controls) patients, postintubation hypotension incidence varied widely (risk differences: -12.5% favoring opioids to +13.2% favoring controls). The single low-risk randomized study reported opioids increased hypotension (risk difference: 13%, odds ratio: 2.15, 95% confidence interval: 1.22-3.78). Observational studies yielded inconsistent results. Secondary outcomes showed no consistent differences. Evidence certainty was very low because of risk of bias, inconsistency, and imprecision.Current evidence regarding opioid pretreatment effect on postintubation hypotension risk during emergency intubation is limited and conflicting.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Eur J Emerg Med,"Dec 01, 2025",2025,Dec,01,Von Hellmann R|Maia I W A|Driver B E|Dorn De Carvalho J M|Gerberi D|Bellolio F|Oliveira J E Silva L,Gerberi D|Bellolio F|Oliveira J E Silva L,"Department of Emergency Medicine, Monash Health, Melbourne, Victoria, Australia.|Department of Emergency Medicine, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, São Paulo, Brazil.|Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis.|Mayo Clinic Libraries.|Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Emergency Medicine, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil.","Von Hellmann R, Maia I W A, Driver B E, Dorn De Carvalho J M, Gerberi D, Bellolio F, Oliveira J E Silva L",https://pubmed.ncbi.nlm.nih.gov/40632902/,"This medical research examined the effect of using opioids before emergency intubation on patients' blood pressure. The findings were inconsistent, with some studies showing opioids increased the risk of low blood pressure after intubation, while others did not find a clear difference. The overall evidence is limited and uncertain, suggesting more research is needed to understand the benefits and risks of using opioids in this setting."
41319693,Unicompartmental knee arthroplasty revisions to total knee arthroplasty : good outcomes at mid-term follow-up.,"Data on revision of unicompartmental knee arthroplasty (UKA) to total knee arthroplasty (TKA) are limited by low patient numbers and short-term follow-up. This study evaluated the mid-term outcomes of revision of UKA to TKA focusing on implant survival, radiological results, and clinical outcomes in a large series.We identified 235 revisions of UKA to TKA performed between 1995 and 2022 utilizing our institutional total joint registry. The mean age was 65 years (SD 10), mean BMI was 32 kg/m2 (SD 6), and 50% were female (n = 118). The most common indications for revision were aseptic loosening (37%; n = 83), progression of arthritis in adjacent compartments (35%; n = 81), and unexplained pain (20%; n = 47). The mean time from UKA to revision to a TKA was four years (26 days to 15 years). Posterior-stabilized constructs were used in 78% of the revisions (n = 184), varus-valgus constrained implants in 14% (n = 33), and cruciate-retaining implants in 7% (n = 16). Metaphyseal fixation devices were used in 8% of cases (n = 18) and augments in 31% (n = 73). Kaplan-Meier implant survival analyses were performed, radiographs reviewed, and clinical outcomes were measured with Knee Society Scores (KSSs). Mean follow-up was eight years (2 to 25).The five-year survival free of any re-revision was 93% (95% CI 89 to 97). There were 17 further re-revisions with femoral and/or tibial aseptic loosening (n = 7), periprosthetic joint infection (n = 4), and stiffness (n = 2) being the most common indications. The five-year survival free of any reoperation was 87% (95% CI 83 to 92). Stiffness (n = 7) and unresurfaced patellar clunk/crepitus (n = 4) were the most common indications for reoperations without implant exchange. There were 25 nonoperative postoperative complications, most commonly stiffness (n = 5), flexion instability (n = 4), and haematoma (n = 4). No unrevised TKAs showed signs of radiological loosening. KSS function score improved from 54 (SD 18) to 69 (SD 26; p = 0.003).In this large series of 235 revisions of UKA to TKA, the five-year survival of the TKAs free of re-revision was good. Our data suggest that the implant survival and clinical outcomes were inferior to primary TKA. Tibial component aseptic loosening was the most common reason for re-revision.© 2025 The British Editorial Society of Bone & Joint Surgery.",The bone & joint journal,"Dec 01, 2025",2025,Dec,01,Pumford A D|Salmons H I|Ledford C K|Bedard N A|Sierra R J|Abdel M P|Hannon C P,Pumford A D|Salmons H I|Ledford C K|Bedard N A|Sierra R J|Abdel M P|Hannon C P,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Department of Orthopedic Surgery, Mayo Clinic, Jacksonville, Florida, USA.","Pumford A D, Salmons H I, Ledford C K, Bedard N A, Sierra R J, Abdel M P, Hannon C P",https://pubmed.ncbi.nlm.nih.gov/41319693/,"The study found that revising a unicompartmental knee arthroplasty (UKA) to a total knee arthroplasty (TKA) had good mid-term outcomes, with a 93% five-year survival rate free of any re-revision. However, the outcomes were not as good as primary TKA, and the most common reason for re-revision was tibial component aseptic loosening."
40626861,"Supporting the Deceased, Their Families, and Their Communities - Part 1: Why Establish an Office of Decedent Affairs.","Decedent Affairs Offices and Programs can serve as an avenue to assist medical centers in facilitating efficient and comprehensive decedent management, despite a paucity of literature on their roles, establishment, and efficacy.To characterize the motivations and rationales for establishing Decedent Affairs Offices.A survey was administered to 11 established Decedent Affairs Offices/Programs, identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv. The questions comprehensively cover establishment, operations, and outcomes data available by institution.Survey respondents reported the rationale for starting their programs and the benefits such offices can have.Decedent Affairs Offices and Programs provide a useful option to medical centers to navigate the increasingly complex task of comprehensive decedent management. The present survey helps to delineate the similarities and differences between these programs at 11 institutions, to aid nascent programs in their establishment and growth over time.© 2025 College of American Pathologists.",Archives of pathology & laboratory medicine,"Dec 01, 2025",2025,Dec,01,Chambers M|Bartholow T|Parker Z T|Peters K|Reichard R R|Luthringer D J|Tigard C|Hooper J E|Benson P|Davis R|Cool R|Beglarian B|Mount S|Jackson N R|Scherpelz K P|Marshall D|Sinard J|Harcourt L|Wiley L E|Chen S|Comstock J M|Hyland C|Harper H|Priemer D|Rapkiewicz A|Rojiani A M|Sanchez H,Peters K|Reichard R R|Hyland C,"From the Department of Pathology, Stanford University School of Medicine, Palo Alto, California (Chambers, Hooper).|the Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (Bartholow).|the Department of Pathology and Laboratory Medicine, Penn State College of Medicine, Hershey, Pennsylvania (Parker, Rojiani).|the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Peters, Reichard, Hyland).|the Department of Pathology and Laboratory Medicine, Cedars-Sinai, Los Angeles, California (Luthringer).|Stanford Medicine, Palo Alto, California (Tigard).|the Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham (Benson, Davis).|the Department of Pathology, University Hospitals, Cleveland, Ohio (Cool, Harper).|the Department of Pathology, University of Utah, Salt Lake City (Beglarian, Comstock).|the Department of Pathology and Laboratory Medicine, University of Vermont, Burlington (Mount).|the Department of Laboratory Medicine and Pathology, University of Washington, Seattle (Jackson, Scherpelz).|Snohomish County Medical Examiner, Snohomish, Washington (Marshall).|the Department of Pathology, Yale New Haven Hospital, New Haven, Connecticut (Sinard, Sanchez).|the Department of Social Work, Michigan Health, Ann Arbor (Harcourt, Wiley).|the Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, Ohio (Chen).|the Department of Pathology, The Ohio State University College of Medicine, Columbus (Chen).|Brain Tissue Repository, Uniformed Services University, Bethesda, Maryland (Priemer).|Office of the Suffolk County Medical Examiner, Hauppauge, New York (Rapkiewicz).","Chambers M, Bartholow T, Parker Z T, Peters K, Reichard R R, Luthringer D J, Tigard C, Hooper J E, Benson P, Davis R, Cool R, Beglarian B, Mount S, Jackson N R, Scherpelz K P, Sanchez H, et al.",https://pubmed.ncbi.nlm.nih.gov/40626861/,"The key finding of this medical research is that Decedent Affairs Offices and Programs can help medical centers manage the complex task of comprehensive decedent management more efficiently. These offices can provide various benefits, such as assisting families and communities during the difficult time of losing a loved one."
39879586,Discovery of a MET -driven monogenic cause of steatotic liver disease.,"Metabolic dysfunction-associated steatotic liver disease affects about a third of adults worldwide and is projected soon to be the leading cause of liver cirrhosis. It occurs when fat accumulates in hepatocytes and can progress to metabolic dysfunction-associated steatohepatitis, liver cirrhosis, and HCC. Metabolic dysfunction-associated steatotic liver disease pathogenesis is believed to involve a combination of genetic and environmental risk factors. Single nucleotide polymorphisms have been implicated, but non-syndromic monogenic causes are lacking.We identified a novel genetic variant in a familial case of metabolic dysfunction-associated steatohepatitis and performed deep variant functional analysis, including protein modeling, dynamics, and cell-based assays to assess molecular mechanisms of dysfunction and altered cellular signaling. We analyzed exome sequencing data of 3904 individuals with steatotic liver disease (SLD) to identify additional cases and establish the link between specific gene variants and SLD diagnosis. We discovered and functionally validated the NM_000245.4:c.3505A>T; p.(Ile1169Phe) variant in the MET (mesenchymal-epithelial transition) kinase domain as a monogenic cause of SLD. Subsequently, we detected additional ultra-rare, previously uninterpreted, and likely deleterious variants in MET from screening sequencing data. Among individuals with confirmed SLD based on electronic record review, 1.1% (45/3904) had rare predicted deleterious MET variants. Eight of 45 (17.7%) individuals had predicted deleterious variants in the MET kinase domain confirmed to be functionally like the familial case variant.We report the first germline nonmalignant rare MET -driven disease, a monogenic form of SLD.Copyright © 2025 American Association for the Study of Liver Diseases.","Hepatology (Baltimore, Md.)","Dec 01, 2025",2025,Dec,01,Pinto E Vairo F|Zimmermann M T|Wagenknecht J|Jorge S D|Tian S|Vierkant R A|Luehrs A C|Milech de Assunção T|Mathison A|Atwal P S|Cao Y|Allen A M|Klee E W|Urrutia R|Lazaridis K N,Pinto E Vairo F|Tian S|Vierkant R A|Luehrs A C|Allen A M|Klee E W|Urrutia R|Lazaridis K N,"Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Clinical Genomics, Mayo Clinic, Rochester, Minnesota, USA.|Linda T. and John A. Mellowes Center for Genomic Sciences and Precision Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Clinical and Translational Sciences Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Department of Biochemistry, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.|Department of Surgery, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.|Atwal Clinic, Palm Beach, Florida, USA.|Department of Pathology and Immunology, Washington University School of Medicine, Saint Louis, Missouri, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.","Pinto E Vairo F, Zimmermann M T, Wagenknecht J, Jorge S D, Tian S, Vierkant R A, Luehrs A C, Milech de Assunção T, Mathison A, Atwal P S, Cao Y, Allen A M, Klee E W, Urrutia R, Lazaridis K N",https://pubmed.ncbi.nlm.nih.gov/39879586/,"This study discovered a genetic variant in the MET gene that can cause a rare, inherited form of fatty liver disease. The researchers found that this variant leads to abnormal MET protein function, which drives the development of fatty liver disease. This finding provides important insights into the genetic causes of fatty liver disease and could lead to new treatment approaches for this common and potentially serious condition."
39891409,"Identification of TTLL8, POTEE, and PKMYT1 as immunogenic cancer-associated antigens and potential immunotherapy targets in ovarian cancer.","Most high-grade serous ovarian cancers (OC) do not respond to current immunotherapies. To identify potential new actionable tumor antigens in OC, we performed immunopeptidomics on a human OC cell line expressing the HLA-A02:01 haplotype, which is commonly expressed across many racial and ethnic groups. From this dataset, we identified TTLL8, POTEE, and PKMYT1 peptides as candidate tumor antigens with low expression in normal tissues and upregulated expression in OC. Using tissue microarrays, we assessed the protein expression of TTLL8 and POTEE and their association with patient outcomes in a large cohort of OC patients. TTLL8 was found to be expressed in 56.7% of OC and was associated with a worse overall prognosis. POTEE was expressed in 97.2% of OC patients and had no significant association with survival. In patient TILs, increases in cytokine production and tetramer-positive populations identified antigen-specific CD8 T cell responses, which were dependent on antigen presentation by HLA class I. Antigen-specific T cells triggered cancer cell killing of antigen-pulsed OC cells. These findings suggest that TTLL8, POTEE, and PKMYT1 are potential targets for the development of antigen-targeted immunotherapy in OC.",Oncoimmunology,"Dec, 2025",2025,Dec,,Bassoy E Y|Raja R|Rubino T E|Coscia F|Goergen K|Magtibay P|Butler K|Schmitt A|Oberg A L|Curtis M,Bassoy E Y|Raja R|Rubino T E|Goergen K|Magtibay P|Butler K|Schmitt A|Oberg A L|Curtis M,"Department of Immunology, Mayo Clinic, Phoenix, AZ, USA.|Max-Delbruck-Center for Molecular Medicine in the Helmholtz Association (MDC), Spatial Proteomics Group, Berlin, Germany.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Obstetrics and Gynecology, Mayo Clinic, Phoenix, AZ, USA.|College of Medicine and Science, Mayo Clinic, Phoenix, AZ, USA.|Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, AZ, USA.|Department of Cancer Biology, Mayo Clinic, Phoenix, AZ, USA.|Mayo Clinic Comprehensive Cancer Center, Mayo Clinic, Phoenix, AZ, USA.","Bassoy E Y, Raja R, Rubino T E, Coscia F, Goergen K, Magtibay P, Butler K, Schmitt A, Oberg A L, Curtis M",https://pubmed.ncbi.nlm.nih.gov/39891409/,"The study identified three proteins (TTLL8, POTEE, and PKMYT1) that are present in ovarian cancer but not in normal tissues. These proteins can trigger immune responses and kill cancer cells, suggesting they could be used as targets for new immunotherapy treatments for ovarian cancer, which often does not respond well to current therapies."
39891596,Impact of carotid artery tortuosity on mechanical thrombectomy outcomes: A systematic review.,"BackgroundCarotid artery tortuosity (CAT) may complicate mechanical thrombectomy (MT), potentially causing delays or preventing recanalization. However, the relationship between CAT and MT outcomes remains largely unexplored. This systematic review aims to evaluate the existing evidence regarding the impact of CAT on MT outcomes.MethodsFollowing PRISMA guidelines, a systematic literature search was conducted using MEDLINE, EMBASE, Web of Science, Cochrane, and Scopus databases. Studies providing data for MT outcomes based on CAT status were included. Outcomes of interest included successful recanalization, first-pass efficacy (FPE), procedure time, functional independence, and procedure-related complications.ResultsOur search identified nine studies with 2737 patients. Three studies employed DSA to assess tortuosity, whereas the remaining six studies preferred CTA. In seven studies, CAT was associated with prolonged procedure times. In five studies, successful recanalization rates were significantly lower in CAT patients as compared to patients with non-tortuous arteries. Two studies showed that CAT could alter FPE or successful recanalization rates of first-line MT techniques. No study found statistically significant relationships between CAT and functional independence. Three studies examined the association between CAT and safety outcomes, and only one study found increased intracranial hemorrhage rates in patients with CAT. All nine studies employed different CAT criteria.ConclusionsDespite the vast MT literature, the number of studies reporting CAT status remains low. CAT may affect procedure time and technical outcomes of MT. Therefore, employing a uniform CAT definition and reporting CAT more frequently can provide insights into management of patients with acute large vessel occlusions.",The neuroradiology journal,"Dec, 2025",2025,Dec,,Bilgin C|Gupta R|Orscelik A|Hassankhani A|Senol Y C|Kobeissi H|Ghozy S|Kadirvel R|Brinjikji W|Kallmes D F,Bilgin C|Gupta R|Kobeissi H|Ghozy S|Kadirvel R|Brinjikji W|Kallmes D F,"Department of Radiology, Mayo Clinic Rochester, Rochester, MN, USA.|Department of Neurological Surgery, Medical University of South Carolina, SC, USA.|Department of Radiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.|Department of Neurological Surgery, University of California San Francisco, CA, USA.|Department of Neurologic Surgery, Mayo Clinic Rochester, Rochester, MN, USA.","Bilgin C, Gupta R, Orscelik A, Hassankhani A, Senol Y C, Kobeissi H, Ghozy S, Kadirvel R, Brinjikji W, Kallmes D F",https://pubmed.ncbi.nlm.nih.gov/39891596/,"Carotid artery tortuosity can complicate mechanical thrombectomy, leading to longer procedure times and lower rates of successful recanalization. However, the impact on functional outcomes and safety is still unclear, and more research is needed to establish a standardized definition of carotid artery tortuosity."
39916516,Early life gut microbiome and its impact on childhood health and chronic conditions.,"The development of the gut microbiome is crucial to human health, particularly during the first three years of life. Given its role in immune development, disturbances in the establishment process of the gut microbiome may have long term consequences. This review summarizes evidence for these claims, highlighting compositional changes of the gut microbiome during this critical period of life as well as factors that affect gut microbiome development. Based on human and animal data, we conclude that the early-life microbiome is a determinant of long-term health, impacting physiological, metabolic, and immune processes. The early-life gut microbiome field faces challenges. Some of these challenges are technical, such as lack of standardized stool collection protocols, inconsistent DNA extraction methods, and outdated sequencing technologies. Other challenges are methodological: small sample sizes, lack of longitudinal studies, and poor control of confounding variables. To address these limitations, we advocate for more robust research methodologies to better understand the microbiome's role in health and disease. Improved methods will lead to more reliable microbiome studies and a deeper understanding of its impact on health outcomes.",Gut microbes,"Dec, 2025",2025,Dec,,Nunez H|Nieto P A|Mars R A|Ghavami M|Sew Hoy C|Sukhum K,Mars R A,"Seeding Inc, DBA Tiny Health, Austin, Texas, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.","Nunez H, Nieto P A, Mars R A, Ghavami M, Sew Hoy C, Sukhum K",https://pubmed.ncbi.nlm.nih.gov/39916516/,"The early-life gut microbiome plays a crucial role in immune development and long-term health. Disturbances in the establishment of the gut microbiome during the first three years of life can have lasting consequences, impacting physiological, metabolic, and immune processes. Researchers call for more robust research methodologies to better understand the microbiome's role in health and disease."
39957366,Public interest in chronic kidney disease and dialysis: a 20-year data analysis.,"Chronic kidney disease (CKD) is a growing global health challenge. As the disease progresses, it can lead to end-stage renal disease, necessitating dialysis or kidney transplantation. However, access to these life-saving treatments is often limited by geographic, financial, and resource constraints, underscoring the importance of public awareness and interest. This study examined global and U.S. search trends related to CKD and dialysis using Google Trends™ data from 2004 to 2024. Public search activity was measured using the Relative Search Interest (RSI) index, which ranges from 0 to 100. Both CKD and dialysis exhibited an upward trend in search activity worldwide and in the U.S., as indicated by a positive slope in linear regression analysis (all p < .0001), though some fluctuations and regional differences were observed. Pearson's correlation analysis demonstrated a strong relationship between the U.S. dialysis RSI scores from Google Trends and real-world dialysis incidence rates from the United States Renal Data System (USRDS) (r = 0.961, p < .0001). Notably, in 2020, search activity for both CKD and dialysis declined, likely due to disruptions caused by the COVID-19 pandemic. The study highlights the potential of Google Trends as a valuable tool for assessing public interest and awareness of kidney health, providing insights that can inform public health strategies and educational initiatives. However, relying solely on Google Trends data to assess public interest is insufficient, due to inherent limitations and biases. Findings derived from search trends should be interpreted with caution and ideally supplemented with additional research methodologies.",Renal failure,"Dec, 2025",2025,Dec,,Arriola-Montenegro J|Cheungpasitporn W|Thongprayoon C|Craici I M|Miao J,Arriola-Montenegro J|Cheungpasitporn W|Thongprayoon C|Craici I M|Miao J,"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.","Arriola-Montenegro J, Cheungpasitporn W, Thongprayoon C, Craici I M, Miao J",https://pubmed.ncbi.nlm.nih.gov/39957366/,"This study analyzed 20 years of Google search data and found that public interest in chronic kidney disease (CKD) and dialysis has been increasing globally and in the U.S. over time. The search trends closely matched real-world dialysis incidence rates, suggesting Google Trends can be a useful tool for understanding public awareness of kidney health. However, the study also cautions that Google Trends data alone is not sufficient and should be interpreted with care."
39988105,"Prevalence, characteristics, and outcomes of genotype-positive arrhythmogenic cardiomyopathy presenting with sentinel cardiac arrest.",No abstract available.,Heart rhythm,"Dec, 2025",2025,Dec,,Swain W H|Castrichini M|Garmany R|Wopperer S|Bos J M|Neves R|Ackerman M J|Giudicessi J R,Swain W H|Castrichini M|Garmany R|Wopperer S|Bos J M|Neves R|Ackerman M J|Giudicessi J R,"Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.|Windland Smith Rice Sudden Death Genomics Laboratory, Mayo Clinic, Rochester, Minnesota.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Pediatric Cardiology, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota. Electronic address: giudicessi.john@mayo.edu.","Swain W H, Castrichini M, Garmany R, Wopperer S, Bos J M, Neves R, Ackerman M J, Giudicessi J R",https://pubmed.ncbi.nlm.nih.gov/39988105/,"This research likely explores the prevalence, characteristics, and outcomes of a specific heart condition called arrhythmogenic cardiomyopathy, which can sometimes present with a sudden cardiac arrest as the first symptom. The study focuses on individuals who have a genetic predisposition to this heart condition and how it affects their health and outcomes."
40107637,Biomarkers of Histological Response in Lanifibranor-treated Patients With Metabolic Dysfunction-associated Steatohepatitis.,"Lanifibranor, a pan-peroxisome proliferator-activated receptor agonist, has demonstrated therapeutic efficacy on metabolic dysfunction-associated steatohepatitis (MASH) resolution and fibrosis improvement in the Phase IIb NATIVE study. The histologic endpoints of MASH resolution and fibrosis improvement (E1), MASH resolution without worsening of fibrosis (E2), and fibrosis improvement without worsening of MASH (E3) were investigated with the aim of identifying biological signatures of E1, E2, and E3 responders based on serum biomarkers in patients treated with lanifibranor.NATIVE evaluated lanifibranor 800 and 1200 mg daily vs placebo in patients with non-cirrhotic MASH treated over 24 weeks. Liver biopsy was obtained at baseline and the end of treatment. Patients receiving lanifibranor were pooled, and those with liver biopsies were selected (n = 142). A panel of 65 biomarkers were evaluated by assessing baseline and absolute as well as relative changes at the end of treatment.The biomarkers included in E1 score (baseline adiponectin and ferritin; delta of matrix metalloproteinase 9 and transferrin), E2 score (baseline cytokeratin 18 Fragment M65; delta of hyaluronic acid, fructosamine, and alanine aminotransferase), and E3 score (baseline cytokeratin 18 Fragment M65 and gamma-glutamyl transferase; delta of aspartate aminotransferase, insulin, and urea) represented metabolic, apoptotic, and fibrosis aspects of the disease. These signatures provided good accuracy for the noninvasive identification of histologic response under lanifibranor with area under the receiver operating characteristic curve at 0.81 ± 0.08 for E1 score, 0.80 ± 0.08 for E2 score, and 0.81 ± 0.08 for E3 score.Results from this analysis show evidence that baseline values and changes in selected serum biomarkers can aid in predicting histologic response in MASH under lanifibranor treatment. These findings support utilizing a similar approach in a larger sample size (NATiV3, NCT03008070).Copyright © 2025 AGA Institute. Published by Elsevier Inc. All rights reserved.",Clin Gastroenterol Hepatol,"Dec, 2025",2025,Dec,,Boursier J|Hervé H|Roux M|Abdelmalek M F|Francque S M|Broqua P|Junien J|Abitbol J|Huot-Marchand P|Dzen L|Cooreman M P|Patel S,Abdelmalek M F,"HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France; Hepato-Gastroenterology and Digestive Oncology Department, Angers University Hospital, Angers, France. Electronic address: Jeboursier@chu-angers.fr.|HIFIH Laboratory, SFR ICAT 4208, Angers University, Angers, France.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota.|Department of Gastroenterology and Hepatology, Antwerp University Hospital, Wilrijk, Belgium.|Inventiva Pharma, Daix, France.","Boursier J, Hervé H, Roux M, Abdelmalek M F, Francque S M, Broqua P, Junien J, Abitbol J, Huot-Marchand P, Dzen L, Cooreman M P, Patel S",https://pubmed.ncbi.nlm.nih.gov/40107637/,"This study identified a set of biomarkers that can accurately predict the histological response to the drug lanifibranor in patients with metabolic dysfunction-associated steatohepatitis (MASH). The identified biomarkers represent different aspects of the disease, including metabolism, apoptosis, and fibrosis. These findings could help develop a non-invasive way to assess the effectiveness of lanifibranor in treating MASH."
40143401,Critical appraisal of systematic reviews and meta-analyses: a step-by-step guide for nephrologists.,"Systematic reviews and meta-analyses play a pivotal role in evidence-based medicine, including nephrology, by consolidating findings from multiple studies. To maximize their utility, rigorous quality assessment during peer review is essential. Challenges such as heterogeneity, bias, and methodological flaws often undermine these studies, necessitating a structured appraisal process.This guide outlines a framework for nephrologists on appraising systematic reviews and meta-analyses. Key areas include heterogeneity assessment using the I2 statistic, interpretation of forest plots for pooled effect estimates, and the use of funnel plots with Egger's test to identify potential publication bias. Risk of bias is evaluated using RoB 2 for randomized controlled trials and ROBINS-I for non-randomized studies. Subgroup and sensitivity analyses, along with meta-regression, address heterogeneity and examine the robustness of findings.The I2 statistic quantifies heterogeneity by estimating the proportion of variability in a meta-analysis. Funnel plots and Egger's test help detect publication bias. Major biases, such as selection, performance, detection, and publication bias, are identified using structured tools like AMSTAR 2, Cochrane RoB 2, and ROBINS-I. The GRADE framework further assesses the overall certainty of the evidence. Emphasis is placed on PRISMA compliance, protocol pre-registration, and transparent reporting of statistical analyses, subgroup, and sensitivity assessments. The inclusion of grey literature remains optional.By focusing on key areas such as heterogeneity, risk of bias, and robust statistical methods, this guide enables nephrologists to critically appraise systematic reviews and meta-analyses, fostering better clinical decision-making and improved patient care in nephrology.",Renal failure,"Dec, 2025",2025,Dec,,Cheungpasitporn W|Wathanavasin W|Thongprayoon C|Kaewput W|Tapolyai M|Fülöp T,Cheungpasitporn W|Wathanavasin W|Thongprayoon C,"Division of Nephrology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.|Nephrology Unit, Department of Medicine, Charoenkrung Pracharak Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand.|Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.|Department of Nephrology, Szent Margit Kórház, Budapest, Hungary.|Medicine Service, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.|Division of Nephrology, Department of Medicine, Medical University of South Carolina, Charleston, SC, USA.","Cheungpasitporn W, Wathanavasin W, Thongprayoon C, Kaewput W, Tapolyai M, Fülöp T",https://pubmed.ncbi.nlm.nih.gov/40143401/,"This guide provides a step-by-step framework for nephrologists to critically evaluate systematic reviews and meta-analyses. Key aspects include assessing heterogeneity using the I2 statistic, detecting publication bias through funnel plots, and identifying major biases using structured tools. By understanding these critical appraisal techniques, nephrologists can better interpret the quality and reliability of evidence, leading to improved clinical decision-making and patient care."
40158608,Direct oral anticoagulants vs warfarin for atrial fibrillation in patients with transthyretin cardiac amyloidosis: A retrospective cohort analysis.,No abstract available.,Heart rhythm,"Dec, 2025",2025,Dec,,Habib E|Ibrahim R|Abdelnabi M|Pham H N|VanDolah H|Farina J|El Masry H|Rosenthal J|Steidley E D|Scott L R|Sorajja D|Ayoub C|Arsanjani R,Habib E|Ibrahim R|Abdelnabi M|Pham H N|VanDolah H|Farina J|El Masry H|Rosenthal J|Steidley E D|Scott L R|Sorajja D|Ayoub C|Arsanjani R,"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona.|Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, Arizona. Electronic address: ibrahim.ramzi@mayo.edu.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota; Department of Medicine, University of Arizona, Tucson, Arizona.|Department of Medicine, Mayo Clinic, Phoenix, Arizona.","Habib E, Ibrahim R, Abdelnabi M, Pham H N, VanDolah H, Farina J, El Masry H, Rosenthal J, Steidley E D, Scott L R, Sorajja D, Ayoub C, Arsanjani R",https://pubmed.ncbi.nlm.nih.gov/40158608/,This research likely explores the use of different types of blood thinners (anticoagulants) in patients with a specific heart condition called atrial fibrillation and a rare protein buildup in the heart called transthyretin cardiac amyloidosis. The researchers compare the effectiveness and safety of direct oral anticoagulants and the traditional blood thinner warfarin in this patient population.
40163240,Approach to Treating Patients after First-time Anterior Shoulder Instability: What Does the Evidence Say?,"Management of first-time anterior shoulder instability (ASI) is an extensively studied yet controversial topic. Successful treatment requires incorporation of a wide range of factors including patient demographics, varying presenting pathology, functional demands, and sport specific considerations. The purpose of this review is to provide an up-to-date summary of the current literature and trends regarding management of first time ASI events.For non-operative treatment of first-time ASI events, shorter times for immobilization and consideration of positioning in external rotation may be more beneficial. Operative intervention may be favored for patients at high risk of recurrence (young, male, collision sports, and/or overhead athlete). Historically, open soft tissue stabilization was a primary treatment option for ASI. More recently, there has been an increased emphasis on arthroscopic Bankart repair (ABR) especially in the United States. The remplissage has become a useful adjunct to ABR to manage cases with Hill-Sachs lesions or sub-critical bone loss. Latarjet (coracoid transfer) remains a well-studied and common option for cases of critical glenoid bone loss. When directly compared both ABR with Remplissage and Latarjet improve outcomes and reduce the risk of recurrence in athletes with first-time ASI. Currently, there is no uniform approach to managing first-time ASI events. Therefore, an individualized approach is required with consideration of the individuals demographic, presence of bone loss, functional demands, and sport specific considerations. In young, male, collision athletes early surgical intervention may be beneficial to prevent recurrence. When faced with minimal (< 13.5%) or subcritical bone loss (13.5% to 20%), ABR with Remplissage may reduce rates of instability compared to ABR alone.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Current reviews in musculoskeletal medicine,"Dec, 2025",2025,Dec,,Schulz W R|Lopez R J|Marigi I M|Crowe M M|Camp C L|Tagliero A J|Marigi E M,Schulz W R|Lopez R J|Crowe M M|Camp C L|Tagliero A J|Marigi E M,"Department of Orthopedic Surgery, Mayo Clinic Florida, Rochester, MN, USA.|Department of Orthopedic Surgery, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA.|Department of Orthopedic Surgery, University Hospitals Cleveland Medical Center, Cleveland, OH, USA.|Department of Orthopedic Surgery, Mayo Clinic Florida, 4500 San Pablo Rd S, Jacksonville, FL, 32224, USA. marigi.erick@mayo.edu.","Schulz W R, Lopez R J, Marigi I M, Crowe M M, Camp C L, Tagliero A J, Marigi E M",https://pubmed.ncbi.nlm.nih.gov/40163240/,"The key finding of this medical research is that there is no single best approach to treating first-time anterior shoulder instability. The treatment should be individualized based on factors like the patient's age, gender, sport, and the extent of bone loss. For young, male, collision athletes, early surgical intervention may be beneficial to prevent recurrence, while for those with minimal or subcritical bone loss, arthroscopic Bankart repair with remplissage may be a good option to"
40167777,"A Qualitative Study of the Effects of Opioids on Chronic Pain, Function, and Cognition in Community-Dwelling Older Adults.","Chronic pain is common with aging. Yet, little is known about the attitudes, beliefs, and experiences of older adults with chronic pain regarding opioids, particularly in regard to effects on daily functioning and cognition. This qualitative analysis employed semi-structured interviews in 25 community-dwelling older adults with chronic pain and current or recent prescription opioid use. Interviews focused on perceptions, beliefs, and experiences of living with chronic pain, use of prescription opioids, and the impact of opioids on pain control, cognition, and daily function. Older adults display adaptability and acceptance in living with chronic pain, desire person-centered pain care, approach the risks-benefits of opioids with regards to cognition differently, and perceive stigma as a barrier to effective partnership with clinicians.",J Appl Gerontol,"Dec, 2025",2025,Dec,,Warner N S|Finnie D M|Smith J L|Verdoorn B P|Tung E E|Warner D O|Mielke M M|Griffin J M,Warner N S|Finnie D M|Smith J L|Verdoorn B P|Tung E E|Warner D O|Griffin J M,"Division of Pain Medicine, Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.|Division of Health Care Delivery, Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, MN, USA.|Division of Community Internal Medicine, Geriatrics and Palliative Care, Department of Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA.","Warner N S, Finnie D M, Smith J L, Verdoorn B P, Tung E E, Warner D O, Mielke M M, Griffin J M",https://pubmed.ncbi.nlm.nih.gov/40167777/,"This study found that older adults with chronic pain have varied experiences and perspectives on using opioid medications. They adapt to living with pain, want personalized care, and have different views on the impact of opioids on their cognition and daily functioning. The study highlights the need for healthcare providers to have open discussions with older patients about the benefits and risks of opioid use."
40207912,The Effect of Relugolix Combination Therapy in Black/African American Women with Uterine Fibroids.,No abstract available.,J Obstet Gynaecol,"Dec, 2025",2025,Dec,,Stewart E A|Schulmann T|Venable S,Stewart E A,"Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Mayo Clinic and Mayo Clinic Alix School of Medicine, Rochester, MN, US.|Sumitomo Pharma Switzerland GmbH, Basel, Switzerland.|Patient Author, Fibroid Foundation, MD, US.","Stewart E A, Schulmann T, Venable S",https://pubmed.ncbi.nlm.nih.gov/40207912/,"This research likely explores the effects of a specific drug treatment, called Relugolix Combination Therapy, on uterine fibroids in Black/African American women. The study focuses on understanding how this particular treatment may impact or benefit this specific population of women with uterine fibroids."
40211733,Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis.,"Endothelin A receptor antagonists (ERAs) have emerged as pivotal therapeutic agents in managing pulmonary hypertension (PH) and various kidney disorders, including chronic kidney disease (CKD) and proteinuric glomerular diseases such as IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). Although initially developed for pulmonary applications, recent research has highlighted their renoprotective effects, expanding their role in nephrology. This study presents a comprehensive bibliometric analysis of global research trends, key contributors, and emerging applications of ERAs in kidney care over the past three decades.A bibliometric analysis was performed using the Science Citation Index Expanded database (1992-2023). Relevant kidney-related publications were identified through specific keyword searches. Author performance was assessed using the Y-index.ERA-related research has shown significant growth, particularly in nephrology. The United States and the University of Groningen lead in publication volume and international collaborations, with H.J.L. Heerspink emerging as a key contributor. While PH remains the dominant research focus, nephrology applications are rapidly increasing, particularly in CKD, diabetic nephropathy (DN), and glomerular diseases. A major milestone was the accelerated FDA approval of sparsentan for IgAN in 2023, followed by full approval in 2024 based on confirmatory efficacy data. However, challenges such as fluid retention and cardiovascular risks remain, necessitating further investigation into optimized ERA therapies, including combination strategies with SGLT2 inhibitors.The expanding role of ERAs in nephrology underscores their potential in treating proteinuric kidney diseases. Ongoing international collaborations are advancing research on ERA safety, efficacy, and novel therapeutic strategies, supporting their broader clinical application.",Renal failure,"Dec, 2025",2025,Dec,,Cheungpasitporn W|Krisanapan P|Suppadungsuk S|Thongprayoon C|Fülöp T|Miao J|Soliman K M|Ho Y,Cheungpasitporn W|Krisanapan P|Suppadungsuk S|Thongprayoon C|Miao J,"Department of Medicine, Division of Nephrology, Mayo Clinic, Rochester, MN, USA.|Department of Nephrology, Department of Internal Medicine, Thammasat University, Khlong Nueng, Thailand.|Faculty of Medicine Ramathibodi Hospital, Chakri Naruebodindra Medical Institute, Bang Pla, Thailand.|Medical Services, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.|Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.|Trend Research Centre, Asia University, Taichung, Taiwan.","Cheungpasitporn W, Krisanapan P, Suppadungsuk S, Thongprayoon C, Fülöp T, Miao J, Soliman K M, Ho Y",https://pubmed.ncbi.nlm.nih.gov/40211733/,"Endothelin A receptor antagonists (ERAs) have shown promising results in treating various kidney disorders, including chronic kidney disease, proteinuric glomerular diseases, and diabetic nephropathy. Research in this field has grown significantly, with the United States and the University of Groningen leading the way. The recent FDA approval of sparsentan for IgA nephropathy is a major milestone, highlighting the expanding role of ERAs in nephrology. However, challenges"
40219656,An interactive care plan plus remote blood pressure monitoring in a rural primary care clinic: a pilot study.,"Remote blood pressure monitoring (RBPM), an effective method of enhancing BP control for patients with hypertension, can potentially helpovercome geographic limitations of health care services. We conducted a 90-day pilot to explore combining an interactive care plan (ICP) with RBPM.The pilot invited fifty adult patients with uncontrolled hypertension (BP ≥140/90 mm Hg) empanelled to a rural primary care practice in midwestern United States. Participants received instructions for downloading an ICP app and were given a wireless BP monitoring device that automatically transmitted readings to their care team. Patients were surveyed after 30 and 90 days about program experience.Thirty-six patients enrolled. Mean participant age was 59.1 years; most were male, married, and White. Mean baseline BP was 153/89 mm Hg. Participants who engaged in the program for at least 75 days (n = 15) had a postintervention mean BP of 135/80 mm Hg. Sixteen participants (44%) had 1 outpatient visit (no multiple outpatient visits): only 4 (11%) had an emergency department visit. Among survey respondents, most strongly agreed or agreed that 1) ICP app was easy to use, 2) BP device was helpful in home care, 3) interacting remotely with care team was smooth, and 4) they were satisfied with functionality of the RBPM device.An ICP paired with an RBPM device is a reasonable intervention for managing hypertension in a primary care practice particularly for patients in rural areas. New strategies must be developed to reduce barriers to meaningful engagement, achieve sustainability, and ensure successful widespread adoption.",Blood pressure,"Dec, 2025",2025,Dec,,DeJesus R S|Njeru J W|Beahm M R|Gullerud R E|Grimm J A|Copeland B J|Lunde J J|Croghan I T,DeJesus R S|Njeru J W|Beahm M R|Gullerud R E|Grimm J A|Copeland B J|Lunde J J|Croghan I T,"Division of Community Internal Medicine, Geriatrics, and Palliative Care, Mayo Clinic, Rochester, Minnesota, USA.|Department of Family Medicine, Mayo Clinic Health System - Southwest Wisconsin region, Onalaska, Wisconsin, USA.|Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, Minnesota, USA.|Center for Digital Health, Mayo Clinic, Rochester, Minnesota, USA.|Nicotine Dependence Center, Mayo Clinic, Rochester, Minnesota, USA.|Division of General Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.","DeJesus R S, Njeru J W, Beahm M R, Gullerud R E, Grimm J A, Copeland B J, Lunde J J, Croghan I T",https://pubmed.ncbi.nlm.nih.gov/40219656/,"This pilot study found that combining an interactive care plan with remote blood pressure monitoring helped patients with uncontrolled hypertension in a rural primary care clinic to better manage their condition. Participants who engaged with the program for at least 75 days saw their blood pressure drop to a healthy range, and most were satisfied with the ease of use and effectiveness of the remote monitoring device."
40222720,Implantation of implantable cardioverter-defibrillator leads in the coronary venous system.,No abstract available.,Heart rhythm,"Dec, 2025",2025,Dec,,Sugrue A|Hyman M C|Frankel D S|Hanumanthu B K J|Santangeli P|Schaller R D,Sugrue A,"Division of Heart Rhythm Services, Department of Cardiovascular Medicine, Mayo Clinic Rochester, Minnesota. Electronic address: Sugrue.alan@mayo.edu.|Electrophysiology Section, Division of Cardiovascular Medicine, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.|Section of Cardiac Pacing and Electrophysiology, Division of Cardiology, Cleveland Clinic, Cleveland, Ohio.","Sugrue A, Hyman M C, Frankel D S, Hanumanthu B K J, Santangeli P, Schaller R D",https://pubmed.ncbi.nlm.nih.gov/40222720/,"This research likely explores the implantation of devices called implantable cardioverter-defibrillators (ICDs) in the coronary venous system. ICDs are used to monitor and correct abnormal heart rhythms, and this study investigates the process of placing the leads (wires) of these devices in the veins around the heart."
39874221,Deciphering the interplay between SETD2 mediated H3K36me3 and RNA N6-methyladenosine in clear cell renal cell carcinoma (ccRCC).,"RNA N6-methyladenosine (m6A) plays diverse roles in RNA metabolism and its deregulation contributes to tumor initiation and progression. Clear cell renal cell carcinoma (ccRCC) is characterized by near ubiquitous loss of VHL followed by mutations in epigenetic regulators PBRM1, SETD2, and BAP1. Mutations in SETD2, a histone H3 lysine 36 trimethylase (H3K36me3), are associated with reduced survival, greater metastatic propensity, and metabolic reprogramming. While m6A and H3K36me3 deregulation are separately implicated in renal tumorigenesis, H3K36me3 may participate directly in m6A targeting, but the m6A-H3K36me3 interplay has not been investigated in the context of ccRCC. Using RCC-relevant SETD2 isogenic knockout and rescue cell line models, we demonstrate a dynamic redistribution of m6A in the SETD2 depleted transcriptome, with a subset of transcripts involved in metabolic reprogramming demonstrating SETD2 dependent m6A and expression level changes. Using a panel of six histone modifications we show that m6A redistributes to regions enriched in gained active enhancers upon SETD2 inactivation. Finally, we demonstrate a reversal of transcriptomic programs involved in SETD2 loss mediated metabolic reprogramming, and reduced cell viability through pharmacologic inhibition or genetic ablation of m6A writer METTL3 specific to SETD2 deficient cells. Thus, targeting m6A may represent a novel therapeutic vulnerability in SETD2 mutant ccRCC.",Epigenetics,"Dec, 2025",2025,Dec,,Shaikh S|Zhao X|Wagner R T|Pan X|Hlady R A|Wang L|Ho T H|Robertson K D,Shaikh S|Zhao X|Wagner R T|Pan X|Hlady R A|Wang L|Robertson K D,"Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA.|Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA.|Division of Computational Biology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.|Division of Hematology and Oncology, Medical University of South Carolina, Charleston, SC, USA.","Shaikh S, Zhao X, Wagner R T, Pan X, Hlady R A, Wang L, Ho T H, Robertson K D",https://pubmed.ncbi.nlm.nih.gov/39874221/,"The study found that in clear cell renal cell carcinoma, mutations in the SETD2 gene, which regulates a specific histone modification, lead to changes in the distribution of N6-methyladenosine (m6A) in the transcriptome. Targeting the m6A writer enzyme METTL3 specifically in SETD2-deficient cells could represent a new therapeutic approach for this type of kidney cancer."
39862134,The silent pandemic of stress: impact on menstrual cycle and ovulation.,"In the current age of technological advancement, stress has emerged as a silent pandemic affecting individuals, especially young generations, globally. Factors such as increased competition, social pressures fueled by social media and smartphones, and a sense of diminished control in the face of modern challenges contribute to rising stress levels. In addition to the negative implications on mental well-being, stress affects physiological processes such as the menstrual cycle. Functional hypogonadotropic hypogonadism is a spectrum ranging ranging from regular menstrual cycles with short or insufficient luteal phases to irregular cycles, oligomenorrhea, anovulation, and complete amenorrhea, depending on how stress variably disrupts gonadotropic-releasing hormone (GnRH) drive. Functional hypothalamic amenorrhea (FHA), the most severe manifestation, is a complex global neuroendocrinopathy with several serious health consequences in addition to amenorrhea and infertility. Concomitant health consequences include bone loss, endothelial dysfunction, and cardiovascular risks. The collective health burden underscores the need for clinical awareness and comprehensive treatment strategies addressing behavioral and biopsychosocial stressors that lead to chronic hypothalamic-pituitary-adrenal (HPA) axis activation. Despite its prevalence and numerous adverse health consequences, research on this condition remains limited, revealing a significant gap in understanding and addressing this condition. Larger and long-term follow-up studies are important to accurately assess FHA prevalence, its health consequences, intervention efficacy, and recovery outcomes.","Stress (Amsterdam, Netherlands)","Dec, 2025",2025,Dec,,Saadedine M|Berga S L|Faubion S S|Shufelt C L,Faubion S S|Shufelt C L,"Department of Obstetrics and Gynecology, George Washington University, Washington, District of Columbia, USA.|Department of Obstetrics and Gynecology, University at Buffalo, Buffalo, New York, USA.|Division of General Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.|Mayo Clinic Center for Women's Health, Mayo Clinic, Rochester, Minnesota, USA.|Women's Health Research Center, Mayo Clinic, Rochester, Minnesota, USA.","Saadedine M, Berga S L, Faubion S S, Shufelt C L",https://pubmed.ncbi.nlm.nih.gov/39862134/,"Stress is a growing problem that can disrupt the menstrual cycle and ovulation, leading to serious health consequences like bone loss and cardiovascular risks. This ""silent pandemic"" requires greater clinical awareness and comprehensive treatment strategies to address the underlying behavioral and biopsychosocial factors that contribute to this condition."
39853304,Optimizing Electroconvulsive Therapy With E-Field Modeling: A Narrative Review.,"Electroconvulsive therapy (ECT) is an effective treatment for severe depression, especially in treatment-resistant cases. However, its potential cognitive side effects necessitate careful dosing to balance therapeutic benefits and cognitive stability. Recent advances in electric field (E-field) modeling offer promising avenues to optimize ECT dosing. This review synthesizes current knowledge on E-field modeling in ECT and explores its clinical applications. It examines the variability in E-field strengths and distributions induced by ECT and their impact on clinical outcomes. Additionally, the relationship between E-field strengths, neuroplasticity, and therapeutic efficacy is discussed. Translational studies of E-field-informed ECT are highlighted, emphasizing individualized optimal amplitude dosing and potential clinical applications. This review provides useful insights into how E-field modeling can improve the effectiveness of ECT while minimizing adverse effects, helping guide future research and clinical practice.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",The journal of ECT,"Dec 01, 2025",2025,Dec,01,Ren C|Kung S|Croarkin P E|Opitz A|Forester B P|Hermida A P|Mueller M|Pagali S R|Petrides G|Seiner S J|Yoon I A|Lapid M I,Kung S|Croarkin P E|Pagali S R|Yoon I A|Lapid M I,"Mayo Clinic, Department of Psychiatry and Psychology, Rochester, MN.|Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN.|Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA.|College of Nursing, Department of Public Health Sciences Medical University of South Carolina, Charleston, SC.|Division of Hospital Internal Medicine, Department of Medicine, Mayo Clinic, Rochester, MN.","Ren C, Kung S, Croarkin P E, Opitz A, Forester B P, Hermida A P, Mueller M, Pagali S R, Petrides G, Seiner S J, Yoon I A, Lapid M I",https://pubmed.ncbi.nlm.nih.gov/39853304/,"Electroconvulsive therapy (ECT) is an effective treatment for severe depression, but it can have cognitive side effects. Recent advances in electric field (E-field) modeling can help optimize ECT dosing to balance the therapeutic benefits and minimize adverse effects. E-field modeling can provide insights into the relationship between E-field strengths, neuroplasticity, and therapeutic efficacy, potentially leading to individualized optimal amplitude dosing and improved clinical outcomes."
38523459,"The ""Woundosome"" Concept and Its Impact on Procedural Outcomes in Patients With Chronic Limb-Threatening Ischemia.",No abstract available.,J Endovasc Ther,"Dec, 2025",2025,Dec,,Patrone L|Pasqui E|Conte M S|Farber A|Ferraresi R|Menard M|Mills J L|Rundback J|Schneider P|Ysa A|Abhishek K|Adams G L|Ahmad N|Ahmed I|Alexandrescu V A|Amor M|Alper D|Andrassy M|Attinger C|Baadh A|Barakat H|Biasi L|Bisdas T|Bhatti Z|Blessing E|Bonaca M P|Bonvini S|Bosiers M|Bradbury A W|Beasley R|Behrendt C|Brodmann M|Cabral G|Cancellieri R|Casini A|Chandra V|Chisci E|Chohan O|Choke E T C|Chong P F S|Clerici G|Coscas R|Costantino M|Dalla Paola L|Dand S|Davies R S M|D'Oria M|Diamantopoulos A|Debus S|Deloose K|Del Giudice C|Donato G d|Rubertis B D|Paul De Vries J|Dias N V|Diaz-Sandoval L|Dick F|Donas K|Dua A|Fanelli F|Fazzini S|Foteh M|Gandini R|Gargiulo M|Garriboli L|Genovese E A|Gifford E|Goueffic Y|Goverde P|Chand Gupta P|Hinchliffe R|Holden A|Houlind K C|Howard D P|Huasen B|Isernia G|Katsanos K|Katzen B|Kolh P|Koncar I|Korosoglou G|Krishnan P|Kroencke T|Krokidis M|Kumarasamy A|Hayes P|Iida O|Alejandre Lafont E|Langhoff R|Lecis A|Lessne M|Lichaa H|Lichtenberg M|Lobato M|Lopes A|Loreni G|Lucatelli P|Madassery S|Maene L|Manzi M|Maresch M|Santhosh Mathews J|McCaslin J|Micari A|Michelagnoli S|Migliara B|Morgan R|Morelli L|Morosetti D|Mouawad N|Moxey P|Müller-Hülsbeck S|Mustapha J|Nakama T|Nasr B|N'dandu Z|Neville R|Noory E|Nordanstig J|Noronen K|Mariano Palena L|Parlani G|Patel A S|Patel P|Patel R|Patel S|Pena C|Perkov D|Portou M|Pratesi G|Rammos C|Reekers J|Riambau V|Roy T|Rosenfield K|Antonella Ruffino M|Saab F|Saratzis A|Sbarzaglia P|Schmidt A|Secemsky E|Siah M|Sillesen H|Simonte G|Sirvent M|Sommerset J|Steiner S|Sakr A|Scheinert D|Shishebor M|Spiliopoulos S|Spinelli A|Stravoulakis K|Taneva G|Teso D|Tessarek J|Theivacumar S|Thomas A|Thomas S|Thulasidasan N|Torsello G|Tripathi R|Troisi N|Tummala S|Tummala V|Twine C|Uberoi R|Ucci A|Valenti D|van den Berg J|van den Heuvel D|Van Herzeele I|Varcoe R|Vega de Ceniga M|Veith F J|Venermo M|Vijaynagar B|Virdee S|Von Stempel C|Voûte M T|Khee Yeung K|Zeller T|Zayed H|Montero Baker M,Virdee S,"West London Vascular and Interventional Center, London North West University Healthcare NHS Trust, London, UK.|Vascular Surgery Unit, Department of Medicine, Surgery and Neuroscience, University of Siena, Siena, Italy.|Division of Vascular and Endovascular Surgery, University of California, San Francisco, CA, USA.|Boston Medical Center, Boston University School of Medicine, Boston, MA.|Diabetic Foot Unit, Clinica San Carlo, Paderno Dugnano, Milan, Italy.|Division of Vascular and Endovascular Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.|Baylor College of Medicine, Michael E. DeBakey Department of Surgery, Houston, Texas, USA.|Advanced Interventional and Vascular Services, LLP, Teaneck, New Jersey.|Division of Vascular and Endovascular Surgery, University of California San Francisco, San Francisco, CA, USA.|Department of Vascular Surgery, Hospital Universitario Cruces, Barakaldo, Spain.|Department of Radiology, University Hospital, Newark, NJ.|UNC REX Healthcare, Raleigh, NC.|Manchester University NHS Foundation Trust, Manchester, United Kingdom.|Department of Interventional Radiology, Guys' and St. Thomas' NHS Foundation Trust, London, United Kingdom.|Department of Thoracic and Vascular Surgery, Princess Paola Hospital, MarcheenFamenne, Belgium.|Department of Interventional Cardiology, U.C.C.I. Polyclinique d'Essey, Nancy, France.|KSU Foot & Ankle Clinic, Independence, OH.|Rkh FürstStirumKlinik, Bruchsal, Germany.|Department of Plastic and Reconstructive Surgery, MedStar Georgetown University Hospital, United States.|Regions Hospital, Saint Paul, Minnesota, USA.|University Hospitals Plymouth NHS Trust; Plymouth; United Kingdom.|Cardiovascular Division, Academic Department of Surgery, Guy's and St Thomas' Hospital NHS Trust, London, United Kingdom.|Department of Vascular Surgery, Athens Medical Center, Athens, Greece.|Texas Vein & Wellness Institute, Houston, TX.|University Hospital Hamburg, Hamburg, Germany.|Division of Cardiology, Department of Medicine, University of Colorado School of Medicine, Aurora, CO, United States.|Department of Vascular Surgery, Santa Chiara Hospital, Trento, Italy.|Department of Vascular Surgery, University Hospital of Bern, University of Bern, Bern, Switzerland.|Department of Vascular Surgery, University of Birmingham, Birmingham, United Kingdom.|Palm Vascular Centers, Miami Beach, FL, United States.|Center for Population Health Innovation (POINT), University Heart and Vascular Center Hamburg, University Medical Center HamburgEppendorf, Hamburg, Germany.|Division of Angiology, Medical University Graz, Austria.|Hospital Beatriz Angelo, Loures, Portugal.|Interventional Radiology Unit, S. Eugenio Hospital, Rome, Italy.|Stanford Health Care, Division of Vascular & Endovascular Surgery, Stanford, CA, United States.|Vascular and Endovascular Surgery Unit, San Giovanni di Dio Hospital, Florence, Italy.|Great Lakes Medical Imaging, Buffalo, NY, United States.|Department of Vascular Surgery, Seng Kang General Hospital, Singapore.|Frimley Park Hospital, Frimley, United Kingdom.|San Carlo Clinic, Paderno Dugnano, Milano, Italy.|Department of Vascular Surgery, Ambroise Paré University Hospital, Assistance PubliqueHôpitaux de Paris, BoulogneBillancourt, France.|Advanced Vascular Centers, Portland, Oregon, United States.|Maria Cecilia Hospital, GVM Care and Research, Cotignola, Italy.|Los Angeles Imaging and Interventional Consultants, PIH Health, Whittier, CA.|Leicester Vascular Institute, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.|Division of Vascular and Endovascular Surgery, CardioThoracoVascular Department, University Hospital of Trieste ASUGI, Trieste, Italy.|Department of Vascular Medicine, Vascular Surgery-Angiology-Endovascular Therapy, University Heart & Vascular Center, University of HamburgEppendorf, Hamburg, Germany.|Department of Vascular Surgery, AZ Sint Blasius, Dendermonde, Belgium.|Department of Radiology, Interventional Radiology, Institut Mutualiste Montsouris, Paris, France.|New York Presbyterian Weill Cornell Medical Center, Mount Sinai Hospital, Columbia University Irving Medical Center and Columbia Vagelos College of Physicians and Surgeons, New York, United States.|Department of Surgery, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.|Department of Thoracic Surgery and Vascular Diseases, Vascular Center, Skåne University Hospital, Malmö, Sweden.|Borgess Heart Institute, Kalamazoo, MI, United States.|Kantonsspital St. Gallen, St. Gallen, and University of Bern, Bern, Switzerland.|Department of Vascular Surgery, Asklepios Clinic Langen, University of Frankfurt, Langen, Germany.|Division of Vascular Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, United States.|Interventional Radiology Unit, Azienda OspedalieroUniversitaria Careggi, Florence, Italy.|Division of Vascular Surgery, Tor Vergata University of Rome, Rome, Italy.|Baylor Scott & White Heart Hospital, Plano, TX, United States.|UOSD Radiologia Interventistica, University Hospital Policlinico Tor Vergata, Roma, Italy.|Vascular Surgery, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, IRCCS Sant'OrsolaMalpighi Hospital, Bologna, Italy.|Vascular Surgery Divisoin, IRCCS Sacro Cuore Don Calabria"" Negrar, Verona, Italy.|Division of Vascular Surgery and Endovascular Therapy, University of Pennsylvania, Philadelphia, PA, United States.|Division of Vascular Surgery, Hartford Hospital, Hartford, CT, United States.|Vascular Center, Groupe Hospitalier Paris Saint Joseph, Paris, France.|Department of Vascular Surgery, ZNA Stuivenberg, Antwerp, Belgium.|Department of Vascular and Endovascular Surgery, Care Hospitals, Banjara Hills, Hyderabad, India.|Department of Vascular Surgery, North Bristol NHS Trust, Bristol, United Kingdom.|Auckland City Hospital, School of Medicine, University of Auckland, Auckland, New Zealand.|Department of Vascular Surgery, Hospital Lillebaelt, University of Southern Denmark, Odense, Denmark.|Nuffield Department of Clinical Neurosciences, Centre for Prevention of Stroke and Dementia, University of Oxford, Oxford, United Kingdom.|Department of Interventional Radiology, Lancashire University Teaching Hospitals, Lancashire Care NHS Foundation Trust, Preston, United Kingdom.|Vascular and Endovascular Surgery Unit, S. Maria Della Misericordia University Hospital, Perugia, Italy.|Department of Interventional Radiology, Patras University Hospital, Patras, Greece.|Miami Cardiac and Vascular Institute, Baptist Health South Florida, Miami, FL, United States.|Department of Biomedical and Preclinical Sciences, University of Liège, Liège, Belgium.|Clinic for Vascular and Endovascular Surgery, Clinical Center of Serbia, Belgrade, Serbia.|Departments of Cardiology, Vascular Medicine and Pneumology, GRN Academic Teaching Hospital Weinheim, Weinheim, Germany.|The Zena and Michael A Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, United States.|Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Augsburg, Augsburg, Germany.|National and Kapodistrian University of Athens, Areteion Hospital, Athens, Greece.|European Vascular Centre AachenMaastricht, Department of Vascular Surgery, Medical Faculty, University Hospital RWTH Aachen, Aachen, Germany.|St John's Innovation Centre, Cambridge, United Kingdom.|Cardiovascular Center, Kansai Rosai Hospital, Inabaso, Hyogo, Amagasaki, Japan.|Department of Radiology, Kantonsspital St.Gallen, Switzerland.|Department of Angiology, St. Gertrauden Hospital, Berlin, Germany.|Centre Hospitalier de Troyes, Troyes, France.|Vascular and Interventional Specialists, Charlotte Radiology, Charlotte, NC, United States.|Ascension Saint Thomas Heart, Ascension Saint Thomas Rutherford, Murfreesboro, TN, United States.|Clinic of Angiology, KarolinenHospital, Arnsberg, Germany.|Department of Vascular Surgery, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal.|UOC Radiologia Interventistica, ASL Roma 2, Ospedale S. Pertini, Rome, Italy.|Vascular and Interventional Radiology Unit, Department of Radiological, Oncological, and AnatomoPathological Sciences, Sapienza University of Rome, Rome, Italy.|Rush University Medical Center, Chicago, IL, United States.|Department of Vascular and Thoracic Surgery, OnzeLieveVrouwziekenhuis Aalst, Aalst, Belgium.|Policlinico Abano Terme, Padova, Italy.|Department of Vascular and Endovascular Surgery, BDF Hospital Royal Medical Services, Bahrain.|Bradenton Cardiology Center, Manatee Memorial Hospital, Bradenton, FL, United States.|The Northern Vascular Centre, Freeman Hospital, Newcastle upon Tyne, United Kingdom.|Department of Biomedical and Dental Sciences and Morphological and Functional Imaging, University of Messina, Messina, Italy.|Vascular and Endovascular Surgery Unit, Pederzoli Hospital, Peschiera del Garda, Italy.|Diagnostic, Vascular & Interventional Radiology, St George's University Hospitals NHS Foundation Trust and St George's, University of London, United Kingdom.|Diabetic Foot Unit and Limb Salvage, Hospital San Juan de Dios, San Jose, Costa Rica.|Department of Surgery, McLaren Health System, Grand Blanc, MI, United States.|St George's Vascular Institute, St George's University Hospital, London, United Kingdom.|Academic Hospital ChristianAlbrechtsUniversity Kiel, Kiel, Germany.|Advanced Cardiac and Vascular Centers for Amputation Prevention, Grand Rapids, MI, United States.|Jikei University Hospital, Department of Surgery, Division of Vascular Surgery, Tokyo, Japan.|CHU Cavale Blanche Brest, Vascular and Endovascular Surgery Department, Brest, France.|Oschner Health, Kenner, LA, United States.|Inova Schar Heart and Vascular, Inova Fairfax Medical Campus, Falls Church, VA, United States.|Department of Cardiology and Angiology, Medical Center, University of Freiburg, Bad Krozingen, Germany.|Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Göteborg, Sweden.|Department of Vascular Surgery, Abdominal Center, Helsinki University Hospital, Helsinki, Finland.|Department of Radiology, Vascular and Interventional Radiology, Medical College of Wisconsin, Milwaukee, WI, United States.|Department of Interventional Radiology, Oxford University Hospitals NHS Foundation Trust, Headley Way, Oxford, United Kingdom.|Miami Cardiac and Vascular Institute, Miami, FL.|Department of Diagnostic and Interventional Radiology, University Hospital Centre Zagreb, Zagreb, Croatia.|Royal Free Vascular, Division of Surgery and Interventional Science, Royal Free Campus, UCL, London, UK.|Unit of Vascular and Endovascular Surgery-IRCCS Ospedale Policlinico San Martino, Department of Surgical Sciences and Integrated Diagnostics (DISC), University of Genoa, Genoa, Italy.|Department of Cardiology and Vascular Medicine, West German Heart and Vascular Center, University of DuisburgEssen, Germany.|Amsterdam UMC, University of Amsterdam, Meibergdreef 9, Amsterdam, Netherlands.|Vascular Surgery Department, Hospital Clínic de Barcelona, Barcelona, Spain.|DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, United States.|Department of Cardiology, Massachusetts General Hospital, Boston, MA, United States.|Department of Interventional Radiology, Ticino Vascular Center, Institute of Imaging of Southern Switzerland, Lugano Regional Hospital, Lugano, Switzerland.|ACV Centers, Grand Rapids, MI, United States.|University Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom.|Interventional cardiology, Maria Cecilia Hospital, Ravenna, Italy.|Department of Angiology, University Hospital Leipzig, Leipzig, Germany.|Smith Center for Cardiovascular Outcomes Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.|Division of Vascular and Endovascular Surgery, Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX, United States.|Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark.|Department General, University Hospital of Granollers, CIBERCV, ISCIII, Granollers, Spain.|PeaceHealth, Vancouver, WA, United States.|Saudi German Hospital, Jeddah, Saudi Arabia.|University Hospitals Cleveland Medical Centre and Case Western Reserve University School of Medicine, Cleveland, OH, United States.|2nd Department of Radiology, Interventional Radiology Unit, Medical School, National and Kapodistrian University of Athens, Attikon, University General Hospital, Athens, Greece.|Interventional Radiology, Hospital S. Eugenio, Rome, Italy.|Department of Vascular Surgery, Ludwig Maximilians University, Germany.|Department Vascular and Endovascular Surgery, Bonifatius Hospital, Lingen, Germany.|Mercy Clinic Heart And Vascular LLC, Saint Louis, MO.|Prince of Wales Hospital, Sydney, NSW, Australia.|University Hospital Münster, Institute for Vascular Research, Franziskus Hospital, Münster, Germany.|University of Queensland, Brisbane, QLD, Australia.|Vascular Surgery Unit, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.|Department of Interventional Radiology, University of Miami Health System, UM Miller School of Medicine, Miami, FL, United States.|Lakeland Vascular Institute, FL United States.|Bath and Weston Vascular Network, Southmead Hospital, North Bristol NHS Trust, Bristol, United Kingdom.|John Radcliffe Hospital, Oxford University Hospitals, Oxford, United Kingdom.|Unit of Vascular Surgery, Department of Medicine and Surgery, Azienda OspedalieroUniversitaria di Parma, Parma, Italy.|Department of Vascular Surgery, King's College Hospital, London, United Kingdom.|Universitätsinstitut für Diagnostische, Interventionelle und Pädiatrische Radiologie, Inselspital, Universitätsspital Bern, Bern, Switzerland.|Department of Radiology, St. Antonius Ziekenhuis, Nieuwegein, Netherlands.|Department of Thoracic and Vascular Surgery, Ghent University Hospital, Ghent, Belgium.|Department of Angiology and Vascular Surgery, University Hospital of GaldakaoUsansolo, Bizkaia, Spain.|New York University Medical Centre, New York, NY and The Cleveland Clinic, Cleveland, OH, United States.|Department of Vascular Surgery, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.|Glenfield Hospital, Leicester, United Kingdom.|The University of Rochester Medical Faculty Group, NY, United States.|Department of Radiology, University College London Hospitals, London, United Kingdom.|Department of Surgery, Prince of Wales Hospital, Sydney, Australia.|Department of Vascular Surgery, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Centres, Amsterdam, Netherlands.|Hope Vascular & Podiatry Clinical Innovation Center, Houston, TX.","Patrone L, Pasqui E, Conte M S, Farber A, Ferraresi R, Menard M, Mills J L, Rundback J, Schneider P, Ysa A, Abhishek K, Adams G L, Ahmad N, Ahmed I, Alexandrescu V A, Montero Baker M, et al.",https://pubmed.ncbi.nlm.nih.gov/38523459/,"This research likely explores the concept of ""woundosome"" and how it affects the outcomes of medical procedures in patients with chronic limb-threatening ischemia. The ""woundosome"" concept may refer to factors that influence the healing of wounds or the overall condition of the affected limb in these patients."
36289157,Turned to Stone: A History of the Neuroleptic Malignant Syndrome.,No abstract available.,Neurocritical care,"Dec, 2025",2025,Dec,,Wijdicks E F M,Wijdicks E F M,"Neurocritical Care Services, Saint Marys Hospital Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. wijde@mayo.edu.",Wijdicks E F M,https://pubmed.ncbi.nlm.nih.gov/36289157/,"This research likely explores the history of a medical condition called Neuroleptic Malignant Syndrome. It may investigate how this syndrome, which can cause muscle rigidity and other severe symptoms, has been understood and treated over time."
37499196,Estimating the impact of balloon guide catheter with mechanical thrombectomy for acute ischemic stroke: A U.S. cost analysis.,"BackgroundBalloon guide catheters (BGCs) can be used adjunctively during mechanical thrombectomy (MT) for acute ischemic stroke (AIS). Evaluating the potential economic impact associated with adjunctive BGC use is an important consideration for resource allocation.MethodsDecision tree models were used to estimate the economic value of BGC use in MT through its impact on functional outcomes. Healthcare utilization cost estimates in the short- and long-term for patients with different 90-day mRS scores were analyzed for MT-only and MT + BGC scenarios. Deterministic (one-way) and probabilistic sensitivity analyses were performed to evaluate the robustness and uncertainty of model parameters.ResultsPer-patient index hospitalization cost was estimated at $65,260 for MT-only and $62,883 for MT + BGC scenarios. Per-patient one-year post-index hospitalization cost was estimated at $27,569 for MT-only and $24,830 for MT + BGC. MT + BGC had a total cost savings of $5117 compared with MT-only. Deterministic (one-way) sensitivity analysis demonstrated that cost saving per patient was most sensitive to the proportion of patients in the mRS 0-2 category in both MT + BGC and MT-only. In a probabilistic sensitivity analysis, mean per-patient costs for the index hospitalization were estimated at $63,737 for MT-only and $61,425 for MT + BGC. Mean per-patient cost estimates one-year post-index hospitalization was $27,445 for MT-only and $24,715 for MT + BGC. MT + BGC had a total cost savings of $5043 compared with MT-only.ConclusionMechanical thrombectomy with adjunctive BGC use may reduce short-term and long-term patient costs due to improved functional outcomes when compared to MT treatment alone for AIS.",Interv Neuroradiol,"Dec, 2025",2025,Dec,,Brinjikji W|Kottenmeier E|Kabiri M|Khaled A|Pederson J M|Al-Bayati A R,Brinjikji W,"Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Health Economics and Market Access, Johnson & Johnson MedTech, Irvine, CA, USA.|Superior Medical Experts, St. Paul, MN, USA.|Nested Knowledge, St. Paul, MN, USA.|University of Pittsburgh Medical Center, Neuroendovascular Surgery & Vascular Neurology, Pittsburgh, PA, USA.","Brinjikji W, Kottenmeier E, Kabiri M, Khaled A, Pederson J M, Al-Bayati A R",https://pubmed.ncbi.nlm.nih.gov/37499196/,"The key finding of this study is that using a balloon guide catheter (BGC) during mechanical thrombectomy for acute ischemic stroke can lead to cost savings compared to mechanical thrombectomy alone. This is due to the improved functional outcomes associated with BGC use, which can reduce short-term and long-term healthcare costs for patients."
37644821,"A review of acute ischemic stroke caused by distal, medium vessel occlusions.","Acute ischemic stroke (AIS) due to distal, medium vessel occlusion (DMVO) is increasingly recognized as the next frontier for mechanical thrombectomy. Distal, medium vessel occlusions are typically defined as an occlusion in the following arteries: anterior cerebral artery, M2-M4 segments of the middle cerebral artery, posterior cerebral artery, posterior inferior cerebellar artery, anterior inferior cerebellar artery, and superior cerebellar artery. It is estimated that 25-40% of all AIS is due to DMVO. Because of the large burden of DMVO, the frequency of literature published regarding these occlusions has greatly increased in recent years. Furthermore, treatment modalities have been created specifically for DMVOs. Due to the rapidly evolving literature on this topic, remaining up to date on DMVO definitions, anatomy, management, imaging, and clinical course is difficult. In this review article, we synthesized existing literature regarding the aforementioned topics and discussed future directions.",Interv Neuroradiol,"Dec, 2025",2025,Dec,,Kobeissi H|Bilgin C|Ghozy S|Kadirvel R|Kallmes D F|Brinjikji W,Kobeissi H|Bilgin C|Ghozy S|Kadirvel R|Kallmes D F|Brinjikji W,"Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.","Kobeissi H, Bilgin C, Ghozy S, Kadirvel R, Kallmes D F, Brinjikji W",https://pubmed.ncbi.nlm.nih.gov/37644821/,"The key finding of this medical research is that distal, medium vessel occlusions (DMVOs) account for a significant portion of acute ischemic strokes, and new treatment modalities have been developed specifically for these types of strokes. This is an important area of research, as understanding and effectively treating DMVOs can have a significant impact on improving outcomes for stroke patients."
38105437,Embolization of arteriovenous malformations of head and neck: A systematic review.,"BackgroundCervicofacial arteriovenous malformations (AVMs) are a significant source of morbidity. Endovascular embolization has emerged as a promising treatment technique for these lesions. However, current literature on cervicofacial AVM embolization mostly consists of single-agent oriented case series, and to date, no comprehensive study has compared the outcomes of available embolic agents.PurposeTo investigate the performance of different embolic agents in the management of cervicofacial AVMs.MethodsWe systematically searched Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials Scopus, and Web of Science. Studies providing data for the endovascular treatment of cervicofacial AVMs were included. The data regarding complication and cure rates were collected for each embolic agent. Pooled event rates were presented as descriptive statistics.ResultsEleven studies comprising 204 patients were included in the review. The overall complete and partial cure rates were 62.2% (127/204) and 36.2% (74/204), respectively. Embolization failed to achieve significant improvement in only 1.6% (3/204) of the patients. The complete cure rates were 87.5% (75-100%) for n-Butyl cyanoacrylate (NBCA, glue), 80.5% (61-100%) for Onyx (Medtronic, MN, USA), and 51.5% (18-85%) for ethanol. The overall complication rate was 30% (61/204). The complication rates were 33% (12.5-53%) for ethanol, 14% (0-28%) for Onyx, and 0% for NBCA.ConclusionsOur systematic review supports that endovascular embolization is an effective treatment option for cervicofacial AVMs. In our review, the use of Onyx and NBCA was associated with consistently high complete cure rates and a promising safety profile. However, more research is needed to investigate the use of different embolic agents in the treatment of cervicofacial AVMs.",Interv Neuroradiol,"Dec, 2025",2025,Dec,,Malik M H|Jabal M S|Kobeissi H|Gupta R|Bilgin C|Brinjikji W,Malik M H|Jabal M S|Kobeissi H|Gupta R|Bilgin C|Brinjikji W,"Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.","Malik M H, Jabal M S, Kobeissi H, Gupta R, Bilgin C, Brinjikji W",https://pubmed.ncbi.nlm.nih.gov/38105437/,"This study found that endovascular embolization, a minimally invasive treatment, can effectively manage cervicofacial arteriovenous malformations (AVMs), which are abnormal connections between arteries and veins in the head and neck area. The use of Onyx and n-Butyl cyanoacrylate (NBCA) as embolic agents showed high complete cure rates and a good safety profile, suggesting they may be preferred options for"
38321966,Cellular Enhancement of Frozen Meniscus Allograft Combining Native Meniscus and Mesenchymal Stromal Cell Injections.,"ObjectiveThis proof-of-concept study investigated an improved cell-based injection therapy combining mesenchymal stem cells (MSCs) and meniscus cells (MCs) to support superior meniscus allograft repopulation and early revival compared to injecting MSCs alone.DesignIn this controlled laboratory study, frozen meniscus allograft samples were injected vertically with a cell suspension containing different ratios of MSCs and MCs or control (lactated ringers) and cultured for 28 days. Samples were analyzed weekly for cell viability, migration, and metabolism using histological and biochemical assays. Tissue medium was analyzed for matrix metalloproteinase (MMP) expression using zymography.ResultsCellular repopulation of frozen allografts injected with different cell suspensions was validated by immunohistochemistry. Significant higher DNA content was evidenced in grafts treated with suspensions of MCs or MC:MSC (1:4 ratio). Cell metabolic activity was significantly different between all treated groups and control group after 1 week. Allografts injected with MCs showed significantly more cell proliferation than injections with MSCs. MMP2 activity was detected in medium of all grafts cellularized with MCs with or without MSCs. Scanning electron microscopy (SEM) analysis showed resolution of the needle puncture, but not in the control group. Cell labeling of MCs upon injection of mixed MC:MSC suspensions revealed a gradual increase in the cell ratio.ConclusionsThe findings of this study establish that injection of MCs with or without MSCs enhances the cellularity of meniscus allograft to support early graft revival and remodeling.",Cartilage,"Dec, 2025",2025,Dec,,Struijk C|Lydon K L|Husen M|Verdonk P|Michielsen J|van Wijnen A J|Krych A J|Saris D B F,Struijk C|Lydon K L|Husen M|Krych A J|Saris D B F,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Orthopedic Surgery, University of Antwerp, Antwerp, Belgium.|Department of Orthopaedic Surgery, Heidelberg University Hospital, Heidelberg, Germany.|Orthoca, Antwerp, Belgium.|Department of Biochemistry, The University of Vermont, Burlington, VT, USA.|Department of Orthopedic Surgery, University Medical Center Utrecht, Utrecht, The Netherlands.","Struijk C, Lydon K L, Husen M, Verdonk P, Michielsen J, van Wijnen A J, Krych A J, Saris D B F",https://pubmed.ncbi.nlm.nih.gov/38321966/,"This study found that injecting a combination of meniscus cells and mesenchymal stem cells into frozen meniscus allografts led to better cell growth, activity, and tissue remodeling compared to injecting stem cells alone. This approach could help improve the success of meniscus transplants, which are important for restoring knee function after injury."
38517078,Digital pathology and spatial omics in steatohepatitis: Clinical applications and discovery potentials.,"Steatohepatitis with diverse etiologies is the most common histological manifestation in patients with liver disease. However, there are currently no specific histopathological features pathognomonic for metabolic dysfunction-associated steatotic liver disease, alcohol-associated liver disease, or metabolic dysfunction-associated steatotic liver disease with increased alcohol intake. Digitizing traditional pathology slides has created an emerging field of digital pathology, allowing for easier access, storage, sharing, and analysis of whole-slide images. Artificial intelligence (AI) algorithms have been developed for whole-slide images to enhance the accuracy and speed of the histological interpretation of steatohepatitis and are currently employed in biomarker development. Spatial biology is a novel field that enables investigators to map gene and protein expression within a specific region of interest on liver histological sections, examine disease heterogeneity within tissues, and understand the relationship between molecular changes and distinct tissue morphology. Here, we review the utility of digital pathology (using linear and nonlinear microscopy) augmented with AI analysis to improve the accuracy of histological interpretation. We will also discuss the spatial omics landscape with special emphasis on the strengths and limitations of established spatial transcriptomics and proteomics technologies and their application in steatohepatitis. We then highlight the power of multimodal integration of digital pathology augmented by machine learning (ML)algorithms with spatial biology. The review concludes with a discussion of the current gaps in knowledge, the limitations and premises of these tools and technologies, and the areas of future research.Copyright © 2024 American Association for the Study of Liver Diseases.","Hepatology (Baltimore, Md.)","Dec 01, 2025",2025,Dec,01,Meroueh C|Warasnhe K|Tizhoosh H R|Shah V H|Ibrahim S H,Meroueh C|Warasnhe K|Tizhoosh H R|Shah V H|Ibrahim S H,"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Artificial Intelligence and Informatics, Mayo Clinic, Rochester, Minnesota, USA.|Division of Pediatric Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.","Meroueh C, Warasnhe K, Tizhoosh H R, Shah V H, Ibrahim S H",https://pubmed.ncbi.nlm.nih.gov/38517078/,"The key finding of this research is that digital pathology and spatial omics technologies can enhance the accuracy and speed of histological interpretation of steatohepatitis, a common liver disease. These advanced techniques, combined with machine learning algorithms, can help improve the diagnosis and understanding of steatohepatitis, leading to better patient care and the development of new treatments."
38747145,Defining Benchmarks for Pelvic Exenteration Surgery: A Multicentre Analysis of Patients With Locally Advanced and Recurrent Rectal Cancers.,"To establish globally applicable benchmark outcomes for pelvic exenteration (PE) in patients with locally advanced primary rectal cancer (LARC) and locally recurrent rectal cancer (LRRC), using outcomes achieved at highly specialised centres.PE is established as the standard of care for selected patients with LARC and LRRC. There are currently no available benchmarks against which surgical performance in PE can be compared for audit and quality improvement.This international multicentre retrospective cohort study included patients undergoing PE for LARC or LRRC at 16 highly experienced centres between 2018 and 2023. Ten outcome benchmarks were established in a lower-risk subgroup. Benchmarks were defined by the 75th percentile of the results achieved at the individual centres.Seven hundred sixty-three patients underwent PE, of which 464 patients (61%) had LARCs and 299 (39%) had LRRCs. Five hundred forty-four patients (71%) who met predefined lower-risk criteria formed the benchmark cohort. For patients with LARC, the calculated benchmark threshold for major complication rate was ≤44%; Comprehensive Complication Index: ≤30.2; 30-day mortality rate: 0%; 90-day mortality rate: ≤4.3%; R0 resection rate: ≥79%. For patients with LRRC, the calculated benchmark threshold for major complication rate was ≤53%; Comprehensive Complication Index: ≤34.1; 30-day mortality rate: 0%; 90-day mortality rate: ≤6%; R0 resection rate: ≥77%.The reported benchmarks for PE in patients with LARC and LRRC represent the best available care for this patient group globally and can be used for rigorous assessment of surgical quality and to facilitate quality improvement initiatives at international exenteration centres.Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.",Annals of surgery,"Dec 01, 2025",2025,Dec,01,Brown K G M|Solomon M J|Koh C E|Sutton P A|Aguiar S|Bezerra T S|Clouston H W|Desouza A|Dozois E J|Ersryd A L|Frizelle F|Funder J A|Garcia-Aguilar J|Garfinkle R|Glyn T|Heriot A|Kanemitsu Y|Kong C Y|Kristensen H Ø|Malakorn S|Mens D M|Nilsson P J|Palmer G J|Pappou E|Quinn M|Quyn A J|Sahakitrungruang C|Saklani A|Solbakken A M|Tiernan J P|Verhoef C|Steffens D,Dozois E J|Garfinkle R,"Department of Colorectal Surgery and Surgical Outcomes Research Centre, Royal Prince Alfred Hospital, Sydney, Australia.|Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UK.|A. C. Camargo Cancer Centre, São Paulo, Brazil.|Department of Surgical Oncology, Tata Memorial Hospital, Mumbai, MH, India.|Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN.|Department of Gastroenterological Surgery, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway.|University of Otago, Christchurch, New Zealand.|Department of Abdominal and Plastic Surgery, University Hospital of Southern Denmark, Vejle, Denmark.|Department of Surgery, Colorectal Surgery Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, NY.|Department of Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.|Department of Colorectal Surgery, National Cancer Center Hospital, Tokyo, Japan.|Academic Department of Surgery, Glasgow Royal Infirmary, University of Glasgow, Glasgow, UK.|Department of Surgery, Aarhus University Hospital, Aarhus, Denmark.|Chulalongkorn Colorectal Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.|Erasmus MC Cancer Institute, University Hospital Rotterdam, The Netherlands.|Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.|The John Goligher Colorectal Surgery Unit, St. James's University Hospital, Leeds Teaching Hospital Trust, Leeds, UK.","Brown K G M, Solomon M J, Koh C E, Sutton P A, Aguiar S, Bezerra T S, Clouston H W, Desouza A, Dozois E J, Ersryd A L, Frizelle F, Funder J A, Garcia-Aguilar J, Garfinkle R, Glyn T, Steffens D, et al.",https://pubmed.ncbi.nlm.nih.gov/38747145/,"This study established global benchmarks for outcomes of pelvic exenteration surgery in patients with advanced or recurrent rectal cancer. The benchmarks, based on data from 16 specialized centers, can be used to assess surgical quality and drive improvements in care for this challenging patient population."
39828268,Osteoarthritis-related knee pain: MRI-guided focused ultrasound ablation treatment.,"Objective: Osteoarthritis of the knee is a common cause of pain, functional disability, and reduced quality of life in the elderly. Despite its prevalence, there are limited currently available noninvasive treatment options. MRI-guided focused ultrasound (MRgFUS) is a noninvasive thermal ablation method which is used in a spectrum of musculoskeletal conditions. It is FDA approved for the treatment of painful bone metastases and osteoid osteoma and has been considered for the treatment of other painful conditions such as osteoarthritis. The purpose of this case report is to describe the use of MRgFUS for the treatment of osteoarthritic knee pain in an active 72-year-old male. Method: The patient suffered significant limitations due to lateral knee pain with jogging and walking down the stairs. MRgFUS ablation treatment was performed to the lateral knee, targeting the periosteum in the patients' area of pain. Results: Following treatment, the patient experienced considerable reduction in his activity limiting symptoms with a duration of at least 6 months. Conclusions: It is important for radiologists to be aware of MRgFUS as an innovative ablation modality. Similar pain reduction was observed in two small series of MRgFUS treatment of knee pain from Japan. MRgFUS appears promising as a safe, noninvasive treatment option for temporary relief of knee pain. This may be particularly valuable for patients who are unwilling or unable to undergo total knee arthroplasty. Future study is needed to assess the efficacy and safety of this treatment in a larger population.",Int J Hyperthermia,"Dec, 2025",2025,Dec,,Tiegs-Heiden C A|Long Z|Lu A|Gorny K R|Hesley G K,Tiegs-Heiden C A|Long Z|Lu A|Gorny K R|Hesley G K,"Department of Radiology, Mayo Clinic, Rochester, MN, USA.","Tiegs-Heiden C A, Long Z, Lu A, Gorny K R, Hesley G K",https://pubmed.ncbi.nlm.nih.gov/39828268/,"This study explores the use of MRI-guided focused ultrasound (MRgFUS) as a noninvasive treatment for knee pain caused by osteoarthritis. The key finding is that a 72-year-old patient experienced significant reduction in activity-limiting knee pain for at least 6 months after the MRgFUS treatment. This suggests that MRgFUS could be a promising, safe, and noninvasive option for providing temporary"
38951365,Early-onset pancreatic cancer and associated metabolic risk factors in the Middle East and North Africa: A 20-year analysis of the Global Burden of Disease Study.,"Early-onset pancreatic cancer (EOPC) is associated with poor prognosis and high disease burden. Metabolic risk factors such as diabetes and obesity are considered risk factors of EOPC. Recently, there has been an increasing number of EOPCs worldwide. However, the analysis of EOPC, including its metabolic risk factors, in the Middle East and North Africa (MENA) region has not been fully addressed.Data from the Global Burden of Disease Study between 2000 and 2019 was used to analyze the prevalence, incidence, deaths and disability-adjusted life years (DALYs) associated with EOPC and its metabolic risk factors. The analysis further categorized the data based on countries, income status and sex and examined the annual percentage change (APC).Approximately 2800 cases, 2400 deaths and 114,000 DALYs were attributable to EOPC in the MENA region. The incidence (APC + 3.42%), death (APC + 0.73%) and DALYs (APC + 3.23%) rates of EOPC increased. In addition, the death and DALY rates of EOPC attributable to obesity and diabetes increased. High and upper-middle-income countries exhibited a higher burden of EOPC than lower-income countries.Over the past two decades, the burden of EOPC and its associated metabolic risk factors has increased. There is an urgent need for region-wide policy development, including screening methods and risk factor reduction, to mitigate the high and rising burden of EOPC in the MENA region.© 2024. Indian Society of Gastroenterology.",Indian J Gastroenterol,"Dec, 2025",2025,Dec,,Danpanichkul P|Uawithya E|Lopimpisuth C|Sukphutanan B|Kulthamrongsri N|Aboona M B|Duangsonk K|Lau S|Simadibrata D M|Daggag H|Wallace M B|Wijarnpreecha K,Kulthamrongsri N|Simadibrata D M|Wallace M B,"Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA. pojsakorndan@gmail.com.|Immunology Unit, Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand. pojsakorndan@gmail.com.|Faculty of Medicine Siriraj Hospital, Mahidol University, Nakhon Pathom, Thailand.|Department of Internal Medicine, University of Miami, Jackson Memorial Hospital, Miami, FL, USA.|Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.|Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Nakhon Pathom, Thailand.|Department of Cardiovascular Medicine, Mayo Clinic Arizona, Phoenix, AZ, USA.|Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.|Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.|Department of Internal Medicine, Metrowest Medical Center, Framingham, MA, USA.|Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.|Imperial College London Diabetes Centre, Abu Dhabi, United Arab Emirates.|Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.|Department of Gastroenterology, Sheikh Shakhbout Medical City, Abu Dhabi, United Arab Emirates.|Division of Gastroenterology and Hepatology, Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA.|Division of Gastroenterology and Hepatology, Department of Internal Medicine, Banner University Medical Center, Phoenix, AZ, USA.|BIO5 Institute, University of Arizona College of Medicine-Phoenix, Phoenix, AZ, USA.","Danpanichkul P, Uawithya E, Lopimpisuth C, Sukphutanan B, Kulthamrongsri N, Aboona M B, Duangsonk K, Lau S, Simadibrata D M, Daggag H, Wallace M B, Wijarnpreecha K",https://pubmed.ncbi.nlm.nih.gov/38951365/,"The key finding of this study is that the burden of early-onset pancreatic cancer and its associated metabolic risk factors, such as diabetes and obesity, has significantly increased in the Middle East and North Africa region over the past 20 years. This highlights the urgent need for region-wide policies to address this growing public health concern, including the development of screening methods and strategies to reduce these risk factors."
39610711,The Digital Revolution in Medicine: Applications in Cardio-Oncology.,"A critical evaluation of contemporary literature regarding the role of big data, artificial intelligence, and digital technologies in precision cardio-oncology care and survivorship, emphasizing innovative and groundbreaking endeavors.Artificial intelligence (AI) algorithm models can automate the risk assessment process and augment current subjective clinical decision tools. AI, particularly machine learning (ML), can identify medically significant patterns in large data sets. Machine learning in cardio-oncology care has great potential in screening, diagnosis, monitoring, and managing cancer therapy-related cardiovascular complications. To this end, large-scale imaging data and clinical information are being leveraged in training efficient AI algorithms that may lead to effective clinical tools for caring for this vulnerable population. Telemedicine may benefit cardio-oncology patients by enhancing healthcare delivery through lowering costs, improving quality, and personalizing care. Similarly, the utilization of wearable biosensors and mobile health technology for remote monitoring holds the potential to improve cardio-oncology outcomes through early intervention and deeper clinical insight. Investigations are ongoing regarding the application of digital health tools such as telemedicine and remote monitoring devices in enhancing the functional status and recovery of cancer patients, particularly those with limited access to centralized services, by increasing physical activity levels and providing access to rehabilitation services.In recent years, advances in cancer survival have increased the prevalence of patients experiencing cancer therapy-related cardiovascular complications. Traditional cardio-oncology risk categorization largely relies on basic clinical features and physician assessment, necessitating advancements in machine learning to create objective prediction models using diverse data sources. Healthcare disparities may be perpetuated through AI algorithms in digital health technologies. In turn, this may have a detrimental effect on minority populations by limiting resource allocation. Several AI-powered innovative health tools could be leveraged to bridge the digital divide and improve access to equitable care.",Current treatment options in cardiovascular medicine,"Dec, 2025",2025,Dec,,Echefu G|Batalik L|Lukan A|Shah R|Nain P|Guha A|Brown S,Brown S,"Division of Cardiovascular Medicine, University of Tennessee, Memphis, TN.|Department of Rehabilitation, University Hospital Brno, Czech Republic.|Department of Physiotherapy and Rehabilitation, Masaryk University, Brno, Czech Republic.|Advocate Illinois Masonic Medical Center, Chicago, IL.|Medical College of Wisconsin, Milwaukee, WI.|Division of Cardiology, Medical College of Georgia, Augusta, GA.|Department of Medicine, Medical College of Wisconsin, Milwaukee, WI.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.|Heart Innovation and Equity Research (HIER) Group, Miami, FL.","Echefu G, Batalik L, Lukan A, Shah R, Nain P, Guha A, Brown S",https://pubmed.ncbi.nlm.nih.gov/39610711/,"The key finding of this research is that artificial intelligence (AI) and digital technologies, such as telemedicine and wearable devices, have great potential to improve the care and outcomes of patients with cancer-related cardiovascular complications. These technologies can automate risk assessment, identify patterns in large data sets, and enhance healthcare delivery, leading to more personalized and effective cardio-oncology care. However, the research also highlights the need to address healthcare disparities that may arise from the use"
39789222,Adjunctive Mantram Repetition Program to Promote Lifestyle Modifications for Managing Impaired Glucose Tolerance: A Case Report from the USA.,"We report the case of a 63-year-old man with impaired fasting glucose who was unable to lose weight, engage in exercise or omit refined carbohydrates from his diet until he initiated the Mantram Repetition Program (MRP). Four months following implementation, the patient had lost weight and fasting glucose levels decreased to near normal. These parameters continued to improve at nine months. The patient attributed his success to the adjunctive mantram repetition program which also improved his mood and wellbeing. Implementation of the MRP may be a useful adjunct to promote lifestyle changes in patients with mental health diagnoses.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Journal of religion and health,"Dec, 2025",2025,Dec,,Prasad K|Prasad A|Bormann J E,Prasad K|Prasad A,"Zumbro Valley Health Center, 343 Woodlake Drive SE, Rochester, MN, 55902, USA. kavita.prasad@zvhc.org.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA. kavita.prasad@zvhc.org.|Department of Cardiology, Mayo Clinic, Rochester, MN, USA.|Hahn School of Nursing and Health Sciences, University of San Diego, San Diego, CA, USA.","Prasad K, Prasad A, Bormann J E",https://pubmed.ncbi.nlm.nih.gov/39789222/,"The key finding of this medical research is that a mantram repetition program helped a patient with impaired glucose tolerance to lose weight, improve his diet, and lower his blood sugar levels. This suggests that this type of program could be a useful addition to help people with mental health conditions make important lifestyle changes to manage their health."
39800093,Epicardial substrate ablation in patients with symptomatic Brugada syndrome: An updated systematic review and single-arm meta-analysis.,"Brugada syndrome (BrS) is a genetic heart disease that predisposes individuals to ventricular arrhythmias and sudden cardiac death. Although implantable cardioverter-defibrillators (ICDs) and quinidine are primary treatments, recurrent BrS-triggered ventricular arrhythmias can persist. In this setting, epicardial substrate ablation has emerged as a promising alternative for symptomatic patients.Evaluate the effectiveness and safety of epicardial substrate ablation in patients with BrS.In this single-arm meta-analysis, we systematically searched PubMed, Embase, and Cochrane databases following PRISMA guidelines for studies including BrS patients with epicardial substrate ablation. Data were extracted, and statistical analysis was performed using random-effects modeling for proportional meta-analysis.Thirteen cohort studies comprising 555 BrS patients were included. The mean age at enrollment was 42.6 ± 12.3 years; 82.7% were male patients, and 50% exhibited spontaneous type 1 Brugada electrocardiographic (ECG) pattern. Pooled analysis demonstrated resolution of the type 1 pattern in 91% of the cases (95% confidence interval [CI] 80-98%; I2 = 86%) and elimination of abnormal electrograms in 91% (95% CI 78-99%; I2 = 74%). Rates of recurrent VT/VF and appropriate ICD therapies during postablation follow-up were 12% (95% CI 4-21%; I2 = 86%) and 8% (95% CI 2-18%; I2 = 87%), respectively.Epicardial substrate ablation shows promise for patients with BrS experiencing BrS-triggered ventricular arrhythmias, offering therapeutic efficacy with an acceptable safety profile. High heterogeneity among studies highlights the need for further research and standardized protocols.Copyright © 2025 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.",Heart rhythm,"Dec, 2025",2025,Dec,,Karlinski Vizentin V|Ferreira Felix I|Pivato da Fonseca R|Bozko Collini M|Pinheiro Braga M A|Serafim Dagostin C|Vidal Armaganijan L|Ackerman M J|Dantas Brígido A R|Dagostin de Carvalho G,Karlinski Vizentin V|Ferreira Felix I|Ackerman M J,"Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Windland Smith Rice Sudden Death Genomics Laboratory, Rochester, Minnesota. Electronic address: karlinskivizentin.vanessa@mayo.edu.|Department of Medicine, Mayo Clinic, Rochester, Minnesota.|Department of Medicine, Federal University of Rio Grande do Sul, Porto Alegre, Brazil.|Department of Medicine, Federal University of Parana, Curitiba, Brazil.|Department of Medicine, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.|Department of Medicine, University of the Extreme South of Santa Catarina, Criciuma, Santa Catarina, Brazil.|Department of Electrophysiology, Dante Pazzanese Institute of Cardiology, São Paulo, Brazil.|Department of Cardiovascular Diseases, Mayo Clinic, Rochester, Minnesota; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Windland Smith Rice Sudden Death Genomics Laboratory, Rochester, Minnesota.|Department of Electrophysiology, University of Sao Paulo Medical School, São Paulo, Brazil.","Karlinski Vizentin V, Ferreira Felix I, Pivato da Fonseca R, Bozko Collini M, Pinheiro Braga M A, Serafim Dagostin C, Vidal Armaganijan L, Ackerman M J, Dantas Brígido A R, Dagostin de Carvalho G",https://pubmed.ncbi.nlm.nih.gov/39800093/,"Epicardial substrate ablation is a promising treatment for patients with Brugada syndrome, a genetic heart condition that can cause life-threatening arrhythmias. This meta-analysis found that the procedure effectively resolves the characteristic ECG pattern and eliminates abnormal electrical signals in the majority of patients, with relatively low rates of recurrent arrhythmias and appropriate ICD therapies during follow-up. These findings suggest that epicardial ablation may be a"
39806780,A practical guide for nephrologist peer reviewers: understanding and appraising Mendelian randomization studies.,"Identifying risk factors for disease onset and progression has been a core focus in nephrology research. Mendelian Randomization (MR) has emerged as a powerful genetic epidemiological approach, utilizing genome-wide association studies (GWAS) to establish causal relationships between modifiable risk factors and kidney disease outcomes. MR uses genetic variants as instrumental variables to infer causal relationships between exposures and disease outcomes. This method leverages the natural randomization of genetic variants to balance confounders, akin to matched cohorts in observational research. The rapid increase in MR studies on kidney disease poses challenges for journals and peer reviewers, especially clinicians unfamiliar with the methodology. High-quality MR studies use strong, well-validated genetic instruments with clear biological relevance, thoroughly testing for pleiotropy and confounding factors using methods like MR-Egger. Sensitivity analyses, such as MR-PRESSO, should ensure findings remain consistent across various assumptions. Effect sizes with confidence intervals should be reported and discussed within established biological mechanisms. Additionally, limitations must be transparently addressed, with recommendations for replication in future studies, to strengthen findings. This article guides readers in understanding MR application in nephrology and identifying high-quality MR studies, helping peers avoid pitfalls while seizing new opportunities in advancing kidney disease research.",Renal failure,"Dec, 2025",2025,Dec,,Qing J|Li Y|Soliman K M|Cheungpasitporn W,Cheungpasitporn W,"Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.|Department of Nephrology, Shanxi Provincial People's Hospital (Fifth Hospital), Shanxi Medical University, Taiyuan, China.|Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina, USA.|Medical Services, Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA.|Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Qing J, Li Y, Soliman K M, Cheungpasitporn W",https://pubmed.ncbi.nlm.nih.gov/39806780/,"Mendelian Randomization (MR) is a powerful genetic approach that can help identify causal relationships between risk factors and kidney disease. This guide helps nephrologists understand and evaluate MR studies, ensuring high-quality research that advances our understanding of kidney disease."
39808529,Human or Machine? A Comparative Analysis of Artificial Intelligence-Generated Writing Detection in Personal Statements.,"This study examines the ability of human readers, recurrence quantification analysis (RQA), and an online artificial intelligence (AI) detection tool (GPTZero) to distinguish between AI-generated and human-written personal statements in physical therapist education program applications.The emergence of large language models such as ChatGPT and Google Gemini has raised concerns about the authenticity of personal statements. Previous studies have reported varying degrees of success in detecting AI-generated text.Data were collected from 50 randomly selected nonmatriculated individuals who applied to the Mayo Clinic School of Health Sciences Doctor of Physical Therapy Program during the 2021-2022 application cycle.Fifty personal statements from applicants were pooled with 50 Google Gemini-generated statements, then analyzed by 2 individuals, RQA, and GPTZero. RQA provided quantitative measures of lexical sophistication, whereas GPTZero used advanced machine learning algorithms to quantify AI-specific text characteristics.Human raters demonstrated high agreement (κ = 0.92) and accuracy (97% and 99%). RQA parameters, particularly recurrence and max line, differentiated human- from AI-generated statements (areas under receiver operating characteristic [ROC] curve = 0.768 and 0.859, respectively). GPTZero parameters including simplicity, perplexity, and readability also differentiated human- from AI-generated statements (areas under ROC curve > 0.875).The study reveals that human raters, RQA, and GPTZero offer varying levels of accuracy in differentiating human-written from AI-generated personal statements. The findings could have important implications in academic admissions processes, where distinguishing between human- and AI-generated submissions is becoming increasingly important. Future research should explore integrating these methods to enhance the robustness and reliability of personal statement content evaluation across various domains. Three strategies for managing AI's role in applications-for applicants, governing organizations, and academic institutions-are provided to promote integrity and accountability in admission processes.Copyright © 2025 Academy of Physical Therapy Education, APTA.","Journal, physical therapy education","Dec 01, 2025",2025,Dec,01,Goodman M A|Lee A M|Schreck Z|Hollman J H,Goodman M A|Lee A M|Schreck Z|Hollman J H,"Margaret A. Goodman , Program in Physical Therapy in the Mayo Clinic School of Health Sciences at the Mayo Clinic College of Medicine and Science and in the Department of Physical Medicine and Rehabilitation at the Mayo Clinic.|Anthony M. Lee , Program in Physical Therapy in the Mayo Clinic School of Health Sciences at the Mayo Clinic College of Medicine and Science and in the Department of Physical Medicine and Rehabilitation at the Mayo Clinic.|Zachary Schreck , Program in Physical Therapy in the Mayo Clinic School of Health Sciences at the Mayo Clinic College of Medicine and Science and in the Department of Physical Medicine and Rehabilitation at the Mayo Clinic.|John H. Hollman , Program in Physical Therapy in the Mayo Clinic School of Health Sciences at the Mayo Clinic College of Medicine and Science and in the Department of Physical Medicine and Rehabilitation at the Mayo Clinic, Siebens 7-55 200 First Street SW Rochester, MN 55905 ( hollman.john@mayo.edu ). Please address all correspondence to John H. Hollman.","Goodman M A, Lee A M, Schreck Z, Hollman J H",https://pubmed.ncbi.nlm.nih.gov/39808529/,"This study compared the ability of human raters, a text analysis tool (RQA), and an AI detection tool (GPTZero) to distinguish between AI-generated and human-written personal statements for physical therapy program applications. The results showed that human raters, RQA, and GPTZero all demonstrated high accuracy in detecting AI-generated text, with important implications for maintaining integrity in academic admissions processes as the use of AI in writing becomes more prevalent."
40249765,Prevalence of Hypercortisolism in Difficult-to-Control Type 2 Diabetes.,"Despite the use of multiple glucose-lowering medications, glycemic targets are not met in a significant fraction of people with type 2 diabetes. In this prospective, observational study we assessed the prevalence of hypercortisolism, a potential contributing factor to inadequate glucose control.Individuals with type 2 diabetes and HbA1c 7.5%-11.5% (58-102 mmol/mol) on two or more glucose-lowering medications with or without micro-/macrovascular complications or taking multiple blood pressure-lowering medications were screened with a 1-mg dexamethasone suppression test. Common causes of false-positive DSTs were excluded. The primary end point was the prevalence of hypercortisolism, defined as post-DST cortisol >1.8 μg/dL (50 nmol/L). Characteristics associated with hypercortisolism were assessed with multiple logistic regression. The percentage and characteristics of participants with hypercortisolism and adrenal imaging abnormalities were also assessed.Post-DST cortisol was unsuppressed in 252 of 1,057 participants (prevalence 23.8%; 95% CI 21.3, 26.5). Hypercortisolism prevalence was 33.3% among participants with cardiac disorders and 36.6% among those taking three or more blood pressure-lowering medications. Adrenal imaging abnormalities were reported in 34.7% of participants with hypercortisolism. Use of sodium-glucose cotransporter 2 inhibitors (odds ratio 1.558), maximum-dose glucagon-like peptide 1 receptor agonists (1.544), tirzepatide (1.981), or a higher number of blood pressure-lowering medications (1.390); older age (1.316); BMI <30 kg/m2 (1.639); non-Latino/Hispanic ethnicity (3.718); and use of fibrates (2.676) or analgesics (1.457) were associated with higher prevalence (all P < 0.03).Hypercortisolism was associated with hyperglycemia in approximately one-quarter of individuals with inadequately controlled type 2 diabetes despite multiple medications.© 2025 by the American Diabetes Association.",Diabetes care,"Dec 01, 2025",2025,Dec,01,Buse J B|Kahn S E|Aroda V R|Auchus R J|Bailey T|Bancos I|Busch R S|Christofides E A|DeFronzo R A|Eilerman B|Findling J W|Fonseca V|Hamidi O|Handelsman Y|Miller H J|Ownby J G|Parker J C|Philis-Tsimikas A|Pratley R|Rosenstock J|Shanik M H|Sloan L L|Umpierrez G|Tudor I C|Schlafly T K|Einhorn D,Bancos I,"University of North Carolina School of Medicine, Chapel Hill, NC.|VA Puget Sound Health Care System and University of Washington, Seattle, WA.|Brigham and Women's Hospital, Harvard Medical School, Boston, MA.|University of Michigan, Ann Arbor, MI.|Headlands Research AMCR Institute, Escondido, CA.|Mayo Clinic, Rochester, MN.|Albany Medical College, Community Endocrine Group, Albany, NY.|Endocrinology Associates, Columbus, OH.|University of Texas Health Science Center at San Antonio, San Antonio, TX.|St. Elizabeth Physicians, Covington, KY.|Medical College of Wisconsin, Milwaukee, WI.|Tulane University, New Orleans, LA.|University of Texas Southwestern Medical Center, Dallas, TX.|Metabolic Institute of America, Tarzana, CA.|NOLA Care Clinical Research Center, Covington, LA.|Atlanta Diabetes Associates, Atlanta, GA.|Accellacare Research, Wilmington Health, Wilmington, NC.|Scripps Whittier Diabetes Institute, Scripps Health, La Jolla, CA.|AdventHealth Translational Research Institute Orlando, Orlando, FL.|Velocity Clinical Research at Medical City Dallas, Dallas, TX.|Endocrine Associates of Long Island, Smithtown, NY.|Texas Institute for Kidney and Endocrine Disorders, Lufkin, TX.|Emory School of Medicine, Emory University, Atlanta, GA.|Corcept Therapeutics Incorporated, Redwood City, CA.","Buse J B, Kahn S E, Aroda V R, Auchus R J, Bailey T, Bancos I, Busch R S, Christofides E A, DeFronzo R A, Eilerman B, Findling J W, Fonseca V, Hamidi O, Handelsman Y, Miller H J, Einhorn D, et al.",https://pubmed.ncbi.nlm.nih.gov/40249765/,"This study found that hypercortisolism, a condition where the body produces too much cortisol, is common in people with type 2 diabetes who have difficulty controlling their blood sugar levels despite taking multiple medications. The study suggests that addressing hypercortisolism could help improve glucose control in these individuals, potentially leading to better health outcomes."
40268755,Autosomal dominant polycystic kidney disease: an overview of recent genetic and clinical advances.,"Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney disease, characterized by the progressive development of multiple kidney cysts, leading to a gradual decline in kidney function. ADPKD is also the fourth leading cause of kidney failure (KF) in adults. In addition to kidney manifestations, ADPKD is associated with various extrarenal features, including liver cysts, cardiovascular abnormalities, intracranial aneurysms, and chronic pain with significant impact on patients' quality of life. While several disease-modifying agents have been tested in ADPKD, tolvaptan remains the only approved drug by the US Food and Drug Administration. The Mayo Imaging Classification is currently the most practical tool for predicting rate of kidney disease progression in ADPKD. This review provides a comprehensive overview of ADPKD, focusing on its genetics, pathophysiology, clinical presentation, management, and prognostic tools. Advances in diagnostic imaging and genetic testing have improved the early detection of ADPKD, allowing better classification of patients and prediction of KF. The review also discusses current therapeutic approaches to ADPKD, including tolvaptan, a vasopressin V2-receptor antagonist. Additionally, we address specific issues in children and pregnant individuals with ADPKD. Despite substantial progress in understanding ADPKD, there is a large need for additional effective treatments and prognostic markers to provide a more personalized care for these patients.",Renal failure,"Dec, 2025",2025,Dec,,Borghol A H|Bou Antoun M T|Hanna C|Salih M|Rahbari-Oskoui F F|Chebib F T,Borghol A H|Bou Antoun M T|Hanna C|Chebib F T,"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.|Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL, USA.|Division of Pediatric Nephrology and Hypertension, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.|Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.|Division of Nephrology and Transplantation, Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands.|Renal Division, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.","Borghol A H, Bou Antoun M T, Hanna C, Salih M, Rahbari-Oskoui F F, Chebib F T",https://pubmed.ncbi.nlm.nih.gov/40268755/,"Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a common inherited kidney disease that causes the development of multiple kidney cysts, leading to kidney failure. While a drug called tolvaptan has been approved to treat ADPKD, there is still a need for more effective treatments and better ways to predict the progression of the disease."
40272362,Sudden Death With Lyme Disease Myocarditis: A Case Report.,"Death from myocarditis due to Lyme disease is uncommon but may be under-recognized. Myocarditis can lead to sudden and/or unexpected death due to fatal cardiac arrhythmias, which may be misattributed to more common causes, such as coronary artery disease. We report an unexpected death in a 69-year-old man from a Lyme-endemic area who had multiple cardiovascular risk factors. His death was initially attributed to coronary artery disease by the local coroner's office but was later confirmed to be due to Lyme disease, based on positive serological testing, characteristic cardiac histopathology findings, and the detection of Borrelia burgdorferi spirochetes, antigens, and DNA in the heart using various methods. Forensic pathologists should maintain a high suspicion of Lyme carditis, particularly in cases of sudden/unexpected death in Lyme-endemic areas. A history of rash or recent insect bites should prompt serologic testing for Lyme disease.Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.",The American journal of forensic medicine and pathology,"Dec 01, 2025",2025,Dec,01,Zhu Y|Villalba J A|Kasten J|DeLeon Carnes M|Bhatnagar J|Zumwalt R,Zhu Y|Zumwalt R,"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.|Infectious Diseases Pathology Branch, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA.","Zhu Y, Villalba J A, Kasten J, DeLeon Carnes M, Bhatnagar J, Zumwalt R",https://pubmed.ncbi.nlm.nih.gov/40272362/,"This case report highlights that Lyme disease can cause a rare but serious condition called myocarditis, which can lead to sudden and unexpected death. The case describes a 69-year-old man from a Lyme-endemic area who died suddenly, and the cause was initially attributed to heart disease. However, further testing confirmed that the death was due to Lyme disease-related myocarditis. This case underscores the importance for medical professionals to consider L"
40582477,Prognostic value of liver biomarker scores for risk stratification in adults with Fontan palliation.,"The assessment and monitoring of Fontan associated liver disease (FALD) is challenging because of variability in clinical presentation and disease progression. The purpose of this study was to compare the prognostic value of liver biomarker scores to baseline (single) liver biomarker score and other modalities of liver disease assessment.Retrospective study of adults with Fontan palliation who had ≥3 consecutive assessments of complete blood count and comprehensive metabolic panel. Model for end-stage liver disease excluding international normalized ratio (MELD-XI), fibrosis-4 (FIB-4), and aspartate transaminase to platelet ratio (APRI) scores were calculated at each visit, and average scores were calculated as the mean of the first 3 measurements. The presence of cirrhosis was determined using 4 different modalities: (1) imaging diagnosis of cirrhosis, (2) clinical diagnosis of cirrhosis, (3) histologic diagnosis of cirrhosis, (4) cirrhosis/portal hypertension based on the varices, ascites, splenomegaly, and thrombocytopenia (VAST) score.Of 344 patients (age 30 ± 9 years, 56% males), the average MELD-XI, FIB-4, and APRI scores were 12.5 ± 4.1, 1.19 ± 0.81, and 0.61 ± 0.46, respectively. All 3 liver biomarker scores were associated with death/transplant, independent of comorbidities and hemodynamic indices. Average liver biomarker scores had superior prognostic performance compared to baseline scores, and multiparametric cirrhosis diagnosis.These data support the use of average liver biomarker scores for risk stratification in the setting of Fontan associated liver disease (FALD). These scores can be seamlessly integrated into routine clinical practice since they are derived from blood tests that are routinely acquired during clinic visits.Copyright © 2025 Elsevier Inc. All rights reserved.",American heart journal,"Dec, 2025",2025,Dec,,Abdelhalim A T|Reddy Y V N|Miranda W R|Kamath P S|Hilscher M|Connolly H M|Egbe A C,Abdelhalim A T|Reddy Y V N|Miranda W R|Kamath P S|Hilscher M|Connolly H M|Egbe A C,"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN. Electronic address: egbe.alexander@mayo.edu.","Abdelhalim A T, Reddy Y V N, Miranda W R, Kamath P S, Hilscher M, Connolly H M, Egbe A C",https://pubmed.ncbi.nlm.nih.gov/40582477/,"This study found that average liver biomarker scores, such as MELD-XI, FIB-4, and APRI, are better at predicting the risk of death or transplant in adults with Fontan palliation compared to single biomarker scores or other methods of assessing liver disease. These easily accessible blood tests can be used to monitor and manage Fontan-associated liver disease."
40506638,MR elastography-based prediction of development of hepatocellular carcinoma in patients with chronic hepatitis B with sustained virological response.,"The goal of this study was to develop a risk score based on MR elastography (MRE) to predict hepatocellular carcinoma (HCC) development in patients with chronic hepatitis B (CHB).A total of 345 patients with CHB who underwent 2D/3D MRE between July 2015 and December 2018 were enrolled and then randomly assigned to training (n = 243) and validation (n = 102) cohorts. An MRE-based HCC risk score was developed for the prediction of HCC development based on a multivariable Cox model and compared with previous clinical scores. The predictive performance was evaluated using the C-index and time-dependent ROC.The 2D/3D MRE-based risk scores incorporating age, platelet count, albumin, and liver stiffness provided better predictive performance in HCC development than three existing clinical risk scores [CAMD (cirrhosis, age, male sex, and diabetes mellitus), PAGE-B (platelet age gender-B), and mPAGE-B (modified platelets, age, gender-hepatitis B)] in the training (C-index: 0.859 and 0.872, respectively, vs 0.762, 0.754 and 0.818, all p value < 0.05) and validation cohorts (C-index: 0.878 and 0.887, respectively, vs 0.815, 0.709 and 0.810, all p value < 0.05). The 2D and 3D MRE-based risk scores provided high negative predictive values in the training and validation cohorts at 3 years (97.8-100.0%) and 5 years (94.6-100.0%) with the two optimal cut-off values of 43.2 and 69.2, respectively, and 56.5 and 71.6, respectively.Both 2D and 3D MRE-based risk scores may serve as a valuable tool for predication of HCC development for CHB patients and provided superior predictive performance compared to existing clinical scores.Question Can MRE be a useful component of a risk score to predict HCC development in CHB patients with sustained virological response? Findings 2D/3D MRE-based stiffness values were independent predictors for HCC development, and the 2D/3D MRE-based risk scores demonstrated better performance than three existing clinical risk scores. Clinical relevance The 2D/3D MRE-based risk scores provide high negative predictive values for HCC development, which may become a noninvasive tool for clinicians to stratify CHB patients for HCC surveillance and to improve early HCC detection and reduce mortality.© 2025. The Author(s), under exclusive licence to European Society of Radiology.",European radiology,"Dec, 2025",2025,Dec,,Chen H|Zhu J|Zhou J|Yin Z|Chen J|Venkatesh S K|Yin M|Ehman R L|Wang J,Yin Z|Chen J|Venkatesh S K|Yin M|Ehman R L,"Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University (SYSU), Guangzhou, People's Republic of China.|Department of Radiology, Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, The Third Affiliated Hospital, Sun Yat-Sen University (SYSU), Guangzhou, People's Republic of China. wangjin3@mail.sysu.edu.cn.","Chen H, Zhu J, Zhou J, Yin Z, Chen J, Venkatesh S K, Yin M, Ehman R L, Wang J",https://pubmed.ncbi.nlm.nih.gov/40506638/,"The study developed an MRI-based risk score that can better predict the development of liver cancer (hepatocellular carcinoma) in patients with chronic hepatitis B who have achieved viral suppression, compared to existing clinical scores. This MRI-based risk score could help clinicians identify high-risk patients for closer cancer surveillance and early detection, potentially reducing liver cancer mortality in this patient population."
40517994,Impact of statin treatment on postoperative atrial fibrillation in surgical aortic valve replacement.,"Postoperative atrial fibrillation (POAF) is a frequent complication after cardiac surgery, associated with significant risk of long-term complications. The aim is to investigate the impact of statin treatment on the risk of POAF, and the association of POAF with mortality in patients undergoing surgical aortic valve replacement (SAVR).This population-based observational study was conducted from January 2016 to April 2022, with follow-up data until April 2024. We included all patients undergoing isolated SAVR with bioprosthetic valve in Western Denmark. Propensity score (PS) matching was employed to create comparable groups, and multivariable Cox regression models to analyze cumulative statin dose-response effect.A total of 1,475 patients undergoing SAVR were included in the study, with a median follow-up of 4.9 years (IQR: 3.1-6.4 years). Among these, 789 patients were statin treated, while 686 were untreated. After PS matching, 493 pairs of patients were identified. In the PS population (history of atrial fibrillation excluded), the adjusted odds ratio (aOR) for POAF was 1.15 (95% CI 0.86-1.54). POAF was associated with a significant risk of new-onset atrial fibrillation (aOR 19.4, 95% CI 11.9-31.6), but not with all-cause mortality after adjustment (aHR 1.37, 95% CI 0.98-1.92). High cumulative statin doses were associated with a significant reduction in mortality (HR 0.89, 95% CI 0.81-0.97).Statin treatment was not associated with reduced risk of POAF following SAVR. POAF was associated with a significant risk of new-onset atrial fibrillation, but not mortality after adjusting for confounders. High cumulative statin doses were significantly associated with a reduced all-cause mortality.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.",American heart journal,"Dec, 2025",2025,Dec,,Krasniqi L|Skovbo J S|Hallas J|Brandes A|Mortensen P E|Gerke O|Ravn E J|Poulsen V|Modrau I S|Müllertz K M|Dahl J S|Riber L P,Dahl J S,"Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark. Electronic address: Lytfi.Krasniqi@rsyd.dk.|Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern Denmark, Odense, Denmark.|Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark.|Department of Cardiology, Esbjerg Hospital - University Hospital of Southern Denmark, Esbjerg, Denmark; Department of Regional Health Research, University of Southern Denmark, Esbjerg, Denmark.|Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark.|Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Nuclear Medicine, Odense University Hospital, Odense, Denmark.|Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark.|Department of Cardiac, Thoracic and Vascular Surgery, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.|Department of Cardiology, Aalborg University Hospital, Aalborg, Denmark.|Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Krasniqi L, Skovbo J S, Hallas J, Brandes A, Mortensen P E, Gerke O, Ravn E J, Poulsen V, Modrau I S, Müllertz K M, Dahl J S, Riber L P",https://pubmed.ncbi.nlm.nih.gov/40517994/,"This study found that statin treatment did not reduce the risk of postoperative atrial fibrillation (POAF) in patients undergoing surgical aortic valve replacement. However, POAF was associated with an increased risk of developing new-onset atrial fibrillation, and high cumulative statin doses were linked to a lower risk of all-cause mortality in these patients."
40532097,Three Proven Strategies to Supercharge Digital Note-Taking in Physician Assistant/Associate Education.,"Research on note-taking strategies in the higher education setting has been in existence since the 1920s. While both pros and cons exist for handwritten and digital note-taking techniques, recent research has focused on novel ways to optimize digital note-taking. With more students using laptops or tablets with a stylus, educators need to be equipped to coach students on evidenced-based ways to improve their digital note-taking.PubMed, ERIC, and CINAHL databases were searched on January 6, 2025, using combinations of the following key words: digital, technology, analogue, note-taking, cognition, memory, laptop, stylus, and tablet. Studies were included if they were performed with adult learners in the higher education setting with a primary focus on note-taking.Three hundred thirty records were screened with 25 included in final review. Thematic analysis identified three emerging themes: (1) collaborative/group note-taking, (2) outlines, and (3) mind mapping, concept maps, or matrixes.Physician assistant/associate faculty can educate students on ways to conduct collaborative or group note-taking, create outlines, and generate mind maps, concept maps, or matrixes. These evidence-based digital note-taking strategies can be conducted independently or as a group. By supplementing these strategies with basic retrieval practices outside of the classroom, students will increase their likelihood of academic success.Copyright © 2025 The Authors. Published by Wolters Kluwer Health, Inc. on behalf of PA Education Association.",J Physician Assist Educ,"Dec 01, 2025",2025,Dec,01,Hoffmann C,Hoffmann C,"Chelsey Hoffmann, PA-C, MS, RD, is a physician assistant of Mayo Clinic, Rochester Minnesota.",Hoffmann C,https://pubmed.ncbi.nlm.nih.gov/40532097/,"The key finding of this research is that three proven digital note-taking strategies - collaborative/group note-taking, creating outlines, and generating mind maps or concept maps - can help physician assistant/associate students improve their academic success. These evidence-based techniques can be used independently or as a group, and when combined with basic retrieval practices, they can significantly enhance students' learning and performance."
40538858,sPatient perception of computed tomography scans in robotic-assisted elective total knee and hip arthroplasty: A cross-sectional study.,"This study evaluates patient perceptions of radiation exposure from preoperative CT scans in robotic-assisted total joint arthroplasty (raTJA). It examines awareness of radiation risks, the impact of prior raTJA experience, and the role of education and previous CT scans in knowledge acquisition. Additionally, it explores patient preferences for CT scans despite radiation exposure.A cross-sectional study was conducted with patients 21 years of age and older who were candidates for a raTJA. A 21-item questionnaire was distributed in an arthroplasty clinic to assess patient demographics, prior CT scan exposure, knowledge of radiation risks, and opinions on preoperative CT scans in raTJA.Of the 155 respondents, 72.9 % were female, with a mean age of 64. The majority (80.7 %) were candidates for TKA, and 16.8 % for THA. While 53.6 % of participants knew that CT scans involve radiation exposure, 81 % were unaware of how much radiation a CT scan produces compared to X-rays. Among patients with prior raTJA, 62 % were aware of radiation risks. Patient knowledge of radiation exposure was not significantly associated with education level or prior CT scans (P > 0.05). Notably, over 90 % of patients preferred a preoperative CT if it enabled robotic assistance, even after learning about radiation exposure.As robotic-assisted TJA becomes more widespread, understanding patient views on preoperative CT scans is increasingly essential. While awareness of radiation exposure was limited, most patients preferred CT imaging if it enabled robotic assistance, highlighting the need for improved education and communication regarding the risks and benefits.IV cross-sectional study.© 2025 Published by Elsevier B.V. on behalf of Professor P K Surendran Memorial Education Foundation.",Journal of orthopaedics,"Dec, 2025",2025,Dec,,Guevara-Serra C|Sanchez-Fernandez H E|Acosta Julbe J I|Hoffman M G|Pinci M V|Torres Lugo N J|Miro H M|Oquendo F A|Otero-López A,Hoffman M G,"Department of Orthopedic Surgery, University of Puerto Rico, Puerto Rico, San Juan, USA.|School of Medicine, University of Puerto Rico, Medical Sciences Campus, Puerto Rico, San Juan, USA.|Department of Orthopaedic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of General Surgery, University of Puerto Rico, Puerto Rico, San Juan, USA.","Guevara-Serra C, Sanchez-Fernandez H E, Acosta Julbe J I, Hoffman M G, Pinci M V, Torres Lugo N J, Miro H M, Oquendo F A, Otero-López A",https://pubmed.ncbi.nlm.nih.gov/40538858/,"The study found that while most patients were unaware of the radiation risks from CT scans, over 90% still preferred to have a preoperative CT scan if it enabled robotic-assisted joint replacement surgery. This highlights the need for better patient education on the risks and benefits of CT scans in this context, as robotic-assisted procedures become more common."
40545643,Gastric Accommodation and Impact on Emptying of Solids in Gastroparesis.,"In healthy controls, higher gastric accommodation (GA) was associated with slower gastric emptying (GE) of solids.In patients with gastroparesis: (1) To investigate the association between GA and GE of solids. (2) To assess the prevalence of abnormally high GA.An electronic medical records (EMR) review (2010-2024) was conducted on 745 adult patients with measured GA following 300 kcal Ensure using SPECT, and scintigraphy-based GE of solids (320 kcal, 30% fat, egg meal). Among these patients, 284 had gastroparesis (GE < 25% emptied at 2 h or < 75% emptied at 4 h). Spearman correlation analysis examined associations between GA volume or ratio and GE at 1, 2, and 4 h, and GE T1/2.Weak positive correlations were observed between GA volume and GE of solids % at 1 and 2 h (respectively Rs = 0.148, p = 0.0234, and Rs = 0.121, p = 0.042). In addition, there was a correlation between GA ratio and GE of solids % at 2 h (Rs = 0.143, p = 0.0160). However, there were no significant correlations of GA with GE % at 4 h or GE T1/2. Among the 284 patients with gastroparesis, we had documented increased GA, assessed by postprandial minus preprandial gastric volume (> 640 mL), in 7.75%, and increased GA by GA ratio > 3.85 in 22.9%.Among patients with gastroparesis, higher GA is associated with accelerated GE of solids in the first 2 h, though the effect size is small. There is no significant effect on delayed GE at 4 h or GE T1/2.© 2025 John Wiley & Sons Ltd.",Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Yang D Y|Abdelnaem N|Matar A|Camilleri M,Yang D Y|Abdelnaem N|Matar A|Camilleri M,"Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA.","Yang D Y, Abdelnaem N, Matar A, Camilleri M",https://pubmed.ncbi.nlm.nih.gov/40545643/,"In patients with gastroparesis, higher gastric accommodation (GA) was associated with slightly faster gastric emptying (GE) of solids in the first 2 hours, but had no significant impact on delayed GE at 4 hours or GE half-time. Increased GA was observed in a small subset of gastroparesis patients."
40550011,Inadequately Controlled Type 2 Diabetes and Hypercortisolism: Improved Glycemia With Mifepristone Treatment.,"In many individuals, type 2 diabetes (T2D) remains poorly controlled despite taking multiple glucose-lowering therapies. Several studies have demonstrated that endogenous hypercortisolism is prevalent among these individuals. We tested whether cortisol-directed therapy improves their glycemic control.In this prospective, multicenter, double-blind study, 136 individuals with T2D (hemoglobin A1c [HbA1c] 7.5%-11.5% [58-102 mmol/mol] on multiple medications) and hypercortisolism (by dexamethasone suppression test) were randomized 2:1 to the glucocorticoid receptor antagonist mifepristone (300-900 mg once daily; n = 91) or placebo (n = 45) for 24 weeks, with stratification by presence/absence of an adrenal imaging abnormality. The primary end point was the change in HbA1c. Secondary end points included changes in glucose-lowering medications, weight, and waist circumference and safety.Mean baseline HbA1c in the study cohort was 8.55% (69.9 mmol/mol). At 24 weeks, the least squares mean (LSM) difference from placebo in HbA1c was -1.32% (95% CI -1.81 to -0.83; P < 0.001). Participants receiving mifepristone experienced reductions in body weight and waist circumference (placebo-adjusted LSM differences of -5.12 kg [95% CI -8.20 to -2.03] and -5.1 cm [-8.23 to -1.99], respectively). Of participants on mifepristone, 46% discontinued therapy, compared with 18% on placebo. Adverse events with mifepristone (>10% of participants) included hypokalemia, fatigue, nausea, vomiting, headache, peripheral edema, diarrhea, and dizziness, consistent with mifepristone's known tolerability profile. Increases in blood pressure also occurred.In individuals with inadequately controlled T2D and hypercortisolism, cortisol-directed medical therapy with mifepristone reduced HbA1c, with a manageable tolerability profile.© 2025 by the American Diabetes Association.",Diabetes care,"Dec 01, 2025",2025,Dec,01,DeFronzo R A|Fonseca V|Aroda V R|Auchus R J|Bailey T|Bancos I|Busch R S|Buse J B|Christofides E A|Eilerman B|Findling J W|Handelsman Y|Kahn S E|Miller H J|Ownby J G|Parker J C|Philis-Tsimikas A|Pratley R|Rosenstock J|Shanik M H|Sloan L A|Umpierrez G|Shambharkar S|Tudor I C|Schlafly T K|Einhorn D,Bancos I,"University of Texas Health Science Center at San Antonio and Texas Diabetes Institute, San Antonio, TX.|Tulane University, New Orleans, LA.|Brigham and Women's Hospital, Harvard Medical School, Boston, MA.|University of Michigan, Ann Arbor, MI.|Headlands Research AMCR Institute, Escondido, CA.|Mayo Clinic, Rochester, MN.|Albany Medical College, Community Endocrine Group, Albany, NY.|University of North Carolina School of Medicine, Chapel Hill, NC.|Endocrinology Associates, Columbus, OH.|St. Elizabeth Physicians, Covington, KY.|Medical College of Wisconsin, Milwaukee, WI.|Metabolic Institute of America, Tarzana, CA.|VA Puget Sound Health Care System and University of Washington, Seattle, WA.|NOLA Care Clinical Research Center, Covington, LA.|Atlanta Diabetes Associates, Atlanta, GA.|Accellacare Research, Wilmington Health, Wilmington, NC.|Scripps Whittier Diabetes Institute, Scripps Health, La Jolla, CA.|AdventHealth Translational Research Institute Orlando, Orlando, FL.|Velocity Clinical Research at Medical City Dallas, Dallas, TX.|Endocrine Associates of Long Island, Smithtown, NY.|Texas Institute for Kidney and Endocrine Disorders, Lufkin, TX.|Emory School of Medicine, Emory University, Atlanta, GA.|Corcept Therapeutics Incorporated, Redwood City, CA.","DeFronzo R A, Fonseca V, Aroda V R, Auchus R J, Bailey T, Bancos I, Busch R S, Buse J B, Christofides E A, Eilerman B, Findling J W, Handelsman Y, Kahn S E, Miller H J, Ownby J G, Einhorn D, et al.",https://pubmed.ncbi.nlm.nih.gov/40550011/,"The key finding of this medical research is that the drug mifepristone, which blocks the effects of the stress hormone cortisol, can improve blood sugar control in people with type 2 diabetes who have high cortisol levels, despite taking multiple diabetes medications. This suggests that targeting cortisol may be a useful approach for managing diabetes in some individuals."
40586937,Substantial decrease in tumor dose over subsequent cyles of [177Lu]Lu-PSMA-radioligand treatment.,No abstract available.,European journal of nuclear medicine and molecular imaging,"Dec, 2025",2025,Dec,,Bogsrud T V|Durski J M|Engelsen O|Zhang J|Thorpe M P|Sartor O,Bogsrud T V|Durski J M|Zhang J|Thorpe M P,"PET Imaging Center, University Hospital of North Norway, Tromso, Norway. tvbog@aol.com.|Nuclear Medicine and PET-center, Aarhus University Hospital, Aarhus, Denmark. tvbog@aol.com.|Department of Radiology, Mayo Clinic, Rochester, MN, USA. tvbog@aol.com.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.|PET Imaging Center, University Hospital of North Norway, Tromso, Norway.|Department of Urology and Medicine, Tulane University, New Orleans, LA, USA.","Bogsrud T V, Durski J M, Engelsen O, Zhang J, Thorpe M P, Sartor O",https://pubmed.ncbi.nlm.nih.gov/40586937/,"This research likely explores the changes in tumor dose over multiple cycles of a specific type of radioligand treatment, [177Lu]Lu-PSMA, which is used to treat certain types of tumors. The findings suggest that the tumor dose decreases substantially over the subsequent cycles of this radioligand treatment."
40502808,Rebuilding the Tower of Babel: The Current Landscape and Emerging Opportunities in DEE-SWAS.,"Developmental/epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS) is newly proposed nomenclature put forth by the International League Against Epilepsy (ILAE) to replace the problematic electrographic and/or clinical phenotypes of electrical status epilepticus of sleep (ESES) and continuous spike-wave in sleep (CSWS). The nomenclature update represents a noble effort to minimize the confusion of how to define and appropriately utilize this alphabet soup of acronyms, thereby aiding in future clinical and research efforts. The name change fails to capture greater challenges within the field, which still plague diagnosis and treatment and stagnates substantive research advancements. Through a directed literature review of DEE-SWAS with emphasis on the new ILAE nomenclature and the RESCUE-ESES trial, we will highlight major persistent quandaries in the field. These include inadequate or insufficient diagnostic biomarkers (ie, the spike wave index), the highly variable clinical manifestations, ranging from dubious associations to profound developmental regression, presumptively caused by spike-wave activation in sleep, and variable and often ineffective treatment paradigms. We will also review the broader diagnostic evaluation of DEE-SWAS. By doing so, we aim to shed light on crucial research and clinical questions that could advance our understanding of diagnosing and treating children with DEE-SWAS, as well as addressing the uncertainty surrounding the neurological effects of sleep-activated epileptiform discharges.© The Author(s) 2025.",Epilepsy currents,"Dec, 2025",2025,Dec,,Stowe R C|Kelley S A|Bhatia S|McLaren J R|Rao L M|Patel S H|Fine A L|Baumer F|Duong P|Pavuluri S|Liu V B|Phillips D J,Fine A L,"Boston Children's Hospital, Harvard Medical School, Boston, MA, USA.|Johns Hopkins Hospital, Baltimore, MD, USA.|Shawn Jenkins Children's Hospital and Medical University of South Carolina, Charleston, SC, USA.|UCLA Mattel Children's Hospital, Los Angeles, CA, USA.|Duke University Medical Center, Durham, NC, USA.|Mayo Clinic, Rochester, MN, USA.|Department of Neurology & Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA.|Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.|University of Nebraska Medical Center, Omaha, NE, USA.|Children's Hospital of Orange County, Orange, CA, USA.","Stowe R C, Kelley S A, Bhatia S, McLaren J R, Rao L M, Patel S H, Fine A L, Baumer F, Duong P, Pavuluri S, Liu V B, Phillips D J",https://pubmed.ncbi.nlm.nih.gov/40502808/,"The study discusses the new terminology ""developmental/epileptic encephalopathy with spike-wave activation in sleep (DEE-SWAS)"" proposed by the International League Against Epilepsy to replace previous confusing acronyms. The key finding is that while the name change aims to improve clinical and research efforts, significant challenges remain in accurately diagnosing and effectively treating children with DEE-SWAS, including the lack of reliable biomarkers and variable clinical manifestations"
40607909,Preoperative von Willebrand factor is an independent predictive biomarker for post-hepatectomy liver failure-A multivariable model with APRI+ALBI.,"Portal hypertension is a key factor in posthepatectomy liver failure (PHLF). While preoperative liver function tests like APRI+ALBI assess liver function, they only partially reflect portal hypertension severity. Elevated von Willebrand factor antigen (vWF-Ag) indicates endothelial dysregulation and correlates with portal hypertension. Combining vWF-Ag with APRI+ALBI may enhance PHLF prediction. A total of 534 patients who underwent liver resection at Mayo Clinic Rochester (2020-2024) were analyzed for PHLF incidence, postoperative morbidity, and 90-day mortality. Predictive probability for PHLF was assessed using receiver operating characteristic analysis and validated in an external Austrian cohort of 283 patients (2008-2017). vWF-Ag was then integrated into the existing APRI+ALBI multivariable model. PHLF grade B/C was reported in 56 patients (10.5%). The 90-day mortality rate was 0.9% (n=5). Using 2 cutoffs (182%, 240%), vWF-Ag was found to be an independent predictive factor for PHLF grade B/C that remained statistically significant upon multivariable analysis. The combination of preoperative APRI+ALBI and vWF-Ag increased the positive predictive value to 27.9% for PHLF grade B/C in the APRI+ALBI high and vWF-Ag high group. Incorporation of vWF-Ag into the established APRI+ALBI-based multivariable model revealed a superior AUC of 0.772 for PHLF risk stratification and was successfully validated in an independent cohort (AUC=0.834). The combination of vWF-Ag with APRI+ALBI demonstrates a favorable predictive potential for PHLF risk assessment. We provide 2 pathways for clinical assessment: (1) a cutoff-based system and (2) a more complex multivariable model that can be calculated in a specifically designed smartphone application.Copyright © 2025 American Association for the Study of Liver Diseases.",Liver Transpl,"Dec 01, 2025",2025,Dec,01,Dong Y|Gregory L A|Podrascanin V|Santol J|Ammann M|Pereyra D|Hackl H|Li Z|Starlinger J|Truty M J|Warner S G|Smoot R L|Gruenberger T|Nagorney D M|Starlinger P P,Dong Y|Gregory L A|Podrascanin V|Santol J|Ammann M|Li Z|Truty M J|Warner S G|Smoot R L|Nagorney D M|Starlinger P P,"Department of Surgery, Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Department of Surgery, HPB Center, Vienna Health Network, Clinic Favoriten and Sigmund Freud Private University, Vienna, Austria.|Department of Surgical Oncology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Surgery, University Hospital Wiener Neustadt, Wiener Neustadt, Austria.|Department of Surgery, Medical University of Vienna, General Hospital, Vienna, Austria.|Institute of Bioinformatics, Biocenter, Medical University Innsbruck, Innsbruck, Austria.|William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, Minnesota, USA.|HowtoHealth GmbH, Berlin, Germany.","Dong Y, Gregory L A, Podrascanin V, Santol J, Ammann M, Pereyra D, Hackl H, Li Z, Starlinger J, Truty M J, Warner S G, Smoot R L, Gruenberger T, Nagorney D M, Starlinger P P",https://pubmed.ncbi.nlm.nih.gov/40607909/,"The key finding of this medical research is that preoperative von Willebrand factor (vWF-Ag) is an independent predictive biomarker for post-hepatectomy liver failure (PHLF). Combining vWF-Ag with existing liver function tests (APRI+ALBI) enhances the prediction of PHLF risk, which can help clinicians better assess and manage patients undergoing liver surgery."
40616415,Efficacy of the Exhalation Delivery System With Fluticasone for Chronic Rhinosinusitis: A Systematic Review and Meta-Analysis.,"Novel biomechanics of the exhalation delivery system can deliver fluticasone (EDS-FLU; XHANCE) to sinonasal areas above the inferior turbinate, especially sinus drainage pathways not reached by standard nasal sprays. This study aimed to evaluate the effectiveness of EDS-FLU in treating chronic rhinosinusitis (CRS).Studies were retrieved from PubMed, SCOPUS, Embase, Web of Science, and Cochrane databases up to April 2024. We analyzed 5 studies that compared EDS-FLU with a control group (exhalation delivery system with placebo) on various outcomes, including the 22-item Sinonasal Outcome Test (SNOT-22), nasal symptom scores (congestion, facial pain, olfactory dysfunction, and rhinorrhea), nasal polyp scores, surgical indication rate, and the incidence of adverse effects.Five studies with 2129 patients were included. EDS-FLU significantly improved SNOT-22 score (-20.9657 [-23.5639; -18.3674]) and the polyp score (-1.5099 [-1.7810; -1.2388]) after 6 months. The incidence of epistaxis was significantly higher in the treatment group compared to the control group (OR = 5.7954 [2.1004; 15.9909]). Effects of EDS-FLU on polyp score (-0.6497 [-0.8186; -0.4807]), responder rate (OR = 2.1755 [1.2784; 3.7020]), complete responder rate (OR = 2.0423 [1.0109; 4.1262]), surgical indication rate (OR = 0.7313 [0.5459; 0.9797]), and SNOT-22 score (-6.1513 [-11.3054; -0.9972]) were significantly higher in the treatment group than in the control group.This study demonstrated that EDS-FLU (372 µg twice daily) produced statistically significant improvements compared to EDS-placebo in multiple subjective and objective outcomes, although some adverse effects, such as epistaxis, may occur.","The Annals of otology, rhinology, and laryngology","Dec, 2025",2025,Dec,,Im Y H|Stybayeva G|Hwang S H,Stybayeva G,"Department of Otolaryngology-Head and Neck Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.|Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.|Department of Otolaryngology-Head and Neck Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.","Im Y H, Stybayeva G, Hwang S H",https://pubmed.ncbi.nlm.nih.gov/40616415/,"The study found that the exhalation delivery system with fluticasone (EDS-FLU) significantly improved symptoms and reduced the need for surgery in patients with chronic rhinosinusitis, although it also increased the risk of nosebleeds. This suggests that EDS-FLU could be an effective treatment option for chronic rhinosinusitis, but patients should be monitored for potential side effects."
40619901,Economic impact of a digital tobacco cessation program: healthcare savings and productivity gains in a self-insured manufacturing company.,"To quantify the return on investment of a digital tobacco cessation program from an employer perspective by analyzing healthcare cost savings and productivity gains in a real-world workplace setting.This quasi-experimental study analyzed medical claims data from a self-insured US manufacturing company, comparing healthcare costs between program enrollees (n = 153) and matched non-enrollees (n = 3,943) over a 12-month post-enrollment period. Exact and propensity score matching were used to address selection bias, followed by difference-in-differences analysis to control for temporal trends. The study population included employees and spouses continuously enrolled in the company health plan from November 2019 through December 2023. Administrative claims data captured all healthcare services, while productivity benefits were estimated through simulation modeling using published parameters and conservative assumptions for absenteeism reduction and presenteeism improvements. The analysis adopted an employer perspective with a 1-year time horizon, incorporating both direct medical cost savings and indirect productivity gains.Program enrollees demonstrated $950 lower annual healthcare costs compared to matched non-enrollees within the first year of enrollment (95% CI = -$2,022-$122; p = 0.083 using difference-in-differences analysis). Productivity gains contributed an additional $960 per enrollee (95% CI = $446-$1,614), resulting from reduced absenteeism and improved workplace performance. Combined healthcare and productivity savings totaled $1,910 per participant (95% CI = $694-$3,158). At a program cost of $200 per participant, this yielded a return on investment of $9.55 for every dollar invested (95% CI = $3.47-$15.79). Sensitivity analyses confirmed robust positive returns across varying assumptions about abstinence rates and productivity parameters.Using rigorous econometric methods to minimize confounding bias, this analysis demonstrates substantial employer cost savings from implementing a digital tobacco cessation program. The nearly 10-fold return on investment, driven by both healthcare savings and productivity improvements, provides compelling economic evidence for employers evaluating digital health solutions in workplace wellness programs.",Journal of medical economics,"Dec, 2025",2025,Dec,,Brault M|Rein D B|Graham A L,Graham A L,"NORC at the University of Chicago, Chicago, IL, USA.|Innovations Center, Truth Initiative, Washington, DC, USA.|Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.","Brault M, Rein D B, Graham A L",https://pubmed.ncbi.nlm.nih.gov/40619901/,"This study found that a digital tobacco cessation program led to significant healthcare cost savings and productivity gains for a self-insured manufacturing company. The program generated a return of $9.55 for every dollar invested, making it a highly cost-effective intervention for employers."
40620096,A practical guide for nephrologist peer reviewers: evaluating artificial intelligence and machine learning research in nephrology.,"Artificial intelligence (AI) and machine learning (ML) are transforming nephrology by enhancing diagnosis, risk prediction, and treatment optimization for conditions such as acute kidney injury (AKI) and chronic kidney disease (CKD). AI-driven models utilize diverse datasets-including electronic health records, imaging, and biomarkers-to improve clinical decision-making. Applications such as convolutional neural networks for kidney biopsy interpretation, and predictive modeling for renal replacement therapies underscore AI's potential. Nonetheless, challenges including data quality, limited external validation, algorithmic bias, and poor interpretability constrain the clinical reliability of AI/ML models. To address these issues, this article offers a structured framework for nephrologist peer reviewers, integrating the TRIPOD-AI (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis-AI Extension) checklist. Key evaluation criteria include dataset integrity, feature selection, model validation, reporting transparency, ethics, and real-world applicability. This framework promotes rigorous peer review and enhances the reproducibility, clinical relevance, and fairness of AI research in nephrology. Moreover, AI/ML studies must confront biases-data, selection, and algorithmic-that adversely affect model performance. Mitigation strategies such as data diversification, multi-center validation, and fairness-aware algorithms are essential. Overfitting in AI is driven by small patient cohorts faced with thousands of candidate features; our framework spotlights this imbalance and offers concrete remedies. Future directions in AI-driven nephrology include multimodal data fusion for improved predictive modeling, deep learning for automated imaging analysis, wearable-based monitoring, and clinical decision support systems (CDSS) that integrate comprehensive patient data. A visual summary of key manuscript sections is included.",Renal failure,"Dec, 2025",2025,Dec,,Wang Y|Cheungpasitporn W|Ali H|Qing J|Thongprayoon C|Kaewput W|Soliman K M|Huang Z|Yang M|Zhang Z,Cheungpasitporn W|Thongprayoon C,"Department of Emergency Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, China.|Department of Emergency Medicine, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.|Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.|University Hospitals of North Midlands, Stoke-on-Trent, UK.|Department of Nephrology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.|Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.|Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, South Carolina, USA.|College of Computer Science and Technology, Zhejiang University, Zhejiang, China.|The Second Department of Critical Care Medicine, The Second Affiliated Hospital of Anhui Medical University, Hefei, P. R. China.|School of Medicine, Shaoxing University, Shaoxing, P.R. China.|Key Laboratory of Precision Medicine in Diagnosis and Monitoring Research of Zhejiang Province, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China.|Longquan Industrial Innovation Research Institute, Lishui, China.","Wang Y, Cheungpasitporn W, Ali H, Qing J, Thongprayoon C, Kaewput W, Soliman K M, Huang Z, Yang M, Zhang Z",https://pubmed.ncbi.nlm.nih.gov/40620096/,"The research provides a practical guide for nephrologist peer reviewers to evaluate artificial intelligence (AI) and machine learning (ML) research in nephrology. The key finding is that while AI/ML can enhance diagnosis, risk prediction, and treatment optimization in conditions like acute kidney injury and chronic kidney disease, challenges such as data quality, limited external validation, and algorithmic bias constrain their clinical reliability. The guide offers a structured framework to address these issues and promote rigorous peer review, enhancing"
40626374,Sex-Dependent Circadian Rhythm Impact on Murine Gastrointestinal Transit.,"The circadian rhythm regulates gastrointestinal motility. In humans and preclinical models, such as rodents, whole gut transit (WGT) is slower during the rest phase compared to the active phase. Investigators typically study GI transit in rodents during the day, which is their rest phase, rather than during the night, which is their active phase. A circadian rhythm reversal in which mice are in a dark room during the working day (reverse light) allows studies on nocturnal animals during their active phase and has been previously shown to reduce WGT time. GI motility is often disrupted in individuals with disorders of gut-brain interaction (DGBI), which are female predominant. However, the effect of circadian rhythm on regional transit and sex dependence of the differences is not known, as most motility studies looking at circadian rhythm reversal are done in male mice.We tested C57BL/6 wild-type male and female mice in rest (12 h of light during the day) and active (reverse cycle for 2 weeks: 12 h of dark during the day) phases. We noted female estrous cycle by visual inspection. We performed carmine WGT by monitoring time-lapse videos of pellet production. We performed fluorescence imaging of excised intestines 30 min after gavage to assess percent fluorescence for each GI region and then examined small intestinal transit (SIT) by measuring geometric center and leading edge. For colonic transit, we monitored bead expulsion time from distal colon to anus.Compared to rest phase, in the active phase, like male mice, female mice had (1) faster WGT, (2) increased frequency of pellet expulsion in the first 3 h of transit, (3) and greater total pellet production. Both male and female mice in their active phase exhibited (4) more contrast emptied from the stomach and they had (5) further leading edge of fluorescence and (6) geometric center, in SIT, and (7) faster colonic bead expulsion times. There were no significant sex differences in the active phase of WGT. In SIT, male mice had further leading edge in the rest phase than female mice, but this difference was not seen in the active phase, and in colonic transit, male mice in both the active and rest phases had faster bead expulsion than female mice.Mice in the active phase have faster regional transit in small and large bowel than mice in the rest phase that collectively contributes to faster WGT times in the active phase of both male and female mice. These findings highlight the importance of circadian biology in sex-dependent rodent GI transit.© 2025 John Wiley & Sons Ltd.",Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Bellampalli S S|Fonar G|Grynyshyn M|Mercado-Perez A|Muchhala K H|Farrugia G|Matveyenko A V|Linden D R|Beyder A,Bellampalli S S|Fonar G|Grynyshyn M|Mercado-Perez A|Muchhala K H|Farrugia G|Matveyenko A V|Linden D R|Beyder A,"Division of Gastroenterology and Hepatology, Enteric NeuroScience Program (ENSP), Mayo Clinic, Rochester, Minnesota, USA.|Medical Scientist Training Program (MSTP), Mayo Clinic, Rochester, Minnesota, USA.|Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, Minnesota, USA.","Bellampalli S S, Fonar G, Grynyshyn M, Mercado-Perez A, Muchhala K H, Farrugia G, Matveyenko A V, Linden D R, Beyder A",https://pubmed.ncbi.nlm.nih.gov/40626374/,"This study found that mice have faster gastrointestinal transit during their active phase compared to their rest phase, and this effect is similar in both male and female mice. The findings suggest that circadian rhythm plays an important role in regulating sex-dependent differences in gut motility, which is relevant for understanding disorders of gut-brain interaction that are more common in women."
40626859,"Supporting the Deceased, Their Families, and Their Communities - Part 2: Practical Guidance for Building an Office of Decedent Affairs.","After-death care can be complicated and time-consuming for clinical staff, and frustrating for bereaved families. Delays and errors can have damaging legal and reputational consequences for hospitals. Offices of Decedent Affairs (ODAs) have been proposed as a solution, and their potential benefits have been described in several single institution reports. The literature lacks a contemporary and comprehensive review of existing ODAs and their approaches.To describe the process of establishing a new ODA and to provide a snapshot of the spectrum of structure, function, and impact of existing ODAs in the United States.A survey was administered to 11 established ODAs spread across the continental United States. Programs were identified through the College of American Pathologists Autopsy Committee and a Medical Autopsy Listserv.Eleven ODAs returned the survey, representing more than 190 cumulative years of experience in decedent care in the hospital setting (median, 10 years). There was a wide range in staffing (both staff size and background) as well as scope of services offered. The median ratio of hospital deaths to full-time equivalent (FTE) staffing was 360 deaths per FTE. Respondents reported that ODAs unburden clinical providers and facilitate decedent management. Some respondents reported a quicker turnover of hospital beds and shorter intervals between pronouncement of death and autopsy. ODAs increased autopsy rates when the autopsy services were part of the ODA.This survey provides practical information for hospitals considering establishing a new ODA and useful benchmarks for existing ODA programs.© 2025 College of American Pathologists.",Archives of pathology & laboratory medicine,"Dec 01, 2025",2025,Dec,01,Chambers M|Bartholow T|Parker Z T|Peters K|Reichard R R|Luthringer D J|Tigard C|Hooper J E|Benson P|Davis R|Cool R|Beglarian B|Mount S|Jackson N R|Scherpelz K P|Marshall D|Sinard J|Harcourt L|Wiley L E|Chen S|Comstock J M|Hyland C|Harper H|Priemer D|Rapkiewicz A|Rojiani A M|Sanchez H,Peters K|Reichard R R|Hyland C,"From the Department of Pathology, Stanford University School of Medicine, Palo Alto, California (Chambers, Hooper).|the Department of Pathology, University of Pittsburgh, Pittsburgh, Pennsylvania (Bartholow).|the Department of Pathology and Laboratory Medicine, Penn State College of Medicine, Hershey, Pennsylvania (Parker, Rojiani).|the Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota (Peters, Reichard, Hyland).|the Department of Pathology and Laboratory Medicine, Cedars-Sinai, Los Angeles, California (Luthringer).|Stanford Medicine, Palo Alto, California (Tigard).|the Department of Anatomic Pathology, University of Alabama at Birmingham, Birmingham (Benson, Davis).|the Department of Pathology, University Hospitals, Cleveland, Ohio (Cool, Harper).|the Department of Pathology, University of Utah, Salt Lake City (Beglarian, Comstock).|the Department of Pathology and Laboratory Medicine, University of Vermont, Burlington (Mount).|the Department of Laboratory Medicine and Pathology, University of Washington, Seattle (Jackson, Scherpelz).|Snohomish County Medical Examiner, Snohomish, Washington (Marshall).|the Department of Pathology, Yale New Haven Hospital, New Haven, Connecticut (Sinard, Sanchez).|the Department of Social Work, Michigan Health, Ann Arbor (Harcourt, Wiley).|the Department of Pathology and Laboratory Medicine, Nationwide Children'Hospital, Columbus, Ohio (Chen).|the Department of Pathology, The Ohio State University College of Medicine, Columbus (Chen).|Brain Tissue Repository, Uniformed Services University, Bethesda, Maryland (Priemer).|Office of the Suffolk County Medical Examiner, Hauppauge, New York (Rapkiewicz).","Chambers M, Bartholow T, Parker Z T, Peters K, Reichard R R, Luthringer D J, Tigard C, Hooper J E, Benson P, Davis R, Cool R, Beglarian B, Mount S, Jackson N R, Scherpelz K P, Sanchez H, et al.",https://pubmed.ncbi.nlm.nih.gov/40626859/,"The key finding of this medical research is that Offices of Decedent Affairs (ODAs) can help hospitals manage the complex and time-consuming process of after-death care, which can benefit both clinical staff and bereaved families. ODAs can unburden providers, facilitate decedent management, and increase autopsy rates, leading to quicker hospital bed turnover and shorter intervals between death and autopsy."
40503944,Enhanced analytic methodology enables postmortem diagnosis of hereditary AApoAI amyloidosis.,No abstract available.,Amyloid,"Dec, 2025",2025,Dec,,Theis J L|Hasadsri L|Dasari S|Theis J D|Vrana J A|Johnson M|Driscoll M|McPhail E D|Rech K L,Theis J L|Hasadsri L|Dasari S|Theis J D|Vrana J A|McPhail E D|Rech K L,"Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN, USA.|Division of Computational Biology, Mayo Clinic, Rochester, MN, USA.|Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.|Department of Pathology, University of Colorado Anschutz Hospital, Aurora, CO, USA.","Theis J L, Hasadsri L, Dasari S, Theis J D, Vrana J A, Johnson M, Driscoll M, McPhail E D, Rech K L",https://pubmed.ncbi.nlm.nih.gov/40503944/,"This research likely explores a new and improved method for diagnosing a type of hereditary amyloidosis, a condition where abnormal proteins accumulate in the body. The enhanced analytic methodology described in the title suggests the researchers have developed a more effective way to identify this hereditary disease, potentially even after the person has passed away."
40493756,Enteric Neuromuscular Manifestations in Neurofibromatosis Type I.,"Several genetic syndromes that affect nerve development and functioning may involve the enteric nervous system and present clinically as dysmotility syndromes, typically in childhood.To review the enteric neuromuscular manifestations, predominantly observed in adults, of neurofibromatosis type I at a tertiary referral center.We conducted a medical records review at the Mayo Clinic and documented clinical manifestations and findings on radiology, pathology, and specialized motility tests of the esophagus, stomach, colon, and rectal evacuatory functions. The tests included scintigraphic gastrointestinal and colonic transit measurements, intraluminal esophageal, gastrointestinal, colonic, and anorectal manometry, and balloon expulsion test.Among 2406 with documented NF1, the gastrointestinal manifestations were obstruction or dysmotility, seen in 2% of the cohort. Thirteen patients had small bowel or colonic obstructions: 4 gastrointestinal stromal tumors, 3 malignant peripheral nerve sheath tumors, 3 neurofibromas, 1 diffuse ganglioneuromatosis, 1 schwannoma, and 1 inflammatory fibroid polyp. In addition, 38 patients had abnormal gut motility, including esophageal achalasia or spasm, delayed gastric emptying, slow colonic transit, and dyssynergic defecation. Gastric, small bowel, and colonic manometry were characterized by normal amplitude incoordinated contractions suggestive of neuropathy. In the few resected specimens, myenteric plexus proliferation or diffuse ganglioneuromatosis was identified histologically.In addition to mechanical obstruction, typically due to benign tumors affecting smooth muscle or components of nerve (sheath or nerve fiber), patients with NF1 may present with dysmotility syndromes such as gastroparesis, slow colonic transit, or global dysmotility. Neuropathic dysmotility in NF1 can be identified by manometry and by histological evidence of myenteric plexus proliferation or diffuse ganglioneuromatosis.© 2025 John Wiley & Sons Ltd.",Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Damianos J A|Matkowskyj K A|Camilleri M,Damianos J A|Matkowskyj K A|Camilleri M,"Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.","Damianos J A, Matkowskyj K A, Camilleri M",https://pubmed.ncbi.nlm.nih.gov/40493756/,"The key finding of this medical research is that in addition to mechanical obstruction, patients with neurofibromatosis type I may also experience gastrointestinal dysmotility, such as gastroparesis, slow colonic transit, or global dysmotility, due to neuropathic changes in the enteric nervous system. This has important implications for the management of gastrointestinal symptoms in individuals with this genetic disorder."
40288733,Impact of Frozen Section Pathology Examination of Surgical Margins in Sublobar Pulmonary Resections for Clinical Stage IA Non-small Cell Lung Cancer.,"Sublobar resections are a valid surgical option for many patients with clinical stage IA non-small cell lung cancer (NSCLC). However, assessment of planned lines of resection can be limited when done using robotic technology. Further, incomplete resections are associated with worse outcomes. This study evaluated routine frozen section pathology (FSP) evaluation of margins during sublobar resections for clinical IA NSCLC.Patients with clinical stage IA NSCLC who underwent lung resections during 2018 to 2023 were reviewed. Only patients with a preoperative intention to undergo sublobar resection were included. FSP reports were compared with final pathology. Operative notes were reviewed to determine changes in surgical plan based on intraoperative FSP evaluation of margins.Of 1008 patients who underwent surgery, 642 (63.7%) had a preoperative plan to undergo sublobar resection. Median preoperative tumor size was 1.5 cm (interquartile range, 1.1-2.0 cm). A positive margin was identified in 8 patients (1.25%) intraoperatively or postoperatively. FSP successfully identified 7 of 8 patients (87.5%) intraoperatively, all corresponding to the parenchymal margin. In 5 of 7 patients (71.4%), the surgeon could alter the procedure to achieve a final negative margin. The final rate of non-R0 resection was 3 of 642 (0.47%). Therefore, FSP decreased the potential rate of non-R0 resection from 1.25% to 0.47% (62% reduction).FSP is a valuable tool to assess resection margins during intended sublobar resections of clinical stage IA NSCLC. Intraoperative margin analysis can identify most patients with positive margins, allowing the surgeon to alter the planned procedure, if appropriate, minimizing non-R0 resections.Copyright © 2025 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.",The Annals of thoracic surgery,"Dec, 2025",2025,Dec,,Ortiz B A|Engrav S K|Roden A C|Boland J M|Aubry M|Abdallah F A|Yi E S|Saddoughi S A|Cassivi S D|Wigle D A|Shen K R|Reisenauer J S|Tapias L F,Ortiz B A|Engrav S K|Roden A C|Boland J M|Aubry M|Abdallah F A|Yi E S|Saddoughi S A|Cassivi S D|Wigle D A|Shen K R|Reisenauer J S|Tapias L F,"Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota.|Mayo Clinic Alix School of Medicine, Rochester, Minnesota.|Division of Anatomic Pathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.|Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, Minnesota. Electronic address: tapias.luis@mayo.edu.","Ortiz B A, Engrav S K, Roden A C, Boland J M, Aubry M, Abdallah F A, Yi E S, Saddoughi S A, Cassivi S D, Wigle D A, Shen K R, Reisenauer J S, Tapias L F",https://pubmed.ncbi.nlm.nih.gov/40288733/,"This study found that using frozen section pathology (FSP) to examine surgical margins during sublobar lung cancer surgery can help identify positive margins in most cases, allowing surgeons to modify the procedure and achieve complete tumor removal. This technique significantly reduced the rate of incomplete (non-R0) resections, which is important for improving outcomes in patients with early-stage lung cancer."
40414371,Do Outcomes Differ After Medial Unicompartmental Knee Arthroplasty Based on Indications? A Prospective Cohort Study.,"Unicompartmental knee arthroplasty (UKA) has grown recently, highlighted by shorter recovery periods and positive clinical outcomes. This study's purpose was to determine whether clinical outcomes differ after medial UKA between patients indicated with strict versus liberal criteria as defined by established literature.We prospectively enrolled 94 patients (110 knees) undergoing UKA by a single surgeon. Patients were categorized preoperatively as strictly or liberally based on published criteria. Patients were recategorized based on intraoperative findings. Patient-reported outcome measures, reoperation, and complications were recorded. The mean length of follow-up within the cohort was 3.3 years (range, 1.7 to 5.3). Preoperatively, 58 patients (53%) met strict criteria and 52 (47%) met liberal criteria. There were 26 strict patients (45%) recategorized intraoperatively to the liberal group due to patello-femoral changes. There were seven patients (four strict and three liberal) excluded as they underwent total knee arthroplasty based on intraoperative findings. The final postoperative group categorization was 28 strict and 75 liberal patients. A two-sample t-test power analysis determined that 45 patients per group were required to identify a Knee Society Score difference of six with 80% power.Preoperative liberal patients had greater improvements in Veterans Rank-12 item mental scores compared to preoperative strict patients at final follow-up (8.67 versus 4.30, P = 0.02). Postoperative liberal patients had greater improvements in University of California, Los Angeles Activity Scale scores compared to postoperative strict patients (2.16 versus 1.11, P = 0.03). Overall survivorship was 98.1%, with no difference between preoperative strict and liberal patients (P = 0.3). There were two preoperative liberal patients revised to a total knee arthroplasty: one for a periprosthetic fracture of the tibia and one for unexplained pain.Stricter indications potentially lead to underutilization of UKA, as demonstrated by similar short-term patient-reported outcomes and survivorship between groups.Copyright © 2025 Elsevier Inc. All rights reserved.",The Journal of arthroplasty,"Dec, 2025",2025,Dec,,Higgins J D D|Hannon C P|Kurina S J|DeBenedetti A|Tseng J|Della Valle C J,Hannon C P,"Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.","Higgins J D D, Hannon C P, Kurina S J, DeBenedetti A, Tseng J, Della Valle C J",https://pubmed.ncbi.nlm.nih.gov/40414371/,"This study found that patients who underwent medial unicompartmental knee arthroplasty (UKA) based on either strict or liberal criteria had similar short-term outcomes and survivorship. This suggests that stricter indications for UKA may lead to underutilization of this procedure, as patients with more liberal criteria also experienced positive results."
40328963,Redefining respiratory sinus arrhythmia as respiratory heart rate variability: an international Expert Recommendation for terminological clarity.,"The variation of heart rate in phase with breathing, known as 'respiratory sinus arrhythmia' (RSA), is a physiological phenomenon present in all air-breathing vertebrates. RSA arises from the interaction of several physiological mechanisms but is primarily mediated by rhythmic changes in cardiac parasympathetic (vagal) activity, increasing heart rate during inspiration and decreasing heart rate during expiration. RSA amplitude is an indicator of autonomic and cardiac health; RSA is diminished or absent in common pathological conditions such as chronic heart failure and hypertension. In this Expert Recommendation, we argue that the term 'RSA', although historically important, is semantically inaccurate and carries misleading pathological connotations, contributing to misunderstanding and misinterpretation of the origin and the physiological importance of the phenomenon. We propose replacing 'RSA' with the term 'respiratory heart rate variability' (RespHRV), which avoids pathological connotations and emphasizes the specific respiratory contribution to heart rate variability. We clarify that RespHRV encompasses respiratory-related heart rate variations in both the low-frequency and high-frequency bands traditionally defined in heart rate variability analysis, and that its amplitude should not be misconstrued as a measure of vagal tone. Adopting the proposed term 'RespHRV' is expected to unify understanding and stimulate further experimental and clinical research into the physiological mechanisms and functional importance of this phenomenon.© 2025. Springer Nature Limited.",Nature reviews. Cardiology,"Dec, 2025",2025,Dec,,Menuet C|Ben-Tal A|Linossier A|Allen A M|Machado B H|Moraes D J A|Farmer D G S|Paterson D J|Mendelowitz D|Lakatta E G|Taylor E W|Ackland G L|Zucker I H|Fisher J P|Schwaber J S|Shanks J|Paton J F R|Buron J|Spyer K M|Shivkumar K|Dutschmann M|Joyner M J|Herring N|Grossman P|McAllen R M|Ramchandra R|Yao S T|Ritz T|Gourine A V,Joyner M J,"INMED, INSERM, Aix-Marseille University, Marseille, France. clement.menuet@inserm.fr.|Insightful Modelling, Auckland, New Zealand.|Manaaki Manawa - The Centre for Heart Research, Department of Physiology, Faculty of Medical & Health Sciences, University of Auckland, Auckland, New Zealand.|INMED, INSERM, Aix-Marseille University, Marseille, France.|Department of Anatomy & Physiology, University of Melbourne, Melbourne, Victoria, Australia.|Department of Physiology, School of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.|Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, São Paulo, Brazil.|Department of Neuroscience, School of Translational Medicine, Monash University, Melbourne, Victoria, Australia.|Burdon Sanderson Cardiac Science Centre and BHF Centre of Research Excellence, Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.|Department of Pharmacology and Physiology, George Washington University, Washington, DC, USA.|Laboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, MA, USA.|School of Biosciences, University of Birmingham, Birmingham, UK.|Translational Medicine and Therapeutics, William Harvey Research Institute, Queen Mary University of London, London, UK.|Department of Cellular and Integrative Physiology, University of Nebraska Medical Center, Omaha, NE, USA.|Department of Pathology, Anatomy, and Cell Biology, Daniel Baugh Institute for Functional Genomics and Computational Biology, Thomas Jefferson University, Philadelphia, PA, USA.|Department of Fundamental Neurosciences, University of Lausanne, Lausanne, Switzerland.|Centre for Cardiovascular and Metabolic Neuroscience, Neuroscience, Physiology & Pharmacology, University College London, London, UK.|University of California Los Angeles (UCLA) Cardiac Arrhythmia Center, Los Angeles, CA, USA.|Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University Hospitals Cleveland Medical Center and Case Western Reserve University, Cleveland, OH, USA.|Center for Sleep Disorders Research, Louis Stokes Cleveland VA Medical Center and Case Western Reserve University, Cleveland, OH, USA.|Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Psychosomatic Medicine, University Hospital Basel, Basel, Switzerland.|The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.|Department of Psychology, Southern Methodist University, Dallas, TX, USA.","Menuet C, Ben-Tal A, Linossier A, Allen A M, Machado B H, Moraes D J A, Farmer D G S, Paterson D J, Mendelowitz D, Lakatta E G, Taylor E W, Ackland G L, Zucker I H, Fisher J P, Schwaber J S, Gourine A V, et al.",https://pubmed.ncbi.nlm.nih.gov/40328963/,"The key finding of this medical research is that the term ""respiratory sinus arrhythmia"" (RSA) should be replaced with ""respiratory heart rate variability"" (RespHRV) to better reflect the physiological nature of the phenomenon and avoid misleading pathological connotations. This change in terminology is expected to unify understanding and promote further research into the importance of respiratory-related heart rate variations."
40345395,Validation of an updated patient-reported outcomes questionnaire for sacral tumors.,"Assessing functional outcomes and quality of life is crucial in evaluating patient and disease management. Sacral tumors are rare and present with complex oncologic backgrounds and diverse symptoms, complicating the development of a clinically relevant and generalizable tool. A previous validation study refined an initial attempt to create a tool specific to sacral tumor patients. This study is the first independent validation of the revised shorter outcome tool.To validate a revised patient-reported outcomes questionnaire specific to patients with sacral tumors. Secondarily, to assess the functional outcomes of patients with sacral tumors.A survey study from a tertiary care multidisciplinary clinic was used for this study.This study included 70 patients with sacral tumors who presented to our institution between October 2017 and June 2022.The following 8 questionnaires included in the revised sacral tumor survey were evaluated: the Patient Reported Outcomes Measurement Information System (PROMIS) Global Health short form v1.1, PROMIS Pain Intensity 3a v1.0, PROMIS Gastrointestinal Bowel Incontinence 4a v1.0, PROMIS Gastrointestinal Constipation 9a v1.0, PROMIS Sexual Function and Satisfaction v1.0 Male and Female, Urogenital Distress Inventory (UDI-6), and PROMIS Ability to Participate in Social Roles and Activities v2.0.Reliability, validity, and instrument coverage were evaluated by determining item completion rate, median score with interquartile range (IQR), and floor and ceiling effects. Internal consistency was measured using Cronbach's alpha. Bias-corrected bootstrapping (1,000 resamples) was applied to calculate the standard error and 95% confidence intervals. Spearman rank correlation coefficients were used to assess the extent of questionnaire convergence and divergence.Our analysis demonstrates moderate to significant floor and ceiling effects among PROMIS Gastrointestinal Symptoms Scale, PROMIS Sexual Function, and Urinary Distress Inventory (16%-61%) with predominantly more ceiling effects. Floor effects were notable for male interest (27%), female interest (29%), and female orgasm (38%). Moderate floor effects were noted for male satisfaction (11%), male orgasm (10%), and lubrication (14%). When controlling for patients with a colostomy, floor effects generally decreased, while ceiling effects showed variable changes. The revised questionnaire demonstrated strong internal consistency, with Cronbach's alpha values exceeding the threshold of 0.7 for all assessments except lubrication. GI bowel incontinence, male satisfaction, female satisfaction, and female interest were potentially redundant with a Cronbach's alpha above 0.9. In convergent validity, we found no significant trend in correlations between scores. Secondarily, when compared to patients with chronic diseases, our population reported similar levels of impaired physical health.Substantial floor and ceiling effects, along with poor convergence, were observed for many of the bowel, bladder, and sexual function questionnaires. Some metrics improved when accounting for patients with colostomies; however, the significant floor and ceiling effects identified in the bowel, bladder, and sexual function surveys must be considered in future research using the modified sacral tumor survey. PROMIS instruments effectively capture the profound impact of sacral tumors and their treatment on patients' physical and mental well-being.Published by Elsevier Inc.",Spine J,"Dec, 2025",2025,Dec,,Gasho J O|Coan J M|Boland P J|Healey J H|Wunder J S|Houdek M T|Hornicek F J|Schwab J H|Tobert D G,Houdek M T,"Keck School of Medicine, University of Southern California, Los Angeles, CA, USA. Electronic address: gasho@usc.edu.|Department of Orthopedic Surgery, Massachusetts General Hospital, Boston, MA, USA.|Department of Surgery, Orthopedic Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.|Musculoskeletal Oncology Unit, Mount Sinai Hospital, University of Toronto, Ontario, Canada.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Orthopedics, University of Miami, Miami, FL, USA.|Department of Orthopedic Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, USA.","Gasho J O, Coan J M, Boland P J, Healey J H, Wunder J S, Houdek M T, Hornicek F J, Schwab J H, Tobert D G",https://pubmed.ncbi.nlm.nih.gov/40345395/,"This study validated a revised patient-reported outcomes questionnaire for patients with sacral tumors, a rare and complex condition. The key finding is that the revised questionnaire demonstrated strong internal consistency, but also substantial floor and ceiling effects in the bowel, bladder, and sexual function domains. This highlights the need to carefully consider these limitations when using this tool to assess the impact of sacral tumors on patients' quality of life."
40351121,Cost per remission for mirikizumab versus ustekinumab for moderately to severely active ulcerative colitis treatment from the United States commercial payer perspective.,"Mirikizumab, approved for the treatment of moderately to severely active ulcerative colitis (UC), may be prescribed in a similar placement to ustekinumab in second-line settings. Payers may compare the economic value when making formulary decisions. This study estimated and compared the cost per remission of the second-line therapies mirikizumab versus ustekinumab in patients with UC.An Excel-based analytic model was developed to estimate the cost per additional patient achieving clinical remission at the end of one year in biologic/Janus kinase inhibitor (JAKi)-experienced patients (second-line therapy) with UC from a United States commercial payer perspective. A network meta-analysis of published pivotal randomized clinical trials was used to derive the number needed to treat (NNT) for clinical response, clinical remission, and endoscopic remission/endoscopic improvement/mucosal healing for ustekinumab and mirikizumab in the study population. The model included the treatment cost (wholesale acquisition costs [WAC] and treatment administration costs) during the induction and maintenance phases. A scenario involving the availability of a ustekinumab biosimilar was also evaluated, assuming the NNT remained the same as ustekinumab but with a WAC set at 50% lower than its current WAC.The costs per patient achieving clinical remission for mirikizumab vs. ustekinumab as a second-line therapy were $461,096 vs. $67,273 during induction and $501,456 vs. $1,079,189 during maintenance. The cost per clinical remission in case of dose escalation during maintenance was lower for mirikizumab vs. ustekinumab ($501,456 vs. $1,569,127). Considering the ustekinumab 130 mg IV biosimilar, the scenario resulted in a lower cost per clinical remission for mirikizumab vs. a ustekinumab biosimilar during the maintenance phase ($501,456 vs. $539,594).Mirikizumab is projected to have a lower cost per remission during maintenance therapy than ustekinumab. Given the need for long-term treatment for this chronic condition, mirikizumab appears to be a cost-efficient treatment option.",Journal of medical economics,"Dec, 2025",2025,Dec,,Gulati A|Mittal N|Kane S|Creveling T|Bires N|Fisher D A|Chanan N|Koushik A K|Upadhyay N,Kane S,"Eli Lilly and Company, Indianapolis, IN, USA.|Department of Gastroenterology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.","Gulati A, Mittal N, Kane S, Creveling T, Bires N, Fisher D A, Chanan N, Koushik A K, Upadhyay N",https://pubmed.ncbi.nlm.nih.gov/40351121/,"This study compared the cost per remission for two treatments for moderate to severe ulcerative colitis - mirikizumab and ustekinumab. The key finding is that mirikizumab had a lower cost per remission during the maintenance phase of treatment compared to ustekinumab, even when considering a potential ustekinumab biosimilar. This suggests that mirikizumab may be a more cost-efficient long-term treatment option for this"
40359009,From embedded interprofessional clinics to expanded alcohol-associated liver disease programs.,"Hazardous alcohol use remains a major contributor to acute and chronic liver disease, while alcohol-associated liver disease (ALD) is a leading indication for liver transplantation. In recent years, embedded, interprofessional ALD clinics have improved access to alcohol use disorder care within hepatology and liver transplantation, but more work is needed to meet this challenge. The literature is lacking regarding scaling procedures to provide services for increasingly large ill patient populations. This article begins to fill this gap by describing ""expanded ALD care"": broad, innovative, longitudinal, interprofessional care delivery strategies surpassing standalone clinics. Drawing from analogous patient populations served by collaborative models in primary care and comprehensive eating disorder treatment, the expanded ALD care framework proposes practical strategies toward specific innovations: equipoise between biomedical and psychosocial care elements, increased clinician number and reach, long-term patient relationships, harm reduction and palliative care, outreach to external agencies and clinicians, and enhanced support for patients and families. The article also defines attributes of innovative healthcare systems that support expanded ALD care.Copyright © 2025 American Association for the Study of Liver Diseases.",Liver Transpl,"Dec 01, 2025",2025,Dec,01,Winder G S|Arab J P|Goswami Banerjee A|Bryce K|Fipps D C|Hussain F|Im G|Omary L|Patel A A|Patel S|Rubman S|Serper M|Shenoy A|Suzuki J|Zimbrean P|Brown K|Abouljoud M|Mellinger J L,Fipps D C,"Department of Psychiatry and Behavioral Medicine, Henry Ford Health, Detroit, Michigan, USA.|Department of Surgery, Henry Ford Health, Detroit, Michigan, USA.|Department of Psychiatry, Michigan State University, East Lansing, Michigan, USA.|Department of Surgery, Michigan State University, East Lansing, Michigan, USA.|Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia, USA.|Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.|Department of Psychiatry and Behavioral Neurosciences, Wayne State University, Detroit, Michigan, USA.|Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Psychiatry, Stanford University, Palo Alto, California, USA.|Department of Internal Medicine, Columbia University, New York City, New York, USA.|Department of Psychiatry, Vanderbilt University, Nashville, Tennessee, USA.|Department of Internal Medicine, University of California-Los Angeles, Los Angeles, California, USA.|Department of Psychiatry, Yale University, New Haven, Connecticut, USA.|Department of Internal Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.|Department of Psychiatry, Columbia University, New York City, New York, USA.|Department of Psychiatry, Brigham and Women's Hospital, Boston, Massachusetts, USA.|Department of Internal Medicine, Henry Ford Health, Detroit, Michigan, USA.|Department of Internal Medicine, Wayne State University, Detroit, Michigan, USA.|Department of Internal Medicine, Michigan State University, East Lansing, Michigan, USA.|Department of Surgery, Wayne State University, Detroit, Michigan, USA.","Winder G S, Arab J P, Goswami Banerjee A, Bryce K, Fipps D C, Hussain F, Im G, Omary L, Patel A A, Patel S, Rubman S, Serper M, Shenoy A, Suzuki J, Zimbrean P, Mellinger J L, et al.",https://pubmed.ncbi.nlm.nih.gov/40359009/,"This research proposes expanding specialized clinics for alcohol-associated liver disease (ALD) to provide more comprehensive, long-term, and collaborative care. The key finding is that broader, innovative care delivery strategies beyond standalone clinics are needed to address the growing population of patients with ALD, a leading cause of liver transplantation. The proposed ""expanded ALD care"" framework aims to improve access to alcohol use disorder treatment and provide holistic support for patients and their families."
40402425,Sentinel Lymph Node Mapping in Esophageal Cancer: Current Status and Future Directions.,"This review provides a comprehensive discussion about the importance of adequate lymphadenectomy, its anatomic and oncologic significance, principles and rationale of sentinel lymph node mapping, current evidence stratified by tracer substrate, challenges, and future directions. Esophageal cancer has one of the worst cancer-related survival rates, and nodal status is the single most significant prognostic factor. Submucosal penetration generally demands esophagectomy, often following neoadjuvant therapy in the presence of deeper extension. Guidelines recommend resecting ≥15 lymph nodes. Variability in surgical approach and dissection in concert with aberrant esophageal lymphatic anatomy make adequate lymphadenectomy difficult.A narrative review was conducted to explore existing literature regarding lymphadenectomy with its requisite anatomic and oncologic significance in esophageal cancer, as well as the rationale for and present state of sentinel lymph node mapping stratified by substrates. Tables and figures were constructed by the authors using Microsoft Office applications and Biorender software, respectively.Sentinel lymph node mapping exploits the tumoral lymphatic network to identify the nodes most prone to metastasis, directing further dissection. Targeting sentinel lymph nodes with dyes, radiotracers, or hybrid tracers can assist surgeons with lymphadenectomy, potentially improving staging accuracy and personalizing care to individual anatomy.While this approach would benefit from larger studies and long-term data, early evaluations suggest improved detection of metastases outside the en bloc field without significantly increasing morbidity.© 2025. Society of Surgical Oncology.",Annals of surgical oncology,"Dec, 2025",2025,Dec,,Chopko T C|Maroun J W|Reisenauer J S|Tapias L F,Chopko T C|Maroun J W|Reisenauer J S|Tapias L F,"Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Division of Thoracic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Tapias.Luis@mayo.edu.","Chopko T C, Maroun J W, Reisenauer J S, Tapias L F",https://pubmed.ncbi.nlm.nih.gov/40402425/,"The key finding of this medical research is that sentinel lymph node mapping can help improve the accuracy of lymph node staging and personalize treatment for esophageal cancer patients. This approach identifies the lymph nodes most likely to contain cancer cells, allowing surgeons to focus their efforts on these specific nodes during lymph node removal, potentially leading to better outcomes for patients."
40407346,Detailed Analysis of Late Adverse Effects of Stereotactic Radiosurgery for Dural Arteriovenous Fistulas: A 20-Year Single-Center Study.,"Dural arteriovenous fistula (DAVF) is characterized by an abnormal vascular connection located within the dura mater. Stereotactic radiosurgery (SRS) offers favorable outcomes for DAVF, with high obliteration rates and low adverse effects. Although short- to mid-term SRS outcomes for DAVFs and long-term outcomes for arteriovenous malformations have been well documented, the long-term outcomes of SRS for DAVF remain unclear. The aim of this study was to elucidate the late radiation-induced complications (LRICs) of SRS for DAVF based on our long-term observational data. Especially, chronic encapsulated hematoma (CEH), which is defined as an organized intraparenchymal hematoma surrounded by a fibrous capsule, was highlighted as a subtype of LRICs.We enrolled 30 consecutive patients with 32 DAVFs who underwent SRS at our institution between 1998 and 2017. Cumulative DAVF obliteration and LRICs rates and associated risk factors were analyzed using the Kaplan-Meier method. Post-SRS signal changes were defined as edematous lesions with high T2 signal intensity that appeared after SRS.The median observation period after the SRS was 99 months. Two asymptomatic CEHs occurred in our cohort and were treated conservatively. The cumulative rates for LRICs after SRS were 5.3% at 8 years and 11.1% at 10 years. Post-SRS signal changes were significantly associated with the occurrence of CEH (25.0% vs 0.0% at 8 years; P = .005; log-rank test).Although SRS is effective in treating DAVFs, it poses a risk for LRICs. Post-SRS signal changes may be useful predictors of LRIC occurrence.Copyright © Congress of Neurological Surgeons 2025. All rights reserved.",Neurosurgery,"Dec 01, 2025",2025,Dec,01,Sato D|Shinya Y|Umekawa M|Hasegawa H|Koizumi S|Katano A|Saito N,Shinya Y,"Department of Neurosurgery, The University of Tokyo Hospital, Tokyo , Japan.|Department of Neurologic Surgery, Mayo Clinic, Rochester , Minnesota , USA.|Department of Radiology, The University of Tokyo Hospital, Tokyo , Japan.","Sato D, Shinya Y, Umekawa M, Hasegawa H, Koizumi S, Katano A, Saito N",https://pubmed.ncbi.nlm.nih.gov/40407346/,"The study found that while stereotactic radiosurgery is an effective treatment for dural arteriovenous fistulas, it can also lead to late radiation-induced complications, including a rare condition called chronic encapsulated hematoma. The study suggests that post-treatment changes in brain imaging may help predict the risk of these long-term complications."
40446886,Premature ventricular complexes quantification in patients with cardiac implantable electronic devices: To Holter or not to Holter-That is the question.,No abstract available.,Heart rhythm,"Dec, 2025",2025,Dec,,Deshmukh A J|Siotis A|Kashou A H,Deshmukh A J|Kashou A H,"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: deshmukh.abhishek@mayo.edu.|Clinical Sciences Helsingborg, Department of Clinical Sciences Lund, Lund University, Helsingborg, Sweden.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota.","Deshmukh A J, Siotis A, Kashou A H",https://pubmed.ncbi.nlm.nih.gov/40446886/,This research likely explores the use of Holter monitoring to quantify premature ventricular complexes (PVCs) in patients with cardiac implantable electronic devices. The study may compare the effectiveness of Holter monitoring versus other methods for detecting and measuring PVCs in this patient population.
40491054,Health insurance and kidney transplantation outcomes in the United States: a systematic review and AI-driven analysis of disparities in access and survival.,"Kidney transplantation is the preferred treatment for end-stage kidney disease (ESKD) in the United States, yet access and outcomes vary by insurance type, race, and socioeconomic status. This systematic review synthesizes U.S.-based evidence on how insurance coverage influences transplant waitlisting, access, and outcomes. AI-assisted analysis was used to quantify disparities and propose policy recommendations.A systematic review of MEDLINE, EMBASE, and the Cochrane Database (through November 2024) was conducted to identify studies on insurance-related disparities in U.S. kidney transplantation (PROSPERO: CRD42023484733). AI-assisted synthesis using o3-mini-high (2025) was employed to identify patterns and guide policy development.Among 2,163 records, 14 studies met inclusion criteria. Patients with Medicare or Medicaid-particularly racial and ethnic minorities-had lower referral rates and higher transplant waitlist rejection compared to those with private insurance. Socioeconomic barriers such as low income and limited education further impaired access and worsened post-transplant outcomes. Publicly insured recipients had higher post-transplant mortality and graft failure rates. Loss of Medicare after 36 months was associated with reduced immunosuppressant adherence and increased rejection. Disparities were amplified by Medicaid expansion variability and inconsistent transplant center policies. AI-assisted analysis confirmed these disparities and generated policy proposals including standardized referral guidelines, lifelong immunosuppressant coverage, targeted financial aid, equity-linked incentives for transplant centers, and scalable digital health solutions.Insurance type, race, and socioeconomic status significantly influence kidney transplant access and outcomes. AI-assisted analysis identified structural inequities and informed targeted policy strategies to advance transplant equity and support broader healthcare reform.",Renal failure,"Dec, 2025",2025,Dec,,Garcia Valencia O A|Suppadungsuk S|Thongprayoon C|Ho Y|Siranart N|Wathanavasin W|Jadlowiec C C|Mao S A|Leeaphorn N|Soliman K M|Ali H|Budhiraja P|Miao J|Cheungpasitporn W,Garcia Valencia O A|Suppadungsuk S|Thongprayoon C|Siranart N|Jadlowiec C C|Mao S A|Leeaphorn N|Budhiraja P|Miao J|Cheungpasitporn W,"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.|Chakri Naruebodindra Medical Institute, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.|Trend Research Centre, Asia University, Wufeng, Taiwan.|Nephrology Unit, Department of Medicine, Charoenkrung Pracharak Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand.|Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Pheonix, AZ, USA.|Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Jacksonville, FL, USA.|Department of Medicine, Division of Nephrology, Medical University of South Carolina, Charleston, SC, USA.|Medical Services, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.|Renal and Transplant Department, University Hospitals of Wales, Cardiff, UK.|Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Pheonix, AZ, USA.","Garcia Valencia O A, Suppadungsuk S, Thongprayoon C, Ho Y, Siranart N, Wathanavasin W, Jadlowiec C C, Mao S A, Leeaphorn N, Soliman K M, Ali H, Budhiraja P, Miao J, Cheungpasitporn W",https://pubmed.ncbi.nlm.nih.gov/40491054/,"The study found that patients with public insurance, such as Medicare or Medicaid, and those from racial/ethnic minorities and low socioeconomic backgrounds, have lower rates of being placed on the kidney transplant waitlist and worse post-transplant outcomes compared to those with private insurance. The researchers used AI analysis to identify key policy recommendations, including standardized referral guidelines, lifelong immunosuppressant coverage, and equity-focused incentives for transplant centers, to address these"
40448332,In Situ Encapsulated/Solid Papillary Breast Carcinoma With Lobular Differentiation.,No abstract available.,International journal of surgical pathology,"Dec, 2025",2025,Dec,,Molina M|Moreno G|Jorns J M,Molina M,"Department of Pathology, Medical College of Wisconsin, Milwaukee, WI, USA.|Department of Laboratory Medicine & Pathology, Mayo Clinic, Rochester, MN, USA.|Heartland Pathology Laboratories, Wichita, KS, USA.","Molina M, Moreno G, Jorns J M",https://pubmed.ncbi.nlm.nih.gov/40448332/,This research likely explores a specific type of breast cancer called in situ encapsulated/solid papillary breast carcinoma with lobular differentiation. It appears to focus on the characteristics and features of this particular form of breast cancer.
40452181,The combination of body mass index and serum creatinine levels predicts survival in patients with Hodgkin lymphoma treated with nivolumab in the CheckMate 205 study.,"Patients with solid tumors and a higher body mass index (BMI) experience improved survival after receiving anti-PD1 antibodies. The predictive role of BMI in Hodgkin Lymphoma (HL), the most sensitive malignancy to PD1-blockade, remains unclear. We analyzed the association between BMI and survival outcomes in patients treated with the anti-PD-1 antibody nivolumab within the CheckMate 205 study. Patients with a lower BMI (<24.03 kg/m2) had a longer progression-free survival (PFS) (46.4% at three years) than those with a higher BMI (≥24.03 kg/m2;19.6%; p = 0.03). Combining the BMI cutoff with serum creatinine (sCr) levels generated a variable (BMCI) stratifying patients into distinct PFS risk groups. Patients with a BMCIhigh (BMI ≥24.03 kg/m2/sCr <0.7 mg/dL) displayed a threefold increased PFS risk (95% CI,1.6-5.7; p < 0.001) than those with a BMCIlow (BMI <24.03 kg/m2/sCr ≥0.7 mg/dL). In a separate analysis of pretreated patients, those with a BMCIhigh had a PFS risk 3.5-fold higher (95% CI,1.9-6.6; p < 0.001) than patients with a BMCIlow. The BMCI maintained its independent significance in a multivariable model including attenuating factors and predictive biomarkers. HL patients with reduced BMI but preserved lean body mass (BMCIlow) exhibit a more favorable response to nivolumab. Results highlight an unexpected side of the 'obesity paradox' in HL.",Oncoimmunology,"Dec, 2025",2025,Dec,,De Filippi R|Morabito F|Tripepi G|Ansell S M|Mele S|Morelli E|Mallardo D|Donnarumma D|Volzone F|Akyol A|Cuccaro A|Saggese M|Bonanni M|Esposito M|Crisci S|Zinzani P L|Pinto A,Ansell S M,"Dipartimento di Medicina Clinica e Chirurgica, Università degli Studi Federico II, Naples, Italy.|Ematologia Oncologica e Trapianto di Cellule Staminali, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.|Consiglio Nazionale delle Ricerche, Istituto di Fisiologia Clinica del Consiglio Nazionale delle Ricerche (CNR), Reggio, Calabria, Italy.|Division of Hematology, Mayo Clinic, Rochester, MN, USA.|Dipartimento Melanoma, Immunologia Oncologica Sperimentale e Terapie Innovative, Istituto Nazionale Tumori-IRCCS-Fondazione 'G. Pascale', Naples, Italy.|Bristol Myers Squibb, Princeton, NJ, USA.|IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ""Seràgnoli"" and Università di Bologna, Bologna, Italy.","De Filippi R, Morabito F, Tripepi G, Ansell S M, Mele S, Morelli E, Mallardo D, Donnarumma D, Volzone F, Akyol A, Cuccaro A, Saggese M, Bonanni M, Esposito M, Crisci S, Pinto A, et al.",https://pubmed.ncbi.nlm.nih.gov/40452181/,The study found that Hodgkin lymphoma patients with a lower body mass index (BMI) and higher serum creatinine levels had better survival outcomes when treated with the immunotherapy drug nivolumab. This suggests that the combination of BMI and serum creatinine levels could be used to predict how well patients with Hodgkin lymphoma will respond to nivolumab treatment.
40459273,Implantable Vagus Nerve Stimulator-Paired Neurorehabilitation for Upper Limb Function After Ischemic Stroke: Evidence From a Systematic Review and Meta-Analysis With Best Practice Recommendations.,"Upper limb motor recovery is limited and affects functional outcomes in stroke survivors. Recent randomized controlled trials have assessed the role of combining vagus nerve stimulation with standard neurorehabilitation. The aim of this review was to evaluate the effectiveness of pairing implanted vagus nerve stimulation (I-VNS) with rehabilitation therapy in ischemic stroke patients and to provide a framework for its integration into standard clinical practice.We searched PubMed, Scopus, CINAHL Plus, Cochrane Central Register of Controlled Trials, and Cochrane Database of Systematic Reviews for articles published from inception to July 2024. Randomized controlled trials and follow-up studies assessing the efficacy and/or safety of I-VNS in stroke rehabilitation were included. The outcomes included upper limb motor function and adverse events related to intervention. The risk of bias was assessed using the Cochrane risk-of-bias tool, and a random-effects model was generated for the meta-analysis using the Meta package in R.The final analysis included 8 studies, with a cumulative sample size of n = 498 patients who underwent I-VNS-paired rehabilitation for upper extremity weakness in unilateral supratentorial stroke. The intervention group (I-VNS) included 245 patients (49.1%) whereas the control group had 252 patients (50.6%). The mean age was 59.0 ± 10.01 years in the intervention group and 61.0 ± 9.7 years in the control group. The intervention group included 155 male patients (63.2%), and the control group had 165 male patients (64.4%). The meta-analyses showed statistically significant improvement in upper limb motor function in the I-VNS-paired rehabilitation group with a mean difference of 2.73 (95% CI: 1.32-4.13; P = .04) in the Fugl-Meyer Assessment for Upper Extremity score. Only one study reported a serious adverse event.A systematic review and meta-analysis of the current literature provides high-level evidence that I-VNS-paired rehabilitation improves functional outcomes and has a favorable safety profile in patients with poststroke upper extremity weakness.Copyright © Congress of Neurological Surgeons 2025. All rights reserved.",Neurosurgery,"Dec 01, 2025",2025,Dec,01,Khan I|Shakir M|Vijayanarasimhan V|Lodhi B A|Parker J J|Miller K J|Khan M|Grewal S S|Ali R,Khan I|Vijayanarasimhan V|Parker J J|Miller K J|Khan M|Grewal S S|Ali R,"Department of Neurological Surgery, University of Missouri, Columbia , Missouri , USA.|Department of Neurological Surgery, Mayo Clinic- Rochester, Rochester , Minnesota , USA.|Department of Neurological Surgery, Mayo Clinic- Jacksonville, Jacksonville , Florida , USA.|Department of Neurological Surgery, Mayo Clinic- Arizona, Scottsdale , Arizona , USA.|Department of Neurology, Mayo Clinic- Rochester, Rochester , Minnesota , USA.","Khan I, Shakir M, Vijayanarasimhan V, Lodhi B A, Parker J J, Miller K J, Khan M, Grewal S S, Ali R",https://pubmed.ncbi.nlm.nih.gov/40459273/,"The key finding of this research is that pairing implantable vagus nerve stimulation with standard rehabilitation therapy significantly improves upper limb motor function in stroke patients, with a favorable safety profile. This suggests that this combined approach could be a promising treatment option to enhance recovery and functional outcomes for stroke survivors with upper extremity weakness."
40459597,Localization of PSMA-avid lesions on PSMA PET-CT on prostate MRI in patients with PI-RADS 3.,"To localize PSMA-avid lesions identified by PSMA PET-CT on separately performed prostate MRI and evaluate imaging findings on fused PET-CT/MRI.Patients without prior history of clinically significant prostate cancer (csPCa: Gleason score [GS] 3 + 4 or higher) who had (1) PI-RADS 3 on prostate MRI between 2021 and 2023, (2) MRI/US fusion targeted biopsy for PI-RADS 3 lesion(s) and systemic biopsy, and (3) subsequent PSMA PET-CT were identified. PSMA PET-CT images were fused onto prostate MRI. PI-RADS 3 lesions were categorized by PRIMARY score. Discordant PSMA-avid lesions with PRIMARY scores 2-5 outside of PI-RADS 3 lesions were identified. Fisher's exact test was used to compare the proportion of csPCa on targeted biopsy between PSMA-positive (PRIMARY score 3 or more) and PSMA-negative (PRIMARY score 1 or 2) PI-RADS 3 lesions. P < 0.05 was considered statistically significant.30 patients (mean age 67 years) with 38 PI-RADS 3 lesions were identified. 29 patients had csPCa, and one patient had GS 6. 22 PI-RADS 3 lesions were PSMA-positive (PRIMARY score 3 or more), of which 18 (81.8%) were csPCa on targeted biopsy; 16 PI-RADS 3 lesions were PSMA-negative, of which 4 (25.0%) were csPCa on targeted biopsy (p < 0.001). Sensitivity and specificity for the presence of csPCa on targeted biopsy was 81.8% and 75.0%. Out of 30 patients, 12 (40.0%) had 16 discordant PSMA-avid (PRIMARY score 2 or more) lesions and 10 patients had 10 discordant PSMA-positive lesions outside PI-RADS 3 lesions In 5 of those 12 (41.7%), discordant PSMA-avid lesions had higher PRIMARY score than PI-RADS 3 lesions. In 4 of those 5 (80%), systemic biopsy showed higher GS than targeted biopsy.Lesion-level analysis showed PSMA-positive PI-RADS 3 lesions had higher probability of csPCa than PSMA-negative PI-RADS 3 lesions. Discordant PSMA-avid lesions with higher PRIMARY score than that of PI-RADS 3 lesions often represented another more aggressive focus not initially identified on MRI.© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",Abdominal radiology (New York),"Dec, 2025",2025,Dec,,Takahashi H|Nakai H|Ballman K V|Lomas D J|Mynderse L A|Kawashima A|Huang S|Legout J D|Young J R|Thorpe M P|Johnson G B|Karnes R J|Sartor A O|Takahashi N,Takahashi H|Nakai H|Ballman K V|Lomas D J|Mynderse L A|Kawashima A|Huang S|Legout J D|Young J R|Thorpe M P|Johnson G B|Karnes R J|Sartor A O|Takahashi N,"Department of Radiology, Mayo Clinic, Rochester, MN, USA. Takahashi.Hiroaki@mayo.edu.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Urology, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Mayo Clinic, Phoenix, AZ, USA.|Department of Radiology, Mayo Clinic, Jacksonville, FL, USA.|Department of Oncology, Mayo Clinic, Rochester, MN, USA.","Takahashi H, Nakai H, Ballman K V, Lomas D J, Mynderse L A, Kawashima A, Huang S, Legout J D, Young J R, Thorpe M P, Johnson G B, Karnes R J, Sartor A O, Takahashi N",https://pubmed.ncbi.nlm.nih.gov/40459597/,"This study found that prostate cancer lesions that are PSMA-positive (have high PSMA uptake) on PET-CT scans are more likely to be clinically significant prostate cancer compared to PSMA-negative lesions, even if they are classified as PI-RADS 3 on MRI. Additionally, the study identified cases where PSMA-positive lesions outside of the PI-RADS 3 lesions represented more"
40476726,Single-Fraction Stereotactic Radiosurgery as Primary Management of Sporadic Meningiomas: A 25-Year Cohort Study.,"Stereotactic radiosurgery (SRS) is increasingly used as a primary treatment modality for intracranial meningiomas. We aim to describe clinical outcomes after single-fraction SRS for sporadic intracranial meningiomas.A prospectively maintained database was reviewed for patients with sporadic meningiomas who underwent SRS (Gamma Knife) as primary treatment modality from April 1997 to February 2022. Primary outcomes included progression-free survival (PFS) and treatment-related complications.Six hundred sixteen patients (653 tumors) underwent SRS with median follow-up of 6.3 years (interquartile range [IQR] 3.1-10.5 years). The median tumor volume was 4.5 cm 3 (IQR 2.0-8.0 cm 3 ). The median margin dose was 15.0 Gy (IQR 14.0-16.0). In-field progression was noted in 7 tumors (1.1%) and marginal progression in 2 tumors (0.3%) for a raw failure rate of 1.4%. PFS estimates at 5, 10, and 15 years were 99.8%, 99.0%, and 93.2%, respectively. Factors associated with reduced PFS on univariable analysis included older age (hazards ratio [HR] 1.14, 95% CI, 1.05-1.22, P < .001), male sex (HR 5.44, 95% CI, 1.45-20.4, P = .010), increasing tumor volume (HR 1.06, 95% CI, 0.99-1.13, P = .028), and lower tumor margin dose (HR 0.65, 95% CI, 0.43-0.97, P = .006). Treatment-related complications were noted in 56 patients (9.1%), of which 45 (7.3%) were temporary, 5 (0.8%) were minor, and 6 (1.0%) were permanent and/or required intervention. Radiosurgical parameters associated with treatment-related complications included increased number of isocenters (odds ratio [OR] 1.09, 95% CI, 1.04-1.14, P < .001), higher 12-Gy volume (OR 1.06, 95% CI, 1.03-1.09, P < .001), larger tumor volume (OR 1.06, 95% CI, 1.02-1.10, P < .001), and lower maximal dose (OR 0.90, 95% CI, 0.82-0.98, P = .11).SRS is effective as a primary treatment modality for sporadic, small-volume to medium-volume intracranial meningiomas. Pre-emptive SRS should be discussed as a safe management strategy compared with observation alone for incidentally discovered meningiomas.Copyright © Congress of Neurological Surgeons 2025. All rights reserved.",Neurosurgery,"Dec 01, 2025",2025,Dec,01,Kumar R|Carlstrom L P|Morshed R|Brown P D|Laack N N|Mahajan A|Graffeo C S|Link M J|Pollock B E,Kumar R|Morshed R|Brown P D|Laack N N|Mahajan A|Link M J|Pollock B E,"Department of Neurologic Surgery, Mayo Clinic, Rochester , Minnesota , USA.|Department of Neurological Surgery, Southern California Kaiser Permanente Medical Group, San Diego , California , USA.|Department of Radiation Oncology, University of California, San Diego , California , USA.|Department of Radiation Oncology, Mayo Clinic, Rochester , Minnesota , USA.|Department of Neurologic Surgery, University of Oklahoma, Oklahoma City , Oklahoma , USA.","Kumar R, Carlstrom L P, Morshed R, Brown P D, Laack N N, Mahajan A, Graffeo C S, Link M J, Pollock B E",https://pubmed.ncbi.nlm.nih.gov/40476726/,"This study found that single-fraction stereotactic radiosurgery (SRS) is an effective primary treatment for small to medium-sized sporadic intracranial meningiomas, with high long-term progression-free survival rates and relatively low rates of treatment-related complications. This suggests that SRS could be a safe and effective alternative to observation for managing incidentally discovered meningiomas."
40481705,Sustained Response to PD-1 Inhibitor in an Adolescent With Recurrent Metastasis of Melanoma of Spitzoid Features.,No abstract available.,International journal of dermatology,"Dec, 2025",2025,Dec,,Tran T S|Nguyen G H|Guo R,Tran T S|Nguyen G H|Guo R,"Department of Dermatology, Mayo Clinic, Rochester, Minnesota, USA.|National Hospital of Dermatology and Venereology, Hanoi, Vietnam.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, Florida, USA.|Department of Dermatology, Mayo Clinic, Jacksonville, Florida, USA.","Tran T S, Nguyen G H, Guo R",https://pubmed.ncbi.nlm.nih.gov/40481705/,"This research likely explores the effectiveness of a specific type of cancer treatment, called PD-1 inhibitor, in treating a rare form of skin cancer called melanoma with Spitzoid features in an adolescent patient. The research focuses on the sustained response, or long-lasting positive effect, of this treatment in a patient with recurrent, or returning, metastatic disease, which means the cancer has spread to other parts of the body."
40953318,Adults With Type 2 Diabetes Benefit From Automated Insulin Delivery Irrespective of C-Peptide Level.,"The Centers for Medicare & Medicaid Services (CMS) requires a low C-peptide level for insulin pump coverage unless the individual is β-cell autoantibody positive, which precludes coverage of automated insulin delivery (AID) systems for many people with type 2 diabetes.In the Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy study evaluating the t:slim X2 insulin pump with Control-IQ+ technology, adults with insulin-treated type 2 diabetes were categorized into high C-peptide (n = 195) and low C-peptide (n = 59) groups based on CMS criteria.In the AID group, mean HbA1c decreased from baseline by 0.8%, which was significantly greater than in the control group with both high (P < 0.001) and low (P = 0.02) C-peptide levels. Results were similar in participants ≥65 years old.The benefit of AID is present with high and low C-peptide levels. Thus, requiring a low C-peptide level as a prerequisite for AID therapy is not warranted.© 2025 by the American Diabetes Association.",Diabetes care,"Dec 01, 2025",2025,Dec,01,Hirsch I B|Kudva Y C|Ahn D T|Blevins T|Rickels M R|Raghinaru D|Lum J W|Kollman C|Pinsker J E|Beck R W,Kudva Y C,"University of Washington School of Medicine, Seattle, WA.|Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department of Internal Medicine, Mayo Clinic, Rochester, MN.|Mary & Dick Allen Diabetes Center, Hoag Memorial Hospital Presbyterian, Newport Beach, CA.|Texas Diabetes and Endocrinology, Austin, TX.|Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.|Jaeb Center for Health Research, Tampa, FL.|Tandem Diabetes Care, San Diego, CA.","Hirsch I B, Kudva Y C, Ahn D T, Blevins T, Rickels M R, Raghinaru D, Lum J W, Kollman C, Pinsker J E, Beck R W",https://pubmed.ncbi.nlm.nih.gov/40953318/,"This study found that adults with type 2 diabetes, regardless of their C-peptide levels, benefited from using automated insulin delivery systems. The key finding is that the requirement of a low C-peptide level for insurance coverage of these systems is not necessary, as the systems were effective in improving blood sugar control in people with both high and low C-peptide levels."
40955059,Toward an Unbiased Deep Learning Classifier of Pediatric Middle Ear Disease.,"Otitis media is the leading cause of healthcare visits and antibiotic prescriptions for children in the United States. Differentiating acute otitis media (AOM) from otitis media with effusion (OME) is crucial for antibiotic stewardship but is often difficult. The objective was to train an artificial intelligence algorithm that accurately predicts the presence and nature of middle ear effusion in pediatric patients using pediatric tympanic membrane (TM) images captured with inexpensive, consumer-grade otoscopes.Prospective cohort study.Tertiary Children's Hospitals.A multicenter study gathered ear images from children aged 6 months to 10 years undergoing myringotomy and tube placement at four pediatric hospitals in the United States. Images were taken with over-the-counter digital otoscopes. Intraoperative middle ear findings were used to label the images. A deep learning algorithm was trained to classify middle ear disease. Performance was assessed by weighted accuracy.From a diverse population of 219 children (42.14% black, Hispanic, Asian, and other), 737 images were obtained, categorized as AOM (73), OME (190), no effusion or infection (274), and no TM in image (200). The classification model achieved a weighted accuracy of 92.5%, ranging 88.4% to 98.8% per individual category.The model demonstrated high accuracy in classifying the middle ear state in young, anesthetized children. Developing an effective deep learning model using diverse, age-representative images from affordable digital otoscopes may move us closer to real-world applications of such technology in clinical practice to validate the role of telemedicine and improve antibiotic stewardship.© 2025 American Academy of Otolaryngology–Head and Neck Surgery Foundation.",Otolaryngol Head Neck Surg,"Dec, 2025",2025,Dec,,Surapaneni S|Rangarajan N|Davis K|Pletcher K|Flowers J|Strub G|Nolder A|King D|Marston A P|Vecchiotti M|Alfonso K|Evans S|Deshpande A|Prickett K|Landry A|Goudy S|Govil N|Messner A|Richter G|Scott A R|Mehta D|Hill C A,Surapaneni S,"College of Human Medicine, Michigan State University, Rochester Hills, Michigan, USA.|Glimpse Diagnostics Inc, Minneapolis, Minnesota, USA.|Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.|Department of Otolaryngology-Head and Neck Surgery, Saint Louis University, St. Louis, Missouri, USA.|College of Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.|Pediatric Otolaryngology, Arkansas Children's Hospital, Little Rock, Arkansas, USA.|Tufts Medical Center, Division of Pediatric Otolaryngology, Boston, Massachusetts, USA.|Department of Otolaryngology-Head and Neck Surgery, University of California Davis, Davis, California, USA.|Department of Otolaryngology, Boston University School of Medicine, Boston, Massachusetts, USA.|Children's Healthcare of Atlanta, Division of Pediatric Otolaryngology, Atlanta, Georgia, USA.|Department of Otolaryngology, Emory School of Medicine, Atlanta, Georgia, USA.|Texas Children's Hospital Pediatric Otolaryngology, Houston, Texas, USA.|Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas, USA.|Division of Pediatric Otolaryngology, Mass Eye and Ear, Boston, Massachusetts, USA.","Surapaneni S, Rangarajan N, Davis K, Pletcher K, Flowers J, Strub G, Nolder A, King D, Marston A P, Vecchiotti M, Alfonso K, Evans S, Deshpande A, Prickett K, Landry A, Hill C A, et al.",https://pubmed.ncbi.nlm.nih.gov/40955059/,"This study developed a deep learning algorithm that can accurately classify different types of middle ear disease in children using images from inexpensive digital otoscopes. The algorithm achieved a high accuracy of 92.5% in identifying acute otitis media, otitis media with effusion, and normal middle ear conditions. This technology has the potential to improve antibiotic stewardship and enable telemedicine applications for diagnosing pediatric ear infections."
40956071,"Pneumocystis jirovecii Pneumonia in Patients Without HIV, Transplant, or Cancer: Missed Opportunities for Prevention.","Pneumocystis jirovecii pneumonia (PJP) is life-threatening for immunocompromised patients. No consensus exists on PJP prophylaxis for immunosuppressed patients without HIV, transplant, or cancer.We retrospectively reviewed the electronic health records of adult immunosuppressed patients with PJP diagnosed between 1990 and 2020 at Mayo Clinic. Patients with HIV, solid organ transplants, or cancer were excluded. Demographic data, treatments, and outcomes were manually abstracted.The most common indications for immunosuppression were rheumatoid arthritis (19.7%), vasculitis (18.1%), and interstitial lung disease (ILD) not related to connective tissue disease (17.6%). Despite having high risk of PJP, 86.0% of patients did not receive PJP prophylaxis. Corticosteroids were the most common immunosuppressive agent used (84.5%), with 64.4% of patients receiving high-dose treatment. Nonbiologic disease-modifying antirheumatic drugs were used for 49.7%, including methotrexate (51.0%), azathioprine (22.9%), and hydroxychloroquine (11.5%). Biologics were prescribed for 25.4%, primarily rituximab (59.2%) and infliximab (22.4%). Hospitalization occurred for 76.7% of patients; 70.3% required intensive care unit (ICU) admission, and 46.6% received mechanical ventilation. The in-hospital mortality rate was 30.4% overall and 53.6% for patients on ventilation. Predictors of death included ILD [odds ratio (OR), 4.61; 95% CI, 1.75-13.00], ICU admission (OR, 3.60; 95% CI, 1.19-11.08), and ventilator use (OR, 3.46; 95% CI, 1.30-9.79). Biologic use was associated with lower odds of death (OR, 0.34; 95% CI, 0.11-0.89).Most patients in our cohort did not receive PJP prophylaxis, and outcomes were poor with high mortality rates. Standardized risk stratification and prophylaxis protocols are needed to improve outcomes.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",J Clin Rheumatol,"Dec 01, 2025",2025,Dec,01,Challener G J|El Labban M|Kanj A N|Ortiz Jaimes G E|Leung S B|Ryu J H|Baqir M,El Labban M|Kanj A N|Ortiz Jaimes G E|Leung S B|Ryu J H|Baqir M,"Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA.|Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.|Resident in the Division of Pulmonary and Critical Care Medicine, Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, MN.|Pharmacy Services, Mayo Clinic, Rochester, MN.","Challener G J, El Labban M, Kanj A N, Ortiz Jaimes G E, Leung S B, Ryu J H, Baqir M",https://pubmed.ncbi.nlm.nih.gov/40956071/,"The key finding of this medical research is that most immunosuppressed patients without HIV, transplant, or cancer who developed Pneumocystis jirovecii pneumonia (PJP) did not receive preventive treatment, and they had high rates of hospitalization, intensive care unit admission, and mortality. This highlights the need for standardized risk assessment and prophylaxis protocols to improve outcomes for these high-risk patients."
40957179,Temporomandibular joint disorder: Etiologies and treatments (part 2).,"Temporomandibular joint (TMJ) disorders (TMDs) are complex conditions affecting the joint and associated musculoskeletal structures, causing pain and functional impairment. This review explores the anatomical basis, etiological factors, and therapeutic strategies for TMD, emphasizing the interplay between TMJ anatomy, pathophysiology, and treatment outcomes. Myogenous and arthrogenous TMDs present distinct anatomical challenges, requiring targeted interventions. Key findings highlight the efficacy of conservative therapies, including behavioral interventions, physical therapies, and occlusal splints, as first-line treatments, followed by low-level laser therapy (LLLT), transcutaneous electrical nerve stimulation (TENS), and dry needling for myofascial pain. Botulinum toxin-A (BoNT-A) (De la Torre Canales G et al., 2024 [1]) is effective for persistent myogenous TMD but reserved for cases unresponsive to first-line treatments. Emerging therapies, such as platelet-rich plasma (PRP) and 3D-printed implants, show promise for refractory cases. This review aims to advance the understanding of TMD from an anatomical perspective, providing evidence-based insights for clinicians and researchers. Part 1 of this series, ""Temporomandibular Disorder: The Anatomy of Pain"", details TMJ anatomy and pain pathways, forming the foundation for this analysis.Copyright © 2025 Elsevier Masson SAS. All rights reserved.",Morphologie : bulletin de l'Association des anatomistes,"Dec, 2025",2025,Dec,,Nieves Del Rio S|Iwanaga J|Shane Tubbs R|Loukas M,Shane Tubbs R|Loukas M,"Department of Anatomical Sciences, St. George's University, School of Medicine, Grenada, West Indies, Grenada; Department of Emergency Medicine, Nuvance Health Vassar Brothers Medical Center, Poughkeepsie, NY, United States.|Department of Neurosurgery, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Neurology, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Structural & Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Neurosurgery and Ochsner Neuroscience Institute, Ochsner Health System, New Orleans, Louisiana, United States; Dental and Oral Medical Center, Kurume University School of Medicine, Fukuoka, Japan; Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan; Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, United States; University of Queensland, Brisbane, Australia.|Department of Anatomical Sciences, St. George's University, School of Medicine, Grenada, West Indies, Grenada; Department of Neurosurgery, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Neurology, Clinical Neuroscience Research Center, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Structural & Cellular Biology, Tulane University School of Medicine, New Orleans, Louisiana, United States; Department of Neurosurgery and Ochsner Neuroscience Institute, Ochsner Health System, New Orleans, Louisiana, United States; Dental and Oral Medical Center, Kurume University School of Medicine, Fukuoka, Japan; Division of Gross and Clinical Anatomy, Department of Anatomy, Kurume University School of Medicine, Fukuoka, Japan; Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, United States; University of Queensland, Brisbane, Australia; Department of Pathology, St. George's University, School of Medicine, Grenada, West Indies, Grenada; Department of Clinical Anatomy, Mayo Clinic, Rochester, Minnesota, United States.|Department of Anatomical Sciences, St. George's University, School of Medicine, Grenada, West Indies, Grenada; Department of Pathology, St. George's University, School of Medicine, Grenada, West Indies, Grenada; Department of Clinical Anatomy, Mayo Clinic, Rochester, Minnesota, United States; Nicolaus Copernicus Superior School, College of Medical Sciences, Olsztyn, Poland. Electronic address: mloukas@sgu.edu.","Nieves Del Rio S, Iwanaga J, Shane Tubbs R, Loukas M",https://pubmed.ncbi.nlm.nih.gov/40957179/,"This review explores the causes and treatments of temporomandiboral joint (TMJ) disorders, which can cause pain and difficulty with jaw movement. The key finding is that conservative therapies, such as behavioral interventions, physical therapy, and dental splints, are often effective as first-line treatments, followed by more advanced therapies like laser therapy and botulinum toxin injections for persistent cases. This research provides evidence-based guidance for clinicians to manage these complex conditions."
41197348,Efficacy and safety of onabotulinumtoxin A in the treatment of platysma prominence: A systematic review and meta-analysis of randomized clinical trials.,"The platysma muscle influences lower face and neck aesthetics and expression. Aging can lead to platysma prominence (PP), manifesting as visible neck bands that affect appearance and well-being. Although surgical treatments exist, they are invasive and carry notable risks. This systematic review and meta-analysis evaluated the efficacy and safety of onabotulinumtoxinA for treating PP.We systematically searched the PubMed, Cochrane Library, and Embase databases through May 2025 for studies comparing onabotulinumtoxinA with placebo. Primary outcomes were ≥1-grade bilateral neck improvement on Participant Allergan Platysma Prominence Scale (P-APPS) and Clinician Allergan Platysma Prominence Scale (C-APPS) at days 14, 60, and 120. Secondary outcomes included patient satisfaction evaluated using the Appearance of Neck and Lower Face Questionnaire and safety indicators such as bruising, hemorrhage, post-dose swallowing or talking difficulties, and other adverse events.Three randomized controlled trials with 1003 intention-to-treat and 912 modified intention-to-treat patients were included. OnabotulinumtoxinA significantly improved P-APPS on days 14 (RR 3.64), 60 (RR 3.46), and 120 (RR 2.57), and C-APPS on days 14 (RR 4.03), 60 (RR 3.73), and 120 (RR 2.21), all p < 0.01. Patient satisfaction was also higher on days 14 (RR 5.71), 60 (RR 5.56), and 120 (RR 5.29), all p < 0.01. No significant differences were found in the safety outcomes between the onabotulinumtoxinA and placebo groups.OnabotulinumtoxinA provides significant and sustained improvements in aesthetic and psychosocial outcomes in patients with PP, without increased risk of adverse events. These findings support its role as a less invasive and effective alternative to surgery.Copyright © 2025 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by Elsevier Ltd. All rights reserved.","Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Dec, 2025",2025,Dec,,Udoma-Udofa O C|Ribeiro L F S|de Freitas L R|de Sousa R A|Borges M d S|de Oliveira T T C|Rajan D|Kreutz-Rodrigues L,Kreutz-Rodrigues L,"Faculty of Medicine, Federal University of Juiz de Fora, Minas Gerais, Brazil. Electronic address: chanrich2000@gmail.com.|Faculty of Medicine, Federal University of São João del-Rei, Divinópolis, Brazil. Electronic address: luizfabioribeiro415@gmail.com.|Faculty of Medicine, Federal University of Juiz de Fora, Minas Gerais, Brazil. Electronic address: lucasrezendedefreitas1@gmail.com.|Faculty of Medicine, Federal University of São João del-Rei, Divinópolis, Brazil. Electronic address: rodrigoalvesmn13@gmail.com.|Faculty of Medicine, Faculty of Minas, Belo Horizonte, Minas Gerais, Brazil. Electronic address: maisaborrges@gmail.com.|Faculty of Medicine, Federal University of São João del-Rei, Divinópolis, Brazil. Electronic address: tauanaterra17@gmail.com.|Faculty of Medicine, Amrita Institute of Medical Sciences, Kochi, India. Electronic address: divyarajan022@gmail.com.|Division of Plastic Surgery, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Electronic address: kreutzrodrigues.lucas@mayo.edu.","Udoma-Udofa O C, Ribeiro L F S, de Freitas L R, de Sousa R A, Borges M d S, de Oliveira T T C, Rajan D, Kreutz-Rodrigues L",https://pubmed.ncbi.nlm.nih.gov/41197348/,"This study found that the use of onabotulinumtoxinA, a type of botulinum toxin, significantly improved the appearance of neck bands (platysma prominence) and increased patient satisfaction, without increasing the risk of adverse events. These findings suggest that onabotulinumtoxinA is an effective and safe alternative to surgical treatments for this common aesthetic concern."
41198633,Advancing kidney care in critical illness - from pathophysiology to precision interventions.,No abstract available.,Current opinion in critical care,"Dec 01, 2025",2025,Dec,01,Kashani K,Kashani K,"Division of Nephrology and Hypertension.|Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.",Kashani K,https://pubmed.ncbi.nlm.nih.gov/41198633/,This research likely explores ways to improve the care and treatment of kidney problems that occur during critical illness. It may focus on understanding the underlying causes of these kidney issues and developing more targeted or personalized interventions to address them.
41198637,The role of diuretics in ICUs: when? which? how?,"The diuretic agents are commonly used in ICUs for various purposes. Despite the widespread utilization of diuretics, there remains substantial ambiguity regarding their indications, ICU-related changes in their pharmacodynamics and pharmacokinetics, dosing, form, and timing of administration, the differences in their utilities based on each organ failure, and their monitoring and safety issues.In the recent past, there have been several clinical trials and large registries or systematic reviews with a focus on the use of diuretic agents in ICUs.In this review article, we outline the essential changes in drug behavior during critical illnesses and organ failures, describe the indications of their use in ICUs (management of fluid overload, electrolyte imbalances, or diagnostic or prognostic tests), assess the impact of different organ failures on the utility and effectiveness of diuretics, review major recent clinical trials related to diuretic comparison, use of multiple classes of diuretics, and monitoring and safety of their use. We also provide some information regarding the safety and adverse effects of diuretic use in the ICU and outline the importance of individualizing their use during critical illnesses.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Current opinion in critical care,"Dec 01, 2025",2025,Dec,01,Kashani K B|Kazory A|de Backer D,Kashani K B,"Division of Nephrology and Hypertension, Division of Pulmonary and Critical Care Medicine, Department of Medicine, Mayo Clinic, Rochester, Minnesota.|Division of Nephrology, Department of Medicine; University of Florida (UF), Gainesville, Florida, USA.|Department of Intensive Care, CHIREC Hospitals, Université Libre de Bruxelles (ULB), Brussels, Belgium.","Kashani K B, Kazory A, de Backer D",https://pubmed.ncbi.nlm.nih.gov/41198637/,"This medical research examines the use of diuretics, or drugs that help remove excess fluid from the body, in intensive care units (ICUs). The key finding is that while diuretics are commonly used in ICUs, there is still uncertainty around when to use them, which type to use, and how to monitor their use and safety. The research highlights the importance of individualizing diuretic use based on a patient's specific condition and organ function during critical illness."
41199600,"Vibe Coding in nephrology education: clinician-led, AI-assisted development of open-source interactive learning tools.","Medical education increasingly incorporates digital technologies; however, many tools remain passive and text-based. Vibe Coding is a clinician-led design framework that embeds expert reasoning and the cognitive 'feel' of clinical decision-making into interactive educational tools. This study demonstrates its application in nephrology training through the rapid development of open-source, AI-assisted, web-based applications. We conducted a proof-of-concept development study using a structured, physician-led, AI-assisted process combining (1) deconstruction of clinical algorithms, (2) natural-language-to-code generation with modern large language models, and (3) iterative refinement of user interfaces. The target audience included nephrology trainees and educators, with source content derived from peer-reviewed educational literature. Four open-source, web-based applications were developed: (1) Kidney Stone Navigator for 24-hour urine analysis interpretation, (2) NephroFlow CKRT Clinical Copilot for dose and anticoagulation management, (3) Renal Tubular Acidosis Diagnostic Assistant for algorithmic diagnosis, and (4) Interactive Guide to Disorders of Volume for dynamic visualization of pathophysiology. Each tool mirrored expert reasoning, integrated automated calculations, and was publicly released on GitHub with live deployment for global educational use. Clinician-led, AI-assisted development enables the translation of static educational materials into interactive, open-access tools. The Vibe Coding framework demonstrates a scalable, reproducible model for innovation in medical education and supports transparent digital scholarship in nephrology.",Renal failure,"Dec, 2025",2025,Dec,,Pesce F|Cheungpasitporn W,Cheungpasitporn W,"Division of Renal Medicine, Ospedale Isola Tiberina - Gemelli Isola, Rome, Italy.|Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy.|Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.","Pesce F, Cheungpasitporn W",https://pubmed.ncbi.nlm.nih.gov/41199600/,"The study demonstrates a clinician-led, AI-assisted framework called ""Vibe Coding"" that rapidly develops interactive, open-source learning tools for nephrology education. The framework combines clinical expertise, natural language processing, and iterative user interface design to create web-based applications that mirror expert reasoning and automate calculations. This approach enables the translation of static educational materials into engaging, accessible tools for trainees and educators worldwide."
41200535,Efficacy and Safety of Radiosurgery in Cavernous Sinus Meningioma: A Systematic Review and Single Meta-Analysis.,"Meningiomas are the most common primary central nervous system tumors, with cavernous sinus meningiomas (CSMs) making up a small fraction (1% of intracranial tumors). CSMs are challenging to treat due to their location and potential invasion. Therapy methods have shifted from aggressive resections to less invasive techniques such as stereotactic radiosurgery, reducing morbidity and improving survival. This study reviews the effectiveness and safety of radiosurgery for CSMs, blending historical and contemporary approaches to guide future treatments.A search was performed in MEDlINE, Embase, and Cochrane databases, following Cochrane and Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. Eligible studies included randomized or observational studies with ≥4 patients reporting on radiosurgery for CSM. The random-effects model was used to calculate a single proportion analysis with 95% CIs. Statistical analyses were performed using RStudio.Twenty seven studies, encompassing 1851 patients, were included in this analysis, with a population median age of 27 years. Outcomes were assessed as follows: the 10-year progression-free survival rate was 87% (323 patients; 95% CI: 73%-100%; I2 = 89.6%), clinical deterioration occurred in 6% of cases (957 patients; 95% CI: 3%-8%; I2 = 71.3%), clinical improvement was observed in 35% of patients (1106 patients; 95% CI: 27%-43%; I2 = 86.6%), major complications rate was 4% (688 patients; 95% CI: 1%-6%; I2 = 71.8%), and minor complications was 2% (653 patients; 95% CI: 0%-3%; I2 = 68.6%).This study reveals stereotactic radiosurgery as an effective treatment of CSMs, showing high long-term progression-free survival and significant tumor control with few complications.© The Author(s) 2025. Published by Wolters Kluwer Health, Inc. on behalf of Congress of Neurological Surgeons.",Neurosurgery practice,"Dec, 2025",2025,Dec,,Palavani L B|Camerotte R|Vilardo M|Vieira Nogueira B|Pari Mitre L|Victor Zattar Ribeiro P|Lepine H|Brenner L B O|Andreão F F|Torregrossa F|Montenegro T S|Bertani R|Moraes F Y|Maldaun M V C|Formentin C,Torregrossa F,"Department of Neurosurgery, Max Planck University Center, Indaiatuba, São Paulo, Brazil.|Department of Neurosurgery, Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.|Department of Neurosurgery, Catholic University of Brasília, Brasília, Brazil.|Department of Neurosurgery, Serra dos Órgãos University Center, Teresópolis, Rio de Janeiro, Brazil.|Faculty of Medicine, Santa Casa de São Paulo School of Medical Sciences, São Paulo, Brazil.|Department of Medical Genetics, State University of São Paulo, Ribeirão Preto, São Paulo, Brazil.|Department of Neurosurgery, University of São Paulo School of Medicine (FMUSP), São Paulo, Brazil.|Department of Neurosurgery, State University of Ponta Grossa, Ponta Grossa, Paraná, Brazil.|Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Departments of Neurosurgery and Otolaryngology-Head and Neck Surgery, Mayo Clinic Rhoton Neurosurgery and Otolaryngology Surgical Anatomy Program, Rochester, Minnesota, USA.|Department of Neurosurgery, Spectrum Health/Michigan State University, Grand Rapids, Michigan, USA.|Department of Neurosurgery, University of São Paulo, São Paulo, Brazil.|Department of Oncology, Queen's University, Kingston, Canada.|Department of Neurosurgery, Sírio Libanês Hospital, São Paulo, Brazil.|Department of Neurosurgery, State University of Campinas, Campinas, São Paulo, Brazil.","Palavani L B, Camerotte R, Vilardo M, Vieira Nogueira B, Pari Mitre L, Victor Zattar Ribeiro P, Lepine H, Brenner L B O, Andreão F F, Torregrossa F, Montenegro T S, Bertani R, Moraes F Y, Maldaun M V C, Formentin C",https://pubmed.ncbi.nlm.nih.gov/41200535/,"Stereotactic radiosurgery is an effective treatment for cavernous sinus meningiomas, with high long-term progression-free survival and tumor control, and few complications. This less invasive approach has improved outcomes compared to more aggressive surgical resections."
41204444,Dyssynergic Defecation Is Associated With Small Intestinal Bacterial Overgrowth.,"Microbial overgrowth (MO) in the small intestine can cause gastrointestinal symptoms and may arise from stasis, such as dysmotility. Microtypes of MO include small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO). Dyssynergic defecation (DD) is associated with constipation and slow colonic transit (STC). Our aim was to assess the relationship between DD and MO.We retrospectively identified patients who underwent both anorectal manometry (ARM) and balloon expulsion testing (BET) for DD, and MO testing using either small intestinal aspirate culture or breath testing. SIBO was analyzed using two culture thresholds: ≥ 105 CFU/mL and ≥ 103 CFU/mL. Chi-square tests compared positive vs. negative results.436 patients underwent culture of SB aspirates. At the ≥ 105 CFU/mL threshold, 41.7% were diagnosed with SIBO, and 87.4% at ≥ 103 CFU/mL. At ≥ 105 CFU/mL, percent anal relaxation was significantly lower in SIBO-positive patients. SIBO patients were more likely to have reduced anal relaxation (p = 0.032), but no other ARM parameters or BET > 60 s. At ≥ 103 CFU/mL, a more negative recto-anal pressure differential (RAPD) was observed, along with a combination of RAPD < -45 mmHg and resting anal pressure > 90 mmHg. 637 patients underwent breath testing for MO, with 174 positive results, predominantly showing IMO (73%). In this group, BET was significantly longer, and anal relaxation was significantly lower. SIBO at ≥ 103 CFU/mL was more prevalent in DD than STC (85.5% vs. 64.7%, p = 0.002). IMO was more common in DD than STC (p = 0.021).DD may be a risk factor for MO, often with evidence of methanogenesis.© 2025 John Wiley & Sons Ltd.",Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Damianos J A|Matar A|Halawi H|Wang X J|Camilleri M,Damianos J A|Matar A|Halawi H|Wang X J|Camilleri M,"Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Mayo Clinic, Rochester, Minnesota, USA.","Damianos J A, Matar A, Halawi H, Wang X J, Camilleri M",https://pubmed.ncbi.nlm.nih.gov/41204444/,"The key finding of this medical research is that dyssynergic defecation, a condition associated with constipation, is linked to small intestinal bacterial overgrowth and intestinal methanogen overgrowth. This suggests that dyssynergic defecation may increase the risk of these microbial imbalances, which can cause gastrointestinal symptoms. The research highlights the potential connection between bowel function and gut microbiome health."
41207179,Genetic susceptibility and validation of angiographic patterns in Takayasu arteritis.,"Prior studies identified subsets of patients with Takayasu arteritis (TAK) based on angiographic patterns of disease in cohorts from India and North America. This study aimed to validate these patterns in a TAK cohort from Turkey and determine the role of genetics in arterial patterns.421 Turkish patients with TAK underwent angiography of the aorta and branch vessels, with disease involvement characterized in 13 arterial territories. K-means cluster analysis identified angiographically-based subgroups. 282 patients with TAK from Turkey and 115 European-American patients from North America were genotyped. Approximately 6.5 million SNPs were evaluated in a meta-analysis of both cohorts. Logistic regressions identified genetic associations with angiographic clusters (threshold for association: p-value<1x10-5). Associated variants were functionally annotated.Three clusters were identified in Turkish patients, validating the previously-identified cluster pattern. Genome-wide meta-analyses revealed a locus in the solute carrier family gene SLC24A2 in Cluster One as the most significant association (rs2891138, OR = 3.34, p-value = 2.32x10-7). Several genetic loci were associated with Cluster Two, including in LGALSL (rs883021, OR = 0.43, p-value = 1.00X10-5), AK4P3 (rs1072778, OR = 0.39, p-value = 4.07X10-6), and TMEM132B (rs4765045, OR = 3.05, p-value = 6.18X10-6). The most significant locus associated with Cluster Three was in FRMD6 (rs55692665, OR = 2.79, p-value = 1.11X10-7). Genetic effects were consistent between the cohorts. Several loci were associated with levels of mRNA expression in arterial tissues. A Cluster Two-associated variant in APBB2 (rs2465578, OR = 0.35, p-value = 6.69x10-6) showed evidence for chromatin interaction with the NSUN7 promoter and increased aortic NSUN7 expression.Genetic factors are associated with distinct subsets of TAK defined by angiographic pattern of disease.Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.",Journal of autoimmunity,"Dec, 2025",2025,Dec,,Casares-Marfil D|Gribbons K B|Saruhan-Direskeneli G|Kaymaz-Tahra S|Quinn K A|Alibaz-Oner F|Grayson P C|Direskeneli H|Sawalha A H|Merkel P A,,"University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.|Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, USA.|Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey.|Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bahceşehir University, Kadıkoy, Istanbul, Turkey.|National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, USA.|Division of Rheumatology, Department of Internal Medicine, Marmara University, School of Medicine, Istanbul, Turkey.|University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. Electronic address: asawalha@pitt.edu.|University of Pennsylvania, Philadelphia, PA, USA. Electronic address: pmerkel@upenn.edu.","Casares-Marfil D, Gribbons K B, Saruhan-Direskeneli G, Kaymaz-Tahra S, Quinn K A, Alibaz-Oner F, Grayson P C, Direskeneli H, Sawalha A H, Merkel P A",https://pubmed.ncbi.nlm.nih.gov/41207179/,"This study identified three distinct subgroups of Takayasu arteritis (TAK) based on angiographic patterns of disease in a Turkish cohort, validating previous findings. Genetic analysis revealed associations between specific genetic variants and these angiographic subgroups, suggesting that genetic factors contribute to the different patterns of arterial involvement in TAK. These findings provide insights into the underlying genetic basis of the heterogeneity observed in TAK and may have implications for personalized management"
41208055,SMARTER Education for a Global Transplant Workforce.,"IPTA created the SMARTER Initiative to address persistent gaps in pediatric transplant education worldwide. Through webinars, podcasts, case discussions, and interactive resources, SMARTER provides trainees and allied professionals with accessible, peer-reviewed content across all major organ systems. The program is designed for global reach, with downloadable modules, mobile compatibility, and recorded sessions to accommodate different regions and time zones. Since its launch, SMARTER has shown strong engagement, with fellows reporting that the platform helps them prepare for board exams, improve clinical decision-making, and connect learning directly to patient care. Survey feedback highlights high satisfaction and identifies opportunities for further growth, such as expanded case-based modules, procedural videos, and simulation exercises. By reducing disparities in transplant training and supporting collaboration, SMARTER is positioned to strengthen existing curricula and promote a better-prepared, more globally connected transplant workforce.© 2025 Wiley Periodicals LLC.",Pediatric transplantation,"Dec, 2025",2025,Dec,,Raina R|Esquivel C|Smith S|Bajpai R|Johnson J N|McCulloch M|Oh J|Pape L|Bonham C A|Bartosh S|Marks S D|Twombley K,Johnson J N,"Department of Pediatric Nephrology, Akron Children's Hospital, Akron, Ohio, USA.|Department of Nephrology, Akron Nephrology Associates, Cleveland Clinic Akron General Medical Center, Akron, Ohio, USA.|Division of Abdominal Transplantation, Department of Surgery, Stanford University, Palo Alto, California, USA.|Department of Medicine, College of Medicine, Northeast Ohio Medical University, Rootstown, Ohio, USA.|Division of Pediatric Cardiology, Department of Pediatric and Adolescent Medicine, Mayo Clinic Children's Center, Rochester, Minnesota, USA.|Department of Paediatric Nephrology, Red Cross Children's Hospital, University of Cape Town, Cape Town, South Africa.|Department of Pediatric Nephrology, University Medical Center Hamburg/Eppendorf, Hamburg, Germany.|Department of Pediatrics II, University Hospital of Essen, Essen, Germany.|Division of Pediatric Nephrology, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.|Department of Paediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.|NIHR Great Ormond Street Hospital Biomedical Research Centre, UCL Great Ormond Street Institute of Child Health, London, UK.|Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina, USA.","Raina R, Esquivel C, Smith S, Bajpai R, Johnson J N, McCulloch M, Oh J, Pape L, Bonham C A, Bartosh S, Marks S D, Twombley K",https://pubmed.ncbi.nlm.nih.gov/41208055/,"The SMARTER Initiative was created to improve global access to pediatric transplant education through webinars, podcasts, and interactive resources. The program has been well-received by trainees, who report that it helps them prepare for exams, make better clinical decisions, and connect their learning to patient care. By reducing disparities in transplant training and promoting collaboration, SMARTER aims to strengthen existing curricula and support a more globally connected transplant workforce."
41208250,Kidney stones and autosomal dominant polycystic kidney disease: a state-of-the-art review.,"Kidney stones (nephrolithiasis/urolithiasis) are a clinically significant yet underrecognized complication of autosomal dominant polycystic kidney disease (ADPKD), with reported prevalence ranging from 3% to 59% due to differences in diagnostic criteria and study design. Patients with ADPKD are predisposed to uric acid and calcium oxalate stones, driven by metabolic abnormalities, such as low urine pH, hypocitraturia, hyperuricosuria, as well as structural factors including cyst-induced distortion of the collecting system and impaired urinary drainage. These anatomical changes complicate both diagnosis and intervention, posing challenges, such as reduced stone-free rates, longer operative times, increased need for repeat procedures, and higher complication risk. While non-contrast computed tomography (CT) remains the diagnostic gold standard, low-dose CT is preferred to minimize cumulative radiation exposure. Management generally aligns with that of the broader population and includes aggressive hydration, correction of metabolic derangements, dietary modification, and individualized urologic intervention. Tolvaptan, a vasopressin V2 receptor antagonist, may have additional benefit by increasing urine volume, reducing supersaturation, and potentially mitigating stone risk. This review integrates nephrology, urology, and imaging perspectives to summarize the current understanding of nephrolithiasis in ADPKD, including its pathophysiology, clinical manifestations, diagnostic challenges, and management. We propose an ADPKD-specific diagnostic and management algorithm to optimize prevention, evaluation, and treatment of stone disease in this complex population.",Renal failure,"Dec, 2025",2025,Dec,,Borghol A H|Azooz M|Bou Antoun M T|Souvalian L|Shami B|Mina J|Munairdjy Debeh F G|Ghanem A|Sandouk H|Rangarajan V|Hanna D|Naranjo C D|Drexler Y|Norouzi S|Noruzi A|Salih M|Klett D E|Porter I E|Dahl N K|Chebib F T,Borghol A H|Bou Antoun M T|Souvalian L|Shami B|Munairdjy Debeh F G|Ghanem A|Sandouk H|Rangarajan V|Hanna D|Klett D E|Porter I E|Dahl N K|Chebib F T,"Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Jacksonville, FL, USA.|Mayo Clinic Florida PKD Center of Excellence, Jacksonville, FL, USA.|School of Osteopathic Medicine in Arizona (ATSU-SOMA), A.T. Still University, Mesa, AZ, USA.|Department of Nephrology and Hypertension, Cleveland Clinic Foundation, Cleveland, OH, USA.|Department of Medicine, Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, FL, USA.|Department of Nephrology, Loma Linda University, Loma Linda, CA, USA.|Department of Internal Medicine, Division of Nephrology and Transplantation, Erasmus MC Rotterdam, Rotterdam, The Netherlands.|Department of Urology, Mayo Clinic, Jacksonville, FL, USA.|Department of Medicine, Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.","Borghol A H, Azooz M, Bou Antoun M T, Souvalian L, Shami B, Mina J, Munairdjy Debeh F G, Ghanem A, Sandouk H, Rangarajan V, Hanna D, Naranjo C D, Drexler Y, Norouzi S, Noruzi A, Chebib F T, et al.",https://pubmed.ncbi.nlm.nih.gov/41208250/,"Kidney stones are a common complication in people with autosomal dominant polycystic kidney disease (ADPKD). The stones are caused by metabolic and structural changes in the kidneys. Diagnosing and treating kidney stones in ADPKD patients can be challenging, but a combination of lifestyle changes, medication, and specialized procedures can help manage the condition."
41209481,A Comprehensive Analysis on the Impact of Hypothermic Machine Perfusion and its Influence on Delayed Graft Function.,"Delayed graft function (DGF) in deceased-donor kidney transplantation increases morbidity, prolongs hospitalization, and increases healthcare costs. Hypothermic machine perfusion (HMP) has emerged as a promising strategy to reduce DGF; however, large-scale real-world data remain limited.We performed a retrospective cohort analysis using the Scientific Registry of Transplant Recipients (2014-2024), including adult dialysis-dependent recipients of deceased-donor kidneys preserved using either static cold storage (SCS) or HMP. The primary outcome was DGF, defined as dialysis requirement within 7 d posttransplant. A matched-pairs analysis was conducted using kidneys from the same donor.The overall cohort included 59 859 recipients (46.8% SCS, 53.2% HMP), with 2208 matched pairs identified. In the overall cohort, HMP grafts had longer cold ischemia times and a higher kidney donor risk index. They were more frequently obtained from older and donation after circulatory death donors. Although the overall DGF incidence was higher with HMP (34.4% versus 30.9%, P < 0.001), matched-pairs analysis revealed significantly lower DGF rates with HMP (29.8% versus 36.1%, P < 0.001). Adjusted analyses identified HMP as protective against DGF (overall cohort odds ratio, 0.71; 95% confidence interval, 0.66-0.78; paired cohort OR, 0.68; 95% CI, 0.50-0.93). Additional modifiable risk factors include prolonged cold ischemia time, higher recipient body mass index, and longer dialysis duration.This real-world study demonstrates that HMP is associated with a significant reduction in DGF risk in kidney transplantation compared with SCS, supporting its broader implementation and targeted management of modifiable risk factors.Copyright © 2025 The Author(s). Transplantation Direct. Published by Wolters Kluwer Health, Inc.",Transplantation direct,"Dec, 2025",2025,Dec,,Li Z|Mahgoub M Y|Alrifai A Z A|Smith B|Ryan R J|Mour G K|Jadlowiec C C|Issa N|Cortez A R|Riad S,Li Z|Mahgoub M Y|Alrifai A Z A|Smith B|Ryan R J|Mour G K|Jadlowiec C C|Issa N|Cortez A R|Riad S,"Division of Transplantation Surgery, Mayo Clinic Transplant Center, Rochester, MN.|Nephrology and Hypertension, Mayo Clinic Transplant Center, Rochester, MN.|Biomedical Statistics and Informatics, Mayo Clinic Transplant Center, Rochester, MN.|Division of Transplant Surgery, Department of Surgery, Mayo Clinic, Phoenix, AZ.","Li Z, Mahgoub M Y, Alrifai A Z A, Smith B, Ryan R J, Mour G K, Jadlowiec C C, Issa N, Cortez A R, Riad S",https://pubmed.ncbi.nlm.nih.gov/41209481/,"This study found that hypothermic machine perfusion (HMP) can significantly reduce the risk of delayed graft function (DGF) in kidney transplantation compared to static cold storage (SCS). HMP was associated with a 32% lower risk of DGF in the matched-pairs analysis, supporting the broader use of this technique to improve outcomes for kidney transplant recipients."
41219075,Commentary on: Lymfactin® gene therapy with vascularized lymph node transfer reduces compression-free swelling and enhances quality of life in BCRL: Final Phase I trial results.,No abstract available.,"Journal of plastic, reconstructive & aesthetic surgery : JPRAS","Dec, 2025",2025,Dec,,Paget J T|Fahradyan V,Paget J T|Fahradyan V,"Division of Plastic Surgery, Department of Surgery, Mayo Clinic, 200 1st St. S.W., Rochester, MN, United States. Electronic address: paget.james@mayo.edu.|Division of Plastic Surgery, Department of Surgery, Mayo Clinic, 200 1st St. S.W., Rochester, MN, United States.","Paget J T, Fahradyan V",https://pubmed.ncbi.nlm.nih.gov/41219075/,"This research likely explores a gene therapy called Lymfactin® that is used in combination with a procedure called vascularized lymph node transfer. The goal of this treatment is to reduce swelling and improve quality of life for people with breast cancer-related lymphedema (BCRL), a common side effect of cancer treatment."
41224426,Anesthesia for Endoscopic Procedures.,"Nonoperating room anesthesia has become an increasingly significant part of anesthetic practices, with endoscopy comprising a large portion of these cases. Unique considerations for anesthesia for endoscopy include specific gastrointestinal conditions which predispose patients to aspiration, as well as particular endoscopic procedures that may require endotracheal intubation. Finally, advances in anesthetic practice have emerged in endoscopy practices as well, creating novel ways to care for patients in unconventional settings. This article goes over management of patients for endoscopy and recent advances in this area that can further optimize patient care in this setting.Copyright © 2025 Elsevier Inc. All rights reserved.",Advances in anesthesia,"Dec, 2025",2025,Dec,,Ramanujan K S|Kor B T|Brakke B D,Ramanujan K S|Kor B T|Brakke B D,"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: Ramanujan.Krishnan@mayo.edu.|Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, MN, USA.","Ramanujan K S, Kor B T, Brakke B D",https://pubmed.ncbi.nlm.nih.gov/41224426/,This research discusses the unique considerations for administering anesthesia during endoscopic procedures. It highlights the importance of managing patients' gastrointestinal conditions and the need for endotracheal intubation in certain procedures. The article also explores recent advancements in anesthetic practices that can improve patient care during endoscopic procedures.
41224427,Anesthesia Care of Lactating Patients.,"Anesthesia providers can make significant impacts on the short-term and long-term health and well-being of lactating patients who present for anesthesia care. Development of a lactation-compatible anesthetic plan that supports the patient's individual breastfeeding goals and provides procedural conditions with symptom management is possible. Considerations for preoperative evaluation, intraoperative medications and management, and postoperative symptom management and care coordination are discussed.Copyright © 2025 Elsevier Inc. All rights reserved.",Advances in anesthesia,"Dec, 2025",2025,Dec,,Dodd S E|Krutsch K E,Dodd S E,"Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA. Electronic address: dodd.sarah@mayo.edu.|Department of Obstetrics and Gynecology, Texas Tech University Health Sciences Center School of Medicine, 1400 S Coulter Street, Amarillo, TX 79106, USA; InfantRisk Center of Excellence.","Dodd S E, Krutsch K E",https://pubmed.ncbi.nlm.nih.gov/41224427/,"This research focuses on providing anesthesia care for breastfeeding patients. It suggests that anesthesia providers can create a plan that supports the patient's breastfeeding goals and manages any symptoms, leading to better short-term and long-term health for the patient and their baby."
41225295,Socioeconomic status and concussion recovery in young athletes.,"Socioeconomic status (SES) may be associated with time to return to play (RTP) after sport-related concussion (SRC), but the literature is limited and has yielded mixed results. The purpose of our study was to determine the association between SES and concussion recovery in high school and middle school athletes.High school and middle school athletes from 24 schools in southeast Minnesota who sustained a SRC between 2020 and 2023 were included in this study. Data obtained for each concussion included date of injury and date of clearance to complete a RTP protocol. A validated measure of SES, HOUSES (HOUsing-based index of SES), was used to determine SES by pairing home addresses to publicly available property data. SES was divided into four quartiles determined for the region (Q1 = lowest SES quartile, Q4 = highest SES quartile). A negative-bimodal regression model was used to analyze the relationship between SES and RTP time.A total of 132 athletes (mean age 15.9 ± 1.5 years, 75.0% male) were included in the study. Among the total cohort, median RTP time was 12.0 days. Within each HOUSES quartile, median RTP time was 16 days in Q1, 12 days in Q2, 13 days in Q3, and 11 days in Q4. After adjusting for sex, race, ethnicity, and prior diagnosis of migraines, attention deficit/hyperactivity disorder, learning disorder, and mood disorder, athletes were estimated to have 23.9% fewer recovery days for each 1-unit increase in HOUSES quartile (p < 0.001).RTP time after concussion may be related to SES in young athletes, with higher SES associated with shorter RTP timelines.",The Physician and sportsmedicine,"Dec, 2025",2025,Dec,,Kreitner L A|Crowley E M|Hentz R C|Wi C I|Soma D B,Kreitner L A|Crowley E M|Hentz R C|Wi C I|Soma D B,"Department of Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN, USA.|Department of Orthopedics - Division of Sports Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Quantitative Health Sciences - Division of Clinical Trials and Biostatistics, Mayo Clinic,Rochester, MN, USA.|Department of Community Pediatrics & Adolescent Medicine, Mayo Clinic, Rochester, MN, USA.","Kreitner L A, Crowley E M, Hentz R C, Wi C I, Soma D B",https://pubmed.ncbi.nlm.nih.gov/41225295/,The study found that young athletes from higher socioeconomic backgrounds had shorter recovery times after a concussion compared to those from lower socioeconomic backgrounds. This suggests that socioeconomic status may play a role in the recovery process for sport-related concussions in young athletes.
41229404,Use of Flexion-Extension MRI to Reveal Occult Spondylotic Compression in Undifferentiated Cervical Myelopathies With Cord T2 Hyperintensity.,"In cervical spondylotic myelopathy (CSM), compression may not be evident in the neutral position, potentially leading to misdiagnosis and delayed treatment. We sought to assess the utility of flexion-extension MRI in revealing occult spondylotic compression in undifferentiated myelopathies with spinal cord T2 hyperintensity.Adult patients with clinical myelopathy and cervical spinal cord T2 hyperintensities who had undergone flexion-extension cervical spine MRI over a >10-year period (December 31, 2012, to October 24, 2023) were retrospectively identified. Demographic, clinical, and radiologic data were collected and analyzed.Ninety patients who underwent flexion-extension MRI for possible CSM were identified. The median age was 58 years (range, 30-81), with 47 of 90 patients (52%) being male. CSM was the final diagnosis in 65 (85% had insidious onset; 12% had reverse Lhermitte phenomenon). Before flexion-extension MRI, 39 of 65 with CSM had an initially uncertain diagnosis and 26 of 65 (40%) were initially given alternative diagnoses, including 19 of 65 (29%) who received immunotherapy and one who underwent spinal cord biopsy. The median delay to diagnosis in these patients was 15 months (range, 0.5-155). Positional compression on flexion-extension MRI at sites of T2 signal hyperintensity was more likely with a final diagnosis of CSM (55/65 [85%]) than with an alternative myelopathy etiology (3/25 [12%]: multiple sclerosis, 2; progressive lateral sclerosis, 1) (p < 0.0001). The odds ratio for CSM in the presence of positional cord compression was 40.3 (95% CI 10.58-137.4; Fisher exact test p < 0.0001). The dynamic changes noted in CSM during flexion-extension MRI included the following: worse in extension, 47 (85%); worse in flexion, 4 (7.5%); worse in both, 4 (7.5%). Decompressive surgery was completed at Mayo Clinic in 46 of 65 patients with CSM (71%). Most reported symptomatic improvement alone (29/43, 67%), nearly a quarter (10/43, 23%) reported improvement in some symptoms but worsening of others, a minority (4/43, 9%) noted only symptom stability, and none described worsening alone (0/43, 0%); 3 were lost to follow-up.Flexion-extension MRI is a cost-effective, accessible technique that can reveal occult CSM or provide clarity when the diagnosis is uncertain, and its use may reduce misdiagnosis and allow earlier treatment of unrecognized CSM.© 2025 American Academy of Neurology.",Neurology. Clinical practice,"Dec, 2025",2025,Dec,,Martinez Sosa S|Krecke K N|Syc-Mazurek S B|Krauss W E|Truitt K|Clarke M J|Flanagan E P,Martinez Sosa S|Krecke K N|Syc-Mazurek S B|Krauss W E|Truitt K|Clarke M J|Flanagan E P,"Department of Neurology, Mayo Clinic, Rochester, MN.|Department of Radiology, Mayo Clinic, Rochester, MN.|Department of Neurosurgery, Mayo Clinic, Rochester, MN.|Spine Center, Mayo Clinic, Rochester, MN.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.","Martinez Sosa S, Krecke K N, Syc-Mazurek S B, Krauss W E, Truitt K, Clarke M J, Flanagan E P",https://pubmed.ncbi.nlm.nih.gov/41229404/,"Flexion-extension MRI can reveal hidden spinal cord compression in patients with cervical myelopathy, leading to more accurate diagnosis and earlier treatment. This technique is particularly useful when the diagnosis is uncertain, as it can distinguish cervical spondylotic myelopathy from other causes of myelopathy."
41190850,Nursing Faculty Perceptions and Integration of Primary Palliative Care Content in Undergraduate Education: National and Local Institution Assessments.,"Undergraduate nursing students require adequate primary palliative care education in their formal education to prepare them to care for the growing population of individuals living with serious illness and their families. This paper aggregates results from 3, nationwide cross-sectional, descriptive, needs assessment studies and one single-institution needs assessment study to explore faculty perceptions and the integration of primary palliative care content in undergraduate nursing programs in the United States. Each study's design and needs assessment survey are described, followed by aggregated results from 137 respondents related to faculty demographics, nursing program details and primary palliative care integration, and faculty perceptions of primary palliative care education. Results from the local needs assessment are presented independently. Findings identify strengths related to faculty perceptions and preparedness. Key curricular gaps and opportunities in primary palliative care education pertain to alignment with competence expectations, supporting the need for academic-practice partnerships.Copyright © 2025 by The Hospice and Palliative Nurses Association. All rights reserved.",J Hosp Palliat Nurs,"Dec 01, 2025",2025,Dec,01,Lippe M|Wolf A|Davis A|Cormack C L|Ehrlich O|Glover T L|Fasolino T|Kirkpatrick A J,Ehrlich O|Glover T L,"Megan Lippe, PhD, MSN, RN, ANEF, FCPN, FAAN, Associate Professor, School of Nursing, University of Texas Health Science Center San Antonio, San Antonio, TX.|Alex Wolf, DNP, APRN, ACHPN, Assistant Professor, School of Nursing, MGH Institute of Health Professions, Boston, MA.|Andra Davis, PhD, MN, RN, Associate Professor, School of Nursing and Health Innovations, University of Portland, Portland, OR.|Carrie L. Cormack, DNP, CPNP, FPCN, FAAN, Associate Professor, College of Nursing, Medical University of South Carolina, Charleston, SC.|Olga Ehrlich, PhD, RN, CHPN, Assistant Professor, School of Nursing, Oakland University, Rochester, MI.|Toni L. Glover, PhD, GNP-BC, ACHPN, FAAN, Associate Professor, School of Nursing, Oakland University, Rochester, MI.|Tracy Fasolino, PhD, FNP-BC, ACHPN, Professor, College of Behavioral, Social, and Health Sciences, Clemson University, Clemson, SC.|Amanda J. Kirkpatrick, PhD, RN, FAAN, FNAP, Professor, College of Nursing, Creighton University, Omaha, NE.","Lippe M, Wolf A, Davis A, Cormack C L, Ehrlich O, Glover T L, Fasolino T, Kirkpatrick A J",https://pubmed.ncbi.nlm.nih.gov/41190850/,"This study examined how nursing faculty perceive and integrate primary palliative care content in undergraduate nursing programs across the United States. The key finding is that while faculty feel prepared to teach palliative care, there are gaps in the curriculum that need to be addressed through partnerships between academic institutions and healthcare providers."
41189599,Multivisceral arterial compression by the median arcuate ligament in a 33-year-old woman.,"Compression of the superior mesenteric artery (SMA) by the median arcuate ligament (MAL) is a rare cause of MAL syndrome. This is a case of a 33-year-old woman with a history of postprandial abdominal pain who was found to have compression of the celiac artery and SMA by the MAL. In this case, both arteries were otherwise healthy, and release of the MAL resulted in resolution of the celiac artery and SMA stenosis and sustained symptomatic relief.© 2025 The Author(s).",Journal of vascular surgery cases and innovative techniques,"Dec, 2025",2025,Dec,,MacArthur T A|Kalra M|Schaller M S,MacArthur T A|Kalra M|Schaller M S,"Division of Vascular & Endovascular Surgery, Gonda Vascular Center, Mayo Clinic, Rochester, MN.","MacArthur T A, Kalra M, Schaller M S",https://pubmed.ncbi.nlm.nih.gov/41189599/,"This medical case study describes a rare condition where a ligament in the abdomen was compressing two important arteries, leading to abdominal pain. The doctors were able to treat this by surgically releasing the ligament, which resolved the artery compression and relieved the patient's symptoms."
41187984,Modeling the effect of glucagon on endogenous glucose production in healthy individuals under meal-like conditions.,"Defective postprandial glucagon suppression contributes to chronic hyperglycemia in type 2 diabetes. Although insulin action and secretion have been extensively and quantitatively studied in the literature, less effort has been made to quantify the glucagon stimulatory effect on endogenous glucose production (EGP). This study aims to model the glucagon effect on EGP in healthy humans, capturing the decline of its action following sustained hyperglucagonemia. We analyzed data from 54 nondiabetic individuals studied on two occasions, where they received a glucose, labeled with [3-3H]-glucose, and an insulin infusion, mimicking systemic appearance after an oral glucose challenge, whereas endogenous hormone secretion was suppressed by somatostatin. Glucagon was infused at a rate of 0.65 ng/kg/min starting at 0 min (nonsuppressed occasion) or 120 min to mimic postprandial glucagon suppression (suppressed occasion). Plasma glucose, insulin, and glucagon concentrations were frequently measured for 300 min, and model-independent estimates of EGP were obtained from tracer specific activity. Several physiological models describing the EGP time course as a function of plasma glucose, insulin, and glucagon concentrations were developed and compared, each implementing a different hypothesis for the evanescence of glucagon effect. The best model successfully described EGP using the glucagon-to-insulin ratio and over-basal glucose to account for the waning glucagon effect. The model precisely estimated hepatic glucagon and insulin sensitivities. However, the glucose effect was excessively delayed, likely reflecting a cascade of other biological signals rather than the direct effect of hyperglycemia on the liver.NEW & NOTEWORTHY The model can be used to quantify hepatic glucagon and insulin sensitivity, accounting also for glucagon evanescence over time. The ability to quantify glucagon effects on postprandial glucose metabolism will further our understanding of its role in the onset and progression of type 2 diabetes. These findings can also be used in the design of novel glucagon-based therapies where accurate modeling of glucagon action is required to meet efficacy and safety standards.","American journal of physiology. Regulatory, integrative and comparative physiology","Dec 01, 2025",2025,Dec,01,Faggionato E|Tonello A|Laurenti M C|Vella A|Dalla Man C,Laurenti M C|Vella A,"Department of Information Engineering, University of Padova, Padova, Italy.|Department of Internal Medicine, Division of Diabetes, Endocrinology and Metabolism, Mayo Clinic, Rochester, Minnesota, United States.","Faggionato E, Tonello A, Laurenti M C, Vella A, Dalla Man C",https://pubmed.ncbi.nlm.nih.gov/41187984/,"This study developed a model to understand how the hormone glucagon affects the production of glucose in healthy individuals after a meal. The key finding is that the model can accurately estimate the sensitivity of the liver to glucagon and insulin, and account for the decreasing effect of glucagon over time. This improved understanding of glucagon's role in glucose metabolism can help in the development of new treatments for type 2 diabetes."
41140417,Surgical Anatomy of the Retrosigmoid Approach with Endoscopic-Assisted Reverse Anterior Petrosectomy: Optimizing Meckel's Cave Access from the Posterior Fossa.,"We investigated the extent of access to Meckel's cave (MC) and the middle cranial fossa (MCF) protecting the internal carotid artery (ICA) using the retrosigmoid approach with endoscopic-assisted reverse anterior petrosectomy (EA-RAP).Five specimens were dissected using the limited and extended EA-RAP. Based on the bone removal of the internal acoustic meatus (IAM) and subarcuate fossa, exposure of the MC and ICA were statistically compared.The limited and extended EA-RAP allowed access to the medial and anterior MC (4 mm posterior to the first genu of the cavernous ICA, and 20 mm posterior to foramen rotundum [FR]). The access to the lateral MC varied with distance of 12 and 8 mm medial to the foramen ovale for the limited and extended EA-RAP, respectively.In the extended EA-RAP, the exposure of the ICA was gained by drilling with the 0-degree endoscope (3 mm) versus 45-degree endoscope (9 mm). The working distances from the midpoint of the IAM to the most medial point of the exposed ICA was 24 mm. The most lateral point of the exposed ICA varied between 0- and 45-degree endoscopes with a distance of 21 and 13 mm, respectively.A coronal plane from the posterior genu of the cavernous ICA and a sagittal plane to the common crus of the semicircular canals can define the area of MCF accessed by the EA-RAP. Drilling of the temporal bone should be carefully customized according to the patient and can be aided by endoscopic assistance for direct visualization to minimize the risk of injuries to ICA.Thieme. All rights reserved.","Journal of neurological surgery. Part B, Skull base","Dec, 2025",2025,Dec,,De Bonis A|Torregrossa F|Dang D D|Leonel L C P C|Mortini P|Link M|Colin D|Peris-Celda M,De Bonis A|Torregrossa F|Dang D D|Leonel L C P C|Link M|Colin D|Peris-Celda M,"Mayo Clinic Rhoton Neurosurgery and Otolaryngology Surgical Anatomy Program, SW, Rochester, Minnesota, United States.|Department of Neurologic Surgery, Mayo Clinic, Rochester, Minnesota, United States.|Department of Neurosurgery and Gamma Knife Radiosurgery, San Raffaele Scientific Institute, Vita-Salute University, Milan, Italy.|Neurosurgical Unit, Department of Biomedicine, Neurosciences and Advanced Diagnostics (BiND), University of Palermo, Palermo, Italy.|Department of Neurosurgery, Inova Fairfax Medical Campus, Falls Church, Virginia, United States.|Department of Otolaryngology/Head and Neck Surgery, Mayo Clinic, Rochester, Minnesota, United States.","De Bonis A, Torregrossa F, Dang D D, Leonel L C P C, Mortini P, Link M, Colin D, Peris-Celda M",https://pubmed.ncbi.nlm.nih.gov/41140417/,"The study investigated the surgical anatomy of the retrosigmoid approach with endoscopic-assisted reverse anterior petrosectomy (EA-RAP) to access Meckel's cave and the middle cranial fossa while protecting the internal carotid artery. The findings show that the EA-RAP technique provides good access to these areas, and the use of endoscopes can help surgeons visualize and navigate the anatomy more effectively, reducing the risk of complications."
41129705,The longitudinal association between dyslipidemia and cognitive trajectory.,"BackgroundThe literature on dyslipidemia and cognitive trajectories among cognitively unimpaired (CU) persons remains inconclusive.ObjectiveTo investigate the association between baseline dyslipidemia and change in global and domain specific (i.e., memory, language, attention/executive function, and visuospatial skills) cognition in a population-based setting and whether the association differs by sex, age, or APOE ɛ4 carrier status.MethodsWe conducted a longitudinal study derived from the Mayo Clinic Study of Aging, involving 4236 CU persons aged ≥ 50 years. We ran linear mixed-effect models to examine baseline dyslipidemia in predicting longitudinal cognitive global and domain-specific z-scores adjusted for age, sex, education, medical comorbidity, repeated cognitive testing, and APOE ɛ4. We examined interactions among dyslipidemia, years since baseline, and separately by sex, age, and APOE ɛ4 carrier status.ResultsOver a median follow-up period of 6.4 years, CU individuals with dyslipidemia showed faster decline in z-scores of all domains, i.e., memory, language, attention/executive function, visuospatial and global cognition relative to CU individuals without dyslipidemia. Three-way interactions showed that dyslipidemia's effect on decline in z-scores of global cognition, attention and visuospatial skills was less pronounced in males than females. Higher age increased dyslipidemia's effect on decline in z-scores of attention but not global cognition or any other domain. APOE ɛ4 carrier status did not modify the effect of dyslipidemia on cognitive z-scores.ConclusionsDyslipidemia was associated with faster global and domain-specific cognitive decline over time in older community-dwelling individuals who were cognitively unimpaired at baseline. The effect of dyslipidemia on cognitive trajectories may be sex-influenced.",Journal of Alzheimer's disease : JAD,"Dec, 2025",2025,Dec,,Pink A|Krell-Roesch J|Syrjanen J A|Vassilaki M|Fields J A|Iglseder B|Aigner E|Kremers W K|Jack C R|Racette S B|Petersen R C|Geda Y E,Krell-Roesch J|Syrjanen J A|Vassilaki M|Fields J A|Kremers W K|Jack C R|Petersen R C,"Department of Geriatrics, Paracelsus Medical University, Salzburg, Austria.|Department of Quantitative Health Sciences, Mayo Clinic Rochester, Rochester, MN, USA.|Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.|Department of Psychiatry and Psychology, Mayo Clinic Rochester, Rochester, MN, USA.|First Department of Medicine, Paracelsus Medical University, Salzburg, Austria.|Department of Radiology, Mayo Clinic Rochester, Rochester, MN, USA.|College of Health Solutions, Arizona State University, Phoenix, Arizona, USA.|Department of Neurology, Mayo Clinic Rochester, Rochester, MN, USA.|Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.","Pink A, Krell-Roesch J, Syrjanen J A, Vassilaki M, Fields J A, Iglseder B, Aigner E, Kremers W K, Jack C R, Racette S B, Petersen R C, Geda Y E",https://pubmed.ncbi.nlm.nih.gov/41129705/,"This study found that older adults with dyslipidemia (high cholesterol) experienced faster decline in their overall cognitive abilities, as well as specific cognitive domains like memory, language, and attention, compared to those without dyslipidemia. The effect of dyslipidemia on cognitive decline was more pronounced in women than men, and increased with age, but was not influenced by genetic risk factors."
41130306,FSTL1 promotes osteoclast differentiation and Accelerates periprosthetic osteolysis via PP2A Cα-Mediated activation of the JNK signaling pathway.,"Periprosthetic osteolysis (PPO) is a common cause of arthroplasty failure, characterized by chronic inflammation and osteoclast differentiation, ultimately necessitating revision surgery. Follistatin-like 1 (FSTL1) is a critical modulator of inflammation and has an important function in different inflammatory disorders, including osteoarthritis and rheumatoid arthritis. This research examines the function of FSTL1 in PPO and elucidates the underlying mechanisms. In human aseptic loosening periprosthetic interface membranes and titanium (Ti) nanoparticle-induced calvarial osteolysis models, FSTL1 expression was markedly elevated. The administration of recombinant FSTL1 (rFSTL1) to calvariae significantly exacerbated Ti nanoparticle-induced bone resorption at osteolytic sites and increased both osteoclastogenesis and pro-inflammatory factor expression. However, the knockdown of FSTL1 using adeno-associated virus (AAV) effectively mitigated calvarial osteolysis and decreased both osteoclastogenesis and pro-inflammatory factor expression. Mechanistically, FSTL1 facilitates osteoclast differentiation and bone resorption through the upregulation of protein phosphatase 2A C subunit alpha (PP2A Cα) expression, which enhances the RANKL-induced activation of the JNK signaling pathway, thereby increasing the expression of downstream transcription factors cellular proto-oncogene Fos (c-Fos) and nuclear factor of activated T cells, cytoplasmic 1 (NFATc1). Furthermore, FSTL1 intensifies the inflammatory response at osteolytic sites, also contributing to the progression of osteolysis. Our findings indicate that FSTL1 may represent a promising therapeutic target for the treatment of periprosthetic osteolysis.Copyright © 2025 Elsevier Inc. All rights reserved.",Biochemical pharmacology,"Dec, 2025",2025,Dec,,Li M|Wang L|Lu F|Li S|Yu Y|Hu H|Yin G|Xu C|Liu Y|Wang Y,Wang Y,"Department of Orthopedics, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province 213003, China; Nanjing Medical University, Nanjing 210000, China.|Department of Orthopedics, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province 213003, China.|Department of Orthopedics, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province 213003, China; Graduate School of Dalian Medical University, Dalian, Liaoning Province 116044, China.|Articular Orthopaedics, The Third Affiliated Hospital of Soochow University, Changzhou 213003, China.|Department of Thoracic Radiation Oncology, Zhejiang Cancer Hospital, Hangzhou 310022, China; Department of Infectious Diseases, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310009, China.|Department of Orthopedics, The Third Affiliated Hospital of Nanjing Medical University (Changzhou No. 2 People's Hospital), Changzhou, Jiangsu Province 213003, China; Department of Orthopedics, The Third Affiliated Hospital of Gansu University of Chinese Medicine, 222 Silong Road, Baiyin 730900, China; Department of Orthopedic Surgery and Biochemistry and Molecular Biology, Mayo Clinic, Rochester, MN, USA. Electronic address: yujiwang1036@njmu.edu.cn.","Li M, Wang L, Lu F, Li S, Yu Y, Hu H, Yin G, Xu C, Liu Y, Wang Y",https://pubmed.ncbi.nlm.nih.gov/41130306/,"The key finding of this research is that the protein FSTL1 promotes the formation and activity of osteoclasts, which are cells that break down bone. This leads to a condition called periprosthetic osteolysis, where bone around a joint replacement implant is lost, causing the implant to become loose and fail. Targeting FSTL1 could be a promising approach to prevent or treat this common complication of joint replacement surgery."
41135560,"Global, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis.","The global burden of sepsis, a life-threatening dysregulated host response to infection leading to organ dysfunction, remains challenging to quantify. We aimed to comprehensively estimate the global, regional, and national burden of sepsis, including the impact of the COVID-19 pandemic and underlying causes of sepsis-related deaths with co-occurring infectious syndromes.We used multiple cause-of-death, hospital, minimally invasive tissue sampling, and linked death certificate and hospital record data representing 149 million deaths, covering 4290 location-years with mortality estimates from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 to capture explicit and implicit sepsis cases and deaths. We estimated age-location-sex-specific fractions of sepsis-related deaths from 195 underlying causes of death and 22 infectious syndromes from 1990 to 2021 using binomial logistic regression models, and estimated sepsis-related deaths using GBD cause-specific mortality estimates. Using 250 million hospital admissions and 7·82 million deaths from hospital data, representing 1310 location-years, we modelled case fatality rates by use of binomial logistic regression, applied to sepsis death estimates to estimate sepsis incidence by age, location, and year.In 2021, we estimated 166 million (95% uncertainty interval 135-201) sepsis cases and 21·4 million (20·3-22·5) all-cause sepsis-related deaths globally, representing 31·5% of total global deaths. Sepsis-related deaths decreased between 1990 and 2019, followed by a surge in 2020 and 2021. As of 2021, individuals aged 15 years and older experienced increases across incidence (230%) and mortality (26·3%) since 1990. Those aged 70 years and older had the highest sepsis-related mortality in 2021 (9·28 million [8·74-9·86] deaths). Sepsis-related deaths from infectious underlying causes decreased from 11·8 million (11·1-12·5) in 1990 to 8·34 million (7·72-9·01) in 2019, then increased by 86·4% to 15·5 million (14·7-16·4) in 2021. Sepsis-related mortality due to non-infectious underlying causes of death increased from 4·69 million (4·35-5·05) in 1990 to 5·81 million (5·40-6·25) in 2021; the leading non-infectious underlying causes of death with sepsis were stroke, chronic obstructive pulmonary disease, and cirrhosis. In 2021, bloodstream infections inclusive of HIV and malaria (3·08 million [2·83-3·35]) and lower respiratory infections inclusive of COVID-19 (11·33 million [1·20-1·47]) were the most prominent infectious syndromes complicating sepsis-related deaths from non-infectious underlying causes, representing a consistent trend since 1990.The global burden of sepsis increased in 2020 and 2021, reversing progress from 1990. Sepsis incidence and mortality increased in people aged 15 years and older, especially those aged 70 years and older, and as a complication of non-infectious underlying causes of death such as stroke, primarily through bloodstream infections and lower respiratory infections. The global burden of sepsis is substantial, and sepsis is increasingly a complication of non-infectious causes of death.Gates Foundation, Wellcome Trust, and Department of Health and Social Care using UK aid funding managed by the Fleming Fund.Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.",The Lancet. Global health,"Dec, 2025",2025,Dec,,,,,,https://pubmed.ncbi.nlm.nih.gov/41135560/,"The study found that the global burden of sepsis, a life-threatening condition caused by infection, has increased significantly in recent years, especially among older adults and as a complication of non-infectious underlying causes like stroke. Sepsis incidence and mortality rose sharply in 2020 and 2021, reversing previous progress, with bloodstream and respiratory infections being the leading contributors to sepsis-related deaths."
41135708,Porto-sinusoidal vascular disorder (PSVD): Survey-based analysis of the usage and drawbacks of this newly proposed terminology.,"The term ""porto-sinusoidal vascular disorder"" (PSVD) has been proposed for morphologic findings commonly seen in non-cirrhotic portal hypertension (PH) but can also be observed without clinically evident PH. To assess current practice patterns among U.S. liver pathologists, a 16-question survey was distributed along with two publications outlining the PSVD proposal. Nearly all respondents (n = 22, 95.75 %) were familiar with the PSVD terminology, but only 5 (21.75 %) used it as a final diagnosis, while 11 (47.75 %) had never used the term. In the presence of PH, 17 (74 %) preferred ""obliterative portal venopathy"", while only 1 (4.25 %) used PSVD. Notably, fewer than 5 % used PSVD in the context of nodular regenerative hyperplasia or incomplete septal fibrosis, although these have been proposed as part of the diagnostic criteria. A significant majority (n = 18, 78.25 %) disagreed with the proposed PSVD terminology, citing the following key concerns: labelling it as a disease entity is misleading (n = 20, 87 %), proposed diagnostic criteria are not supported by data (n = 15, 65.25 %), and labelling a process as PSVD does not seem accurate when only portal vein (n = 12, 52.25 %) or sinusoidal (n = 16, 69.5 %) changes are present. Over half (n = 13, 56.5 %) found it arbitrary to exclude certain vascular diseases from definition of PSVD (e.g., hepatic vein obstruction, sarcoidosis, schistosomiasis), given frequent histologic overlap across pre-hepatic, sinusoidal and post-hepatic etiologies of PH. In conclusion, ""PSVD"" terminology has not been adopted as a diagnostic term by most US liver pathologists who participated in this survey, emphasizing the need for a clearer, evidence-based terminology to describe these vascular changes.Copyright © 2025 Elsevier Inc. All rights reserved.",Human pathology,"Dec, 2025",2025,Dec,,Albayrak N E|Jain D|Torbenson M|Bellizzi A M|Chatterjee D|Fiel M I|Gill R M|Gonzalez R S|Guindi M|Hart J A|Kleiner D E|Kim G E|Naini B V|Pai R K|Ranguelov R D|Shafizadeh N|Stevenson H L|Wang H|Ward S C|Wen K W|Kakar S,Torbenson M,"Department of Pathology, University of California, San Francisco, CA, USA.|Department of Pathology, Yale School of Medicine, New Haven, CT, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.|Department of Pathology, University of Iowa, Iowa City, IA, USA.|Department of Pathology and Laboratory Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.|Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.|Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, USA.|Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.|Department of Pathology, University of Chicago, Chicago, IL, USA.|Laboratory of Pathology, National Cancer Institute, Bethesda, MD, USA.|Department of Pathology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.|Department of Laboratory Medicine and Pathology, Mount Sinai Hospital, Toronto, Ontario, Canada.|Department of Pathology, Southern California Permanente Medical Group, Woodland Hills Medical Center, Los Angeles, CA, USA.|Department of Pathology, University of Texas Medical Branch at Galveston, Galveston, TX, USA.|Department of Pathology, University of California, San Francisco, CA, USA. Electronic address: sanjay.kakar@ucsf.edu.","Albayrak N E, Jain D, Torbenson M, Bellizzi A M, Chatterjee D, Fiel M I, Gill R M, Gonzalez R S, Guindi M, Hart J A, Kleiner D E, Kim G E, Naini B V, Pai R K, Ranguelov R D, Kakar S, et al.",https://pubmed.ncbi.nlm.nih.gov/41135708/,"The study found that the proposed term ""porto-sinusoidal vascular disorder (PSVD)"" has not been widely adopted by U.S. liver pathologists, who expressed concerns about its accuracy and lack of supporting data. The majority of respondents preferred other terms, such as ""obliterative portal venopathy,"" to describe the vascular changes commonly seen in non-cirrhotic portal hypertension. The findings highlight the need for a clearer, evidence-"
41136078,From Inpatient to Home: Optimizing Transitions of Care for Patients on Long-Term Noninvasive Ventilation.,"Noninvasive ventilation (NIV) is widely accepted as an intervention that helps patients with cardiopulmonary diseases and sleep-related breathing disorders transition from hospital to home. NIV can alleviate symptoms, normalize arterial blood gases, improve health-related quality of life, reduce hospital readmissions, and mortality in certain patient groups. However, reimbursement constraints and the lack of standardized discharge pathways may compromise the effectiveness of this process and the quality of care in this fragile population.Copyright © 2025 Elsevier Inc. All rights reserved.",Sleep medicine clinics,"Dec, 2025",2025,Dec,,Rodriguez F F|Selim A|Selim B,Rodriguez F F|Selim B,"Division of Pulmonary and Critical Care Medicine, Mayo Clinic Center for Sleep Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA.|Department of Emergency Medicine, Veterans Affairs Medical Center, 1400 VFW Parkway, West Roxbury, MA 02132, USA.|Division of Pulmonary and Critical Care Medicine, Mayo Clinic Center for Sleep Medicine, Mayo Clinic, 200 First Street Southwest, Rochester, MN 55905, USA. Electronic address: Selim.bernardo@mayo.edu.","Rodriguez F F, Selim A, Selim B",https://pubmed.ncbi.nlm.nih.gov/41136078/,"Noninvasive ventilation (NIV) can help patients with breathing problems transition from the hospital to home. However, challenges with reimbursement and lack of standardized discharge procedures may affect the quality of care for these patients. The key finding is that optimizing the transition process for patients on long-term NIV is important to ensure they receive the best possible care."
41138688,Subcentimeter Pulmonary Nodules in Patients With Clinical Stage I Non-Seminoma: Impact on Risk and Patterns of Disease Relapse.,"Indeterminate subcentimeter pulmonary nodules identified during the initial staging of patients with clinical stage I non-seminoma germ cell tumor (NSGCT) remain of uncertain clinical significance and yet can increase patient anxiety and cloud management decisions. We seek to evaluate the incidence and risk of disease recurrence in stage I NSGCT patients with subcentimeter pulmonary nodules.Patients with clinical stage I NSGCT receiving an orchiectomy from 2003 to 2024 with at least 3-months of follow-up were identified (n = 215). Patient demographics, pathologic characteristics, administration of adjuvant therapy, and disease relapse data were collected. Initial staging imaging reports were reviewed identifying patients with SPN (< 1cm). The relationship between SPN and disease recurrence was investigated.We identified 215 patients with stage I NSGCT, of whom 71 (33.0%) had SPN on initial staging imaging. A total of 52 patients (24.2%) received adjuvant treatment (primary RPLND 31 patients, primary chemotherapy 21 patients), with no significant difference in therapy between patients with and without SPN (P = .09). At a median follow-up of 22-months, disease recurrence occurred in 51 (23.7%) patients. The presence of SPN was not associated with increased risk of disease recurrence on univariate analysis (P = .12) and was associated with a decreased risk of recurrence on multivariable analysis (OR (95% CI): 0.38 (0.17, 0.83); P = .02). Of 6 patients who progressed to metastatic lung disease, only 1 patient had SPN at the time of presentation.Our study suggests that SPN in stage I NSGCT are not associated with an increased risk of disease relapse. These findings may be used in patient counseling and to avoid overtreatment in management decisions.Copyright © 2025 Elsevier Inc. All rights reserved.",Clinical genitourinary cancer,"Dec, 2025",2025,Dec,,Durant A M|Pandit K|Islam N|Nguyen M|Meagher M|Dabbas M|Mi L|Lyon T D|Millard F|Boorjian S A|Leibovich B|Tyson M D|Bagrodia A,Durant A M|Islam N|Nguyen M|Mi L|Lyon T D|Boorjian S A|Leibovich B|Tyson M D,"Department of Urology, Mayo Clinic, Phoenix, AZ. Electronic address: durant.adri@mayo.edu.|Department of Urology, UC San Diego School of Medicine, La Jolla, CA.|Department of Urology, Mayo Clinic, Phoenix, AZ.|Department of Urology, Mayo Clinic, Jacksonville, FL.|Department of Urology, Mayo Clinic, Rochester, MN.","Durant A M, Pandit K, Islam N, Nguyen M, Meagher M, Dabbas M, Mi L, Lyon T D, Millard F, Boorjian S A, Leibovich B, Tyson M D, Bagrodia A",https://pubmed.ncbi.nlm.nih.gov/41138688/,"The key finding of this medical research is that subcentimeter pulmonary nodules (SPN) in patients with clinical stage I non-seminoma germ cell tumor are not associated with an increased risk of disease relapse. This suggests that the presence of SPN should not lead to overtreatment, and can be used to guide patient counseling and management decisions."
41141606,The continuum of prevention and heart failure in cardiovascular medicine: A joint scientific statement from the Heart Failure Society of America and the American Society for Preventive Cardiology.,"Heart disease is the leading cause of death worldwide, with heart failure (HF) recognized as its most severe and debilitating manifestation. Though remarkable advancements have led to the establishment of life-saving and quality-of-life-enhancing medical and device-based therapies for HF, HF-related mortality trends have increased over the past decade. To combat this worldwide epidemic, care must evolve so that preventative recommendations are not siloed from HF management. Prevention must be prioritized more broadly, not only in the early detection and deterrence of HF, but across a patient's lifespan in conjunction with therapeutic intervention. Members of the Heart Failure Society of America and the American Society for Preventive Cardiology created this joint Societal Scientific Statement on the Prevention of Heart Failure to emphasize the links between cardiovascular disease prevention and HF and offer a conceptual roadmap along which to consider all aspects of preventative care. This includes primary prevention to reduce the burden of HF, secondary prevention to reduce the impact of HF among those with an established diagnosis of HF, and tertiary prevention, which encompasses the management of risk factors in patients who require advanced therapies, including durable mechanical circulatory support and heart transplantation.© 2025 The Author(s).",American journal of preventive cardiology,"Dec, 2025",2025,Dec,,Lala A|Beavers C|Blumer V|Brewer L|De Oliveira-Gomes D|Dunbar S|Every H|Ferraro R|Ky B|Januzzi J|Marvel F|Mentz R|Michos E|Narula J|Nasir K|Natarajan P|Peterson L A|Rodriguez F|Shapiro M D|Skowronski J|Starling R C|Taub P|Tedford R J|Youmans Q|Zieroth S|Gulati M,Brewer L|Peterson L A,"The Mount Sinai Fuster Heart Hospital and Department of Population Health Science, Icahn School of Medicine, United States.|University of Kentucky College of Pharmacy, Lexington, KY, United States.|Inova Schar Heart and Vascular Institute, Inova Fairfax Medical Campus, Falls Church, VA, United States.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, United States.|Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, United States.|Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, GA, United States.|Johns Hopkins Hospital, Department of Medicine, Division of Cardiology, Baltimore, MD, United States.|Department of Medicine, Division of Cardiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.|Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.|Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, United States.|Division of Cardiology, Massachusetts General Hospital, Baim Institute for Clinical Research, Harvard Medical School, Boston, MA, United States.|Ciccarone Center for the Prevention of Cardiovascular Disease, Division of Cardiology, Department of Medicine Johns Hopkins University School of Medicine Baltimore Maryland, United States.|Duke Clinical Research Institute, Durham, NC, United States.|Division of Cardiology, Department of Medicine, The University of Texas Health Science Center at Houston, McGovern Medical School, Memorial Hermann Hospital, Houston, TX, United States.|Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist, Houston, TX, United States.|Department of Medicine, Harvard Medical School and Center for Genomic Medicine and Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, United States.|Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA, United States.|Department of Cardiology, Mayo Clinic, Phoenix, AZ, United States.|Division of Cardiovascular Medicine, Department of Medicine, and the Stanford Cardiovascular Institute, Stanford University, Palo Alto, CA, United States.|Center for Prevention of Cardiovascular Disease, Section on Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States.|Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, United States.|Department of Cardiovascular Medicine, Cleveland Clinic, Kaufman Center for Heart Failure Treatment and Recovery, Cleveland, OH, United States.|Division of Cardiovascular Medicine, UC San Diego School of Medicine, La Jolla, CA, United States.|Department of Medicine, Division of Cardiology, Medical University of South Carolina, Charleston, United States.|Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.|Section of Cardiology, Max Rady College of Medicine, University of Manitoba Winnipeg, Manitoba, Canada.|Barbra Streisand Women's Heart Center, Smidt Heart Institute at Cedars Sinai Medical Center, Los Angeles, California and The Baim Institute for Clinical Research, Boston, CA, United States.","Lala A, Beavers C, Blumer V, Brewer L, De Oliveira-Gomes D, Dunbar S, Every H, Ferraro R, Ky B, Januzzi J, Marvel F, Mentz R, Michos E, Narula J, Nasir K, Gulati M, et al.",https://pubmed.ncbi.nlm.nih.gov/41141606/,"This medical research emphasizes the importance of prioritizing prevention across a patient's lifespan to combat the growing heart failure epidemic. It outlines a comprehensive approach to prevention, including primary prevention to reduce the burden of heart failure, secondary prevention to minimize the impact for those already diagnosed, and tertiary prevention for patients requiring advanced therapies. The key finding is the need to integrate preventative recommendations with heart failure management for more effective cardiovascular care."
41177682,Comparative analysis of three approaches for minimally invasive incision-dominant hepatectomy: a multi-center analysis of patients undergoing resection of segments VII and VIII in the AMILES registry.,"Despite the popularity of minimally invasive liver surgery (MILS), the optimal approach for incision dominant hepatectomy remains unclear.We used the Americas Minimally Invasive Liver Resection Database (AMILES)to compare outcomes in patients undergoing incision-dominant hepatectomy (IDH) via different minimally invasive surgical (MIS) approaches.We identified 197 patients across 15 centers undergoing resection of segment VII and/or VIII. Of these patients, 138 patients underwent laparoscopic hepatectomy (LapH), 28 underwent hand-assisted laparoscopic hepatectomy (Hand-LapH), and 31 underwent robotic hepatectomy (RoboH). Our analysis indicated that there were no differences in outcomes in terms of post-operative complications (14.8 % LapH vs. 22.2 % Hand-LapH vs. 22.6 % RoboH, p = 0.400), ICU admission (10.2 % LapH vs. 11.1 % Hand-LapH vs. 19.4 % RoboH, p = 0.347) or achievement of R0 resection (86.2 % LapH vs. 100 % Hand-LapH vs. 83.9 % RoboH, p = 0.193). However, Hand-LapH was associated with significantly greater EBL (475 mL Hand-LapH vs. 200 mL RoboH vs. 100 mL LapH, p = 0.001) and LOS (median 4 days Hand-LapH vs. 3 days LapH vs. 2 days RoboH, p = 0.003) compared to other approaches.Our results demonstrate that MIS IDH can be performed safely, with some differences in outcomes across each technique.Copyright © 2025. Published by Elsevier Ltd.",HPB (Oxford),"Dec, 2025",2025,Dec,,Yin H|Ganjouei A A|Wang J J|Onkendi E O|Sucandy I|Shah M|Helton W S|Kamath A|Polanco P M|Simo K|Iannitti D|Hogg M E|Serrano P E|Geller D|Tohme S|Warner S|Cleary S|Adam M A|Alseidi A,Warner S,"UCSF School of Medicine, San Francisco, CA, USA.|UCSF Department of Surgery, San Francisco, CA, USA.|Texas Tech University Health Sciences Center, Lubbock, TX, USA.|AdventHealth Tampa, Tampa, FL, USA.|Emory University, Atlanta, GA, USA.|Virginia Mason Medical Center, Seattle, WA, USA.|Allina Health Cancer Institute, Minneapolis, MN, USA.|UT Southwestern, Dallas, TX, USA.|Promedica Health System, Toledo, OH, USA.|Atrium Health Carolinas, Charlotte, NC, USA.|Northshore University HealthSystem, Evanston, IL, USA.|McMaster University, Hamilton, ON, Canada.|University of Pittsburgh Medical Center, Pittsburgh, PA, USA.|Mayo Clinic, Rochester, MN, USA.|UHN - Toronto General Hospital, Toronto, ON, Canada.|UCSF Department of Surgery, Division of Surgical Oncology, San Francisco, CA, USA.|UCSF Department of Surgery, Division of Surgical Oncology, San Francisco, CA, USA. Electronic address: adnan.alseidi@ucsf.edu.","Yin H, Ganjouei A A, Wang J J, Onkendi E O, Sucandy I, Shah M, Helton W S, Kamath A, Polanco P M, Simo K, Iannitti D, Hogg M E, Serrano P E, Geller D, Tohme S, Alseidi A, et al.",https://pubmed.ncbi.nlm.nih.gov/41177682/,"This study compared three minimally invasive surgical approaches for removing segments VII and VIII of the liver. The key finding is that all three approaches - laparoscopic, hand-assisted laparoscopic, and robotic - had similar outcomes in terms of complications, intensive care unit admission, and complete tumor removal. However, the hand-assisted laparoscopic approach was associated with greater blood loss and longer hospital stays compared to the other two methods."
41157887,An Annual Review of Important Apheresis Articles in 2024 From the American Society for Apheresis Attending Physician Subcommittee.,"The American Society for Apheresis (ASFA) Attending Physician Subcommittee of the Physicians' Committee performed an annual review of articles published in 2024 related to apheresis medicine. The 10 seminal apheresis articles selected by the subcommittee members are summarized in this review. PubMed was used to identify manuscripts published in 2024 in four areas of interest: donor apheresis, therapeutic apheresis, apheresis education, and apheresis for cellular therapy. Only full length, peer-reviewed manuscripts in English with data from human subjects were included. Case reports, review articles, and meta-analyses were excluded. Articles were considered seminal if they met at least one of the following previously established criteria: novel finding(s), practice-altering outcomes, international in scope, randomized-controlled trial, relevant to current clinical practice, and/or provide evidence for category III or IV indications based on the ASFA 9th special issue of the Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach.© 2025 Wiley Periodicals LLC.",Journal of clinical apheresis,"Dec, 2025",2025,Dec,,Lu W|Costa V|Wu D W|Alsammak M|Banez-Sese G|Chhibber V|Gupta G K|Levenbrown Y|Li Y|Mattiazzi A D|Noland D K|Saint Martin M C|Singh N|Siwach G|Stephens L D|Wehrli G|Tanhehco Y C,Lu W,"Department of Laboratory Medicine and Pathology, Center of Regenerative Biotherapeutics, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pathology, New York University Langone Health, New York, New York, USA.|Department of Pathology and Laboratory Medicine, New York University Langone Hospital-Brooklyn, Brooklyn, New York, USA.|Department of Pathology and Laboratory Medicine, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania, USA.|Department of Pathology and Laboratory Medicine, Inova Fairfax Hospital Medical Campus, Inova Health System, Falls Church, Virginia, USA.|Department of Pathology and Laboratory Medicine, Northwell Health, Manhasset, New York, New York, USA.|Transfusion Medicine and Cell Therapy, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.|Division of Pediatric Critical Care, Nemours Children's Hospital, Wilmington, Delaware, USA.|Pediatrics, Sidney Kimmel Medical College of Jefferson University, Philadelphia, Pennsylvania, USA.|Department of Pathology and Laboratory Medicine, Tufts Medical Center, Boston, Massachusetts, USA.|Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.|Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.|Transfusion Medicine Division, Department of Pathology and Genomic Medicine, Houston Methodist System, Houston, Texas, USA.|Division of Laboratory Medicine, Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama, USA.|Currently working and gaining experience as observer, USA.|Department of Pathology, University of California San Diego, La Jolla, California, USA.|University Hospitals Samaritan Medical Center, Ashland, Ohio and Department of Pathology, Case Western Reserve University, Cleveland, Ohio, USA.|Department of Pathology and Cell Biology, Vagelos College of Physicians and Surgeons, Columbia University Irving Medical Center, New York, New York, USA.","Lu W, Costa V, Wu D W, Alsammak M, Banez-Sese G, Chhibber V, Gupta G K, Levenbrown Y, Li Y, Mattiazzi A D, Noland D K, Saint Martin M C, Singh N, Siwach G, Stephens L D, Tanhehco Y C, et al.",https://pubmed.ncbi.nlm.nih.gov/41157887/,"This medical review summarizes the 10 most important apheresis research articles published in 2024. The key findings from these studies could lead to improvements in donor apheresis, therapeutic apheresis, apheresis education, and apheresis for cellular therapy, which could have a significant impact on patient care."
41158156,Fertility preservation in the setting of a new uterine smooth muscle tumor of uncertain malignant potential (STUMP) diagnosis.,"Smooth muscle tumors of uncertain malignant potential (STUMPs) of the uterus present unique challenges to patients and their care teams. Although the diagnosis primarily affects perimenopausal women, in rare cases, it can be seen in younger women desiring fertility preservation. Systematic reviews in available literature support fertility-preserving management options, such as myomectomy, to be equally efficacious in preventing disease progression into sarcoma development compared to hysterectomy.Through careful multidisciplinary collaboration among experts within gynecologic oncology surgery, pathology, radiology, reproductive endocrinology & infertility, and maternal-fetal medicine, we report two cases in which fertility-preserving management was successfully implemented for uterine STUMP.Preservation of fertility in the management of STUMP tumors until childbearing has been completed appears feasible and safe via multidisciplinary care and with close surveillance.© 2025 The Author(s).",Gynecologic oncology reports,"Dec, 2025",2025,Dec,,Tung-Mabry M E|Warring S K|Schoolmeester J K|Shahi M|VanBuren W M|Bakkum-Gamez J N,Tung-Mabry M E|Warring S K|Schoolmeester J K|Shahi M|VanBuren W M|Bakkum-Gamez J N,"Division of Gynecologic Oncology Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Jacksonville, FL, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.","Tung-Mabry M E, Warring S K, Schoolmeester J K, Shahi M, VanBuren W M, Bakkum-Gamez J N",https://pubmed.ncbi.nlm.nih.gov/41158156/,"This medical research explores fertility preservation options for women with a rare uterine tumor called smooth muscle tumor of uncertain malignant potential (STUMP). The key finding is that fertility-preserving treatments, such as myomectomy, can be as effective as hysterectomy in preventing the tumor from becoming cancerous, allowing women to have children. This is an important discovery that gives younger women with STUMP more options to preserve their fertility."
41160916,Ventral cord herniation.,No abstract available.,J Clin Neurosci,"Dec, 2025",2025,Dec,,Rai P|Praveen N|Buzzelli M|Lakhani D A,Rai P|Praveen N,"Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: raipranjal2@gmail.com.|Department of Radiology, Mayo Clinic, Rochester, MN 55905, USA.|Department of Radiology, West Virginia University, Morgantown, WV 26506, USA.|Department of Radiology, West Virginia University, Morgantown, WV 26506, USA; Department of Neuroradiology, Rockefeller Neuroscience Institute, West Virginia University, Morgantown, WV 26506, USA.","Rai P, Praveen N, Buzzelli M, Lakhani D A",https://pubmed.ncbi.nlm.nih.gov/41160916/,This research likely explores a condition where a part of the spinal cord protrudes through an opening in the ventral (front) side of the spinal column. This could be a medical condition that may require treatment or further investigation.
41168548,Switching from Rituximab to Eculizumab in US Patients with Neuromyelitis Optica Spectrum Disorder: Impact on Hospitalizations.,"Neuromyelitis optica spectrum disorder (NMOSD), a rare autoimmune disease, affects the optic nerves and spinal cord. Rituximab is often used off-label to treat NMOSD; however, comparator-controlled trial data are limited. Eculizumab is approved for treatment of anti-aquaporin-4 antibody-positive (AQP4-Ab+) NMOSD. Outcomes data for patients who switch from rituximab to eculizumab are limited.This retrospective study used claims data from the IQVIA PharMetrics® Plus database (1/1/2015-3/31/2022). Patients aged ≥ 18 years with NMOSD treated with rituximab were identified and split into two groups: patients with an eculizumab claim after rituximab (switch group, n = 20) and patients without an eculizumab claim (control group, n = 525). Hospitalization rates and duration were assessed 6 months before and 6 months after the switch date (switch group) or reference date (1-year post-rituximab initiation; control group).The percentage of patients hospitalized in the switch group decreased after transitioning to eculizumab (45.0% vs. 10.0%; p = 0.034) corresponding to a decreased mean number of hospitalizations per patient from 1.1 to 0.1 (p = 0.005). The percentage of patients hospitalized in the control group was similar before and after the reference date (10.1% vs. 9.3%; p = 0.755) corresponding to a mean number of hospitalizations per patient of 0.160 and 0.156 (p = 0.922), respectively. In the switch group, median (interquartile range [IQR]) hospitalization duration decreased from 8.5 (5.0-11.0) days before switching to eculizumab to 2.5 (2.2-2.8) days after switching (p < 0.001). Median (IQR) hospitalization duration in the control group was 4.0 (2.0-9.0) days before and 4.0 (2.0-6.0) days after the reference date.Although the claims-based analysis and small patient numbers limit generalizability, we observed a reduction in hospitalizations number and length of stay in a cohort of patients with NMOSD who switched from rituximab to eculizumab.© 2025. The Author(s).",Neurology and therapy,"Dec, 2025",2025,Dec,,Lee J|Kielhorn A|Fam S|Riser E|Flanagan E P,Flanagan E P,"Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA, USA.|Alexion, AstraZeneca Rare Disease, 121 Seaport Blvd, Boston, MA, USA. adrian.kielhorn@alexion.com.|Alabama Neurology Associates, 3105 Independence Dr, Suite 105, Birmingham, AL, USA.|Mayo Clinic, 200 First St. SW, Eighth Floor, Rochester, MN, USA.","Lee J, Kielhorn A, Fam S, Riser E, Flanagan E P",https://pubmed.ncbi.nlm.nih.gov/41168548/,This study found that patients with a rare autoimmune disorder called neuromyelitis optica spectrum disorder (NMOSD) who switched from the drug rituximab to eculizumab had a significant decrease in the number and duration of their hospitalizations. This suggests that switching to eculizumab may be a more effective treatment option for managing NMOSD symptoms and reducing the burden on patients.
41172964,Oral Toxicities of PSMA-Targeted Therapies: Mitigation Strategies and Translational Opportunities.,"Prostate-specific membrane antigen (PSMA) has gained prominence as a key target in the treatment of metastatic castration-resistant prostate cancer (mCRPC) therapy. Integrating radionuclide therapies such as Lutetium-177 [177Lu]-PSMA-617 has significantly advanced treatment outcomes while posing unique challenges related to off-tumor toxicities in other tissues that express PSMA, particularly in salivary glands. Furthermore, there are novel cancer therapeutics in development including PSMA-targeted immunotherapies and antibody drug conjugates which hold promise for the treatment of prostate cancer and may contribute to the burden of oral toxicity. The oral toxicity of PSMA-targeted radioligand therapy arises from PSMA-mediated salivary gland uptake and radionuclide retention, differing fundamentally from the nonspecific tissue damage mechanisms of traditional external beam radiotherapy. In parallel, targeted therapies, including small molecules and monoclonal antibodies, exert direct effects by binding to PSMA and delivering anti-tumor metabolites and/or amplifying the immune response. The resultant off-tumor on-target tissue damage can lead to distinct oral complications such as xerostomia, dysgeusia and mucositis. Although PSMA-targeted therapies are primarily used for the management of prostate cancer, they are also being explored in treatment of salivary gland malignancies including adenoid cystic carcinoma. This review explores the mechanisms and clinical manifestations of PSMA-related oral toxicities in the context of prostate cancer, diagnosis, possible mitigation strategies, the need for preclinical models to study regulation of PSMA expression leading to oral toxicities, current challenges and future directions.Copyright © 2025 The Author(s). Published by Elsevier Inc. All rights reserved.",Clinical genitourinary cancer,"Dec, 2025",2025,Dec,,Emperumal C P|Kannan N|Childs D S|Keenan B P,Emperumal C P|Kannan N|Childs D S,"Department of Diagnosis and Preventive Sciences, Division of Oral Diagnosis, University of Oklahoma College of Dentistry, Oklahoma City, OK; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.|Department of Medical Oncology, Mayo Clinic, Rochester, MN.|Division of Hematology/Oncology, Department of Medicine, Cancer Immunotherapy Program, University of California San Francisco, San Francisco, CA. Electronic address: bridget.Keenan@ucsf.edu.","Emperumal C P, Kannan N, Childs D S, Keenan B P",https://pubmed.ncbi.nlm.nih.gov/41172964/,"The key finding of this medical research is that PSMA-targeted therapies for prostate cancer can cause oral toxicities, such as dry mouth and taste changes, due to the expression of PSMA in salivary glands. This poses a significant challenge in the management of prostate cancer, and the review explores potential mitigation strategies and the need for further research to understand the regulation of PSMA expression and its impact on oral health."
41177680,Real-World Outcomes of Enfortumab Vedotin and Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Retrospective Analysis.,"Enfortumab vedotin plus pembrolizumab has emerged as a new standard of care for previously untreated patients with advanced urothelial carcinoma following the EV-302 trial. However, data on its efficacy and safety in routine clinical practice remain limited. Herein, we evaluated real-world clinical outcomes for patients with advanced urothelial carcinoma receiving the combination as first-line or subsequent-line therapy.This retrospective cohort study included adults (≥18 years) with histologically confirmed bladder or upper tract urothelial carcinoma (other histologic type variants were also included), who initiated treatment with enfortumab vedotin-pembrolizumab therapy between May 2020 and December 2024 at the Mayo Clinic. Patients initiating therapy after December 2024 or with incomplete data were excluded. Patients were stratified by line of therapy: Cohort A included patients who received enfortumab vedotin-pembrolizumab as first-line therapy, and Cohort B included patients who received it as subsequent-line therapy. The primary endpoint was to estimate median progression-free survival in cohort A and cohort B.A total of 183 patients with advanced urothelial carcinoma treated with the enfortumab vedotin-pembrolizumab combination were included. The median age at treatment initiation was 71.9 years (IQR, 64.7-77.4). Most patients were male (71.0%) and white (90.7%). The median progression-free survival was 12.9 months (95% CI, 9.5-NE) in Cohort A and 9.3 months (95% CI, 6.3-NE) in Cohort B. This difference was not statistically significant (HR, 1.30; 95% CI, 0.83-2.04; P = .246). Treatment-related adverse events of any grade were reported in 93.4% of patients, with 30.6% experiencing Grade ≥3 AEs.In this real-world cohort, enfortumab vedotin-pembrolizumab combination demonstrated meaningful clinical activity and manageable toxicity in both first-line and subsequent-line settings, consistent with results from the EV-302 trial.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.",Clinical genitourinary cancer,"Dec, 2025",2025,Dec,,Jain P|Naqvi S A A|Tripathi N|Oberoi J K|Humayun M A|Zakharia Y|Orme J J|Kase A|Childs D S|Chen R|Riaz I B|Singh P,Jain P|Naqvi S A A|Tripathi N|Oberoi J K|Humayun M A|Zakharia Y|Orme J J|Kase A|Childs D S|Chen R|Riaz I B|Singh P,"Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ; Division of Internal Medicine, Sinai Hospital of Baltimore, Baltimore, MD.|Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ; Division of Internal Medicine, Mayo Clinic, Phoenix, AZ.|Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ; Division of Internal Medicine, Creighton University, Phoenix, AZ.|Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ.|Division of Hematology and Medical Oncology, Mayo Clinic, Rochester, MN.|Division of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL.|Division of Hematology and Medical Oncology, Mayo Clinic, Phoenix, AZ. Electronic address: Singh.Parminder@mayo.edu.","Jain P, Naqvi S A A, Tripathi N, Oberoi J K, Humayun M A, Zakharia Y, Orme J J, Kase A, Childs D S, Chen R, Riaz I B, Singh P",https://pubmed.ncbi.nlm.nih.gov/41177680/,"This study found that the combination of enfortumab vedotin and pembrolizumab, a new standard of care for advanced urothelial carcinoma, showed promising results in real-world clinical practice, with median progression-free survival of around 12 months in both first-line and subsequent-line settings. The treatment was generally well-tolerated, though some patients experienced adverse events."
41229567,Adapting the World Health Organization 5 Well-Being Index for Emergency Activation and Response Planning in a US Health Care Setting.,"To test the World Health Organization 5 Well-Being Index assessment tool as a practical way of detecting well-being changes across health care providers (HCPs) during high-consequence infectious disease (HCID) outbreaks.The study took place from October 2014 to March 2015 at a Midwest referral hospital with 2059 beds on 2 campuses. The study focused on a group of HCPs recruited for Ebola emergency response planning during the HCID outbreak in Africa.Average well-being scores were worse during the initial weeks and months of the Ebola emergency response planning. Scores were lower (worse) among employees actively involved in response planning.Health care personnel (HCP) responding to HCID outbreaks face significant physical, cognitive, and emotional stressors Despite this, well-being assessments are not consistently integrated into emergency response plans. The World Health Organization 5 Well-Being Index assessment tool offers a practical way to detect well-being changes across HCP during HCID outbreak and response.© 2025 The Authors.","Mayo Clinic proceedings. Innovations, quality & outcomes","Dec, 2025",2025,Dec,,Breeher L E|Lees E H|Farah W H|Newcomb R D|Hainy C M|Callies B I|Schroeder P T|Swift M D,Breeher L E|Lees E H|Farah W H|Newcomb R D|Hainy C M|Callies B I|Schroeder P T|Swift M D,"Division of Public Health, Infectious Disease, and Occupational Medicine, Mayo Clinic, Rochester, MN.|Occupational Health Services, Practice Administration, Mayo Clinic, Rochester, MN.|Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.|Global Security, Mayo Clinic, Rochester, MN.|Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.","Breeher L E, Lees E H, Farah W H, Newcomb R D, Hainy C M, Callies B I, Schroeder P T, Swift M D",https://pubmed.ncbi.nlm.nih.gov/41229567/,"The study found that healthcare workers involved in emergency response planning for the Ebola outbreak had lower well-being scores, indicating increased physical, cognitive, and emotional stress. The World Health Organization 5 Well-Being Index assessment tool can be a practical way to monitor the well-being of healthcare workers during high-consequence infectious disease outbreaks, which is important for supporting their mental health and resilience."
41230003,Transcriptional pause release at enhancers mediates cell identity.,"This short review highlights recent findings related to transcription factor-mediated RNA polymerase II (Pol II) pause release at enhancers and its role in regulating cell identity. We discuss how the transcriptional state of Pol II, either paused or released, shapes enhancer-promoter interactions, thereby influencing gene expression programs that define cell identity. We further summarize current knowledge of DNA-binding transcription factors that regulate Pol II pause release at enhancers and explore how this process influences cell identity. We propose a novel concept of therapy-induced molecular amnesia, where temporary inhibition of enhancer-proximal Pol II pause release and enhancer RNA transcription affects enhancer-promoter interactions differently in distinct cellular contexts. In some contexts, preservation of enhancer-promoter interactions allows rapid transcriptional reactivation and maintenance of cell identity upon recovery. In other contexts, repeated inhibition of enhancer RNA transcription leads to the permanent dissociation of enhancer-promoter interactions and loss of cell identity. Our model suggests that manipulating Pol II pause release at enhancers could selectively reverse certain aggressive tumor cell identities, limit tumor cell plasticity, and improve therapy responsiveness.© The Author(s) 2025. Published by Oxford University Press.",NAR cancer,"Dec, 2025",2025,Dec,,Ekstrom T L|Johnsen S A,Ekstrom T L,"Robert Bosch Center for Tumor Diseases, Stuttgart70376,Germany.|Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN, United States.|University of Tübingen, Tübingen, Germany.","Ekstrom T L, Johnsen S A",https://pubmed.ncbi.nlm.nih.gov/41230003/,"The key finding of this research is that the release of RNA polymerase II from a paused state at enhancer regions plays a crucial role in regulating cell identity. This process can be manipulated to potentially reverse aggressive tumor cell identities, limit tumor cell plasticity, and improve cancer therapy responsiveness."
41230245,Socio-Demographic Modifiers Shape Large Language Models' Ethical Decisions.,"The ethical alignment of large language models (LLMs) in clinical decision making remains unclear, particularly their susceptibility to socio-demographic biases. We therefore tested whether LLMs shift medical ethical decisions in healthcare when presented with socio-demographic cues. Using 100 clinical vignettes, each posing a yes or no choice between two ethical principles, we compared the responses of nine open-source LLMs (Llama 3.3-70B, Llama 3.1-8B, Llama-3.1-Nemotron-70B, Gemma-2-27B, Gemma-2-9B, Phi-3.5-mini, Phi-3-medium, Qwen-2.5-72B, and Qwen-2.5-7B). Each scenario and modifier combination was repeated 10 times per model for a total of approximately 0.5 million experiments. All models changed their responses when introduced with socio-demographic details (p < 0.001). High-income modifiers increased utilitarian choices and decreased beneficence and nonmaleficence preferences, and marginalized-group modifiers raised autonomy considerations. Although some models demonstrated greater consistency than others, none maintained consistency across all scenarios, with the largest shifts observed in utilitarian choices. These results reveal that current LLMs can be steered by socio-demographic cues in ways not clinically justified, posing risks for equitable care in healthcare-informatics applications. This underscores the need for careful auditing and alignment strategies that ensure LLMs behave in ways consistent with widely accepted ethical principles while remaining attentive to the diversity, complexity, and contextual sensitivity required in real-world clinical practice.The online version contains supplementary material available at 10.1007/s41666-025-00211-x.© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2025. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.",Journal of healthcare informatics research,"Dec, 2025",2025,Dec,,Sorin V|Korfiatis P|Collins J D|Apakama D|Omar M|Glicksberg B S|Yeow M|Brandeland M|Nadkarni G N|Klang E,Sorin V|Korfiatis P|Collins J D|Yeow M|Brandeland M,"Department of Radiology, Mayo Clinic College of Medicine and Science, Mayo Clinic, Rochester, MN USA.|The Windreich Department of Artificial Intelligence and Human Health, Mount Sinai Health System, New York, NY USA.|The Hasso Plattner Institute for Digital Health at Mount Sinai, Mount Sinai Health System, New York, NY USA.|Division of Community Internal Medicine, Geriatrics and Palliative Care, Mayo Clinic, Rochester, MN USA.|Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai, New York, NY USA.","Sorin V, Korfiatis P, Collins J D, Apakama D, Omar M, Glicksberg B S, Yeow M, Brandeland M, Nadkarni G N, Klang E",https://pubmed.ncbi.nlm.nih.gov/41230245/,"This study found that large language models (LLMs) used in clinical decision-making can be influenced by socio-demographic factors, leading to biased ethical choices that may not be clinically justified. The models were more likely to make utilitarian decisions when presented with high-income modifiers, and more likely to consider autonomy when presented with marginalized-group modifiers. These findings highlight the need for careful auditing and alignment strategies to ensure LLMs behave consistently with ethical"
41293230,Serous maculopathy in congenital cavitary optic disc anomaly: A case series.,"This study aims to describe an adult child and parent with cavitary optic disc anomalies (CODA) with associated serous maculopathy and a non-coding triplication upstream of MMP19.Retrospective, single-institution, observational case series.4 eyes of 2 related patients.This retrospective chart review used electronic medical records to summarize patient medical history, ophthalmology consultations, whole genome analysis, and imaging.Descriptive analysis of multimodal imaging and genomic sequencing.Patient 1, a 23-year-old male, was referred for visual changes in the setting of paraganglioma. He had evidence of optic disc asymmetry and serous sensory retinal detachment. Whole genome analysis was positive for a triplication upstream of the MMP19 coding region associated with CODA. His mother, patient 2, a 46-year-old female with history of bilateral optic pits, was evaluated after her son was diagnosed with CODA. She had the same MMP 19 triplication. Imaging revealed evidence of resolved serous maculopathy.We describe inherited CODA with evidence of current or resolved serous maculopathy.© 2025 The Authors.",American journal of ophthalmology case reports,"Dec, 2025",2025,Dec,,Krivit J|Reiter G S|Ye R Z|Darr K|Schimmenti L A|Iezzi R,Krivit J|Reiter G S|Ye R Z|Darr K|Schimmenti L A|Iezzi R,"Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Ophthalmology, Medical University of Vienna, Vienna, Austria.|Department of Medical Genetics, Mayo Clinic, Rochester, Minnesota, USA.","Krivit J, Reiter G S, Ye R Z, Darr K, Schimmenti L A, Iezzi R",https://pubmed.ncbi.nlm.nih.gov/41293230/,"This study found that a genetic mutation upstream of the MMP19 gene can cause a rare eye condition called cavitary optic disc anomaly, which can lead to fluid buildup in the retina and vision problems. The researchers identified this genetic mutation in a parent and child with the condition, and found that the child had active fluid buildup while the parent had resolved fluid buildup, suggesting the condition can change over time."
41278392,Maternal and Perinatal Outcomes in Pregnancies With Type 1 Diabetes and Controls During a 15-Year Period (2006-2020).,"To study contemporaneous pregnancy outcomes in women with Type 1 Diabetes (T1D).We retrospectively studied maternal and perinatal outcomes in women with T1D, and their age and gravidity matched healthy controls (N=161 pairs) who were admitted to Mayo Clinic, Rochester, MN, for delivery from January 01, 2006, to December 31, 2020, and provided research authorization for access to medical records. Data were initially electronically retrieved with subsequent manual review.We assessed 13 maternal and 22 perinatal outcome variables in 161 women with T1D and 161 healthy women matched on relevant variables. The combined study population had a mean age of 29±5 years, basic metabolic index (BMI) of 27.5±6 kg/m2, with a mean glycated hemoglobin in the T1D group of 7.74±1.64, 6.67±1.11, and 6.93±3.1 in the first, second and third trimesters, respectively. Preeclampsia, hypothyroidism, polyhydramnios, induced premature labor and preterm delivery (including medically indicated), and cesarean section were more common in women with T1D. Perinatal outcomes more prevalent among T1D pregnancies were preterm delivery, large for gestational age, cardiac (structural and functional defects), upper gastrointestinal complications, jaundice, neonatal hypoglycemia treated with intravenous dextrose only, hypoxia, respiratory distress syndrome with or without respiratory failure, and neonatal sepsis.Pregnancies with T1D continue to be associated with suboptimal glycemic control and higher maternal and perinatal morbidity, as compared to pregnancies in women without T1D, reinforcing the urgent need for the development of interventions to improve pregnancy outcomes.© 2025 The Authors.","Mayo Clinic proceedings. Innovations, quality & outcomes","Dec, 2025",2025,Dec,,Rizvi S R|Desjardins D|Kaur R J|Wood-Wentz C M|Crusan D J|Reid C|Trinidad M C|Bailey K R|Kudva Y C,Rizvi S R|Desjardins D|Kaur R J|Wood-Wentz C M|Crusan D J|Reid C|Trinidad M C|Bailey K R|Kudva Y C,"Division of Endocrinology, Diabetes, Metabolism & Nutrition, Mayo Clinic, Rochester, MN.|Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.|Division of Maternal Fetal Medicine Mayo Clinic, Rochester, MN.","Rizvi S R, Desjardins D, Kaur R J, Wood-Wentz C M, Crusan D J, Reid C, Trinidad M C, Bailey K R, Kudva Y C",https://pubmed.ncbi.nlm.nih.gov/41278392/,"This study found that pregnancies in women with type 1 diabetes have higher rates of maternal complications, such as preeclampsia and preterm delivery, as well as more perinatal issues, including large babies and neonatal hypoglycemia, compared to pregnancies in women without diabetes. These findings highlight the ongoing need for better interventions to improve outcomes for women with type 1 diabetes during pregnancy."
41278612,Social support intervention for enhancing smoking treatment utilization and cessation among veterans in the United States: A pilot study.,"Social support interventions may enhance access and use of evidence-based tobacco cessation treatments (EBCTs). We assessed the feasibility of a proactive social support intervention for Veterans who smoke.We used national Veterans Health Administration (VHA) data to identify Veterans who smoke cigarettes in the United States. We mailed invitation letters to a random national sample, followed by telephone outreach. Veteran-support person dyads were randomly assigned to intervention or control conditions. Support persons in the intervention group additionally received a 1-call coaching session. Assessments were conducted at baseline, 1-month, and 4-months post-randomization. Data collection occurred from March 2021 - August 2022.A total of 27 dyads were randomized. Two-thirds of Veteran participants were women. Veteran follow-up survey response rates were 81.5 %. Intervention participants reported a higher rate of cessation medication use (57.1 % vs. 30.8 %), use of any EBCT (64.3 % vs. 38.5 %), and biochemically confirmed seven-day point-prevalence abstinence (14.3 % vs 7.7 %) than control participants. The proactive recruitment rate was 6 % for Veterans, 74 % for support persons, and a 93 % support person completion rate for the coaching call intervention.Recruitment methods were feasible, especially for women Veterans. A proactive social support intervention shows promise for increasing Veteran utilization of EBCTs.Published by Elsevier Inc.",Preventive medicine reports,"Dec, 2025",2025,Dec,,Branson M|Patten C|Hammett P|Brockman T|Nelson D|Rogers E|Fu S S,Patten C|Brockman T,"VHA HSR Center for Care Delivery and Outcomes Research, Minneapolis VHA Health Care System, Minneapolis, MN, United States.|Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, United States.|Department of Medicine, University of Minnesota, Minneapolis, MN, United States.|Department of Population Health, NYU Grossman School of Medicine, New York, NY, United States.","Branson M, Patten C, Hammett P, Brockman T, Nelson D, Rogers E, Fu S S",https://pubmed.ncbi.nlm.nih.gov/41278612/,This study tested a social support intervention to help veterans in the United States quit smoking. The key finding is that veterans who received the intervention were more likely to use smoking cessation treatments and quit smoking compared to the control group. The study suggests that a proactive social support intervention could be an effective way to increase the use of evidence-based smoking cessation treatments among veterans.
41280515,Medial Collateral Ligament Repair With Internal Suture Brace Augmentation in Total Knee Arthroplasty.,"Medial collateral ligament (MCL) insufficiency during or after total knee arthroplasty (TKA) is a challenging scenario that often necessitates constrained implants or allograft reconstruction. This series describes 3 patients who underwent MCL repair with internal suture brace augmentation (ISBA). Two patients (ages 54 and 51) had chronic valgus instability after primary TKA and were treated with revision surgery using a more constrained implant or liner plus ISBA. A third patient (age 77) sustained an intraoperative MCL disruption during primary TKA and was managed acutely with ISBA. At 12-34.5 months of follow-up, all patients achieved full motion and medial stability. ISBA provided soft-tissue reinforcement and may represent a useful adjunct for medial instability, though its long-term effectiveness remains uncertain.© 2025 The Authors.",Arthroplasty today,"Dec, 2025",2025,Dec,,Guarin Perez S F|Alarcon Perico D|Mallet K E|Sierra R J|Cates R A,Guarin Perez S F|Alarcon Perico D|Mallet K E|Sierra R J|Cates R A,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Orthopedic Surgery, Hospital Serena del Mar, Cartagena, Colombia.","Guarin Perez S F, Alarcon Perico D, Mallet K E, Sierra R J, Cates R A",https://pubmed.ncbi.nlm.nih.gov/41280515/,"This medical research describes a technique called internal suture brace augmentation (ISBA) that can be used to repair the medial collateral ligament (MCL) during or after total knee replacement surgery. The key finding is that ISBA helped restore stability and full range of motion in three patients with MCL issues, suggesting it may be a useful option for managing medial instability in knee replacement surgeries."
41281446,Blood and tissue dysregulated bile acids and short-chain fatty acids in cholangiocarcinoma.,"Dysregulated bile acid (BA) homeostasis has been implicated in the initiation and progression of cholangiocarcinoma (CCA). The aim of this study was to investigate the roles of circulating and tumor BAs, oxysterols, short-chain fatty acids (SCFAs), transcriptomic changes, and stool microbiota composition in CCA, and their potential diagnostic and therapeutic implications.We used ultra-performance liquid chromatography-tandem mass spectrometry to quantify BAs, oxysterols, and SCFAs in serum from patients with benign focal nodular hyperplasia (n = 27), primary sclerosing cholangitis (PSC; n = 20), intrahepatic CCA (iCCA; n = 29), and extrahepatic CCA (eCCA; n = 35), and in tumor and adjacent non-tumor iCCA (n = 30) and eCCA (n = 26) tissues. Publicly available liver transcriptome and gut microbiome datasets were analyzed to assess BA metabolic pathway activity and related gene expression profiles.Total primary conjugated BA levels and the taurine-to-glycine ratio of conjugated BAs were significantly elevated in the serum of patients with PSC and CCA compared to controls with focal nodular hyperplasia (p <0.05). Transcriptomic analysis revealed a significant downregulation of GLYAT and BAAT, key genes involved in glycine and taurine conjugation, in PSC and CCA (p <0.05). Hepatic oxysterol levels were increased concomitantly with BAs in patients with CCA. Among SCFAs, butyric acid was positively correlated with conjugated BAs in the serum of patients with iCCA, whereas acetic acid was negatively correlated with BAs in the serum of patients with non-PSC-eCCA (p <0.05). Conjugated BAs were positively correlated with carbohydrate antigen 19-9 levels in patients with iCCA and non-PSC-eCCA.Profound alterations in serum and tissue levels of primary and taurine-conjugated BAs occur during cholangiocarcinogenesis. Further elucidation of the mechanisms regulating BA and oxysterol metabolism in CCA may offer new avenues for diagnosis and therapy.Cholangiocarcinomas (CCAs) are aggressive malignancies with limited therapeutic options. Although CCA cells exhibit distinct metabolic profiles, investigating their regulation through the enterohepatic axis remains challenging. In this study, targeted metabolomics was used to analyze bile acid (BA) profiles in serum and liver tissue, serum short-chain fatty acids, and hepatic oxysterol levels in patients with intrahepatic and extrahepatic CCA, compared to controls with focal nodular hyperplasia and primary sclerosing cholangitis. Liver transcriptome analysis revealed differentially expressed genes involved in BA metabolism in patients with primary sclerosing cholangitis and CCA. Correlations were also examined between BAs, oxysterols, short-chain fatty acids, clinical features, and microbiome components implicated in CCA development. These findings provide new insights into BA dysregulation in CCA and establish a foundation for the development of novel diagnostic biomarkers and therapeutic strategies.© 2025 The Authors.",JHEP reports : innovation in hepatology,"Dec, 2025",2025,Dec,,Liu Y|Hassan H|Brooks T R|VanLith C|Cooley M|Elgozair M|Ahmed F Y|Giama N H|Campbell N A|Su L|Tai Y|Ren J|Zhou H|Roberts L R,Liu Y|Hassan H|Brooks T R|VanLith C|Cooley M|Elgozair M|Ahmed F Y|Giama N H|Campbell N A|Roberts L R,"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota 55902, USA.|Department of Gastroenterology and Hepatology, The Second Hospital of Dalian Medical University, Dalian, Liaoning Province 116023, China.|Xiamen University Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, Fujian Province 361001, China.|Mayo Clinic Graduate School of Biomedical Sciences, Mayo Clinic, Rochester, Minnesota 55902, USA.|Department of Microbiology and Immunology, Medical College of Virginia, Virginia Commonwealth University and Richmond VA Medical Center, Richmond, VA 23298, USA.","Liu Y, Hassan H, Brooks T R, VanLith C, Cooley M, Elgozair M, Ahmed F Y, Giama N H, Campbell N A, Su L, Tai Y, Ren J, Zhou H, Roberts L R",https://pubmed.ncbi.nlm.nih.gov/41281446/,"The key finding of this study is that cholangiocarcinoma (CCA) is associated with significant alterations in bile acid (BA) homeostasis, including elevated levels of primary conjugated BAs and changes in BA metabolic pathways. These dysregulated BA profiles, along with associated changes in oxysterols and short-chain fatty acids, may serve as potential diagnostic biomarkers and offer new avenues for CCA therapy."
41282583,A Comprehensive Approach to Responsible AI Development and Deployment.,"Integrating artificial intelligence (AI) into health care offers the potential to address critical challenges related to access to care, workforce burnout, and health inequities. Despite its promise, AI adoption remains limited due to safety, efficacy, and equity concerns. This paper presents a novel and comprehensive framework for responsible AI development, evaluation, and deployment in health care, encompassing four key phases: (1) AI Solution Design and Development, (2) AI Solution Qualification, (3) AI Solution Efficacy and Safety Evaluation, and (4) AI Solution Impact. By establishing rigorous standards for operational, clinical, and technical quality, the framework aims to guide AI developers and health care professionals toward creating AI solutions that are ethical, effective, and scalable. This structured approach fosters collaboration and mitigates risks to help AI achieve its full potential in improving patient outcomes and health care efficiency.© 2025 The Authors.",Mayo Clinic proceedings. Digital health,"Dec, 2025",2025,Dec,,Makhni S|Rico J|Cerrato P|Hill B|Overgaard S|Wu J|Fairbanks J|Tripp R|Redziniak J|Blundo R|Otley C|Halamka J,Makhni S|Rico J|Cerrato P|Hill B|Overgaard S|Wu J|Fairbanks J|Tripp R|Redziniak J|Blundo R|Otley C|Halamka J,"Department of Hospital Internal Medicine, Mayo Clinic Rochester, Mayo Clinic Platform, Rochester, MN.|Mayo Clinic Platform, Mayo Clinic, Rochester, MN.|Mayo Clinic, Rochester, MN.|Department of Dermatology, Mayo Clinic, Mayo Clinic Platform, Rochester, MN.","Makhni S, Rico J, Cerrato P, Hill B, Overgaard S, Wu J, Fairbanks J, Tripp R, Redziniak J, Blundo R, Otley C, Halamka J",https://pubmed.ncbi.nlm.nih.gov/41282583/,"This research proposes a comprehensive framework to ensure the responsible development and deployment of AI in healthcare. The key finding is that by establishing rigorous standards for AI solutions, the framework can help create AI tools that are ethical, effective, and scalable, ultimately improving patient outcomes and healthcare efficiency."
41283678,A Tale of Two Organs: The Liver-Lung Axis in Pulmonary Disease.,No abstract available.,Comprehensive Physiology,"Dec, 2025",2025,Dec,,Jose A|DuBrock H M|Singh N|Kolls J|Krowka M|Oliveira R K F|Raevens S|Tonelli A R|Del Valle K|Ventetuolo C E|Raj U,DuBrock H M|Krowka M|Del Valle K,"University of Cincinnati, Cincinnati, Ohio, USA.|Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.|Brown University, Providence, Rhode Island, USA.|Tulane School of Medicine, New Orleans, Louisiana, USA.|Federal University of Sao Paulo (Unifesp), Sao Paulo, Brazil.|University of Ghent, Ghent, Belgium.|Cleveland Clinic, Cleveland, Ohio, USA.|University of Illinois, Chicago, Illinois, USA.","Jose A, DuBrock H M, Singh N, Kolls J, Krowka M, Oliveira R K F, Raevens S, Tonelli A R, Del Valle K, Ventetuolo C E, Raj U",https://pubmed.ncbi.nlm.nih.gov/41283678/,"This research likely explores the relationship between the liver and the lungs, and how this relationship may contribute to the development or progression of lung diseases. It suggests that the liver and lungs may work together in a way that affects the health of the lungs, and this connection could be important for understanding and treating pulmonary (lung) diseases."
41294263,Renal Replacement Therapy in Lupus Nephritis-Related End-Stage Kidney Disease: A Systematic Review and Meta-Analysis.,"To assess the impact of renal replacement therapy in people with lupus nephritis (LN)-associated end-stage kidney disease (ESKD) and support the development of the 2024 American College of Rheumatology LN treatment guidelines.We conducted a systematic literature review and meta-analysis to address three Population, Intervention, Comparison, and Outcome (PICO) questions related to renal replacement therapy for ESKD due to LN, including comparisons of kidney transplant versus dialysis, hemodialysis versus peritoneal dialysis, and preemptive kidney transplant versus no preemptive kidney transplant. Outcomes of interest included mortality, cardiovascular (CV) events, infections, lupus flares, disease-related damage, graft failure, and quality of life. We conducted a meta-analysis and analyzed hazard ratios for time-to-event analyses and risk ratios for dichotomous outcomes, as well as absolute risk estimates.Sixteen comparative observational studies addressed at least one of the three PICO questions. Kidney transplant was found to reduce the risks of all-cause mortality, CV mortality, infection-related mortality, and CV events compared with dialysis (high certainty). Dialysis modality (peritoneal vs hemodialysis) was not associated with mortality (high certainty) or with other outcomes of infection, CV complications, and systemic lupus erythematosus flares (low certainty). Preemptive kidney transplant was associated with lower risks of graft failure and mortality (low certainty).This systematic review identified improved outcomes with kidney transplant versus dialysis for people with LN-associated ESKD and potential benefits of preemptive kidney transplant. This evidence supports the use of kidney transplant as a preferred renal replacement therapy for people with LN-ESKD.© 2025 The Author(s). ACR Open Rheumatology published by Wiley Periodicals LLC on behalf of American College of Rheumatology.",ACR open rheumatology,"Dec, 2025",2025,Dec,,Kawtharany H|Jorge A|Azzam M|Bartels C M|Cunha J S|DeQuattro K|Fava A|Figueroa-Parra G|Garg S|Greco J|Cuéllar-Gutiérrez M C|Iyer P|Johannemann A S|Kasturi S|Khawandi J|Kirou K A|Legge A|Liang K V|Lockwood M M|Sanchez-Rodriguez A|Turgunbaev M|Williams J N|Sammaritano L R|Askanase A|Bermas B L|Dall'Era M|Duarte-García A|Hiraki L T|Rovin B|Son M B F|Turner A S|Mustafa R A,Figueroa-Parra G|Cuéllar-Gutiérrez M C|Sanchez-Rodriguez A|Duarte-García A,"University of Kansas, Kansas City.|Massachusetts General Hospital, Boston.|University of Wisconsin, Madison.|Warren Alpert Medical School of Brown University, Providence, Rhode, Island.|University of Pennsylvania, Philadelphia.|Johns Hopkins University, Baltimore, Maryland.|Mayo Clinic, Rochester, Minnesota, and University Hospital ""Dr. José Eleuterio González,"" Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico.|The Ohio State University Wexner Medical Center, Columbus.|Mayo Clinic, Rochester, Minnesota, and Hospital del Salvador, Santiago, Chile.|University of California Irvine Medical Center, Orange.|Carolina Arthritis Center, Greenville, North Carolina.|Tufts Medical Center, Boston, Massachusetts.|Hospital for Special Surgery - Weill Cornell Medicine, New York, New York.|Dalhousie University, Halifax, Nova Scotia, Canada.|Georgetown University Hospital, Washington, District of Columbia.|Mayo Clinic, Rochester, Minnesota, and Internal Medicine Department, Private Assistance Institution, The American British Cowdray Medical Center, Mexico City, Mexico.|American College of Rheumatology, Atlanta, Georgia.|Washington University, St. Louis, Missouri.|Columbia University, New York, New York.|University of Texas Southwestern Medical Center, Dallas.|University of California, San Francisco.|Mayo Clinic, Rochester, Minnesota.|The Hospital for Sick Children, Toronto, Ontario, Canada.|The Ohio State University, Columbus.|Boston Children's Hospital, Boston, Massachusetts.","Kawtharany H, Jorge A, Azzam M, Bartels C M, Cunha J S, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Greco J, Cuéllar-Gutiérrez M C, Iyer P, Johannemann A S, Kasturi S, Khawandi J, Mustafa R A, et al.",https://pubmed.ncbi.nlm.nih.gov/41294263/,"The key finding of this medical research is that kidney transplant is associated with better outcomes, including reduced mortality and cardiovascular events, compared to dialysis for people with lupus nephritis-related end-stage kidney disease. The research also suggests potential benefits of preemptive kidney transplant. These findings support the use of kidney transplant as the preferred renal replacement therapy for this patient population."
41271295,The authors reply.,No abstract available.,Kidney international,"Dec, 2025",2025,Dec,,Klomjit N|Zand L,Klomjit N|Zand L,"Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA; Division of Nephrology and Hypertension, University of Minnesota, Minneapolis, Minnesota, USA.|Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA. Electronic address: zand.ladan@mayo.edu.","Klomjit N, Zand L",https://pubmed.ncbi.nlm.nih.gov/41271295/,"This research likely explores the authors' response to a previous publication or study. It may involve the authors clarifying, defending, or expanding on their original work in light of feedback or critiques from other researchers."
41294306,Long-Term Outcomes of Patients Who Receive a Liver Transplant for Hepatitis B With Limited Use of Hepatitis B Immunoglobulin.,"Chronic hepatitis B virus (HBV) infection is a leading cause of cirrhosis and hepatocellular carcinoma (HCC). Post-transplant HBV reinfection represents an important post-liver transplantation (LT) complication, which can result in death or graft loss. Hepatitis B immunoglobulin (HBIG) has proven effective in preventing reinfection; however, its high cost and patient inconvenience underscore the need for alternative strategies. In this study, we evaluated the long-term outcomes of HBV-positive LT recipients who received very short-term HBIG immunoprophylaxis combined with life-long antiviral therapy. We conducted a single-center, retrospective cohort study of patients who underwent LT for HBV between 2002 and 2022. Viremic patients received an intraoperative and six consecutive daily doses of HBIG, while non-viremic patients received two doses only post-LT, along with long-term antiviral therapy. The primary outcome was HBV reinfection. Secondary outcomes included death-censored graft survival and overall survival. Seventy-six patients were included. Of these, only three experienced HBV reinfection over the study period. The cumulative incidence of reinfection at 1, 12, 24, and 48 months was observed to be 1.37%, 2.76%, 2.76%, and 2.76%, respectively. The 1-, 3-, and 5-year death-censored graft survival rates were 94%, 94%, and 92%, respectively. The 1-, 3-, and 5-year overall survival rates were 92%, 92%, and 85%, respectively. A very short-term HBIG protocol produced excellent post-transplant outcomes for HBV-positive LT recipients, with very low rates of HBV reinfection and excellent graft and overall survival.© 2025 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",Clinical transplantation,"Dec, 2025",2025,Dec,,Roldan G A|Loon E|Lake J|Lim N,Lim N,"Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.|Department of Medicine, University of Minnesota, Minneapolis, Minnesota, USA.|Department of Medicine, Gastroenterology and Hepatology, University of Rochester, Rochester, New York, USA.","Roldan G A, Loon E, Lake J, Lim N",https://pubmed.ncbi.nlm.nih.gov/41294306/,"This study found that a short-term hepatitis B immunoglobulin (HBIG) protocol, combined with long-term antiviral therapy, resulted in very low rates of hepatitis B virus (HBV) reinfection and excellent graft and overall survival in liver transplant recipients with HBV. This suggests that this alternative strategy can be an effective and more cost-effective approach for preventing HBV reinfection after liver transplantation."
41308685,"Misclassification of p16-positive, HPV-negative patients biases de-escalation trials - Authors' reply.",No abstract available.,The Lancet. Oncology,"Dec, 2025",2025,Dec,,Routman D M|Lewis J S|Ma D J,Routman D M|Lewis J S|Ma D J,"Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.|Division of Anatomic Pathology, Mayo Clinic Arizona, Phoenix, AZ, USA.|Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA. Electronic address: ma.daniel@mayo.edu.","Routman D M, Lewis J S, Ma D J",https://pubmed.ncbi.nlm.nih.gov/41308685/,"This research likely explores the issue of misclassifying patients who have a certain type of cancer marker (p16-positive) but do not have the virus that typically causes that cancer (HPV-negative). This misclassification could lead to biased results in clinical trials that are testing whether certain treatments can be reduced or ""de-escalated"" for these patients."
41308688,Neurocognitive outcomes in patients with brain metastases: a systematic review.,"Multimodality therapy, including surgery, radiotherapy, and systemic therapy, has significantly improved overall survival for patients with brain metastases. However, treatment-related neurocognitive sequelae remain a major challenge in survivorship. Although advances in radiotherapy delivery techniques have reduced toxicity, the potential interaction with chemotherapy, targeted therapy, and immunotherapy, and the consequent effect on neurocognitive outcomes is poorly characterised. We conducted a systematic review of clinical trials reporting neurocognitive endpoints in patients with brain metastases receiving radiotherapy with or without other concurrent systemic therapies. Neurocognitive outcomes were manually extracted from published reports. 39 studies from 1997 to 2024 involving 6617 patients met inclusion criteria (n=27 whole-brain radiotherapy; n=12 radiosurgery), including six studies evaluating combined-modality therapy. Baseline neurocognitive disability was frequently observed, and the majority of randomised trials evaluating advanced radiotherapy delivery techniques (hippocampal avoidance and radiosurgery) compared with whole-brain radiotherapy reported reduced cognitive decline and improved quality of life. There was no signal for increased toxicity with combined-modality therapy, including radiotherapy with concurrent systemic therapy, although evaluable trials were few in number. Given improvements in survival for patients with brain metastases, characterisation of long-term neurocognitive outcomes is growing in importance. There is an urgent need for targeted research to resolve evidence gaps around modality-specific neurocognitive toxicity and optimal sequencing of therapies. Systemic issues, such as integration of routine neuropsychological screening or assessment and incorporation of rehabilitation strategies into neuro-oncology care pathways, warrant evaluation. Exploration of emerging strategies, ranging from neuroprotectants to dose-sparing radiotherapy techniques, could further mitigate long-term adverse effects.Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.",The Lancet. Oncology,"Dec, 2025",2025,Dec,,Bou Dargham T|Winter S F|Batich K|Gehring K|Parsons M W|Dietrich J|Mullikin T|Reitman Z J|Floyd S R|Kirkpatrick J P|Sperduto P W|Hattangadi-Gluth J|Shih H A|Brown P D|Mehta M|Sulman E P|Peters K B|Vaios E J,Brown P D,"Department of Neurosurgery, Duke University Medical Center, Durham, NC, USA.|Department of Neurology, Division of Neuro-Oncology, Massachusetts General Hospital, Boston, MA, USA.|Department of Cognitive Neuropsychology, Tilburg University, Tilburg, Netherlands; Department of Neurosurgery, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands.|Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA.|Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA.|Department of Radiation Oncology, University of California, San Diego, CA, USA.|Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.|Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.|Department of Radiation Oncology, Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, NY, USA.|Department of Radiation Oncology, Duke University Medical Center, Durham, NC, USA. Electronic address: eugene.vaios@duke.edu.","Bou Dargham T, Winter S F, Batich K, Gehring K, Parsons M W, Dietrich J, Mullikin T, Reitman Z J, Floyd S R, Kirkpatrick J P, Sperduto P W, Hattangadi-Gluth J, Shih H A, Brown P D, Mehta M, Vaios E J, et al.",https://pubmed.ncbi.nlm.nih.gov/41308688/,"The key finding of this medical research is that while multimodality therapy has improved overall survival for patients with brain metastases, treatment-related neurocognitive issues remain a significant challenge. The review suggests that advanced radiotherapy delivery techniques, such as hippocampal avoidance and radiosurgery, may reduce cognitive decline and improve quality of life compared to whole-brain radiotherapy. The research highlights the urgent need for further studies to address evidence gaps and explore strategies to miti"
41310918,Beyond Structure: The Interplay of Bone and Brain During Alzheimer's Disease.,"Alzheimer's disease (AD), a leading cause of dementia in the elderly, is traditionally characterized by neurodegeneration driven by amyloid-beta plaques and tau tangles. However, emerging evidence reveals that AD's impact extends beyond the brain, significantly affecting skeletal health. This review integrates clinical and transgenic mouse model data to elucidate the mechanistic interplay between AD pathology and bone metabolism. AD patients exhibit increased risk for hip fractures and low bone mineral density (BMD), independent of cognitive impairment severity. We found altered calcium and alkaline phosphate levels in the blood of patients with mild cognitive impairment and AD, as assessed from the Alzheimer's Disease Neuroimaging Initiative data. Convergent risk factors-age, sex, APOE4 genotype, smoking, and vitamin D deficiency-contribute to both neurodegeneration and bone fragility. Key molecular pathways, such as Wnt/β-catenin signaling and TREM2-mediated osteoclast regulation, underscore shared mechanisms driving disease pathology in both systems. Mouse models of AD consistently demonstrate disrupted bone remodeling, impaired osteoblast function, and heightened osteoclast activity. Therapeutic strategies targeting overlapping pathways, including lithium, anti-FSH antibodies, and NF-κB inhibitors, show promise in mitigating both cognitive decline and bone loss. Collectively, these insights advocate for a more integrated view of AD that includes skeletal comorbidities, potentially guiding the development of dual-purpose interventions.© 2025 American Physiological Society.",Comprehensive Physiology,"Dec, 2025",2025,Dec,,Pinnamaneni A|Akkiraju A|Park H I|Ch V R S R|Ayalasomayajula V|Bandela M|Kaipa S|Khosla S|Zeineh M|Suryadevara V,Khosla S,"Duke University, Durham, North Carolina, USA.|The Harker School, San Jose, California, USA.|Department of Radiology, Molecular Imaging Program at Stanford (MIPS), Stanford University School of Medicine, Stanford, California, USA.|College of Engineering, Northeastern University, Boston, Massachusetts, USA.|Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, Illinois, USA.|Kogod Center on Aging and Division of Endocrinology, Mayo Clinic, Rochester, Minnesota, USA.","Pinnamaneni A, Akkiraju A, Park H I, Ch V R S R, Ayalasomayajula V, Bandela M, Kaipa S, Khosla S, Zeineh M, Suryadevara V",https://pubmed.ncbi.nlm.nih.gov/41310918/,"Alzheimer's disease not only affects the brain but also impacts bone health. Patients with Alzheimer's have an increased risk of hip fractures and low bone density, independent of cognitive impairment. The shared risk factors and molecular pathways between neurodegeneration and bone fragility suggest the need for a more integrated approach to treating Alzheimer's, including therapies that target both cognitive decline and bone loss."
41311730,Infective Endocarditis Risk After Invasive Dental Procedures.,"To quantify the risk of infective endocarditis (IE) following different invasive dental procedures in patients with cardiac risk factors that place them at low-risk, moderate-risk, or high-risk of developing IE.The linked IBM MarketScan administrative databases were used to integrate deidentified patient-level health data for all enrollees over 18 years of age with employer-provided commercial/Medicare-supplemental medical and dental coverage, or Medicaid benefits, with more than 16 months of data from May 1, 2007, to August 31, 2015.In the resulting 9.6 million patient cohort, IE incidence in the 4-months following 53.6 million invasive dental procedures was quantified. In high-risk individuals (e.g. previous IE, prosthetic/repaired heart valves, or cyanotic congenital heart disease), IE incidence in the 4 months following an IDP was 2195 IE cases/million procedures - ∼125 times higher than in low-risk (OR 126.3; 95% CI, 113.5-140.6; P<.001). The IE-risk was even greater following extractions (incidence 8680 IE cases/million extractions, OR 171.4; 95% CI, 136.7-214.8; P<.001) or other oral surgical procedures (incidence 13,458 IE cases/million procedures; OR 245.5; 95% CI, 165.1-365.1; P<.001). Moderate-risk individuals were at significantly lower IE-risk, and low-risk individuals were at negligible risk.The risk of IE was high in high-risk individuals following all types of IDP (particularly following extractions and other oral surgical procedures) and vastly exceeded the risk of adverse drug reactions following antibiotic prophylaxis. Our data therefore support guidance recommending high-risk individuals receive antibiotic prophylaxis and provide quantitative information concerning the IE-risk that can be used to educate and obtain informed consent from patients.© 2025 The Authors.","Mayo Clinic proceedings. Innovations, quality & outcomes","Dec, 2025",2025,Dec,,Thornhill M H|Lockhart P B|Dayer M J|Prendergast B D|Baddour L M,Baddour L M,"Unit of Oral & Maxillofacial Medicine, Surgery and Pathology, School of Clinical Dentistry, University of Sheffield, UK.|Department of Oral Medicine/Oral & Maxillofacial Surgery, Wake Forest University School of Medicine, Atrium Health - Carolinas Medical Center, Charlotte, NC.|Cardiovascular Research Institute, Mater Private Network, Dublin, Ireland, and Faculty of Health, University of Plymouth, UK.|Department of Cardiology, St Thomas' Hospital and Cleveland Clinic, London, UK.|Division of Public Health, Infectious Diseases and Occupational Medicine, Departments of Medicine and Cardiovascular Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN.","Thornhill M H, Lockhart P B, Dayer M J, Prendergast B D, Baddour L M",https://pubmed.ncbi.nlm.nih.gov/41311730/,"The study found that people at high risk of infective endocarditis (IE) have a significantly higher risk of developing IE after invasive dental procedures, especially extractions and other oral surgeries. This information supports the recommendation for high-risk individuals to receive antibiotic prophylaxis before such procedures to prevent this serious heart infection."
41312564,Evaluation of platelet dense granules by transmission electron microscopy in healthy pediatric donors and pediatric patients with suspected platelet disorders.,"Whole mount (WM) platelet transmission electron microscopy (PTEM) is a standard method for evaluating platelet dense granules (DG). However, because of the lack of a pediatric/adolescent mean DG/platelet reference range (RR), the prevalence of platelet DG deficiency in patients with suspected inherited platelet disorders (IPD) is mostly unknown in our practice. This study aimed to establish a local pediatric/adolescent RR for mean DG/platelet in a cohort of pediatric patients with clinical suspicion of IPD, which was used to determine the prevalence and clinical and laboratory features of platelet DG deficiency.WM-PTEM was performed on healthy donors. The mean DG/platelet RR was calculated by averaging the DG of 100 platelets per donor. Patients who underwent laboratory evaluation of suspected IPD were evaluated. PTEM results, clinical histories, other laboratory testing results, and pediatric ISTH BAT scores (normal < 3; abnormal ≥3) were collected and analyzed.Healthy donors (n = 77, 41.6% female), ages 3-18 years, had a mean of 2.7 DG/platelet (±0.5), ranging from 1.9 to 3.8 per platelet. The mean DG/platelet did not correlate with age or gender. The tentative RR was calculated to be 1.9 to 3.8 DG/platelet. Of the 72 patients with suspected IPD (age 3-18 years, 69.4% female), 31 patients had BAT scores < 3 and 41 patients had BAT scores ≥3 (range 0-11). Eighteen patients (25%) were diagnosed with DG deficiency. The mean DG/platelet in patients with bleeding scores ≥3 vs. those with bleeding scores < 3 was similar. There was no difference in the number of patients with normal or abnormal bleeding scores in groups with normal vs decreased mean DG/platelet (p = .42) based on the pediatric DG/platelet RR. Platelet DG deficiency was also not correlated with abnormal platelet function testing results.Approximately 25% of pediatric patients with suspected IPD were found to have platelet DG deficiency. However, the mean DG/platelet did not correlate with the ISTH BAT scores or platelet function testing results.",Platelets,"Dec, 2025",2025,Dec,,Greenmyer J R|Chen D|Howell K G|Fischer K M|Johnson B|Drapeau N|Stromback L R|Charlesworth J E|Gossman S C|Gamez J D|Pruthi R K|Warad D M,Greenmyer J R|Chen D|Howell K G|Fischer K M|Johnson B|Drapeau N|Stromback L R|Charlesworth J E|Gossman S C|Gamez J D|Pruthi R K|Warad D M,"Division of Pediatric Hematology and Oncology, Mayo Clinic, Rochester, MN USA.|Special Coagulation Laboratory, Division of Hematopathology, Mayo Clinic, Rochester, MN, USA.|Electron Microscopy Core Facility, Mayo Clinic, Rochester, MN, USA.|Division of Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN, USA.","Greenmyer J R, Chen D, Howell K G, Fischer K M, Johnson B, Drapeau N, Stromback L R, Charlesworth J E, Gossman S C, Gamez J D, Pruthi R K, Warad D M",https://pubmed.ncbi.nlm.nih.gov/41312564/,"This study established a reference range for the number of dense granules in platelets of healthy children and adolescents. It found that 25% of pediatric patients with suspected inherited platelet disorders had a lower number of dense granules, but this did not correlate with their bleeding symptoms or platelet function test results. This suggests that platelet dense granule deficiency may be more common in this population than previously thought, but its clinical significance requires further investigation."
41273257,Optimized dose schedule of rucaparib and liposomal irinotecan/5-fluorouracil in metastatic gastrointestinal cancers: A phase 1 study.,"This phase 1 study aimed to determine the maximum tolerated dose (MTD) and evaluate the safety and preliminary efficacy of rucaparib (RUB), a poly(adenosine diphosphate ribose) polymerase (PARP) inhibitor, combined with liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU) in metastatic gastrointestinal (GI) cancers. RUB targets DNA repair pathways, showing efficacy in tumors with homologous recombination deficiency, such as BRCA mutations. Preclinical data suggest synergy with irinotecan, but overlapping toxicities pose challenges.Eighteen patients with metastatic GI cancers, who previously progressed on at least one systemic therapy, were enrolled. A novel sequential dosing regimen, informed by nal-IRI pharmacokinetic analysis, was used. Twelve patients were evaluable for dose-limiting toxicity (DLT) and 12 for response per Response Evaluation Criteria in Solid Tumors v1.1 criteria.The MTD was established as RUB 600 mg twice daily, nal-IRI 50 mg/m2, and 5-FU 2400 mg/m2 over 46 hours. The objective response rate (ORR) was 33% (4 of 12), and the disease control rate (DCR) was 75% (9 of 12). Common grade 3 adverse events included diarrhea (33%) and neutropenia (25%), with no grade 4/5 events. Responses were notable in patients with somatic ATM and BRCA mutations, especially those with prior platinum exposure. No DLTs occurred at the recommended phase 2 dose.This optimized dosing schedule successfully established the MTD for RUB with nal-IRI and 5-FU, overcoming prior challenges with PARP inhibitor and irinotecan combinations. The promising ORR and DCR support further evaluation of this regimen in advanced GI malignancies.© 2025 American Cancer Society.",Cancer,"Dec 01, 2025",2025,Dec,01,Eslinger C|Walden D|Krivonos A|Fadra N|Zemla T|Ma W W|El-Rayes B|Alese O|Halfdanarson T|Hobday T|Bruggeman S|Jaszewski B|Ou F|Sonbol M B|Ahn D|Borad M J|Wu C|McWilliams R|Bekaii-Saab T,Eslinger C|Walden D|Krivonos A|Fadra N|Zemla T|El-Rayes B|Alese O|Jaszewski B|Ou F|Sonbol M B|Ahn D|Borad M J|Wu C|Bekaii-Saab T,"Department of Hematology-Oncology, Mayo Clinic, Phoenix, Arizona, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.|Department of Hematology-Oncology, Cleveland Clinic, Cleveland, Ohio, USA.|Department of Oncology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, Georgia, USA.","Eslinger C, Walden D, Krivonos A, Fadra N, Zemla T, Ma W W, El-Rayes B, Alese O, Halfdanarson T, Hobday T, Bruggeman S, Jaszewski B, Ou F, Sonbol M B, Ahn D, Bekaii-Saab T, et al.",https://pubmed.ncbi.nlm.nih.gov/41273257/,"This phase 1 study found that a specific combination of the PARP inhibitor rucaparib, liposomal irinotecan, and 5-fluorouracil was safe and effective in treating metastatic gastrointestinal cancers. The study established the maximum tolerated dose and showed promising response rates, particularly in patients with certain genetic mutations. These findings support further investigation of this combination therapy for advanced gastrointestinal cancers."
41267959,Single-Portal Arthroscopy Improves the Assessment of Radial-sided Disorders of the Wrist.,"This study aimed to describe the technique, indications, and advantages of the single-portal arthroscopic approach for the diagnosis and staging of chronic radial-sided disorders, including scapholunate interosseous ligament (SLIL) tear, scapholunate advanced collapse (SLAC) and scaphoid nonunion advanced collapse (SNAC) deformities.The single portal technique was used in 138 patients affected by suspected SLIL lesions, SLAC and SNAC wrist injuries with positive clinical symptoms and inconclusive imaging (X-ray and MRI). It was used to grade the nature of the SLIL lesion and the extension of the osteochondral damage in the SLAC and SNAC wrist deformity to guide appropriate treatment.Patients were divided into group 1 (SLIL: 45 cases), group 2a (SLAC: 65 cases), and group 2b (SNAC: 28 cases). In group 1, stage 4 SLIL lesions were confirmed in 36 cases and 9 were assessed as SLAC wrist deformity. In group 2a, single-portal arthroscopy confirmed the preoperative diagnosis in 74% of cases. In the remaining 26% of patients, arthroscopy modified the preoperative diagnosis: 1 case of SLAC 1 resulted in SLAC 2, 14 cases of SLAC 2 resulted in SLAC 3, 1 case of SLAC 3 resulted in SLAC 2. A case of SLAC 2 turned out to be an SLIL lesion stage 4. In group 2b, single-portal arthroscopy confirmed the preoperative diagnosis in 86% of cases. In the remaining 14% (4 cases), it modified the preoperative diagnosis: 1 of SNAC 1 resulted in SNAC 2 and the other in SNAC 3, 1 case of SNAC 2 turned out to be an SNAC 3, and 1 case of SNAC 3 resulted in SNAC 4.Single-portal wrist arthroscopy modified the preoperative diagnosis of wrist pathology in 42 patients over 138 cases. The use of single-portal wrist arthroscopy should be considered in the evaluation of the radiocarpal and midcarpal joints to allow accurate visualization of the joint surfaces for surgeon and patient planning.Observational study level of evidence IV.Thieme. All rights reserved.",Journal of wrist surgery,"Dec, 2025",2025,Dec,,Luchetti R|Montanari S|Marcovici L L|Cozzolino R|Kakar S|Atzei A,Kakar S,"Rimini Hand & Upper Limb Surgery and Rehabilitation, Rimini, Italy.|Jewish Hospital of Rome, Rome, Italy.|Campano Hand & Wrist Surgery and Rehabilitation Center, Scafati, Italy.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.|Pro-Mano, Hand Surgery and Rehabilitation, Treviso, Italy.","Luchetti R, Montanari S, Marcovici L L, Cozzolino R, Kakar S, Atzei A",https://pubmed.ncbi.nlm.nih.gov/41267959/,"The study found that a single-portal arthroscopic approach can improve the assessment and diagnosis of chronic radial-sided wrist disorders, such as scapholunate ligament tears and scaphoid nonunion advanced collapse deformities. This technique allows for better visualization of the joint surfaces, leading to more accurate diagnosis and treatment planning for patients."
41231712,Imaging in Renovascular Hypertension: State of the Art.,"Renovascular hypertension (RVH) results from activation of the renin-angiotensin system by renal arterial stenosis (RAS). RAS can result from either intrinsic narrowing or extrinsic compression. Intrinsic narrowing may be caused by atherosclerosis, fibromuscular dysplasia, vasculitis, dissection, thrombus, aneurysm, arteriovenous fistula, neurofibromatosis type 1, or midaortic syndrome. Extrinsic compression can be from retroperitoneal fibrosis, neoplasm, or subcapsular hematoma or fluid. Diagnostic evaluation for RVH is triggered by either a high index of suspicion in a patient with hypertension or incidental detection of RAS at noninvasive imaging. Renal US, primarily with Doppler, is a common modality used for initial screening of RVH, especially when renal function is decreased. US can be used to evaluate hemodynamically significant RAS, including in stents, and also for parenchymal evaluation. MR angiography (MRA) is an excellent modality for RVH evaluation, typically used following US. In patients with decreased renal function, MRA can be performed without contrast material or with ferumoxytol, but group 2 gadolinium-based contrast agents are safe. CT angiography offers excellent spatial resolution that is ideal for the evaluation of distal small renal arterial branches and for assessment of in-stent stenosis following intervention. Conventional angiography is the reference standard, now reserved only for interventional procedures. Imaging also plays an important role in excluding other causes of secondary hypertension and evaluating complications of RVH. The management of RVH depends on the cause and involves a combination of medical treatment and surgical or interventional procedures. Interventional options include angioplasty, stent placement, and embolization. ©RSNA, 2025 Supplemental material is available for this article.",Radiographics,"Dec, 2025",2025,Dec,,Gonzalez T V|Bookwalter C|Khandelwal A|François C J|Takahashi E A|Rajiah P S,Gonzalez T V|Bookwalter C|Khandelwal A|François C J|Takahashi E A|Rajiah P S,"Department of Radiology, Mayo Clinic, 200 1st St SW, Rochester, MN 55905.","Gonzalez T V, Bookwalter C, Khandelwal A, François C J, Takahashi E A, Rajiah P S",https://pubmed.ncbi.nlm.nih.gov/41231712/,"The key finding of this medical research is that renovascular hypertension, a type of high blood pressure caused by narrowing of the renal arteries, can be effectively evaluated using various imaging techniques, including ultrasound, MRI, and CT angiography. These imaging methods can help diagnose the underlying cause and guide appropriate treatment, which may involve medication, surgery, or interventional procedures."
41240917,"Lifetime and 10-year absolute risk of cognitive impairment in relation to amyloid PET severity: a retrospective, longitudinal cohort study.","A key knowledge gap concerns the lifetime risk of developing cognitive impairment among individuals who are cognitively unimpaired with abnormal Alzheimer's disease biomarkers. Our aim was to compute lifetime and 10-year absolute risk of cognitive impairment as a function of continuous amyloid PET.In this retrospective, longitudinal cohort study of data from participants of the population-based Mayo Clinic Study of Aging (Olmsted County, MN, USA), we computed lifetime and 10-year absolute risk of cognitive impairment in participants who were cognitively unimpaired and aged 50 years or older at enrolment. The primary predictor of interest was biological Alzheimer's disease severity, based on amyloid PET centiloid value. Starting age, sex, and APOE ε4 carriership status were also predictors. Outcomes were incident mild cognitive impairment (MCI), dementia, and death, which were ascertained or estimated via multistate hidden Markov modelling both in study and out of study.Between Nov 29, 2004, and Dec 2, 2024, 5158 participants (2623 [51%] women and 2535 [49%] men) who are cognitively unimpaired and 700 (307 [44%] women and 393 [56%] men) with MCI were included for analysis. Lifetime risk of MCI and dementia increased monotonically with increasing centiloid value (p<0·0001), which was the predictor with the largest effect. Lifetime risk of MCI for male APOE ε4 carriers who are cognitively unimpaired at a starting age of 75 years was 56·2% (95% CI 50·5-61·9) for centiloid 5, 60·2% (54·9-65·6) for centiloid 25, 71·0% (65·2-76·7) for centiloid 50, 75·2% (69·1-81·2) for centiloid 75, and 76·5% (70·5-82·4) for centiloid 100. Lifetime risk of MCI for female APOE ε4 carriers who are cognitively unimpaired at a starting age of 75 years was 68·9% (63·7-74·1) for centiloid 5, 71·3% (66·6-76·0) for centiloid 25, 77·6% (72·5-82·7) for centiloid 50, 81·2% (76·7-85·7) for centiloid 75, and 83·8% (78·5-89·1) for centiloid 100. Within each centiloid group, and for both men and women, lifetime and 10-year absolute risk for MCI and dementia was greater for APOE ε4 carriers than for non-carriers (p<0·0001). Biological severity of Alzheimer's disease was a predictor of 10-year absolute risk of MCI and dementia (p<0·0001); however, starting age (p<0·0001) had a more prominent effect. The rate of incident dementia was two times greater among individuals who had previously left the study than those who remained in the study.Lifetime and 10-year absolute risk for MCI and dementia among individuals who are currently cognitively unimpaired increase with increasing biological severity of Alzheimer's disease. This information should be important for risk-benefit evaluation of therapeutic interventions in the future. The high lifetime risk in participants with higher centiloid values addresses academic controversies concerning risk of future impairment associated with biomarkers of Alzheimer's disease among individuals who are cognitively unimpaired. Ascertainment and modelling of out-of-study outcomes are necessary for accurate lifetime risk estimates.US National Institutes of Health, GHR Foundation, and the Alexander Family.Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.",The Lancet. Neurology,"Dec, 2025",2025,Dec,,Jack C R|Hu M|Wiste H J|Knopman D S|Vemuri P|Graff-Radford J|Lowe V J|Vassilaki M|Cogswell P M|Schwarz C G|Algeciras-Schimnich A|Petersen R C|Therneau T M,Jack C R|Hu M|Wiste H J|Knopman D S|Vemuri P|Graff-Radford J|Lowe V J|Vassilaki M|Cogswell P M|Schwarz C G|Algeciras-Schimnich A|Petersen R C|Therneau T M,"Department of Radiology, Mayo Clinic, Rochester, MN, USA. Electronic address: jack.clifford@mayo.edu.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Neurology, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine, Mayo Clinic, Rochester, MN, USA.","Jack C R, Hu M, Wiste H J, Knopman D S, Vemuri P, Graff-Radford J, Lowe V J, Vassilaki M, Cogswell P M, Schwarz C G, Algeciras-Schimnich A, Petersen R C, Therneau T M",https://pubmed.ncbi.nlm.nih.gov/41240917/,"This study found that the lifetime risk of developing mild cognitive impairment or dementia increases significantly as the severity of Alzheimer's disease biomarkers, measured by amyloid PET scans, increases. The risk is even higher for individuals who carry the APOE ε4 gene. This information can help guide future preventive and therapeutic interventions for Alzheimer's disease."
41235131,Expanding the Phenotype Spectrum of β-Mannosidosis.,"β-mannosidosis is an ultra-rare lysosomal storage disorder caused by a deficiency of β-mannosidase, which catalyzes the last step of glycoprotein degradation. Owing to the limited number of reported cases, information on the natural history of the disease and brain imaging is scarce. We report 6 new cases and review them together with all the previously reported cases in the literature.We describe the clinical features of 6 unrelated patients with β-mannosidosis, their variants in MANBA, enzyme activity, urine oligosaccharide profiles, brain MRI findings, and longitudinal MRI changes in 2 of them. We also review previously reported patients to broaden the spectrum of clinical features and identify genotype-phenotype correlations.Developmental regression, dysphagia, obsessive-compulsive-like behavior, and erythromelalgia are newly described features associated with β-mannosidosis among the 6 patients from our cohort. Nystagmus in association with β-mannosidosis was also found in 1 patient. Half the patients have abnormal brain MRIs, showing delayed myelination before 2 years of age and diffuse hypomyelination thereafter. A new oligosaccharide was found in the urine of the 2 most severely affected patients. Including our 6 patients, a total of 46 cases from 37 different families have been reported. The mean age of diagnosis is 12.8 years, and the mean age of symptom onset is 2.4 years. Hearing loss was the initial symptom most frequently reported, and intellectual disability was the most frequent symptom overall. Across the cohort, 29 pathogenic MANBA variants were identified, 61.8% were private, and 38.2% have the recurrent c.2158-2A>G variant. Neuroimaging abnormalities were reported in 40% of published cases and included cortical and subcortical atrophy, basal ganglia and white matter calcification, hydrocephalus, periventricular and subcortical white matter hyperintensities, and delayed myelination.Genotype-phenotype correlation in β-mannosidosis remains elusive, likely due to phenotypic variability, disease rarity, and lack of association between the enzyme activity and the clinical severity. Modifier genes in the N-glycan degradation pathway, such as CTBS, may influence disease expression. β-mannosidosis should be considered as a differential diagnosis in patients with syndromic or apparently nonsyndromic hearing loss, unexplained brain hypomyelination, behavioral disturbances, and intellectual disability.Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.",Neurology. Genetics,"Dec, 2025",2025,Dec,,Martin Rios A M|Gibbs L H|Stepien K M|Hall K|Hall P L|Bentz Pino G|Wang R Y|Pillai N R|Lund T|Orchard P J|Kimonis V E,Hall P L|Bentz Pino G,"Division of Genetics, Department of Pediatrics, University of California, Irvine, Orange, CA.|Department of Radiological Sciences, School of Medicine, University of California, Irvine, Orange, CA.|Adult Inherited Metabolic Diseases Department, Salford Royal Organization, Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom.|CHOC Children's Hospital, Orange, CA.|Biochemical Genetics Laboratory, Division of Laboratory Genetics and Genomics, Mayo Clinic, Rochester, MN.|Division of Metabolic Disorders CHOC Children's Hospital, Orange, CA.|Department of Pediatrics, University of California-Irvine School of Medicine, Irvine, CA.|Division of Genetics and Metabolism, Department of Pediatrics, University of Minnesota, Minneapolis, MN.|Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.|Department of Neurology, University of California, Irvine, Orange, CA; and.|Department of Pathology, University of California, Irvine, Orange, CA.","Martin Rios A M, Gibbs L H, Stepien K M, Hall K, Hall P L, Bentz Pino G, Wang R Y, Pillai N R, Lund T, Orchard P J, Kimonis V E",https://pubmed.ncbi.nlm.nih.gov/41235131/,"This study describes 6 new cases of the rare genetic disorder β-mannosidosis, which is caused by a deficiency in an enzyme that breaks down certain sugars. The researchers found that β-mannosidosis can cause a wider range of symptoms than previously known, including developmental regression, difficulty swallowing, and abnormal behavior. Brain imaging also revealed new patterns of brain changes associated with the disorder. These findings expand our understanding of this rare condition and may help clinicians"
41235993,Cycle characterisation and clinical complications in patients with cyclic Cushing's syndrome: insights from an international retrospective cohort study.,"Cyclic Cushing's syndrome (cCS) features fluctuating cortisol secretion, often causing diagnostic errors or delays, and possibly poorer outcomes. We aimed to identify unpublished cCS cases to characterise clinical challenges and guide strategies for improving outcomes by characterising cycle patterns, peak frequency, and evaluating complications.This was a retrospective observational study at 43 endocrine centres in 21 countries, including patients with confirmed Cushing's syndrome showing two or more hypercortisolaemic peaks and one or more spontaneous eucortisolaemic or hypocortisolaemic trough. Data included both clinical (eg, comorbidities and physical signs of cortisol excess) and biochemical (eg, screening and confirmatory tests) parameters, imaging, treatment, complications, and outcomes.Between Dec 1, 2023 and Feb 2, 2025, 116 potentially eligible patients were identified and 110 were included. Most patients were female (84 [76%] of 110 patients), with a median age at diagnosis of 44·0 years (IQR 31·8-58·3). cCS origin was pituitary in 70 (64%), ectopic in 25 (23%), adrenal in three (3%), and occult in 12 (11%). Cyclicity was primarily determined by 24 h urinary free cortisol, with median peaks of 7·40 × ULN (range 0·44-299) and troughs of 0·31 × ULN (0·02-0·98). The median peak count was 3·0 (IQR 2·0-4·0), mostly (55 [86%] of 64 patients) occurring at irregular intervals, and was most frequent and pronounced in ectopic cCS. Symptoms worsened in 87 (81%) of 108 patients during peaks and improved in 79 (74%) of 107 patients during troughs; 31 (28%) of 110 patients had spontaneous adrenal insufficiency. Bilateral inferior petrosal sinus sampling (BIPSS) was performed during troughs in 14 patients (18% of the 78 procedures done). Imaging missed tumours in 35 (32%) of the 110 patients, and nine (8%) underwent unwarranted surgeries at the wrong anatomical site due to misclassification. After 5·8 years (IQR 2·6-10·5) median follow-up, 55 (50%) of 110 patients had complete biochemical surgical remission, seven (6%) had spontaneous remission, 22 (20%) were medically controlled, six (5%) had partial remission, 11 (10%) remained uncontrolled, nine (8%) were lost to follow-up. During the entire observation period, 3% (3/110) died. Delayed diagnosis (45 [41%] of 110 patients) and therapy (47 [43%]) were also observed.Even in specialised centres, cCS diagnosis and management remain challenging with high rates of spontaneous adrenal insufficiency, inappropriate surgeries, and poor outcomes. Ectopic cCS showed the most frequent and severe peaks. These findings might help to guide imaging localisations or the timing of BIPSS in patients with active occult ACTH-dependent cCS. Hypercortisolism needs to be biochemically confirmed before BIPSS to enable correct tumour localisation. Patients with suspected or proven cCS should be equipped with salivary cortisol collection kits to capture dynamic changes as well as being prescribed glucocorticoids to be used as a precaution.None.Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.",The lancet. Diabetes & endocrinology,"Dec, 2025",2025,Dec,,Nowak E|Zhang Q|Zhang S|Zhao Y|Ye H|Machado M C|Moises C C S|Tóth M|Stark J|Yuen K C J|Gurnell M|MacFarlane J|McCormack A|Govinna M|Gilis-Januszewska A|Minasyan M|Bonaventura I|Czepielewski M A|Ferriere A|Gadelha M|Isidori A M|Kastelan D|Maiter D|Tabarin A|Alexandraki K I|Chang J|Frontera E D|Hanzu F A|Matikainen N|Miljic D|Pichler R|Popovic V|Spencer-Segal J L|Tordjman K|Akirov A|Araujo-Castro M|Arvat E|Bancos I|Bioletto F|Burman P|Castinetti F|Detomas M|Fassnacht M|Feelders R A|Fountas A|Igaz P|Ilic S|Isand K|Kaltsas G|Meyer G|Parasiliti-Caprino M|Newell-Price J|Ragnarsson O|Valassi E|Vila G|Wass J|Yoel U|Fleseriu M|Reincke M,Bancos I,"Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany. Electronic address: elisabeth.nowak@med.uni-muenchen.de.|Department of Neurosurgery, National Center for Neurological Disorders, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.|Department of Endocrinology and Metabolism, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.|Neuroendocrine Unit, Division of Endocrinology and Metabolism, University of Sao Paulo Medical School, Sao Paulo, Brazil.|Department of Internal Medicine and Oncology, ENETS Center of Excellence and ENDO-ERN HCP, Faculty of Medicine, Semmelweis University, Budapest, Hungary.|Department of Neuroendocrinology and Neurosurgery, Barrow Pituitary Center, Barrow Neurological Institute, University of Arizona College of Medicine and Creighton University School of Medicine, Phoenix, AZ, USA.|Cambridge Endocrine Molecular Imaging Group, Institute of Metabolic Science, University of Cambridge & NIHR Cambridge Biomedical Research Centre, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK.|St Vincent's Hospital, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.|Department of Endocrinology, Jagiellonian University, Medical College, Krakow, Poland.|Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.|Division of Endocrinology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; Programa de Pós-graduação Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.|Department of Endocrinology, Diabetes, and Nutrition, University Hospital of Bordeaux, Pessac, France.|Neuroendocrinology Division, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, Brazil.|Department of Endocrinology, University Hospital Centre Zagreb, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia.|Department of Endocrinology, Cliniques Universitaires Saint-Luc, UCLouvain, Bruxelles, Belgium.|2nd Department of Surgery, Aretaieio Hospital, National and Kapodistrian University of Athens, Athens, Greece.|Division of Endocrinology, Gerontology, and Metabolism, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.|Division of Metabolism, Endocrinology and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, USA.|Endocrinology and Nutrition Department and Institut de Investigacions Biomediques Pi I Sunyer Barcelona, Hospital Clínic of Barcelona, University Barcelona, Barcelona, Spain.|Endocrinology, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; European Reference Network on Rare Endocrine Conditions, Helsinki University Hospital, Helsinki, Finland.|Clinic for Endocrinology, Diabetes, and Metabolic Diseases, University Clinical Center of Serbia, Belgrade, Serbia; Faculty of Medicine, University of Belgrade, Belgrade, Serbia.|Institute of Nuclear Medicine, Kepler University Hospital, Neuromed Campus, Linz, Austria.|Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan, Ann Arbor, MI, USA; Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI, USA.|Institute of Endocrinology, Metabolism, and Hypertension, Tel Aviv Sourasky Medical Center; Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel.|Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; Endocrine Institute, Rabin Medical Center, Petach-Tikva, Israel.|Department of Endocrinology and Nutrition, Hospital Universitario Ramón y Cajal, Instituto de Investigación Ramón y Cajal, Madrid, Spain; Universidad de Alcalá, Madrid, Spain.|Department of Medical Sciences, University of Turin, Turin, Italy.|Division of Endocrinology, Diabetes, and Nutrition, Mayo Clinic, Rochester, MN, USA.|Department of Endocrinology, Skåne University Hospital, Lund University, Malmö, Sweden.|Aix Marseille University, AP-HM, Inserm, Marseille Medical Genetics, Marseille Rare Disease Institute, Marseille, France; Department of Endocrinology, CRMR HYPO, La Conception University Hospital, AP-HM, Marseille, France.|Department of Internal Medicine I, Division of Endocrinology and Diabetes, University Hospital, University of Würzburg, Würzburg, Germany.|Department of Internal Medicine, Division of Endocrinology, Erasmus Medical Center, Rotterdam, The Netherlands; Holman Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, New York University Langone Medical Center, New York, NY, United States.|Department of Endocrinology, and Diabetes Center, G Gennimatas General Hospital of Athens, Athens, Greece.|Department of Endocrinology and Department of Internal Medicine and Oncology, Faculty of Medicine, Semmelweis University, Budapest, Hungary.|Department of Endocrinology, North Estonia Medical Centre, Tallinn, Estonia.|Neuroendocrine Tumor Unit, 1st Department of Propaedeutic Internal Medicine, Laiko General Hospital, National and Kapodistrian University of Athens, Athens, Greece.|Medical Clinic 1, Department of Endocrinology, University Hospital, Goethe University Frankfurt, Frankfurt, Germany.|School of Medicine and Population Heath, University of Sheffield, Sheffield, UK.|Department of Endocrinology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Internal Medicine and Clinical Nutrition and Wallenberg Center for Molecular and Translational Medicine, University of Gothenburg, Gothenburg, Sweden.|Endocrinology Department, Germans Trias i Pujol Hospital and Research Institute, CIBERER Unit 747, Barcelona, Spain; Universitat Internacional de Catalunya (UIC), Barcelona, Spain.|Clinical Division of Endocrinology and Metabolism, Department of Medicine III, Medical University of Vienna, Vienna, Austria.|Department of Endocrinology, Churchill Hospital, University of Oxford, Oxford, UK.|Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er Sheva, Israel.|Pituitary Center, Departments of Medicine and Neurological Surgery, Oregon Health & Science University, Portland, OR, USA.|Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany.","Nowak E, Zhang Q, Zhang S, Zhao Y, Ye H, Machado M C, Moises C C S, Tóth M, Stark J, Yuen K C J, Gurnell M, MacFarlane J, McCormack A, Govinna M, Gilis-Januszewska A, Reincke M, et al.",https://pubmed.ncbi.nlm.nih.gov/41235993/,"Cyclic Cushing's syndrome is a rare condition with fluctuating cortisol levels, often leading to delayed diagnosis and poor outcomes. This international study found that ectopic cyclic Cushing's syndrome had the most frequent and severe cortisol peaks, and many patients experienced spontaneous adrenal insufficiency, inappropriate surgeries, and poor long-term control. The findings highlight the challenges in diagnosing and managing this condition, and suggest the need for improved imaging"
41236348,"Starve the tumor, fuel the immune fire: Short-term starvation enhances checkpoint blockade via macrophage reprogramming in HCC.",No abstract available.,"Hepatology (Baltimore, Md.)","Dec 01, 2025",2025,Dec,01,Dong Y|Ilyas S I,Dong Y|Ilyas S I,"Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.","Dong Y, Ilyas S I",https://pubmed.ncbi.nlm.nih.gov/41236348/,"This research likely explores how short-term starvation can enhance the effectiveness of cancer immunotherapy in liver cancer. It suggests that starvation can reprogram macrophages, a type of immune cell, to better fight the tumor."
41236349,A strategic plan of RETREAT: Time to translate validation into action.,No abstract available.,"Hepatology (Baltimore, Md.)","Dec 01, 2025",2025,Dec,01,Li Z|Ilyas S I,Li Z|Ilyas S I,"Division of Transplant Surgery, William J. von Liebig Transplant Center, Mayo Clinic, Rochester, Minnesota, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.","Li Z, Ilyas S I",https://pubmed.ncbi.nlm.nih.gov/41236349/,"This research likely explores the development of a strategic plan for a process called ""RETREAT."" The title suggests that the research aims to translate previous validation efforts into concrete actions or implementation."
41236351,"It's not you, it's MET: When MASH gets personal.",No abstract available.,"Hepatology (Baltimore, Md.)","Dec 01, 2025",2025,Dec,01,Ozmert E H|Ilyas S I,Ozmert E H|Ilyas S I,"Department of Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.","Ozmert E H, Ilyas S I",https://pubmed.ncbi.nlm.nih.gov/41236351/,"This research likely explores the relationship between the MASH (Mitogen-Activated Protein Kinase) signaling pathway and personal or individual factors. It suggests that the MET (Mesenchymal-Epithelial Transition) protein, which is involved in the MASH pathway, may play a role in shaping personal or individual characteristics."
41240916,"Global, regional, and national burden of headache disorders, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.","The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 estimates health loss from migraine, tension-type headache, and medication-overuse headache. This study presents updated results on headache-attributed burden from 1990 to 2023, along with clinical and public health implications.Data on the prevalence, incidence, or remission of migraine, tension-type headache, and medication-overuse headache were extracted from published population-based studies. We used hierarchical Bayesian meta-regression modelling to estimate global, regional, and country-level prevalence of headache disorders. For the first time in GBD 2023, age-specific and sex-specific estimates of time in symptomatic state were applied by meta-analysing individual participant data from 41 653 individuals from the general populations of 18 countries from all parts of the world. Disability weights were applied to calculate years lived with disability (YLDs). Since medication-overuse headache is a sequela of a mistreated primary headache (due to medication overuse), its burden was reattributed to migraine or tension-type headache, informed by a meta-analysis of three longitudinal studies.In 2023, 2·9 billion individuals (95% uncertainty interval 2·6-3·1) were affected by headache disorders, with a global age-standardised prevalence of 34·6% (31·6-37·5) and a YLD rate of 541·9 (373·4-739·9) per 100 000 population, with 487·5 (323·0-678·8) per 100 000 population attributed to migraine. The prevalence rates of these headache disorders have remained stable over the past three decades. YLD rates due to headache disorders were more than twice as high in females (739·9 [511·2-1011·5] per 100 000) as in males (346·1 [240·4-481·8] per 100 000). Medication-overuse headache contributed 58·9% of the YLD estimates for tension-type headache in males and 56·1% in females, as well as 22·6% of the YLD estimates for migraines in males and 14·1% in females.Headache disorders, in particular migraine, continue to be a major global health challenge, emphasising the need for effective management and prevention strategies. Much headache-attributed burden could be averted or eliminated by avoiding overuse of medication (including over-the-counter medication), underscoring the importance of public education.Gates Foundation.Copyright © 2025 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.",The Lancet. Neurology,"Dec, 2025",2025,Dec,,,,,,https://pubmed.ncbi.nlm.nih.gov/41240916/,"Headache disorders, especially migraine, remain a major global health challenge, affecting 2.9 billion people worldwide in 2023. The burden of these disorders, measured in years lived with disability, is more than twice as high in females compared to males. Medication overuse is a significant contributor to this burden, highlighting the need for better management and prevention strategies to reduce the impact of headache disorders globally."
41244748,"Treatment Modalities, Pain Response, and Referrals for Hypermobile Ehlers-Danlos Syndrome and Hypermobility Spectrum Disorders: A Retrospective Study.","To gain a better understanding of preferred treatment modalities and referrals to better treat and manage pain symptoms, we conducted a retrospective longitudinal cohort study of patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD).A retrospective analysis of self-reported data in 290 patients diagnosed with hEDS or HSD according to the 2017 Criteria from November 1, 2019, to June 12, 2023, who completed intake and outtake questionnaires. Patients were asked questions on the severity of hypermobile, joint and muscle pain, and whether clinical referral and/or medications/treatments improved their pain.Less than 30% of patients with hEDS and HSD reported improvement of hypermobility, joint or muscle pain from any of 17 treatment modalities listed in the outtake questionnaire. Patients self-reported that physical activity/exercise significantly or borderline significantly improved pain symptoms (hypermobility pain hEDS, n=36 (46.8%) vs 10 (76.9%), P=.07; HSD, n=77 (47.8%) vs 16 (88.9%), P=.001; joint pain hEDS, n=29 (45.3%) vs 17 (73.9%), P=.03; HSD, n=59 (42.8%) vs 32 (86.5%), P<.0001; muscle pain hEDS, n=25 (44.6%) vs 12 (75.0%), P=.05; HSD, n= 59 (45.4%) vs 25 (89.3%), P<.0001), whereas patients with HSD reported that physical therapy also improved pain (hypermobility pain HSD, n=78 (48.5%) vs 15 (83.3%), P=.006; joint pain HSD, n=62 (44.9%) vs 28 (75.7%), P=.001; muscle pain HSD, n=60 (46.2%) vs 20 (71.4%), P=.02). In contrast, patients with hEDS reported that topical medications made their muscle pain worse (n=27 (48.2%) vs 3 (18.8%), P=.05) and patients with HSD that injections made their joint pain worse (n=39 (28.3%) vs 4 (10.8%), P=.03). Most patients reported that referrals improved their pain. However, 40% or more reported that referrals to allergy and immunology and rheumatology departments worsened their pain.This study identified patient perceptions on treatments and referrals that improved or made their pain worse. These findings provide a starting point for future treatment guidelines, decision aids, and research on patient-reported outcomes.© 2025 The Authors.","Mayo Clinic proceedings. Innovations, quality & outcomes","Dec, 2025",2025,Dec,,Wilson F C|Bruno K A|Fairweather D|Carroll M G|Darakjian A A|Gajarawala S|Zeman A M|Shirey D|Buck T R|Bruce B K|Gehin J M|Boucher L M|Greenaway M S|Shufelt C L|Knight D R T,Wilson F C|Bruno K A|Fairweather D|Carroll M G|Darakjian A A|Gajarawala S|Zeman A M|Shirey D|Buck T R|Bruce B K|Gehin J M|Boucher L M|Shufelt C L|Knight D R T,"Department of General Internal Medicine, Mayo Clinic, Jacksonville, FL.|Department of Cardiovascular Medicine, Mayo Clinic, Jacksonville, FL.|Division of Cardiovascular Medicine, University of Florida, Gainesville, FL.|Department of Physical Medicine and Rehabilitation, Mayo Clinic, Jacksonville, FL.|Department of Psychiatry and Psychology, Mayo Clinic, Jacksonville, FL.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN.|Curtin School of Allied Health, Curtin University, Whadjuk Nyoongar Country, Perth, Australia.","Wilson F C, Bruno K A, Fairweather D, Carroll M G, Darakjian A A, Gajarawala S, Zeman A M, Shirey D, Buck T R, Bruce B K, Gehin J M, Boucher L M, Greenaway M S, Shufelt C L, Knight D R T",https://pubmed.ncbi.nlm.nih.gov/41244748/,"This study found that less than 30% of patients with hypermobile Ehlers-Danlos syndrome (hEDS) and hypermobility spectrum disorders (HSD) reported improvement in their pain symptoms from various treatments. However, patients reported that physical activity/exercise and physical therapy significantly improved their pain, while some medications and referrals to certain departments made their pain worse. These findings can help guide future treatment recommendations and research on patient-reported outcomes for these conditions."
41264508,Practical Tips and Tricks for Salvaging ECG-gated Cardiac CT from Motion Artifacts.,"Despite technical advances and careful preparation, motion artifacts are commonly encountered in cardiac CT. Artifacts due to patient motion or breathing are not correctable and may necessitate repeat scanning; however, cardiac motion artifacts may be mitigated without repeating the scan. Cardiac motion artifacts may manifest as blur, transition, interpolation, or duplication. Blur artifact due to mismatch between cardiac motion speed and the scanner's temporal resolution can be mitigated by using a different cardiac phase, a motion-correction algorithm, or multisegment reconstruction. Transition artifact at the interface between different scanned segments with different R-R interval lengths may be mitigated by using a different cardiac phase or edge-correction algorithms. Interpolation artifact results when the pitch is too high for the heart rate (HR) at some point of a retrogated scan, either due to the patient taking a deep breath, missing electrocardiographic (ECG) synchronization (sync)-points, or long ECG pauses after premature atrial contractions (PACs) or premature ventricular contractions (PVCs). The scanner fills the data gaps by interpolating (ie, ""smearing"") data from above and below the gap. Duplication artifact results when the pitch is too low for the HR at some point of a retrogated scan, due to contrast material injection, medications, premature or extra beats, or spurious ECG sync-points. Interpolation and duplication artifacts can often be mitigated by manipulating ECG sync-points. In sync-point editing, sync-points are added (eg, for a missed R wave) or deleted (eg, tagging of a tall T wave, exercise spike, or bifid R waves) such that every R wave (and only R waves) are tagged. In sync-point composing, sync-points are artificially manipulated to improve image quality in arrhythmias with variable R-R intervals (eg, PACs or PVCs, atrial fibrillation). ©RSNA, 2025 Supplemental material is available for this article. See the invited commentary by Ufuk and Landeras in this issue.",Radiographics,"Dec, 2025",2025,Dec,,Jokerst C E|Rajiah P S,Jokerst C E|Rajiah P S,"Department of Radiology, Mayo Clinic Arizona, Phoenix, Ariz.|Department of Radiology, Division of Cardiovascular Imaging, Mayo Clinic, 200 First St SW, Rochester, MN 55905.","Jokerst C E, Rajiah P S",https://pubmed.ncbi.nlm.nih.gov/41264508/,"The key finding of this medical research is that cardiac motion artifacts in CT scans can be mitigated without repeating the scan by using techniques such as adjusting the cardiac phase, applying motion-correction algorithms, and manipulating the electrocardiographic synchronization points. These practical tips and tricks can help improve the quality of cardiac CT images and reduce the need for repeat scans."
41244751,How to Interpret a Nerve Conduction Study: A Stepwise Approach.,No abstract available.,Neurology. Education,"Dec, 2025",2025,Dec,,Zelikovich A S|Pucci G F|Minkis J|Pinto M V,Pinto M V,"Department of Neurology, Lenox Hill Hospital, Northwell Health, New York, NY.|Department of Neurology, University of Pittsburgh, PA; and.|Department of Neurology, Mayo Clinic, Rochester, MN.","Zelikovich A S, Pucci G F, Minkis J, Pinto M V",https://pubmed.ncbi.nlm.nih.gov/41244751/,"This research likely explores how to properly interpret the results of a nerve conduction study, which is a medical test used to assess the health of the nerves. The study likely provides a step-by-step guide or approach to help healthcare professionals accurately interpret the data from this type of diagnostic test."
41245542,"Early stoppage of empirical antibiotic therapy in paediatric acute leukaemia with high-risk febrile neutropenia: a randomized, open-label, phase 3, non-inferiority trial.","Empirical antibiotic therapy (EAT) is commonly continued until recovery of neutrophil counts in paediatric acute leukaemia with high-risk febrile neutropenia. This study assessed whether early discontinuation of EAT was non-inferior to the continuation of EAT until absolute neutrophil count (ANC) ≥500/μL among children with high-risk febrile neutropenia.This open-label, phase 3, non-inferiority, randomized trial was conducted between October 2018 and August 2024 and enrolled children aged 2-18 years with acute leukaemia experiencing high-risk febrile neutropenia during induction chemotherapy. Patients clinically stable and afebrile for ≥72 h on EAT, with ANC <500/μL and no documented infection, were randomized to either stop EAT or continue it until ANC ≥500/μL. The primary outcome was proportion of fever recurrence, with a non-inferiority margin of 15 percentage points. Secondary outcomes included antibiotic duration, hospital readmissions, use of third-line antibiotics, use of therapeutic antifungals, and mortality. This study is registered at Clinical Trial Registry of India (CTRI/2018/015994).Of 280 patients randomized, 278 were analysed (140 stop arm, 138 continuation arm). Median age (IQR) was 8 (5-14) years, with 34.2% being female. Fever recurrence occurred in 52.1% (73/170) and 47.1% (65/138) children in stop and continuation arms respectively. The difference in fever recurrence between the arms was 5.0 percentage points (90% CI: -4.8 to 14.8 percentage points), establishing non-inferiority of the stop arm. The median (IQR) days of EAT after randomization were shorter in the stop arm [4.2 (0-10) vs 11 (7.2-15); p < 0.0001]. Mortality, hospital readmission, third-line antibiotic use, or therapeutic antifungal use did not differ between the two arms.Early discontinuation of EAT in paediatric acute leukaemia with high-risk febrile neutropenia was non-inferior to continuation of EAT until recovery of ANC.None.© 2025 The Author(s).",EClinicalMedicine,"Dec, 2025",2025,Dec,,Chellapuram S K|Kn S K|Sra M S|Giri R K|Pushpam D|Batra A|Vishnubhatla S|Ganguly S|Bakhshi S,Sra M S,"Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi, India.|Division of Hematology, Mayo Clinic, Rochester, MN, United States.|Department of Biostatistics, All India Institute of Medical Sciences (AIIMS), New Delhi, India.|Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India.","Chellapuram S K, Kn S K, Sra M S, Giri R K, Pushpam D, Batra A, Vishnubhatla S, Ganguly S, Bakhshi S",https://pubmed.ncbi.nlm.nih.gov/41245542/,"This study found that in children with acute leukemia and high-risk febrile neutropenia, early discontinuation of empirical antibiotic therapy was non-inferior to continuing it until the neutrophil count recovered. This suggests that antibiotics can be stopped earlier in these patients, potentially reducing antibiotic exposure and associated side effects without compromising outcomes."
41250307,Balance Revisited.,No abstract available.,Techniques in hand & upper extremity surgery,"Dec 01, 2025",2025,Dec,01,Shin A Y,Shin A Y,"Division of Hand Surgery, Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.",Shin A Y,https://pubmed.ncbi.nlm.nih.gov/41250307/,"This research likely explores the concept of balance, which is a fundamental aspect of various fields such as physics, biology, and even personal well-being. The study may investigate new perspectives or revisit existing theories related to the idea of balance, aiming to provide a deeper understanding of this important concept."
41250932,Elevated Serum Bile Acids Predict Poor Liver Outcomes in Children With Alagille Syndrome: Results From the GALA Study Group.,"Alagille syndrome (ALGS) is a rare disorder characterised by cholestasis and extrahepatic manifestations. Given the current era of ileal bile acid transporter (IBAT) inhibitor therapies that reduce serum bile acid (SBA) levels, we evaluated whether SBA predicts liver disease outcomes in ALGS.Patients were ascertained from the Global ALagille Alliance (GALA) cohort. A prognostic threshold of SBA 102 μmol/L was assessed as a time-dependent covariate in Cox regression analyses for native liver survival (NLS) and event-free survival (EFS), while adjusting for total bilirubin (TB) levels.570 GALA patients were included (348 [61%] male). There was a moderate positive correlation between SBA and TB (Pearson correlation = 0.47, p < 0.001). SBA below 102 μmol/L was a significant predictor of outcomes (NLS: HR = 3.78, 95% CI 2.39-5.99, p < 0.001; EFS: HR = 3.44, 95% CI 2.35-5.04, p < 0.001). SBA remained a significant predictor for improved EFS after adjusting for TB clearance at 1 year (TB < 2 mg/dL; HR = 2.00, 95% CI 1.10-3.65, p = 0.02). Median SBA in the first year of life above 102 μmol/L, predicted lower NLS (67.2% vs. 83.5% at 7 years p = 0.05) and EFS (63.4% vs. 80.9% at 7 years, p = 0.02).Lower SBA in children with ALGS liver disease predicts improved NLS and EFS. SBA is also associated with NLS in children with ALGS who clear their bilirubin, that is, those with anicteric cholestasis. Although the patients studied here did not receive IBAT inhibition, these data suggest that lowering SBA may improve important clinical outcomes.© 2025 The Author(s). Liver International published by John Wiley & Sons Ltd.",Liver Int,"Dec, 2025",2025,Dec,,Perez C F M|Vandriel S M|Gonzales E M|Wang J|Li L|She H|Jankowska I|Czubkowski P|Gliwicz-Miedzińska D|Jacquemin E|Bouligand J|D'Antiga L|Nicastro E|Fischler B|Arnell H|Siew S M|Stormon M|Loomes K M|Piccoli D A|Rand E B|Squires J E|Karpen S J|Romero R|Kasahara M|Önal Z|Sokal É|Demaret T|Wiecek S|Lacaille F|Debray D|Hardikar W|Shankar S|Valentino P L|Sundaram S S|Ebel N H|Feinstein J A|Waisbourd-Zinman O|Lin H C|Rock N|Verkade H J|Jensen M K|Jaramillo C|Kim K M|Oh S H|Brecemiclj J|Alam S|Indolfi G|Blondet N|Fawaz R|Nastasio S|Calvo P L|Nebbia G|Arikan C|Larson-Nath C|Zizzo A N|Sandahl T D|Tzivinikos C|El-Koofy N M|Elmonem M A|Aqul A A|Karnsakul W|Bulut P|Kerkar N|Wolters V M|Roberts A J|Evans H M|Sanchez M C|Cavalieri M L|Kelly D A|Hartley J|Lee W S|Hajinicolaou C|Lertudomphonwanit C|Fischer R T|Bernabeu J Q|Quiros-Tejeira R E|Ferreira C T|Carvalho E|Eshun J|Zellos A|Dezsőfi A|Pinto R B|Schwarz K|Rogalidou M|Garcia J|Tamara M L|Beretta M|Mujawar Q|Santos-Silva E|Busoms C M|Lurz E|Gonçalves C|Jimenez-Rivera C|Banales J M|Thompson R J|Hansen B E|Kamath B M,Kerkar N,"Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children and the University of Toronto, Toronto, Canada.|Pediatric Hepatology and Liver Transplantation Unit, National Reference Centre for Rare Pediatric Liver Diseases, FILFOIE, ERN RARE LIVER, Bicêtre Hospital, AP-HP, Université Paris-Saclay, Le Kremlin-Bicêtre, and Inserm U1193, Hepatinov, University of Paris-Saclay, Orsay, France.|Children's Hospital of Fudan University, The Center for Pediatric Liver Diseases, Shanghai, China.|Department of Gastroenterology, Hepatology, Nutrition Disturbances and Pediatrics, The Children's Memorial Health Institute, Warsaw, Poland.|Service de Génétique Moléculaire, Pharmacogénétique et Hormonologie, Hôpitaux Universitaires Paris-Saclay, Assistance Publique-Hôpitaux de Paris, Centre Hospitalier Universitaire de Bicêtre, Le Kremlin-Bicêtre, France.|Ospedale Papa Giovanni XXIII, Pediatric Hepatology, Gastroenterology and Transplantation, Bergamo, Italy.|Department of Medicine and Surgery, University of Milano, Milan, Italy.|Department of Paediatric Gastroenterology, Hepatology and Nutrition, Astrid Lindgren Children's Hospital, Karolinska University Hospital and CLINTEC, Karolinska Institutet, Stockholm, Sweden.|Department of Paediatric Gastroenterology, Hepatology and Nutrition, Astrid Lindgren Children's Hospital, Karolinska University Hospital and Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.|Department of Gastroenterology, The Children's Hospital at Westmead, Sydney, Australia.|Division of Gastroenterology, Hepatology and Nutrition, The Children's Hospital of Philadelphia and the University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.|Division of Pediatric Gastroenterology and Hepatology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.|Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Healthcare of Atlanta and Emory University School of Medicine, Atlanta, Georgia, USA.|Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, Richmond, Virginia, USA.|Organ Transplantation Center, National Center for Child Health and Development, Tokyo, Japan.|Pediatric Gastroenterology, Hepatology and Nutrition Department, Istanbul University Istanbul Medical Faculty, Istanbul, Turkey.|Cliniques Universitaires Saint-Luc, Service De Gastroentérologie and Hépatologie Pédiatrique, Brussels, Belgium.|Department of Pediatrics, Medical University of Silesia, Katowice, Poland.|Pediatric Gastroenterology-Nutrition and Hepatology Units, Necker-Enfants Malades Hospital, University of Paris, Paris, France.|Pediatric Liver Unit, National Reference Centre for Rare Pediatric Liver Diseases (Biliary Atresia and Genetic Cholestasis), FILFOIE, ERN RARE LIVER, Necker-Enfants Malades Hospital, University of Paris, Paris, France.|Department of Gastroenterology and Clinical Nutrition, Royal Children's Hospital, Melbourne, Australia.|Mazumdar Shaw Medical Center, Narayana Health, Bangalore, India.|Gastroenterology and Hepatology Division, Department of Pediatrics, University of Washington, Seattle Children's Hospital, Seattle, Washington, USA.|Section of Gastroenterology, Hepatology and Nutrition, Department of Pediatrics and the Digestive Health Institute, Children's Hospital of Colorado and University of Colorado School of Medicine, Aurora, Colorado, USA.|Division of Gastroenterology, Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California, USA.|Department of Pediatrics (Cardiology), Stanford University School of Medicine, Lucile Packard Children's Hospital, Palo Alto, California, USA.|Schneider Children's Medical Center of Israel, Institute of Gastroenterology, Nutrition and Liver Diseases, Petah Tikva, Israel.|Division of Pediatric Gastroenterology, Department of Pediatrics, Oregon Health and Science University, Portland, Oregon, USA.|Division of Pediatric Specialties, Department of Pediatrics, Gynecology, and Obstetrics, Swiss Pediatric Liver Center, University Hospitals Geneva and University of Geneva, Geneva, Switzerland.|Department of Pediatrics, Center for Liver, Digestive, and Metabolic Diseases, University Medical Center Groningen, Groningen, the Netherlands.|Division of Pediatric Gastroenterology, Hepatology and Nutrition, Primary Children's Hospital, University of Utah, Salt Lake City, Utah, USA.|Department of Pediatrics, Asan Medical Center Children's Hospital, University of Ulsan College of Medicine, Seoul, Republic of Korea.|Pediatric Gastroenterology, Hepatology and Nutrition, and Department of Pediatrics, Faculty of Medicine, University Medical Center Ljubljana, Ljubljana, Slovenia.|Department of Pediatric Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.|Meyer Children's University Hospital IRCCS, Florence, Italy.|Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut, USA.|Division of Gastroenterology, Hepatology, and Nutritions, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.|Pediatric Gastroenterology Unit, Regina Margherita Children's Hospital, Azienda Ospedaliera-Universitaria Citta' della Salute e della Scienza, Turin, Italy.|Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Servizio di Epatologia Pediatrica, Milan, Italy.|Department of Pediatric Gastroenterology and Organ Transplant, Koc University School of Medicine, Istanbul, Turkey.|Division of Pediatric Gastroenterology, Hepatology, and Nutrition, University of Minnesota, Minneapolis, Minnesota, USA.|Division of Paediatric Gastroenterology and Hepatology, Children's Hospital, London Health Sciences Centre, Western University, London, Ontario, Canada.|Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark.|Department of Paediatric Gastroenterology, Al Jalila Children's Specialty Hospital, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai, UAE.|Department of Pediatrics, Faculty of Medicine, Cairo University, Cairo, Egypt.|Department of Clinical and Chemical Pathology, Faculty of Medicine, Cairo University, Cairo, Egypt.|University of Texas Southwestern Medical Center in Dallas and Children's Health, Dallas, Texas, USA.|Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.|Division of Pediatric Gastroenterology and Hepatology, Phoenix Children's Hospital, Phoenix, Arizona, USA.|Massachusetts General Brigham for Children, Boston, Massachusetts, USA.|University of Rochester Medical Center, Rochester, New York, USA.|Department of Pediatric Gastroenterology, University Medical Center Utrecht, Utrecht, the Netherlands.|Department of Paediatric Gastroenterology, Starship Child Health, Auckland, New Zealand.|Hospital Italiano Buenos Aires, Pediatric Gastroenterology and Hepatology Division, Buenos Aires, Argentina.|Liver Unit, Birmingham Women's and Children's Hospital NHS Trust and University of Birmingham, Birmingham, UK.|Department of Paediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.|Division of Paediatric Gastroenterology, Department of Paediatrics and Child Health, Chris Hani Baragwanath Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.|Division of Gastroenterology, Department of Pediatrics, Ramathibodi Hospital Mahidol University, Bangkok, Thailand.|Section of Hepatology, Department of Gastroenterology, Children's Mercy Kansas City, Kansas City, Kansas, USA.|Pediatric Hepatology and Liver Transplant Department, Hospital Universiatri Vall d'Hebron, Barcelona, Spain.|Department of Liver and Gastrointestinal Diseases, Biodonostia Health Research Institute - Donostia University Hospital - University of the Basque Country (UPV/EHU), San Sebastian, Spain.|Department of Pediatrics, Children's Hospital and Medical Center and University of Nebraska Medical Center, Omaha, Nebraska, USA.|Pediatric Gastroenterology Service, Hospital da Criança Santo Antônio, Universidade Federal de Ciências da Saúde de Porto Alegre, Complexo Hospitalar Santa Casa, Porto Alegre, Rio Grande do Sul, Brazil.|Pediatric Gastroenterology Department, Hospital de Base do Distrito Federal, Hospital da Criança de Brasília, Centro Universitário de Brasília, Brasília, Distrito Federal, Brazil.|Department of Pediatric Gastroenterology, Le Bonheur Children's Hospital and The University of Tennessee Health Science Center, Memphis, Tennessee, USA.|Mitera Children's Hospital, Athens, Greece.|First Department of Paediatrics, Semmelweis University, Budapest, Hungary.|Division of Pediatric Gastroenterology, Hospital Criança Conceição, Grupo Hospitalar Conceição, Porto Alegre, Rio Grande do Sul, Brazil.|Division of Pediatric Gastroenterology, Rady Children's Hospital San Diego, University of California San Diego, San Diego, California, USA.|Division of Gastroenterology and Hepatology, First Department of Paediatrics, University of Athens, ""Aghia Sofia"" Children's Hospital, Athens, Greece.|Division of Pediatric Gastroenterology, Hepatology and Nutrition, Miami Transplant Institute, University of Miami, Miami, Florida, USA.|Paediatric Gastroenterology Unit, Cruces University Hospital, Bilbao, Spain.|Faculty of Health Sciences, Wits Donald Gordon Medical Centre, University of the Witwatersrand, Johannesburg, South Africa.|Section of Pediatric Gastroenterology, Department of Pediatrics, University of Manitoba, Winnipeg, Canada.|Centro Hospitalar Universitário de Santo António, Centro Materno-Infantil do Norte Albino Aroso, Porto, Portugal.|UCIBIO - Applied Molecular Biosciences Unit, Biochemistry Laboratory, Department of Biological Sciences, Faculdade de Farmácia, Universidade do Porto, Porto, Portugal.|Pediatric Gastroenterology Hepatology and Nutrition Unit, Hospital Sant Joan de Déu, Esplugues de Llobregat, Spain.|Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, LMU Munich, Munich, Germany.|European Reference Network on Hepatological Diseases (ERN RARE-LIVER), Hamburg, Germany.|Pediatric Gastroenterology/Hepatology Center Lisbon, Lisbon, Portugal.|Division of Gastroenterology, Hepatology and Nutrition, Children's Hospital of Eastern Ontario, Ottawa, Canada.|Department of Hepatology and Gastroenterology, Biodonostia Health Research Institute - Donostia University Hospital, Universidad del País Vasco (UPV/EHU), Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), San Sebastián, Spain.|Institute of Liver Studies, King's College London, London, UK.|Toronto General Hospital University Health Network, Toronto, Canada.|Institute of Health Policy, Management and Evaluation, Toronto, Canada.","Perez C F M, Vandriel S M, Gonzales E M, Wang J, Li L, She H, Jankowska I, Czubkowski P, Gliwicz-Miedzińska D, Jacquemin E, Bouligand J, D'Antiga L, Nicastro E, Fischler B, Arnell H, Kamath B M, et al.",https://pubmed.ncbi.nlm.nih.gov/41250932/,"The key finding of this study is that lower serum bile acid (SBA) levels in children with Alagille syndrome (ALGS) predict improved liver disease outcomes, including longer native liver survival and event-free survival. This suggests that therapies that lower SBA, such as ileal bile acid transporter (IBAT) inhibitors, may have the potential to improve clinical outcomes for children with ALGS."
41256799,Physician Body-Site Expertise and Stereotactic Radiosurgery/Stereotactic Body Radiation Therapy Rounds Review.,"Contouring targets for stereotactic body radiation therapy (SBRT) requires expertise for each body site. Likewise, peer reviewers require sufficient expertise to provide an adequate review. In this work, we investigate physician self-reported expertise for performing peer review by body site and how the quality of SBRT peer review is impacted by the expertise of the reviewer.The results of 7 years of SBRT rounds, which included information on body site, attending and reviewing physicians, changes to targets, prescriptions, and planning target volume, were analyzed. We surveyed physicians on their expertise for reviewing each body site and defined them as being an expert by body site if they indicated a moderate or high level of competence. Multivariable logistic regression models were used to assess the association between reviewing physician expertise and planning data changes, and whether this varied by body site or by presenting physician expertise. Models were adjusted for physician and case characteristics, and generalized estimating equations were used to account for the correlation of cases reviewed by the same physician.The survey response rate was 95% (20/21) with 4103 cases for analysis. Reviewing physician experts were more likely to make any change, gross target volume, and prescription compared with reviewing physicians who were nonexperts. Controlling for physician expertise and case characteristics, brain, liver, spine, and stereotactic radiosurgery cases have an increased odds of any change being made when compared to lung cases, with odds ratios of 2.42 (95% CI, 1.78-3.30), 1.55 (95% CI, 1.19-2.01), 1.7 (95% CI, 1.31-2.20), and 2.18 (95% CI, 1.73-2.77), respectively.The extent to which changes are made during contour review is associated with both peer reviewer disease-site expertise and disease site. In larger radiation oncology departments relying on a general coverage model, rather than review by disease-site experts, peer review results in variations in the outcome of the preplanning review.© 2025 The Authors.",Advances in radiation oncology,"Dec, 2025",2025,Dec,,Covington E|Suresh K|Dragovic A|Feng M|Hearn J|Jagsi R|Lawrence T|Owen D|Spratt D|Cuneo K|Hadley S W,Owen D,"Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.|Department of Radiation Oncology, UCSF, San Francisco, California.|Emory Winship Cancer Institute, Emory University, Atlanta, Georgia.|Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota.|Department of Radiation Oncology, Case Western Reserve, Cleveland, Ohio.","Covington E, Suresh K, Dragovic A, Feng M, Hearn J, Jagsi R, Lawrence T, Owen D, Spratt D, Cuneo K, Hadley S W",https://pubmed.ncbi.nlm.nih.gov/41256799/,"The study found that physicians with expertise in a specific body site were more likely to make changes to the radiation therapy plan during peer review, compared to non-experts. This suggests that having disease-site experts conduct peer review is important to ensure the quality of stereotactic radiosurgery and stereotactic body radiation therapy plans."
41260749,Do Outcomes Differ After Medial Unicompartmental Knee Arthroplasty Based on Indications? A Prospective Cohort Study.,No abstract available.,The Journal of arthroplasty,"Dec, 2025",2025,Dec,,Higgins J D D|Hannon C P|Kurina S J|DeBenedetti A|Tseng J|Della Valle C J,Hannon C P,"Department of Orthopedic Surgery, Rush University Medical Center, Chicago, Illinois.|Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota.","Higgins J D D, Hannon C P, Kurina S J, DeBenedetti A, Tseng J, Della Valle C J",https://pubmed.ncbi.nlm.nih.gov/41260749/,"This research likely explores the outcomes of a specific type of knee replacement surgery, called medial unicompartmental knee arthroplasty, and whether the reasons for the surgery (indications) affect the results. The researchers conducted a prospective cohort study, which means they followed a group of patients over time to compare the outcomes based on the different reasons for the surgery."
41127122,Gender differences in symptom profiles of individuals being treated for mood disorders.,"A growing body of research suggests that symptoms of mood disorders vary by gender. Such differences could reflect unique mood phenotypes for women and men. We examined whether women and men with mood disorders had comparable or distinct profiles of anxiety and depressive symptoms, along with demographic and clinical variables associated with these profiles.Our research involved a secondary analysis of data collected from 36,381 adults (age 18-98; 67.2 % women and 32.8 % men) through the National Network of Depression Center's Mood Outcomes Program. Latent class analysis (LCA) and logistic regression modeling were used to examine the aims. Symptoms included in the LCA were derived from the Patient Health Questionnaire-9 and the Generalized Anxiety Disorder Scale.Four latent classes were identified and labeled based on their predominant symptoms (BIC: 629,688.56; VLMR: 3787.30, p < .01). Women had greater odds of experiencing 'Demoralized Depression' than men (OR = 1.22, p = .001), with women of reproductive age having the greatest odds. Men had greater odds than women of having symptom profiles that reflected 'Anxious Arousal' (OR = .88, p = .001) or 'Mild Fatigue and Insomnia' (OR = .89, p = .001). There was no gender difference in the odds of a 'Comorbid Anxiety and Depression' profile.Results suggest gender-specific phenotypes that differentially characterize mood disturbances, although effect sizes were small. Further research is needed to confirm these phenotypes and identify sexually dimorphic biomarkers or psychosocial exposures that may underlie gender differences. Understanding the heterogeneity of phenotypes can inform precision-based assessment and treatment of mood disorders, improving affective well-being of women and men in the long term.© 2025 Published by Elsevier Inc. on behalf of Anxiety and Depression Association of America.",Journal of mood and anxiety disorders,"Dec, 2025",2025,Dec,,Weiss S J|Nagle-Yang S|Flynn H|Cooper B|Muzik M|Simeonova D I|Ozerdem A,Ozerdem A,"Department of Community Health Systems, University of California, San Francisco, CA 94158, USA.|Department of Psychiatry, University of Colorado, Anschutz Medical Campus, Aurora, CO 80045, USA.|Department of Behavioral Sciences and Social Medicine, Florida State University, Tallahassee, FL 32306, USA.|Departments of Psychiatry and Obstetrics & Gynecology, University of Michigan, Ann Arbor, MI 48109, USA.|Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, USA.|Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.","Weiss S J, Nagle-Yang S, Flynn H, Cooper B, Muzik M, Simeonova D I, Ozerdem A",https://pubmed.ncbi.nlm.nih.gov/41127122/,"The study found that women are more likely to experience ""demoralized depression,"" while men are more likely to have symptom profiles reflecting ""anxious arousal"" or ""mild fatigue and insomnia."" These gender-specific differences in mood disorder symptoms could inform more personalized assessment and treatment approaches, potentially improving mental health outcomes for both women and men."
41123217,"SH2B3 (Lnk) Mutations in Myeloid Neoplasms: Morphologic Spectrum, Co-Mutation Patterns, and Clinical Correlates.",No abstract available.,American journal of hematology,"Dec, 2025",2025,Dec,,Tefferi A|Yousuf M|Wu S J|Bashir Y A|Fathima S|Reichard K K|Zepeda Mendoza C J|Pardanani A|He R|Gangat N,Tefferi A|Yousuf M|Wu S J|Bashir Y A|Fathima S|Reichard K K|Zepeda Mendoza C J|Pardanani A|He R|Gangat N,"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Tefferi A, Yousuf M, Wu S J, Bashir Y A, Fathima S, Reichard K K, Zepeda Mendoza C J, Pardanani A, He R, Gangat N",https://pubmed.ncbi.nlm.nih.gov/41123217/,"This research likely explores the genetic mutations in the SH2B3 (Lnk) gene and their impact on different types of blood cancers, known as myeloid neoplasms. The study may investigate the various forms of these blood cancers, the patterns of co-occurring genetic mutations, and how these factors relate to the clinical characteristics and outcomes of patients with these conditions."
41123216,JAK2 Unmutated Erythrocytosis: 2026 Update on Diagnosis and Management.,"JAK2 unmutated erythrocytosis encompasses a heterogeneous spectrum of hereditary and acquired entities.The foremost step is excluding polycythemia vera (PV) with JAK2 mutation screening (exons 12-15). Apparent polycythemia such as physiological outliers or relative polycythemia secondary to volume contraction should be considered. A historical overview of hematocrit (Hct) and hemoglobin (Hgb) levels helps distinguish longstanding from acquired erythrocytosis. Serum erythropoietin (Epo) levels are variably informative.Hereditary erythrocytosis should be considered in longstanding erythrocytosis with a positive family history; causes include EPOR mutations (subnormal Epo), high oxygen affinity hemoglobin variants, PIEZO1 mutations, 2,3-bisphosphoglycerate deficiency, methemoglobinemia, and germline oxygen sensing pathway mutations (HIF2A-PHD2-VHL).Acquired erythrocytosis results from central (cardiopulmonary disease) or peripheral (renal artery stenosis) hypoxia, Epo-producing tumors (renal cell carcinoma) or drugs (testosterone, sodium glucose co-transporter-2 inhibitors (SGLT2-i), erythropoiesis stimulating agents).Idiopathic erythrocytosis is an ill-defined terminology that presumes the existence of an increased Hgb/Hct level without an identifiable etiology.Cytoreductive therapy should be avoided. Phlebotomy should be considered for symptom control. Cardiovascular risk optimization and low-dose aspirin are advised, while the role of HIF2A inhibitors remains unclear.EPO mutations which produce hyperactive, hepatic-like Epo were identified. In cases with negative workup but high clinical suspicion, an expanded next generation sequencing panel for hereditary erythrocytosis is recommended. Among drugs, SGLT2-i-associated erythrocytosis is increasingly recognized.Advances in molecular hematology are expected to improve the characterization of ""idiopathic erythrocytosis"". Results from prospective studies are needed to elucidate the underlying pathology and guide management.© 2025 Wiley Periodicals LLC.",American journal of hematology,"Dec, 2025",2025,Dec,,Gangat N|Szuber N|Tefferi A,Gangat N|Tefferi A,"Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Hematology, University of Montreal, Montréal, Quebec, Canada.","Gangat N, Szuber N, Tefferi A",https://pubmed.ncbi.nlm.nih.gov/41123216/,"The key finding of this medical research is that JAK2 unmutated erythrocytosis encompasses a range of hereditary and acquired conditions. The impact is that this understanding can help guide the diagnosis and management of this complex disorder, which is important for providing appropriate treatment and monitoring for patients."
41117748,The Hemojuvelin-Hepcidin Axis as a Target for the Treatment of Anemia or Conversely Polycythemia.,Targeting hemojuvelin-hepcidin axis for the treatment of anemia or polycythemia.© 2025 Wiley Periodicals LLC.,American journal of hematology,"Dec, 2025",2025,Dec,,Gangat N|Tefferi A,Gangat N|Tefferi A,"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.","Gangat N, Tefferi A",https://pubmed.ncbi.nlm.nih.gov/41117748/,"This research focuses on the hemojuvelin-hepcidin axis, which plays a key role in regulating iron levels in the body. By targeting this axis, the researchers believe they can develop new treatments for both anemia (low iron) and polycythemia (high iron). This finding could lead to more effective and personalized therapies for these common blood disorders."
41016082,Deep learning in abdominopelvic digital subtraction angiography: a systematic review of interventional radiology applications.,"Deep learning (DL) is increasingly explored in interventional radiology (IR) applications. This systematic review evaluates current DL-based applications for digital subtraction angiography (DSA) in abdominopelvic interventions, summarizes performance, and identifies gaps in the literature.Following PRISMA guidelines, we searched MEDLINE, Scopus, and Google Scholar for studies published up to February 1, 2025. English-language original articles assessing DL methods for automatic DSA image analysis were included, and study quality was evaluated with QUADAS-2.Nine studies were included. Two focused on hemorrhage detection, in which area under the curve (AUC) values ranged between 0.80-0.85. Four examined image enhancement, one performed vessel segmentation, and one applied classification of the anatomic location. Only a single study evaluated treatment response prediction, with an accuracy of 0.75. Most models were tested on small datasets from single centers, limiting their generalizability.Preliminary studies show that DL can improve hemorrhage detection, image quality, and vessel segmentation in DSA. However, larger, prospectively validated datasets are warranted. Currently no FDA-approved DL tools exist for abdominal or pelvic DSA. Future efforts should explore advanced generative AI and multimodal approaches.Copyright © 2025. Published by Elsevier B.V.",European journal of radiology,"Dec, 2025",2025,Dec,,Raskin D|Klang E|Barash Y|Korfiatis P|Partovi S|McCarthy C J|Nadkarni G|Collins J D|Sorin V,Korfiatis P|Collins J D|Sorin V,"Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA. Electronic address: raskind@ccf.org.|Division of Data-Driven and Digital Medicine (D3M), Icahn School of Medicine at Mount Sinai, New York, NY, USA.|Division of Vascular and Interventional Radiology, Department of Radiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Interventional Radiology, Cleveland Clinic, Cleveland, OH, USA.","Raskin D, Klang E, Barash Y, Korfiatis P, Partovi S, McCarthy C J, Nadkarni G, Collins J D, Sorin V",https://pubmed.ncbi.nlm.nih.gov/41016082/,"This review found that deep learning can improve the analysis of digital subtraction angiography (DSA) images in interventional radiology, particularly for detecting hemorrhage and enhancing image quality. However, the studies were limited to small datasets, and no FDA-approved deep learning tools for abdominal or pelvic DSA currently exist. Larger, prospective studies are needed to further develop and validate these deep learning applications for clinical use."
41016226,Parents' perspectives on cost conversations in pediatric asthma care: Findings from a qualitative interview study.,"Asthma care teams may be well-positioned to help parents navigate the high cost of pediatric asthma care, but little is known about how cost concerns are addressed in specialty clinics. To inform future interventions to support cost conversations and reduce cost burden, we sought to understand how parents and asthma care teams discuss costs, as well as parents' preferences for cost conversations.We interviewed 21 parents with asthma care cost concerns recruited from a large pediatric asthma specialty clinic in North Carolina. We used thematic analysis to qualitatively describe parents' experiences of and preferences for cost conversations.Parents described incurring a range of direct and indirect asthma care costs, with direct costs being especially burdensome for commercially-insured children. Parents wanted cost conversations to be a routine part of office visits to reduce assumptions and stigma about their ability to afford care. Yet, cost conversations were inconsistent. When cost conversations did occur, the care team often found ways to reduce costs, such as switching to lower-cost medications. Most parents believed that both families and the asthma care team would benefit from having more cost-related information. Parents had mixed views on having cost conversations in front of their children.Findings of our qualitative study suggest that asthma care teams have opportunities to address and destigmatize parents' financial concerns by making cost conversations part of routine care.Parents want asthma care teams to regularly initiate cost of care conversations, while carefully considering their preferences for privacy when discussing costs in front of children. Parents and care teams likely need more information about costs and available resources to maximize the impact of these conversations.Copyright © 2025 Elsevier B.V. All rights reserved.",Patient education and counseling,"Dec, 2025",2025,Dec,,Heisler-MacKinnon J A|Kong W Y|Kennedy K L|Loughlin C E|Lawler C N|Galbraith A A|Gilkey M B,Kong W Y,"Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA; Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599-7440, USA. Electronic address: heislerm@email.unc.edu.|Division of Epidemiology, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN 55905, USA.|Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599-7440, USA.|Department of Pediatrics, Division of Pulmonology, UNC School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7220, USA.|Department of Pediatrics, UNC Children's Research Institute, UNC School of Medicine, Chapel Hill, NC 27599, USA.|Department of Pediatrics, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA 02119, USA.|Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC 27514, USA; Department of Health Behavior, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599-7440, USA.","Heisler-MacKinnon J A, Kong W Y, Kennedy K L, Loughlin C E, Lawler C N, Galbraith A A, Gilkey M B",https://pubmed.ncbi.nlm.nih.gov/41016226/,"This study found that parents of children with asthma often face high costs for their child's care, and they want their healthcare team to regularly discuss these costs with them. Parents believe that open conversations about costs can help reduce the financial burden and stigma associated with affording asthma treatment. The study suggests that incorporating cost discussions into routine asthma care could benefit both families and healthcare providers."
41016943,Refining PET-based response in extramedullary multiple myeloma using total lesion glycolysis.,"Positron Emission Tomography (PET)-based assessments are an integral part of response assessment in patients with multiple myeloma (MM) with extramedullary disease (EMD), yet their utility in EMD remains to be systematically studied. We retrospectively evaluated 95 patients with EMD undergoing FDG PET/CT imaging for metabolic response assessment using visual Deauville Scores (DS) and total lesion glycolysis (TLG). TLG responses were categorized as complete metabolic response (CMR; 100% reduction), major metabolic response (MMR; <100% to ≥50% reduction), and non-significant metabolic response (NMR; <50% reduction). The median progression-free survival (PFS) differed significantly by DS (22.4 vs. 4.3 vs. 2.8 months for DS ≤ 3, =4, and =5, respectively; p < 0.0001) and by TLG response (36.5 vs. 5.4 vs. 2.2 months for CMR, MMR, NMR; p < 0.0001). TLG offered better discrimination than DS, with approximately one-third of patients in each DS stratum being reclassified by the TLG stratification. In a multivariable analysis, TLG response [HR 2.6 (95% CI: 1.8-3.8), p < 0.0001] remained independently prognostic after adjusting for cytogenetics, triple-class refractoriness, and de novo EMD status. The 18-month OS rates were 89%, 42% and 19% for the TLG CMR, MMR, and NMR cohorts (p < 0.001). These findings support the integration of TLG into response criteria for EMD.© 2025. The Author(s), under exclusive licence to Springer Nature Limited.",Leukemia,"Dec, 2025",2025,Dec,,Zanwar S|Belge Bilgin G|Broski S M|Thorpe M|Bilgin C|Gonsalves W|Kapoor P|Kourelis T|Hayman S|Abdallah N|Binder M|Cook J|Dispenzieri A|Dingli D|Gertz M A|Leung N|Lin Y|Muchtar E|Warsame R|Kyle R A|Rajkumar S V|Kumar S,Zanwar S|Belge Bilgin G|Broski S M|Thorpe M|Bilgin C|Gonsalves W|Kapoor P|Kourelis T|Hayman S|Abdallah N|Binder M|Cook J|Dispenzieri A|Dingli D|Gertz M A|Leung N|Lin Y|Muchtar E|Warsame R|Kyle R A|Rajkumar S V|Kumar S,"Division of Hematology, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Division of Hematology, Mayo Clinic, Rochester, MN, USA. Kumar.Shaji@mayo.edu.","Zanwar S, Belge Bilgin G, Broski S M, Thorpe M, Bilgin C, Gonsalves W, Kapoor P, Kourelis T, Hayman S, Abdallah N, Binder M, Cook J, Dispenzieri A, Dingli D, Gertz M A, Kumar S, et al.",https://pubmed.ncbi.nlm.nih.gov/41016943/,This study found that using total lesion glycolysis (TLG) to measure metabolic response on PET scans provides better prediction of progression-free survival and overall survival in patients with extramedullary multiple myeloma compared to the standard Deauville Score. Incorporating TLG into response criteria could improve assessment of treatment effectiveness in this patient population.
41017326,"From the Editor-in-Chief's Desk: Advancing Patient-Centered Care in ADHD, Anxiety, and Mood Disorders.",No abstract available.,Journal of child and adolescent psychopharmacology,"Dec, 2025",2025,Dec,,Croarkin P E,Croarkin P E,"Mayo Clinic Children's Research Center, Mayo Clinic, Rochester, Minnesota, USA.",Croarkin P E,https://pubmed.ncbi.nlm.nih.gov/41017326/,"This research likely explores ways to improve patient-centered care for individuals with ADHD, anxiety, and mood disorders. The study may focus on identifying and addressing the specific needs and preferences of patients in order to provide more personalized and effective treatment approaches for these mental health conditions."
41019914,A Model for Developing Subspecialty Clinical Practice Guidelines: The Geriatric Emergency Department Guidelines 2.0.,"The original consensus-based Geriatric Emergency Department (GED) Guidelines, published in 2014, established a framework of core principles for delivering high-quality, age-appropriate emergency care for older adults. In response to significant advances in geriatric emergency medicine research and evolving clinical priorities, we developed the GED Guidelines 2.0 to ensure continued relevance, clinical utility, and evidence-based rigor. This concept paper describes the systematic and iterative process undertaken to update the guidelines, including the formation of multidisciplinary working groups and the application of the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology. Unlike the original GED Guidelines, our approach prioritized methodological transparency, formalized evidence grading, and consensus building grounded in systematic reviews and meta-analyses. We describe the identification, recruitment, and collaboration of multidisciplinary clinical and academic experts working together to improve the care of older adults in the emergency department. Through this multidisciplinary effort, key geriatric domains were selected, priority topics identified, and systematic reviews and meta-analyses conducted to generate a robust evidence base for future guideline and policy development. The GED Guidelines 2.0 represents the first emergency medicine (EM) subspecialty guideline effort to fully adopt the GRADE framework, offering a novel blueprint for future EM guideline development.© 2025 The Author(s).",Journal of the American College of Emergency Physicians open,"Dec, 2025",2025,Dec,,Gunaga S|Carpenter C R|Kennedy M|Southerland L T|Lo A X|Lee S|Swan K|Mowbray F|Skains R M|Hogan T M|Casey M F|Ouchi K|George N R|de Wit K|Gettel C J|Selman K|Ragsdale L C|Chary A N|van Oppen J D|Arendts G|Maddow C L|Hunold K M|Tyler K R|Khoujah D|Hwang U|Liu S,Carpenter C R,"Department of Emergency Medicine, Henry Ford Health, Wyandotte Hospital, Wyandotte, Michigan, USA.|Envision Healthcare, Ann Arbor, Michigan, USA.|Department of Osteopathic Medical Specialties, Michigan State University College of Osteopathic Medicine, East Lansing, Michigan, USA.|Department of Emergency Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Emergency Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.|Department of Emergency Medicine, Harvard Medical School, Boston, Massachusetts, USA.|Department of Emergency Medicine, The Ohio State University, Columbus, Ohio, USA.|Department of Emergency Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.|Department of Emergency Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.|College of Nursing & College of Human Medicine, Michigan State University, East Lansing, Michigan, USA.|Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA; Geriatric Research, Education and Clinical Center, Birmingham VAMC, Birmingham, Alabama, USA.|Section of Emergency Medicine, Department of Medicine, University of Chicago Pritzker School of Medicine, Chicago, Illinois, USA.|Department of Emergency Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA.|Department of Emergency Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.|Department of Emergency Medicine, Division of Critical Care, University of New Mexico School of Medicine, Albuquerque, New Mexico, USA.|Department of Emergency Medicine, Queens University, Kingston, Ontario, Canada.|Department of Emergency Medicine, Yale University, New Haven, Connecticut, USA.|Center for Outcomes Research and Evaluation, Yale School of Medicine, New Haven, Connecticut, USA.|Department of Emergency Medicine, Cooper Medical School of Rowan University, Camden, New Jersey, USA.|Department of Emergency Medicine, Durham VA Health Care System, Durham, North Carolina, USA.|Department of Emergency Medicine, Duke University School of Medicine, Durham, North Carolina, USA.|Department of Emergency Medicine, Medicine-Section of Health Services Research, Baylor College of Medicine, Houston, Texas, USA.|Centre for Urgent and Emergency Care Research, University of Sheffield, Sheffield, United Kingdom.|University of Western Australia Medical School, Crawley, Western Australia, Australia.|Department of Emergency Medicine, University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas, USA.|Department of Emergency Medicine, University of California Davis School of Medicine, Sacramento, California, USA.|Department of Emergency Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA.|Geriatric Research, Education and Clinical Center, James J. Peters VAMC, Bronx, New York, USA.|Department of Emergency Medicine and Population Health, NYU Grossman School of Medicine, New York, USA.","Gunaga S, Carpenter C R, Kennedy M, Southerland L T, Lo A X, Lee S, Swan K, Mowbray F, Skains R M, Hogan T M, Casey M F, Ouchi K, George N R, de Wit K, Gettel C J, Liu S, et al.",https://pubmed.ncbi.nlm.nih.gov/41019914/,"The researchers developed an updated set of Geriatric Emergency Department (GED) Guidelines to improve emergency care for older adults. The new guidelines were created through a systematic and collaborative process, including multidisciplinary experts and the use of rigorous evidence-based methods. This approach serves as a model for developing high-quality, evidence-based clinical practice guidelines in other medical subspecialties."
41020750,Quality indicators for cell collections for immune effector cell and gene therapy: recommendations from the American Society for Apheresis.,"Immune effector cell (IEC) therapies provide increasingly important treatment options for patients with certain hematologic malignancies. Apheresis comprises a critical step, providing the starting material from which peripheral-blood derived IEC therapies are manufactured. Regulatory and accreditation bodies providing laws, regulations, guidance, and standards appropriately impose high quality goals for apheresis collection facilities, but they are often not all congruent with clinical trial requirements. Multiple efforts are underway to standardize apheresis procedures for IEC therapies. However, few publications give practical guidance on establishing quality indicators for apheresis collection facilities. Recognizing this, the American Society for Apheresis (ASFA) Clinical Applications Committee (Immune Effector Cell Therapy Subcommittee) sought to review and define the quality indicators that can be applied at each phase of the collection process. This paper is primarily focused on apheresis collection facilities in the United States (US), but general concepts may be applicable outside of the US as well. These recommendations are also endorsed by the Foundation for the Accreditation of Cellular Therapy (FACT), Association for the Advancement of Blood and Biotherapies (AABB), and International Society for Cell & Gene Therapy (ISCT).Copyright © 2025 International Society for Cell & Gene Therapy. Published by Elsevier Inc. All rights reserved.",Cytotherapy,"Dec, 2025",2025,Dec,,Aqui N A|Shi P A|Park Y A|Tanhehco Y C|Thibodeaux S R|Schwartz J|Su L|Gupta G K|Winters J L|Wu Y Y|Schneiderman J|AlMozain N|Nazli S|Mamo T|Lu W|Lamba D S|Hofmann J C|Liu H D,Su L|Winters J L|Nazli S|Lu W,"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.|Lindsley F. Kimball Research Institute, New York Blood Center, New York, New York, USA.|Department of Pathology and Laboratory Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.|Department of Pathology and Cell Biology, Division of Transfusion Medicine and Cellular Therapy, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.|Department of Pathology and Immunology, WashU University School of Medicine, St. Louis, Missouri, USA.|Foundation for the Accreditation of Cellular Therapy Omaha, Nebraska, USA.|Department of Pathology and Laboratory Medicine, Mayo Clinic Arizona, Phoenix, Arizona, USA.|Department of Pathology and Laboratory Medicine, Division of Transfusion Medicine and Cellular Therapy, Memorial Sloan Kettering Cancer Center, New York, New York, USA.|Department of Laboratory Medicine and Pathology, Division of Transfusion Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pathology and Laboratory Medicine, University of Miami, Miami, Florida, USA.|Department of Pediatric Hematology/Oncology/Neuro-Oncology/Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.|Department of Pathology & Laboratory Medicine, Hematopathology & Transfusion Medicine, King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia.|Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, Minnesota, USA.|Department of Laboratory Medicine and Pathology, Center for Regenerative Biotherapeutics, Mayo Clinic, Rochester, Minnesota, USA.|Department of Transfusion Medicine, Post Graduate Institute of Medical Education and Research, Chandigarh, India.|Department of Pathology and Laboratory Medicine, University of California San Francisco, San Francisco, California, USA.|Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, Florida, USA. Electronic address: hien.liu@moffitt.org.","Aqui N A, Shi P A, Park Y A, Tanhehco Y C, Thibodeaux S R, Schwartz J, Su L, Gupta G K, Winters J L, Wu Y Y, Schneiderman J, AlMozain N, Nazli S, Mamo T, Lu W, Liu H D, et al.",https://pubmed.ncbi.nlm.nih.gov/41020750/,"This research provides recommendations from the American Society for Apheresis on quality indicators for cell collections used in immune effector cell and gene therapy. The key finding is the establishment of standardized quality guidelines for the critical apheresis collection step, which is essential for the manufacture of these promising new therapies for certain blood cancers."
41022566,Weight Loss Effect of Lisdexamfetamine in Children with Severe Obesity: A Case Series.,"Background: Pharmacological options for severe obesity in early childhood are limited. While lisdexamfetamine is approved for attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder, its role in managing obesity in children without these conditions has not been well studied. This case series assessed the effect of lisdexamfetamine on weight in young children with severe obesity but without ADHD or binge eating disorder. Methods: We conducted a retrospective chart review of six children with severe obesity treated with lisdexamfetamine for weight management. Demographic, anthropometric, and metabolic data were collected. One patient had Prader-Willi syndrome (PWS); the others had no known syndromic obesity. Results: Median age at treatment initiation was 6.5 years (range: 4.5-14), with equal male and female distribution. Median treatment duration was 12 months (range: 12-24), and mean maximum tolerated lisdexamfetamine dose was 35 mg (range: 10-60). In patients without syndromic obesity (n = 5) including one child with hypothalamic obesity, lisdexamfetamine significantly reduced body mass index (BMI) percent of the 95th percentile at 12 months (median change -24%, range: -18 to -28, p = 0.031), equating to a 13.8% reduction in BMI. Height percentile remained unchanged (p = 0.59). The patient with PWS did not achieve lasting weight loss. Three children reported decreased appetite. Conclusions: Lisdexamfetamine was associated with weight loss in young children with severe obesity without genetic syndromes. Further studies are warranted to assess the long-term efficacy and safety of lisdexamfetamine in the management of pediatric obesity.",Childhood obesity (Print),"Dec, 2025",2025,Dec,,Salama M|Hassan D|Pittock S|Kumar S,Salama M|Hassan D|Pittock S|Kumar S,"Division of Pediatric Endocrinology and Metabolism, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Salama M, Hassan D, Pittock S, Kumar S",https://pubmed.ncbi.nlm.nih.gov/41022566/,"This case series found that the medication lisdexamfetamine helped young children with severe obesity, but not those with Prader-Willi syndrome, lose a significant amount of weight over 12 months. This suggests lisdexamfetamine could be a potential treatment option for managing obesity in children, but more research is needed to confirm its long-term effectiveness and safety."
41023550,ASO Visual Abstract: The Association of Clinical Stage at Presentation with Overall Survival in Patients with HER2-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy.,No abstract available.,Annals of surgical oncology,"Dec, 2025",2025,Dec,,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,Tashjian N L|Hoskin T L|Leon-Ferre R A|Boughey J C,"Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA.|Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, USA.|Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, USA. Boughey.Judy@mayo.edu.","Tashjian N L, Hoskin T L, Leon-Ferre R A, Boughey J C",https://pubmed.ncbi.nlm.nih.gov/41023550/,This research likely explores the relationship between the stage of breast cancer at the time of diagnosis and the overall survival of patients with HER2-positive breast cancer who receive neoadjuvant (pre-surgery) chemotherapy. The study aims to understand how the stage of cancer at presentation affects the long-term outcomes for patients with this specific type of breast cancer.
41025810,Letter: Blood Pressure Targets After Aneurysmal Subarachnoid Hemorrhage: Is Lower Better?,No abstract available.,Neurosurgery,"Dec 01, 2025",2025,Dec,01,Hawkes M A|Lanzino G|Rabinstein A A,Hawkes M A|Lanzino G|Rabinstein A A,"Department of Neurology, Mayo Clinic, Rochester , Minnesota , USA.|Neuronal Engeneering and Precision Surgery Laboratory, Mayo Clinic, Rochester , Minnesota , USA.|Department of Neurosurgery, Mayo Clinic, Rochester , Minnesota , USA.","Hawkes M A, Lanzino G, Rabinstein A A",https://pubmed.ncbi.nlm.nih.gov/41025810/,"This research likely explores the appropriate blood pressure targets for individuals who have experienced an aneurysmal subarachnoid hemorrhage, a type of stroke. The study may investigate whether lower blood pressure levels are more beneficial for the recovery and outcomes of these patients."
41031364,Clinical implications of progressive systemic ventricular dysfunction in adults with Fontan palliation.,"The purpose of this study was to determine the clinical implications of progressive systemic ventricular (SV) systolic dysfunction in adults with Fontan palliation.Retrospective study of Fontan patients with ≥2 echocardiograms at Mayo Clinic. SV systolic function was assessed using echo-derived ejection fraction (Echo_EF) at baseline, and annually for 3 years. Temporal decline in SV systolic function was estimated as relative change (relative Δ_Echo_EF)/year. Exploratory analysis was performed to assess the effect of guideline-directed medical therapy (GDMT) on Echo_EF.Of 414 patients (age 27 ± 9 years; males 228 [55 %]), 287 (69 %) and 127 (31 %) had dominant morphologic left ventricle (LV) and right ventricle (RV), respectively. Assessment of Echo_EF was feasible in 1464 of 1603 echocardiograms (91 %). The baseline Echo_EF was 54 % (48-58), and the relative Δ_Echo_EF was -3.9 % (95 %CI -6.3 to -2.5 %)/year. The predictors of progressive SV systolic dysfunction were older age, morphologic RV, ≥moderate atrioventricular valve regurgitation, cardiac implantable electronic devices, and atrial fibrillation. Progressive SV systolic dysfunction was associated with an approximately 2-fold increase in death/transplant (hazard ratio 1.92, p = 0.009), independent of baseline Echo_EF and comorbidities. GDMT was associated with improvement in Echo_EF in patients with morphologic LV.The current study underscores the importance of longitudinal echocardiographic monitoring of SV systolic function, and the potential clinical benefits of GDMT in patients with morphologic LV. Further studies are required to determine whether interventions such as valve surgery, rhythm control strategy, and physiologic pacing would prevent or reverse SV systolic dysfunction.© 2025 The Authors.",International journal of cardiology. Congenital heart disease,"Dec, 2025",2025,Dec,,Bai M|Bahnasy A|Aboelmaaty S|Ellabbad M|Ali A|Egbe A C,Bai M|Bahnasy A|Aboelmaaty S|Ellabbad M|Ali A|Egbe A C,"Department of Cardiovascular Medicine, Mayo Clinic Rochester, MN 55905, USA.","Bai M, Bahnasy A, Aboelmaaty S, Ellabbad M, Ali A, Egbe A C",https://pubmed.ncbi.nlm.nih.gov/41031364/,"This study found that progressive systemic ventricular dysfunction is common in adults with Fontan palliation and is associated with a higher risk of death or transplant. However, guideline-directed medical therapy may improve ventricular function in patients with a morphologic left ventricle, highlighting the importance of regular echocardiographic monitoring and potential interventions to prevent or reverse this condition."
41031742,Defining IgM Multiple Myeloma.,No abstract available.,American journal of hematology,"Dec, 2025",2025,Dec,,Bhatt M|Zimmowitch A|Audil H Y|Rajkumar S V,Bhatt M|Zimmowitch A|Audil H Y|Rajkumar S V,"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Bhatt M, Zimmowitch A, Audil H Y, Rajkumar S V",https://pubmed.ncbi.nlm.nih.gov/41031742/,"This research likely explores a type of cancer called multiple myeloma, which affects the immune system. Specifically, it focuses on defining a particular form of this cancer that involves a specific type of antibody called IgM."
41032187,The impact of social determinants of health on Black men at the point of prostate cancer diagnosis: a scoping review.,"Prostate cancer (CaP) disproportionately affects Black men, who face higher rates of late diagnosis and more aggressive disease. This study explores the social determinants of health and emotional support at the point of prostate cancer diagnosis (PPCD) and how these factors influence navigation, emotional responses, and healthcare behaviors among Black men.A comprehensive scoping review was conducted following the PRISMA Extensions framework. Articles were sourced from PubMed, PsycINFO, Embase, Web of Science, and Scopus databases up to May 2022. Screening and reference management were completed using Covidence and Zotero software.Analysis of 72,710 participants revealed that race and socio-demographics significantly impacted prostate cancer treatment delays, emotional well-being, and substance use in Black men. Five studies examined quality of life, showing that factors such as medical mistrust, fatalism, exercise, and spirituality influence well-being.The PPCD phase is crucial for addressing the emotional, socioeconomic, and spiritual factors that shape Black men's experiences with CaP. This review underscores the importance of individualized, culturally sensitive approaches to reduce disparities and improve support for Black prostate cancer survivors.© 2025. The Author(s).",Cancer causes & control : CCC,"Dec, 2025",2025,Dec,,Fullwood D|Fallon E|Asto-Flores E|Gordon V|Bolajoko O O|Jett H|Fudge M|Pressey S|Young M E|Ngufor C|Odedina F,Fullwood D|Fallon E|Asto-Flores E|Gordon V|Bolajoko O O|Jett H|Fudge M|Pressey S|Young M E|Ngufor C|Odedina F,"iCCaRE for Black Men Consortium, Mayo Clinic, Jacksonville, FL, USA. fullwood.dottington@mayo.edu.|Mayo Clinic Comprehensive Cancer Center, Mayo Clinic Florida, 4500 San Pablo Rd, Vincent A. Stabile Building 751N, Jacksonville, FL, 32224, USA. fullwood.dottington@mayo.edu.|Department of Education, College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.|iCCaRE for Black Men Consortium, Mayo Clinic, Jacksonville, FL, USA.|College of Medicine and Science, Mayo Clinic, Rochester, MN, USA.","Fullwood D, Fallon E, Asto-Flores E, Gordon V, Bolajoko O O, Jett H, Fudge M, Pressey S, Young M E, Ngufor C, Odedina F",https://pubmed.ncbi.nlm.nih.gov/41032187/,"This study found that social factors like race, income, and medical mistrust significantly impact the experiences of Black men with prostate cancer, leading to delays in treatment and poorer emotional well-being. The findings highlight the need for more personalized, culturally-sensitive approaches to support Black prostate cancer patients and address the underlying social determinants of health that contribute to disparities in this community."
41035742,Applications of spectral CT calcium suppression for percutaneous bone tumor ablation procedures.,Two cases are presented in which spectral CT calcium suppression was perceived as beneficial for percutaneous cryoablation of bone tumors. Cases include cryoablation of a lytic sacral/iliac bone metastasis and cryoablation of recurrent pigmented villonodular synovitis (PVNS) at the posterior aspect of the right knee. Calcium suppression images have a potential role in the visualization of bone lesions for treatment planning and the visualization of ice ball growth for treatment monitoring.© 2025 The Authors. Published by Elsevier Inc. on behalf of University of Washington.,Radiology case reports,"Dec, 2025",2025,Dec,,Musa J|Atwell T D|Adamo D A|Parvinian A|Huber N R|Korani S S|Welch B T|Favazza C P|Hibbert R,Musa J|Atwell T D|Adamo D A|Parvinian A|Huber N R|Korani S S|Welch B T|Favazza C P|Hibbert R,"Department of Radiology, Mayo Clinic, Rochester, Minnesota, USA.|Philips Innovation Lab, Rochester, Minnesota, USA.","Musa J, Atwell T D, Adamo D A, Parvinian A, Huber N R, Korani S S, Welch B T, Favazza C P, Hibbert R",https://pubmed.ncbi.nlm.nih.gov/41035742/,"The study found that spectral CT calcium suppression can be beneficial for visualizing bone tumors and monitoring their treatment through cryoablation procedures. This technique can help doctors better plan and monitor the treatment of bone tumors, which could lead to more effective and targeted treatments."
41035945,"Allostatic Load Patterns by U.S. Citizenship Status and Length of U.S. Residency Among Adults, 2009-2018.","Emerging research has documented that having a non-citizen status (e.g., temporary visa, undocumented) induces stress and, as a result, has adverse impacts on health. It is unclear whether chronic stress differs by citizenship status and length of U.S. residency using clinical biomarkers. The objective of this study was to examine allostatic load (or cumulative stress) by citizenship status and length of U.S. residency among U.S. adults.The study sample included 27,705 adult respondents (aged ≥20 years) from the 2009-2018 National Health and Nutrition Examination Surveys. Multivariable Poisson regression models were estimated with U.S. citizenship status (U.S.-born citizens, naturalized citizens, noncitizens) and U.S. residency (shorter: <15 years, longer: ≥15 years) on allostatic load. Allostatic load was defined with summative scores of 10 biomarkers (systolic blood pressure, diastolic blood pressure, high-density lipoprotein, total cholesterol, HbA1c, BMI, albumin, estimated glomerular filtration rate, white blood cell count, and asthma).Naturalized citizens with shorter U.S. residency (females only) and noncitizens with shorter U.S. residency had lower allostatic load than U.S.-born citizens. Naturalized citizens with longer U.S. residency had greater allostatic load than naturalized citizens with shorter U.S. residency (females only). Noncitizens with longer U.S. residency had higher allostatic load than both noncitizens with shorter U.S. residency and naturalized citizens with shorter U.S. residency (females only).This study demonstrates nuanced impacts on allostatic load by citizenship status and length of U.S. residency, with differences by sex. The findings infer that citizenship status contributes to health inequities among immigrants, with greater attention needed to unpack citizenship-stress mechanisms.© 2025 The Author(s).",AJPM focus,"Dec, 2025",2025,Dec,,Tsuchiya K|Taylor H O|Suglia S F|Niño M D|O'Campo P|Demmer R T,Demmer R T,"Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.|Factor-Inwentash Faculty of Social Work, University of Toronto, Toronto, Canada.|Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia.|Department of Sociology & Criminology, Fulbright College of Arts & Sciences, University of Arkansas, Fayetteville, Arkansas.|Li Ka Shing Knowledge Institute, Unity Health Toronto, Toronto, Canada.|Mayo Clinic, Rochester, Minnesota.|Division of Epidemiology & Community Health, School of Public Health, University of Minnesota, Minneapolis, Minnesota.","Tsuchiya K, Taylor H O, Suglia S F, Niño M D, O'Campo P, Demmer R T",https://pubmed.ncbi.nlm.nih.gov/41035945/,"This study found that non-citizens and naturalized citizens with shorter U.S. residency had lower levels of chronic stress, as measured by allostatic load, compared to U.S.-born citizens. However, non-citizens and naturalized citizens with longer U.S. residency had higher levels of chronic stress, suggesting that the length of time living in the U.S. can impact the health of immigrants."
41038751,"Treatment Accessibility, Availability, and Healthcare Costs for Multiple Myeloma in South Asian Countries.","Multiple myeloma (MM) is a hematological malignancy with rising incidence globally, including in South Asia. Despite advances in treatment, access to essential drugs, diagnostic tools, and stem cell transplantation remains inconsistent across the region. This study assesses the availability, accessibility, and cost of MM treatments in South Asian countries to identify gaps in care and inform healthcare policy.A cross-sectional, descriptive study was conducted through a web-based survey targeting physicians managing MM patients in Bangladesh, Bhutan, India, Maldives, Myanmar, Nepal, Pakistan, and Sri Lanka. The survey covered institutional healthcare structures, drug availability, treatment regimens, diagnostic access, and patient out-of-pocket expenditures (OOPE). Data were analyzed to evaluate disparities in MM care across public and private healthcare sectors.Public and private healthcare institutions coexist in all studied countries except Bhutan, where MM care is primarily public. Physicians reported a high OOPE for MM treatment, with patients covering an average of 70% of total medical costs. Key diagnostic investigations such as serum protein electrophoresis, immunofixation, and free light chain assays were unavailable in public hospitals in 62.5% of the countries, while minimal residual disease estimation via flow cytometry was available publicly only in India. PET scans were available in public hospitals in India, Bangladesh, Sri Lanka, and Pakistan, but remained cost-prohibitive. Lenalidomide and bortezomib were available in public institutions in 75% of the countries, while advanced therapies like daratumumab were largely restricted to private institutions in 62.5% of the countries. IV melphalan was unavailable in public institutions in 62.5% of the countries. Autologous stem cell transplant (ASCT) centers were reported in 75% of the studied countries; however, cryopreservation facilities were limited to 25% of the countries, and mobilization agents like plerixafor were accessible in 62.5%. The most commonly used first-line therapy for transplant-eligible patients in public institutions was VRd (bortezomib, lenalidomide, dexamethasone) in 50% of the countries, while private institutions more frequently incorporated daratumumab (VRd-D). Only India had a dedicated myeloma patient support group, whereas general oncology support groups were reported in 62.5% of the countries.There are significant disparities in MM treatment accessibility across South Asia. Public sector institutions often lack essential diagnostic tools and advanced therapies, forcing patients to rely on private healthcare at high OOPE. Improved government policies, financial assistance programs, and public-private partnerships are needed to enhance drug accessibility, diagnostic infrastructure, and transplant availability.Copyright © 2025 Elsevier Inc. All rights reserved.","Clinical lymphoma, myeloma & leukemia","Dec, 2025",2025,Dec,,Yanamandra U|Raphael C|Peela R|Saleh A J M|Dorji T|Juneh H|Gyi A A|Jha A|Mir M A|Somawardana B|Kabir A L|Poudyal B|Wimalachandra M|Aziz Z|Williams S|Usmani S|Kumar S|Malhotra P,Kumar S,"Command Hospital, Pune, India; Armed Forces Medical College, Pune, India; Civil Service Hospital, Kathmandu, Nepal. Electronic address: udayj2@gmail.com.|Armed Forces Medical College, Pune, India; University of Colombo, Colombo, Sri Lanka. Electronic address: celineraphael25@gmail.com.|Armed Forces Medical College, Pune, India. Electronic address: rupikapeela973@gmail.com.|Evercare Hospital, Dhaka, Bangladesh.|Department of Internal Medicine, Central Regional Referral Hospital, Gelephu, Bhutan.|Maldives National Defence Force, Male, Maldives.|North Okkalapa General Hospital, Yangon, Myanmar.|Bhaktapur Cancer Hospital, Bhaktapur, Nepal.|Shifa International Hospital, Islamabad, Pakistan.|Kings Hospital, Colombo, Sri Lanka.|Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh.|Civil Service Hospital, Kathmandu, Nepal.|University of Colombo, Colombo, Sri Lanka.|Hameed Latif Hospital, Lahore, Pakistan.|Memorial Sloan Kettering Cancer Center, New York, United States.|Mayo Clinic, Rochester, Minnesota, United States.|Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. Electronic address: malhotrapankaj@hotmail.com.","Yanamandra U, Raphael C, Peela R, Saleh A J M, Dorji T, Juneh H, Gyi A A, Jha A, Mir M A, Somawardana B, Kabir A L, Poudyal B, Wimalachandra M, Aziz Z, Williams S, Malhotra P, et al.",https://pubmed.ncbi.nlm.nih.gov/41038751/,"The study found significant disparities in the accessibility and affordability of multiple myeloma (MM) treatment across South Asian countries. Public healthcare institutions often lack essential diagnostic tools and advanced therapies, leading to high out-of-pocket expenses for patients seeking care in the private sector. Improving government policies, financial assistance programs, and public-private partnerships could enhance access to MM care in the region."
41015180,Validation and Clinical Utility of a Pan-Cancer Circulating Tumor DNA Assay as a First-Approach Test.,"The feasibility of circulating tumor (ct)-DNA assays in first-approach pan-cancer genomic profiling is not well established. Furthermore, low ctDNA levels limit assay sensitivity, which challenges adaptation to clinical genomic profiling. In this study, a 33-gene next-generation sequencing-based ctDNA panel was validated, and these issues were investigated using real-world clinical data. The cohorts included 123 patients who underwent first-approach ctDNA testing, and 48 patients for whom matched tissue was tested at the same time-point. The overall ctDNA assay failure rate was 0%. Insufficient tumor tissue was the main reason for liquid biopsy (69%). The most common primary cancer profiled was lung (39.0%), followed by colon (13.8%), bile duct (8.9%), pancreas (8.1%), and breast and prostate (each 4.1%). Tier I variants were detected in 33.3% of patients, and Tier I or II variants were detected in 65.0% (including 54.5% cholangiocarcinomas, in which tissue biopsy may be challenging due to anatomic location). Compared with matched tissue, ctDNA showed 76% sensitivity for Tier I variants. Actionable variants were increased by 14.3% with ctDNA versus tissue testing alone. ctDNA results preceded tissue results by an average of 21 days. High feasibility, actionability, and sensitivity support ctDNA assays as a potential first-line genomic test, especially in specific tumor types for advanced tumors with insufficient or unavailable tissue.Copyright © 2025 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.",The Journal of molecular diagnostics : JMD,"Dec, 2025",2025,Dec,,Kanwar N|Campion M B|Schneider A R|Milosevic D|Sosa C|Wojcik A A|Halling K C|Rumilla K M|Lo Y|Niu Z|Geiersbach K B|DiGuardo M A|Kipp B R|Zheng G,Kanwar N|Campion M B|Schneider A R|Milosevic D|Sosa C|Wojcik A A|Halling K C|Rumilla K M|Lo Y|Niu Z|Geiersbach K B|DiGuardo M A|Kipp B R|Zheng G,"Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.|Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota; Division of Transfusion Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.|Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: zheng.gang@mayo.edu.","Kanwar N, Campion M B, Schneider A R, Milosevic D, Sosa C, Wojcik A A, Halling K C, Rumilla K M, Lo Y, Niu Z, Geiersbach K B, DiGuardo M A, Kipp B R, Zheng G",https://pubmed.ncbi.nlm.nih.gov/41015180/,"This study validated a blood-based genetic test that can detect cancer-related genetic changes in patients with various types of cancer. The test was found to be highly feasible, able to detect actionable genetic changes in a significant proportion of patients, and able to provide results faster than traditional tissue-based testing. These findings suggest that this blood-based genetic test could be a useful first-line approach for cancer genomic profiling, particularly for certain cancer types where obtaining tissue samples may be challenging."
41015136,Design and methods of the AUTOMATED-WCT trial: evaluating machine learning-based ECG support for WCT interpretation.,"Distinguishing wide complex tachycardia (WCT) as ventricular tachycardia (VT) or supraventricular WCT (SWCT) is critical yet challenging. Manual ECG algorithms require substantial expertise and are inconsistently applied, and contemporary computerized ECG interpretation (CEI) systems often return only a generic ""wide complex tachycardia"" label. Novel machine learning-based ECG models (Solo Model, Paired Model) can provide a VT probability or a direct VT/SWCT classification, but they have not yet been evaluated in a prospective, randomized, workflow-integrated trial.We will conduct a prospective, multicenter, investigator-initiated, open-label, four-arm randomized reader trial. Physicians (attendings and fellows in cardiology, emergency medicine, critical care) will be randomized 1:1:1:1 to: (1) Control #1-WCT ECG only; (2) Control #2-WCT ECG + baseline ECG; (3) Solo Model-WCT ECG + model output (no baseline ECG); (4) Paired Model-WCT ECG + baseline ECG + model output. Each participant will interpret 20 adjudicated WCT ECGs on a secure virtual platform, classify rhythm, rate confidence and percieved usefulness, and indicate likely next steps in clinical management.WCT classification accuracy. Secondary endpoints: sensitivity, specificity, PPV, NPV, F1 score, time to diagnosis, interpreation confidence, perceived usefulness, and intended management after diagnosis.The AUTOMATED-WCT Trial will be the first randomized, multicenter evidence on machine learning-based ECG decision support for WCT differentiation.Copyright © 2025. Published by Elsevier Inc.",Current problems in cardiology,"Dec, 2025",2025,Dec,,May A M|LoCoco S|Mikhova K M|Ghadban R|Cuculich P S|Cooper D H|Maddox T M|Thakkar P|Deych E|Rowlandson I|Siotis A|Anavaker N|Noseworthy P A|Kashou A,Anavaker N|Noseworthy P A|Kashou A,"Department of Medicine, Division of Cardiovascular Diseases, Washington University School of Medicine in St. Louis, St. Louis, MO, USA. Electronic address: may.adam@wustl.edu.|Department of Medicine, Division of Cardiovascular Diseases, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.|Division of Biostatistics, Washington University School of Medicine in St. Louis, St. Louis, MO USA.|GE HealthCare, Wauwatosa, WI, USA.|Lund University, Lund, Sweden.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota, USA.","May A M, LoCoco S, Mikhova K M, Ghadban R, Cuculich P S, Cooper D H, Maddox T M, Thakkar P, Deych E, Rowlandson I, Siotis A, Anavaker N, Noseworthy P A, Kashou A",https://pubmed.ncbi.nlm.nih.gov/41015136/,"This study evaluates the use of machine learning-based ECG models to help healthcare providers distinguish between different types of wide complex tachycardia (WCT), a critical but challenging task. The key finding will be the accuracy of these models in correctly classifying WCT as ventricular tachycardia or supraventricular tachycardia, which could significantly improve patient care and outcomes."
41006824,"Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.","Metabolic and alcohol-related liver disease (MetALD) is a newly defined entity within the spectrum of steatotic liver disease, characterized by the interplay of cardiometabolic risk factors and alcohol consumption. The evolving epidemiology and complex pathophysiology of MetALD present unique challenges and opportunities for clinical trial design. Inclusion criteria should require simultaneous evidence of metabolic dysfunction (at least two cardiometabolic features) and verified quantifiable alcohol exposure recorded over the preceding 3-6 months. Traditional histological end points are limited by invasiveness, sampling error and interpretative variability. Thus, imaging modalities, serum-based fibrosis biomarkers and quantitative measures of alcohol intake are gaining relevance as non-invasive, reproducible and patient-centric end points aiming to improve trial feasibility. Furthermore, incorporating alcohol biomarkers, stratifying patients by metabolic risk factor burden, and using adaptive designs of trials might enhance the precision and generalizability of MetALD clinical trials. Although uncertainties remain regarding optimal patient selection criteria, event rates and the dynamic interplay between metabolic dysfunction and alcohol intake, ongoing research efforts aim to refine diagnostic criteria, standardize methodologies and validate novel end points. These advances will ultimately accelerate drug development, improve trial efficiency and foster interventions to treat MetALD.© 2025. Springer Nature Limited.",Nature reviews. Gastroenterology & hepatology,"Dec, 2025",2025,Dec,,Diaz L A|Thiele M|Louvet A|Lee B P|Ajmera V|Tavaglione F|Hsu C L|Huang D Q|Pose E|Bataller R|McClain C|Mellinger J|Tincopa M|Mitchell M C|Ratziu V|Rinella M E|Sarin S K|Shah V H|Szabo G|Wong V W|Bansal M B|Leggio L|Kamath P S|Krag A|Sanyal A J|Arrese M|Arab J P|Anstee Q M|Mathurin P|Loomba R,Shah V H|Kamath P S,"MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA.|Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.|Center for Liver Research, Department of Gastroenterology and Hepatology, Odense University Hospital, Odense, Denmark.|Institute of Clinical Research, University of Southern Denmark, Odense, Denmark.|Service des maladies de l'appareil digestif, University Hospital of Lille, Lille, France.|Unité INSERM INFINITE, Lille, France.|Division of Gastroenterology and Liver Disecases, University of Southern California Keck School of Medicine, Los Angeles, CA, USA.|Institute for Addiction Science, University of Southern California, Los Angeles, CA, USA.|Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.|Division of Gastroenterology and Hepatology, Department of Medicine, National University Health System, Singapore, Singapore.|Liver Unit, Hospital Clinic and Institut d'Investigacions Biomediques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.|Department of Medicine, University of Louisville, Louisville, KY, USA.|Robley Rex Louisville Veterans Affairs Medical Center, Louisville, KY, USA.|Department of Internal Medicine, Division of Gastroenterology & Hepatology, Henry Ford Health-Michigan State University, Detroit, MI, USA.|Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.|Sorbonne Université, Paris, France.|ICAN (Institute of Cardiometabolism and Nutrition), Paris, France.|Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Paris, France.|INSERM UMRS 1138 CRC, Paris, France.|Pritzker School of Medicine, University of Chicago, Chicago, IL, USA.|Department of Hepatology and Liver Transplantation, Institute of Liver & Biliary Sciences, New Delhi, India.|Division of Gastroenterology and Hepatology, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.|Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.|Department of Medicine and Therapeutics, Chinese University of Hong Kong, Hong Kong, China.|Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA.|Clinical Psychoneuroendocrinology and Neuropsychopharmacology Section, Translational Addiction Medicine Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA.|National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Baltimore, MD, USA.|Division of Gastroenterology, Hepatology, and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.|Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.|NIHR Newcastle Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.|MASLD Research Center, Division of Gastroenterology and Hepatology, University of California San Diego, San Diego, CA, USA. roloomba@health.ucsd.edu.","Diaz L A, Thiele M, Louvet A, Lee B P, Ajmera V, Tavaglione F, Hsu C L, Huang D Q, Pose E, Bataller R, McClain C, Mellinger J, Tincopa M, Mitchell M C, Ratziu V, Loomba R, et al.",https://pubmed.ncbi.nlm.nih.gov/41006824/,"The key finding of this medical research is that the evolving epidemiology and complex pathophysiology of metabolic and alcohol-related liver disease (MetALD) present unique challenges and opportunities for clinical trial design. The research suggests that using non-invasive methods, such as imaging and serum-based biomarkers, as well as incorporating alcohol biomarkers and adaptive trial designs, can improve the precision and feasibility of MetALD clinical trials, ultimately accelerating drug development an"
40983150,Management of Perianal Abscesses in Infants: A Systematic Review From the APSA Outcomes and Evidence-Based Practice Committee.,"Management of infant perianal disease, including perianal abscess and fistula-in- ano (FIA), remains controversial. There is lack of consensus regarding the risks and benefits of operative and non-operative approaches.The American Pediatric Surgical Association Outcomes and Evidence Based Practice Committee created a priori consensus-based questions regarding the various approaches to management of perianal abscess and FIA in infants. A comprehensive search strategy was created, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to identify and review relevant articles and answer the established questions.Over 2460 titles and abstracts were screened to identify 31 manuscripts describing the expected course of perianal disease when managed with nonoperative management (NOM) strategies (such as hygiene, sitz baths, and systemic antibiotics), operative intervention for abscess only (incision and drainage (I&D)) or direct surgical management of the FIA (e.g. upfront fistulotomy). Initial failure of NOM is approximately 37.5 %. Recurrence rate after initial success with NOM or I&D is approximately 21 % and 24 %, respectively. The rate of FIA development is approximately 21 % after NOM and 20 % after I&D. Recurrence after operative management of FIA, regardless of approach, is 7 %. Time to complete resolution varies widely and does not appear to differ based on treatment strategy.Both operative and non-operative approaches can be safely used in the management of perianal abscess and FIA but recurrence is common regardless of approach. Risks and benefits of each approach should be considered on a case-by-case basis.Systematic Review of level 3-4 studies.Level 4.Copyright © 2025 Elsevier Inc. All rights reserved.",Journal of pediatric surgery,"Dec, 2025",2025,Dec,,Acker S N|Sulkowski J|Chang H L|Cyrus J|Christison-Lagay E|Mansfield S A|Diesen D L|Gulack B C|Russell K|Beres A L|Rentea R M|Yousef Y|Alemayehu H|Danko M E|Kabagambe S K|Kulaylat A N|Levene T L|Pennell C|Polites S F|Ramjist J K|Rich B S|Scholz S|Skarda D E|Tashiro J|Hey M T|Ignacio R|Baird R|Kelley-Quon L I|Ricca R,Polites S F,"Division of Pediatric Surgery, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA; Research Outcomes in Children's Surgery, Center for Children's Surgery, Children's Hospital Colorado, University of Colorado School of Medicine, Aurora, CO, USA. Electronic address: Shannon.acker@childrenscolorado.org.|Division of Pediatric Surgery, University of Chicago, Chicago, IL, USA.|Department of Surgery, Johns Hopkins All Children's Hospital, St. Petersburg, FL, USA.|Health Sciences Library, Virginia Commonwealth University School of Medicine, Richmond, VA, USA.|Division of Pediatric Surgery, Yale School of Medicine, New Haven, CT, USA.|Division of Pediatric Surgery, Department of Surgery, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, OH, USA.|Division of Pediatric Surgery, Department of Surgery, UT Southwestern Medical Center, Dallas, TX, USA.|Division of Pediatric Surgery, Department of Surgery, Rush University Medical Center, Chicago, IL, USA.|Division of Pediatric Surgery, Department of Surgery, University of Utah, Salt Lake City, UT, USA.|Division of Pediatric General and Thoracic Surgery, St. Christopher's Hospital for Children, Drexel University College of Medicine, Philadelphia PA, USA.|Division of Pediatric Surgery, Children's Mercy- Kansas City, University of Missouri- Kansas City, Kansas City, MO, USA.|Joe DiMaggio Children's Hospital, Memorial Healthcare System, Hollywood, FL, USA.|Division of Pediatric Surgery, Children's Healthcare of Atlanta, Emory University School of Medicine, Atlanta, GA, USA.|Division of Pediatric Surgery, Department of Surgery, University of Virginia, Charlottesville, VA, USA.|Division of Pediatric Surgery, Department of Surgery, Penn State Children's Hospital, Hershey, PA, USA.|Division of Pediatric Surgery, Mercy Hospital, Saint Louis, MO, USA.|Division of Pediatric Surgery, Mayo Clinic, Rochester, MN, USA.|Division of General & Thoracic Surgery, The Hospital for Sick Children, University of Toronto, Temetry School of Medicine, Toronto, ON, USA.|Division of Pediatric Surgery, Cohen Children's Medical Center, Northwell Health, New Hyde Park, NY, 11042, USA.|Division of Pediatric General and Thoracic Surgery, UPMC Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.|Division of Pediatric Surgery, Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA.|Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.|Division of Pediatric Surgery, Dept of General Surgery, UCSD School of Medicine, USA.|Division of Pediatric Surgery, BC Children's Hospital, Vancouver, Canada.|Division of Pediatric Surgery, Children's Hospital Los Angeles, Department of Surgery, Keck School of Medicine of University of Southern California, Los Angeles, CA, USA.","Acker S N, Sulkowski J, Chang H L, Cyrus J, Christison-Lagay E, Mansfield S A, Diesen D L, Gulack B C, Russell K, Beres A L, Rentea R M, Yousef Y, Alemayehu H, Danko M E, Kabagambe S K, Ricca R, et al.",https://pubmed.ncbi.nlm.nih.gov/40983150/,"The key finding of this medical research is that both operative and non-operative approaches can be used to manage perianal abscesses in infants, but recurrence is common regardless of the approach. The impact of this finding is that healthcare providers should consider the risks and benefits of each approach on a case-by-case basis when treating perianal abscesses in infants."
40958754,Prolonged Therapeutic Serum Asparaginase Activity Levels After Administration of Calaspargase Pegol.,No abstract available.,Pediatric blood & cancer,"Dec, 2025",2025,Dec,,Martin C E|O'Keefe M B|Gullickson T|Kohorst M A|Srinivasan A|Galardy P J|McAllister L|Kalmes J L|Kuhn A K,Martin C E|O'Keefe M B|Gullickson T|Kohorst M A|Srinivasan A|Galardy P J|McAllister L|Kalmes J L|Kuhn A K,"Department of Pharmacy, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pediatric and Adolescent Medicine, Division of Pediatric Hematology/Oncology, Mayo Clinic, Rochester, Minnesota, USA.","Martin C E, O'Keefe M B, Gullickson T, Kohorst M A, Srinivasan A, Galardy P J, McAllister L, Kalmes J L, Kuhn A K",https://pubmed.ncbi.nlm.nih.gov/40958754/,This research likely explores the effects of a specific drug called calaspargase pegol on the levels of an enzyme called asparaginase in the blood over an extended period of time. The study appears to investigate how long the therapeutic levels of asparaginase remain in the body after administering this particular drug.
40960222,A structured training curriculum for robot-assisted radical nephroureterectomy: a Delphi consensus study.,"To develop an internationally validated, structured robot-assisted radical nephroureterectomy (RARNU) training programme through expert consensus.A RARNU-specific questionnaire was developed/adapted from previously published, validated questionnaires for robot-assisted urological procedures. This included five key domains and 11 surgical steps. In all, 30 upper tract urothelial carcinoma experts were invited to participate. A two-stage modified Delphi approach was employed. Consensus was defined as ≥80% agreement. Modifications and additional statements were proposed during the second round following qualitative/quantitative feedback from the initial round.Response rates for the first and second Delphi rounds were 80% (24/30) and 92% (22/24), respectively. All agreed that adoption of a standardised training curriculum can improve clinical outcomes during the RARNU learning curve. There was ≥92% agreement on all proposed RARNU steps. Five RARNU clinical modules of increasing complexity were defined using individual step difficulty and number of prior RARNU cases required, with ≥96% agreement among respondents. Respondents unanimously agreed that the final assessment should be based on a procedure-specific scale focusing on the hilar dissection, ureteric dissection, and bladder cuff excision steps. No consensus was reached for the annual minimum RARNU volume required for eligibility as a RARNU curriculum host centre.This is the first structured training curriculum for RARNU using international expert consensus. This will help guide surgical educators and trainees toward independent completion of a full RARNU.© 2025 BJU International.",BJU international,"Dec, 2025",2025,Dec,,Moghaddam F S|Ghoreifi A|Sayyid R K|Wu Z|Abdollah F|Antonelli A|Eun D D|Guo S|Hung A J|Ma L|Margulis V|Matin S F|Mehrazin R|Porter J|Potretzke A|Pradere B|Roupret M|Seisen T|Shariat S F|Simone G|Stein R J|Wang L|Wu J|Xylinas E|Yao L|Zargar H|Autorino R|Cacciamani G E|Djaladat H,Potretzke A,"Institute of Urology, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.|Department of Urology, Changhai Hospital, Naval Medical University, Shanghai, China.|Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA.|Department of Urology, University of Verona, Verona, Italy.|Department of Urology, Lewis Katz School of Medicine, Temple University, Philadelphia, PA, USA.|Department of Urology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.|Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA, USA.|Department of Urology, Peking University Third Hospital, Beijing, China.|Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX, USA.|Department of Urology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.|Swedish Medical Group, Seattle, WA, USA.|Department of Urology, Mayo Clinic, Rochester, MN, USA.|Department of Urology, La Croix du Sud Hospital, Quint Fonsegrives, France.|GRC 5 Predictive Onco-Uro, Department of Urology, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.|Urology, GRC 5 Predictive Onco-Uro, AP-HP, Pitie-Salpetriere Hospital, Sorbonne University, Paris, France.|Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.|Department of Urology, IRCCS ""Regina Elena"" National Cancer Institute, Rome, Italy.|Glickman Urological & Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.|The Third Xiangya Hospital, Central South University, Changsha, China.|The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China.|Bichat Claude Bernard Hospital, Public Assistance of Paris Hospitals, Paris, France.|Peking University First Hospital, Beijing, China.|Department of Urology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.|Department of Urology, Rush University, Chicago, IL, USA.","Moghaddam F S, Ghoreifi A, Sayyid R K, Wu Z, Abdollah F, Antonelli A, Eun D D, Guo S, Hung A J, Ma L, Margulis V, Matin S F, Mehrazin R, Porter J, Potretzke A, Djaladat H, et al.",https://pubmed.ncbi.nlm.nih.gov/40960222/,"This study developed an internationally validated, structured training program for robot-assisted radical nephroureterectomy (RARNU) through expert consensus. The key finding is that the training program includes five clinical modules of increasing complexity, with a focus on specific surgical steps like hilar dissection and bladder cuff excision. This standardized curriculum can help improve clinical outcomes during the RARNU learning curve."
40975265,IgG3κ Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency.,"Lecithin cholesterol acyltransferase (LCAT) deficiency, inherited or acquired, is characterized by markedly low plasma high-density lipoprotein (HDL) cholesterol levels and increased unesterified cholesterol. We report a case of an elderly patient with persistently very low HDL and proteinuria. Serum cholesteryl esters were markedly low, and kidney biopsy revealed diffuse global glomerular lipid deposition, classic for LCAT deficiency, whereas genetic testing for variants associated with LCAT deficiency was negative. Kidney biopsy also showed concomitant monoclonal (IgG3κ) membranous nephropathy (MN). Proteomic analysis of glomeruli detected spectra for LCAT and serum amyloid P (SAP), suggesting that LCAT could be a target antigen in monoclonal MN with SAP enrichment and associated LCAT deficiency. Furthermore, lipidomic analysis revealed an accumulation of phosphatidylcholines and sphingomyelin and a decrease in ceramides. The patient was treated with daratumumab, and at 22 months follow-up his proteinuria was decreased while HDL level remained low.Copyright © 2025 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.",Am J Kidney Dis,"Dec, 2025",2025,Dec,,Bu L|Lee J H|Quigley M M|Elahimehr R|Theis J D|Perrizo R L|Dasari S|Garrett T J|Nasr S H,Bu L|Theis J D|Perrizo R L|Dasari S|Nasr S H,"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: bu.lihong@mayo.edu.|Department of Chemistry, University of Florida, Gainesville, Florida.|Diagnostic Services, Scripps Medical Foundation/Scripps Clinic Medical Group, Scripps Health, San Diego, California.|Nephrology, Scripps Health, San Diego, California.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota.|Department of Chemistry, University of Florida, Gainesville, Florida; Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota. Electronic address: nasr.samih@mayo.edu.","Bu L, Lee J H, Quigley M M, Elahimehr R, Theis J D, Perrizo R L, Dasari S, Garrett T J, Nasr S H",https://pubmed.ncbi.nlm.nih.gov/40975265/,"The key finding of this medical research is that a patient with acquired lecithin cholesterol acyltransferase (LCAT) deficiency, characterized by low HDL cholesterol levels, also had monoclonal membranous nephropathy, a type of kidney disease. The researchers suggest that LCAT could be a target antigen in this type of kidney disease, and the patient's condition improved with treatment targeting the abnormal antibody."
40976252,Reducing alcohol-associated liver disease burden in the general population.,"The prevalence of alcohol use disorder (AUD) and alcohol-associated liver disease (ALD) is rising. The National Institute on Alcohol Abuse and Alcoholism organised a multistakeholder workshop focused on reducing the burden of ALD. Decreasing ALD morbidity and mortality requires a multipronged approach, including increased population-based screening for AUD, early recognition of ALD, and multidisciplinary treatment. Recommended screening tools for alcohol use include the alcohol use disorders identification test for consumption (AUDIT-C). In patients with elevated AUDIT-C scores (AUDIT-C score of ≥3 points in women, ≥4 points in men), screening for fibrosis is recommended using non-invasive blood-based tests, such as the Fibrosis-4 index. Sequential testing using blood-based and imaging-based non-invasive liver disease assessment is preferred to blood-based tests alone to increase the positive predictive value of referral pathways. Screening, brief intervention, and referral to treatment are effective for reducing unhealthy alcohol use among adults who are not alcohol dependent. Integrated care models that incorporate mental health treatment into general medical settings are crucial for AUD and ALD. Emerging care models, such as multidisciplinary ALD clinics and substance use navigators, can improve patient engagement and outcomes. Markers of success include a reduction in per capita alcohol consumption, declines in morbidity and mortality related to AUD and ALD, and a decrease in health-care costs.Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.",The lancet. Gastroenterology & hepatology,"Dec, 2025",2025,Dec,,Asrani S K|Mellinger J|Sterling S|Lucey M R|Bradley K A|Bhala N|Bray J|Chen P|DiMartini A|Fernandez A|Ghadiali M|Haque L Y|Khalili M|Lee B|Lin L A|Pillai A A|Satre D D|Sengupta S|Serper M|Simonetto D|Thiele M|Welsh J|Wu T|Zsohar J|Shah V H,Simonetto D|Wu T|Shah V H,"Baylor University Medical Center, Dallas, TX, USA. Electronic address: Sumeet.Asrani@BSWHealth.org.|Henry Ford Hospital, Detroit, MI, USA.|Kaiser Permanente, Oakland, CA, USA.|University of Wisconsin, Madison, WI, USA.|Kaiser Permanente Washington Health Research Institute, Seattle, WA, USA.|University of Nottingham, Nottingham, UK; University of Melbourne, Parkville, VIC, Australia.|University of North Carolina Greensboro, Greensboro, NC, USA.|Johns Hopkins University, Baltimore, MD, USA.|University of Pittsburgh, Pittsburgh, PA, USA.|University of Michigan, Ann Arbor, MI, USA.|Kaiser Permanente, San Francisco, CA, USA.|Yale University, New Haven, CT, USA.|Baylor University Medical Center, Dallas, TX, USA.|University of Southern California, Los Angeles, CA, USA.|University of Chicago, Chicago, IL, USA.|Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA; Division of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.|Cleveland Clinic, Cleveland, OH, USA.|University of Pennsylvania, Philadelphia, PA, USA.|Mayo Clinic College of Medicine, Rochester, MN, USA.|Odense University Hospital, Odense, Denmark.|Emory University, Atlanta, GA, USA.","Asrani S K, Mellinger J, Sterling S, Lucey M R, Bradley K A, Bhala N, Bray J, Chen P, DiMartini A, Fernandez A, Ghadiali M, Haque L Y, Khalili M, Lee B, Lin L A, Shah V H, et al.",https://pubmed.ncbi.nlm.nih.gov/40976252/,"The key finding of this medical research is that reducing the burden of alcohol-associated liver disease (ALD) requires a multifaceted approach, including increased screening for alcohol use disorder, early recognition of ALD, and integrated care models that combine mental health treatment and general medical care. The impact of this approach could lead to a reduction in alcohol consumption, decreased ALD-related morbidity and mortality, and lower healthcare costs."
40976882,Shoulder Arthrodesis With Reamer Irrigation Aspiration Bone Grafting in Patients With Brachial Plexus Injury.,"Brachial plexus injuries (BPI) can result in irreversible functional loss of shoulder girdle musculature leading to humeral head subluxation and instability. The resultant mechanical pain can be debilitating and unresponsive to neuropathic pain medications. Surgical intervention, in the form of shoulder arthrodesis (SA), stabilizes the joint and can help to relieve this mechanical pain. Outcomes after SA have been variable in the general population, with high reported rates of nonunion. This is of particular concern in patients with BPI as they often have disuse osteopenia. Here, we describe the use of the Reamer-Irrigator-Aspirator system (RIA, DePuy Synthes, Raynham, MA) for harvesting of autologous bone graft that is used in conjunction with plate and screw fixation for SA in patients with BPI. This study details the operative technique as well as the early outcomes in the first 4 patients.Copyright © 2025 Wolters Kluwer Health, Inc. All rights reserved.",Techniques in hand & upper extremity surgery,"Dec 01, 2025",2025,Dec,01,Tagliero L E|Cancio-Bello A M|Yuan B J|Shin A Y,Tagliero L E,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN.","Tagliero L E, Cancio-Bello A M, Yuan B J, Shin A Y",https://pubmed.ncbi.nlm.nih.gov/40976882/,"The study found that using the Reamer-Irrigator-Aspirator system to harvest bone graft for shoulder arthrodesis in patients with brachial plexus injury can help stabilize the shoulder joint and relieve debilitating mechanical pain, which is a common issue in this patient population."
40982265,Pediatric bowling injuries presenting to U.S. emergency departments: a descriptive epidemiologic study.,"Bowling is a popular youth sport, but despite its popularity, there is limited research on pediatric bowling-related injuries. Therefore, the purpose of the current study was to identify common injury locations and types among pediatric bowlers and assess differences in common injured body locations and diagnoses based on age and sex.Data were sourced from the National Electronic Injury Surveillance System (NEISS) for the period 2014-2023, focusing on individuals 18 years old or younger. The data sourced from NEISS are raw numbers of cases, not stratified/weighted data. Injuries were categorized by body locations and diagnoses, and chi-square test was performed to compare injury patterns between pre-adolescents (5-10 years) and adolescents (11-18 years), as well as between males and females, with odds ratios (OR) and 95% confidence interval to determine significance.A total of 755 injuries were analyzed: 375 in pre-adolescents and 380 in adolescents, with 399 injuries in males and 356 in females. Overall, the most frequently injured body locations were the finger (30.7%), face (9.3%), wrist (8.6%), knee (7.4%), and lumbar spine (6.8%). Pre-adolescents experienced more finger (OR = 4.00, p < 0.001) and face (OR = 8.00, p < 0.001) injuries, while adolescents had more wrist (OR = 2.38, p = 0.001), knee (OR = 6.63, p < 0.001) and lumbar spine (OR = 4.41, p < 0.001) injuries. Males had a higher frequency of finger injuries (OR = 1.55, p = 0.006), whereas females experienced more wrist injuries (OR = 2.19, p = 0.003). Regarding diagnoses, pre-adolescents had a higher proportion of fractures (OR = 3.40, p < 0.001), contusions/abrasions (OR = 1.74, p = 0.007), lacerations (OR = 8.00, p < 0.001), and crushing injuries (OR = 2.91, p = 0.034), while adolescents had more sprains/strains (OR = 4.78, p < 0.001). Males were more likely to suffer fractures (OR = 2.11, p < 0.001), and females more likely to sustain sprains/strains (OR = 2.32, p < 0.001).These findings suggest that finger, face, and wrist injuries are common among youth bowlers. Differences in injury patterns may be attributed to variations in skeletal maturity, physiology, and experience. These results underscore the need for targeted prevention strategies and further research in pediatric bowling.",The Physician and sportsmedicine,"Dec, 2025",2025,Dec,,Swanson T|Mikhail D|Sugimoto D|Soma D|Jones J|Radel L,Swanson T|Soma D|Radel L,"Physical Medicine & Rehabilitation, Mayo Clinic, Rochester, MN, USA.|Orthopedic Surgery, University Texas Southwestern Medical Center, Dallas, TX, USA.|Division of Sports Medicine, Boston Children's Hospital, Boston, MA, USA.|Sports Medicine Division, The Micheli Center for Sports Injury Prevention, Waltham, MA, USA.|Department of Pediatrics, Scottish Rite for Children, Dallas, TX, USA.","Swanson T, Mikhail D, Sugimoto D, Soma D, Jones J, Radel L",https://pubmed.ncbi.nlm.nih.gov/40982265/,"This study found that the most common bowling injuries in children and adolescents are to the finger, face, wrist, knee, and lower back. Younger children are more likely to have finger and face injuries, while older children are more prone to wrist, knee, and lower back injuries. Boys are more likely to have finger injuries and fractures, while girls are more likely to have wrist injuries and sprains/strains. These findings highlight the need for targeted injury prevention strategies"
40985236,Myeloproliferative Neoplasms-Unclassifiable (MPN-U): A Carefully Curated Series of 30 Mayo Clinic Patients.,No abstract available.,American journal of hematology,"Dec, 2025",2025,Dec,,Abdelaziz R M|Faldu P|Fathima S|Zepeda Mendoza C J|Pardanani A|He R|Orazi A|Reichard K K|Gangat N|Tefferi A,Abdelaziz R M|Faldu P|Fathima S|Zepeda Mendoza C J|Pardanani A|He R|Reichard K K|Gangat N|Tefferi A,"Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Pathology, Texas Tech University Health Sciences Center, El Paso, Texas, USA.","Abdelaziz R M, Faldu P, Fathima S, Zepeda Mendoza C J, Pardanani A, He R, Orazi A, Reichard K K, Gangat N, Tefferi A",https://pubmed.ncbi.nlm.nih.gov/40985236/,"This research likely explores a specific type of blood cancer called Myeloproliferative Neoplasms-Unclassifiable (MPN-U). The researchers have carefully studied a group of 30 patients with this condition at the Mayo Clinic, providing insights into the characteristics and management of this rare form of blood cancer."
41005569,Revisiting proliferative glomerulonephritis with monoclonal immunoglobulin deposits through immunoglobulin repertoire sequencing.,"Proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) is classified within the spectrum of monoclonal gammopathy of renal significance (MGRS). However, PGNMID features an unexpected low rate of detectable monoclonal gammopathy, questioning the reality of an underlying clonal disorder in most cases.We reviewed a cohort of 56 patients with PGNMID focusing on hematological characteristics. To detect discrete underlying clones, we used a highly sensitive high-throughput immunoglobulin (Ig) repertoire sequencing assay from RNA bone marrow (RACE-RepSeq). We also challenged the monoclonality of kidney deposits using immunofluorescence with antibodies specific for light chain (LC) variable region subgroups.RACE-RepSeq detected a bone marrow clone corresponding to the deposited Ig in only 23% of the whole cohort. As previously reported, PGNMID-IgG3 was the predominant subtype (41/56, 73%), with an over-representation of IgG3 kappa deposits (33/56, 59%). The low prevalence of clonal disorders was driven by PGNMID-IgG3 cases, with only 4/41 (9.8%) patients showing an IgG3-secreting bone marrow clone by RACE-RepSeq. In all seven clone-negative PGNMID-IgG3 kappa cases studied by immunofluorescence with anti-LC variable domain antibodies, glomerular deposits stained for all tested Vκ subgroups, ruling out their monoclonal nature. Compared to control individuals, immunoglobulin repertoire analyses in 24 patients without a detectable clone failed to detect any bias toward the deposited isotype, but showed increased IgG1 representation, suggesting an infectious trigger.Our results suggest that PGNMID is a heterogeneous condition. The predominant subtype most often involves oligoclonal or polyclonal production of nephrotoxic IgG3 and may not derive from a clonal B-cell disorder. Such cases should no longer be classified as MGRS.Copyright © 2025 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.",Kidney international,"Dec, 2025",2025,Dec,,Javaugue V|Pascal V|Nasr S H|Bender S|Derouault P|Dasari S|Madden B J|Charlesworth M C|Karlin L|Lebas C|Ulrich M|Gnemmi V|Goujon J|Roussel M|Jaccard A|Leung N|Sirac C|Bridoux F,Nasr S H|Dasari S|Madden B J|Charlesworth M C|Leung N,"CNRS U7276, INSERM U1262, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Université de Limoges, Limoges, France; Department of Nephrology, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», CIC INSERM U1402, Centre Hospitalier Universitaire et Université de Poitiers, Poitiers, France.|CNRS U7276, INSERM U1262, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Université de Limoges, Limoges, France; Laboratory of Immunology and Immunogenetics, Centre Hospitalier Universitaire de Limoges, Limoges, France.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.|CNRS U7276, INSERM U1262, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Université de Limoges, Limoges, France.|Department of BioInformatics, Centre Hospitalier Universitaire de Limoges, Limoges, France.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.|Medical Genome Facility, Proteomics Core, Mayo Clinic, Rochester, Minnesota, USA.|Department of Clinical Hematology, Centre Hospitalier Universitaire Lyon Sud, Hospices Civils de Lyon, Pierre-Benite, France.|Department of Nephrology, Centre Hospitalier Universitaire de Lille, Lille, France.|Department of Nephrology, Centre Hospitalier de Valenciennes, Valenciennes, France.|Department of Pathology, Centre Hospitalier Universitaire de Lille, Lille, France.|Department of Pathology, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Centre Hospitalier Universitaire de Poitiers, Poitiers, France.|CNRS U7276, INSERM U1262, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Université de Limoges, Limoges, France; Department of Hematology, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Centre Hospitalier Universitaire de Limoges, Limoges, France.|Division of Nephrology and Hypertension and Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.|CNRS U7276, INSERM U1262, Centre de Référence Maladies Rares «Amylose AL et Autres Maladies par Dépôts d'Immunoglobulines Monoclonales», Université de Limoges, Limoges, France. Electronic address: christophe.sirac@unilim.fr.","Javaugue V, Pascal V, Nasr S H, Bender S, Derouault P, Dasari S, Madden B J, Charlesworth M C, Karlin L, Lebas C, Ulrich M, Gnemmi V, Goujon J, Roussel M, Jaccard A, Bridoux F, et al.",https://pubmed.ncbi.nlm.nih.gov/41005569/,"This study found that in most cases of proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID), the deposits are not actually from a single clonal source, as previously thought. Instead, the deposits often come from oligoclonal or polyclonal production of a specific type of antibody (IgG3). This suggests that PGNMID may not always be caused by an underlying clonal disorder, and the"
40988594,Does RECIST 1.1 Predict Nodal Response to Neoadjuvant Chemo-Immunotherapy in Breast Cancer?,"Neoadjuvant chemoimmunotherapy (NACI) for node-positive breast cancer may induce immune cell activation in regional lymph nodes (LN), confounding post-NACI imaging. Here we evaluated RECIST 1.1 criteria to predict post-NACI pathologic LN status.We studied patients with biopsy-proven cN+ non-distant metastatic breast cancer receiving NACI operated on 03/2020-09/2024 with both pre- and post-NACI cross-sectional imaging. Per RECIST 1.1, LN short axis diameter (SAD) was measured in target (defined as SAD ≥ 15 mm) and nontarget (SAD 10-14.9 mm) LNs. Groups were compared using Fisher's exact test.75 patients, median age 53 years, were studied: 61% cN1, 12% cN2, and 27% cN3. Baseline median number of imaging-suspicious LN was 4 (IQR 2-5). Post-NACI, 64% had a nodal pathologic complete response (pCR/ypN0). 55% met RECIST 1.1 LN assessment criteria. 21 of 32 (66%) with an imaging CR (iCR) were ypN0, while 8 of 9 (89%) without an iCR were ypN0. Neither target (p = 0.24) nor combined target/nontarget LN iCR (p = 0.76) predicted ypN status. Nodal pCR rates were higher in those with ≤ 1 versus > 1 suspicious LN post-NACI (71% vs. 42%, p = 0.03).RECIST 1.1 criteria did not predict nodal pCR for NACI-treated node-positive breast cancer patients. Other post-NACI imaging assessment strategies are needed.© 2025 Wiley Periodicals LLC.",Journal of surgical oncology,"Dec, 2025",2025,Dec,,Redaelli M|Steadman J A|Hoskin T L|Hieken T J,Redaelli M|Steadman J A|Hoskin T L|Hieken T J,"Department of Surgery, Division of Breast and Melanoma Surgical Oncology, Rochester, Minnesota, USA.|Division of Clinical Trials and Biostatistics, Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.","Redaelli M, Steadman J A, Hoskin T L, Hieken T J",https://pubmed.ncbi.nlm.nih.gov/40988594/,"The study found that the RECIST 1.1 criteria, which are commonly used to assess tumor response, did not accurately predict the pathological response of lymph nodes in breast cancer patients treated with neoadjuvant chemoimmunotherapy. The researchers suggest that new imaging assessment strategies are needed to better evaluate the response of lymph nodes to this type of treatment."
40988652,An examination of anhedonia as a predictor of response with transcranial magnetic stimulation treatment for youth with depression.,"This exploratory study examined the relationship between the change in anhedonia symptoms and treatment response in adolescents receiving 1 Hz or 10 Hz transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD). Participants were aged 12-18 years, had a depressive symptom score of 40 or higher on the Children's Depressed Rating Scale-Revised (CDRS-R), and were randomized to either the 1 Hz (n = 22) or 10 Hz (n = 19) group for 30 daily TMS treatments over the left dorsolateral prefrontal cortex (LDLPFC). Anhedonia was measured using items from the Beck Depression Inventory-II and CDRS-R. Treatment outcome was assessed with the Clinical Global Impressions-Improvement scales (CGI-I). Logistic regression was used to estimate the odds of CGI-I treatment response from the change in anhedonia symptoms (baseline to week 6), and a linear mixed model of repeated measures analyzed the change in anhedonia (baseline, weeks 4 and 6) compared between the TMS treatment groups over the 6-week study period. TMS stimulus frequency did not affect the change in anhedonia and CGI-I response. There was a significant inverse relationship concerning the change in anhedonia symptoms and CGI-I response for both the 10 Hz (p = 0.0109, δ= -0.8581, SE= 0.3371) and 1 Hz (p = 0.0277, δ= -1.1017, SE=0.5003) groups. Thus, as anhedonia symptoms improved over the 6 weeks, the probability of CGI-I response at week 6 increased for both the 1 Hz and 10 Hz TMS groups. An adjusted least squares for anhedonia revealed a significant improvement in anhedonia for TMS groups (10 Hz, p < 0.0001, d=0.9032; 1 Hz, p < 0.0001, d=0.8536). Future studies of anhedonia may inform precision TMS treatments for youth.© 2025 The Authors. Published by Elsevier Inc. on behalf of Anxiety and Depression Association of America.",Journal of mood and anxiety disorders,"Dec, 2025",2025,Dec,,Hecker J C|Nakonezny P A|Bakir C N|Azamet I|Romanowicz M|Shekunov J|Vande Voort J L|Lujan J L|Croarkin P E,Hecker J C|Bakir C N|Azamet I|Romanowicz M|Shekunov J|Vande Voort J L|Lujan J L|Croarkin P E,"Center for Clinical and Translational Science, Mayo Clinic Graduate School of Biomedical Sciences, Rochester, MN 55905, USA.|Department of Population and Data Sciences, UT Southwestern Medical Center, Dallas, TX 75390, USA.|Mayo Clinic School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, MN 55905, USA.|Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN 55905, USA.|Department of Neurologic Surgery and Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN 55905, USA.","Hecker J C, Nakonezny P A, Bakir C N, Azamet I, Romanowicz M, Shekunov J, Vande Voort J L, Lujan J L, Croarkin P E",https://pubmed.ncbi.nlm.nih.gov/40988652/,"This study found that improvements in anhedonia (lack of pleasure) during transcranial magnetic stimulation (TMS) treatment were associated with better response to treatment in adolescents with depression. Both 1 Hz and 10 Hz TMS treatments led to significant improvements in anhedonia, suggesting that targeting anhedonia may be an important factor in developing effective TMS treatments for depression in young people."
40989056,Retroperitoneal extrarenal Wilms tumor: A diagnostic challenge and kidney-sparing approach.,"This is a report of a 2-year-old female who presented with a large right retroperitoneal mass that was abutting the right kidney but appeared distinct with absence of the ""claw sign."" Biopsy showed Wilms tumor. Following neoadjuvant chemotherapy, the tumor remained associated with the kidney, though without clear renal origin. Intraoperatively, an extrarenal Wilms tumor was confirmed, and tumor resection was performed without nephrectomy. Postoperatively, the patient underwent kidney-sparing proton beam flank radiation and completed chemotherapy. Imaging remains negative for recurrence, and there is no postradiation atrophy of the right kidney 18 months following completion of therapy. A high index of suspicion is needed for extrarenal, retroperitoneal Wilms tumor to allow for kidney-sparing treatment.© 2025 The Authors. Published by Elsevier Inc. on behalf of University of Washington.",Radiology case reports,"Dec, 2025",2025,Dec,,Debertin J G|Hull N C|Dean Potter D|Allen-Rhoades W A|Laack N N|Polites S F,Debertin J G|Hull N C|Dean Potter D|Allen-Rhoades W A|Laack N N|Polites S F,"Mayo Clinic Alix School of Medicine, Mayo Clinic Rochester, Rochester, MN, USA.|Pediatric Radiology Division, Department of Radiology, Mayo Clinic Rochester, Rochester, MN, USA.|Division of Pediatric Surgery, Department of Surgery, Mayo Clinic Rochester, 200 1st Street SW, Rochester, MN 55901, USA.|Division of Pediatric Hematology and Oncology, Department of Pediatrics, Mayo Clinic Rochester, Rochester, MN, USA.|Department of Radiation Oncology, Mayo Clinic Rochester, Rochester, MN, USA.","Debertin J G, Hull N C, Dean Potter D, Allen-Rhoades W A, Laack N N, Polites S F",https://pubmed.ncbi.nlm.nih.gov/40989056/,"This report describes a rare case of a Wilms tumor, a type of kidney cancer, that developed outside the kidney. The doctors were able to remove the tumor without removing the kidney, allowing the child to keep their kidney. This kidney-sparing approach is important, as it can help preserve kidney function in young patients with this rare type of tumor."
40991017,Pancreatic cancer-related diabetes and type 2 diabetes differ in multiple aspects of glucose homeostasis.,"Pancreatic ductal adenocarcinoma-related diabetes mellitus (PDAC-DM) is a paraneoplastic syndrome with a poorly understood pathophysiology. PDAC-DM is often clinically confused with type 2 diabetes, resulting in delayed cancer detection and poorly individualised hyperglycaemia treatment. We investigated whether these forms of diabetes can be distinguished at the metabolic level.Adults with either cancer treatment-naive PDAC-DM (n=28) or type 2 diabetes (n=97), and with diabetes onset within 3 years, underwent mixed-meal tolerance tests to investigate glucose metabolism. Outcomes included insulin sensitivity (Matsuda index), insulin secretion (insulinogenic index), beta cell function (oral disposition index), insulin clearance, and postprandial glucagon, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) responses.Compared with type 2 diabetes, individuals with PDAC-DM showed ~2.5-fold greater insulin sensitivity, ~81% lower insulin secretion and ~40% lower beta cell function. Insulin clearance was higher in the PDAC-DM group than the type 2 diabetes group, with and without adjustment for insulin sensitivity. Glucagon and GLP-1 levels increased after a meal in both groups, but levels were higher in the PDAC-DM group. GIP levels were similar between groups. The metabolic differences between groups persisted after adjustment for age, sex and BMI.PDAC-DM and type 2 diabetes are metabolically distinct, with different defects responsible for hyperglycaemia. PDAC-DM is characterised predominantly by insulin deficiency and displays higher insulin sensitivity than type 2 diabetes. There are also differences in alpha cell regulation and insulin clearance compared with type 2 diabetes. These findings identify biological characteristics that may have implications for individualised treatment of PDAC-DM and guide diagnostic biomarker discovery for early PDAC diagnosis.© 2025. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",Diabetologia,"Dec, 2025",2025,Dec,,Toledo F G S|Li Y|Wang F|Bellin M D|Brand R|Cusi K|Fisher W|Kudva Y C|Park W G|Saeed Z I|Yadav D|Considine R V|Graham S C|Andersen D K|Serrano J|Goodarzi M O|Hart P A,Kudva Y C,"Division of Endocrinology and Metabolism, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. toledofs@upmc.edu.|Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Departments of Pediatrics and Surgery, University of Minnesota Medical School, Minneapolis, MN, USA.|Division of Gastroenterology, Hepatology and Nutrition, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.|Division of Endocrinology, Diabetes and Metabolism, University of Florida, Gainesville, FL, USA.|Department of Surgery, Baylor College of Medicine, Houston, TX, USA.|Division of Endocrinology, Mayo Clinic College of Medicine, Rochester, MN, USA.|Division of Gastroenterology & Hepatology, Stanford University School of Medicine, Stanford, CA, USA.|Division of Endocrinology, Indiana University School of Medicine, Indianapolis, IN, USA.|Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, NIH, Bethesda, MD, USA.|Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.|Division of Gastroenterology, Hepatology, and Nutrition, The Ohio State University Wexner Medical Center, Columbus, OH, USA.","Toledo F G S, Li Y, Wang F, Bellin M D, Brand R, Cusi K, Fisher W, Kudva Y C, Park W G, Saeed Z I, Yadav D, Considine R V, Graham S C, Andersen D K, Serrano J, Hart P A, et al.",https://pubmed.ncbi.nlm.nih.gov/40991017/,"The study found that pancreatic cancer-related diabetes (PDAC-DM) and type 2 diabetes have distinct metabolic differences, with PDAC-DM characterized by greater insulin sensitivity but lower insulin secretion and beta cell function. These findings suggest that PDAC-DM and type 2 diabetes require different treatment approaches and could help in the early diagnosis of pancreatic cancer."
40996347,Validation of BLAST and BLAST-Mol Risk Models in Chronic Myelomonocytic Leukemia: Mayo-Humanitas Collaborative Project Involving 1101 Patients.,The current study validates the predictive performance of the BLAST and BLAST-Mol risk models in a large two-center international cohort with a total of 1101 patients with newly diagnosed CMML.© 2025 Wiley Periodicals LLC.,American journal of hematology,"Dec, 2025",2025,Dec,,Fathima S|Alsugair A|Yousuf M|Faldu P|Csizmar C|Nakhleh M|Mangaonkar A A|Pardanani A|Lanino L|Campagna A|Maggioni G|Reichard K K|He R|Gangat N|Patnaik M M|Della Porta M G|Tefferi A,Fathima S|Alsugair A|Yousuf M|Faldu P|Csizmar C|Nakhleh M|Mangaonkar A A|Pardanani A|Reichard K K|He R|Gangat N|Patnaik M M|Tefferi A,"Divisions of Hematology and Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Internal Medicine, Division of Hematology, Yale School of Medicine, New Haven, Connecticut, USA.|Department of Hematology Oncology, IRCCS Humanitas Research Hospital, Milan, Italy.|Department of Biomedical Sciences, Humanitas University, Milan, Italy.","Fathima S, Alsugair A, Yousuf M, Faldu P, Csizmar C, Nakhleh M, Mangaonkar A A, Pardanani A, Lanino L, Campagna A, Maggioni G, Reichard K K, He R, Gangat N, Patnaik M M, Tefferi A, et al.",https://pubmed.ncbi.nlm.nih.gov/40996347/,"This study validated two risk models, BLAST and BLAST-Mol, that can help predict the prognosis of patients with chronic myelomonocytic leukemia, a type of blood cancer. The study involved over 1,000 patients, making it a large and comprehensive analysis. These validated risk models can help doctors better understand the likely course of the disease and guide treatment decisions for patients with this condition."
40996861,Inhibition of lipolysis in visceral adipose tissue from obese mice and humans prevents impairment of endothelial Kir2.1 channels.,"Accumulation of abdominal visceral adipose tissue (VAT) is a major risk factor for cardiovascular disease. Obesity-induced endothelial dysfunction is a precursor to severe disease, and we and others have shown that arteries embedded in VAT, but not subcutaneous adipose tissue, exhibit robust endothelial dysfunction. Using a mouse model of diet-induced obesity, we recently linked VAT from obese mice to the impairment of endothelial Kir2.1, a critical regulator of endothelial function. However, the mechanism by which VAT impairs Kir2.1 is unclear. As Kir2.1 impairment is dependent on endothelial CD36, we hypothesized that lipolytic VAT induces Kir2.1 impairment through fatty acids (FA). To test this, we first treated endothelial cells with palmitic acid (PA) to determine whether the addition of exogenous FAs recapitulated our original finding of Kir2.1 dysfunction when challenged with VAT. PA inhibited Kir2.1 assessed via whole-cell patch-clamp electrophysiology, an effect that was dependent on endothelial CD36. To determine whether inhibiting VAT lipolysis prevents Kir2.1 dysfunction in the presence of VAT in obese mice and humans, VAT was pretreated with small molecule inhibitors of adipose triglyceride lipase prior to incubating endothelial cells with adipose tissue. This approach also prevented VAT-induced impairment of endothelial Kir2.1 suggesting that VAT-derived FAs may play a role. Furthermore, inhibition of lipolysis in the VAT of obese mice and humans significantly reduced endothelial FA uptake, similar to that observed when CD36 was downregulated. These findings advance our understanding of the relationship between VAT and endothelial Kir2.1 impairment and place VAT-derived FAs as potential paracrine mediators.","Channels (Austin, Tex.)","Dec, 2025",2025,Dec,,Hudgins E C|Johnson E J|Rokka S|Kashyap B|Mahugu A|Nguyen T|Tascone A R|McCarthy E|Halbert C|Fancher I S,Nguyen T,"Department of Kinesiology and Applied Physiology, College of Health Sciences, University of Delaware, Newark, DE, USA.|Department of Physiology and Biomedical Engineering, Mayo Clinic, Rochester, MN, USA.|Christiana Care Health System, Department of Surgery, Section of Bariatric Surgery, Wilmington, DE, USA.","Hudgins E C, Johnson E J, Rokka S, Kashyap B, Mahugu A, Nguyen T, Tascone A R, McCarthy E, Halbert C, Fancher I S",https://pubmed.ncbi.nlm.nih.gov/40996861/,"The key finding of this research is that inhibiting lipolysis (breakdown of fat) in visceral adipose tissue (VAT) from obese mice and humans prevents the impairment of endothelial Kir2.1 channels, which are critical for endothelial function. This suggests that VAT-derived fatty acids may play a role in the impairment of endothelial function, and targeting lipolysis in VAT could be a potential"
41044428,"Author Correction: Stereotactic radiosurgery for patients with brain metastases: current principles, expanding indications and opportunities for multidisciplinary care.",No abstract available.,Nature reviews. Clinical oncology,"Dec, 2025",2025,Dec,,Mansouri A|Ozair A|Bhanja D|Wilding H|Mashiach E|Haque W|Mikolajewicz N|de Macedo Filho L|Mahase S S|Machtay M|Metellus P|Dhermain F|Sheehan J|Kondziolka D|Lunsford L D|Niranjan A|Minniti G|Li J|Kalkanis S N|Wen P Y|Kotecha R|McDermott M W|Bettegowda C|Woodworth G F|Brown P D|Sahgal A|Ahluwalia M S,Brown P D,"Department of Neurosurgery, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. amansouri@pennstatehealth.psu.edu.|Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA. amansouri@pennstatehealth.psu.edu.|Department of Neurosurgery, Penn State College of Medicine, Pennsylvania State University, Hershey, PA, USA. amansouri@pennstatehealth.psu.edu.|Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, USA.|Department of Neurological Surgery, NYU Langone Health, New York University, New York, NY, USA.|Department of Neurosurgery, Penn State College of Medicine, Pennsylvania State University, Hershey, PA, USA.|Division of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.|Peter Gilgan Centre for Research and Learning, Hospital for Sick Children, Toronto, Ontario, Canada.|Penn State Cancer Institute, Penn State Health Milton S. Hershey Medical Center, Hershey, PA, USA.|Department of Radiation Oncology, Penn State Cancer Institute, Hershey, PA, USA.|Department of Neurosurgery, Ramsay Santé, Hôpital Privé Clairval, Marseille, France.|Radiation Therapy Department, Institut Gustave Roussy, Villejuif, France.|Department of Neurological Surgery, University of Virginia, Charlottesville, VA, USA.|Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.|Department of Radiological Sciences, Oncology and Anatomical Pathology, Sapienza IRCCS Neuromed, Pozzilli, Italy.|Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.|Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA.|Center For Neuro-Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.|Department of Radiation Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA.|Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA.|Department of Neurosurgery, Miami Neuroscience Institute, Baptist Health South Florida, Miami, FL, USA.|Department of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA.|Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.|Brain Tumour Program, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.|University of Maryland-Medicine Institute for Neuroscience Discovery, Baltimore, MD, USA.|Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.|Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada.|Herbert Wertheim College of Medicine, Florida International University, Miami, FL, USA. manmeeta@baptisthealth.net.|Department of Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. manmeeta@baptisthealth.net.","Mansouri A, Ozair A, Bhanja D, Wilding H, Mashiach E, Haque W, Mikolajewicz N, de Macedo Filho L, Mahase S S, Machtay M, Metellus P, Dhermain F, Sheehan J, Kondziolka D, Lunsford L D, Ahluwalia M S, et al.",https://pubmed.ncbi.nlm.nih.gov/41044428/,"This research likely explores the use of stereotactic radiosurgery, a specialized radiation therapy, for treating brain metastases, which are cancerous tumors that have spread to the brain from other parts of the body. The research may also discuss the evolving principles and expanding indications for this treatment approach, as well as the potential benefits of a multidisciplinary approach to patient care."
41045031,"Prevalence of Concurrent (Double-Positive) JAK2, CALR, or MPL Mutations and Corresponding Clinicopathologic Features: Analysis of 21556 Mayo Clinic NGS Studies Including 2651 Informative Cases.",No abstract available.,American journal of hematology,"Dec, 2025",2025,Dec,,He R|Ollila P L|Zhang X|Yuan J|Shi M|Rangan A|Gangat N|Chen D|Tefferi A|Viswanatha D S,He R|Ollila P L|Zhang X|Yuan J|Shi M|Rangan A|Gangat N|Chen D|Tefferi A|Viswanatha D S,"Division of Hematopathology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Hematopathology, Mayo Clinic, Jacksonville, Florida, USA.|Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.","He R, Ollila P L, Zhang X, Yuan J, Shi M, Rangan A, Gangat N, Chen D, Tefferi A, Viswanatha D S",https://pubmed.ncbi.nlm.nih.gov/41045031/,"This research likely explores the occurrence of multiple genetic mutations (JAK2, CALR, or MPL) in patients with certain blood disorders. The study analyzes a large number of genetic tests from patients to understand the prevalence and clinical characteristics associated with the presence of these concurrent mutations."
41045034,"Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma.","Light chain multiple myeloma (LCMM) is a subtype of multiple myeloma (MM) characterized by the exclusive production of immunoglobulin light chains and accounts for 15%-20% of newly diagnosed MM. A comprehensive comparison of LCMM with MM producing intact immunoglobulin (non-LCMM) remains limited. In this retrospective study, we described distinct clinical and cytogenetic features and assessed long-term outcomes in 852 LCMM patients diagnosed between 01/01/2004 and 12/31/2022, compared with non-LCMM controls matched for age, sex, and year of diagnosis. On univariable analysis, LCMM patients were more likely to present with elevated creatinine (> 2 mg/dL), beta-2-microglobulin ≥ 5.5 mg/L, elevated LDH, hypercalcemia, t(11;14), del(13q), and t(6;14). Conversely, IMS-IMWG high-risk disease, hyperdiploidy, t(4;14), and serum albumin < 3.5 g/dL were less common. On multivariable analysis, elevated creatinine (OR: 5.1, 95% CI: 1.2-27, p = 0.04), t(11;14) (OR: 2.6, 95% CI: 1.3-5.2, p = 0.006), and del(13q) (OR: 4.1, 95% CI: 2.1-8.2, p < 0.001) were independently associated with LCMM, while IMS-IMWG high-risk disease (OR: 0.3, 95% CI: 0.1-0.8, p = 0.02) and hyperdiploidy (OR: 0.3, 95% CI: 0.1-0.7, p = 0.002) were less frequent. Despite these differences, progression-free survival with frontline treatment (HR: 0.97, 95% CI: 0.84-1.11, p = 0.63) and overall survival (HR: 0.99, 95% CI: 0.87-1.13, p = 0.94) were similar between LCMM and non-LCMM patients. This study highlights the distinct clinical and cytogenetic features of LCMM, marked by higher rates of renal failure, t(11;14), and del(13q), lower prevalence of IMS-IMWG high-risk disease, and comparable survival outcomes.© 2025 Wiley Periodicals LLC.",American journal of hematology,"Dec, 2025",2025,Dec,,Bolarinwa A|Zanwar S|Abdallah N|Buadi F K|Hayman S R|Gertz M A|Dispenzieri A|Muchtar E|Kapoor P|Gonsalves W|Kourelis T|Dingli D|Warsame R|Leung N|Cook J|Binder M|Lin Y|Hwa Y|Rogers M G|Hobbs M|Fonder A|Jevremovic D|Rajkumar S V|Kumar S K,Bolarinwa A|Zanwar S|Abdallah N|Buadi F K|Hayman S R|Gertz M A|Dispenzieri A|Muchtar E|Kapoor P|Gonsalves W|Kourelis T|Dingli D|Warsame R|Leung N|Cook J|Binder M|Lin Y|Hwa Y|Rogers M G|Hobbs M|Fonder A|Jevremovic D|Rajkumar S V|Kumar S K,"Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.","Bolarinwa A, Zanwar S, Abdallah N, Buadi F K, Hayman S R, Gertz M A, Dispenzieri A, Muchtar E, Kapoor P, Gonsalves W, Kourelis T, Dingli D, Warsame R, Leung N, Cook J, Kumar S K, et al.",https://pubmed.ncbi.nlm.nih.gov/41045034/,"This study found that light chain multiple myeloma (LCMM) has distinct clinical and genetic features compared to other types of multiple myeloma, such as higher rates of kidney problems, specific genetic changes, and lower rates of high-risk disease. However, the study also showed that the long-term outcomes for LCMM patients are similar to those with other types of multiple myeloma when treated."
41102379,"Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis.","Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) encompasses three rare yet interrelated diseases: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Despite increasing recognition, the diagnosis of AAV remains challenging, even in specialized medical centres, owing to its clinical heterogeneity, overlap with mimicking conditions, and the variable performance of ANCA testing. The assessment of a patient suspected of AAV requires a timely synthesis of symptoms, physical examination, laboratory tests, histopathology and imaging data to substantiate the diagnosis, exclude alternative diagnoses, assess disease activity and extent, and enable rapid initiation of appropriate therapies. Classification is similarly complex, and evolving classification systems are based on clinical phenotype, ANCA specificity or a combination of both, each with implications for disease monitoring, therapeutic decisions and trial design. Assessing disease severity and predicting prognosis are fundamental but complicated by the diverse patterns of organ involvement, relapsing-remitting course and co-morbidities. Although validated tools exist for measuring disease activity, organ damage and prognosis, many limitations remain, particularly in identifying smouldering disease, irreversible damage and risk of relapse. Emerging therapies have improved outcomes, with recovery of kidney function, better overall survival and improved glucocorticoid-related toxicity, but patients with AAV continue to experience high risks of chronic morbidity and early mortality. This Review explores current challenges and opportunities in the diagnosis, classification and prognostic assessment of AAV, and outlines a structured framework to support personalized and outcome-focused care.© 2025. Springer Nature Limited.",Nature reviews. Rheumatology,"Dec, 2025",2025,Dec,,Casal Moura M|Merkel P A|Jayne D|Cid M C|Basu N|Hellmich B|Terrier B|Rutgers A|Gordon J|Verhoeven P|Kullman J|Langford C A|Bajema I M|Geetha D|Fervenza F C|Kitching A R|Stone J H|Specks U|Kronbichler A,Casal Moura M|Fervenza F C|Specks U,"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA. casalmoura.marta@mayo.edu.|Departamento de Biomedicina, Faculdade de Medicina da Universidade do Porto, Porto, Portugal. casalmoura.marta@mayo.edu.|Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, USA.|Division of Epidemiology, Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.|Department of Medicine, University of Cambridge, Cambridge, UK.|Vasculitis Research Unit, Department of Autoimmune Diseases, Hospital Clinic University of Barcelona, Barcelona, Spain.|Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain.|Institute of Infection and Immunity, University of Glasgow, Glasgow, UK.|Department of Internal Medicine, Rheumatology, Pneumology, Nephrology and Diabetology, Medius Kliniken, University of Tübingen, Kirchheim-Teck, Germany.|National Referral Center for Rare Systemic Autoimmune Diseases, Université Paris Cité, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Paris, France.|Vasculitis Expertise Centre Groningen, Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Centre Groningen, Groningen, The Netherlands.|Vasculitis Foundation, Kansas City, MO, USA.|Dutch Patient Vasculitis Organization, Maarsen, The Netherlands.|Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, USA.|Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.|Division of Nephrology, Johns Hopkins University, Baltimore, MD, USA.|Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.|Centre for Inflammatory Diseases, Monash University Department of Medicine, Monash Medical Centre, Clayton, Victoria, Australia.|Harvard Medical School, Massachusetts General Hospital, Boston, MA, USA.|Division of Pulmonary and Critical Care, Department of Medicine, Mayo Clinic College of Medicine and Science, Rochester, MN, USA.|Department of Medicine, University of Cambridge, Cambridge, UK. andreas.kronbichler@i-med.ac.at.|Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden. andreas.kronbichler@i-med.ac.at.|Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria. andreas.kronbichler@i-med.ac.at.","Casal Moura M, Merkel P A, Jayne D, Cid M C, Basu N, Hellmich B, Terrier B, Rutgers A, Gordon J, Verhoeven P, Kullman J, Langford C A, Bajema I M, Geetha D, Fervenza F C, Kronbichler A, et al.",https://pubmed.ncbi.nlm.nih.gov/41102379/,"The key finding of this medical research is that diagnosing, classifying, and predicting the prognosis of ANCA-associated vasculitis (AAV) remains challenging due to its clinical complexity and the limitations of current diagnostic tools. Despite improved treatments, patients with AAV continue to face high risks of chronic health problems and early death, highlighting the need for better strategies to personalize and optimize their care."
41090475,Meta-Analysis: Efficacy and Safety of Sequestrants for Bile Acid Diarrhoea.,"Bile acid diarrhoea, a common cause of diarrhoea-predominant irritable bowel syndrome, has a similar prevalence to coeliac disease and inflammatory bowel diseases. The mainstay of treatment is bile acid sequestrants (BAS). The effectiveness of using bile acid-targeted therapies remains unclear.To compare BAS with placebo for bile acid diarrhoea.We conducted a systematic review and meta-analysis of randomised controlled trials comparing BAS to placebo using a comprehensive search of databases from inception to 8/1/2023. Inclusion required unequivocal diagnosis using serum or faecal biochemical parameters, or 75SeHCAT. Co-primary endpoints were ≥ 30% improvement in bowel movement consistency and frequency averaged over 7 days. Adverse effects were also summarised.Database search resulted in 1152 citations; 1 additional study was added. Ultimately, 6 trials (5 parallel arm, 1 crossover) involving 182 participants evaluated the effectiveness of BAS over 1-8 weeks. Participants were between the third and seventh decades of life and mostly female. The risk of bias was low except in one parallel and one crossover trial. Meta-analysis of parallel-design trials of sequestrants only showed a clinically significant reduction in stool consistency and frequency with pooled relative risks of 1.50 (95% CI: 1.14-1.96) and 2.80 (95% CI: 1.68-4.67), respectively. There was no observable heterogeneity (I2 = 0%), and the certainty of evidence was moderate. There was no statistically significant difference in adverse effects.This study quantifies the significant and rapid improvement in both stool consistency and frequency with BAS in patients with objective diagnosis of bile acid diarrhoea. Sequestrants also appear well tolerated.© 2025 John Wiley & Sons Ltd.",Alimentary pharmacology & therapeutics,"Dec, 2025",2025,Dec,,Dilmaghani S|BouSaba J|Lupianez-Merly C|Prokop L|Murad M H|Camilleri M,Dilmaghani S|BouSaba J|Lupianez-Merly C|Prokop L|Murad M H|Camilleri M,"Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Division of Library Services, Mayo Clinic, Rochester, Minnesota, USA.|Evidence-Based Practice Center, Kern Center for the Science of Healthcare Delivery, Mayo Clinic, Rochester, Minnesota, USA.","Dilmaghani S, BouSaba J, Lupianez-Merly C, Prokop L, Murad M H, Camilleri M",https://pubmed.ncbi.nlm.nih.gov/41090475/,"This study found that bile acid sequestrants, a type of medication, can significantly improve stool consistency and frequency in people with bile acid diarrhoea, a common cause of irritable bowel syndrome. The treatment was also well-tolerated, making it a potentially effective option for managing this condition."
41094343,Peri-intubation Cardiovascular Collapse During Emergency Airway Management.,"Emergency airway management is a lifesaving procedure but can be associated with significant risks, including hypoxia, hypotension, cardiac arrest, and death. Peri-intubation hypotension, reported in ≥ 40% of cases, is strongly associated with increased morbidity and mortality. While clinical guidelines emphasize the importance of preoxygenation and hemodynamic optimization prior to intubation, the latter remains poorly defined, with limited available data to guide evidence-based strategies to mitigate cardiovascular collapse during rapid sequence intubation. This review synthesizes current knowledge on the epidemiology, risk factors, and pathophysiology of peri-intubation hemodynamic deterioration. We review targeted strategies for hemodynamic optimization of physiologic parameters before intubation. These include volume expansion with fluid resuscitation, vasopressor utilization, selection of pharmacologic agents, invasive hemodynamic monitoring, and advanced preoxygenation techniques. In selected high-risk patients, we also discuss the potential role of extracorporeal membrane oxygenation as an adjunctive or rescue therapy. Our goal is to provide airway specialists with a comprehensive framework for mitigating cardiovascular collapse during emergent airway management and to stimulate further research into this high-risk and understudied domain.© 2025. The Author(s).",Pulmonary therapy,"Dec, 2025",2025,Dec,,Garcia S I|Smischney N J|Sandefur B J|D'Andria Ursoleo J|Kelm D J|Wieruszewski P M,Garcia S I|Smischney N J|Sandefur B J|Kelm D J|Wieruszewski P M,"Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Anesthesiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.|Department of Anesthesia and Intensive Care, IRCCS San Raffaele Scientific Institute, Milan, Italy.|Department of Anesthesiology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. wieruszewski.patrick@mayo.edu.|Department of Pharmacy, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA. wieruszewski.patrick@mayo.edu.","Garcia S I, Smischney N J, Sandefur B J, D'Andria Ursoleo J, Kelm D J, Wieruszewski P M",https://pubmed.ncbi.nlm.nih.gov/41094343/,"The key finding of this medical research is that emergency airway management can lead to significant cardiovascular risks, including hypotension and cardiac arrest, which are strongly associated with increased morbidity and mortality. The review discusses strategies to optimize hemodynamics and mitigate these risks, such as fluid resuscitation, vasopressor use, and advanced preoxygenation techniques, which can help improve patient outcomes during emergency airway management."
41098767,Multi-modal mixed-type structural equation modeling with structured sparsity for subgroup discovery from heterogeneous health data.,"The increasing availability of health data from resources such as large biobanks, electronic healthcare records, medical tests, and wearable sensors, has set the stage for the development of novel machine learning (ML) models for multi-modal mixed-type data to capture the complexity of human health and disease. Clustering is a type of ML model that aims to identify homogenous subgroups from heterogeneous data, providing a data-driven solution to targeted, subgroup-specific study and intervention. While such data contain diverse and complementary information to facilitate decision making and improve population health, clustering of high-dimensional multi-modal mixed-type data poses major challenges to existing ML and statistical models. We propose a novel Multi-modal Mixed-type Structural Equation Model (M2-SEM) with structured sparsity to cluster heterogeneous health data for precise subgroup discovery. To accommodate a mix of continuous and categorical data modalities, we developed a novel Gauss-Hermite-enabled Expectation-Majorization-Minimization (GH-EMM) algorithm that integrates the GH quadrature and the Majorization Maximization (MM) algorithm within the Expectation Maximization (EM) framework for efficient model estimation. The proposed M2-SEM and GH-EMM are first tested in extensive simulation studies in comparison with benchmarks, and then applied to identify subgroups of individuals with low- and high-risk of developing adverse cardiometabolic (CM) outcomes based on a full spectrum of CM risk factors such as poor nutrition and mental health, physical inactivity, and sleep deprivation. These findings shed light on the promise of using multi-modal mixed-type health data for early identification and targeted intervention of at-risk individuals for health promotion at the population level.",IISE transactions,"Dec, 2025",2025,Dec,,Ding Y|Somers V K|Si B,Somers V K,"Thomas J. Watson College of Engineering and Applied Science, State University of New York at Binghamton, Binghamton NY.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester MN.|Industrial Engineering, School of Computing and Augmented Intelligence, Arizona State University, Tempe AZ.","Ding Y, Somers V K, Si B",https://pubmed.ncbi.nlm.nih.gov/41098767/,"The study developed a novel machine learning model, called M2-SEM, to identify subgroups within heterogeneous health data, such as electronic health records and wearable sensor data. The model can handle a mix of continuous and categorical data to uncover hidden patterns and risk factors related to cardiometabolic health. This approach could enable targeted interventions and early identification of individuals at high risk of adverse health outcomes, ultimately improving population health."
41099578,A collaborative approach to amyloidosis and a multidisciplinary care framework - position statement from the International Society of Amyloidosis.,No abstract available.,Amyloid,"Dec, 2025",2025,Dec,,Sanchorawala V|Wechalekar A|Mollee P|Sekijima Y|Maurer M S|Leung N|Schönland S O|Kumar S,Leung N|Kumar S,"Amyloidosis Center, Boston Medical Center and Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA.|National Amyloidosis Center, University College London, Royal Free Campus, London, UK.|Princess Alexandra Hospital and University of Queensland, Brisbane, Queensland, Australia.|Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, 390-8621, Japan.|Columbia University Irving Medical Center, New York, NY, USA.|Mayo Clinic, Rochester, MN, USA.|Amyloidosis Center, Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg University, Heidelberg, Germany.","Sanchorawala V, Wechalekar A, Mollee P, Sekijima Y, Maurer M S, Leung N, Schönland S O, Kumar S",https://pubmed.ncbi.nlm.nih.gov/41099578/,"This research likely explores a collaborative approach to managing amyloidosis, a condition where abnormal proteins accumulate in the body. The research proposes a multidisciplinary care framework, which involves different healthcare professionals working together to provide comprehensive care for patients with amyloidosis."
41101382,Incidence and risk of gastric neuroendocrine tumors and adenocarcinoma in patients with atrophic gastritis/pernicious anemia.,"Atrophic gastritis (AG), particularly in the context of autoimmune mechanisms or chronic Helicobacter pylori infection, is a recognized precursor to gastric neoplasia. However, surveillance strategies remain inconsistent. This study aimed to determine the cumulative incidence and risk factors for gastric neuroendocrine tumor (gNET) and adenocarcinoma (AC) in a large United States-based cohort of patients with AG.A retrospective cohort study of 224 patients diagnosed with AG at a single tertiary center between 2010 and 2023 was conducted. Patients with prevalent gNET (n = 25) or AC (n = 7) were excluded from respective survival analyses. Kaplan-Meier methods estimated 5- and 10-year cumulative incidence, and univariate Cox regression identified risk factors for neoplastic progression.Among 199 patients at risk of gNET, the 5- and 10-year cumulative incidence rates were 6% and 18%, respectively. Hypergastrinemia and alcohol use disorder were associated with increased gNET risk. For the 217 patients at risk of AC, the 5- and 10-year cumulative incidence rates were 3% and 9%, respectively. Severe dysplasia and a history of peptic ulcer disease were the strongest predictors of AC. Histologic severity alone was not a reliable predictor of neoplastic progression.Patients with AG face significantly elevated risks of both gNET and AC compared with the general population. Risk stratification based on clinical and biochemical factors - such as hypergastrinemia, alcohol use, and dysplasia - may better inform surveillance strategies than histology alone. These findings support more personalized endoscopic surveillance protocols in high-risk populations with AG.Copyright © 2025. Published by Elsevier Inc.",J Gastrointest Surg,"Dec, 2025",2025,Dec,,Christenson R V|Muaddi H|Siegler E|Teel A|Sonik R|Wasif N|Halfdanarson T R|Poruk K|Schupack D|Ebner D|Vierkant R A|Grotz T E,Christenson R V|Muaddi H|Siegler E|Teel A|Sonik R|Wasif N|Halfdanarson T R|Poruk K|Schupack D|Ebner D|Vierkant R A|Grotz T E,"Department of Surgery, Mayo Clinic, Rochester, MN, United States.|Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, United States.|Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, United States.|Division of Surgical Oncology and Endocrine Surgery, Department of Surgery, Mayo Clinic Arizona, Phoenix, AZ, United States.|Division of Medical Oncology, Mayo Clinic Cancer Center, Rochester, MN, United States.|Division of Surgical Oncology, Department of Surgery, Mayo Clinic Florida, Jacksonville, FL, United States.|Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.|Division of Hepatobiliary and Pancreas Surgery, Mayo Clinic, Rochester, MN, United States. Electronic address: Grotz.Travis@mayo.edu.","Christenson R V, Muaddi H, Siegler E, Teel A, Sonik R, Wasif N, Halfdanarson T R, Poruk K, Schupack D, Ebner D, Vierkant R A, Grotz T E",https://pubmed.ncbi.nlm.nih.gov/41101382/,"This study found that patients with atrophic gastritis, a precursor to stomach cancer, have a significantly higher risk of developing gastric neuroendocrine tumors and adenocarcinoma compared to the general population. The researchers suggest that risk factors like high stomach acid levels, alcohol use, and severe cell changes should guide more personalized screening and monitoring for these patients."
41101392,Dual amyloidosis: A clinicopathologic and proteomic analysis of 111 patients.,"Patients with two different amyloid types are rare. It is critical to identify all types of amyloid in a patient as amyloid therapies vary dramatically depending on the specific precursor protein.To analyze the clinicopathologic and proteomic features in patients with two types of amyloid.We queried our reference laboratory database of 51,309 amyloid specimens from all anatomic sites typed by mass spectrometry-based proteomics (LC-MS/MS) for patients diagnosed with two different amyloid types. Demographic data (patient age, sex, and anatomic site), mass spectrometry proteomic features, and clinical history, when available, were reviewed.We identified 111 patients with two amyloid types: 83 male (75 %), 28 female (25 %). The median age at initial diagnosis was 78 years (range 45-96 years). 56 patients (50 %) had cardiac involvement. The two amyloid types were present either in the same anatomic compartment within a single specimen (48 patients, 43 %), in different anatomic compartments within a single specimen (43 patients, 39 %), or in two different anatomic locations (20 patients, 18 %). The most common combination was AL plus ATTR (69 patients, 62 %), which occurred in 68 % of patients with cardiac involvement.It is crucial to identify all amyloid types in all cases, including careful morphologic review to evaluate for distinct areas with different distribution, and consider the possibility of a second amyloid type when the clinical findings are not explained by the initial amyloid type. In some patients, this may require biopsy from a second anatomic site.Copyright © 2025 Elsevier Inc. All rights reserved.",Human pathology,"Dec, 2025",2025,Dec,,Dalland J C|Dasari S|Theis J D|Howard M T|Vrana J A|Dao L N|Chiu A|Rech K L|Larson D P|Nasr S H|Grogan M|Dispenzieri A|McPhail E D,Dalland J C|Dasari S|Theis J D|Howard M T|Vrana J A|Dao L N|Chiu A|Rech K L|Larson D P|Nasr S H|Grogan M|Dispenzieri A|McPhail E D,"Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Electronic address: Dalland.joanna@mayo.edu.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.|Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.|Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.","Dalland J C, Dasari S, Theis J D, Howard M T, Vrana J A, Dao L N, Chiu A, Rech K L, Larson D P, Nasr S H, Grogan M, Dispenzieri A, McPhail E D",https://pubmed.ncbi.nlm.nih.gov/41101392/,"The key finding of this study is that some patients can have two different types of amyloid proteins, which is a rare condition. Identifying all types of amyloid is crucial, as the treatment for each type can be very different. The study found that the most common combination was AL and ATTR amyloid, which occurred in 62% of the patients, especially those with cardiac involvement."
41102925,Response to Maximilian and Gasche.,No abstract available.,Neurogastroenterology and motility,"Dec, 2025",2025,Dec,,Quigley E M M|Kashyap P|Moayyedi P|Simren M|Vanner S,Kashyap P,"Lynda K and David M Underwood Center for Digestive Health, Houston Methodist Hospital and Weill Cornell Medical College, Houston, Texas, USA.|Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.|Farncombe Institute, McMaster University, Hamilton, Ontario, Canada.|Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.|GI Diseases Research Unit, Queen's University, Kingston, Ontario, Canada.","Quigley E M M, Kashyap P, Moayyedi P, Simren M, Vanner S",https://pubmed.ncbi.nlm.nih.gov/41102925/,"This research likely explores a response or reaction to the work of Maximilian and Gasche. It may analyze or critique their previous research or ideas, or it may build upon their findings in some way."
41048590,Identifying preoperative radiographic metrics to guide surgical selection in lumbar spondylolisthesis and stenosis.,"""Instability"" often drives the decision to add fusion to decompression, yet most instability criteria lean solely on sagittal translation and have never been rigorously validated. The potential of a metric for sagittal plane translation to help decide whether fusion should be added to decompression surgery for symptomatic lumbar stenosis with spondylolisthesis was recently reported. Building on imaging and outcomes from that study, we investigated whether other motion metrics may help to predict postoperative disability and patient-reported outcomes in lumbar stenosis with spondylolisthesis.Radiographic metrics were retrospectively calculated from the prospectively collected flexion-extension radiographs of 61 patients with lumbar spinal stenosis and spondylolisthesis. A threshold-limit graphical approach was used to identify metrics and thresholds predictive of the Oswestry Disability Index, leg/buttock pain, and patient satisfaction. Outcomes were compared across groups defined by these threshold levels using statistical analysis.Decompression-only surgery was associated with poorer outcomes in patients exhibiting vertical instability or significant spondylolisthesis changes between flexion and extension. Conversely, decompression-plus-fusion surgery yielded worse outcomes in cases without substantial dynamic spondylolisthesis.A broader definition of spinal instability may be needed when deciding whether to include fusion in treating lumbar stenosis with spondylolisthesis. Preoperative vertical instability and dynamic slip may be important in addition to translational instability. Larger prospective studies are warranted, but these metrics could help guide the decision on whether fusion is necessary and likely to improve outcomes for a common spinal disorder.© 2025 The Authors.",North American Spine Society journal,"Dec, 2025",2025,Dec,,Hipp J A|Currier B L|Grieco T F|Van Susante J L C,Currier B L,"Medical Metrics, Inc., 2000 Bering, Suite 800, Houston, TX 77057, United States.|Department of Orthopedics, Mayo Clinic, 565 1st St SW, Rochester, MN 55902, United States.|Department of Orthopedics, Rijnstate Hospital, Wagnerlaan 55, 6815 AG Arnhem, The Netherlands.","Hipp J A, Currier B L, Grieco T F, Van Susante J L C",https://pubmed.ncbi.nlm.nih.gov/41048590/,"The key finding of this medical research is that preoperative radiographic metrics, such as vertical instability and dynamic slip, can help guide the decision on whether to include fusion in the treatment of lumbar spinal stenosis with spondylolisthesis. This is important because a broader definition of spinal instability may be needed to improve patient outcomes, rather than relying solely on sagittal translation."
41106127,Quantitative angiogenesis-based ultrasound biomarkers for differentiating radiologically challenging breast lesions: Radial scar vs invasive ductal carcinoma.,"To investigate the effectiveness of quantitative biomarkers derived from quantitative high-definition microvasculature imaging (qHDMI) for differentiation of radial scar (RS) and invasive ductal carcinoma (IDC).A total of 64 breast lesions from 62 participants were analyzed using breast pathology as the gold standard. Ultrasound data were processed with the qHDMI framework to visualize tumor microvessel networks and extract eight morphological biomarkers. Biomarker distributions were compared between groups using a two-sided Wilcoxon rank-sum test, and ROC AUC values with 95 % confidence intervals (CI) were calculated. P-values were adjusted for multiple testing using the Benjamini-Hochberg FDR method at a 5 % threshold.Seventeen lesions were pathologically confirmed as RS and 47 as IDC. qHDMI biomarkers revealed distinct microvascular differences between the two groups. Overall, IDC lesions showed denser, thicker, and more complex microvessels. Five biomarkers demonstrated statistically significant distribution differences: vessel density (p-value: 0.016, adjusted p-value: 0.0288), number of vessel segments (p-value: 0.0055, adjusted p-value: 0.0288), number of branch points (p-value: 0.0098, adjusted p-value: 0.0288), maximum diameter (p-value: 0.014, adjusted p-value: 0.0288), and microvessel fractal dimension (p-value: 0.018, adjusted p-value: 0.0288). The AUC and CIs for these five biomarkers were 0.70, [0.56, 0.82] for vessel density, 0.73, [0.60, 0.86] for number of vessel segments, 0.71, [0.58, 0.83] for number of branch points, 0.70, [0.57, 0.82] for maximum diameter, and 0.70, [0.54, 0.82] for fractal dimension.Distributions of qHDMI-derived biomarkers revealed distinct microvascular structural differences between RS and IDC, suggesting qHDMI may enhance diagnostic accuracy in distinguishing the two.Copyright © 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.","Breast (Edinburgh, Scotland)","Dec, 2025",2025,Dec,,Sabeti S|Adl Parvar T|Metanat P|Larson N B|Fazzio R T|Fatemi M|Alizad A,Sabeti S|Adl Parvar T|Metanat P|Larson N B|Fazzio R T|Fatemi M|Alizad A,"Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, 55905, MN, USA.|Department of Radiology, Mayo Clinic College of Medicine and Science, Rochester, 55905, MN, USA.|Department of Quantitative Health Sciences, Mayo Clinic College of Medicine and Science, Rochester, 55905, MN, USA.|Department of Physiology and Biomedical Engineering, Mayo Clinic College of Medicine and Science, Rochester, 55905, MN, USA; Department of Radiology, Mayo Clinic College of Medicine and Science, Rochester, 55905, MN, USA. Electronic address: Alizad.Azra@mayo.edu.","Sabeti S, Adl Parvar T, Metanat P, Larson N B, Fazzio R T, Fatemi M, Alizad A",https://pubmed.ncbi.nlm.nih.gov/41106127/,"This study found that quantitative ultrasound biomarkers related to tumor blood vessels can help differentiate between radial scar and invasive ductal carcinoma, two types of breast lesions that can be challenging to distinguish using standard imaging. The key finding is that invasive ductal carcinoma lesions have denser, thicker, and more complex blood vessel networks compared to radial scar lesions, which could improve the accuracy of breast cancer diagnosis."
41109059,Disparities while listing for orthotopic heart transplantation: A systematic review and meta-analysis.,"Disparities in orthotopic heart transplant (OHT) listing exist due to race, gender, insurance access, socioeconomic status (SES) and access to healthcare. This study aims to investigate the impact of these factors on the inequities encountered within the pre-transplantation process.Literature search was conducted up to July 2024, focusing on disparities in organ transplant outcomes. The primary endpoint was the recipient acceptance rate. Secondary endpoints were donor acceptance, waitlist urgency (status 1, 1A, or 1A exception), waitlist mortality (death while on the list), and waitlist duration (time from listing to transplantation).A total of 40 studies involving 506,459 patients at listing for OHT were included. Disparities in education level, gender, and insurance were not associated with recipient acceptance rate. However, black patients have a significantly lower recipient acceptance rate compared to the white patients (HR 0.86, 95 % CI: 0.84-0.89, I2 = 15.8 %). For waitlist urgency, black patients were more likely to be listed for status 1 (OR 1.24, 95 % CI: 1.11-1.39, I2 = 85.2 %). For waitlist mortality, there was no significant association with race, gender, insurance, income and education level, but the introduction of the 2018 policy led to a significantly lower waitlist mortality (HR 0.61, 95 % CI: 0.52-0.72, I2 = 0.0 %).Race remains a primary determinant of inequity in transplant access. Addressing racial disparity is crucial for achieving equitable access to care for all patients with end-stage heart disease.Copyright © 2025 The Authors. Published by Elsevier Inc. All rights reserved.","Transplantation reviews (Orlando, Fla.)","Dec, 2025",2025,Dec,,Phutinart S|Thamthanaruk A|Siranart N|Chuanchai W|Sowalertrat W|Chumpangern Y|Pajareya P,Siranart N,"Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.|Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.|Department of Radiology, Prince of Songkhla University, Bangkok, Thailand.|Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.|Faculty of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand.. Electronic address: patavee.pd@gmail.com.","Phutinart S, Thamthanaruk A, Siranart N, Chuanchai W, Sowalertrat W, Chumpangern Y, Pajareya P",https://pubmed.ncbi.nlm.nih.gov/41109059/,"The key finding of this medical research is that race remains a primary determinant of inequity in access to orthotopic heart transplantation. Black patients have a significantly lower recipient acceptance rate compared to white patients, despite no significant disparities in other factors like gender, insurance, and socioeconomic status. Addressing this racial disparity is crucial to ensure equitable access to heart transplantation for all patients with end-stage heart disease."
41110123,Novel Identification of Genetic Variants in Musculoskeletal Pathways Implicated in Familial Femoroacetabular Impingement.,"Femoroacetabular impingement (FAI) of the hip results from altered morphology of the proximal femur and/or acetabulum, creating abnormal contact between these structures during normal hip range of motion. The etiology of this structural phenotype is unknown. This study aimed to identify common single-nucleotide variants (SNVs) among two families with seemingly heritable FAI. Additionally, this study examined biologic networks among proteins encoded by identified SNVs and surveyed the literature regarding the role of these proteins in musculoskeletal development. Methodologically, blood samples were collected from affected and unaffected members of two separate families with a pattern of heritable FAI. Exome sequencing identified SNVs, and a protein-protein interaction network assessment, in addition to a literature review, was performed to better understand the role of variant-associated genes in musculoskeletal development. Results showed 33 and 43 variant-associated genes affected in Family 1 and Family 2, respectively. Although no overlap in variant-associated genes was found between families, network analysis showed that variant-associated genes are functionally interconnected and are known to interact with each other. Furthermore, the variant-associated genes are broadly associated with musculoskeletal development. Ultimately, genetic analysis of two families of multiple generations of FAI revealed variations in genes regulating musculoskeletal development, with several being critical local regulators of bone morphogenesis.© 2025 Orthopaedic Research Society.",J Orthop Res,"Dec, 2025",2025,Dec,,Wyles C C|Trousdale W H|Paradise C R|Trousdale R T|Klee E W|Sierra R J,Wyles C C|Trousdale W H|Paradise C R|Trousdale R T|Klee E W|Sierra R J,"Department of Orthopedic Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Center for Regenerative Medicine, Mayo Clinic, Rochester, Minnesota, USA.|Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota, USA.|Department of Quantitative Health Sciences, Mayo Clinic, Rochester, Minnesota, USA.|Center for Individualized Medicine, Mayo Clinic, Rochester, Minnesota, USA.","Wyles C C, Trousdale W H, Paradise C R, Trousdale R T, Klee E W, Sierra R J",https://pubmed.ncbi.nlm.nih.gov/41110123/,"This study identified genetic variants in two families with a history of femoroacetabular impingement (FAI), a condition that causes abnormal hip joint shape and function. The researchers found that the identified variants are involved in the development and regulation of the musculoskeletal system, suggesting a genetic basis for FAI. These findings could lead to better understanding and potential treatments for this condition."
41110931,Amyloid and Light Chain Deposition Disorders.,"Amyloidosis and Light Chain Deposition Disease (LCDD) are disorders characterized by the deposition of abnormal proteins in tissues, leading to organ damage. Pulmonary involvement in amyloidosis can manifest as diffuse alveolar-septal amyloidosis, nodular or cystic pulmonary amyloidosis, or tracheobronchial involvement. The types of amyloidosis-immunoglobulin light chain), serum amyloid A, and transthyretin (ATTR)-affect the lungs differently, with ATTR being rare. LCDD, which primarily affects the kidneys, may also cause lung abnormalities, such as cystic or nodular disease. Both conditions are diagnosed through biopsy and imaging, with therapies targeting the underlying plasma cell or inflammatory disorders.Copyright © 2025 Elsevier Inc. All rights reserved.",Clinics in chest medicine,"Dec, 2025",2025,Dec,,Baqir M|Moua T|Ryu J H,Baqir M|Moua T|Ryu J H,"Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, Minnesota 55905, USA. Electronic address: baqir.misbah@mayo.edu.|Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Mayo Clinic College of Medicine and Science, 200 First Street SW, Rochester, Minnesota 55905, USA.","Baqir M, Moua T, Ryu J H",https://pubmed.ncbi.nlm.nih.gov/41110931/,"Amyloidosis and Light Chain Deposition Disease (LCDD) are conditions where abnormal proteins accumulate in the body, leading to organ damage. The lungs can be affected in different ways, depending on the type of amyloidosis. Both conditions are diagnosed through biopsy and imaging, and treatments focus on addressing the underlying causes."
41111231,"Artificial intelligence, machine learning, telemedicine, and digital transformation in nephrology and transplantation.",No abstract available.,Renal failure,"Dec, 2025",2025,Dec,,Thongprayoon C|Wathanavasin W|Cheungpasitporn W,Thongprayoon C|Wathanavasin W|Cheungpasitporn W,"Division of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN, USA.|Nephrology Unit, Department of Medicine, Charoenkrung Pracharak Hospital, Bangkok Metropolitan Administration, Bangkok, Thailand.","Thongprayoon C, Wathanavasin W, Cheungpasitporn W",https://pubmed.ncbi.nlm.nih.gov/41111231/,"This research likely explores the use of artificial intelligence, machine learning, telemedicine, and digital transformation in the field of nephrology (the study of the kidneys) and transplantation. It may investigate how these advanced technologies can be applied to improve the diagnosis, treatment, and management of kidney-related conditions and transplant procedures."
41114682,Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis.,"We performed an updated systematic review and network meta-analysis to inform the 2025 American Gastroenterological Association Clinical Guidelines on the management of moderate-to-severe Crohn's disease (CD).We searched multiple electronic databases from inception through August 14, 2024, to identify randomized controlled trials in adults with moderate-to-severe CD, comparing advanced therapies (eg, tumor necrosis factor antagonists, vedolizumab, interleukin 12/23, or interleukin 23p19 antagonists, and/or Janus kinase inhibitors) with placebo or another active comparator. Our primary outcomes were induction and maintenance of clinical remission; analyses were stratified by biologic therapy exposure status. We performed a network meta-analysis using a frequentist approach and applied the Grading of Recommendations, Assessment, Development and Evaluation to appraise certainty of evidence.We identified 28 trials of induction therapy and 22 trials of maintenance therapy of advanced therapies in patients with moderate-to-severe CD. In biologic-naïve patients, moderate-to-high certainty evidence supported the use of infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, and guselkumab, and low certainty evidence supported the use of certolizumab pegol and upadacitinib over no treatment for inducing remission. Among active comparators, moderate-to-high certainty evidence supported the use of adalimumab and ustekinumab compared with certolizumab pegol and upadacitinib. Among patients with prior exposure to biologics, moderate-to-high certainty evidence supported the use of adalimumab, ustekinumab, risankizumab, guselkumab, and upadacitinib, and low certainty evidence supported the use of vedolizumab and mirikizumab, over no treatment, for inducing remission. Among active comparators, moderate certainty evidence supported the use of risankizumab and guselkumab compared with vedolizumab and ustekinumab.Using Grading of Recommendations, Assessment, Development and Evaluation to appraise quality of evidence, this updated network meta-analysis can inform positioning of advanced therapies for the treatment of biologic-naïve and biologic-exposed patients with moderate-to-severe CD.Copyright © 2025 AGA Institute. Published by Elsevier Inc. All rights reserved.",Gastroenterology,"Dec, 2025",2025,Dec,,Singh S|Murad M H|Yuan Y|Ananthakrishnan A N|Click B|Syal G|Haydek J P|Agrawal M|Kappelman M D|Lewis J D|Scott F I,Singh S|Murad M H,"Division of Gastroenterology and Hepatology, Department of Medicine, Mayo Clinic Arizona, Scottsdale, Arizona. Electronic address: singh.siddharth@mayo.edu.|Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, Minnesota.|Division of Gastroenterology, Western University, London, Ontario, Canada.|Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.|Crohn's and Colitis Center, Division of Gastroenterology and Hepatology, University of Colorado, Anschutz Medical Campus, Denver, Colorado.|Vatche & Tamar Manoukian Division of Digestive Diseases, School of Medicine, University of California, Los Angeles, Los Angeles, California.|Division of Gastroenterology and Hepatology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.|The Dr. Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York; Department of Environmental Medicine, Icahn School of Medicine at Mount Sinai, New York New York; Center for Molecular Prediction of Inflammatory Bowel Disease (PREDICT), Department of Clinical Medicine, Aalborg University, Copenhagen, Denmark.|Division of Pediatric Gastroenterology, Department of Pediatrics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina; Center for Gastrointestinal Biology and Disease, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.|Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenterology and Hepatology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.","Singh S, Murad M H, Yuan Y, Ananthakrishnan A N, Click B, Syal G, Haydek J P, Agrawal M, Kappelman M D, Lewis J D, Scott F I",https://pubmed.ncbi.nlm.nih.gov/41114682/,"This study evaluated the effectiveness of various advanced therapies for managing moderate-to-severe Crohn's disease. The key finding is that several biologic and Janus kinase inhibitor medications, such as infliximab, adalimumab, and ustekinumab, were found to be effective for inducing remission in both biologic-naïve and biologic-exposed patients. This information can help guide treatment decisions for patients with moderate-to-severe"
41090230,Effects of High- Versus Low-Sodium Oxybate on Blood Pressure in Patients With Narcolepsy.,"People with narcolepsy are at increased risk for hypertension and cardiovascular disease; excessive sodium intake is linked to both.We studied patients with narcolepsy and office systolic blood pressures (BPs) of 130 to 155 mm Hg taking twice-nightly high-sodium oxybate for ≥6 weeks who switched to low-sodium oxybate at the same dosage. The primary end point was the change from baseline in mean 24-hour ambulatory systolic BP at the end of treatment (≈6 weeks after switching). Secondary and exploratory end points included changes in diastolic BP, office BP, and 24-hour sodium excretion.Patients (n=43) had a mean age of 45 years, were 65% female, 33% on antihypertensives, with baseline mean (SD) office BP of 138.0/85.2 (5.7/6.6). Mean (SD) total high- and low-sodium oxybate dosages of 8.0 (1.1) and 8.1 (1.1) g/night, respectively, represented 1456.5 (206.2) and 117.8 (16.3) mg of sodium. The median 24-hour urinary sodium was 4278 mg/d at baseline and 2703 mg/d at the end of treatment (median change, 1288 mg/d). Mean (SE) 24-hour ambulatory systolic BPs at baseline and study end were 132.3 (1.8) and 128.2 (1.8) mm Hg (least-squares mean change, -4.1 [95% CI, -6.9 to -1.4] mm Hg; 1-sided P=0.0019). BP changes by narcolepsy subtype, sex, body mass index, baseline office BP, and baseline antihypertensive use were consistent with the overall effect size.People with narcolepsy switching from high- to low-sodium oxybate showed substantially reduced daily medication-related sodium intake and significant 24-hour BP reductions. These results demonstrate the importance of reducing pharmaceutical sodium content in this elevated cardiovascular risk patient population.URL: https://www.clinicaltrials.gov; Unique identifier: NCT05869773.","Hypertension (Dallas, Tex. : 1979)","Dec, 2025",2025,Dec,,White W B|Kovacs R J|Alexander J K|Baranak C|Nichols D A|Fuller D S|Dai J|Whalen M|Ajayi A|Hutchinson B|Dauvilliers Y|Somers V K,Somers V K,"Calhoun Cardiology Center, University of Connecticut School of Medicine, Farmington (W.B.W.).|Jazz Pharmaceuticals, Palo Alto, CA (J.K.A., D.A.N., J.D., M.W.).|Jazz Pharmaceuticals, Philadelphia, PA (C.B., D.S.F.).|Children's Lung, Asthma and Sleep Specialists, Winter Park, FL (A.A.).|Chesapeake Cardiac Care, Bowie, MD (B.H.).|Sleep-Wake Disorders Unit, Gui-de-Chauliac Hospital, CHU Montpellier, Institute of Neurosciences of Montpellier, University of Montpellier, France (Y.D.).|Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (V.K.S.).","White W B, Kovacs R J, Alexander J K, Baranak C, Nichols D A, Fuller D S, Dai J, Whalen M, Ajayi A, Hutchinson B, Dauvilliers Y, Somers V K",https://pubmed.ncbi.nlm.nih.gov/41090230/,"Patients with narcolepsy who switched from high-sodium to low-sodium oxybate medication experienced a significant reduction in their 24-hour blood pressure. This finding highlights the importance of reducing sodium content in medications for patients with narcolepsy, who are at increased risk of hypertension and cardiovascular disease."
41089037,"Change of guard at Amyloid - a tribute to outgoing Editor in Chief, Professor Per Westermark.",No abstract available.,Amyloid,"Dec, 2025",2025,Dec,,Kumar S,Kumar S,"Mark and Judy Mullins Professor of Hematological Malignancies Consultant Division of Hematology Professor of Medicine Chair, Myeloma, Amyloidosis and Dysproteinemia Group Research Chair Division of Hematology Mayo Clinic, Rochester, MN, USA.",Kumar S,https://pubmed.ncbi.nlm.nih.gov/41089037/,"This research likely explores the transition of leadership or editorship for a scientific journal focused on amyloid, a type of protein. The research may pay tribute to the outgoing Editor-in-Chief, Professor Per Westermark, who has played a significant role in the journal's direction and management."
41088512,Workload and Fairness: An Overdue Conversation About Clinical Faculty.,No abstract available.,J Physician Assist Educ,"Dec 01, 2025",2025,Dec,01,Bradford P|Hodgin F|McNicholl J|Min E A|Nandwana B|Strelow B,Strelow B,"Director of Clinical Education, Associate Program Director, Professor, of West Chester University Physician Assistant Program, West Chester, PA.|Director of Clinical Education, Associate Professor, of Cedarville University, Cedarville, OH.|Lead Clinical Coordinator, Assistant Professor, of Thomas Jefferson University Physician Assistant Program, Philadelphia, Pennsylvania and Voorhees, NJ.|Director of Clinical Education, Associate Program Director, Associate Professor, of Northwestern University Feinberg School of Medicine Physician Assistant Program, Chicago, IL.|Director of Clinical Education, Assistant Professor, of Wayne State University Physician Assistant Program, Detroit, MI.|Assistant Professor of Medicine, at Mayo Clinic, Rochester, MN.","Bradford P, Hodgin F, McNicholl J, Min E A, Nandwana B, Strelow B",https://pubmed.ncbi.nlm.nih.gov/41088512/,"This research likely explores the workload and fairness issues faced by clinical faculty in academic settings. It suggests that the conversation about these challenges has been overdue, implying that the research aims to shed light on the experiences and concerns of clinical faculty members."
41085387,In Reply: Are There Differences in 2-Year Outcomes Between 2-Level Anterior Cervical Diskectomy and Fusion Versus Single-Level Anterior Cervical Corpectomy and Fusion to Treat Cervical Myelopathy? A Quality Outcomes Database Study.,No abstract available.,Neurosurgery,"Dec 01, 2025",2025,Dec,01,Berlin C|Ibrahim S|Mummaneni P V|Chan A K|Chou D|Fu K|Bydon M|Bisson E F|Shaffrey C I|Gottfried O N|Asher A L|Coric D|Potts E|Foley K T|Wang M Y|Virk M S|Knightly J J|Meyer S|Park P|Upadhyaya C D|Tumialán L M|Turner J|Uribe J|Haid R W|Yen C|Shaffrey M E,Ibrahim S|Bydon M,"Department of Neurosurgery, University of Virginia, Charlottesville , Virginia , USA.|Department of Neurosurgery, Mayo Clinic Neuro-Informatics Lab, Mayo Clinic, Rochester , Minnesota , USA.|Department of Neurological Surgery, University of California, San Francisco , California , USA.|Department of Neurosurgery, Columbia University, New York , New York , USA.|Department of Neurological Surgery, Weill Cornell Medicine, New York , New York , USA.|Department of Neurosurgery, University of Utah, Salt Lake City , Utah , USA.|Department of Neurosurgery, Duke University Medical Center, Durham , North Carolina , USA.|Carolina Neurosurgery and Spine Associates, Carolinas Medical Center, Charlotte , North Carolina , USA.|Goodman Campbell Brain and Spine, Carmel , Indiana , USA.|Semmes Murphey Neurologic and Spine Institute, Memphis , Tennessee , USA.|Department of Neurological Surgery, University of Miami, Miami , Florida , USA.|Atlantic Neurosurgical Specialists, Altair Health Spine and Wellness Center, Morristown , New Jersey , USA.|Department of Neurosurgery, University of North Carolina, Chapel Hill , North Carolina , USA.|Department of Neurosurgery, Barrow Neurological Institute, St Joseph's Hospital and Medical Center, Phoenix , Arizona , USA.|Atlanta Brain and Spine Care, Atlanta , Georgia , USA.","Berlin C, Ibrahim S, Mummaneni P V, Chan A K, Chou D, Fu K, Bydon M, Bisson E F, Shaffrey C I, Gottfried O N, Asher A L, Coric D, Potts E, Foley K T, Wang M Y, Shaffrey M E, et al.",https://pubmed.ncbi.nlm.nih.gov/41085387/,"This research likely explores the differences in outcomes between two common surgical treatments for cervical myelopathy (a condition that affects the spinal cord in the neck). The study compares the results of a 2-level anterior cervical diskectomy and fusion procedure to a single-level anterior cervical corpectomy and fusion procedure over a 2-year period, using data from a quality outcomes database."
41048829,Demographic and regional trends of mortality in patients with cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019.,"National estimates of deaths related to cardiovascular disease (CVD) and liver cirrhosis remain ambiguous. The purpose of this study was to observe the contemporary trends in CVD and liver cirrhosis-related mortality in the United States.We evaluated the trends using the CDC WONDER database to identify adults with CVD and liver cirrhosis associated death between 1999 and 2019. Age-adjusted mortality rates (AAMRs) per 100,000 population and associated average annual percent changes (AAPCs) with 95 % confidence intervals (CIs) were assessed using Joinpoint regression.Between 1999 and 2019, a total of 374,090 deaths occurred due to CVD and liver cirrhosis. In the overall population, the AAMR increased from 7.54 (95 % CI 7.41-7.67) in 1999 to 10.55 (95 % CI 10.43-10.68) with an AAPC of 1.68 (95 % CI 1.59-1.77). The highest AAMRs were seen in males, Native Americans, and those living in West. A substantial increase in AAMRs was observed in all age groups with the highest seen in 70-84 year group. Moreover, non-metropolitan cities had a much higher increase in AAMRs compared to large metropolitan cities. The highest AAMRs were observed in California whereas the lowest in Utah.There is a rising trend of CVD and liver cirrhosis-associated mortality in all groups. However, disparities continue to exist in association with gender, race, age, and geographical region. Future trials should address alleviating CVD and liver cirrhosis-related deaths in all population groups equitably.© 2025 The Authors.",Atherosclerosis plus,"Dec, 2025",2025,Dec,,Yasmin F|Moeed A|Fahim M A A|Kumar G|Shaharyar M|Asghar M S,Shaharyar M|Asghar M S,"Yale School of Medicine, New Haven, CT, USA.|Dow University of Health Sciences, Karachi, Pakistan.|Mayo Clinic, Rochester, MN, USA.|AdventHealth, Sebring, FL, USA.","Yasmin F, Moeed A, Fahim M A A, Kumar G, Shaharyar M, Asghar M S",https://pubmed.ncbi.nlm.nih.gov/41048829/,"The study found a concerning increase in deaths related to cardiovascular disease and liver cirrhosis in the United States between 1999 and 2019, with the highest rates observed in males, Native Americans, and those living in the West. The findings highlight the need for targeted interventions to address these disparities and reduce the burden of these conditions across all population groups."
41050744,Mental stress is associated with coronary endothelial dysfunction in women with chest pain and non-obstructive coronary artery disease.,"We evaluate the association between chronic mental stress (MS) and coronary endothelial function in patients with chest pain and nonobstructive coronary artery disease (CAD) separately in males and females.Patients with nonobstructive CAD (stenosis <40 %) at coronary angiography underwent an invasive assessment for coronary endothelial dysfunction (CED). Macrovascular CED was defined as a percentage change in coronary artery diameter to acetylcholine (%ΔCADAch) ≤ -10 % and microvascular CED was defined as a percentage change in coronary blood flow to acetylcholine (%ΔCBFAch) ≤-50 %. Patients completed a questionnaire within 2 years of the index procedure that included questions regarding chronic MS. The frequency of macrovascular, microvascular and any type of CED was compared across groups. Logistic regression analyses were performed to assess the association between MS and CED.Between January 2017 and December 2022, 211 patients (mean (sd) age 54.4 (13.6) yrs, 71.0 % female) were included. One hundred forty-two (67.3 %) patients had any type of CED. In females with significant MS there was a higher proportion of individuals with any type of CED compared to without CED (43 (42.6 %) vs. 12 (24.5 %), p = 0.0362). In a multivariable analysis MS was associated with any type of CED in females: OR (95 % CI) 2.70 (1.24-6.25); p = 0.0156.Chronic MS is associated with CED in females with chest pain and nonobstructive CAD. Chronic MS may underly the mechanism for chest pain in these patients and may play a contributory to cardiovascular disease through its association with endothelial dysfunction.© 2025 The Authors.",International journal of cardiology. Heart & vasculature,"Dec, 2025",2025,Dec,,Sara J D S|Rajai N|Breitinger S|Medina-Inojosa B|Lerman L O|Lerman A,Sara J D S|Rajai N|Breitinger S|Medina-Inojosa B|Lerman L O|Lerman A,"Department of Cardiovascular Medicine, Mayo College of Medicine, Rochester, MN, USA.|Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.|Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.","Sara J D S, Rajai N, Breitinger S, Medina-Inojosa B, Lerman L O, Lerman A",https://pubmed.ncbi.nlm.nih.gov/41050744/,"The key finding of this medical research is that chronic mental stress is associated with coronary endothelial dysfunction (a sign of impaired blood vessel function) in women with chest pain and non-obstructive coronary artery disease. This suggests that chronic mental stress may contribute to the development of cardiovascular disease in these patients, highlighting the importance of addressing mental health in the management of heart-related conditions."
41056403,Pilot Pragmatic Trial of a Community Paramedic Diabetes Self-Management Education Program for Adults With Diabetes.,"To evaluate the impact of community paramedic (CP)-delivered, in-home diabetes self-management education and support (DSMES) for adults with poorly managed diabetes.In a pragmatic, single-arm pilot trial, adults with HbA1c ≥9% and a recent emergency department or hospital visit received a 1-month CP-led DSMES intervention. Outcomes included HbA1c, health care engagement, and patient-reported satisfaction.Seventy participants (median age 61 years, 50% rural, 84% with type 2 diabetes) completed the intervention. HbA1c declined from 9.8% to 8.2% at 4 months (P < 0.001). Engagement with primary care, endocrinology, and DSMES improved. Satisfaction was high (mean rating 9 out of 10).CP-led DSMES improved glycemic management and care engagement in underserved populations. This scalable model warrants further study.© 2025 by the American Diabetes Association.",Diabetes care,"Dec 01, 2025",2025,Dec,01,Ducharme-Smith A|Juntunen M|Espinoza A|Liedl C|Fischer K|Meilander A|Quillen J|McCoy R G,Ducharme-Smith A|Juntunen M|Espinoza A|Liedl C|Fischer K|Meilander A|Quillen J|McCoy R G,"Division of Community Internal Medicine, Geriatrics, and Palliative Care, Department of Medicine, Mayo Clinic, Rochester, MN.|Mayo Clinic Ambulance, Rochester, MN.|Division of Endocrinology, Diabetes, & Nutrition, Department of Medicine, Mayo Clinic, Rochester, MN.|Clinical Trials and Biostatistics, Mayo Clinic, Rochester, MN.|Early Cancer Therapeutics, Mayo Clinic, Rochester, MN.|Clinical Trials and Biostatistics, Mayo Clinic, Phoenix, AZ.|University of Maryland Institute for Health Computing, North Bethesda, MD.","Ducharme-Smith A, Juntunen M, Espinoza A, Liedl C, Fischer K, Meilander A, Quillen J, McCoy R G",https://pubmed.ncbi.nlm.nih.gov/41056403/,"This study found that a community paramedic-led diabetes education program helped adults with poorly managed diabetes improve their blood sugar levels and engage more with their healthcare providers. The program was well-received by participants, suggesting it could be a promising approach to support underserved populations with diabetes."
41062366,"Erratum to ""Duration of resuscitation interruption using point-of-care ultrasound versus traditional manual pulse check: A systematic review and meta-analysis"" [American Journal of Emergency Medicine 98C (2025) 145-152].",No abstract available.,The American journal of emergency medicine,"Dec, 2025",2025,Dec,,Saadi Neto E|Scapin M|Lazaro-Paulina F|Campbell R L|Molinari D F|Kummer T,Saadi Neto E|Lazaro-Paulina F|Campbell R L|Molinari D F|Kummer T,"Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA. Electronic address: saadineto.eduardo@mayo.edu.|Department of Neurosurgery, Universidade Estadual De Londrina, PR, Brazil.|Department of Emergency Medicine, Mayo Clinic, Rochester, MN, USA.","Saadi Neto E, Scapin M, Lazaro-Paulina F, Campbell R L, Molinari D F, Kummer T",https://pubmed.ncbi.nlm.nih.gov/41062366/,"This research likely explores the duration of interruptions in resuscitation efforts when using point-of-care ultrasound compared to the traditional manual pulse check. The study appears to be a systematic review and meta-analysis, which means it combines and analyzes data from multiple previous studies on this topic."
41062404,Predicting recurrence after radical nephroureterectomy for upper tract urothelial carcinoma: Development and validation of the JIKEI-YAYOI score.,"Recent clinical trials have highlighted the benefits of adjuvant therapies for upper tract urothelial carcinoma (UTUC), although their application remains limited by patient-specific factors. This study aimed to develop a prognostic model to predict postoperative outcomes and identify patients who would benefit from adjuvant therapy.We conducted a retrospective analysis of 700 UTUC patients who underwent radical nephroureterectomy at Jikei University Hospital and its affiliated institutions (development cohort), and 405 patients treated at Mayo Clinic (validation cohort). Patients who received neoadjuvant or adjuvant chemotherapy were excluded. In the development cohort, clinical and pathological variables were analyzed to construct a risk prediction model for postoperative recurrence. Statistical analyses included Kaplan-Meier estimation, Cox proportional hazards regression, and internal validation using bootstrapping. The model was externally validated using data from the validation cohort.The final model incorporated pT stage, pN stage, tumor grade, and lymphovascular invasion, resulting in the novel ""JIKEI-YAYOI"" risk score (range: 0-7). The model demonstrated excellent discrimination (C-index: 0.815) and calibration. Patients were stratified into low, intermediate, and high-risk groups, each with distinct recurrence-free survival rates. The JIKEI-YAYOI score provided accurate, individualized risk predictions, facilitating clinical decision-making regarding adjuvant therapy.The JIKEI-YAYOI score reliably predicts disease recurrence following radical surgery for UTUC, supporting personalized patient management and informed decisions about adjuvant therapy.Copyright © 2025 Elsevier Inc. All rights reserved.",Urologic oncology,"Dec, 2025",2025,Dec,,Iwamoto Y|Foss H|Ishiyama Y|Taneda Y|Kagawa H|Uchida N|Koike Y|Hara S|Miyajima K|Iwatani K|Imai Y|Tashiro K|Tsuzuki S|Miki J|Gupta S|Boorjian S A|Potretzke A|Urabe F|Kimura T,Foss H|Gupta S|Boorjian S A|Potretzke A,"Department of Urology, The Jikei University School of Medicine, Tokyo, Japan.|Department of Urology, Mayo Clinic, Rochester, MN.|Department of Urology, Tokyo Women Medical University, Tokyo, Japan; Department of Urology, University of Florida Jacksonville, Jacksonville, FL.|Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei University Kashiwa Hospital, Chiba, Japan.|Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei Katsushika Medical Center, Tokyo, Japan.|Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Atsugi City Hospital, Kanagawa, Japan.|Department of Pathology, Mayo Clinic, Rochester, MN.|Department of Urology, The Jikei University School of Medicine, Tokyo, Japan; Department of Urology, Jikei The 3rd Hospital, Tokyo, Japan. Electronic address: furabe0809@gmail.com.","Iwamoto Y, Foss H, Ishiyama Y, Taneda Y, Kagawa H, Uchida N, Koike Y, Hara S, Miyajima K, Iwatani K, Imai Y, Tashiro K, Tsuzuki S, Miki J, Gupta S, Kimura T, et al.",https://pubmed.ncbi.nlm.nih.gov/41062404/,"The study developed and validated the JIKEI-YAYOI score, a prognostic model that accurately predicts the risk of disease recurrence after surgery for upper tract urothelial carcinoma. This tool can help clinicians identify patients who may benefit from additional treatment, enabling personalized management of this cancer."
41067302,Encapsulated mesenchymal stem cell-derived exosomes promote optic nerve regeneration and functional recovery in a mouse model of optic nerve crush injury.,"Optic nerve injury (ONI) is a major cause of irreversible blindness, and current treatments have limited success. This study investigated the therapeutic potential of encapsulated exosomes derived from mesenchymal stem cells (MSC-exosomes) in a mouse model of optic nerve crush (ONC) injury, with the hypothesis that encapsulation would enhance exosome stability and efficacy, promoting optic nerve regeneration and functional recovery.Exosomes derived from human umbilical cord MSCs were isolated and characterized, then encapsulated within a biocompatible hydrogel. Mice subjected to ONC injury received one of the following treatments: hydrogel alone (ONC + HG), exosomes alone (ONC + EXO), or encapsulated exosomes (ONC+ enEXO). Visual evoked potentials (VEPs) were assessed at 21 days post-injury (dpi). Gene expression of regeneration-associated markers (Sox2, Pax6, Brn3, NG2, NF200), retinal ganglion cell (RGC) survival, and axonal regeneration were evaluated using real-time PCR, immunofluorescence, retrograde tracing, and histological analysis.Encapsulated exosomes significantly improved VEP parameters, increased the expression of key regeneration-associated genes, and promoted RGC survival and axonal regeneration compared to ONC, ONC + HG, and ONC + EXO groups.These findings provide strong evidence for the therapeutic potential of hydrogel-encapsulated MSC-derived exosomes as a promising treatment for ONC.Hydrogel, Exosome, NF200, Sox2, Pax6, Brn3, NG2, MSC secretome, RGC trophic factors.Copyright © 2025 Elsevier Inc. All rights reserved.",Life sciences,"Dec 01, 2025",2025,Dec,01,Shoae-Hassani A|Niknam P|Ahmadirad N|Abri Aghdam K|Javan M|Mirshahi R|Naseripour M|Dehghan S,Niknam P,"Eye Research Center, The Five Senses Health Institute, Moheb Kowsar Hospital, Iran University of Medical Sciences, Tehran, Iran; Stem Cells and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran.|Department of Ophthalmology, Mayo clinic, Rochester, MN, USA.|Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran.|Eye Research Center, The Five Senses Health Institute, Moheb Kowsar Hospital, Iran University of Medical Sciences, Tehran, Iran.|Department of Physiology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran; Institute for Brain Sciences and Cognition, Tarbiat Modares University, Tehran, Iran.|Eye Research Center, The Five Senses Health Institute, Moheb Kowsar Hospital, Iran University of Medical Sciences, Tehran, Iran; Stem Cells and Regenerative Medicine Research Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: dehghan.sa@iums.ac.ir.","Shoae-Hassani A, Niknam P, Ahmadirad N, Abri Aghdam K, Javan M, Mirshahi R, Naseripour M, Dehghan S",https://pubmed.ncbi.nlm.nih.gov/41067302/,"This study found that encapsulated exosomes derived from mesenchymal stem cells can significantly improve visual function, promote nerve regeneration, and increase survival of retinal ganglion cells in a mouse model of optic nerve injury. These results suggest that this treatment approach has great potential as a new therapy for optic nerve injuries, which are a major cause of blindness."
41070137,Outcomes of Early-Life Focal Cortical Dysplasia-Related Epilepsy: A PERC Surgery Study.,"Focal cortical dysplasia (FCD) is the most common cause of surgically treatable drug-resistant epilepsy (DRE) in children. Surgical outcomes are poorly defined in early-onset FCD-DRE. The purpose of this study was to evaluate clinical and presurgical characteristics relating to surgical outcomes in early-life (seizure onset <4 months old) FCD-DRE.A multicenter prospective cohort was analyzed from the Pediatric Epilepsy Research Consortium (PERC) Surgery Database to identify patients with pathologically confirmed FCD-DRE and seizure onset younger than 4 months old. Clinical characteristics, presurgical workup, and surgical intervention and outcomes data were collected and analyzed. Primary outcome was to evaluate whether earlier surgery is associated with seizure freedom; secondary outcomes evaluated clinical/presurgical predictors of seizure freedom and safety.Thirty-one patients with FCD-DRE were identified from 18 PERC centers. Median age at seizure onset was 2.4 months (interquartile range 1.2-3.6 months). Four patients had focal to bilateral tonic-clonic seizures (FBTCS); 35% (n = 11) had epileptic spasms. Median age at phase 1 referral was 2.0 years (0.7-4.0 years). Median age at surgery was 2.6 years (1.1-5.5 years). Pathology was type II, 65% (n = 20); type I, 26% (n = 8); and type III, 6% (n = 2). Seizure freedom was achieved in 65% (n = 20) with median follow-up 2.5 years (1.3-4 years). Age at seizure onset/referral/surgery, surgery type, and experiencing FBTCS were not associated with seizure-free outcome. Type IIB pathology had 89% (n = 8) seizure-free outcome. Epileptic spasms had 45% seizure-free outcome. Transient neurologic deficits occurred in 2 patients, and an expected neurologic deficit in 1 (visual field cut from occipital lobectomy). There were no deaths.This study finds high rates of seizure-free outcome in epilepsy surgery for early-onset FCD-DRE across all pathologies and procedures with minimal complication rates and no deaths. Focal cortical dysplasia type IIB is associated with very high rates of seizure-free outcome. Epileptic spasms were associated with lower seizure-free outcome. The study also fails to confirm a high rate of multilobar unilateral hypoplasia with severe epilepsy in children, a type I FCD variant that has been reported as a common etiology of early-life FCD.© 2025 American Academy of Neurology.",Neurology. Clinical practice,"Dec, 2025",2025,Dec,,Cohen N T|Depositario-Cabacar D F|Oluigbo C O|Ostendorf A P|Wong-Kisiel L|Fedak Romanowski E|McNamara N A|Tatachar P|Eschbach K|Alexander A L|Pichon P D|Ciliberto M A|Gonzalez-Giraldo E|Bernardo D|Auguste K I|Coryell J|Arredondo K H|Novotny E J|Reddy S B|Ganesh A|Marashly A|Javarayee P K|Singh R K|Bolton J B|Grinspan Z M|Karia S|Karakas C|Lin J|Knox A T|Wolf S M|Abel T J|Samanta D|Armstrong D M|Pavuluri S|Hyslop A|Galan F N|Miller D J|Hauptman J S|Caraway A R|Perry M S|Gaillard W D,Wong-Kisiel L,"Center for Neuroscience, Children's National Hospital, The George Washington University School of Medicine, Washington, DC.|Nationwide Children's Hospital and the Ohio State University, Columbus, OH.|Division of Epilepsy, Department of Neurology, Mayo Clinic, Rochester, MN.|Michigan Medicine Pediatric Neurology, CS Mott Children's Hospital, Ann Arbor, MI.|Division of Neurology-Epilepsy Center, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, IL.|Department of Pediatrics, Section of Neurology, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora.|Department of Neurosurgery, Pediatrics, University of Colorado School of Medicine, Children's Hospital Colorado, Aurora.|Department of Neurology, Children's Hospital of Orange County, CA.|Child Neurology, Department of Pediatrics, University of Iowa, Iowa City.|Department of Neurology, Division of Epilepsy, University of California-San Francisco.|University of California San Francisco Weill Institute for Neurosciences, Benioff Children's Hospital.|Department of Pediatrics, Oregon Health and Sciences University, Portland.|Department of Neurology, Dell Medical School, The University of Texas at Austin.|Division of Pediatric Neurology, Departments of Neurology and Pediatrics, Seattle Children's Hospital, Neurosciences, University of Washington.|Division of Pediatric Neurology, Department of Pediatrics, Monroe Carell Jr. Children's Hospital at Vanderbilt, Vanderbilt University Medical Center, Nashville, TN.|Epilepsy Division, Neurology Department, The Johns Hopkins University, Baltimore, MD.|Division of Child Neurology, Department of Neurology, Medical College of Wisconsin, Milwaukee.|Department of Pediatrics, Atrium Health-Levine Children's Hospital, Wake Forest University School of Medicine, Charlotte, NC.|Department of Neurology, Boston Children's, MA.|Department of Pediatrics, Department of Neurology Department of Population Health Sciences, Weill Cornell Medicine, New York, NY.|Division of Child Neurology, Department of Pediatrics, Norton Children's Neuroscience Institute, University of Louisville, KY.|Department of Pediatric Neurology, Children's Healthcare of Atlanta, Emory University School of Medicine, GA.|Department of Neurology, University of Wisconsin School of Medicine and Public Health, Madison.|Boston Children's Health Physicians of New York and Connecticut, Maria Fareri Children's Hospital, New York Medical College, Valhalla.|Department of Neurological Surgery, Department of Bioengineering, University of Pittsburgh, PA.|Child Neurology Division, Department of Pediatrics, University of Arkansas for Medical Sciences, Little Rock.|Department of Pediatrics and Department of Neurology, University of Texas Southwestern Medical Center, Dallas.|Children's Hospital and Medical Center, Omaha, NE.|Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Palo Alto, CA.|Department of Child and Adolescent Neurology, Nemours Children's Health, Jacksonville, FL.|Department of Neurology, Indiana University School of Medicine, Indianapolis.|Department of Neurosurgery, Phoenix Children's Hospital, AZ; and.|Department of Neurology, Jane and John Justin Institute for Mind Health, Cook Children's Medical Center, Fort Worth, TX.","Cohen N T, Depositario-Cabacar D F, Oluigbo C O, Ostendorf A P, Wong-Kisiel L, Fedak Romanowski E, McNamara N A, Tatachar P, Eschbach K, Alexander A L, Pichon P D, Ciliberto M A, Gonzalez-Giraldo E, Bernardo D, Auguste K I, Gaillard W D, et al.",https://pubmed.ncbi.nlm.nih.gov/41070137/,"This study found that early surgical treatment of drug-resistant epilepsy caused by focal cortical dysplasia in children can lead to high rates of seizure freedom, with minimal complications. The study also identified that focal cortical dysplasia type IIB is associated with the best surgical outcomes, while epileptic spasms are linked to lower seizure-free rates."
41070138,Outcomes of Maintenance Immunotherapy in a Cohort of Patients With Susac Syndrome: A 2-Center Large Case Series.,"Susac syndrome (SuS) is a rare autoimmune disorder characterized by the classic clinical triad of encephalopathy, sensorineural hearing loss, and branch retinal artery occlusion (BRAO). Maintenance immunotherapy is important in most cases to prevent new attacks that can cause significant disability. However, owing to the rarity of SuS, there are few large studies evaluating the efficacy of immunotherapies in SuS. In this large case series, we evaluated the association of utilized immunotherapies and relapse rates in the management of SuS from a large multicenter cohort.Retrospective data analysis of 54 patients with definite or probable SuS diagnoses who were evaluated and managed at 2 academic medical centers in the United States. The percentage with relapse and annualized relapse rate (ARR) were calculated for each immunotherapy.The median age at diagnosis of SuS was 36.5 years (interquartile range 30-46 years), and 61% were female. On maintenance immunotherapy, the relapse rate and median ARR were as follows: mycophenolate mofetil 40% (12 of 30 with a median duration of 1.08 years; ARR 0), low or intermediate dose IV immunoglobulin (IVIG) 42.3% (11 of 26 with a median duration of 0.75 years; ARR 0.1), high dose IVIG 11.7% (2 of 17 with a median duration of 0.58 years; ARR 0), cyclophosphamide 36.3% (8 of 22 with a median duration 0.5 years; ARR 0), rituximab 38% (8 of 21 with a median duration of 1.58 years; ARR 0), azathioprine 60% (3 of 5 with a median duration of 1.33 years; ARR 0.1), methotrexate 66.6% (2 of 3 with a median duration of 5.5 years, ARR 0.1), infliximab 0% (0 of 1 with duration of 0.66 years; ARR 0), maintenance plasma exchange 0% (0 of 1 with duration of 1.25 years; ARR 0), and tocilizumab 0% (0 of 1 with duration of 0.91; ARR 0).Our relatively large cohort of patients with SuS shows a variety of maintenance immunotherapies are used with varying response rates. Among our patients, a number of refractory cases required aggressive and combination of immunotherapies.© 2025 American Academy of Neurology.",Neurology. Clinical practice,"Dec, 2025",2025,Dec,,Moheb N|Tajfirouz D A|Chodnicki K D|McKeon A|Rattanathamsakul N|Salman A|Rettenmaier L A|Varma-Doyle A|Chwalisz B K|Chen J J,Moheb N|Tajfirouz D A|Chodnicki K D|McKeon A|Rattanathamsakul N|Chen J J,"Department of Ophthalmology, Mayo Clinic, Rochester, MN.|Department of Neurology, Mayo Clinic, Rochester, MN.|Department of Neurology, Lehigh Valley Fleming Neuroscience Institute, Allentown, PA.|George Washington University School of Medicine and Health Sciences, Washington, DC.|Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and.|Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA.","Moheb N, Tajfirouz D A, Chodnicki K D, McKeon A, Rattanathamsakul N, Salman A, Rettenmaier L A, Varma-Doyle A, Chwalisz B K, Chen J J",https://pubmed.ncbi.nlm.nih.gov/41070138/,"This study examined the effectiveness of different maintenance immunotherapies in treating Susac syndrome, a rare autoimmune disorder. The key finding is that while various immunotherapies were used, some were more effective than others in preventing relapses, with high-dose intravenous immunoglobulin and infliximab showing the lowest relapse rates. This information can help guide treatment decisions for patients with this debilitating condition."
41070715,"Protocols, Complications, and Outcomes of Pressurized Intraperitoneal Aerosol Chemotherapy for Patients With Peritoneal Metastasis: A Systematic Review of the Literature.","The use of pressurized intraperitoneal aerosol chemotherapy (PIPAC) is becoming more frequent for patients with unresectable peritoneal metastases. This systematic review explores the indications, protocols, feasibility, safety, oncological outcomes, patient reported outcomes and quality of life outcomes for patients being treated with PIPAC.A review of PubMed, Embase and the Cochrane Library was undertaken to identify studies pertaining to patients undergoing treatment with PIPAC. Clinicopathological characteristics, treatment protocols, safety data, treatment response data and outcome data were extracted from relevant studies and included in the analysis.Data from 1980 patients undergoing 4454 PIPAC procedures for peritoneal metastases from a range of primary cancers was extracted. The treatment protocols identified were relatively homogenous across all studies. Grade 3/4 complications, grade 3/4 toxicity and procedure related mortality occurred infrequently. At least partial histological response was seen in 61.8% of patients. Overall survival for studies presenting data for mixed primary tumors ranged from 8 to 25 months. Quality of life and function were relatively stable throughout treatment.PIPAC is a safe and feasible treatment option for patients with peritoneal metastases. Ongoing studies are required to evaluate how it compares to best option standard of care chemotherapy.© 2025 Wiley Periodicals LLC.",Journal of surgical oncology,"Dec, 2025",2025,Dec,,Reynolds I S|Duggan W P|McKenna N P|Merchea A|Mulsow J,Reynolds I S|McKenna N P|Merchea A,"Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota, USA.|Royal College of Surgeons in Ireland, Dublin, Ireland.|Division of Colon and Rectal Surgery, Mayo Clinic, Jacksonville, Florida, USA.|Department of Colorectal Surgery, Mater Misericordiae University Hospital, Dublin, Ireland.|National Centre for Peritoneal Malignancy, Mater Misericordiae University Hospital, Dublin, Ireland.","Reynolds I S, Duggan W P, McKenna N P, Merchea A, Mulsow J",https://pubmed.ncbi.nlm.nih.gov/41070715/,"PIPAC is a new treatment option for patients with peritoneal metastases, which involves delivering chemotherapy directly into the abdomen as an aerosol. This systematic review found that PIPAC is generally safe, with low rates of serious complications, and can lead to partial tumor response in over 60% of patients. While more research is needed, PIPAC appears to be a promising treatment for this difficult-to-treat condition."
41073262,Optimizing value-based care and patient experience following pancreatectomy: initial experience with remote post-hospital patient monitoring.,"Pancreatectomies confer risks of morbidity, extended hospital stays, and readmissions. Building on previous monitoring of non-surgical patients' post-discharge, we implemented a remote monitoring program to reduce inpatient healthcare utilization and enhance in-home recovery following pancreatectomy. Herein, we report our initial experience with the Pancreatectomy Remote Patient Monitoring (PREMO) program.Eligible patients undergoing pancreatectomy 10/2022-2/2023 were invited to participate in PREMO for 30 days or until ""graduation"" criteria were met. The PREMO cohort was compared by descriptive statistical analysis to a historical control group of patients (N = 751) undergoing pancreatectomy from 1/2019-12/2021.Of the ninety-one patients enrolled in PREMO, the median hospital length of stay was 6.0 days (IQR 3) compared to 7.0 days (IQR 5) in the historical control group (n=751) (P=0.01). The enrolled population and Whipple subgroup had lower rates of readmissions at 7, 14, 30, and 60 days. Post-graduation surveys reported that patients agreed that they would recommend PREMO to others (98%) and felt more comfortable managing their health at home (92%).PREMO was successfully implemented, conferred excellent patient-reported care quality, and an observed reduction in LOS and readmissions. Ongoing studies are evaluating an expanded PREMO version toward enhancing value-based post-pancreatectomy care.Copyright © 2025 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.",HPB (Oxford),"Dec, 2025",2025,Dec,,Busch J J|Ilmer M|Shah P|Truty M J|Kendrick M|Starlinger P P|Smoot R|Thiels C A|Warner S G,Busch J J|Ilmer M|Shah P|Truty M J|Kendrick M|Starlinger P P|Smoot R|Thiels C A|Warner S G,"Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA; Department of General, Visceral, and Transplant Surgery, Ludwig-Maximilians-University Munich, Germany; German Cancer Consortium (DKTK), German Cancer Research Centre (DKFZ), Heidelberg, Germany.|Department of Endocrinology, Mayo Clinic, Rochester, MN, USA.|Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, Mayo Clinic, Rochester, MN, USA. Electronic address: warner.susanne@mayo.edu.","Busch J J, Ilmer M, Shah P, Truty M J, Kendrick M, Starlinger P P, Smoot R, Thiels C A, Warner S G",https://pubmed.ncbi.nlm.nih.gov/41073262/,The key finding of this medical research is that a remote patient monitoring program called PREMO helped reduce hospital length of stay and readmission rates for patients who underwent pancreatectomy surgery. Patients reported high satisfaction with the program and felt more comfortable managing their health at home. This suggests that remote monitoring can improve value-based care and patient experience after major abdominal surgeries.
41075528,Final analysis from an open-label extension study of fenfluramine for the treatment of seizures in Lennox-Gastaut syndrome: long-term impact on patients and caregivers.,"To describe long-term safety and effectiveness of fenfluramine in pediatric and adult patients with Lennox-Gastaut syndrome (LGS) from the final analysis of an open-label extension (OLE) study.Patients (aged 2-35y) who participated in the randomized controlled trial (RCT) were eligible to continue in this OLE (NCT03355209). Fenfluramine 0.2 mg/kg/day was initiated; after one month, titration up to 0.7 mg/kg/day (26 mg/day maximum) was allowed. Key endpoints: incidence of treatment-emergent adverse events (TEAEs), median percentage change from RCT baseline in frequency of seizures associated with a fall, improvement by caregivers and investigators on Clinical Global Impression-Improvement (CGI-I), change from baseline in Quality of Life in Childhood Epilepsy Questionnaire scores, and Hospital Anxiety and Depression Scale (HADS) in parents/caregivers.247 patients enrolled: 158 (64.0 %) patients completed this OLE. Mean ± SD age, 14.3 ± 7.6y; median fenfluramine exposure, 364d (range, 19-537); mean ± SD fenfluramine daily dose, 0.4 ± 0.1 mg/kg/day. TEAEs in ≥10 % of patients: decreased appetite, fatigue, nasopharyngitis, seizure, pyrexia; no valvular heart disease or pulmonary arterial hypertension cases. Median change in frequency of seizures associated with a fall from Month 2 to end of study: -31.1 % (n = 240; P < 0.0001); pediatric: -27.6 % (n = 170; P = 0.0005), adult: -40.0 % (n = 70; P < 0.0001). On last-visit CGI-I, caregivers and investigators rated 59.9 % and 57.0 % of patients as improved, respectively. At Month 12, mean overall patient quality of life and caregiver anxiety on HADS significantly improved from baseline.These results support the long-term safety and effectiveness of fenfluramine in patients with LGS, with no new safety signals identified, and sustained reductions in seizures and improvement in global functioning observed.Copyright © 2025 UCB Pharma S.A. Published by Elsevier Inc. All rights reserved.",Epilepsy & behavior : E&B,"Dec, 2025",2025,Dec,,Knupp K G|Scheffer I E|Schoonjans A|Sullivan J|Lagae L|Auvin S|Thiele E A|Guerrini R|Zuberi S M|Nabbout R|Riney K|Nickels K C|Davis R|Lock M D|Dai D|Minh T|Zhang Roper R|Dickson N|Langlois M|Lothe A|Gil-Nagel A,Nickels K C,"University of Colorado Anschutz Medical Campus, Aurora, CO, USA. Electronic address: Kelly.knupp@childrenscolorado.org.|University of Melbourne, Austin Health, Heidelberg, Melbourne, Victoria, Australia; The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, Victoria, Australia; University of Melbourne, Royal Children's Hospital, Parkville, Victoria, Australia; Murdoch Children's Research Institute, Parkville, Victoria, Australia. Electronic address: i.scheffer@unimelb.edu.au.|University Hospital Antwerp, Antwerp, Belgium. Electronic address: an-sofie.schoonjans@uza.be.|Weill Institute for Neurosciences and Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA. Electronic address: joseph.sullivan@UCSF.edu.|University of Leuven, Leuven, Belgium; Leuven Childhood Epilepsy Center, Leuven Brain Institute, UZ Leuven, Member of the European Reference Network (ERN) EpiCARE, Leuven, Belgium. Electronic address: lieven.lagae@uzleuven.be.|AP-HP, Reference Center for Rare Epilepsies, Member of the ERN EpiCARE, Hôpital Universitaire Robert Debré, Paris, France; Institut Hospitalo-Universitaire Robert-Debré du Cerveau de l'Enfant, Paris, France; Université Paris-Cité, INSERM NeuroDiderot, Paris, France; Institut Universitaire de France (IUF), Paris, France. Electronic address: stephane.auvin@aphp.fr.|Massachusetts General Hospital, Boston, MA, USA. Electronic address: ethiele@mgh.harvard.edu.|Meyer Children's Hospital IRCCS, Member of the ERN EpiCARE, Florence, Italy; University of Florence, Florence, Italy. Electronic address: renzo.guerrini@unifi.it.|Paediatric Neurosciences Research Group, School of Health and Wellbeing, University of Glasgow, Glasgow, UK; Royal Hospital for Children, Glasgow, UK; Queen Elizabeth University Hospital, Member of the ERN EpiCARE, Glasgow, UK. Electronic address: sameer.zuberi@gla.ac.uk.|Reference Centre for Rare Epilepsies, Necker Enfants Malades Hospital, APHP, Member of the ERN EpiCARE, Paris, France; Institut Imagine, U 1163, Paris, France; Université Paris Cité, Paris, France. Electronic address: rima.nabbout@aphp.fr.|The University of Queensland, St Lucia, QLD 4067, Australia; Queensland Children's Hospital, South Brisbane, QLD 4101, Australia; Children's Health Queensland, Queensland Hospital and Health Service, South Brisbane, QLD 4101, Australia. Electronic address: kate.riney@health.qld.gov.au.|Mayo Clinic, Rochester, MN, USA. Electronic address: nickels.katherine@mayo.edu.|Neurology and Epilepsy Research Center, Orlando, FL, USA. Electronic address: majrdavis@aol.com.|Independent Statistical Consultant, Haiku, HI, USA. Electronic address: mike@lockstats.com.|Syneos Health, Morrisville, NC, USA. Electronic address: david.dai@syneoshealth.com.|UCB, Morrisville, NC, USA. Electronic address: Timothy.minh@ucb.com.|UCB, Slough, UK. Electronic address: rebecca.zhangroper@ucb.com.|UCB, Morrisville, NC, USA. Electronic address: najla.dickson@ucb.com.|UCB, Colombes, France. Electronic address: melanie.langlois@ucb.com.|UCB, Colombes, France. Electronic address: amelie.lothe@ucb.com.|Hospital Ruber Internacional, Madrid, Spain. Electronic address: agnagel@neurologiaclinica.es.","Knupp K G, Scheffer I E, Schoonjans A, Sullivan J, Lagae L, Auvin S, Thiele E A, Guerrini R, Zuberi S M, Nabbout R, Riney K, Nickels K C, Davis R, Lock M D, Dai D, Gil-Nagel A, et al.",https://pubmed.ncbi.nlm.nih.gov/41075528/,"This study found that the drug fenfluramine is safe and effective for long-term treatment of seizures in people with Lennox-Gastaut syndrome, a severe form of epilepsy. Patients experienced a significant reduction in seizures associated with falls, and their overall quality of life and their caregivers' anxiety levels improved over time. These findings suggest fenfluramine could be a valuable long-term treatment option for this difficult-to-treat condition."
41075701,Multimodality imaging of giant cell arteritis.,No abstract available.,J Clin Neurosci,"Dec, 2025",2025,Dec,,Rai P|Bathla G,Rai P|Bathla G,"Department of Radiology, Mayo Clinic, Rochester, MN 55901, United States. Electronic address: rai.pranjal@mayo.edu.|Department of Radiology, Mayo Clinic, Rochester, MN 55901, United States. Electronic address: bathla.girish@mayo.edu.","Rai P, Bathla G",https://pubmed.ncbi.nlm.nih.gov/41075701/,"This research likely explores the use of multiple imaging techniques, such as different types of scans, to study and diagnose a condition called giant cell arteritis. Giant cell arteritis is a type of inflammation in the blood vessels, and this study seems to focus on using various imaging methods to better understand and detect this disease."
41075866,Surgical management of small bowel neuroendocrine neoplasms in Crohn's disease: a multicenter retrospective analysis.,"Crohn's disease (CD) is associated with an increased risk of small bowel neuroendocrine neoplasms (SBNENs). However, data on postsurgical outcomes are limited. This multicenter study aimed to analyze the clinicopathological characteristics, surgical management, and outcomes of patients with CD who underwent surgery for SBNENs.A multicenter, retrospective analysis was conducted on patients with a history of CD who underwent surgical resection for an SBNEN between September 1992 and March 2025. Data on patient and tumor characteristics, surgical details, and postoperative outcomes were collected and analyzed. Time-to-event analysis was used to determine the recurrence and survival rates.The study included 22 patients (63.4% male) with a median age of 49 years at CD diagnosis. An interval of 108 months was noted between CD diagnosis and SBNEN detection. SBNENs were often an incidental finding during surgery (36.4%). Most tumors were in the ileum (72.7%), were grade 2 (72.7%), and presented with nodal metastases (59.1%). Complete surgical resection (R0) was achieved in 90.9% of cases, primarily through an open approach (68.2%). The postoperative morbidity rate was 50%. No local recurrences occurred over a median follow-up of 120 months, but distant recurrence (liver metastases) was observed in 13.6% of patients, with a cancer-related mortality rate of 9.1%.Surgical resection for SBNENs in patients with CD provides excellent long-term oncologic control, although it is associated with considerable perioperative morbidity. The diagnosis is often delayed or incidental, underscoring the need for increased clinical suspicion and potentially enhanced surveillance strategies in this high-risk population.Copyright © 2025. Published by Elsevier Inc.",J Gastrointest Surg,"Dec, 2025",2025,Dec,,Violante T|Ferrari D|Larson D W|Rottoli M|Gomaa I A|Aboelmaaty S A|Cheng J|Novelli M|Shawki S S|Garoufalia Z|Wignakumar A|Dourado J|Wexner S|Calini G|Cardelli S|Binetti M|Sissa L|Halfdanarson T|Mathis K L,Violante T|Ferrari D|Larson D W|Gomaa I A|Aboelmaaty S A|Cheng J|Novelli M|Shawki S S|Halfdanarson T|Mathis K L,"Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, United States; Orsi Academy, Melle, Belgium.|Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, United States; Istituto Nazionale dei Tumori, Milan, Italy.|Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, United States.|Surgery of the Alimentary Tract, Istituto di Ricovero e Cura a Carattere Scientifico Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.|Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, United States; Department of Statistics, Alma Mater Studiorum - University of Bologna, Bologna, Italy.|Ellen Leifer Shulman and Steven Shulman Digestive Disease Center, Cleveland Clinic Florida, Weston, FL, United States.|School of General Surgery, Alma Mater Studiorum - University of Bologna, Bologna, Italy.|Medical Oncology, Mayo Clinic, Rochester, MN, United States.|Division of Colon and Rectal Surgery, Mayo Clinic, Rochester, MN, United States. Electronic address: mathis.kellie@mayo.edu.","Violante T, Ferrari D, Larson D W, Rottoli M, Gomaa I A, Aboelmaaty S A, Cheng J, Novelli M, Shawki S S, Garoufalia Z, Wignakumar A, Dourado J, Wexner S, Calini G, Cardelli S, Mathis K L, et al.",https://pubmed.ncbi.nlm.nih.gov/41075866/,"This study found that surgical removal of small bowel neuroendocrine tumors in patients with Crohn's disease can provide good long-term cancer control, despite a high rate of postoperative complications. However, these tumors are often detected late or incidentally, highlighting the need for increased monitoring in this high-risk group."
41076458,Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment.,"The primary goal in the management of neovascular age-related macular degeneration (nAMD) is to optimise visual acuity outcomes for patients. Landmark clinical trials have demonstrated improved visual outcomes with standard-of-care vascular endothelial growth factor (VEGF) inhibitors, principally targeting a single ligand (VEGF-A). However, in the real-world setting, not all patients attain optimal visual outcomes with these monotherapies. The role of the VEGF-A and VEGF receptor (VEGFR)-2 axis in angiogenesis and vascular permeability is well characterised, but other VEGF family members, including VEGF-C and VEGF-D, which activate VEGFR-2 and VEGFR-3, have also been implicated in nAMD pathogenesis. This may explain the heterogeneous responses observed with current therapies that primarily inhibit VEGF-A signalling, and in patients who continue to lose vision despite treatment, the consequences can be profound. Vision loss affects daily living and can lead to increased cost of care and susceptibility to falls and injuries. This review will explore the VEGF family of ligands and receptors and their role in nAMD, as well as novel therapeutics in development that target mediators beyond VEGF-A with the potential to provide improved vision benefits to patients. In particular, sozinibercept, an investigational trap biologic inhibitor of VEGF-C and VEGF-D ligands, has shown promising efficacy with superior vision gains when used in combination with ranibizumab dosed monthly (standard-of-care therapy) vs. standard-of-care alone (i.e. monthly ranibizumab). This adds to the increasing evidence that multifaceted approaches that target the VEGF family beyond VEGF-A have the potential to provide better vision outcomes for patients with nAMD.© 2025. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.","Eye (London, England)","Dec, 2025",2025,Dec,,Khanani A M|Bakri S J|Regillo C|Weng C Y|Wong T Y|Baldwin M E|Han J J|Leitch I M,Bakri S J,"Sierra Eye Associates, Reno, NV, USA. arshad.khanani@gmail.com.|University of Nevada, Reno School of Medicine, Reno, NV, USA. arshad.khanani@gmail.com.|Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA.|Mid Atlantic Retina, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA, USA.|Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA.|Singapore Eye Research Institute, Singapore National Eye Centre, Singapore, Singapore.|Beijing Visual Science and Translational Eye Research Institute, School of Clinical Medicine, Beijing Tsinghua Changgung Hospital, Tsinghua Medicine, Tsinghua University, Beijing, China.|Opthea Limited, Opthea Limited, South Yarra, VIC, Australia.","Khanani A M, Bakri S J, Regillo C, Weng C Y, Wong T Y, Baldwin M E, Han J J, Leitch I M",https://pubmed.ncbi.nlm.nih.gov/41076458/,"The key finding of this medical research is that targeting VEGF-C and VEGF-D, in addition to VEGF-A, can provide better vision outcomes for patients with neovascular age-related macular degeneration (nAMD) compared to the current standard of care that primarily targets VEGF-A. This suggests that a multifaceted approach addressing the VEGF family beyond VEGF-A has the potential to improve vision for"
41320809,Outcomes of mechanical thrombectomy after recent cardiovascular procedures: a multicenter descriptive cohort.,"Large vessel occlusions (LVOs) in ischemic stroke represent a critical challenge, particularly in the peri-procedural setting of cardiovascular procedures (CVPs). Mechanical thrombectomy (MT) is a well-established treatment for LVOs; however, its outcomes in patients following recent CVPs remain unclear.This multicenter retrospective cohort study aimed to evaluate the outcomes of MT in patients with ischemic stroke occurring within 30 days of CVPs.We analyzed data from four centers, including patients aged ≥18 years who underwent MT for LVO within 30 days of CVPs. CVPs included both surgical (e.g. CABG, valve replacement) and minimally invasive procedures (e.g. TAVR, PCI). Baseline characteristics, procedural metrics, and outcomes, including NIHSS and mRS scores, were collected. Statistical analyses were performed using R software.Of 8,947 screened stroke patients, 27 met the inclusion criteria. The median age was 69 years (IQR 60-83), and 56% were male. Anterior circulation occlusions were present in 93% of cases, with a median baseline NIHSS score of 18 (IQR 14-21). Successful reperfusion (TICI ≥2b) was achieved in 85% of cases, with a median of one thrombectomy pass. At 90 days, 30% of patients achieved functional independence (mRS 0-2), while the mortality rate was 44%. Procedural complications were rare (3.7%).MT in patients with peri-procedural LVO after CVPs demonstrates success but poor functional recovery compared with baseline. These findings highlight the need for prospective studies to identify patients who may benefit most from MT in this high-risk population.",Neurological research,"Nov 30, 2025",2025,Nov,30,Ghozy S|Tolba H|Liu M|Dmytriw A A|Ortega Moreno D A|Attar H|Khan M S|Cancelliere N M|Tariq I|Kadirvel R|Lazzaro M A|Qureshi A I|Pereira V M|Rabinstein A A|Kallmes D F,Ghozy S|Liu M|Kadirvel R|Rabinstein A A|Kallmes D F,"Department of Radiology, Mayo Clinic, Rochester, MN, USA.|Department of Neurologic Surgery, Mayo Clinic, Rochester, MN, USA.|Department of Neurology, University of Missouri, Columbia, MO, USA.|Department of Neurology, Medical College of Wisconsin, Milwuakee, WI, USA.|Department of Neurology, Mayo Clinic, Rochester, MN, USA.|Neuroendovascular Program, Massachusetts General Hospital & Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.|Neurovascular Centre, Divisions of Therapeutic Neuroradiology & Neurosurgery, St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.|Zeenat Qureshi Stroke Institute, Columbia, MO, USA.","Ghozy S, Tolba H, Liu M, Dmytriw A A, Ortega Moreno D A, Attar H, Khan M S, Cancelliere N M, Tariq I, Kadirvel R, Lazzaro M A, Qureshi A I, Pereira V M, Rabinstein A A, Kallmes D F",https://pubmed.ncbi.nlm.nih.gov/41320809/,"The study found that mechanical thrombectomy, a procedure to remove blood clots in the brain, can be successful in treating strokes that occur after recent cardiovascular procedures. However, only 30% of patients achieved functional independence, and the mortality rate was high at 44%. These findings suggest the need for further research to identify the patients who may benefit most from this treatment in this high-risk population."
41318933,"Consensus practice guidelines on sacroiliac joint complex pain from a multispecialty, international working group.","The past two decades have witnessed tremendous growth in the appreciation and treatment of sacroiliac joint (SIJ) complex pain, including anatomical dissections that shed light on innervation, an appreciation for the contribution of extra-articular components to SIJ complex pain, the advent of radiofrequency ablation (RFA) and a host of minimally invasive surgical techniques. Yet, there is no standardization on diagnosis and treatment paradigms.In February 2023, the Boards of Directors for the American Academy of Pain Medicine (AAPM) and American Society of Regional Anesthesia & Pain Medicine (ASRA-PM) approved the development of multispecialty guidelines on SIJ complex pain. Thirty partner organizations with clinical and scientific interests in SIJ complex pain were identified, and formal letters of request-for-participation were sent to each, along with a request for nominees to serve on the committee. Twenty five organizations agreed to participate in addition to the Departments of Defense and Veterans Affairs. A steering committee developed 21 questions, which spanned criteria for diagnosis, non-interventional and interventional treatments including surgery, technical parameters on how to optimize results, and what constitutes positive outcomes. Questions were methodically assigned to specialized modules comprising 4-5 members with complementary expertise, who collaborated with the Subcommittee Lead and one of three Committee Chairs to develop preliminary drafts. Following thorough revisions, these drafts were subsequently submitted to the full committee for comprehensive review. A modified Delphi method was used in which the answers to questions were sent to the committee en bloc and comments were returned in a non-blinded fashion to the Chairs, who incorporated the comments and sent out revised versions until consensus was achieved. During a committee meeting before commencement, it was agreed that recommendations would be noted when there was >50% agreement among committee members, but that a formal recommendation would require ≥75% consensus.Twenty-one organizations formally endorsed the guidelines. The American Society of Anesthesiologists, and American Academy of Physical Medicine & Rehabilitation, and the North American Spine Society affirmed the benefit of the guidelines but did not officially endorse them. The American Academy of Neurology declined to affirm the benefit of the guidelines citing ""lack of relevance to their membership."" Per policies, while the Departments of Defense and Veterans Affairs did not formally review the guidelines for endorsement, their representatives approved them. In addition to being endorsed or the benefit affirmed by all voting organizations, complete consensus from committee members was obtained on all 21 questions. On 2 recommendations, there were dissensions from 3 societies who thought that selecting patients for sacral lateral branch RFA and minimally invasive fusion should be based on ≥75% relief from 2 blocks instead of at least 50% relief from a single block before RFA, and greater than 50% pain relief with documented functional improvement after a single block before fusion. One additional society (Latin American Society of Regional Anesthesia) abstained on the statement that the evidence is stronger for extra-articular than intra-articular injections. The committee found that a battery of physical exam tests has reasonable sensitivity, but lower specificity, for identifying intra-articular but not extra-articular pathology, with negative tests having greater predictive value than positive ones. Intra-articular injections have diagnostic validity for SIJ intra-articular, but not extra-articular pain. There is unclear or negative evidence for imaging. The prevalence rates of intra-articular and extra-articular pathology are comparable, with both intra- and extra-articular steroid injections providing at least 4 weeks of relief in well-selected patients. However, the evidence is slightly stronger for extra-articular corticosteroid injections to provide short-term relief. The evidence base for non-interventional therapies is indirect, extrapolated mostly from low back pain studies. There is weak evidence supporting dextrose-based prolotherapy and platelet-rich plasma to provide at least 3 months of pain relief. There is strong evidence for sacral lateral branch RFA to provide relief for at least 6 months in individuals with extra-articular pathology, with face validity and indirect evidence from randomized trials supporting sacral lateral branch blocks as a prognostic tool. There is stronger evidence for larger lesions or more aggressive lesioning strategies than for less stringent techniques. There is weak evidence to support non-steroidal anti-inflammatory drugs to prevent neuritis after RFA, and in most cases anticoagulation does not require cessation in the periprocedural perioid. With an aggressive lesioning strategy, sensory stimulation provides minimal therapeutic benefit, with weak, extrapolated evidence that motor stimulation can provide safety benefit. The cutoff to designate diagnostic or prognostic blocks as positive is most commonly set at 50%, with higher values not shown to improve outcomes for more definitive procedures; for therapeutic treatment outcomes, the evidence supports a lower threshold of ≥30% pain relief or meaningful benefit on non-pain outcomes (eg, opioid cessation) for designation of a positive response. For carefully selected patients with intra-articular SIJ complex pain based on controlled blocks who have failed conservative therapies, there is weak or very weak evidence that minimally invasive SIJ fusion can provide benefit for at least one year.SIJ complex pain remains an underappreciated source of chronic low back pain, affecting between 15% and 30% of patients with axial pain predominantly below L5. Answers to many questions were limited by low-quality evidence, indicating the need for better research. SIJ complex pain is a multifarious condition (ie, pain can be from different portions of both the intra- and extra-articular components of the joint) for which an interdisciplinary, multimodal treatment plan can optimize treatment outcomes.© The Author(s) or their employers 2025. Published concurrently by Oxford University Press on behalf of the American Academy of Pain Medicine and American Society of Regional Anesthesia & Pain Medicine 2025, published by BMJ Group.","Pain medicine (Malden, Mass.)","Nov 30, 2025",2025,Nov,30,McCormick Z L|Hurley R W|Anitescu M|Bhaskar A|Bhatia A|Cassidy R C|Chen A S|Dawson T C|De Andrés Ares J|de Campos J L|Hayek S M|Hernández-Porras B C|Kissoon N R|Kohan L R|Elgueta Le Beuffe M F|Moon J Y|Provenzano D A|Reece D E|Schuster N M|Smith C C|Stout A|Szadek K|Thomas D|Tontisirin N|Vagg M F|Van Zundert J|Woodbury A|Cohen S P,Kissoon N R,"Department of Physical Medicine and Rehabilitation, University of Utah School of Medicine, Salt Lake City, UT, United States.|Departments of Anesthesiology, Translational Neuroscience, and Public Health Sciences, and Pain Outcomes Lab, Wake Forest University School of Medicine, Winston-Salem, NC, United States.|Department of Anesthesia and Critical Care Medicine, University of Chicago Medicine, Chicago, IL, United States.|Pain Management Centre, Charing Cross Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.|Department of Anesthesia and Pain Medicine, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada.|Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON, Canada.|University of Kentucky College of Medicine/UK Healthcare, Lexington, KY, United States.|Department of Orthopaedic Surgery, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.|Department of Anesthesiology & Pain Medicine, University of Washington School of Medicine, Seattle, WA, United States.|Department of Anesthesiology, Hospital Universitario La Paz, Madrid, Spain.|Department of Anesthesiology, Hospital Vera Cruz, Brazil.|Department of Anesthesiology and Perioperative Medicine, Case Western Reserve University School of Medicine, University Hospitals Cleveland Medical Center, Cleveland, OH, United States.|Asociación Mexicana para el Estudio y Tratamiento del Dolor.|Division of Pain Medicine, Department of Anesthesiology & Perioperative Medicine, Mayo Clinic, Rochester, MN, United States.|Department of Anesthesiology, University of Virginia Health System, Charlottesville, VA, United States.|Departament of Anesthesiology, Pontificia Universidad Catolicade Chile, Santiago, Chile.|Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.|Pain Diagnostic and Interventional Care, Sewickley, PA, United States.|Department of Physical Medicine & Rehabilitation, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.|UC San Diego Center for Pain Management, Department of Anesthesiology, UC San Diego Health System, La Jolla, CA, United States.|Department of Physical Medicine & Rehabilitation, Columbia University, New York, NY, United States.|Center for Spine Health, Neurological Institute, Cleveland Clinic, Case Western Reserve Lerner College of Medicine, Cleveland, OH, United States.|Anesthesiology and Pain Treatment, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.|Department of Anesthesiology, Yale School of Medicine, New Haven, CT, United States.|Department of Anesthesiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.|Deakin University Medical School, VIC, Australia.|Department of Anesthesiology, Intensive Care, Emergency Medicine and Multidisciplinary Pain Center, Ziekenhuis Oost-Limburg, Belgium.|Department of Anesthesiology and Pain Medicine, Maastricht University Medical Center, The Netherlands.|Mental Health and Neuroscience Research Institute, Division Translational Neuroscience, Maastricht University, The Netherlands.|Emory University School of Medicine, Atlanta VA Healthcare System, Atlanta, GA, United States.|Departments of Anesthesiology, Neurology, Physical Medicine & Rehabilitation, Psychiatry, and Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, United States.|Departments of Physical Medicine & Rehabilitation and Anesthesiology, Walter Reed National Military Medical Center, Uniformed Services University of the Health Sciences, Bethesda, MD, United States.","McCormick Z L, Hurley R W, Anitescu M, Bhaskar A, Bhatia A, Cassidy R C, Chen A S, Dawson T C, De Andrés Ares J, de Campos J L, Hayek S M, Hernández-Porras B C, Kissoon N R, Kohan L R, Elgueta Le Beuffe M F, Cohen S P, et al.",https://pubmed.ncbi.nlm.nih.gov/41318933/,"The key findings of this medical research are:

1) Sacroiliac joint (SIJ) complex pain is a common but underappreciated source of chronic low back pain, affecting 15-30% of patients.

2) The guidelines provide recommendations for diagnosing and treating SIJ complex pain, including the use of physical exams, injections, radiofrequency ablation, and minimally invasive fusion surgery in carefully selected patients.

3"
